{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['c:\\\\Users\\\\ambre\\\\Desktop\\\\INSA\\\\5A\\\\202320\\\\Tesis_I\\\\APP\\\\front\\\\src', 'c:\\\\Python311\\\\python311.zip', 'c:\\\\Python311\\\\Lib', 'c:\\\\Python311\\\\DLLs', '', 'C:\\\\Users\\\\ambre\\\\AppData\\\\Roaming\\\\Python\\\\Python311\\\\site-packages', 'C:\\\\Users\\\\ambre\\\\AppData\\\\Roaming\\\\Python\\\\Python311\\\\site-packages\\\\win32', 'C:\\\\Users\\\\ambre\\\\AppData\\\\Roaming\\\\Python\\\\Python311\\\\site-packages\\\\win32\\\\lib', 'C:\\\\Users\\\\ambre\\\\AppData\\\\Roaming\\\\Python\\\\Python311\\\\site-packages\\\\Pythonwin', 'c:\\\\Python311', 'c:\\\\Python311\\\\Lib\\\\site-packages', 'c:\\\\Python311\\\\Lib\\\\site-packages\\\\vboxapi-1.0-py3.11.egg', 'c:\\\\Users\\x07mbre\\\\AppData\\\\Roaming\\\\Python\\\\Python311\\\\Scripts']\n"
     ]
    }
   ],
   "source": [
    "import sys\n",
    "print(sys.path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "sys.path.append('c:\\\\Users\\ambre\\AppData\\Roaming\\Python\\Python311\\Scripts')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain_community.document_loaders.pdf import PyPDFLoader\n",
    "from langchain_community.document_loaders.pdf import PyPDFDirectoryLoader"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "rawDataset = \"../public/rawDataset/\"\n",
    "txt_directory = \"front/ProcessedDataset/txt/\"\n",
    "scraped_directory = \"front/ProcessedDataset/scraped/\"\n",
    "embeddings_directory = \"front/embeddings/\"\n",
    "\n",
    "loader = PyPDFDirectoryLoader(rawDataset)\n",
    "docs = loader.load()\n",
    "\n",
    "# pages = loader.load_and_split()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Document(page_content='CORRECTION\\nCorrigendum to ‘Guideline No. 431: Postpartum Hemorrhage and\\nHemorrhagic Shock ’[Journal of Obstetrics and Gynaecology\\nCanada 2022; 44(12): 1293-1310.E1]\\nDebbie Robinson, MD, Winnipeg, MB\\nMelanie Basso, RN, MSN, Vancouver, BCCynthia Chan, MD, London, ONKirsten Duckitt, MD, Campbell River, BCRyan Lett, MD, Regina, SK\\nThe authors regret that there is a typo on page 1302 in Table 6 (under the Carboprost column in the Repeat dosing\\nrow). The information in the cell was input as “Every 15 min, max 5 doses ”but it should be “Every 15 min, max 8\\ndoses ”.\\nThe authors would like to apologise for any inconvenience caused.DOI of original article: https://doi.org/10.1016/j.jogc.2022.10.002\\nDebbie Robinson\\ndebrobinson25@gmail.com\\nJ Obstet Gynaecol Can 2023; -(-):1\\nhttps://doi.org/10.1016/j.jogc.2023.06.007\\nª2023 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by\\nElsevier Inc. All rights reserved.\\n-JOGC -2023 l1\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Correccion de Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 0}), Document(page_content='Int J Gynecol Obstet. 2022;157(Suppl. 1):3–50.    \\u2003|\\u20033\\n wileyonlinelibrary.com/journal/ijgoDOI: 10.1002/ijgo.14116  \\nSUPPLEMENT ARTICLE\\nFIGO recommendations on the management of postpartum \\nhemorrhage 2022\\nMaria Fernanda  Escobar1,2\\u2003|   Anwar H. Nassar3\\u2003|   Gerhard Theron4,5\\u2003|   Eythan R. Barnea6\\u2003|   \\nWanda Nicholson7\\u2003|   Diana Ramasauskaite8\\u2003|   Isabel Lloyd9,10\\u2003|   Edwin  Chandraharan11\\u2003|   \\nSuellen Miller12\\u2003|   Thomas Burke13,14\\u2003|   Gabriel  Ossanan15\\u2003|   Javier Andres Carvajal1,2\\u2003|   \\nIsabella  Ramos1,2\\u2003|   Maria Antonia  Hincapie1,2\\u2003|   Sara  Loaiza1,2\\u2003|   Daniela Nasner1,2\\u2003|   \\nFIGO Safe Motherhood and Newborn Health Committee*\\n1Obstetric High Complexity Unit, Fundación Valle del Lili, Cali, Colombia\\n2Department of Obstetrics and Gynecology, School of Medicine, Universidad Icesi, Cali, Colombia\\n3Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Beirut, Lebanon\\n4Department of Obstetrics and Gynecology, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa\\n5Tygerberg Hospital, Cape Town, South Africa\\n6Society for Investigation or Early Pregnancy (SIEP), New York, New York, USA\\n7Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina, USA\\n8Center of Obstetrics and Gynecology, Vilnius University Medical Faculty, Vilnius, Lithuania\\n9Department of Obstetrics and Gynecology, Universidad de Panamá, Panama City, Panamá\\n10Hospital Santo Tomas, Panama City, Panamá\\n11Department of Obstetrics and Gynecology, St George’s University Hospitals NHS Foundation Trust, London, UK\\n12Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, California, USA\\n13Division of Global Health and Human Rights, Massachusetts General Hospital, Department of Emergency Medicine, Harvard Medical School, Boston, \\nMassachusetts, USA\\n14Harvard T.H. Chan School of Public Health, Boston, USA\\n15Department of Obstetrics and Gynecology, Federal University of Minas Gerais, Belo Horizonte, Brazil\\nCorrespondence\\nAnwar H. Nassar, Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Beirut, Lebanon.\\nEmail: an21@aub.edu.lb\\n©  2022 The Authors. International Journal of Gynecology & Obstetrics  published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology \\nand Obstetrics.*Members of the FIGO Safe Motherhood and Newborn Health Committee, 2018–  2021, are listed at the end of the document. \\nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction \\nin any medium, provided the original work is properly cited and is not used for commercial purposes.Author Contributions\\nConceptualization: MFE, AN, GT, EB, WN, DR, IL. Manuscript writing: MFE, AN, GT, TB, EB, WN, DR, IL, EC, SM, RB, GO, JC, IR, MAI, SL, DN. Review and approval \\nof manuscript: MFE, AN, GT, EB, WN, DR.\\nConflicts of Interest\\nGT reports a research grant from the South African Medical Research Council to fund Sinapi Biomedical to develop the Ellavi UBT and conduct associated \\nresearch. EB reports part ownership of BioIncept. EC was a member of the Guideline Development Group for the RCOG’s PPH Greentop Guideline (2016), and \\nthe FIGO Guideline on Placenta Acreta Spectrum (2018). SM reports that Regents, University of California receives a royalty fee from LifeWrap-  NASG for the \\nuse of the trademark name (“LifeWrap”) for a Non-  pneumatic Anti-  Shock Garment (NASG). TB reports PPH research funded by the Gates Foundation; PPH \\nImplementation efforts funded by RzHC; PPH Implementation efforts funded by UK AID; PPH Implementation efforts funded by Grand Challenges Canada; \\nPPH efforts and research funded by USAID; PPH efforts by Norway Government. Other authors report no conflicts of interest.\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 0}), Document(page_content='4\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\nMETHODS\\nThe recommendations were developed as a synthesis and update of evidence from the literature. They are based on the FIGO Safe \\nMotherhood and Newborn Health Committee (SMNH) guidelines that were published in 20121 and include research and consensus guide-\\nlines. For the present document, a bibliographic review was performed, and studies from LMICs and across regions were identified using \\nthe search engines PubMed, Medline, Embase, Science Direct, and Google Scholar. According to the GRADE (Grading of Recommendations \\nAssessment, Development and Evaluation) approach, this update does not generate a universal level of evidence. However, each section and \\nthe generated conclusions and recommendations use the degrees of evidence that were identified in the bibliographic review.\\nREFERENCE\\n 1. Lalonde A. International Federation of Gynecology and Obstetrics. Prevention and treatment of postpartum hemorrhage in low-  resource settings. \\nInt J Gynecol Obstet . 2012;117:108-  118.PURPOSE AND SCOPE\\nThe purpose of this document is to update key concepts in the management of postpartum hemorrhage (PPH) and give clear and precise tools \\nto health personnel in low-  and middle-  income countries (LMICs) to perform evidence-  based treatments, with the aim of reducing related \\nmaternal morbidity and mortality.\\nTARGET AUDIENCE\\nGynecologists, obstetricians, midwives, nurses, general practitioners, and other health personnel in charge of the care of pregnant women \\nwith PPH.Keywords:  FIGO recommendations, management, postpartum hemorrhage, PPH, PPH prevention, PPH treatmentDisclaimer\\nThese FIGO recommendations are not intended to be a sole source of guidance or prescriptive protocol in managing PPH. They are designed to assist stakeholders \\nby providing an evidence-  based framework for decision-  making in a PPH setting. The clinical judgment of the doctor or other practitioner, in the context of the \\nclinical presentation of the patient and the available resources for diagnosis and treatment, should always inform the choice of clinical procedure and treatment plan.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 1}), Document(page_content='\\u2003\\u2002\\u2003|\\u20035\\nESCOBAR Et Al.\\nContents\\n1. Executive summary 7\\n2. FIGO  recommendations for the prevention and treatment of postpartum hemorrhage 8\\n2.1. FIGO recommendations for prevention of postpartum hemorrhage 8\\n2.2. FIGO recommendations for treatment of postpartum hemorrhage 8\\n3. Background 10\\n3.1. Introduction 10\\n3.2. Past FIGO recommendations for PPH 10\\n3.3. Definition of postpartum hemorrhage 10\\n3.4. Etiologies/risk factors 10\\n4. Postpartum hemorrhage bundle care 13\\n5. Shock index evidence in postpartum hemorrhage evaluation and management 15\\n5.1. Assessment of circulating blood volume in postpartum hemorrhage 15\\n6. Review of guidelines around the world 17\\n6.1. Guidelines that address the prevention of postpartum hemorrhage 17\\n6.2 Guidelines that address the treatment of postpartum hemorrhage 20\\n7. Medical prevention and treatment 27\\n7.1. Carbetocin versus oxytocin use in PPH: recent evidence 27\\n7.1.1. Clinical evidence for PPH prevention: oxytocin versus carbetocin (vaginal delivery) 27\\n7.1.2. Clinical evidence for PPH prevention: oxytocin versus carbetocin (cesarean delivery) 27\\n8. Tranexamic acid 30\\n8.1. Administration of TXA 30\\n8.2. TXA as a prophylactic measure 30\\n8.3. Adverse reactions to TXA 31\\n8.4. Contraindications 31\\n8.5. Implementation of treatment with TXA 31\\n9. Nonsurgical conservative management 32\\n9.1. Nonpneumatic antishock garment (NASG) 32\\n9.1.1. Safety 32\\n9.1.2. Effectiveness and advantages 32\\n9.1.3. Indications 33\\n9.1.4. Instructions for use 33\\n9.1.5. Monitoring and removal 33\\n9.1.6. Adverse effects 34\\n9.1.7. Contraindications 34\\n9.2. Uterine balloon tamponade 34\\n9.2.1. Available UBT devices 35\\n9.2.2. Tamponade effect 35\\n9.2.3. Free flow tamponade device 35\\n9.2.4. Drainage port 35\\n9.2.5. Correct placement 35\\n9.2.6. Assessment of effect 35\\n9.2.7. Transfer 36\\n9.2.8. UBT after cesarean delivery 36\\n9.2.9. Combining UBT with compression sutures 36\\n9.2.10. Other uses of UBT 36\\n9.3. Uterine artery embolization 37\\n9.3.1. Complications 38\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 2}), Document(page_content='6\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\n9.3.2. Implementation of treatment 38\\n10. Surgical treatment 39\\n10.1. Uterine compression sutures for PPH 39\\n10.1.1. Commonly used compression sutures for managing PPH 39\\n10.2. Uterine artery ligation 40\\n10.3. Bilateral internal iliac artery ligation 41\\n10.4. Hysterectomy 41\\n11. Assessment and resuscitation 43\\n11.1. Damage control resuscitation in PPH 43\\n11.1.1. Decision for damage control surgery 43\\n11.1.2. Bleeding control 43\\n11.1.2.1. Initial laparotomy 43\\n11.1.2.2. Resuscitation –  ICU 44\\n11.1.2.3. Definitive surgery 44\\n11.1.2.4. Definitive closure of abdominal wall and cavity 44\\n11.1.3. Complications 44\\n11.1.4. Final objectives in resuscitation 44\\n11.2. Resuscitation 45\\n11.2.1. Hypotensive resuscitation 45\\n11.2.2. Intravenous fluids 45\\n11.2.3. Targeted blood pressure 45\\n11.2.4. Aggressive approach and adverse outcomes 45\\n11.2.5. Evidence 45\\n11.2.6. Hemostatic resuscitation 46\\n11.2.7. Transfusion ratios 46\\n11.2.8. Fibrinogen and cryoprecipitate 46\\n11.2.9. Massive transfusion protocols 46\\n11.2.10. Adverse outcomes 47\\n12. Key statements 48\\n13. Implementation of the FIGO recommendations by health systems and national societies for the management of postpartum \\nhemorrhage50\\nMembers of the FIGO Safe Motherhood and Newborn Health Committee, 2018–  2021 50\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 3}), Document(page_content='\\u2003\\u2002\\u2003|\\u20037\\nESCOBAR Et Al.\\n1\\u2003|\\u2003EXECUTIVE SUMMARY\\nFIGO (International Federation of Gynecology and Obstetrics) \\nis actively contributing to the global effort to reduce maternal \\ndeath and disability around the world. Its mission statement re -\\nflects a commitment to promoting health, human rights, and well-  \\nbeing of all women, especially those at the most significant risk of \\ndeath and disability associated with childbearing. FIGO provides \\nevidence-  based interventions that can reduce the incidence of \\nmaternal morbidity and mortality when applied with informed \\nconsent.\\nPostpartum hemorrhage (PPH) continues to be the leading \\ncause of maternal morbidity and mortality in most countries \\naround the world. Despite multiple collaborative efforts at all \\nlevels, there is still a lack of implementation or adherence to \\nthe recommendations for management of PPH when faced with this obstetric emergency. In part, this delay in implementation \\nlies in the lack of information from current evidence and a lack \\nof unification of the multiple guidelines for diagnosis and strat -\\negies to control bleeding. To provide clear and practical tools \\nto approach this obstetric emergency, especially for low-  and \\nmiddle-  income countries (LMICs), the FIGO Safe Motherhood \\nand Newborn Health Committee (SMNH), supported by a group \\nof experts worldwide, developed this updated review. It aims to \\nprovide multiple alternatives for the diagnosis and management \\nof PPH tailored to the resources available at the institutional, \\nlocal, or regional level. This document reflects the best available \\nevidence, drawn from scientific literature and expert opinion, on \\nthe prevention and treatment of PPH in low-  resource settings. \\nFIGO believes that the greatest impediment in the adoption of \\na given strategy is the absence of an effective implementation \\ntool.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 4}), Document(page_content='8\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\n2\\u2003|\\u2003FIGO RECOMMENDATIONS FOR \\nTHE PREVENTION AND TREATMENT OF \\nPOSTPARTUM HEMORRHAGE\\nHealth workers at all levels of care (particularly in LMICs) need \\nto have access to appropriate medications1 and training in PPH \\nprevention and management procedures. All attempts should be \\nmade to reduce PPH using cost-  effective, resource-  appropriate \\ninterventions. At first, all should be done to avoid PPH and re -\\nduce the need for expensive, lifesaving surgical interventions. The \\nroutine use of active management of the third stage of labor by \\nall attendants, regardless of where they practice, should be rec -\\nommended.2 All birth attendants must know how to provide safe \\ncare (physiologic management) to prevent PPH in the absence of \\nuterotonic drugs.3\\n2.1\\u2003 |\\u2003 FIGO recommendations for prevention of \\npostpartum hemorrhage\\n1. The use of uterotonics for prevention of PPH during the third \\nstage of labor is recommended for all births.4,5 Oxytocin (10 IU \\nintravenously/intramuscularly [IV/IM]) is recommended for the \\nprevention of PPH for vaginal delivery and cesarean section.4,5 \\nIn settings where oxytocin is used, attention should be paid \\nto the oxytocin cold chain.6\\n2. In settings where oxytocin is unavailable or its quality can-\\nnot be guaranteed, the use of other injectable uterotonics (if \\nappropriate ergometrine/methylergometrine 200 μg IM/IV;  \\nhypertensive disorders can be safely excluded prior to its use) \\nor oral misoprostol (400–600 µg orally) or carbetocin 100 µg \\nIM/IV is recommended for the prevention of PPH.4,5\\n3. The combinations of ergometrine plus oxytocin or misoprostol plus \\noxytocin may be more effective uterotonic drug strategies for the \\nprevention of PPH ≥500 ml compared with the current standard, \\noxytocin. This comes at the expense of a higher risk of adverse ef -\\nfects (vomiting and hypertension with ergometrine and fever with \\nmisoprostol).7\\n4. In settings where skilled birth attendants are not present to ad -\\nminister injectable uterotonics and oxytocin is unavailable, the \\nadministration of misoprostol (400–  600 μ g orally) by community \\nhealthcare workers and lay health workers is recommended for \\nthe prevention of PPH.4,5\\n5. In settings where skilled birth attendants are unavailable, con -\\ntrolled cord traction (CCT) is not recommended.4\\n6. Sustained uterine massage is not recommended as an interven -\\ntion to prevent PPH in women who have received prophylactic \\noxytocin.8\\n7. Postpartum abdominal uterine tonus assessment for early identi -\\nfication of uterine atony is recommended for all women.4\\n8. Oxytocin (IV or IM) and CCT is the recommended method for removal \\nof the placenta for the prevention of PPH in cesarean delivery.42.2\\u2003 |\\u2003 FIGO recommendations for treatment of \\npostpartum hemorrhage\\n 1. Intravenous oxytocin alone is the recommended first-  line \\nuterotonic drug for the treatment of PPH.3,4\\n 2. If intravenous oxytocin is unavailable, or if the bleeding \\ndoes not respond to oxytocin, the use of intramuscular er -\\ngometrine, oxytocin–  ergometrine fixed dose, or a prosta -\\nglandin drug (including sublingual misoprostol, 800  μg) is \\nrecommended.3,4,9,10\\n 3. There is no evidence about the safety and efficacy of an additional \\n800- μg dose of misoprostol for treatment of PPH when given to \\nwomen who have already received 600 μg of prophylactic misopros -\\ntol orally.\\n 4. The use of isotonic crystalloids is recommended in preference to \\nthe use of colloids for the initial intravenous fluid resuscitation \\nof women with PPH.4,11\\n 5. Early use of intravenous tranexamic acid as soon as PPH is diag -\\nnosed but within 3 h of birth in addition to standard care is rec -\\nommended for women with clinically diagnosed PPH following \\nvaginal birth or cesarean delivery.12– 14\\n 6. Administration of 1 g (100 mg/ml) tranexamic acid intravenously at \\n1 ml/min (i.e. administered over 10 min), with a second dose of 1 g in -\\ntravenously if bleeding continues after 30 min, or if bleeding restarts \\nwithin 24 h of completing the first dose. Reducing maternal deaths \\ndue to bleeding through scaling up of tranexamic acid for PPH treat -\\nment could have a positive impact on health equity and improve out -\\ncomes among disadvantaged women, especially in LMICs.15\\n 7. Uterine massage is recommended for the treatment of PPH.3,4\\n 8. The use of bimanual uterine compression or external aortic \\ncompression for the treatment of PPH due to uterine atony after \\nvaginal birth is recommended as a temporizing measure until ap -\\npropriate care is available.3,4\\n 9. If women do not respond to treatment using uterotonics, or \\nif uterotonics are unavailable, the use of uterine balloon tam -\\nponade is recommended as an effective nonsurgical technique \\nthat can potentially improve survival in women with PPH due to \\nuterine atony after ruling out retained products of conception \\nor uterine rupture as a contributing factor.3,4,16\\n 10. Use of the nonpneumatic antishock garment is recommended \\nas a temporizing measure until appropriate care is available.3,4\\n 11. The use of uterine packing is not recommended for the treat -\\nment of PPH due to uterine atony after vaginal birth.3,4\\n 12. Uterine artery embolization can be another conservative man -\\nagement measure for PPH if technical conditions and skilled \\nhuman resources are available for its use.17\\n 13. If bleeding does not stop despite treatment using uterotonics \\nand other available conservative interventions (e.g. uterine mas -\\nsage, balloon tamponade), the use of surgical interventions is \\nrecommended.3,4 Surgical interventions include the use of com -\\npression suture techniques,18 uterine and hypogastric artery li -\\ngation, and hysterectomy.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 5}), Document(page_content=\"\\u2003\\u2002\\u2003|\\u20039\\nESCOBAR Et Al.\\n 14. The priority is to stop the bleeding before the patient develops \\ncoagulation problems and organ damage from under-  perfusion. \\nConservative approaches should be tried first, rapidly moving to \\nmore invasive procedures if these do not work.\\nREFERENCES\\n 1. World Health Organization. WHO Model List of Essential \\nMedicines. Accessed December 16, 2021. https://www.who.int/\\ngroup s/exper  t- commi  ttee-  on- selec  tion-  and-  use-  of- essen  tial- \\nmedic  ines/essen  tial- medic  ines-  lists\\n 2. Begley CM, Gyte GM, Devane D, McGuire W, Weeks A. Active ver -\\nsus expectant management for women in the third stage of labour. \\nCochrane Database Syst Rev . 2011(11):CD007412.\\n 3. Lalonde A; International Federation of Gynecology and Obstetrics. \\nPrevention and treatment of postpartum hemorrhage in low- \\nresource settings. Int J Gynecol Obstet . 2012;117:108–  118.\\n 4. World Health Organization. WHO recommendations for the pre -\\nvention and treatment of postpartum haemorrhage. Accessed \\nAugust 11, 2021. https://www.who.int/repro  ducti  vehea  lth/publi  \\ncatio  ns/mater  nal_perin  atal_healt  h/97892  41548  502/en/\\n 5. World Health Organization. WHO recommendations: Uterotonics \\nfor the prevention of postpartum haemorrhage. Accessed August \\n11, 2021. https://apps.who.int/iris/bitst  ream/handl  e/10665/  \\n27727  6/97892  41550  420-  eng.pdf?ua =1\\n 6. Oliver VL, Lambert PA, Than KK, et al Knowledge, perception and \\npractice towards oxytocin stability and quality: a qualitative study \\nof stakeholders in three resource limited countries. PLoS One . \\n2018;13:e0203810.\\n 7. Gallos I, Williams H, Price M, et al. Uterotonic drugs to prevent \\npostpartum haemorrhage: a network meta-  analysis. Health Technol \\nAssess . 2019;23:1–  356.\\n 8. Hofmeyr GJ, Abdel-  Aleem H, Abdel-  Aleem MA. Uterine massage \\nfor preventing postpartum haemorrhage. Cochrane Database Syst \\nRev. 2013;(7):CD006431. 9. International Federation of Gynecology and Obstetrics. Be an ad -\\nvocate for better PPH management. Accessed January 7, 2021. \\nhttps://www.figo.org/news/be-  advoc  ate- bette  r- pph-  manag  ement\\n 10. Morris JL, Winikoff B, Dabash R, et al FIGO's updated recommen -\\ndations for misoprostol used alone in gynecology and obstetrics. Int \\nJ Gynecol Obstet . 2017;138:363–  366.\\n 11. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid re -\\nsuscitation in critically ill patients. Cochrane Database Syst Rev . \\n2013;(2):CD000567.\\n 12. WOMAN Trial Collaborators. Effect of early tranexamic acid administra -\\ntion on mortality, hysterectomy, and other morbidities in women with \\npost-  partum haemorrhage (WOMAN): an international, randomised, \\ndouble-  blind, placebo-  controlled trial. Lancet . 2017;389:2105–  2116.\\n 13. World Health Organization. WHO recommendation on tranexamic \\nacid for the treatment of postpartum haemorrhage. Accessed \\nAugust 11, 2021. https://www.who.int/repro  ducti  vehea  lth/publi  \\ncatio  ns/trane  xamic  - acid-  pph-  treat  ment/en/\\n 14. Shakur H, Beaumont D, Pavord S, Gayet-  Ageron A, Ker K, Mousa \\nH. Antifibrinolytic drugs for treating primary postpartum haemor -\\nrhage. Cochrane Database Syst Rev . 2018;(2):CD012964.\\n 15. World Health Organization. State of Inequality: Reproductive \\nMaternal Newborn and Child Health: Interactive Visualization of \\nHealth Data. Accessed August 11, 2021. https://www.who.int/\\ndocs/defau lt-  sourc  e/gho- docum  ents/healt  h- equit  y/state - of- inequ  \\nality/  state  - of- inequ  ality  - repro  ducti  ve- mater  nal- new-  born-  and-  \\nchild  - health.pdf?sfvrs  n=f4034  289_2\\n 16. Tindell K, Garfinkel R, Abu-  Haydar E, et al Uterine balloon tam -\\nponade for the treatment of postpartum haemorrhage in resource- \\npoor settings: a systematic review. BJOG . 2013;120:5–  14.\\n 17. Mahankali SS. Interventional radiology: a disruptive innovation \\nwhich is transforming management of post-  partum haemorrhage. \\nJ Obstet Anaesth Crit Care . 2017;7:65–  68.\\n 18. Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z. \\nTreatment for primary postpartum haemorrhage. Cochrane \\nDatabase Syst Rev . 2014;(2):CD003249.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 6}), Document(page_content=\"10\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\n3\\u2003|\\u2003 BACKGROUND\\n3.1\\u2003 |\\u2003 Introduction\\nPostpartum hemorrhage (PPH) is an obstetric emergency complicat -\\ning 1%–  10% of all deliveries.1 It continues to be the leading obstetric \\ncause of maternal death.1 In 2015, it was reported to be responsible \\nfor more than 80 000 maternal deaths worldwide.1 Its distribution \\nvaries across regions, with the highest prevalence of 5.1%–  25.7% \\nreported in Africa, followed by North America at 4.3%–  13% and Asia \\nat 1.9%–  8%.2 The incidence of PPH has also been on the rise,2– 5 in-\\ncreasing from 5.1%–  6.2% in Canada between 2003 and 2010,3 and \\nfrom 2.9%–  3.2% in the USA between 2010 and 2014.4\\n3.2\\u2003 |\\u2003 Past FIGO recommendations for PPH\\nFIGO has made several recommendations in the past 20 years for \\nthe management and treatment of PPH (Table 1). This document will \\nupdate the recommendations and discuss new approaches.\\n3.3\\u2003 |\\u2003 Definition of postpartum hemorrhage\\nThe lack of consistency in the definition of PPH has been a major \\nlimitation to the ability to compare prevalence in different stud -\\nies (Table 2). Classically, it was defined as quantified bleeding of \\nmore than 500 ml for vaginal deliveries and more than 1000 ml \\nfor cesarean deliveries, occurring within the first 24 h of delivery.1 However, this definition did not focus on clinical signs and symp -\\ntoms of hemorrhage, and thus prevented early detection in many \\ncases. Therefore, in 2017, the American College of Obstetricians \\nand Gynecologists (ACOG) changed the definition to blood loss of \\nmore than or equal to 1000 ml, or blood loss that was accompanied \\nby signs or symptoms of hypovolemia occurring within 24 h after \\nbirth, regardless of the mode of delivery.6 In contrast, the Royal \\nCollege of Obstetricians and Gynaecologists (RCOG) defines PPH \\naccording to the volume of blood lost: minor (between 500 and \\n1000 ml) and major ( >1000  ml).7 However, the volume of estimated \\nblood loss remains unreliable in many cases, and therefore much \\nattention should be directed to the general clinical status of the \\npatient instead.8 Several tools for assessment of blood loss have \\nbeen used as accurate estimation will directly influence the diag -\\nnosis and management of PPH. Many groups cite visual estimation \\nas part of blood loss assessment, but as it has high potential to un -\\nderestimate hemorrhage, use of additional tools for more objective \\nestimation, such as gravimetric measurement, direct blood collec -\\ntion techniques, and evaluation of clinical parameters, have been \\nproposed.9– 17 Recently, some guidelines have incorporated the \\nshock index9,11,14,17 and obstetric early warning systems into their \\nrecommendations to evaluate bleeding.11,14,17\\n3.4\\u2003 |\\u2003 Etiologies/risk factors\\nWhile there exist several identifiable risk factors for PPH, most \\ncases occur unexpectedly.6,18 An easy way to remember the most \\ncommon etiologies is to remember the four T’s19:\\nTABLE 1 \\u2003FIGO recommendations on the management of postpartum hemorrhage\\nFIGO recommendation Year References\\nManagement of the third stage of labor to prevent post- \\npartum hemorrhage2003 International Confederation of Midwives; International Federation of \\nGynaecologists and Obstetricians. Joint statement: management \\nof the third stage of labour to prevent post-  partum haemorrhage. J \\nMidwifery Womens Health. 2004  Jan-  Feb;49(1):76–  7.\\nPostpartum hemorrhage today: ICM/FIGO initiative \\n2004–  20062006 Lalonde A, Daviss BA, Acosta A, Herschderfer K. Int J Gynecol Obstet . \\n2006;94:243–  253.\\nPrevention and treatment of post-  partum haemorrhage: \\nnew advances for low resource settings2006 Joint Statement: ICM and FIGO https://www.who.int/pmnch/  event  \\ns/2006/figo2  006st  ateme nteng.pdf\\nPrevention and treatment of postpartum hemorrhage in \\nlow-  resource settings2012 Lalonde A; International Federation of Gynecology and Obstetrics. Int J \\nGynecol Obstet . 2012;117:108–  118.\\nPrevention of postpartum hemorrhage with misoprostol 2012 International Federation of Gynecology and Obstetrics. Int J Gynecol \\nObstet . 2012;119:213–  214.\\nTreatment of postpartum hemorrhage with misoprostol 2012 International Federation of Gynecology and Obstetrics. Int J Gynecol \\nObstet . 2012;119:215–  216.\\nNon-  pneumatic anti-  shock garment to stabilize women \\nwith hypovolemic shock secondary to obstetric \\nhemorrhage2015 FIGO Safe Motherhood and Newborn Health Committee; International \\nFederation of Gynecology and Obstetrics. Int J Gynecol Obstet . \\n2015;128:194–  195.\\nFIGO's updated recommendations for misoprostol used \\nalone in gynecology and obstetrics2017 Morris JL, Winikoff B, Dabash R, et al. Int J Gynecol Obstet . \\n2017;138:363–  366.\\nAffordable and low-  maintenance obstetric devices 2019 Ayres-  de- Campos D, Stones W, Theron G; FIGO Safe Motherhood and \\nNewborn Health Committee. Int J Gynecol Obstet . 2019;146:25–  28.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 7}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 11\\nESCOBAR Et Al.\\n1. Tone: uterine atony (accounts for 70% of PPH cases).20\\n2. Trauma: genital tract trauma.\\n3. Tissue: retained products of conception.\\n4. Thrombin: coagulopathy.\\nUterine atony can be anticipated after prolonged labor partic -\\nularly with the use of oxytocin, in pregnancies complicated with \\nchorioamnionitis, high parity, general anesthesia, and other factors \\nthat lead to uterine overdistension such as multiple fetal gesta -\\ntion, polyhydramnios, and fetal macrosomia.6,20 Trauma accounts \\nfor 15%–  20% of cases,21 and is mostly attributed to perineal or \\ncervical lacerations, perineal hematomas, episiotomies, or uterine \\nrupture.6,20 These occur in the setting of precipitous uncontrolled \\ndeliveries or operative vaginal deliveries.6 Retained products of \\nconception can increase the risk of PPH by 3.5 times.22 Risk fac -\\ntors include succenturiate placenta and previous instrumenta -\\ntion.6 Coagulation problems can be divided into inherited, such \\nas von Willebrand diseases, hemophilia, and idiopathic thrombo -\\ncytopenic purpura, and acquired, such as the use of anticoagu -\\nlant therapy20 and the occurrence of disseminated intravascular \\ncoagulopathy after placental abruption, pre-  eclampsia with severe \\nfeatures, intrauterine fetal demise, sepsis, or amniotic fluid embo-\\nlism.6,20,23 Other etiologies include uterine inversion and abnormal \\nplacentation.\\nREFERENCES\\n 1. Borovac-  Pinheiro A, Pacagnella RC, Cecatti JG, et al Postpartum \\nhemorrhage: new insights for definition and diagnosis. Am J Obstet \\nGynecol . 2018;219:162–  168.\\n 2. Calvert C, Thomas SL, Ronsmans C, Wagner KS, Adler AJ, Filippi \\nV. Identifying regional variation in the prevalence of postpartum \\nhaemorrhage: a systematic review and meta-  analysis. PLoS One . \\n2012;7:e41114.\\n 3. Mehrabadi A, Liu S, Bartholomew S, et al Temporal trends in post -\\npartum hemorrhage and severe postpartum hemorrhage in Canada \\nfrom 2003 to 2010. J Obstet Gynaecol Can . 2014;36:21–  33. 4. Reale SC, Easter SR, Xu X, Bateman BT, Farber MK. Trends in \\nPostpartum Hemorrhage in the United States From 2010 to 2014. \\nAnesth Analg . 2020;130:e119–  e122.\\n 5. Carroli G, Cuesta C, Abalos E, Gulmezoglu AM. Epidemiology of \\npostpartum haemorrhage: a systematic review. Best Pract Res Clin \\nObstet Gynaecol . 2008;22:999–  1012.\\n 6. Committee on Practice Bulletins-  Obstetrics. Practice bulletin no. \\n183: postpartum hemorrhage. Obstet Gynecol . 2017;130:e168–  e186.\\n 7. Prevention and management of postpartum haemorrhage: green- \\ntop guideline no. 52. BJOG . 2017;124:e106–  e149.\\n 8. Dahlke JD, Mendez-  Figueroa H, Maggio L, et al Prevention and \\nmanagement of postpartum hemorrhage: a comparison of 4 na -\\ntional guidelines. Am J Obstet Gynecol . 2015;213:76.e1–  76.e10.\\n 9. Pan American Health Organization. Guidelines for the prevention, \\ndiagnosis and treatment of obstetric hemorrhage [in Portuguese]. \\nPAHO; 2018.\\n 10. Leduc D, Senikas V, Lalonde AB. No. 235-  active management of \\nthe third stage of labour: prevention and treatment of postpartum \\nhemorrhage. J Obstet Gynaecol Can . 2018;40:e841–  e855.\\n 11. Mavrides E, Allard S, Chandraharan E, et al.; on behalf of the Royal \\nCollege of Obstetricians and Gynaecologists. Prevention and man -\\nagement of postpartum haemorrhage. BJOG . 2016;124:e106–  e149.\\n 12. Sentilhes L, Vayssière C, Deneux-  Tharaux C, et al Postpartum hem -\\norrhage: guidelines for clinical practice from the French College of \\nGynaecologists and Obstetricians (CNGOF): in collaboration with \\nthe French Society of Anesthesiology and Intensive Care (SFAR). \\nEur J Obstet Gynecol Reprod Biol . 2016;198:12– 21.\\n 13. Royal Australian and New Zealand College of Obstetricians and \\nGynaecologists. RANZCOG statement. Management of postpar -\\ntum hemorrhage. Accessed August 11, 2021. https://ranzc  og.edu.\\nau/RANZC  OG_SITE/media/  RANZC  OG-  MEDIA/  Women  %27s%20\\nHea  lth/State  ment%20and  %20gui delin  es/Clini cal-  Obste trics/  \\nManag  ement  - of- Postp  artum  - Haemo  rrhag  e- (C- Obs-  43)-  Revie  w- \\nJuly-  2017.pdf?ext =.pdf\\n 14. Sri Lanka College of Obstetrician and Gynecologists. SLCOG \\nGuideline on Management of Primary PostPartum Haemorrhage. \\nAccessed August 11, 2021. https://www.slcog.lk/wp- conte  nt/\\nuploa  ds/2021/02/SLCOG  - Guide  line- on- Manag  ement  - of- Prima  ry- \\nPost-  Partu  m- Haemo  rrhag  e- 03.- 2020.pdf\\n 15. Shields LE, Goffman D, Caughey A; Committee on Practice \\nBulletins—  Obstetrics. ACOG practice bulletin: Clinical manage-\\nment guidelines for obstetrician-  gynecologists. Obstet Gynecol . \\n2017;130(4):e168–  e186.TABLE 2 \\u2003Summary of postpartum hemorrhage definitions from high-  quality guidelines around the world\\nGuideline Definition\\nAmerican College of Obstetricians and Gynecologists (2017)\\nDutch Society of Obstetrics and Gynecology (2012)>1000 ml regardless of route of delivery\\nAny blood loss that causes hemodynamic instability\\nFederation of Obstetric and Gynaecological Societies of India (2015)\\nFrench College of Gynaecologists and Obstetricians/French Society of \\nAnesthesiology and Intensive Care (2016)\\nThe Royal Australian and New Zealand College of Obstetricians and \\nGynaecologists (2017)\\nWorld Health Organization (2012)>500 ml regardless of route of delivery\\nSevere PPH > 1000  ml\\nInternational Federation of Gynecology and Obstetrics (2012)\\nSociety of Obstetricians and Gynaecologists of Canada (2018)Vaginal delivery > 500 ml, cesarean delivery > 1000  ml\\nAny blood loss that has the potential to produce \\nhemodynamic instability\\nRoyal College of Obstetricians and Gynaecologists (2016) >500 ml regardless of the route of delivery\\nPPH mild: 500–  1000 ml, moderate: 1000–  2000 ml, severe: \\n>2000  ml\\nGerman Society of Gynecology and Obstetrics/Austrian Society of Obstetrics \\nand Gynecology/Swiss Society of Gynaecology and Obstetrics (2018)Vaginal delivery ≥500 ml or cesarean delivery ≥1000 ml\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 8}), Document(page_content='12\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\n 16. Schlembach D, Helmer H, Henrich W, et al. Peripartum haemor -\\nrhage, diagnosis and therapy. Guideline of the DGGG, OEGGG \\nand SGGG (S2k Level, AWMF Registry No. 015/063, March 2016). \\nGeburtshilfe Frauenheilkd . 2018;78:382–  399.\\n 17. Fawcus S. Alerts for managing postpartum haemorrhage. S Afr Med \\nJ. 2018;108:1013–  1017.\\n 18. Newsome J, Martin JG, Bercu Z, Shah J, Shekhani H, \\nPeters G. Postpartum hemorrhage. Tech Vasc Interv Radiol . \\n2017;20:266–  273.\\n 19. Anderson J, Etches D. Prevention and management of postpartum \\nhemorrhage. Am Fam Physician . 2007;75:875–  882. 20. Oyelese Y, Anant CV. Postpartum hemorrhage: epidemiology, risk \\nfactors, and causes. Clin Obstet Gynecol . 2010;53:147– 156.\\n 21. Sentilhes L, Merlot B, Madar H, Sztark F, Brun S, Deneux-  Tharaux \\nC. Postpartum haemorrhage: prevention and treatment. Expert Rev \\nHematol . 2016;9:1043–  1061.\\n 22. Sheiner E, Sarid L, Levy A, Seidman DS, Hallak M. Obstetric risk fac -\\ntors and outcome of pregnancies complicated with early postpar -\\ntum hemorrhage: a population-  based study. J Matern Fetal Neonatal \\nMed. 2005;18:149–  154.\\n 23. Evensen A, Anderson JM, Fontaine P. Postpartum hemorrhage: \\nprevention and treatment. Am Fam Physician . 2017;95:442–  449.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 9}), Document(page_content=\"\\u2003\\u2002\\u2003|\\u2003 13\\nESCOBAR Et Al.\\n4\\u2003|\\u2003POSTPARTUM HEMORRHAGE BUNDLE \\nCARE\\nMultimodal strategies have been implemented in high-  income coun -\\ntries to control pathologies with high mortality rates such as PPH. \\nThese initiatives that involve multiple intervention points and actors \\nhave been called “bundles” or intervention packages, which consist \\nof the implementation of a group of interventions as well as multi -\\ndisciplinary programs that standardize and comprehensively address \\nthe management of pathologies.1– 6 Bundles represent a selection of \\nexisting guidelines and recommendations in a form that aids system -\\natic implementation and a consistency of practice.\\nThe California Maternal Quality Care Collaborative (CMQCC) \\nWorking Group on obstetrical hemorrhage developed the Improving \\nthe Health Care Response to Obstetric Bleeding Toolkit in 2010 \\nto help obstetric providers, clinical staff, hospitals, and healthcare organizations develop methods within their facility for timely rec -\\nognition and an organized and rapid response to bleeding. In March \\n2015, version 2.0 was updated with the latest evidence-  based \\nchanges.6\\nIn 2015, work groups of the National Partnership for Maternal \\nSafety —  within the Council on Patient Safety in Women's Health \\nCare that represents all major women's healthcare professional or -\\nganizations in the USA —  developed an obstetric hemorrhage safety \\nbundle. The goal of the partnership was the adoption of the safety \\nbundle by every birthing facility. This consensus bundle is organized \\ninto four action domains: readiness; recognition and prevention; re-\\nsponse; and reporting and systems learning. There are 13 key ele -\\nments within these four action domains (Table 3).\\nIn 2017, the World Health Organization (WHO) carried out a \\ntechnical consultation among international maternal health experts \\nto evaluate the development of care bundles for PPH. A total of 730 \\nTABLE 3 \\u2003Obstetric hemorrhage safety bundle action domains from the National Partnership for Maternal Safety, Council on Patient \\nSafety in Women's Healtha\\nDomain Key elements\\nReadiness (Every Unit) 1. Hemorrhage cart with supplies, checklist, and instruction cards for uterine balloon tamponade \\nand compression sutures.\\n2. Immediate access to hemorrhage medications (kit or equivalent).\\n3. A response team to call when help is needed (blood bank, advanced gynecologic surgery, other \\nsupport and tertiary services).\\n4. Massive and emergency-  release transfusion protocols (type-  O negative or uncross-  matched).\\n5. Unit education on protocols, unit-  based drills (with post drill debriefs).\\nRecognition and Prevention (Every Patient) 1. Assessment of hemorrhage risk (prenatal, on admission, and at other appropriate times).\\n2. Measurement of cumulative blood loss (formal and as quantitative as possible).\\n3. Active management of the third stage of labor (department-  wide protocol).\\nResponse (Every Hemorrhage) 1. Uni-  standard, stage-  based obstetric hemorrhage emergency management plan with checklists.\\n2. Support program for patients, families, and staff for all significant hemorrhages.\\nReporting and Systems Learning (Every \\nUnit)1. Establish a culture of huddles for high-  risk patients and post-  event debriefs to identify successes \\nand opportunities.\\n2. Multidisciplinary review of serious hemorrhages for systems issues.\\n3. Outcomes monitoring and process metrics in perinatal quality improvement committee.\\naReproduced from Council on Patient Safety in Women's Health Care.7 © 2015 American College of Obstetricians and Gynecologists. Reproduced \\nwith kind permission.\\nTABLE 4 \\u2003Final care bundles for postpartum hemorrhagea\\nPPH care bundle Components\\nFirst response \\nPPH bundleUterotonic drugs\\nIsotonic crystalloids\\nTranexamic acid\\nUterine massage\\nNotes: Initial fluid resuscitation is performed together with intravenous (IV) administration of uterotonics. If IV uterotonics \\nare not available, fluid resuscitation should be started in parallel with sublingual misoprostol or other parenteral \\nuterotonics. If PPH is in the context of placental retention, the placenta should be extracted, and a single dose of \\nantibiotics should be administered. If lacerations are encountered, they should be repaired.\\nResponse to \\nrefractory \\nPPH bundleCompressive measures (aortic compression or bimanual uterine compression)\\nIntrauterine balloon tamponade\\nNon-  pneumatic antishock garment\\nNotes: A continuing dose of uterotonics (e.g. oxytocin diluted in isotonic crystalloids) and a second dose of tranexamic acid \\nshould be administered during the application of this bundle.\\naReproduced from Althabe et al.8\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 10}), Document(page_content=\"14\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\narticles were reviewed and 430 were used for the construction of \\nthe theoretical framework of the process. The consultation led to \\na definition of two care bundles, which are summarized in Table 4.\\nThe first response PPH bundle must be implemented at both the \\nprimary healthcare and hospital levels. The discussion about the re -\\nsponse to refractory PPH bundle raised some controversy. For the \\nfirst response PPH bundle, the next phase is the development of \\nan implementation strategy, culminating in a model for use at the \\nfacility level in LMICs. For the response to refractory PPH bundle, it \\nis a priority to solve pending controversies, including the operational \\ndefinition of refractory PPH, and to better understand the effective -\\nness of various uterine balloon tamponade (UBT) devices.REFERENCES\\n 1. Einerson BD, Miller ES, Grobman WA. Does a postpartum hemor -\\nrhage patient safety program result in sustained changes in man -\\nagement and outcomes? Am J Obstet Gynecol . 2015;212:140–  144.\\n 2. Shields LE, Wiesner S, Fulton J, Pelletreau B. Comprehensive mater -\\nnal hemorrhage protocols reduce the use of blood products and im -\\nprove patient safety. Am J Obstet Gynecol . 2015;212:272–  280.\\n 3. Council on Patient Safety in Women's Health Care. Maternal safety. \\nAccessed August 25, 2021. https://safeh  ealth  caref  oreve  rywom  \\nan.org/counc  il/patie nt-  safet  y- bundl  es/mater  nal- safet  y- bundl  es/\\n 4. Institute for Healthcare Improvement. Evidence-  based care bun -\\ndles. Accessed November 15, 2020. http://www.ihi.org/Topic  s/\\nBundl  es/Pages/  defau lt.aspx\\n 5. Main EK, Goffman D, Scavone BM, et al National partnership \\nfor maternal safety: consensus bundle on obstetric hemorrhage. \\nObstet Gynecol . 2015;126:155–  162.\\n 6. California Maternal Quality Care Collaborative Improving Health \\nCare Response to Obstetric Hemorrhage. Accessed November 8, \\n2021. https://www.cmqcc.org/resou  rces-  tool-  kits/toolk  its/ob-  \\nhemor  rhage -  toolkit\\n 7. Council on Patient Safety in Women's Health Care. Patient safety \\nbundle: Obstetric hemorrhage. Accessed January 7, 2022. \\nhttps://safeh  ealth  caref  oreve  rywom  an.org/wp-  conte  nt/uploa  \\nds/safe-  healt  h- care-  for- every  - woman  - Obste  tric- Hemor  rhage  \\n- Bundle.pdf\\n 8. Althabe F, Therrien MNS, Pingray V, et al. Postpartum hemorrhage \\ncare bundles to improve adherence to guidelines: a WHO technical \\nconsultation. Int J Gynecol Obstet . 2020;148:290–  299.BOX 1\\u2003FIGO recommends incorporation of the PPH \\nbundle approach in the management of PPH.\\nFIGO considers that the bundle care approach can improve \\npatient outcomes when adherence to all components is high. \\nEvery health system needs to adopt a bundle and there are \\nmany available for use. Place the bundle in every maternity \\nhospital and train to all elements of bundle, from arrival on ob -\\nstetrics service to transfer to higher level of care.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 11}), Document(page_content=\"\\u2003\\u2002\\u2003|\\u2003 15\\nESCOBAR Et Al.\\n5\\u2003|\\u2003SHOCK INDEX EVIDENCE IN \\nPOSTPARTUM HEMORRHAGE EVALUATION \\nAND MANAGEMENT\\nShock refers to a reduction in tissue perfusion, which is insuf -\\nficient to meet the metabolic requirements of tissues and organs. \\nInsufficient blood flow may be clinically identified as the develop -\\nment of one or more of the following: lactic acidosis, altered men -\\ntal status, oliguria, and tachycardia. Vital signs monitoring is key \\nto hemodynamic assessment and prompt intervention.1 In healthy \\npregnant and postpartum women, cardiologic physiologic com -\\npensatory mechanisms prevent changes in vital signs until a large \\nvolume of blood has been lost (usually > 1000 ml). Hence, changes \\nin clinical and vital signs that result from hemorrhage appear late \\nin the process and may not lead to early identification of PPH. \\nThis in turn makes it difficult to establish cutoff points to trigger \\nclinical interventions. Moreover, because traditional vital signs \\nchange late and are less reliable as triggers for clinical actions, \\nother indicators could help to characterize maternal hypovolemia \\ncaused by bleeding.2 Although the use of conventional individual \\nvital signs (pulse and systolic blood pressure) may lack accuracy in \\nthe assessment of hypotension, a simple combination of both may \\ntransform routine clinical parameters into a more accurate indica -\\ntor of hypovolemia, such as the shock index (SI). SI is defined as \\nthe ratio of heart rate to systolic blood pressure.3,4 The SI may im -\\nprove the predictive capability of individual clinical signs, which \\naids early identification of women at risk of hypovolemia as the \\nresult of obstetric causes.5 Moreover, the SI has been proposed \\nas a reliable indicator of adverse maternal outcomes,6 and its val -\\nues have been set to indicate clinical management.7 However, the \\nassociation between shock parameters and advanced treatment \\nmodalities in severe PPH has yet to be reported.\\n5.1\\u2003 |\\u2003 Assessment of circulating blood volume in \\npostpartum hemorrhage\\nThe essential cornerstone of management of PPH involves prompt \\ndiagnosis and rapid replacement of lost blood volume, as well as \\nthe oxygen-  carrying capacity of blood, accompanied by immediate \\nmedical and surgical measures to address the underlying cause(s), \\nand hence prevent more loss. To assess the patient's condition, SI \\nhas been introduced as a simple and clinically effective vital sign.\\nThe SI has been shown to have an inverse linear relation -\\nship with left ventricular stroke work in acute circulatory failure. \\nTherefore, a concurrent reduction of left ventricular stroke work \\n(induced by hemorrhage, trauma, or sepsis) was associated with an \\nelevation of the SI and a deterioration in left ventricular mechanical \\nperformance. Poor left ventricular function or persistent abnormal \\nelevation of the SI after aggressive therapy and hemodynamic sta -\\nbilization was associated with increased mortality in critically ill, \\ntraumatized patients.8 In obstetric and nonobstetric circumstances, \\nthe absence of a significant drop in blood pressure in patients with PPH may mask the actual hypovolemic status due to physiological \\ncompensatory mechanisms.9 For that reason, the SI was the only \\npromising marker that indicated the severity of blood loss.2,5\\nThe SI, together with the rule of 30, are important tools that may \\naid clinicians in an emergency to determine the amount of blood loss \\nand the degree of hemodynamic instability. Before the fall in systolic \\nblood pressure, heart rate rises to compensate for the blood loss, \\nand thus the SI increases. The rule of 30 is an approximated blood \\nloss of 30% of normal (70 ml/kg in adults, 100 ml/kg throughout \\npregnancy), defined by a fall of 30% in hematocrit, a fall of 30% in \\nhemoglobin (approximately 3 g/dl), a fall of 30 mm Hg in systolic \\nblood pressure, and a rise in pulse rate by 30 beats per minute.10 It \\nhas been shown that an SI ≥0.9 is associated with increased mortal -\\nity and an SI >1 increases the likelihood of blood transfusion.11,12 To \\ndate, standard obstetric SI has been defined as 0.7–  0.9 compared \\nwith 0.5–  0.7 for the nonpregnant population, taking into account \\nthat the hemodynamic changes of pregnancy may delay the recogni -\\ntion of hypovolemia.5 If intravascular volume depletion is suspected, \\na rapid clinical assessment is required because the patient's clinical \\ncondition can deteriorate, leading to the development of hemor -\\nrhagic shock rapidly. Proper medical record-  taking skills may high -\\nlight symptoms associated with shock such as pain and overt blood \\nloss, as well as general malaise, anxiety, and dyspnea. Notably, in set -\\ntings where few PPH treatment options exist, and in cases of home \\ndeliveries, diagnosis and treatment or referral must occur even ear -\\nlier than in hospital settings to improve outcomes. For that reason, \\nSI may be a valuable threshold in LMICs, where mortality is highest \\nand is often related to delays in complication recognition, transpor -\\ntation, and level of care at the facility.2 A threshold of SI ≥0.9  should \\nbe tested to alert community healthcare providers of the need for \\nurgent transfer.13\\nREFERENCES\\n 1. Schorn MN. Measurement of blood loss: review of the literature. J \\nMidwifery Womens Health . 2010;55:20–  27.\\n 2. Borovac-  Pinheiro A, Pacagnella RC, Cecatti JG, et al Postpartum \\nhemorrhage: new insights for definition and diagnosis. Am J Obstet \\nGynecol . 2018;219:162–  168.\\n 3. Arulkumaran S, Karoshi M, Keith LG, Lalonde AB, B-  Lynch C. A com -\\nprehensive textbook of postpartum hemorrhage: an essential clinical \\nreference for effective management . Sapiens Publishing; 2012.\\n 4. Rady MY, Nightingale P, Little RA, Edwards JD. Shock index: \\na re-  evaluation in acute circulatory failure. Resuscitation . \\n1992;23:227–  234.\\n 5. Pacagnella RC, Souza JP, Durocher J, et al A systematic review of \\nthe relationship between blood loss and clinical signs. PLoS One . \\n2013;8:e57594.BOX 2\\u2003FIGO recommends use of the shock index in \\nthe diagnosis and management of PPH.\\nFIGO considers that the shock index can be a marker of the \\nseverity of PPH and can alert teams to hemodynamic instabil -\\nity when its value is greater than 0.9.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 12}), Document(page_content='16\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\n 6. El Ayadi AM, Nathan HL, Seed PT, et al Vital sign prediction of ad -\\nverse maternal outcomes in women with hypovolemic shock: the \\nrole of shock index. PLoS One . 2016;11:e0148729.\\n 7. Le Bas A, Chandraharan E, Addei A, Arulkumaran S. Use of the “ob -\\nstetric shock index” as an adjunct in identifying significant blood \\nloss in patients with massive postpartum hemorrhage. Int J Gynecol \\nObstet . 2014;124:253–  255.\\n 8. Rady MY, Smithline HA, Blake H, Nowak R, Rivers E. A compar -\\nison of the shock index and conventional vital signs to identify \\nacute, critical illness in the emergency department. Ann Emerg Med . \\n1994;24:685–  690.\\n 9. Troiano NH, Witcher PM, Baird SM. High-  Risk & Critical Care \\nObstetrics . Lippincott Williams & Wilkins; 2018. 10. Chandraharan E, Arulkumaran S. Obstetric and Intrapartum \\nEmergencies: A Practical Guide to Management . Cambridge University \\nPress; 2012.\\n 11. Vandromme MJ, Griffin RL, Kerby JD, McGwin G Jr, Rue LW 3rd, \\nWeinberg JA. Identifying risk for massive transfusion in the rela -\\ntively normotensive patient: utility of the prehospital shock index. J \\nTrauma . 2011;70(2):384–  390; discussion 388–  90.\\n 12. Cannon CM, Braxton CC, Kling-  Smith M, Mahnken JD, Carlton E, \\nMoncure M. Utility of the shock index in predicting mortality in \\ntraumatically injured patients. J Trauma . 2009;67:1426–  1430.\\n 13. Nathan HL, El Ayadi A, Hezelgrave NL, et al Shock index: an ef -\\nfective predictor of outcome in postpartum haemorrhage? BJOG . \\n2015;122:268–  275.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 13}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 17\\nESCOBAR Et Al.\\n6\\u2003|\\u2003REVIEW OF GUIDELINES AROUND \\nTHE WORLD\\nGuidelines are defined as systematically developed statements \\nthat assist practitioners to take decisions about appropriate \\nhealth care in specific clinical circumstances.1 Over the past dec -\\nades, many national and international PPH guidelines have been \\ndeveloped and become part of obstetric clinical practice around \\nthe world. PPH guidelines usually address similar topics (e.g. di -\\nagnosis, prevention, and treatment of PPH) but may differ in their \\nrecommendations.2– 4 These differences are because most of the \\nrecommendations are based on observational studies, clinical \\njudgment, and expert opinion. There are few randomized con -\\ntrolled trials available to produce strong recommendations for the \\nmanagement of PPH due to the emergency of the condition that \\nhinders this type of study. In the absence of randomized trials, \\nguidelines gather the best available evidence. In addition, popula -\\ntion characteristics, cultural aspects, resources availability, as well \\nas frequency and timing of updates may influence the guidelines’ \\ncontents and justify some disparities.1– 4\\nREFERENCES\\n 1. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical \\nguidelines: potential benefits, limitations, and harms of clinical \\nguidelines. BMJ . 1999;318:527–  530.\\n 2. Sentilhes L, Goffinet F, Vayssière C, Deneux-  Tharaux C. Comparison \\nof postpartum haemorrhage guidelines: discrepancies underline \\nour lack of knowledge. BJOG . 2017;124:718–  722.\\n 3. Bohlmann MK, Rath W. Medical prevention and treatment of post -\\npartum hemorrhage: a comparison of different guidelines. Arch \\nGynecol Obstet . 2014;289:555–  567.\\n 4. Dahlke JD, Mendez-  Figueroa H, Maggio L, et al Prevention and \\nmanagement of postpartum hemorrhage: a comparison of 4 na -\\ntional guidelines. Am J Obstet Gynecol . 2015;213(1):76.e1–  76.e10.\\n6.1\\u2003 |\\u2003 Guidelines that address the prevention of \\npostpartum hemorrhage\\nActive management of third stage of labor is frequently discussed \\nin guidelines.1– 7 There is consensus that all women should receive \\nuterotonics after delivery as it has proven to reduce PPH rates. \\nOxytocin has been cited as the drug of choice by most guidelines, \\nbut its dosages and route of administration vary largely, especially \\nwhen considering mode of delivery.1– 5,7– 10 In 2012, FIGO established \\nrecommendations for the prevention of PPH11 and in 2018 WHO \\nupdated its recommendation for pharmacological PPH prevention \\nand reinforced the use of oxytocin (10 IU intramuscularly or intra -\\nvenously) as the drug of choice.12 WHO also recommends the use \\nof carbetocin (if cost-  effective), ergot alkaloids (alone or combined \\nif there are no contraindications), or oral misoprostol in settings \\nwhere oxytocin is not available or its quality cannot be guaranteed. \\nMisoprostol is also recommended when the use of other injectable \\nuterotonics is not possible due to unavailability or contraindication \\nto use such as hypertension in the context of ergometrine.12,13 The Society of Obstetricians and Gynaecologists of Canada (SOGC) has \\nupdated its publication and reinforced the use of carbetocin as a \\nfirst-  line uterotonic for prevention at cesarean delivery or vaginal \\ndelivery with one risk factor.6 The German/Austrian/Swiss guideline \\nmentions that prophylaxis during cesarean delivery can consist of \\nadministering either oxytocin or carbetocin.5 Other prophylactic \\nstrategies have been proposed in guidelines, but many had no great \\nconsensus or no clear benefits.1– 7 Table 5 summarizes various PPH \\nprevention strategies described by different societies worldwide.\\nREFERENCES\\n 1. Prevention and management of postpartum haemorrhage: green- \\ntop guideline no. 52. BJOG . 2017;124:e106–  e149.\\n 2. Sentilhes L, Vayssière C, Deneux-  Tharaux C, et al Postpartum hem -\\norrhage: guidelines for clinical practice from the French College of \\nGynaecologists and Obstetricians (CNGOF): in collaboration with \\nthe French Society of Anesthesiology and Intensive Care (SFAR). \\nEur J Obstet Gynecol Reprod Biol . 2016;198:12– 21.\\n 3. World Health Organization. WHO Recommendations for the \\nPrevention and Treatment of Postpartum Haemorrhage. Accessed \\nAugust 11, 2021. https://www.who.int/repro  ducti  vehea  lth/publi  \\ncatio  ns/mater  nal_perin  atal_healt  h/97892  41548  502/en/\\n 4. Committee on Practice Bulletins-  Obstetrics. Practice bulletin no. \\n183: postpartum hemorrhage. Obstet Gynecol . 2017;130:e168–  e186.\\n 5. Schlembach D, Helmer H, Henrich W, et al. Peripartum haemor -\\nrhage, diagnosis and therapy. Guideline of the DGGG, OEGGG \\nand SGGG (S2k Level, AWMF Registry No. 015/063, March 2016). \\nGeburtshilfe Frauenheilkd . 2018;78:382–  399.\\n 6. Leduc D, Senikas V, Lalonde AB. No 235-  active management of \\nthe third stage of labour: prevention and treatment of postpartum \\nhemorrhage. J Obstet Gynaecol Can . 2018;40:e841– e855.\\n 7. Organization PAH. Guidelines for the prevention, diagnosis and treat -\\nment of obstetric hemorrhage  [in Portuguese]. PAHO; 2018.\\n 8. Fawcus S. Alerts for managing postpartum haemorrhage. S Afr Med \\nJ. 2018;108:1013–  1017.\\n 9. Sri Lanka College of Obstetrician and Gynecologists. SLCOG \\nGuideline on Management of Primary PostPartum Haemorrhage. \\nAccessed August 11, 2021. https://www.slcog.lk/wp- conte  nt/\\nuploa  ds/2021/02/SLCOG  - Guide  line-  on- Manag  ement  - of- Prima  ry- \\nPost-  Partu  m- Haemo  rrhag  e- 03.- 2020.pdf\\n 10. Fuchther C, Ortiz EI, Escobar MF, Lizaola H. Hemorragia Postparto: \\nen donde estamos y hacia donde vamos. Federación Latinoamericna \\nde Sociedades de Ginecologia y Obstetricia. Accessed August 11, BOX 3\\u2003FIGO recommends use of oxytocin (10 IM/IV) \\nfor prevention of PPH for all births as a first-  line \\nuterotonic agent.\\n• If oxytocin is not available or its quality is in doubt, other \\noptions include carbetocin, misoprostol, or ergot alkaloids.\\n• Controlled cord traction is recommended for vaginal births \\nin settings where skilled birth attendants are available.\\n• Early cord clamping ( <1 min after birth) is not recommended \\nunless the neonate needs immediate resuscitation.\\n• Postpartum assessment of uterine tonus is recommended \\nfor all women.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 14}), Document(page_content='18\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\nTABLE 5 \\u2003Summary of postpartum hemorrhage prevention strategies from high-  quality guidelines around the world\\nGuideline/year of \\npublicationActive \\nmanagement of \\nthird stage of laborPharmacological prevention\\nOther considerations1st line \\nuterotonic Oxytocin Alkaloid ergot Misoprostol Carbetocin TXA\\nFIGO 2012 Recommended:\\nAdministration of \\nuterotonics \\nafter deliveryOxytocin 10 IU/ml IM or 5 IU slow \\nIV push within the \\nfirst minute after \\ndeliveryErgometrine or \\nmethylergometrine \\n0.2 mg IM, if oxytocin is \\nnot available or cannot \\nbe safety used600 μ g orally within \\nthe first minute \\nafter delivery, if \\noxytocin is not \\navailable or cannot \\nbe safety usedNot mentioned Not mentioned Controlled cord traction \\n(only when a skilled \\nattendant is present \\nat delivery), uterine \\nmassage after delivery\\nFOGSI 2015 Recommended:\\nUterotonic agent \\nat the time \\nof birth, late \\ncord clamp and \\ncontrolled cord \\ntractionOxytocin Mentioned 10–  40 IU; \\nIV or IM or umbilical \\ncord vein, IMM or \\nintramyometrialIf oxytocin is not available: \\nErgometrine 0.25 mg IM \\nor IMM400–  600 μg (oral, \\nper rectum, per \\nvagina or rectal \\nroute) can be \\nused if injectable \\nuterotonics are not \\navailableNot mentioned Not mentioned Nipple stimulation or early \\nbreast feeding\\nRCOG 2016 Recommended:\\nRoutine \\nadministration \\nof uterotonics \\nafter deliveryOxytocin Vaginal birth: 10 IU IM\\nCesarean: 5 IU IV, slowlyErgometrine–  oxytocin may \\nbe used in the absence of \\nhypertension.\\nDoes not mention dosagesMentioned, \\nwithout dosage \\nrecommendationsMentioned, \\nwithout dosage \\nrecommendationsConsider TXA: \\n0.5–  1.0 g IV, \\nplus oxytocin, \\nat cesarean \\nin women at \\nincreased riskPrefer deferred cord \\nclamping (RCOG 2015)\\nUterine massage is of no \\nbenefit for prevention\\nCNGOF/SFAR 2016 Recommended:\\nAdministration of \\nuterotonics \\nafter deliveryOxytocin 5 or 10 IU IM or IV slow\\nAt cesarean: Routine \\nmaintenance can be \\nperformed as long as \\nit does not exceed \\n10 IU/hNot mentioned Not mentioned Mentioned (in the \\nabsence of a no \\ninferiority trial, \\noxytocin remains \\nthe reference for \\npreventing PPH \\nafter cesarean \\ndeliveries)TXA must not be \\nused routinely \\nfor PPH \\npreventionRoutine cord drainage, \\ncontrolled cord traction, \\nuterine massage, \\nroutine voiding after \\ndelivery, early or \\nlate cord clamping, \\nbreastfeeding and any \\nparticular position are \\nnot recommended for \\nPPH prevention\\nACOG 2017 Recommended:\\nRoutine \\nadministration \\nof uterotonics \\nafter deliveryOxytocin Mentioned 10 IU IV \\nor IMMentioned in association with oxytocin, but did not \\ndiscuss dosages and their sole useNot mentioned Data is insufficient \\nto recommend \\nitNipple stimulation or \\nbreastfeeding has no \\neffect on prevention.\\nPrefer delayed cord \\nclamping (ACOG \\n2017–  2)\\nRANZCOG 2017 Recommended:\\nUterotonics and \\nassisted \\nplacenta \\ndeliveryOxytocin Recommended, but do \\nnot mention dosagesNot mentioned Used when oxytocin \\nis not available. \\nDoes not discuss \\ndosagesNot mentioned Not mentioned Identify risk factors. \\nDetermine placental \\nlocation by antenatal \\nultrasound\\nWHO 2018* Recommended: Oxytocin 10 IU IM or IV for all \\nbirthsIn settings where oxytocin is unavailable, or its quality is not guaranteed: ergots \\nalone or associated; or misoprostol; or carbetocin can be usedNot mentioned Injectable prostaglandins \\nare not recommended\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 15}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 19\\nESCOBAR Et Al.\\nGuideline/year of \\npublicationActive \\nmanagement of \\nthird stage of laborPharmacological prevention\\nOther considerations1st line \\nuterotonic Oxytocin Alkaloid ergot Misoprostol Carbetocin TXA\\n*(Supersedes previous \\n2012 WHO \\nguideline \\nrecommendations \\nof uterotonics for \\nthe prevention of \\nPHH)WHO guideline \\n(2012): \\nUterotonics, \\nlate cord clamp \\nand controlled \\ncord traction \\nif skilled \\nattendantRegardless of route of \\ndeliveryErgometrine or M-  Ergometrine: \\n0.2 mg IM or IV or \\nCombination: oxytocin \\n5 IU+Ergometrine 0.5 mg \\nIM (after hypertension is \\nexcluded prior to its use)Misoprostol 400  μg \\nor 600 μ g, \\norally.\\nIf injectable \\nuterotonics are \\nnot feasibleCarbetocin: 100 μ g IM \\nor IV.\\nWhere its cost is \\ncomparable to \\nother effective \\nuterotonicsRecommended for the \\nprevention of PPH. \\n(Carboprost or \\nsulprostone)\\nSOGC 2018 Recommended: \\nUterotonics, \\nlate cord clamp \\nand controlled \\ncord tractionVaginal low risk: \\nOxytocin\\nCesarean:\\nCarbetocinVaginal: 10 IU IM or \\noxytocin, 20–  40 IU \\nin 1000 ml, 150 ml \\nper hour.Ergonovine, 0.2 mg IM\\nWhen oxytocin is not available600–  800 μg (oral, \\nsublingual, or \\nrectal route)\\nWhen oxytocin is \\nnot availableCarbetocin, 100 μ g \\ngiven as an IV bolus \\nover 1 minNot mentioned Suggest considering \\ncarbetocin for high-  risk \\nwomen delivering \\nvaginally\\nDGGG/OEGGG/SSGO \\n2018Recommended: \\nOxytocin after \\nbirthVaginal: \\nOxytocin\\nCesarean: \\nOxytocin or \\ncarbetocin3– 5 IU slow IV Not mentioned Not mentioned 100 µg by short infusion \\nor slow IV infusionNot mentioned Immediate cord clamping \\nand controlled cord \\ntraction have no impact \\non reducing PPH and \\nshould not be carried \\nout\\nFLASOG 2018 Recommended Oxytocin 10 IU IM or IV Not mentioned 600 ug oral when \\noxytocin is not \\navailableNot Mentioned Not mentioned Controlled cord traction, \\n(only when a skilled \\nattendant is present \\nat delivery), uterine \\nmassage after delivery\\nAbbreviations: TXA, tranexamic acid; FIGO, International Federation of Gynecology and Obstetrics; IU, international unit; IM, intramuscular; IV, intravenous; FOGSI, Federation of Obstetric and \\nGynaecological Societies of India; IMM, intramammary; RCOG, Royal College of Obstetricians and Gynaecologists; CNGOF/SFAR, College of Gynaecologists and Obstetricians/French Society of \\nAnesthesiology and Intensive Care; ACOG, American College of Obstetricians and Gynecologists; RANZCOG, Royal Australian and New Zealand College of Obstetricians and Gynaecologists; WHO, World \\nHealth Organization; SOGC, Society of Obstetricians and Gynaecologists of Canada; DGGG/OEGGG/SSGO, German Society of Gynecology and Obstetrics/Austrian Society of Obstetrics and Gynecology/\\nSwiss Society of Gynaecology and Obstetrics, FLASOG, Federación Latinoamericana de Sociedades de Obstetricia y Ginecología.TABLE 5 \\u2003(Continued)\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 16}), Document(page_content='20\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\n2021. https://www.flasog.org/stati  c/libro s/Hemor  ragia  - Postp  ar to-  \\n17OCT UBRE.pdf\\n 11. Lalonde A; International Federation of Gynecology and Obstetrics. \\nPrevention and treatment of postpartum hemorrhage in low- \\nresource settings. Int J Gynaecol Obstet . 2012;117(2):108–  118.\\n 12. World Health Organization. WHO recommendations: Uterotonics \\nfor the prevention of postpartum haemorrhage. Accessed August \\n25, 2021. https://apps.who.int/iris/bitst  ream/handl  e/10665/  \\n27727  6/97892  41550  420-  eng.pdf?ua =1\\n 13. Althabe F, Therrien MNS, Pingray V, et al. Postpartum hemorrhage \\ncare bundles to improve adherence to guidelines: A WHO technical \\nconsultation. Int J Gynecol Obstet . 2020;148:290–  299.\\n6.2\\u2003 |\\u2003 Guidelines that address the treatment of \\npostpartum hemorrhage\\nPPH guidelines frequently recommend a multidisciplinary approach \\nfor reaching effective early control of bleeding. Treatment should be \\ndirected to the specific cause of PPH (uterine atony, genital trauma, \\nretained placenta, and/or coagulopathy) and therapeutic steps \\nshould move from the less invasive method to the more complex and \\nradical approach. A set of initial measures also seems to be consen -\\nsual in most guidelines and consist of maintenance of two large IV \\nlines, supplementation of oxygen, strict monitoring of women, crys -\\ntalloids infusion, and measures to avoid hypothermia and evaluate \\nthe PPH cause.1– 9\\nIf atony is the etiology, most guidelines suggest perform -\\ning temporary mechanical measures, such as uterine massage \\nor uterine bimanual compression, with concurrent pharmaco -\\nlogical treatment.1– 10 Uterotonics are considered the first-  line \\ntreatment for uterine atony. Intravenous oxytocin is usually the \\npreferred drug and route of administration, but its dosage varies \\nwidely. When oxytocin fails to control PPH, guidelines recom -\\nmend the use of an additional drug, such as ergot alkaloids, in -\\njectable prostaglandins, or misoprostol.1– 4,6–  8,10 SOGC mentions \\ncarbetocin as a uterotonic available for treatment,5 and the \\nGerman/Austrian/Swiss guidelines highlight that the use of car -\\nbetocin to treat PPH is currently not sufficiently investigated4 \\n(Table  6).\\nSince publication of the World Maternal Antifibrolytic (WOMAN) \\ntrial,11 tranexamic acid (TXA), an antifibrinolytic drug, has been in -\\ncorporated into PPH guidelines around the world.4,6–  10,12,13 WHO \\nhas updated this topic and recommends the use of TXA, as soon as \\npossible, within the first 3 h from birth, at a dose of 1 g intravenously, \\nregardless of the route of birth.12,13 However, some guidelines do \\nnot cite it5 or do not add it in a definitive manner because their last \\nupdate occurred before the WOMAN trial results.1,2 Another drug \\nthat has been discussed in many guidelines is recombinant activated \\nfactor VII for massive PPH; however, there is no consensus about \\nits use.1– 6\\nWhen pharmacological treatment fails in controlling hemor -\\nrhage, guidelines usually recommend some mechanical, radiologi -\\ncal, and more conservative surgical approaches before performing \\nhysterectomy. The available guidelines are summarized in Table 6. The most cited ones are uterine balloon tamponade (UBT), uterine \\ncompressive sutures (UCS), pelvic vascular ligation (PVL), and embo -\\nlization.1– 7,10 Uterine packing with gauze is also mentioned in some \\nguidelines, but its use is controversial.3,5 ACOG mentions the use of \\na gauze soaked with thrombin.6\\nGerman/Austrian/Swiss guidelines cite the use of intrauter -\\nine packing with a gauze coated with a hemostatic agent.4 Due \\nto the lack of evidence, guidelines do not necessarily recommend \\nthese conservative approaches in a well-  defined, step-  wise pro -\\ngression, and their utilization depends mainly on the availability \\nof resources, professional familiarity with technique, and clinical \\ncircumstances.10\\nUBT is typically indicated as the treatment of choice when uter -\\nine atony is refractory to uterotonics after vaginal delivery as it is \\nless invasive than the other procedures.1– 3,6–  9 This should be con -\\nsidered after ruling out retained products of conception, ruptured \\nuterus, or vaginal or cervical laceration as a contributing factor. If \\nUBT fails to control bleeding in these cases, invasive treatments by \\narterial embolization or, most commonly, by surgical approaches are \\nrecommended (Table 7). UCS and/or PVL are recommended to avoid \\nhysterectomy when laparotomy is performed. The most mentioned \\nUCS techniques in guidelines are B- Lynch, Hayman, and/or Cho su -\\ntures, while the most cited PVL techniques are bilateral uterine and/\\nor utero-  ovarian vessel ligations and, less frequently, hypogastric \\nligature.1– 10 PVL and UCS can also be used together.\\nEmbolization is also cited as a conservative therapeutic strat -\\negy; however, it is most often indicated in places where spe -\\ncialized equipment and professionals are available in a timely \\nmanner.1– 5,7,10 Therefore, these conditions may limit its use in \\nacute bleedings.\\nIf bleeding is severe, especially in low-  resource settings, some \\nguidelines recommend the use of temporizing measures such as \\naortic compression and, more recently, the nonpneumatic antishock \\ngarment (NASG), to reduce blood loss until appropriate care is avail -\\nable or while awaiting transfer to a higher-  level facility.3,7,14,15 NASG \\nhas been recommended by WHO and FIGO for postpartum women \\nwith severe hemorrhage showing signs of shock or hemodynamic \\ninstability at all levels of care, especially at the primary healthcare \\nlevel or if transport to a higher facility is necessary.3,14,15\\nRegarding hysterectomy, it is usually recommended when other \\nprocedures have failed to control massive bleeding or when they \\nwere not indicated. Guidelines highlight that hysterectomy should \\nbe performed “sooner rather than later,” before the patient devel -\\nops coagulopathy.1– 7,9,10 Recently, damage control surgery (intra- \\nabdominal or pelvic packing) has been mentioned in some PPH \\nguidelines as an approach for critically ill patients with persistent \\nbleeding after hysterectomy.4,7\\nFinally, many guidelines also address statements for the manage -\\nment of genital tract trauma (especially uterine inversion and uterine \\nrupture), coagulopathy disorders, and retained placenta in obstetric \\npatients. Because of the high maternal morbidity and mortality re -\\nlated to the placenta accreta spectrum and its relation to the high \\nrates of cesarean deliveries in many countries around the world, \\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 17}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 21\\nESCOBAR Et Al.\\nTABLE 6 \\u2003Summary of pharmacological treatment from high-  quality guidelines around the world\\nGuideline/\\nyear of \\npublicationPharmacological treatment\\n1st line \\nuterotonic Oxytocin Ergot alkaloids Misoprostol Injectable prostaglandin TXA Carbetocin\\nFIGO 2012 Oxytocin 10 IU IM\\nor\\n20– 40 IU in 1 L of normal saline \\nat 60 drops per minute\\nContinue oxytocin infusion \\n(20 IU in 1 L of IV fluid at \\n40 drops per minute) until \\nhemorrhage stopsErgometrine or \\nmethylergometrine \\n(used if oxytocin is \\nnot available or if \\nbleeding continues \\ndespite having used \\noxytocin): 0.2 mg IM \\nor can be given slowly \\nIV, repeated every \\n2– 4 h (maximum of 5 \\ndoses)If oxytocin is not \\navailable or \\nadministration is \\nnot feasible):\\nSingle dose of 800 μ g \\nsublingually \\n(4×200 μ g tablets)Carboprost (should be \\noffered as the third \\nline of treatment): \\n0.25 mg IM Q15 min \\n(maximum 2  mg)Not mentioned Carbetocin \\nrecommended \\nas a second- \\nline treatment: \\n100 μg IM or \\nIV over 1 min\\nWHO 2012 Oxytocin Does not specify Ergometrine or oxytocin- \\nergometrine if IV \\noxytocin fails or if it is \\nnot available. Dosages \\nnot specified800 μ g sublingual \\nif IV oxytocin \\nfails or if it is not \\navailableDoes not specify Use in all cases of PPH, \\nregardless of the \\ncause. Used as soon \\nas possible. Dose: \\n1 g IV, over 10 min, \\nwithin 3 h of birth, \\nwith a second dose \\nof 1 g IV if bleeding \\ncontinues after 30 min \\nor restart within 24 h \\nof completing the first \\ndose\\nFOGSI 2015 Oxytocin 10– 40 IU in 1 L of normal saline Methylergonovine 0.2  mg \\nIM800–  1000  μg \\nrectally;\\n200 μ g orally \\nplus 400 μ g \\nsublingually;\\nor\\n200 μ g orally plus \\n400 μ g rectally250 μ g IM every 15–  90   \\nmin, as needed, up to \\na total dose of 2 mgNot mentioned Not mentioned\\nRCOG 2016 Oxytocin \\n(preferred \\ninitially)Oxytocin 5 IU, by slow IV \\ninjection (may have repeat \\ndose); oxytocin infusion \\n(40 IU in 500 ml isotonic \\ncrystalloids at 125 ml/h) \\nunless fluid restriction is \\nnecessaryErgometrine 0.5 mg, \\nslow IV or IM \\n(contraindicated \\nin women with \\nhypertension)800 μ g sublingual Carboprost 0.25 mg IM, \\nrepeated at intervals \\nof not less than \\n15 min to a maximum \\nof 8 doses (use with \\ncaution in women \\nwith asthma)Consider TXA 1 g IV\\n(Continues)\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 18}), Document(page_content=\"22\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\nGuideline/\\nyear of \\npublicationPharmacological treatment\\n1st line \\nuterotonic Oxytocin Ergot alkaloids Misoprostol Injectable prostaglandin TXA Carbetocin\\nACOG 2017 Healthcare \\nprovider's \\ndiscretion10– 40 IU per 500–  1000 ml as \\ncontinuous infusion (IV) or \\n10 IU IMMethylergonovine 0.2  mg \\nIM, every 2–  4 h.\\nContraindicated in \\nhypertension600–  100 μg, oral, \\nsublingual, or \\nrectalCarboprost 0.25 mg IM, \\nevery 15–  90 min, \\n8 doses maximum \\n(can be used as \\nintramyometrial).\\nContraindicated in \\nasthmaShould be considered \\nwhen initial medical \\ntherapy fails. Earlier \\nuse is likely to be \\nsuperior to delayed \\ntreatment\\nCNGOF/SFA \\nR 2016Oxytocin 5– 10 IU slow IV or IM followed \\nby 5–  10 IU/h, IV, for 2 h. \\nCumulative dose must not \\nexceed 40 IU (IM route is only \\nan option for vaginal birth)Not mentioned It is not \\nrecommended \\nas a second-  line \\ntreatmentSulprostone within \\n30 min, if oxytocin \\nfails1 g, renewable once \\nif ineffective the \\nfirst time, limited to \\ncases of sulprostone- \\nresistant PPH\\nRANZCOG \\n2017Does not \\nclearly \\nspecify5 IU by slow IV injection and \\n40 IU in an IV infusion over \\n4 hErgometrine 0.25 mg \\nby slow IV or IM, \\nrepeated if necessary, \\nevery 5 min up to a \\nmaximum of 1 mg; \\nin the absence of \\ncontraindicationsUp to 1000 μ g \\nrectallyCarboprost 0.25 mg IM, \\nrepeat as required \\nat intervals of not \\nless than 15 min \\nup to 8 doses \\n(maximum 2 mg); \\nor intramyometrial \\ninjection of \\n0.5 mg, under the \\nresponsibility of the \\nadministering clinician \\nContraindicated if \\nsignificant history of \\nasthmaDose: 1 g IV, with a \\nclinical diagnosis \\nof PPH. The dose \\nis repeated after \\n30 min if bleeding was \\npersistent\\nSOGC 2018 Does not \\nclearly \\nspecify10 IU IM (consider ability of the \\nmedication to reach a uterus \\nwith poor tissue perfusion); \\n5 IU IV push; 20–  40 IU in \\n250 ml of normal saline, \\ninfused IV at 500–  1000 ml/hErgometrine 0.25 mg IM \\nor IV, can be repeated \\nevery 2 h400–  800 μg; onset \\nof effects is \\nfaster with oral \\nor sublingual than \\nrectally\\n800–  1000  μg; effects \\nare longer lasting \\nwith rectal than \\nwith oralCarboprost 0.25 mg IM \\nor intramyometrially; \\ncan be repeated every \\n15 min, to a maximum \\nof 2 mg (8 doses)\\nAsthma is a relative \\ncontraindication\\nCarbetocin: 100 µ g IM or \\nIV over 1 minNot mentioned Carbetocin \\nrecommendedTABLE 6 \\u2003(Continued)\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 19}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 23\\nESCOBAR Et Al.\\nGuideline/\\nyear of \\npublicationPharmacological treatment\\n1st line \\nuterotonic Oxytocin Ergot alkaloids Misoprostol Injectable prostaglandin TXA Carbetocin\\nGerman/\\nAustrian/ \\nSwiss \\n2018Oxytocin 3\\u200a– – 5 IU in 10 ml of NaCl 0.9% \\nslow IV bolus. If necessary, \\nit is followed by 10\\u200a– \\u200a40 IU \\noxytocin in 500-  1000mL \\nsaline as a continuous \\ninfusion\\nMaximum of 6 IU undiluted \\noxytocin can be administered \\nIV, slowly. Oxytocin IM only if \\nnecessaryNot recommended \\nroutinely. If used, \\ncaution with adverse \\neffects.\\nMethylergometrine \\nshould not be used \\nas IV bolus. Does not \\nmention dosagesIf first-  line \\nuterotonics are \\nnot effective: \\n800–  1000  μg \\nrectally or 600 μ g \\norally\\nAfter administration \\nof oxytocin may \\nbe consideredIf first-  line uterotonics \\nare ineffective. \\nOption: sulprostone \\n500 μ g in 500 ml IV \\n(pump). Initial dose: \\n100–  500 ml/h.\\nMaintenance: \\n100 ml/h. Maximum \\n1000  μg/10 h or \\n1500 μ g daily. \\nIntramyometrial \\napplication is \\ncontraindicatedEarly use if required.\\n1– 2 g (15\\u200a–  \\u200a30 mg/kg), \\nto be repeated as \\nneededCarbetocin not \\nrecommended\\nFLASOG \\n2018Oxytocin 40 IU in 500 ml crystalloids at \\n60 ml per hour. Dose from \\n80– 160 thousand units per \\nminuteMethylergonovine \\n0.2 mg IM, repeat \\nif necessary, after \\n20 min and then \\nevery 4 h up to a \\nmaximum of 5 doses800 ug sublingual or \\nrectal single doseNot mentioned 1 g IV, the same dose \\ncan be repeated after \\n30 min if bleeding \\npersistsNot mentioned\\nAbbreviations: TXA, tranexamic acid; FIGO, International Federation of Gynecology and Obstetrics; IU, international unit; IM, intramuscular; IV, intravenous; WHO, World Health Organization; FOGSI, \\nFederation of Obstetric and Gynaecological Societies of India; RCOG, Royal College of Obstetricians and Gynaecologists; ACOG, American College of Obstetricians and Gynecologists; CNGOF/\\nSFAR, College of Gynaecologists and Obstetricians/French Society of Anesthesiology and Intensive Care; RANZCOG, Royal Australian and New Zealand College of Obstetricians and Gynaecologists; \\nSOGC, Society of Obstetricians and Gynaecologists of Canada; DGGG/OEGGG/SSGO, German Society of Gynecology and Obstetrics/Austrian Society of Obstetrics and Gynecology/Swiss Society of \\nGynaecology and Obstetrics, FLASOG, Federación Latinoamericana de Sociedades de Obstetricia y Ginecología.TABLE 6 \\u2003(Continued)\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 20}), Document(page_content='24\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\nTABLE 7 \\u2003Summary of postpartum hemorrhage mechanical, surgical, and radiological treatment from high-  quality guidelines around the world\\nGuideline/\\nyear of \\npublicationMechanical, radiological, and surgical treatments\\nTamponade technique Compressive uterine sutures Vessel ligation Embolization Hysterectomy NASG Other techniques\\nFIGO 2012 Bimanual compression of \\nthe uterus (external \\nor internal). IBT \\nrecommendedB- Lynch or Cho sutures should \\nbe tried first if bleeding does \\nnot stop despite treatment \\nwith uterotonics or other \\nconservative interventionsUterine, utero- ovarian, \\nand hypogastric vessel \\nligation may be tried \\nafter compression \\nsutureRecommended In case life-  threatening \\nbleeding continues \\neven after ligationRecommended as \\na temporizing \\nmeasureAortic compression\\nWHO 2012 Bimanual uterine compression: \\ntemporizing measure for \\natony at vaginal delivery.\\nIBT: if uterotonics fail \\nor are not available; \\nUterine packing is not \\nrecommendedCompression sutures may \\nbe attempted as a first \\nconservative surgical \\napproach for atonyUterine, utero- ovarian, \\nand hypogastric vessel \\nligation may be tried \\nafter compression \\nsutureRecommended as a \\ntreatment for PPH \\ndue to uterine atonyWhen life-  threatening \\nbleeding continues \\neven after ligation, \\nsubtotal or totalRecommended as \\na temporizing \\nmeasureUterine massage. External \\naortic compression as a \\ntemporizing measure\\nRCOG 2016 IBT: recommended as first-  line \\n“surgical” interventionB- Lynch, Hayman Stepwise uterine \\ndevascularization; \\nBilateral internal iliac \\nligationRecommended, even \\nafter hysterectomySooner rather than later (to \\ndiscuss with a second \\nexperienced clinician \\nif feasible) Technique: \\nsubtotal\\nis preferredNot mentioned Compression of the aorta\\nRub up the uterine fundus\\nFOGSI 2015 Bimanual compression–  hand \\nin vagina elevating uterus \\nstretches uterine arteryB- Lynch, Hayman, Cho suture Stepwise devascularization: \\nunilateral or bilateral; \\nlow uterine vessel \\nligation or bilateral \\novarian vessel ligationRecommended when \\nthe routine medical \\nand conservative \\nmethods of bleeding \\ncontrol have been \\ntried and not found \\neffectiveLast option, it reflects \\nthe failure of all other \\nmethods at stopping \\nPPHMentioned:\\nResearch was \\nongoing to \\nevaluate the \\npotential \\nbenefits and \\nharms of this \\ninterventionCompression of aorta \\nagainst vertebrae \\nuseful emergency \\nmeasure for 10 min\\nACOG 2017 Bimanual uterine compression.\\nIBT: when uterotonics and \\nbimanual uterine massage \\nfail.\\nIf balloon system is not \\navailable, pack with gauzeSecondary treatment for atony \\nunresponsive to medical \\nmanagement.\\nCited: B-  Lynch, Cho, and \\nHayman; can be associated \\nwith vessel ligationsWhen less invasive \\napproaches fail; bilateral \\nuterine artery (most \\ncommon), utero-  \\novarian vessels, and/or \\ninternal iliac artery (less \\nfrequently\\nused)Recommended in \\nstable patient, with \\npersistent slow \\nbleeding and when \\nless invasive therapy \\nhas failedWhen conservative \\ntherapies have failed as \\na definitive treatmentNot mentioned Uterine massage\\nCNGOF/SFAR \\n2016IBT: can be performed if \\nsulprostone fails and \\nbefore contemplating \\neither surgery or \\ninterventional radiologyIn cases of PPH resistant to \\npharmacological treatment; \\ncan be associated with vessel \\nligations; no technique for \\nconservative surgery is \\nfavored over anotherLigation (bilateral ligation \\nof the uterine arteries \\n(BLUA) or bilateral \\nligation of the internal \\niliac arteries (BLIIA). \\nNo technique for \\nconservative surgery is \\nfavored over anotherRecommended Massive PPH; if previous \\nsurgical procedure fails; \\ntotal or subtotalNot mentioned Uterine massage\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 21}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 25\\nESCOBAR Et Al.\\nGuideline/\\nyear of \\npublicationMechanical, radiological, and surgical treatments\\nTamponade technique Compressive uterine sutures Vessel ligation Embolization Hysterectomy NASG Other techniques\\nRANZCOG \\n2017Bimanual compression; IBT: \\nrecommendedB- Lynch Bilateral ligation of uterine \\narteries; bilateral ligation \\nof internal iliac arteries \\nby an experience \\noperatorRecommended; it needs \\nequipment and \\nexpertise; should \\nnot preclude other \\napproachesSooner rather than later Not mentioned Uterine massage\\nProcedures should not necessarily be a stepwise progression and both order and utilization will depend on the services/clinical experience and the individual clinical circumstances\\nSOGC 2018 Bimanual uterine compression: \\nuntil further measures \\nare taken, or assistance \\narrives.\\nIBT: when medical therapy fails \\nfor uterine atony; consider \\nuterine packingB- Lynch, vertical compression, \\nand ChoUterine and hypogastric \\nartery ligation if \\nbleeding continues (after \\ncompression sutures in \\natony)Option when there is \\nactive PPH, in a \\nstable woman, and \\nbefore surgical \\nintervention (it \\nrequires expertise \\nand equipment)Failure of previous \\ninterventions; subtotal \\nor totalNot mentioned Uterine massage; external \\naortic compression\\nGerman/\\nAustrian/\\nSwiss \\n2018Bimanual uterine compression\\nUBT: does not preclude other \\nnecessary therapeutic \\noptions. Fill with liquid at \\nbody temperature, not air)\\nUterine packing with chitosan-  \\ncovered gauze (special \\ngauze with hemostatic \\nagent)Strongly recommended, \\nparticularly to treat atony. \\nChoice of appropriate suture \\ndepends on indication (atony, \\nbleeding from placental bed, \\ndiffuse bleeding)In addition to simple \\nligature of uterine \\nartery, stepwise uterine \\ndevascularization can be \\nperformed. Ligature or \\ninternal iliac artery must \\nonly be carried out as a \\nlast resort and only by \\nexperienced surgeonRecommended; \\nradiologist should \\nbe notified \\nearly (e.g. when \\ncompression suture is \\nunsuccessful)Must not be delayed or left \\ntoo late.\\nTotal hysterectomy: should \\nbe considered for \\nplacental disorder. \\nSupracervical: the \\nprocedure of choice \\nfor atonyNot mentioned Uterine massage\\nBimanual compression of \\naorta\\nPelvis-  abdominal packing: \\nif bleeding persists \\nafter hysterectomy\\nFLASOG 2018 Bimanual uterine compression.\\nIBT: when uterotonics and \\nbimanual uterine massage \\nfail.B- Lynch, Hayman, Cho suture Stepwise uterine \\ndevascularization; \\nBilateral internal iliac \\nligation. Recommended \\naccording to the \\ncompetencies of the \\nmedical staffRecommended primarily \\nfor vaginal trauma \\nwhen availableIn case life-  threatening \\nbleeding and when \\nconservative therapies \\nhave failed as a \\ndefinitive treatmentRecommended as \\na temporizing \\nmeasure and \\nas part of the \\ntreatmentCompression of the aorta\\nAbbreviation: NASG, nonpneumatic antishock garment; IBT, uterine balloon tamponade; FIGO, International Federation of Gynecology and Obstetrics; WHO, World Health Organization; RCOG, Royal \\nCollege of Obstetricians and Gynaecologists; FOGSI, Federation of Obstetric and Gynaecological Societies of India; ACOG, American College of Obstetricians and Gynecologists; CNGOF/SFAR: College \\nof Gynaecologists and Obstetricians/French Society of Anesthesiology and Intensive Care; RANZCOG, Royal Australian and New Zealand College of Obstetricians and Gynaecologists; SOGC, Society of \\nObstetricians and Gynaecologists of Canada; FLASOG, Federación Latinoamericana de Sociedades de Obstetricia y Ginecología.TABLE 7 \\u2003(Continued)\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 22}), Document(page_content='26\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\nFIGO and other medical societies have specific guidelines for the \\nplacenta accreta spectrum.16– 19\\nREFERENCES\\n 1. Prevention and management of postpartum haemorrhage: green- \\ntop guideline no. 52. BJOG . 2017;124:e106–  e149.\\n 2. Sentilhes L, Vayssière C, Deneux-  Tharaux C, et al Postpartum hem -\\norrhage: guidelines for clinical practice from the French College of \\nGynaecologists and Obstetricians (CNGOF): in collaboration with \\nthe French Society of Anesthesiology and Intensive Care (SFAR). \\nEur J Obstet Gynecol Reprod Biol . 2016;198:12– 21.\\n 3. World Health Organization. WHO Recommendations for the \\nPrevention and Treatment of Postpartum Haemorrhage. Accessed \\nAugust 18, 2021. https://www.who.int/repro  ducti  vehea  lth/publi  \\ncatio  ns/mater  nal_perin  atal_healt  h/97892  41548  502/en/\\n 4. Schlembach D, Helmer H, Henrich W, et al. Peripartum haemor -\\nrhage, diagnosis and therapy. Guideline of the DGGG, OEGGG \\nand SGGG (S2k Level, AWMF Registry No. 015/063, March 2016). \\nGeburtshilfe Frauenheilkd . 2018;78:382–  399.\\n 5. Leduc D, Senikas V, Lalonde AB. No. 235-  active management of \\nthe third stage of labour: prevention and treatment of postpartum \\nhemorrhage. J Obstet Gynaecol Can . 2018;40:e841–  e855.\\n 6. Committee on Practice Bulletins-  Obstetrics. Practice bulletin no. \\n183: postpartum hemorrhage. Obstet Gynecol . 2017;130:e168–  e186.\\n 7. Organization PAH. Guidelines for the prevention, diagnosis and treat -\\nment of obstetric hemorrhage  [in Portuguese]. PAHO; 2018. 8. Fawcus S. Alerts for managing postpartum haemorrhage. S Afr Med \\nJ. 2018;108:1013–  1017.\\n 9. Sri Lanka College of Obstetrician and Gynecologists. SLCOG \\nGuideline on Management of Primary PostPartum Haemorrhage. \\nAccessed August 25, 2021. https://www.slcog.lk/wp- conte  nt/\\nuploa  ds/2021/02/SLCOG  - Guide  line- on- Manag  ement  - of- Prima  ry- \\nPost-  Partu  m- Haemo  rrhag  e- 03.- 2020.pdf\\n 10. Royal Australian and New Zealand College of Obstetricians and \\nGynaecologists. RANZCOG statement. Management of postpar -\\ntum hemorrhage. Accessed August 25, 2021. https://ranzc  og.edu.\\nau/RANZC  OG_SITE/media/  RANZC  OG-  MEDIA/  Women  %27s%20\\nHea  lth/State  ment%20and  %20gui delin  es/Clini cal-  Obste trics/  \\nManag  ement  - of- Postp  artum  - Haemo  rrhag  e- (C- Obs-  43)-  Revie  w- \\nJuly-  2017.pdf?ext =.pdf\\n 11. WOMAN Trial Collaborators. Effect of early tranexamic acid adminis -\\ntration on mortality, hysterectomy, and other morbidities in women with \\npost-  partum haemorrhage (WOMAN): an international, randomised, \\ndouble-  blind, placebo-  controlled trial. Lancet . 2017;389:2105–  2116.\\n 12. World Health Organization. WHO Recommendation on Tranexamic \\nAcid for the Treatment of Postpartum Haemorrhage. Accessed \\nAugust 21: 2021. https://www.who.int/repro  ducti  vehea  lth/publi  \\ncatio  ns/trane  xamic  - acid-  pph-  treat  ment/en/\\n 13. Vogel JP, Oladapo OT, Dowswell T, Gülmezoglu AM. Updated WHO \\nrecommendation on intravenous tranexamic acid for the treatment \\nof post-  partum haemorrhage. Lancet Glob Health . 2018;6:e18–  e19.\\n 14. Althabe F, Therrien MNS, Pingray V, et al. Postpartum hemorrhage \\ncare bundles to improve adherence to guidelines: a WHO technical \\nconsultation. Int J Gynecol Obstet . 2020;148:290–  299.\\n 15. FIGO Safe Motherhood and Newborn Health Committee, \\nInternational Federation of Gynecology and Obstetrics. Practice \\nGuideline. Non-  pneumatic anti-  shock garment to stabilize women \\nwith hypovolemic shock secondary to obstetric hemorrhage. Int J \\nGynecol Obstet . 2015;128:194–  195.\\n 16. Jauniaux E, Ayres-  de- Campos D; FIGO Placenta Accreta Diagnosis \\nand Management Expert Consensus Panel. FIGO consensus guide -\\nlines on placenta accreta spectrum disorders: Introduction. Int J \\nGynecol Obstet . 2018;140:261–  264.\\n 17. Jauniaux E, Alfirevic Z, Bhide AG, et al. Placenta prae -\\nvia and placenta accreta: diagnosis and management. BJOG . \\n2019;126(1):e1–  e48.\\n 18. American College of Obstetricians and Gynecologists; Society for \\nMaternal-  Fetal Medicine. Obstetric care consensus no. 7: placenta \\naccreta spectrum. Obstet Gynecol . 2018;132:e259–  e275.\\n 19. Fuchtner C, Ortiz EI, Escobar MF, Lizaola H. Hemorragia \\nPostparto: en donde estamos y hacia donde vamos. Federación \\nLatinoamericana de Sociedades de Ginecologia y Obstetricia. \\nAccessed August 11, 2021. https://www.flasog.org/stati c/libro  s/\\nHemor  ragia  - Postp  arto-  17OCT UBRE.pdfBOX 4\\u2003FIGO recommends the preparedness of \\nobstetric care teams for the management of PPH \\naccording to the updated guidelines established \\nlocally, regionally, or globally.\\n• These guidelines should include medical and nonmedical \\ntreatment options according to the degree of development \\nof each country or region.\\n• Local, regional, and national medical and nonmedical op -\\ntions for prevention and treatment of PPH need to con -\\nsider the resources available locally.\\n• National societies are encouraged to lobby to establish a \\nPPH bundle approach and ensure availability of medical \\nsupplies and surgical equipment.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 23}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 27\\nESCOBAR Et Al.\\n7\\u2003|\\u2003MEDICAL PREVENTION AND \\nTREATMENT\\n7.1\\u2003 |\\u2003 Carbetocin versus oxytocin use in PPH: recent \\nevidence\\nOxytocin has been traditionally used as the first-  line uterotonic for \\nthe prevention of PPH. Since 1992, carbetocin has been extensively \\ntested in the management of PPH.1,2 Beyond its uterotonic effects, \\ncarbetocin may also promote blood coagulation.3\\n7.1.1\\u2003 |\\u2003 Clinical evidence for PPH prevention: \\noxytocin versus carbetocin (vaginal delivery)\\nThe Heat-  Stable Carbetocin versus Oxytocin to Prevent \\nHemorrhage after Vaginal Birth (CHAMPION) study provided \\nnew evidence comparing oxytocin and carbetocin.4 It studied \\n29 645 women with cervical dilation < 6 cm having a singleton \\npregnancy and planned for vaginal delivery. Patients were rand -\\nomized to receive intramuscular injection of 100  µg heat-  stable \\ncarbetocin (Paban) or 10 IU oxytocin in 10 different countries. \\nThe data showed that for PPH prevention, heat-  stable carbetocin \\nwas not inferior to oxytocin administration for blood loss of at \\nleast 500 ml (RR 1.01; 95% CI, 0.95–  1.06) or the use of additional \\nuterotonic agents. Noninferiority was not shown for the outcome \\nof blood loss of at least 1000 ml (RR 1.04; 95% CI, 0.87–  1.25). In \\nthis study, when the two drugs were compared, the following re -\\nsults were obtained: in women with > 500 ml blood loss, additional \\nuterotonic agents were required in almost 15% of cases in both \\narms. When blood loss exceeded 1000 ml, the requirement for \\nadditional uterotonics was only 1.5% in both arms.3 Therefore, ac -\\ncess to drugs is key since oxytocin has problems with drug purity \\nin low-  resource settings. The safety profile appeared to be similar \\nfor both drugs.\\nMore recently, a network meta-  analysis including 140 random -\\nized trials with data from 88 947 women was developed to identify \\nthe most effective uterotonic drug(s) to prevent PPH and generate \\na ranking according to their effectiveness and adverse effect pro -\\nfile.5 The data showed that compared with oxytocin, the combina -\\ntion of ergometrine plus oxytocin had a risk ratio of 0.69 (95% CI, \\n0.57–  0.83), and was more effective; however, with only moderate \\nquality evidence and with higher risk of adverse effects such as \\nvomiting and hypertension. For carbetocin, the risk ratio was 0.72 \\n(95% CI, 0.52–  1.00), and although it was significant, there was very \\nlow-  quality evidence. Finally, for misoprostol plus oxytocin the risk \\nratio was 0.73 (95% CI, 0.60–  0.90), with moderate quality evidence \\nand higher risk of fever.5 In a low-  risk setting there may be advan -\\ntages to using well-  tested and readily available drugs. When the \\ncarbetocin effect was compared with the use of rectal misoprostol \\nfor preventing PPH in low-  risk patient populations in a random -\\nized controlled trial among 150 pregnant women, the data showed the superiority of carbetocin for efficacy.6 This was evidenced in \\nall indices tested; beyond blood loss, patients had a shorter third \\nstage of labor and reduced need for additional uterotonic drugs. \\nAdditionally, adverse effects such as diarrhea, shivering, and fever \\nwere more pronounced with misoprostol administration.6 In a ran -\\ndomized controlled trial of patients with severe pre-  eclampsia, car -\\nbetocin was shown to be a good alternative to oxytocin, requiring \\na lower volume per dose.7\\n7.1.2\\u2003 |\\u2003 Clinical evidence for PPH prevention: \\noxytocin versus carbetocin (cesarean delivery)\\nCesarean delivery is a surgical procedure requiring high skill, oper -\\nating time, anesthesia, intravenous fluids, and different drugs. The \\naddition of carbetocin, therefore, is expected to be of benefit and \\nthe need for a single drug administration reduces the need for an \\nintensive management team, which is generally required following a \\ncesarean delivery. A Cochrane review including 11 studies showed \\nthat despite a statistically significant reduction in the need for fur -\\nther uterotonics in the carbetocin group compared with oxytocin in \\nwomen undergoing a cesarean delivery, no statistically significant \\ndifferences in terms of the risk of PPH were noted.8 In 2018 a meta- \\nanalysis to analyze the effectiveness of carbetocin compared with \\noxytocin for the prevention of PPH in cesarean deliveries (seven \\nstudies involving 2012 patients) demonstrated a significant reduc -\\ntion in the rates of PPH (RR 0.79; 95% CI, 0.66–  0.94, P = 0.009), use \\nof additional uterotonics (RR 0.57; 95% CI, 0.49–  0.65, P < 0.001), \\nand transfusion (RR 0.31; 95% CI, 0.15–  0.64, P = 0.002) when carbe -\\ntocin was used instead of oxytocin. However, despite the potential \\nbenefits, the disparity between the cost of carbetocin and oxytocin \\nsuggests that a locoregional cost-  effectiveness analysis should be \\nperformed before making the decision to adopt carbetocin for rou -\\ntine prophylaxis.9\\nIn 2020, sequential trial analysis of five randomized controlled \\ntrials of studies with data on women (a total of 1214) undergoing \\nnonelective cesarean deliveries, where carbetocin was compared \\nwith oxytocin, was performed.10 The need for additional uteroton -\\nics was reduced with carbetocin compared with oxytocin (OR 0.30; \\n95% CI, 0.11–  0.86; I2, 90.60%). Trial sequential analysis (TSA) con -\\nfirmed that the information size needed to show a significant re -\\nduction in the need for additional uterotonics had been exceeded. \\nNo significant differences were shown with respect to any of the \\nsecondary outcomes, but there was significant heterogeneity be -\\ntween the studies. The authors concluded that further trials utiliz -\\ning consistent core outcomes are needed to determine an effect \\non PPH.10\\nOn the other hand, a single center study was carried out to \\nevaluate the cost-  effectiveness of carbetocin compared with oxy -\\ntocin when used for prophylaxis against PPH. With approximately \\n3000 cesarean deliveries per year, the study showed that the use \\nof carbetocin could prevent 108 episodes of PPH, 104 episodes \\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 24}), Document(page_content=\"28\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\nof transfusion, and 455 patients would require fewer uteroton -\\nics. Their cost-  saving per PPH case was USD$ 278.70.11 Another \\nstudy where 1500 cesarean deliveries (both elective and emer -\\ngency) were analyzed over 12 months, carbetocin use, as opposed \\nto oxytocin use, reduced 30 (88 vs 58) PPH events ( >500 ml blood \\nloss) and saved £27 518. Carbetocin had a 91.5% better outcome \\nand was 69.4% cheaper.12 When compared with the need for ad -\\nditional uterotonics in the carbetocin group, none required addi -\\ntional medication versus 71.5% in the oxytocin group ( P < 0.01). \\nIn another prospective cohort study, carbetocin used for 400 \\npatients undergoing cesarean delivery led to reduced PPH and \\nthe use of other oxytocic agents, saving £68.93 per patient.13 In \\n2019, a systematic review of the cost-  effectiveness of uterotonic \\nagents for the prevention of PPH was published with 15 studies \\nacross all income categories that compared misoprostol versus no \\nuterotonic (five studies) or versus oxytocin (one study), carbeto -\\ncin versus oxytocin (eight studies), and one study comparing nu -\\nmerous uterotonics.14 The evidence on the cost-  effectiveness of \\nvarious uterotonic agents was not generalizable to different con -\\ntexts. In the absence of reliable evidence, the choice of uterotonic \\nwill likely be highly influenced by uterotonic price and contextual \\nfactors. In the context of cesarean delivery, carbetocin was more \\ncost favorable than oxytocin. The authors concluded the quality \\nof the evidence provided by these studies has a lack of sensitivity \\nanalyzes and incomplete description of the methods of outcome \\nand costs measurements in most studies. In addition, some studies \\nfrom middle-  income countries favoring carbetocin were funded by \\nthe manufacturer. They interpreted findings from these studies \\nand those of the conference abstracts with limited data cautiously, \\nowing to the potential risk of bias and imprecision. Therefore, it \\ncan be easily inferred that the relative cost-  effectiveness of car -\\nbetocin is still inconclusive.\\nBeyond its primary efficacy, which is reduced blood loss, a \\ndrug's safety profile must also be considered before wide-  scale \\nutilization. The adverse effects of carbetocin and oxytocin were \\nexamined in a small, randomized study.15 The data showed that car -\\nbetocin had a lower rate of nausea. In contrast with other clinical \\nindices, including the need to stabilize systolic blood pressure and \\nheart rate, no other differences were noted.15 Since anesthesiolo -\\ngists administer carbetocin for cesarean delivery, the requirement \\nfor increased dose beyond the standard 100 ug in some instances \\nwas raised.16 The longer half-  life of carbetocin prevents additional \\ndosing in case of a persistent bleed and does not permit additional \\noxytocin administration. The increase in carbetocin dose from \\n100 µg to 140 µ g injection increases cardiovascular complications.17 \\nThus, in cases of pre-  eclampsia, close attention is warranted for \\npreserving patient safety before high dose carbetocin is adminis -\\ntered. Also, in those cases, oxytocin doses must be increased to \\ncontrol bleeding beyond the standard treatment, mainly if the drug \\nwas used during labor, which may also increase complications rate. \\nA case report showed that carbetocin administration for a patient \\nwith asthma led to nearly fatal bronchospasm and cardiac arrest requiring resuscitation, which was successful.18 Therefore, this \\ndrug should be used with caution in patients with asthma or those \\nwith advanced pulmonary pathology. This and other studies show \\ninconsistency in adverse events data and indicate that the utility \\nof carbetocin should be further assessed in additional pregnancy \\npathologies to establish the population in which the risk–  benefit \\nprofile is favorable.\\nREFERENCES\\n 1. Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin, a long- \\nacting oxytocin analog on the postpartum uterus. Clin Pharmacol \\nTher. 1992;52:60– 67.\\n 2. Arrowsmith S, Wray S. Oxytocin: its mechanism of action \\nand receptor signalling in the myometrium. J Neuroendocrinol . \\n2014;26:356–  369.\\n 3. Gallos ID, Coomarasamy A. Carbetocin: worth the extra expense? \\nBest Pract Res Clin Obstet Gynaecol . 2019;61:55–  65.\\n 4. Widmer M, Piaggio G, Nguyen TMH, et al Heat-  stable carbetocin \\nversus oxytocin to prevent hemorrhage after vaginal birth. N Engl J \\nMed. 2018;379:743–  752.\\n 5. Gallos ID, Williams HM, Price MJ, et al. Uterotonic agents for \\npreventing postpartum haemorrhage: a network meta-  analysis. \\nCochrane Database Syst Rev . 2018;(4):CD011689.\\n 6. Maged AM, Waly M, Fahmy RM, et al Carbetocin versus rectal \\nmisoprostol for management of third stage of labor among women \\nwith low risk of postpartum hemorrhage. Int J Gynecol Obstet . \\n2020;148:238–  242.\\n 7. Reyes OA, Gonzalez GM. Carbetocin versus oxytocin for preven -\\ntion of postpartum hemorrhage in patients with severe preeclamp -\\nsia: a double-  blind randomized controlled trial. J Obstet Gynaecol \\nCan. 2011;33:1099–  1104.\\n 8. Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum \\nhaemorrhage. Cochrane Database Syst Rev . 2012;(2):CD005457.\\n 9. Voon HY, Suharjono HN, Shafie AA, Bujang MA. Carbetocin versus \\noxytocin for the prevention of postpartum hemorrhage: A meta- \\nanalysis of randomized controlled trials in cesarean deliveries. \\nTaiwan J Obstet Gynecol . 2018;57:332–  339.\\n 10. Onwochei DN, Owolabi A, Singh PM, Monks DT. Carbetocin com -\\npared with oxytocin in non-  elective Cesarean delivery: a systematic \\nreview, meta-  analysis, and trial sequential analysis of randomized- \\ncontrolled trials. Can J Anaesth . 2020;67(11):1524–  1534.\\n 11. Voon HY, Shafie AA, Bujang MA, Suharjono HN. Cost effectiveness \\nanalysis of carbetocin during cesarean section in a high volume ma -\\nternity unit. J Obstet Gynaecol Res . 2018;44:109–  116.\\n 12. Van der Nelson HA, Draycott T, Siassakos D, Yau CWH, Hatswell \\nAJ. Carbetocin versus oxytocin for prevention of post-  partum \\nhaemorrhage at caesarean section in the United Kingdom: an \\neconomic impact analysis. Eur J Obstet Gynecol Reprod Biol . \\n2017;210:286–  291.BOX 5\\u2003FIGO reaffirms its recommendation \\nregarding oxytocin as the first choice for prevention \\nof PPH in vaginal and cesarean deliveries.\\nIn settings where oxytocin is unavailable (or its quality can -\\nnot be guaranteed), the use of other uterotonics (carbe -\\ntocin, ergometrine/methylergometrine, or misoprostol) is \\nrecommended.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 25}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 29\\nESCOBAR Et Al.\\n 13. Luni Y, Borakati A, Matah A, Skeats K, Eedarapalli P. A prospec -\\ntive cohort study evaluating the cost-  effectiveness of carbetocin \\nfor prevention of postpartum haemorrhage in caesarean sections. J \\nObstet Gynaecol . 2017;37:601–  604.\\n 14. Lawrie TA, Rogozińska E, Sobiesuo P, Vogel JP, Ternent L, Oladapo \\nOT. A systematic review of the cost-  effectiveness of uterotonic \\nagents for the prevention of postpartum hemorrhage. Int J Gynaecol \\nObstet . 2019;146(1):56–  64.\\n 15. Mannaerts D, Van der Veeken L, Coppejans H, Jacquemyn Y. \\nAdverse effects of carbetocin versus oxytocin in the prevention of \\npostpartum haemorrhage after caesarean section: a randomized \\ncontrolled trial. J Pregnancy . 2018;2018:1374150. 16. Muggleton E. Oxytocin study raises concerns about carbetocin use. \\nAnesth Analg . 2018;126:1423.\\n 17. Nguyen-  Lu N, Carvalho JC, Farine D, Seaward G, Ye XY, Balki M. \\nCarbetocin at cesarean delivery for labour arrest: a sequential \\nallocation trial to determine the effective dose. Can J Anaesth . \\n2015;62(8):866–  874.\\n 18. Pérez-  Nieto OR, Castañón-  González JA, Lima-  Lucero IM, Delsol \\nLAG. Near fatal bronchospasm and bradycardia after carbetocin \\nadministration. Med Intensiva . 2018;42:319–  321.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 26}), Document(page_content='30\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\n8\\u2003|\\u2003TRANEXAMIC ACID\\nTranexamic acid (TXA) is a synthetic analogue of the amino acid \\nlysine that inhibits fibrinolysis by reducing the binding of plasmi -\\nnogen and tissue plasminogen activator (tPA) to fibrin.1 Labeled \\nindications of this medication are cyclic heavy menstrual bleeding, \\nand oral procedures in patients with hemophilia. An antifibrinolytic \\ndrug is useful because hyperfibrinolysis and fibrinogen depletion \\nare common in the early stages of major postpartum bleeding, and \\nalthough existing medical and surgical interventions can be used to \\ntreat postpartum bleeding, TXA offers an alternative way to sup -\\nport hemostasis.\\n8.1\\u2003 |\\u2003 Administration of TXA\\n1. Administration of TXA is recommended as soon as the di -\\nagnosis of PPH is made if the diagnosis is made within 3 h \\nof delivery . When more than 3 h has elapsed since delivery, \\nthere is no clear evidence of benefit from TXA administration. \\nTXA for PPH treatment is given 1 g IV over 10 min within \\n3 h of vaginal or cesarean delivery. One gram (10 ml of a \\n100 mg/ml solution) is infused over 10–  20 min because infu -\\nsion >1 ml/min can cause hypotension. If bleeding continues \\nafter 30 min or stops and restarts within 24 h after the first \\ndose, a second dose of 1 g may be given. The antifibrinolytic \\neffect lasts up to 7–  8 h in the serum. The concentration in \\nbreast milk is approximately one hundredth of the serum peak \\nconcentration, so it is unlikely to have antifibrinolytic effects \\nin the infant.2,3 The WOMAN trial found that administration \\nof TXA within 3 h of delivery to women with established \\nPPH decreases maternal mortality secondary to bleeding and \\nreduces the need for laparotomy to control hemorrhage.2\\n2. TXA, as a management strategy, in addition to uterotonics re -\\nduced the risk of PPH in randomized trials . Its use is effective \\nin high-  risk clinical settings (e.g. delivery of patients who refuse \\nblood products, patients with a significant risk for PPH such as \\nplacenta accreta or placenta previa or previous PPH). Usually, \\n1 g TXA intravenously is recommended within 10 min after vag -\\ninal delivery in addition to oxytocin, cord traction, and uterine \\nmassage.4,5 A Cochrane review of antifibrinolytic agents used \\nfor the treatment for PPH identified three eligible trials, two \\nof which compared intravenous TXA with placebo or standard \\ncare (the WOMAN trial and a French trial).4,6 A meta-  analysis \\nof 20 172 women from the WOMAN trial and the French trial \\n(152 women with PPH received high-  dose TXA, a loading dose \\nof 4 g over 1 h followed by an infusion of 1 g over 6 h) showed \\nthat TXA reduces the risk of death due to bleeding (RR 0.81; \\n95% CI, 0.65–  1.00), with early treatment being more effective. \\nWHO updated its recommendation on the early use of TXA for \\nthe treatment of PPH (within 3 h of birth) with intravenous TXA \\nusing the same dosing regimen as in the WOMAN trial: a fixed \\ndose of 1 g in 10 ml (100 mg/ml) intravenously at a rate of 1 ml/min. A second 1 g intravenous dose should be administered if \\nbleeding continues after 30 min or restarts within 24 h of the \\nfirst dose.\\n3. TXA should be given to all women with clinically estimated blood \\nloss of more than 500 ml after vaginal birth or 1000 ml after ce -\\nsarean delivery, or any blood loss that is sufficient to compromise \\nhemodynamic stability, regardless of the cause of hemorrhage . \\nTXA forms a reversible complex that displaces plasminogen from \\nfibrin resulting in inhibition of fibrinolysis and inhibition of the \\nproteolytic activity of plasmin. TXA is recommended for PPH \\nmanagement. It is given concomitantly with other drugs and pro -\\ncedures for control of bleeding. An antifibrinolytic drug is useful \\nbecause hyperfibrinolysis and fibrinogen depletion are common \\nin the early stages of major postpartum bleeding. Delay in treat -\\nment, even if short, reduces the benefit of TXA administration. \\nThe WOMAN trial found that TXA reduced death due to bleeding \\nin women with PPH by 20%–  30% and was not associated with \\nan increase in adverse effects. It also reduced the incidence of \\nlaparotomy to control bleeding by 36% but did not reduce hys -\\nterectomy rates. However, the decision to perform hysterectomy \\nwas sometimes made at the same time as randomization, so some \\nhysterectomies were performed before or concurrently with ad -\\nministration of TXA.2,3\\n8.2\\u2003 |\\u2003 TXA as a prophylactic measure\\nAlthough the WOMAN trial presents evidence for the use of \\nTXA to treat established PPH, there is limited evidence for its \\nrole in prevention of PPH. Reviews and meta-  analyses of multi -\\nple trials have shown that prophylactic use of TXA may decrease \\nboth postpartum bleeding and the need for blood transfusions.7,8 \\nHowever, larger adequately powered, multicenter randomized \\ncontrolled trials are needed before the prophylactic use of TXA \\ncan be recommended for the prevention of PPH. In 2021, a mul -\\nticenter, double-  blind, randomized controlled trial was conducted \\nwith 4551 women undergoing cesarean delivery before or during \\nlabor at 34 or more gestational weeks who received an intrave -\\nnously administered prophylactic uterotonic agent and either TXA \\n(1 g) or placebo. Among women who underwent cesarean delivery \\nand received prophylactic uterotonic agents, TXA treatment re-\\nsulted in a significantly lower incidence of calculated estimated \\nblood loss greater than 1000 ml or red-  cell transfusion by day 2 \\ncompared with placebo, but it did not result in a lower incidence \\nof hemorrhage-  related secondary clinical outcomes.9 Several sys -\\ntematic reviews related to the treatment of PPH exist. Mousa \\net al.10 conducted a review that sought to include studies examin -\\ning the effectiveness of all types of treatments for PPH. However, \\ntheir review primarily included studies involving treatment with \\nmisoprostol, and little evidence regarding TXA. They concluded \\nthat more research was needed regarding the effectiveness of \\nTXA for treatment of PPH.10 Additionally, the existing systematic \\nreviews that examined TXA for prophylaxis against PPH (where \\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 27}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 31\\nESCOBAR Et Al.\\nall laboring patients receive TXA) did not address the potential \\neffects of administering TXA only to mothers with PPH.11 FIGO \\ndoes not recommend the use of TXA prophylactically, given the \\nlimited evidence in that regard.\\n8.3\\u2003 |\\u2003 Adverse reactions to TXA\\n1. Greater than 10%: headache (oral: 50%), abdominal pain (oral: \\n20%), back pain (oral: 21%), musculoskeletal pain (oral: 11%), \\nnasal signs and symptoms (oral: 25%; including sinus symptoms).\\n2. 1%– 10%: fatigue (oral: 5%), anemia (oral: 6%), arthralgia (oral: 7%), \\nmuscle cramps (oral: ≤7%), muscle spasm (oral: ≤7%).\\n3. Less than 1%: allergic dermatitis, allergic skin reaction, anaphylac -\\ntic shock, anaphylactoid reaction, anaphylaxis, cerebral thrombo -\\nsis, chromatopsia, conjunctivitis (ligneous), deep vein thrombosis, \\ndiarrhea, dizziness, hypersensitivity reaction, hypotension (with \\nrapid intravenous injection), nausea, pulmonary embolism, renal \\ncortical necrosis, retinal artery occlusion, retinal vein occlusion, \\nseizure, ureteral obstruction, visual disturbance, vomiting.\\n8.4\\u2003 |\\u2003 Contraindications\\nHypersensitivity to TXA or any component of the formulation.\\n8.5\\u2003 |\\u2003 Implementation of treatment with TXA\\n1. TXA should always be readily available in obstetric care fa -\\ncilities. It is cost-  effective, heat stable, and widely available \\nwith a long shelf life. An economic evaluation that used data \\nfrom the WOMAN trial to assess the cost-  effectiveness of \\nearly TXA for usual care of women with PPH in Nigeria and \\nPakistan concluded that it is likely to be highly cost-  effective.4\\n2. TXA should be used in addition to all usual treatments for the \\nmanagement of PPH including medical (uterotonics), nonsurgical, \\nand surgical interventions.2,3\\n3. It has a wide therapeutic index, and a further intravenous in -\\njection could be given when this becomes possible. Alternative \\nroutes of administration should be a research priority, as recom -\\nmended by WHO.12\\n4. Owing to improvements in emergency obstetric care, including \\nuse of TXA as a first-  line therapy, more women will survive PPH \\nthan ever before. Furthermore, the incidence of PPH is increas -\\ning,1 and consequently the number of women who will experience \\nits physical and psychological consequences will also increase. More research is needed on how to reduce the risk factors for \\nPPH.\\nREFERENCES\\n 1. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic \\nacid on surgical bleeding: systematic review and cumulative meta- \\nanalysis. BMJ . 2012;344:e3054.\\n 2. WOMAN Trial Collaborators. Effect of early tranexamic acid ad -\\nministration on mortality, hysterectomy, and other morbidities in \\nwomen with post-  partum haemorrhage (WOMAN): an interna -\\ntional, randomised, double-  blind, placebo-  controlled trial. Lancet . \\n2017;389:2105–  2116.\\n 3. Gayet-  Ageron A, Prieto-  Merino D, Ker K, et al. Effect of treatment \\ndelay on the effectiveness and safety of antifibrinolytics in acute \\nsevere haemorrhage: a meta-  analysis of individual patient-  level \\ndata from 40 138 bleeding patients. Lancet . 2018;391:125–  132.\\n 4. Shakur H, Beaumont D, Pavord S, Gayet-  Ageron A, Ker K, Mousa \\nHA. Antifibrinolytic drugs for treating primary postpartum haem -\\norrhage. Cochrane Database Syst Rev . 2018;(2):CD012964.\\n 5. Saccone G, Della Corte L, D’Alessandro P, et al Prophylactic use \\nof tranexamic acid after vaginal delivery reduces the risk of pri -\\nmary postpartum hemorrhage. J Matern Fetal Neonatal Med . \\n2020;33:3368–  3376.\\n 6. Ducloy-  Bouthors A-  S, Jude B, Duhamel A, et al High-  dose \\ntranexamic acid reduces blood loss in postpartum haemorrhage. \\nCrit Care . 2011;15:R117.\\n 7. Alam A, Choi S. Prophylactic use of tranexamic acid for postpartum \\nbleeding outcomes: a systematic review and meta-  analysis of ran -\\ndomized controlled trials. Transfus Med Rev . 2015;29:231–  241.\\n 8. Sentilhes L, Lasocki S, Ducloy-  Bouthors AS, et al Tranexamic acid \\nfor the prevention and treatment of postpartum haemorrhage. Br J \\nAnaesth . 2015;114:576–  587.\\n 9. Sentilhes L, Sénat MV, Le Lous M, et al Tranexamic acid for the \\nprevention of blood loss after cesarean delivery. N Engl J Med . \\n2021;384:1623–  1634.\\n 10. Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z. \\nTreatment for primary postpartum haemorrhage. Cochrane \\nDatabase Syst Rev . 2014;(2):CD003249.\\n 11. Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for pre -\\nventing postpartum haemorrhage. Cochrane Database Syst Rev . \\n2015;(6):CD007872.\\n 12. Kramer MS, Berg C, Abenhaim H, et al Incidence, risk factors, and \\ntemporal trends in severe postpartum hemorrhage. Am J Obstet \\nGynecol . 2013;209(449):e1–  7.BOX 6\\u2003FIGO recommends administration of \\ntranexamic acid as soon as the diagnosis of PPH is \\nmade, as long as this is within 3 h postpartum.\\nOne gram of tranexamic acid, intravenously over 10 min is to \\nbe given regardless of the cause of PPH. If bleeding continues \\nafter 30 min or stops and restarts within 24 h after the first \\ndose, a second dose of 1 g may be given.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 28}), Document(page_content=\"32\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\n9\\u2003|\\u2003NONSURGICAL CONSERVATIVE \\nMANAGEMENT\\n9.1\\u2003 |\\u2003 Nonpneumatic antishock garment (NASG)\\nThe NASG is a low-  technology, affordable, first-  aid compres -\\nsion device for the management and stabilization of women with \\nhypovolemic shock due to PPH and management of refractory \\nPPH.1 This device serves as a temporizing measure to recover \\nhemodynamic stability to allow definitive surgical interventions, \\nblood transfusions, or transfer to more specialized healthcare \\nfacilities.2– 4\\nThe NASG is a lightweight, lower body compression device com -\\nprising six articulated neoprene and hook-  and-  loop fastener seg -\\nments that provide lower body circumferential counterpressure to \\nimprove cardiac output and blood pressure.5\\nThe estimated circumferential pressure applied by the NASG is \\naround 20–  40 mm Hg. Direct abdominal and pelvic compression \\nreduces the total vascular space in the lower body and decreases \\npelvic perfusion to pelvic compartment organs and smaller pelvic \\nblood vessels, promoting hemorrhage arrest.6 Additionally, the pres -\\nsure applied increases cardiac output and the central circulation, al -\\nlowing an increased distribution of blood flow to vital upper body \\norgans (heart, lung, brains) and contributing to a rapid recovery from \\nshock.1,7\\nLikewise, the direct compression of the descending aorta re -\\nduces bleeding from the uterine arteries and the mesenteric bed's \\nvasculature, perhaps decreasing up to 90% of blood flow at the level \\nof the superior mesenteric artery.1,8\\nA further property of the NASG that makes it useful for maternal \\nhemorrhage is the easy access to the vagina and perineum, thereby \\nfacilitating genital medical and surgical interventions. Additionally, \\nit is extremely cost-  effective even for very low-  resource settings, \\nand is reusable as it can be disinfected and washed over 100 times \\nwithout losing its compressive effects.3 It is also adjustable for many \\nwomen of different girths and heights.\\n9.1.1\\u2003 |\\u2003 Safety\\nAccording to human studies, the NASG is a safe device, with no ad -\\nverse effects such as abdominal wall lesions or other types of po -\\ntential injuries secondary to the circumferential pressure applied, \\nindependent of the patient's body mass index or the strength used \\nto close each of the segments of the garment.2 In multiple studies, \\nthere were no adverse events associated with NASG use: no in -\\ncreased rates of dyspnea, cardiac, or renal dysfunctions. In fact, in \\nall studies of NASG involving extremely ill women with severe PPH, \\nthere were decreased rates of all severe maternal morbidities.4\\nDoppler studies of the distal aorta when the NASG is applied \\nhave shown a drop in the flow rate (volume/time) up to 33%. \\nAdditionally, when the garment's abdominal and pelvic segments are placed, the resistive index (inversely proportional to flow rate) of the \\ninternal iliac arteries increases.7\\n9.1.2\\u2003 |\\u2003 Effectiveness and advantages\\nMultiple studies have been carried out to assess the efficacy and ef -\\nfectiveness of the NASG. Observational quasi-  experimental studies \\nat referral centers in Egypt, Nigeria, India, Zambia, and Zimbabwe \\nshowed a 48% drop in maternal mortality related to hypovolemic \\nshock (secondary to PPH).2 Overall, the groups that received NASG \\ntreatment required fewer transfers to higher complexity facilities \\nas well as abdominal hysterectomies (for definitive therapeutic ap -\\nproach) than women in the control groups, with a relative risk of 0.44 \\n(95% CI, 0.23–  0.86).9\\nA randomized controlled trial implemented in Zambia and \\nZimbabwe demonstrated that early placement of the NASG at pri -\\nmary healthcare centers was associated with a statistically signifi -\\ncant decline in shock recovery time (defined as shock index < 0.9), \\nwith a median time to recovery of 170 min for the NASG group ver -\\nsus 209 min for the control group, with a hazard ratio of 1.2 (95% CI, \\n1.02–  1.52, P = 0.03). Although the reduction in mortality and severe \\nmaternal morbidities (54%) in this study was not statistically signif -\\nicant (perhaps due to much smaller sample size than was necessary \\nto show statistical significance), it is still significant considering the \\nseriousness of the outcomes.10\\nIn 2015, a systematic review of quasi-  experimental studies and \\nthe trial above compared PPH standard care versus standard care \\nplus NASG. It found that the use of the NASG combined with stan -\\ndard PPH care reduces both maternal mortality (48%), with a relative \\nrisk of 0.52 (95% CI, 0.36–  0.77) and a 68% reduction in combined \\nadverse outcomes, mortality, and severe morbidities (RR 0.31; 95% \\nCI, 0.17–  0.59). Furthermore, safety was demonstrated by the ab -\\nsence of differences in adverse events among groups.2\\nEffectiveness outside of clinical trials has been reported in one \\nlarge implementation project in Tanzania that was conducted in \\n280 healthcare facilities in four rural regions, with over 1700 women \\nwith PPH, 24.5% ( n = 419) of whom had severe PPH and hypovolemic \\nshock.11 Of these women, 70.8% received the NASG, which indicated \\nhigh utilization and high acceptability. There was also a temporal as -\\nsociation of a 67% reduced risk of mortality among women with se -\\nvere PPH during the project (RR 0.33; 95% CI, 0.16–  0.60).\\nUse of the NASG is recommended for the clinical stabilization \\nand safe transfer to high complexity centers in the clinical scenario \\nof PPH. This device is currently used in over 50 countries world -\\nwide, and it has been recommended in many national and interna -\\ntional guidelines such as GLOWM, WHO, FIGO, and others.12– 15 \\nThis device should be present in every healthcare facility, as it has \\nproven to be effective and safe, granting significant reductions in \\nPPH-  related mortality.3,15,16 Besides the acceptability demonstrated \\nin the Tanzania study, qualitative research in a few settings has re -\\nported high acceptability from women and providers.11,17–  19\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 29}), Document(page_content=\"\\u2003\\u2002\\u2003|\\u2003 33\\nESCOBAR Et Al.\\n9.1.3\\u2003 |\\u2003 Indications\\nWomen with PPH presenting with clinical signs or laboratory find -\\nings compatible with shock or hemodynamic instability are suitable \\nfor treatment with the NASG. It is important to note that the gar -\\nment serves as a temporizing measure. Thus, once hemodynamic \\nstability is restored, patients should receive definitive medical and \\nsurgical treatment. Table 8 provides a reference for the indications \\nfor NASG application.3\\n9.1.4\\u2003 |\\u2003 Instructions for use\\nThe NASG is composed of six articulated segments. The first three \\nsegments are bilateral and independent segments for the lower \\nbody parts: ankles, calves, and thighs. The other three circumferen -\\ntial segments are placed over the pelvic and abdominal areas. It must \\nfirst be unfolded entirely and placed under the patient's body. To \\nassure proper application of the garment, placement of the superior \\nedge of segment 6 (the superior segment) over the lower rib should \\nbe confirmed. The device can be adjusted to all sizes and heights. For \\ninstance, in shorter patients, segment 1 can be folded into segment \\n2 to keep the first applied segment at the ankle and it can be per -\\nformed whenever someone who is competent to insert it is available.For garment applications, each segment must be stretched and \\nclosed as tightly as possible, starting at the ankles with segment 1 \\nand continuing with the remaining segments successively.5 It is im -\\nportant to try to keep both knees uncovered by the leg segments to \\npreserve joint mobility. The leg segments of the NASG can be placed \\nby one or two people, depending on the availability of healthcare \\npersonnel. Appliers can use the pubic symphysis as an anatomical \\nreference point for placing segment 4. Appliers can use the umbili -\\ncus as guidance for placing segments 5 and 6. Although all segments \\nshould be closed firmly and tightly, the abdominal section must not \\nbe closed too tightly in order to maintain adequate respiration. For \\nthat reason, it is advised that only one person should close segments \\n5 and 6. If there is more than one person available, two people can \\ncoordinate their actions, with one person presenting the opposite \\nsegment to the person who will close both segments together. If the \\npatient shows signs of respiratory distress, abdominal segments (5 \\nand 6) can be loosened, but not completely opened.\\nIf the patient requires surgical intervention the leg sections should \\nremain closed, while the pelvic and abdominal segments can be tem -\\nporarily opened, just before the skin incision is made, and then closed \\nonce the procedure is concluded. In addition, a drop in blood pres -\\nsure should be expected when the abdominal and pelvic segments are \\nopened, and hence appropriate measures should be taken.\\n9.1.5\\u2003 |\\u2003 Monitoring and removal\\nPatients using the NASG should be closely followed with continuous \\nmonitoring of heart rate and blood pressure and optimal fluid resus -\\ncitation.5 This device can be used safely for up to 48 h as a tempo -\\nrizing measure until hemodynamic stability or adequate hemorrhage \\ncontrol is achieved. Nevertheless, there are reports of the NASG \\nused for longer than 72 h. To safely remove the NASG, healthcare \\nprofessionals must verify the following criteria: blood loss <50  ml/h, \\nheart rate < 100 bpm, and systolic blood pressure ≥100  mm  Hg (rule \\nof 100’s) for at least 2 h.5 Once the following criteria are corrobo -\\nrated, it is safe to start removing the garment. The intravenous line \\nshould remain in situ during the removal. Removal should follow the \\nsame steps as application, starting with segment 1 at the ankles and \\nmoving slowly up to segment 6. Every time a segment is opened, a \\n15- min period is allowed to re-  evaluate vital signs and check for ac -\\ntive bleeding. If vital signs remain stable and there are no signs of ac -\\ntive bleeding, it is safe to open the next segment. However, if systolic \\nblood pressure drops ≥20 mm Hg or heart rate increases ≥20 bpm \\n(rule of 20’s) or active bleeding is identified, all of the segments must \\nbe rapidly closed again. Once removed, the NASG should be placed in \\na biohazard container and sent to be laundered, dried, and refolded. \\nVideos and presentation slides of correct application, use, removal, \\nand cleaning can be obtained for free at: www.safem  other  hood.\\nucsf.edu. These instructions must be followed strictly, as incorrect \\nremoval of the garment could result in hemodynamic instability and \\nrecurrence of shock, especially if the abdominal segment is the first \\nsegment to be opened.5 In the absence of hemodynamic instability TABLE 8 \\u2003Indications for NASG applicationa\\nFIGO recommendations on use of the nonpneumatic anti-  shock \\ngarment for hypovolemic shock secondary to obstetric hemorrhage\\nPopulation Any pregnant or postpartum woman with \\nsevere hemorrhage showing signs \\nof shock/hemodynamic instability, \\nat the primary healthcare level or if \\ntransport to higher facility is necessary: \\nEBL 500 ml, SBP < 100 mm Hg, pulse \\n>100 bpm; at high-  level facilities: EBL \\n>1000 ml, SBP < 90 mm Hg, pulse \\n>110 bpm (or per facility protocols)\\nRecommendation Rapidly apply NASG starting at the ankles. \\nNASG to remain in place until source of \\nbleeding found, and bleeding decreased \\nto 25–  50 ml/h\\nScientific evidence 4 pre/post studies, 1 randomized controlled \\ntrial, 1 systematic review\\nModifications Depending on capacity of facility and \\nstaff, the NASG could either be applied \\nas first-  line first aid before any other \\nintervention or could be used to reverse \\nshock when other methods to stop \\nbleeding have failed, or while awaiting \\ndefinitive therapy (embolization, surgery, \\nblood transfusions)\\nGrade B (temporizing measure)\\nAbbreviations: EBL, estimated blood loss; SBP, systolic blood pressure; \\nNASG, nonpneumatic anti-  shock garment.\\naSource: FIGO Safe Motherhood and Newborn Health Committee [3]. \\nReproduced with permission from FIGO.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 30}), Document(page_content='34\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\nsigns, the whole garment can be removed in 1 h and 15 min. Routine \\nfollow-  up laboratories, including hemoglobin and hematocrit are \\nencouraged. Values over 7.5 mg/dl of hemoglobin and a hematocrit \\n>23% are recommended; however, there is neither consensus nor \\nevidence about these values, and further research is needed.\\n9.1.6\\u2003 |\\u2003 Adverse effects\\nCurrently, no adverse effects have been documented with correct \\nimplementation of the NASG4; no increase in shock-  related organ \\ndysfunction adverse effects have been noted.9\\n9.1.7\\u2003 |\\u2003 Contraindications\\nCurrently, there are no absolute medical contraindications for NASG \\nuse.3 Cardiac and pulmonary comorbidities such as heart failure, \\nsevere mitral stenosis, and pulmonary hypertension are considered \\nrelative contraindications in nonobstetric patients. Although in se-\\nvere hemorrhage, benefits are thought to outweigh any potential \\nharm.5\\nREFERENCES\\n 1. Escobar MF, Füchtner CE, Carvajal JA, et al Experience in the use of \\nnon-  pneumatic anti-  shock garment (NASG) in the management of \\npostpartum haemorrhage with hypovolemic shock in the Fundación \\nValle Del Lili, Cali, Colombia. Reprod Health . 2017;14:58.\\n 2. Pileggi-  Castro C, Nogueira-  Pileggi V, Tunçalp Ö, Oladapo OT, Vogel \\nJP, Souza JP. Non-  pneumatic anti-  shock garment for improving \\nmaternal survival following severe postpartum haemorrhage: a sys -\\ntematic review. Reprod Health . 2015;12:28.\\n 3. FIGO Safe Motherhood and Newborn Health Committee, \\nInternational Federation of Gynecology and Obstetrics. Non- \\npneumatic anti-  shock garment to stabilize women with hypovole -\\nmic shock secondary to obstetric hemorrhage. Int J Gynecol Obstet . \\n2015;128:194–  195.\\n 4. Althabe F, Therrien MNS, Pingray V, et al. Postpartum hemorrhage \\ncare bundles to improve adherence to guidelines: a WHO technical \\nconsultation. Int J Gynecol Obstet . 2020;148:290–  299.\\n 5. Miller S, Martin HB, Morris JL. Anti-  shock garment in post -\\npartum haemorrhage. Best Pract Res Clin Obstet Gynaecol . \\n2008;22:1057–  1074.\\n 6. Kerr NL, Hauswald M, Tamrakar SR, Wachter DA, Baty GM. An in -\\nexpensive device to treat postpartum hemorrhage: a preliminary \\nproof of concept study of health provider opinion and training in \\nNepal. BMC Pregnancy Childbirth . 2014;14:81.\\n 7. Lester F, Stenson A, Meyer C, Morris J, Vargas J, Miller S. \\nImpact of the Non-  pneumatic Antishock Garment on pelvic blood flow in healthy postpartum women. Am J Obstet Gynecol . \\n2011;204(409):e1–  5.\\n 8. Hauswald M, Greene ER. Regional blood flow after pneu -\\nmatic anti-  shock garment inflation. Prehosp Emerg Care . \\n2003;7:225–  228.\\n 9. Mourad-  Youssif M, Ojengbede OA, Meyer CD, et al Can the Non- \\npneumatic Anti-  Shock Garment (NASG) reduce adverse maternal \\noutcomes from postpartum hemorrhage? Evidence from Egypt and \\nNigeria. Reprod Health . 2010;7:24.\\n 10. Miller S, Bergel EF, El Ayadi AM, et al Non-  pneumatic anti-  shock \\ngarment (NASG), a first-  aid device to decrease maternal mortality \\nfrom obstetric hemorrhage: a cluster randomized trial. PLoS One . \\n2013;8:e76477.\\n 11. Mbaruku G, Therrien MS, Tillya R, et al Implementation project of the \\nnon-  pneumatic anti-   shock garment and m-  communication to enhance \\nmaternal health care in rural Tanzania. Reprod Health . 2018;15:177.\\n 12. World Health Organization. Managing complications in pregnancy \\nand childbirth: a guide for midwives and doctors. Accessed August \\n11, 2021. https://apps.who.int/iris/bitst  ream/handl  e/10665/  \\n25576  0/97892  41565  493-  eng.pdf;jsess  ionid  =8D2D1  DE3DF  \\n5C2CC  ED6EF  CE711  D80B8  04?seque nce =1\\n 13. Weeks A. The prevention and treatment of postpartum haem -\\norrhage: what do we know, and where do we go to next? BJOG . \\n2015;122:202–  210.\\n 14. Hofmeyr GJ, Qureshi Z. Preventing deaths due to haemorrhage. \\nBest Pract Res Clin Obstet Gynaecol . 2016;36:68– 82.\\n 15. Tunçalp O, Souza JP, Gülmezoglu M. World Health Organization. \\nNew WHO recommendations on prevention and treat -\\nment of postpartum hemorrhage. Int J Gynecol Obstet . \\n2013;123:254–  256.\\n 16. Lalonde A; International Federation of Gynecology and Obstetrics. \\nPrevention and treatment of postpartum hemorrhage in low- \\nresource settings. Int J Gynecol Obstet . 2012;117:108–  118.\\n 17. Jordan K, Butrick E, Yamey G, Miller S. Barriers and facilita -\\ntors to scaling up the non-  pneumatic anti-  shock garment for \\ntreating obstetric hemorrhage: a qualitative study. PLoS One . \\n2016;11:e0150739.\\n 18. Onyewuenyi A, Tilla R, Kinyonge I, et al. A qualitative approach to \\nunderstanding the impact of misuse and misdiagnosis: Monitoring \\nuse of the non-  pneumatic antishock garment in Tanzania. Annals of \\nGlobal Health . 2016;82:489–  490.\\n 19. Berdichevsky K, Tucker C, Martínez A, Miller S. Acceptance of a new \\ntechnology for management of obstetric hemorrhage: a qualitative \\nstudy from rural Mexico. Health Care Women Int . 2010;31:444–  457.\\n9.2\\u2003 |\\u2003 Uterine balloon tamponade\\nDespite active management of the third stage of labor, 2%–  7% of \\nwomen experience postpartum blood loss of more than 500 ml.1 \\nUterine balloon tamponade (UBT) is both a diagnostic and thera -\\npeutic tool. If bleeding does not stop after its insertion, then it is \\nbetter to review the etiology of PPH. Placement of a UBT device \\nshould be considered early when emergency measures for man -\\nagement of PPH are initiated. It should be performed by compe -\\ntent healthcare providers who are trained in its insertion to avoid \\ncomplications that can arise from misplacement. Perineal, vaginal, \\nand cervical tears and ruptured uterus must be excluded, and the \\nplacenta carefully assessed for completeness to rule out retained \\nfragments of the placenta. First-  line emergency interventions for \\natonic PPH include uterine massage, initiation of large intravenous BOX 7\\u2003FIGO recommends that all healthcare facilities \\nhave the NASG as an effective nonsurgical device that \\ncan be used as a temporary measure to recover \\nhemodynamic stability for the management and \\ntransfer of a patient to a high level of care.  \\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 31}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 35\\nESCOBAR Et Al.\\naccess, emptying the uterus and bladder, and administration of \\noxytocin and TXA (first response bundle). If the uterus fails to \\ncontract, ergometrine or misoprostol should be administered, bi -\\nmanual uterine or aortic compression should be initiated, a UBT \\nplaced, and the NASG applied (response to refractory PPH bun -\\ndle).2 These two sets of approaches have recently been defined as \\nthe “PPH bundle”.3\\nObservational studies have reported UBT success rates between \\n83% and 95% overall with nearly 100% survival among women with \\nuncontrolled hemorrhage when a UBT device was placed before the \\nonset of advanced shock.4– 6 The integration of UBT into PPH clinical \\npathways in high-  income countries has been shown to avert hyster -\\nectomy and significantly reduce the need for PPH-  related invasive \\nprocedures such as artery ligation, uterine compression sutures, and \\narterial embolization.7– 10\\nA 2020 systematic review and meta-  analysis showed an overall \\npooled success rate of 85.9% (95% CI, 83.9–  87.9%) for the treatment \\nof PPH, with higher pooled success rates corresponding to PPH due \\nto uterine atony and placenta previa, and lower pooled success rates \\nfor PPH due to placenta accreta spectrum (PAS) and retained prod -\\nucts of conception.11 A safety trial in Kenya and Sierra Leone on a \\nuniquely designed condom uterine tamponade device (ESM-  UBT) \\ndemonstrated no increased risk of infections or perineal injuries, and \\nsuccess rates of condom UBT devices appear to be comparable to \\nthose of Bakri balloons.12 Available UBT devices and specific consid -\\nerations are described below.\\n9.2.1\\u2003 |\\u2003 Available UBT devices\\nUterine balloon devices can be divided into two groups:\\n1. Fixed volume devices: condom uterine balloons (ESM-  UBT kit, \\nCG balloon), Bakri balloon, Rusch balloon, and Ebb system.12– 16\\n2. Free flow devices: the glove balloon, Ellavi UBT, and Zukovski \\nballoon.17– 19 The glove and Ellavi balloons allow intrauterine pres -\\nsure control according to systolic blood pressure. The Zukovski \\nballoon uses 50 cm (3.8 cmHg) pressure for inflating the balloon.\\n9.2.2\\u2003 |\\u2003 Tamponade effect\\nThe mechanism of action of UBT devices is likely multifactorial. Two \\nproposed mechanisms include device stimulation of receptors, which in \\nturn stimulates uterine contraction, as well as the direct application of \\nhydrostatic pressure against the bleeding sinuses. It has been proposed \\nthat if uterine wall pressure exerted by a UBT equals the systolic arte -\\nrial pressure of the bleeding sinuses, a tamponade effect is created.14 \\nHowever, Georgiou20 measured intraluminal pressures in Bakri bal -\\nloons in two cases where UBTs had been placed and discovered that \\ntamponade occurred at UBT device pressures lower than systolic blood \\npressures. Further research is needed to better understand the precise \\nbiomechanical relationship between a UBT device and a bleeding uterus.9.2.3\\u2003 |\\u2003 Free flow tamponade device\\nBlood is supplied to the uterus via maternal arterial blood that \\npasses through the myometrium through low resistance sinuses.21 \\nFollowing delivery of the placenta, the muscle fibers of the myome -\\ntrium contract and retract, closing off the sinuses and limiting blood \\nloss. While the immediate aim in PPH due to atonic uterus is to arrest \\nblood loss, the ultimate goal is to employ best practice interventions \\nto facilitate contraction of the myometrium. The surgical glove bal -\\nloon, the Ellavi UBT, and the Zukovsky balloon are free flow systems \\nthat allow water to be expelled from the balloon to theoretically \\nbetter allow for the natural physiological process of contraction and \\nretraction of the myometrium once the uterus has recovered.17– 19 \\nHowever, almost all commercially available UBT devices are low- \\npressure, high-  volume systems that allow for easy UBT expulsion \\nwhen the uterus regains its tone and begins to contract.\\n9.2.4\\u2003 |\\u2003 Drainage port\\nThe need for a drainage port with a UBT device is questionable.13,14,16 \\nDrainage ports are only a few millimeters in diameter and there -\\nfore are easily obstructed by clotted blood. Furthermore, since the \\nsource of bleeding in atonic uterus is from the site of placental im -\\nplantation, which encompasses only about 20% of the uterine cavity, \\na drainage port is less likely to be in proximity to the bleeding site.\\n9.2.5\\u2003 |\\u2003 Correct placement\\nMultiple techniques have been described on the best approach to \\nplace a UBT device. The approach should in part be determined by \\nthe device being used (e.g. stiffness of the introducing end and num -\\nber of balloons). To ensure that the balloon could engage within the \\narea that is actively bleeding, all UBTs should be inserted through \\nthe cervix and positioned to sit in the upper uterine segment. One \\napproach includes placing the hand into the uterus and ensuring that \\nthe fingertips reach the thick anterior and posterior layers of the \\nupper segment. The UBT is then fed into the upper segment of the \\nuterus with the free hand. When withdrawing the uterine hand, the \\ntubing is held with the free hand. While the balloon is filled, two fin -\\ngers are held in the vagina below the cervix to prevent inadvertent \\nballoon expulsion.\\n9.2.6\\u2003 |\\u2003 Assessment of effect\\nMultiple studies have shown that women with uncontrolled PPH \\nfrom an atonic uterus will almost universally survive if a UBT device \\nis placed in a timely fashion. If UBTs are placed before patients pro -\\ngress to advanced shock, success rates approach 100%.6 However, \\nstudies such as by Dumont et al.22 and Natarajan et al.23 have shown \\nthat improvised UBTs, delays in recognition of PPH, and lack of \\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 32}), Document(page_content='36\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\naction on actual UBT placement may be barriers to improved out -\\ncomes. While different UBT systems may fill to their desired states \\nat different rates, it is even more important to recognize that impro -\\nvised and untested UBTs are less often used. Moreover, whenever \\nthey are, their use is often delayed, they are more difficult to place, \\nfall out more easily, and are associated with overall lower success \\nrates.12– 14,17,19 Therefore, immediate recognition of PPH and emer -\\ngency action with a quality UBT device is imperative to save lives.\\n9.2.7\\u2003 |\\u2003 Transfer\\nMany studies report high rates of hemorrhage control after UBT \\ninsertion thus rendering transfers unnecessary. Most often, incor -\\nrect diagnosis and misplacement are the cause of UBT failure. If \\nbleeding recurs or the patient continues to be unstable after UBT \\ninsertion, then consideration of transfer to higher levels of care \\nshould be made. Transfer can occur with both fixed-  volume bal -\\nloons and closed-  off free-  flow balloons, but all UBTs must be care -\\nfully secured to prevent accidental displacement. A transfer plan \\nshould be in place in all obstetric settings, regardless of whether it \\nwill be needed or not. This is an absolute necessity in PPH bundles.\\n9.2.8\\u2003 |\\u2003 UBT after cesarean delivery\\nUse of UBTs for hemorrhage control after cesarean delivery is a \\ncommonly performed technique worldwide, but there is scant sup -\\nporting literature. There are a few reports on successful outcomes \\nwith use of UBT in placenta previa. It appears that UBT has higher \\nsuccess rates in women with PPH after vaginal delivery than after \\ncesarean delivery.11,18,24– 26\\n9.2.9\\u2003 |\\u2003 Combining UBT with compression sutures\\nPlacing a UBT after application of uterine compression sutures \\nrequires control of the amount of pressure exerted in the uterus \\nto prevent uterine necrosis. Although uterine necrosis is possible \\nfollowing the insertion of compression sutures alone, the risk un -\\nderstandably would increase with pressure exerted from inside the \\nuterus when UBT is used additionally. Cases with uterine necro -\\nsis following insertion of compression sutures have been reported \\nwith and without UBT.27,28 The surgical glove balloon and the Ellavi \\nUBT are UBT devices that allow the intrauterine pressure to be \\ncontrolled by adjusting the height of the intravenous fluid bag or \\nsupply bag above the patient.17,18 With systolic blood pressure of \\n100 mm Hg and the supply bag or intravenous infusion fluid 1.3 m \\nabove the patient, the pressure exerted by the balloon will be \\n100 mm Hg. The specific gravity of mercury is 13 times more than \\nwater. The device used for the balloon must be large enough to be \\ninflated with fluid without requiring any expansion pressure. This is \\nachieved by using a surgical glove and the Ellavi UBT.17,189.2.10\\u2003 |\\u2003 Other uses of UBT\\nWhile the use of UBT for uncontrolled PPH is fairly well estab -\\nlished, published case reports and senior leaders in obstetrics and \\ngynecology have described successful use of UBTs in other cir -\\ncumstances, such as in molar pregnancy-  associated hemorrhage, \\nplacenta accreta, retained placenta, and in cases of intentional \\nvaginal and cervical placement to temporize uncontrolled bleed -\\ning from lacerations.29\\nWHO recently published recommendations regarding use of \\nUBT in the context of PPH due to uterine atony after vaginal birth \\nin women who do not respond to standard first-  line treatment.30 \\nAccording to WHO, among the prerequisites for use of UBT, evi -\\ndence supports the need for access to surgical intervention and \\nblood products, as well as the availability of health personnel skilled \\nin its use. They recognize that conditions may not be operationalized \\nacross all clinical settings and that observational studies suggest a \\nsubstantial reduction in the risk of maternal morbidity and mortality \\nfollowing uterine balloon tamponade, and that further research is \\nneeded in low-  resource settings.\\nREFERENCES\\n 1. Begley CM, Gyte GM, Devane D, McGuire W, Weeks A. Active ver -\\nsus expectant management for women in the third stage of labour. \\nCochrane Database Syst Rev . 2011;(11):CD007412.\\n 2. Escobar MF, Füchtner CE, Carvajal JA, et al Experience in the \\nuse of non-  pneumatic anti-  shock garment (NASG) in the man -\\nagement of postpartum haemorrhage with hypovolemic shock \\nin the Fundación Valle Del Lili, Cali, Colombia. Reprod Health . \\n2017;14:58.\\n 3. Althabe F, Therrien MNS, Pingray V, et al. Postpartum hemorrhage \\ncare bundles to improve adherence to guidelines: a WHO technical \\nconsultation. Int J Gynecol Obstet . 2020;148:290–  299.\\n 4. Laas E, Bui C, Popowski T, Mbaku OM, Rozenberg P. Trends in the \\nrate of invasive procedures after the addition of the intrauterine \\ntamponade test to a protocol for management of severe postpar -\\ntum hemorrhage. Am J Obstet Gynecol . 2012;207(281):e1–  7.\\n 5. Revert M, Cottenet J, Raynal P, Cibot E, Quantin C, Rozenberg P. \\nIntrauterine balloon tamponade for management of severe post -\\npartum haemorrhage in a perinatal network: a prospective cohort \\nstudy. BJOG . 2017;124:1255–  1262.\\n 6. Burke TF, Danso-  Bamfo S, Guha M, Oguttu M, Tarimo V, Nelson \\nBD. Shock progression and survival after use of a condom uterine \\nballoon tamponade package in women with uncontrolled postpar -\\ntum hemorrhage. Int J Gynecol Obstet . 2017;139:34–  38.\\n 7. Gauchotte E, De La Torre M, Perdriolle-  Galet E, Lamy C, Gauchotte \\nG, Morel O. Impact of uterine balloon tamponade on the use of \\ninvasive procedures in severe postpartum hemorrhage. Acta Obstet \\nGynecol Scand . 2017;96(7):877– 882.BOX 8\\u2003FIGO recommends uterine balloon \\ntamponade in the context of refractory PPH.\\nUterine balloon tamponade has proven to be an effective \\nnonsurgical technique so that when employed rapidly by a \\nproperly trained person, as the only prerequisite for its use, it \\ncan potentially improve survival in women with PPH.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 33}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 37\\nESCOBAR Et Al.\\n 8. Revert M, Rozenberg P, Cottenet J, Quantin C. Intrauterine balloon \\ntamponade for severe postpartum hemorrhage. Obstet Gynecol . \\n2018;131:143–  149.\\n 9. Pendleton AA, Natarajan A, Ahn R, Nelson BD, Eckardt MJ, Burke \\nTF. Emergency hysterectomy for uncontrolled postpartum hemor -\\nrhage may be averted through uterine balloon tamponade in Kenya \\nand Senegal. Int J Gynecol Obstet . 2016;133:124.\\n 10. Pendleton AA, Natarajan A, Ahn R, Nelson BD, Eckardt MJ, Burke \\nTF. A qualitative assessment of the impact of a uterine balloon tam -\\nponade package on decisions regarding the role of emergency hys -\\nterectomy in women with uncontrolled postpartum haemorrhage \\nin Kenya and Senegal. BMJ Open . 2016;6:e010083.\\n 11. Suarez S, Conde-  Agudelo A, Borovac-  Pinheiro A, et al Uterine \\nballoon tamponade for the treatment of postpartum hemorrhage: \\na systematic review and meta-  analysis. Am J Obstet Gynecol . \\n2020;222:293.e1–  293.e52.\\n 12. Ramanathan A, Eckardt MJ, Nelson BD, et al Safety of a condom \\nuterine balloon tamponade (ESM-  UBT) device for uncontrolled pri -\\nmary postpartum hemorrhage among facilities in Kenya and Sierra \\nLeone. BMC Pregnancy Childbirth . 2018;18:168.\\n 13. Mishra N, Agrawal S, Gulabani K, Shrivastava C. Use of an inno -\\nvative condom balloon tamponade in postpartum haemorrhage: a \\nreport. J Obstet Gynaecol India . 2016;66:63–  67.\\n 14. Tolosa JE, Bakri YN, Arulkumaran S. Intrauterine balloon tampon -\\nade for control of postpartum hemorrhage. This topic last updated: \\nMarch 12, 2018. Accessed August 25, 2021. https://sniv3  r2.github.\\nio/d/topic.htm?path =intra uteri  ne- ballo  on- tampo nade-  for- contr  ol- \\nof- postp artum  - hemor  rhage\\n 15. Georgiou C. Balloon tamponade in the management of postpartum \\nhaemorrhage: a review. BJOG . 2009;116:748–  757.\\n 16. Dildy GA, Belfort MA, Adair CD, et al Initial experience with a dual- \\nballoon catheter for the management of postpartum hemorrhage. \\nAm J Obstet Gynecol . 2014;210(136):e1–  6.\\n 17. Fawcus S, Moodley J. A Monograph of the Management \\nof Postpartum Haemorrhage. National Committee for the \\nConfidential Enquiries into Maternal Deaths in South Africa. \\nNational Department of Health South Africa. 2010.\\n 18. Theron GB. Management of postpartum hemorrhage with free- \\nflow pressure controlled uterine balloon. Int J Gynecol Obstet . \\n2018;142:371– 373.\\n 19. Usage of the Zhukovsky Balloon Tamponade for PPH Free Flow \\nballoon tamponade. 2014. Accessed August 25, 2021. http://www.\\nyoutu  be.com/watch  ?v=qrT8x  suB980\\n 20. Georgiou C. Intraluminal pressure readings during the establish -\\nment of a positive ‘tamponade test’ in the management of postpar -\\ntum haemorrhage. BJOG . 2010;117:295–  303.\\n 21. Cronjé HS, Cilliers JBF, du Toit MA. Clinical Obstetrics –  a Southern \\nAfrican perspective , 4th edn. Van Schaik Publishers; 2016.\\n 22. Dumont A, Bodin C, Hounkpatin B, et al Uterine balloon tampon -\\nade as an adjunct to misoprostol for the treatment of uncontrolled \\npostpartum haemorrhage: a randomised controlled trial in Benin \\nand Mali. BMJ Open . 2017;7:e016590.\\n 23. Natarajan A, Alaska Pendleton A, Nelson BD, et al Provider expe -\\nriences with improvised uterine balloon tamponade for the man -\\nagement of uncontrolled postpartum hemorrhage in Kenya. Int J \\nGynecol Obstet . 2016;135:210–  213.\\n 24. Cho HY, Park YW, Kim YH, Jung I, Kwon JY. Efficacy of intrauterine \\nBakri balloon tamponade in cesarean section for placenta previa \\npatients. PLoS One . 2015;10:e0134282.\\n 25. Soyama H, Miyamoto M, Sasa H, et al. Effect of routine rapid inser -\\ntion of Bakri balloon tamponade on reducing hemorrhage from pla -\\ncenta previa during and after cesarean section. Arch Gynecol Obstet . \\n2017;296:469–  474.\\n 26. Maher MA, Abdelaziz A. Comparison between two management \\nprotocols for postpartum hemorrhage during cesarean section in placenta previa: Balloon protocol versus non-  balloon protocol. J \\nObstet Gynaecol Res . 2017;43:447–  455.\\n 27. Treloar EJ, Anderson RS, Andrews HS, Bailey JL. Uterine necrosis \\nfollowing B-  Lynch suture for primary postpartum haemorrhage. \\nBJOG . 2006;113:486– 488.\\n 28. Lodhi W, Golara M, Karangaokar V, Yoong W. Uterine necrosis fol -\\nlowing application of combined uterine compression suture with \\nintrauterine balloon tamponade. J Obstet Gynaecol . 2012;32:30–  31.\\n 29. Makin J, Suarez-  Rebling DI, Varma Shivkumar P, Tarimo V, Burke \\nTF. Innovative uses of condom uterine balloon tamponade for post -\\npartum hemorrhage in India and Tanzania. Case Rep Obstet Gynecol . \\n2018;2018:4952048.\\n 30. World Health Organization. WHO recommendation on uterine bal -\\nloon tamponade for the treatment of postpartum haemorrhage . WHO; \\n2021. Accessed August 25, 2021. https://apps.who.int/iris/handl  \\ne/10665/  340796\\n9.3\\u2003 |\\u2003 Uterine artery embolization\\nSince the first report of the successful use of uterine artery emboliza -\\ntion (UAE) for the treatment of PPH in 1979, success rates have been \\nfrequently reported at 90%. However, unlike the medical and surgi -\\ncal treatments for PPH, no randomized controlled trials regarding its \\neffectiveness have been conducted. The decision to perform uterine \\nartery embolization in patients with persistent uterine bleeding should \\nbe made in consultation with an interventional radiologist. Although \\nembolization may be considered as the technique of choice for manag -\\ning PPH by some authors, certain practical issues must be considered.1\\nUterine artery embolization has been shown to be effective in \\nthe treatment of various causes of PPH including placenta accreta:  \\nBoth UAE and uterine artery ligation have reported success rates of \\ngreater than 90% with low complication rates. If both techniques are \\navailable, embolization is the preferred first choice as it obviates lap -\\narotomy. Ligation can be attempted subsequently if embolization is \\nunsuccessful. In contrast, after an unsuccessful uterine artery ligation, \\nembolization may be extremely difficult or even impossible, leaving \\nhysterectomy as the only remaining option. Some cases may require \\nhysterectomy because of failure of embolization. UAE has shown to be \\neffective in controlling secondary bleeding and the placenta was found \\nto gradually decrease in size in all patients. UAE plays an important role \\nin managing these patients because it is effective at reducing uteropla -\\ncental blood flow to further induce thrombosis of the intervillous space \\nand to achieve necrosis of the retained placental tissue.2– 7 Selective \\nUAE is effective in the control of PPH, thus avoiding hysterectomy.\\nAvailability of resources to perform the procedure:  A radiologist \\ntrained in embolization techniques is a prerequisite, as is the appro -\\npriate equipment for vascular intervention. Digital road-  mapping \\nmay be required, and the possible complexity means that this proce -\\ndure can only be performed in a fully equipped X-  ray department.8 \\nThe interventional radiologist inserts sheaths into both femoral ar -\\nteries to deploy a deflated occlusion balloon into each of the internal \\niliac arteries.9 The sheaths are removed, and the deflated balloons \\nremain in place until after delivery. After the patient has undergone \\na cesarean delivery, the interventional radiologist will inflate the \\nballoons if needed based on the amount of bleeding. If inflating the \\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 34}), Document(page_content=\"38\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\nballoons is postponed, the balloons may remain in place for up to a \\nfew days until the patient's providers are certain she will not begin \\nto bleed again; the balloons can then be removed.9\\nUAE has become recognized as a relatively safe technique when \\npreserving the patient's fertility is a priority10– 12: Catheterization of \\nthe uterine arteries with temporary occlusion by endovascular bal -\\nloon is considered a valid option in the management of patients at \\nhigh risk of bleeding, in particular those with a pre-  existing diagnosis \\nof placenta accreta in patients requesting to preserve their uterus. \\nOjala et al.13 and Badawy14 described a series of cases in patients \\nwho underwent embolization of the uterine arteries. Catheterization \\naverted hysterectomy in close to 80% of cases.\\n9.3.1\\u2003 |\\u2003 Complications\\nSome studies have documented resumption of menses and even \\npregnancies after the procedure.15 Complications of pelvic embo -\\nlization for PPH occur at a rate of 8.7%. The most common com -\\nplication is low-  grade fever. Less common complications are pelvic \\ninfection, groin hematoma, iliac artery perforation, transient buttock \\nischemia, transient foot ischemia, and bladder gangrene. Lee et al.16 \\nlisted dissection of the uterine arteries, hematoma at the puncture \\nsite, paresthesia, and lower limb edema as complications.\\nCurrently, most PPH cases requiring hysterectomy are related to \\nplacenta previa.17 . These patients are commonly diagnosed before \\ndelivery and are usually delivered by elective cesarean delivery. This \\nplanning may allow increased use of invasive radiological services \\nin the management of such cases by inserting the intra-  arterial bal -\\nloons before going to surgery.\\n9.3.2\\u2003 |\\u2003 Implementation of treatment\\n1. A radiologist trained in embolization techniques is a prerequisite, \\nas is the appropriate equipment for vascular intervention. Digital \\nroad-  mapping may be required, and the possible complexity \\nmeans that this procedure can only be performed in a fully \\nequipped X-  ray department.8\\n2. The obstetrics staff and interventional radiologist select the ap -\\npropriate operative procedure (UAE or cesarean hysterectomy) \\nbased on the patient's clinical condition and a refractory response \\nto conservative medical management.8\\n3. UAE is preferred for patients who have a stable systolic and dias -\\ntolic blood pressure or heart rate.REFERENCES\\n 1. Kim TH, Lee HH, Kim JM, Ryu AL, Chung SH, Seok LW. Uterine \\nartery embolization for primary postpartum hemorrhage. Iran J \\nReprod Med . 2013;11:511–  518.\\n 2. Ganguli S, Stecker MS, Pyne D, Baum RA, Fan CM. Uterine artery \\nembolization in the treatment of postpartum uterine hemorrhage. J \\nVasc Interv Radiol . 2011;22:169–  176.\\n 3. Bros S, Chabrot P, Kastler A, et al Recurrent bleeding within \\n24 hours after uterine artery embolization for severe postpartum \\nhemorrhage: are there predictive factors? Cardiovasc Intervent \\nRadiol . 2012;35:508–  514.\\n 4. Hong TM, Tseng HS, Lee RC, Wang JH, Chang CY. Uterine artery \\nembolization: an effective treatment for intractable obstetric hae -\\nmorrhage. Clin Radiol . 2004;59:96–  101.\\n 5. Jung HN, Shin SW, Choi S-  J, et al Uterine artery embolization for \\nemergent management of postpartum hemorrhage associated with \\nplacenta accreta. Acta Radiol . 2011;52:638–  642.\\n 6. Soyer P, Morel O, Fargeaudou Y, et al Value of pelvic embolization \\nin the management of severe postpartum hemorrhage due to pla -\\ncenta accreta, increta or percreta. Eur J Radiol . 2011;80:729–  735.\\n 7. Diop AN, Chabrot P, Bertrand A, et al Placenta accreta: manage -\\nment with uterine artery embolization in 17 cases. J Vasc Interv \\nRadiol . 2010;21:644–  648.\\n 8. Wee L, Barron J, Toye R. Management of severe postpar -\\ntum haemorrhage by uterine artery embolization. Br J Anaesth . \\n2004;93:591–  594.\\n 9. Mahankali SS. Interventional radiology: a disruptive innovation \\nwhich is transforming management of post-  partum haemorrhage. \\nJournal of Obstetric Anaesthesia and Critical Care . 2017;7:65–  68.\\n 10. Angstmann T, Gard G, Harrington T, Ward E, Thomson A, Giles W. \\nSurgical management of placenta accreta: a cohort series and sug -\\ngested approach. Am J Obstet Gynecol . 2010;202(38):e1–  9.\\n 11. Mushtaq S, Kurdi W, Al-  Shammari M. Prophylactic catheters place -\\nment and intraoperative internal iliac artery embolisation in a pa -\\ntient with placenta accreta. J Obstet Gynaecol . 2007;27:853–  855.\\n 12. Thon S, McLintic A, Wagner Y. Prophylactic endovascular place -\\nment of internal iliac occlusion balloon catheters in parturients with \\nplacenta accreta: a retrospective case series. Int J Obstet Anesth . \\n2011;20:64–  70.\\n 13. Ojala K, Perälä J, Kariniemi J, Ranta P, Raudaskoski T, Tekay A. \\nArterial embolization and prophylactic catheterization for the \\ntreatment for severe obstetric hemorrhage. Acta Obstet Gynecol \\nScand . 2005;84:1075–  1080.\\n 14. Badawy SZ, Etman A, Singh M, Murphy K, Mayelli T, Philadelphia M. \\nUterine artery embolization: the role in obstetrics and gynecology. \\nClin Imaging . 2001;25:288–  295.\\n 15. Gizzo S, Saccardi C, Patrelli TS, et al. Fertility rate and subse -\\nquent pregnancy outcomes after conservative surgical techniques \\nin postpartum hemorrhage: 15 years of literature. Fertil Steril . \\n2013;99(7):2097–  2107.\\n 16. Lee HY, Shin JH, Kim J, et al Primary postpartum hemorrhage: out -\\ncome of pelvic arterial embolization in 251 patients at a single insti -\\ntution. Radiology . 2012;264:903–  909.\\n 17. Gibbins KJ, Einerson BD, Varner MW, Silver RM. Placenta previa \\nand maternal hemorrhagic morbidity. J Matern Fetal Neonatal Med . \\n2018;31(4):494–  499.\\nBOX 9\\u2003FIGO recommends uterine artery \\nembolization for refractory bleeding uncontrolled by \\nmedical and nonsurgical treatment modalities with \\nthe availability of trained personnel and necessary \\nequipment for using this technology.  \\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 35}), Document(page_content=\"\\u2003\\u2002\\u2003|\\u2003 39\\nESCOBAR Et Al.\\n10\\u2003 |\\u2003SURGICAL TREATMENT\\n10.1\\u2003 |\\u2003 Uterine compression sutures for PPH\\nWhen a decision is made for surgical intervention, adequate opera -\\ntive theatre should be set up with adequate anesthesia, surgical and \\nnursing staff, and blood should be available for transfusion. Upon \\nlaparotomy, bleeding at the surgical site should be minimized by ad -\\nequate packing to minimize time lost for suturing while active bleed -\\ning is ongoing. In all cases the uterus should be fully exteriorized, if \\npossible. Blood loss should be minimized while fully extending the \\nuterus, causing vasoconstriction and a tourniquet placed around the \\nlow segment until surgical compression sutures are successfully ap -\\nplied.1 This enables the surgical team to use the following described \\nmethods by applying the uterine compression sutures with a high \\ndegree of safety. In addition, injections of vasopressin at a dose \\nof 4 U in 20 ml of saline in the placental bed after removal of the \\nplacenta may lead to reduced blood loss as well.2 Placement of en -\\ndouterine square hemostatic sutures may also be used to control \\nbleeding from the placental bed.3\\nHemostatic suturing technique as a second-  line strategy for con -\\ntrol of uterine bleeding due to uterine atony is an effortless, fast, and \\nconservative surgical procedure. It can be performed satisfactorily \\nafter a cesarean delivery or after a vaginal delivery.4 Complications \\nrelated to its application have been identified but there are no re -\\nports of deaths related to compression sutures. Complications can \\ninclude uterine synechia or ischemia, uterine necrosis,5 intrauterine \\ninfection,6 and strangulation of the intestinal loop and abdominal \\nomentum when nonabsorbable stitches are used,7 but nonabsorb -\\nable sutures can be used if other types of sutures are not available.\\nWhile most births are uncomplicated, obstetricians are often \\nfaced with PPH at the time of vaginal or cesarean delivery.8,9 If ini -\\ntial management with fundal massage, manual uterine compression, \\nor uterotonics (oxytocin, misoprostol, methergine, or carboprost \\ntromethamine) does not adequately reduce bleeding, placement of \\ncompression sutures can be done to slow bleeding and stabilize the \\npatient, avoid hysterectomy, and ultimately reduce maternal mor -\\nbidity or death. The three most used compression suture techniques \\nfor PPH are B- Lynch,10 Hayman,11 and Pereira.12 Other compression \\nsutures are cited in the literature, such as Cho, Ouahba, Hackethal, \\nand Massuba.8 If a Bakri balloon is available, the obstetrician can \\ncombine any of these three compression sutures with the placement \\nof the balloon to tamponade bleeding. In some instances, expedient \\nplacement of an O’Leary stitch for temporary devascularization of \\nthe uterine arteries can decrease bleeding and allow additional time \\nfor placement of the compression sutures. As with the conduct of \\ncesarean delivery, specific practical issues have to be considered. \\nFirst, the obstetrician should be well versed in sterile pelvic vascular \\noperative techniques, as placement of sutures will occur at the time \\nof cesarean delivery or with laparotomy following vaginal delivery \\nand PPH. Second, since time is critical to reducing maternal blood \\nloss, an operative team with the technical skills for additional an -\\nesthesia, administration of blood products, and surgical assistance is crucial to the success of surgical management. Three commonly \\nused compression sutures are described below and existing data are \\nsummarized on the effectiveness of each compression technique.\\n10.1.1\\u2003 |\\u2003 Commonly used compression sutures for \\nmanaging PPH\\nThe B-  Lynch suture was first introduced in 1997 by Christopher \\nLynch to address hemorrhage with open hysterotomy at the time \\nof cesarean delivery.10 A suture is placed on the right side of the \\nhysterotomy, entering at the base of the incision and exiting at the \\ntop.13 The suture is then carried across the top of the right fundus \\nand a posterior stitch is placed, with the entrance of the suture at \\nthe same level of the anterior suture and exiting on the left posterior \\nside of the uterus at the level of the uterine incision. Suture is then \\nlooped over the left fundus, and another stitch is placed at the top \\nof the left side of the uterine incision and exiting at the base of the \\nincision. The suture is then tugged tightly, compressing the body of \\nthe uterus with placement of a surgeon's knot. Following placement \\nof the B-  Lynch suture, the transverse hysterotomy is closed in the \\nusual fashion. In the original description of B- Lynch, a chromic su -\\nture was used. Subsequent case studies have reported successful \\nuse of a monocryl suture.\\nAdditional options for compression sutures include the \\nHayman and Pereira. In 2002, the Hayman suture was designed to \\nbe a technically easier alternative to the B-  Lynch suture that could \\nbe placed expediently and not require hysterotomy. The steps for \\nplacing a Hayman suture include two to four longitudinal (on the \\nleft and right side of the uterus) sutures that pass directly from \\nthe anterior uterine wall and through the posterior uterine wall \\nand are tied using a surgeon's knot at the fundus. A transverse \\ncervicoisthmic suture traversing the anterior and posterior uterine \\nwalls can be placed to address bleeding from the lower uterine \\nsegment.\\nThe Pereira compression technique includes five sutures, com -\\nbining two longitudinal sutures with three transverse sutures. The \\nadvantage of the Pereira sutures is that placement occurs in the \\nsubmucosal region and avoids the endometrial cavity. However, at -\\ntention is needed for correct placement of the transverse sutures to \\nprevent damage to the uterine vessels and ureters.\\nBased on the available literature, the success rate of compres -\\nsion sutures in achieving hemostasis is 76%–  100%.14 To date, no \\nrandomized controlled trials or controlled studies have compared \\nthe efficacy of the different compression sutures. In the three orig -\\ninal studies for B-  Lynch, Hayman, and Pereira, success rates were \\nreported as 100% (5/5 for B-  Lynch, 3/3 for Hayman, and 7/7 for \\nPereira). In a systematic review,14 the overall success rate of com -\\npression sutures was reported as 91.7%. Given the broad use of \\ncompression sutures and the impact on maternal morbidity and \\nmortality, it is unlikely that a randomized controlled trial to compare \\nthe efficacy of different compression techniques will be conducted. \\nHowever, an observational study comparing the effectiveness of \\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 36}), Document(page_content='40\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\ndifferent compression sutures on estimated blood loss and measures \\nof maternal morbidity is an obvious next step to move the literature \\nforward.\\nREFERENCES\\n 1. Huijgen QCA, Gijsen AF, Hink E, Van Kesteren PJM. Cervical tourni -\\nquet in case of uncontrollable haemorrhage during caesarean sec -\\ntion owing to a placenta accreta. Case Reports . 2013;2013(apr22 \\n1):bcr2013009237.\\n 2. Kato S, Tanabe A, Kanki K, et al Local injection of vasopressin re -\\nduces the blood loss during cesarean section in placenta previa. J \\nObstet Gynaecol Res . 2014;40:1249–  1256.\\n 3. Arduini M, Epicoco G, Clerici G, Bottaccioli E, Arena S, Affronti G. \\nB- Lynch suture, intrauterine balloon, and endouterine hemostatic \\nsuture for the management of postpartum hemorrhage due to pla -\\ncenta previa accreta. Int J Gynecol Obstet . 2010;108(3):191–  193.\\n 4. Kayem G, Kurinczuk JJ, Alfirevic Z, Spark P, Brocklehurst P, Knight \\nM. Specific second-  line therapies for postpartum haemorrhage: a \\nnational cohort study. BJOG . 2011;118:856–  864.\\n 5. Joshi VM, Shrivastava M. Partial ischemic necrosis of the \\nuterus following a uterine brace compression suture. BJOG . \\n2004;111:279–  280.\\n 6. Ochoa M, Allaire AD, Stitely ML. Pyometria after hemostatic square \\nsuture technique. Obstet Gynecol . 2002;99:506–  509.\\n 7. Wu HH, Yeh GP. Uterine cavity synechiae after hemostatic square \\nsuturing technique. Obstet Gynecol . 2005;105(5 Pt 2):1176–  1178.\\n 8. Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z. \\nTreatment for primary postpartum haemorrhage. Cochrane \\nDatabase Syst Rev . 2014;(2):CD003249.\\n 9. Cunningham FG, Leveno KJ, Bloom SL, et al. Williams Obstetrics , \\n23rd edn. McGrawHill; 2010.\\n 10. B- Lynch C, Coker A, Lawal AH, Abu J, Cowen MJ. The B-  Lynch \\nsurgical technique for the control of massive postpartum haem -\\norrhage: an alternative to hysterectomy? Five cases reported. Br J \\nObstet Gynaecol . 1997;104:372–  375.\\n 11. Hayman RG, Arulkumaran S, Steer PJ. Uterine compression sutures: \\nsurgical management of postpartum hemorrhage. Obstet Gynecol . \\n2002;99:502–  506.\\n 12. Pereira A, Nunes F, Pedroso S, Saraiva J, Retto H, Meirinho M. \\nCompressive uterine sutures to treat postpartum bleeding second -\\nary to uterine atony. Obstet Gynecol . 2005;106:569–  572.\\n 13. Price N, B-  Lynch C. Technical description of the B-  Lynch brace su -\\nture for treatment of massive postpartum hemorrhage and review \\nof published cases. Int J Fertil Womens Med . 2005;50:148–  163.\\n 14. Doumouchtsis SK, Papageorghiou AT, Arulkumaran S. Systematic \\nreview of conservative management of postpartum hemorrhage: \\nwhat to do when medical treatment fails. Obstet Gynecol Surv . \\n2007;62:540–  547.\\n10.2\\u2003 |\\u2003 Uterine artery ligation\\nUterine artery ligation has been described for the control of PPH \\nsince 1960; it is considered a simple, fast-  performing technique1 and \\none of the most popular fertility-  preserving surgical techniques.2 It is an effective management strategy for bleeding control with suc -\\ncess rates of 42% and 88% described.3– 6\\nThe recent evidence on the effectiveness of uterine artery ligation \\nto control bleeding in PPH is centered on case reports, mainly asso -\\nciated with other techniques and with the use of tranexamic acid.7– 11 \\nThe success rates for the procedure are higher depending on the time \\nof the intervention from the beginning of the bleeding, the presence \\nof coagulopathy, and the expertise of the surgeons.12,13 The latest \\nCochrane systematic review of mechanical and surgical interventions \\nfor treating primary PPH found no controlled clinical trials evaluating \\nits effectiveness for uterine artery ligation.14\\nREFERENCES\\n 1. O\\'Leary JL, O\\'Leary JA. Uterine artery ligation in the control \\nof intractable postpartum hemorrhage. Am J Obstet Gynecol . \\n1966;94(7):920–  924.\\n 2. Verit FF, Çetin O, Keskin S, Akyol H, Zebitay AG. Does bilateral \\nuterine artery ligation have negative effects on ovarian reserve \\nmarkers and ovarian artery blood flow in women with postpartum \\nhemorrhage? Clin Exp Reprod Med . 2019;46(1):30–  35.\\n 3. Joshi VM, Otiv SR, Majumder R, Nikam YA, Shrivastava M. Internal \\niliac artery ligation for arresting postpartum haemorrhage. BJOG . \\n2007;114:356–  361.\\n 4. Papp Z, Tóth-  Pál E, Papp C, et al. Hypogastric artery ligation for \\nintractable pelvic hemorrhage. Int J Gynecol Obstet . 2006;92(1):  \\n27– 31.\\n 5. Ledee N, Ville Y, Musset D, Mercier F, Frydman R, Fernandez H. \\nManagement in intractable obstetric haemorrhage: an audit study \\non 61 cases. Eur J Obstet Gynecol Reprod Biol . 20 01;94:189– 196.\\n 6. Unal O, Kars B, Buyukbayrak EE, Karsidag AY, Turan C. The effec -\\ntiveness of bilateral hypogastric artery ligation for obstetric hem -\\norrhage in three different underlying conditions and its impact on \\nfuture fertility. J Matern Fetal Neonatal Med . 2011;24:1273–  1276.\\n 7. Abbas AM, Shady NW, Sallam HF. Bilateral uterine artery ligation \\nplus intravenous tranexamic acid during cesarean delivery for pla -\\ncenta previa: a randomized double-  blind controlled trial. J Gynecol \\nObstet Hum Reprod . 2019;48(2):115–  119.\\n 8. Kaya B, Tuten A, Daglar K, et al B-  Lynch uterine compression su -\\ntures in the conservative surgical management of uterine atony. \\nArch Gynecol Obstet . 2015;291(5):1005–  1014.\\n 9. Kaya B, Tuten A, Daglar K, et al Balloon tamponade for the man -\\nagement of postpartum uterine hemorrhage. J Perinat Med . \\n2014;42(6):745–  753.\\n 10. Danisman N, Kahyaoglu S, Celen S, et al. The outcomes of surgical \\ntreatment modalities to decrease \"near miss\" maternal morbidity \\ncaused by peripartum hemorrhage. Eur Rev Med Pharmacol Sci . \\n2014;18(7):1092–  1097.\\n 11. Kaya B, Damarer Z, Daglar K, Unal O, Soliman A, Guralp O. Is there \\nyet a role for internal iliac artery ligation in obstetric hemorrhage \\nwith the current gain in popularity of other uterus sparing tech -\\nniques? J Matern Fetal Neonatal Med . 2017;30(11):1325–  1332.\\n 12. American College of Obstetricians and Gynecologists. \\nACOG Practice Bulletin: Clinical Management Guidelines for BOX 10\\u2003FIGO recommends compression sutures as \\none of the options to control PPH when medical and \\nnonsurgical treatment modalities fail.  \\nBOX 11\\u2003FIGO recommends uterine artery ligation as \\none of the options to rapidly control PPH when \\nmedical, nonsurgical approaches, and compression \\nsutures fail.  \\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 37}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 41\\nESCOBAR Et Al.\\nObstetrician-  Gynecologists Number 76, October 2006: postpar -\\ntum hemorrhage. Obstet Gynecol . 2006;108(4):1039–  1047.\\n 13. Vanwinkel S, Claes L, Van den Bosch T. Obstetrical outcome after \\nB- Lynch sutures and ligation of uterine arteries: a case report. Case \\nRep Womens Health . 2021;30:e00303.\\n 14. Kellie FJ, Wandabwa JN, Mousa HA, Weeks AD. Mechanical and \\nsurgical interventions for treating primary postpartum haemor -\\nrhage. Cochrane Database Syst Rev . 2020;(7):CD013663.\\n10.3\\u2003 |\\u2003 Bilateral internal iliac artery ligation\\nInternal iliac artery ligation was first performed by Kelly in 1894,1 \\nwith reported success rates between 40% and 100%.2,3 It reduces \\npelvic blood flow by half and pulse pressure by 85%, thereby simu -\\nlating a venous rather than an arterial circulation, and promoting \\nhemostasis.1,2 Although this technique provides a rapid and effec -\\ntive way to control hemorrhage, it remains underused because of \\nunderstandable fear of injury to surrounding structures: internal and \\nexternal iliac arteries and ureters2,4 and should only be considered if \\nexperienced pelvic surgeons are available. Internal iliac artery liga -\\ntion may avoid the need for hysterectomy in the context of uterine \\natony.2 In addition, in cases of traumatic PPH such as uterine rupture \\nand extensive genital injuries, internal artery ligation clears the op -\\nerative field and facilitates hysterectomy.2\\nDuring the procedure, the common iliac artery is identified. \\nAfter dissection, the ureter is visualized crossing the common iliac \\nartery at its bifurcation. The common iliac artery branches into an \\ninternal iliac (hypogastric) artery, coursing medially and inferiorly, \\nand the external iliac artery coursing laterally and superiorly. The \\narteries are not infrequently adherent to the underlying veins and \\nrequire appropriate dissection.5 With right-  angled forceps a su -\\nture is introduced between the artery and the vein, and a knot is \\nmade.4,5\\nNoteworthy is that even after bilateral internal iliac artery li -\\ngation, the vascular supply to the pelvis is not completely compro -\\nmised due to the extensive collateral circulation that exists.4,5 The \\nrevascularization is provided by the deep femoral artery, the anas -\\ntomosis between the medial femoral circumflex and obturator ar -\\ntery, and that between the lateral femoral circumflex and superior \\ngluteal artery, and the ovarian artery.4,5 Obstetricians ought to be \\nmore familiar with this procedure as it is an effective and rapid way \\nto control PPH.REFERENCES\\n 1. Burchell RC. Physiology of internal iliac artery ligation. J Obstet \\nGynaecol Br Commonw . 1968;75:642–  651.\\n 2. Joshi VM, Otiv SR, Majumder R, Nikam YA, Shrivastava M. Internal \\niliac artery ligation for arresting postpartum haemorrhage. BJOG . \\n2007;114:356–  361.\\n 3. Wang CY, Pan HH, Chang CC, Lin CK. Outcomes of hypogastric \\nartery ligation and transcatheter uterine artery embolization in \\nwomen with postpartum hemorrhage. Taiwan J Obstet Gynecol . \\n2019;58:72–  76.\\n 4. Selçuk İ, Uzuner B, Boduç E, Baykuş Y, Akar B, Güngör T. Step-  by- \\nstep ligation of the internal iliac artery. J Turk Ger Gynecol Assoc . \\n2019;20:123–  128.\\n 5. B- Lynch C, Keith LG, Campbell WB. Internal iliac (hypogastric) ar -\\ntery ligation. In: Arulkumaran S, Karoshi M, Keith LG, Lalonde AB, B- \\nLynch C. eds. A Comprehensive Textbook of Postpartum Hemorrhage , \\n2nd edn. Sapiens Publishing; 2012:441–  447.\\n10.4\\u2003 |\\u2003 Hysterectomy\\nPeripartum hysterectomy is performed in the treatment of PPH \\nwhen all other conventional methods fail to control the bleeding.1 \\nThe prevalence is higher in low-  income regions than in high-  income \\nregions (2.8 and 0.7 per 1000 deliveries, respectively).2 The in -\\ncidence of this procedure has been on the rise, increasing by 15% \\nin the USA between 1994 and 2007.3 Similarly, in Turkey, the rate \\nhas increased from 0.03% in 2000–  2006 to 0.07% in 2007–  2013. \\nIn most of the studies, this was attributed to the increased rates of \\ncesarean delivery.1– 5\\nThe most common indications for peripartum hysterectomy are \\nplacental pathology such as abnormal placentation, placenta previa, \\nand placental abruption (38%), uterine atony (27%), and uterine rup -\\nture (26%).2 Peripartum hysterectomy is associated with high rates \\nof maternal morbidity and complications due to the need for blood \\ntransfusions, coagulation disorders, injury to the urinary tract, the \\nneed for re-  exploration in case of persistent bleeding, and postop -\\nerative fever.1\\nThe maternal mortality rate varies according to countries, rang -\\ning from 0% in Turkey,6 the UK,7 and New Zealand,8 to 3.2% in \\nAustralia,9 and as high as 11.8% in Nigeria.10\\nREFERENCES\\n 1. Demirci O, Tuğrul AS, Yilmaz E, Tosun Ö, Demirci E, Eren YS. \\nEmergency peripartum hysterectomy in a tertiary obstetric center: \\nnine years evaluation. J Obstet Gynaecol Res . 2011;37:1054–  1060.BOX 12\\u2003FIGO recommends internal iliac artery \\nligation as one of the options to rapidly control PPH \\nfor management of PPH when medical, nonsurgical \\napproaches, and compression sutures fail.\\nFIGO also recommends that all obstetricians familiarize them -\\nselves with the internal iliac artery location and with the tech -\\nnique of its ligation.BOX 13\\u2003FIGO recommends abdominal hysterectomy \\nas treatment for PPH when all other medical, \\nnonsurgical, and surgical treatment modalities have \\nfailed to control PPH.\\nCare must be taken to have adequate blood supplies. Subtotal \\nhysterectomy can shorten the procedure and is important in a \\nhemodynamically unstable patient.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 38}), Document(page_content='42\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\n 2. Van den Akker T, Brobbel C, Dekkers OM, Bloemenkamp KW. \\nPrevalence, indications, risk indicators, and outcomes of emer -\\ngency peripartum hysterectomy worldwide: a systematic review \\nand meta-  analysis. Obstet Gynecol . 2016;128:1281–  1294.\\n 3. Bateman BT, Mhyre JM, Callaghan WM, Kuklina EV. Peripartum \\nhysterectomy in the United States: nationwide 14 year experience. \\nAm J Obstet Gynecol . 2012;206(63):e1– 8.\\n 4. Temizkan O, Angın D, Karakuş R, Şanverdi İ, Polat M, Karateke \\nA. Changing trends in emergency peripartum hysterectomy in a \\ntertiary obstetric center in Turkey during 2000–  2013. J Turk Ger \\nGynecol Assoc . 2016;17:26–  34.\\n 5. Chawla J, Arora D, Paul M, Ajmani SN. Emergency obstetric hyster -\\nectomy: a retrospective study from a Teaching Hospital in North \\nIndia over eight years. Oman Med J . 2015;30:181–  186.\\n 6. Danisman N, Baser E, Togrul C, Kaymak O, Tandogan M, Gungor \\nT. Emergency peripartum hysterectomy: experience of a major referral hospital in Ankara. Turkey. J Obstet Gynaecol . 2015;35:  \\n19– 21.\\n 7. Jones B, Zhang E, Alzouebi A, et al Maternal and perinatal out -\\ncomes following peripartum hysterectomy from a single tertiary \\ncentre. Aust N Z J Obstet Gynaecol . 2013;53:561–  565.\\n 8. Wong TY. Emergency peripartum hysterectomy: a 10-  year review \\nin a tertiary obstetric hospital. N Z Med J . 2011;124:34–  39.\\n 9. Awan N, Bennett MJ, Walters WA. Emergency peripartum hyster -\\nectomy: a 10-  year review at the Royal Hospital for Women, Sydney. \\nAust N Z J Obstet Gynaecol . 2011;51:210–  215.\\n 10. Akintayo AA, Olagbuji BN, Aderoba AK, Akadiri O, Olofinbiyi BA, \\nBakare B. Emergency peripartum hysterectomy: a multicenter \\nstudy of incidence, indications and outcomes in Southwestern \\nNigeria. Matern Child Health J . 2016;20:1230–  1236.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 39}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 43\\nESCOBAR Et Al.\\n11\\u2003 |\\u2003ASSESSMENT AND RESUSCITATION\\n11.1\\u2003 |\\u2003 Damage control resuscitation in PPH\\nHemorrhagic shock is the most frequent type of shock in ob -\\nstetric patients.1 Blood loss exceeding 40% of total blood vol -\\nume leads to global hypoxia and metabolic acidosis.2 These \\nmetabolic complications, accompanied by organ hypoperfusion, \\ntrigger an irreversible state of coagulopathy, bolstering hemor -\\nrhage and inducing multiple organ dysfunction and death.3 The \\nconcept of damage control resuscitation (DCR) was first reported \\nby trauma surgeons and its applicability has spread in traumatic \\nand nontraumatic scenarios in general surgery, orthopedics, and \\nobstetrics.4 DCR consists of a series of strategies to minimize \\nhemorrhage, prevent the deadly triad (coagulopathy, acidosis, and \\nhypothermia), and maximize tissue oxygenation. This is achieved \\nby a staged surgical approach that minimizes operative time, \\ncounteracting life-  threatening conditions and deferring the de-\\nfinitive surgical procedures until normal physiology is restored at \\nthe intensive care unit (ICU).5– 7\\nEfforts in DCR are focused on permissive resuscitation by \\nblood product transfusion, use of massive blood transfusion \\nprotocols, limited use of crystalloids, bleeding control (including \\ndamage control surgery [DCS] and damage control interventional \\nradiology [DCIR]), and physiological and biochemical stabilization \\nin the ICU.4– 6 DCR is usually reserved for severely injured patients \\nwho may not survive the surgical efforts to achieve primary re -\\npair in the operating room.4 It is evident that this approach can be \\nconsidered only in higher-  level care facilities where there is avail -\\nability of experienced personnel with 24-  h laboratory and blood \\nbank services.\\nThe most important aspects of DCS are described below. \\nHypotensive and hemostatic reanimation are discussed in sections \\n11.2.1 and 11.2.6, respectively.\\n11.1.1\\u2003 |\\u2003 Decision for damage control surgery\\nPhysiological and metabolic markers have been proposed to \\nidentify patients that could benefit from DCS.4 Three parameters \\nhave been described in the literature as significant clinical indica -\\ntors for early implementation of DCR and DCS8: acidosis (base \\ndeficit >8), blood loss > 1500  ml, and hypothermia (temperature \\n<35°C). Other important parameters to consider are systolic \\nblood pressure < 70 mm Hg, maternal blood pH < 7.1, and persis -\\ntent bleeding despite several transfusions (defined as 6 units of \\npacked red blood cells by some authors7 and > 10 units by oth -\\ners4) (Table 9).\\nContinuous vital sign monitoring and serial monitoring with blood \\ngas analysis and body temperature are recommended. Operative \\ntime and number of blood units transfused are also crucial for DCR \\ndecision-  making.411.1.2\\u2003 |\\u2003 Bleeding control\\nAfter identifying eligible DCS patients, when medical and surgical \\nconservative measures to control bleeding fail, a sequential four- \\nphase approach should be performed.4\\nInitial laparotomy\\nThe primary objective is hemorrhage control, which is achieved \\nby an abdominal hysterectomy. The type of hysterectomy to \\nbe performed depends on the preference and expertise of the \\noperator and the clinical condition of the patient; other factors \\nsuch as age, cause of hemorrhage, hemodynamic stability, and \\npelvic anatomy must be considered.9 According to several stud -\\nies, there are no statistically significant differences between \\ntotal and subtotal hysterectomy in terms of complications, blood \\ntransfusions, and ICU admission.9– 11 Subtotal hysterectomy has \\nbeen associated with quicker hemorrhage control and shorter \\noperative times, hence is the preferred approach over total \\nhysterectomy.9,11\\nThe bleeding site must be identified to pick the most suitable \\napproach. When the bleeding is in the lower uterine segment, \\ncervix, or vaginal fornices, a subtotal hysterectomy may not be \\nthe most effective approach for hemorrhage control since the ar -\\nterial circulation of the cervix has a high blood flow rate and could \\ncause bleeding persistence. In these cases, total hysterectomy is \\npreferred.9,10\\nOperative time is a crucial determinant in patient survival. \\nProlonged operative time has been linked to adverse outcomes as it \\ncan institute an irreversible physiologic insult; thus, the need to keep \\noperative time under 90  min.4TABLE 9 \\u2003Alternative indications for damage control surgery \\nsecondary to postpartum hemorrhagea\\nIndication\\nSystolic blood pressure < 70 mm Hg\\nBody temperature < 34ºC\\nMaternal blood pH < 7.1\\nVenous bleeding not suitable for surgical control\\nPersistent bleeding despite several transfusions of blood products \\n(>10 units of PRBC)\\nMassive transfusion: 6 units of Red Blood Cells (during the first 4 h)\\nIncreasing and continuous need for fluids due to active nonarterial \\nbleeding\\nHemodynamic instability, requiring persistent vasopressor support \\nor that results in the development of ventricular arrhythmias\\nCoagulopathy resulting from a combination of hypothermia \\n(temperature < 35°C), acidosis (pH < 7.3), and loss of coagulation \\nfactors\\nDuration of surgery > 90 min\\naSource: Carvajal et al. [4] and Pacheco et al. [7]. Adapted with \\npermission.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 40}), Document(page_content='44\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\nAs in other surgical specialties, packing is the cornerstone of \\nobstetric DCS.4,7 Pelvic packing should be performed with at least \\n7– 10 compresses, according to reported experience.2,12 Aside from \\npelvic packing, temporary abdominal closure is performed along -\\nside, as a complementary feature of the procedure. The latter can \\nbe achieved using a negative pressure system like vacuum pack or \\npartial closure with a Viaflex bag (Bogota Bag) without the need \\nfor negative pressure.2,12 Currently, there is neither consensus nor \\nsufficient evidence regarding the use of prophylactic antibiotics in \\npatients undergoing DCS with abdominal packing.4 Several surgi -\\ncal guidelines recommend the administration of a single preopera -\\ntive dose of broad-  spectrum antibiotics, which theoretically should \\nprovide sufficient coverage for aerobic and anaerobic microorgan -\\nisms.4,13,14 Other experts suggest administration of prophylactic \\nbroad-  spectrum antibiotics every 6–  8 h until the abdominal packing \\nis removed. Nevertheless, further studies are necessary to provide \\nevidence-  based recommendations in the obstetric population.7\\nResuscitation –   ICU\\nAt this stage, the patient must be transferred to the ICU to address \\nthe physiologic derangements of the hemorrhagic patient: coagula -\\ntion disorders and metabolic abnormalities.6 Interdisciplinary care \\ninvolving the obstetrician and critical care specialist is key for these \\npatients as complications could arise at any time.4 It is crucial to ac -\\ncurately quantify the accumulation of blood in the abdominal cavity. \\nThe optimal device to do so, after partial abdominal closure, is the \\nvacuum pack, which allows a more precise quantification of bleeding \\nduring the postoperative period. In patients without coagulopathy, \\nthe drainage of > 400 ml/h of blood through the vacuum pack repre -\\nsents an early indication for laparotomy.4\\nDefinitive surgery\\nAfter restoring normal physiology, it is considered safe to review the \\nabdominal cavity. Ideally, this should be performed 48–  72 h after the \\ninitial surgical procedure.4 Patients may require one or more surgical \\ninterventions, depending on the operative findings. In cases where \\nfurther interventions are warranted, it is recommended to continue \\nwith techniques of temporary closure of the abdominal cavity.15\\nDefinitive closure of abdominal wall and cavity\\nThe final stage is the definitive closure of the abdominal wall, which \\nis performed after all surgeries have been successfully completed \\nand all additional damage has been repaired.4\\n11.1.3\\u2003 |\\u2003 Complications\\nThe majority of DCS complications depend on the time of closure \\nof the abdominal fascia. It is important to consider that the number \\nof reinterventions is directly related to a higher percentage of infec -\\ntious complications, wound dehiscence, and abdominal wall closure \\nproblems.16 The main complications include infection of the surgical \\nwound in 28% of cases, presence of intra-  abdominal collections in 20%, and evisceration in 10% of patients.2 Implementation of pro -\\nphylactic antibiotic therapy could counteract these complications, as \\nit targets the polybacterial flora present in the female genital tract. \\nAn interdisciplinary approach could be required in case of complica -\\ntions derived from injuries secondary to the surgical procedure such \\nas urinomas, perforations, or fistulas, among others.17\\n11.1.4\\u2003 |\\u2003 Final objectives in resuscitation\\nDCR should be maintained as long as there are signs of bleeding and \\ncoagulopathy. A continuous assessment of the hemodynamic and \\nphysiological status of the patient is required. Monitoring several \\nresuscitation parameters is essential until tissue hypoxia reverts. \\nThese parameters include pH, base deficit, lactate, hematocrit, and \\ncoagulation—  ideally evaluated with conventional laboratory tests \\nand point-  of- care testing (POCT) of viscoelastic coagulation such \\nas thromboelastography (TEG) and rotational thromboelastometry \\n(ROTEM). In patients with a clinical trend toward improvement, the \\ndecision to perform definitive surgery is appropriate.4\\nREFERENCES\\n 1. Pacheco LD, Saade GR, Gei AF, Hankins GD. Cutting-  edge advances \\nin the medical management of obstetrical hemorrhage. Am J Obstet \\nGynecol . 2011;205:526–  532.\\n 2. Ordóñez CA, Nieto AJ, Carvajal JA, et al Damage control surgery \\nfor the management of major obstetric hemorrhage: experience \\nfrom the Fundación Valle del Lili, Cali, Colombia. Panamerican \\nJournal of Trauma, Critical Care and Emergency Surgery . 2017;6:1– 7.\\n 3. Clark SL, Hankins GD. Preventing maternal death: 10 clinical dia -\\nmonds. Obstet Gynecol . 2012;119(2 Pt 1):360–  364.\\n 4. Carvajal JA, Ramos I, Kusanovic JP, Escobar MF. Damage- \\ncontrol resuscitation in obstetrics. J Matern Fetal Neonatal Med . \\n2022;35:785–  798.\\n 5. Bogert JN, Harvin JA, Cotton BA. Damage control resuscitation. J \\nIntensive Care Med . 2016;31:177– 186.\\n 6. West N, Dawes R. Trauma resuscitation and the damage control \\napproach. Surgery . 2018;36:409–  416.\\n 7. Pacheco LD, Lozada MJ, Saade GR, Hankins GDV. Damage-  control \\nsurgery for obstetric hemorrhage. Obstet Gynecol . 2018;132:423–  427.\\n 8. Ordoñez CA, Badiel M, Pino LF, et al Damage control resuscita -\\ntion: Early decision strategies in abdominal gunshot wounds \\nusing an easy “ABCD” mnemonic. J Trauma Acute Care Surg . \\n2012;73:1074–  1078.\\n 9. Gungor T, Simsek A, Ozdemir AO, Pektas M, Danisman N, \\nMollamahmutoglu L. Surgical treatment of intractable postpartum BOX 14\\u2003FIGO recommends that damage control \\nresuscitation (DCR) should be implemented in the \\nmanagement algorithms for major obstetric \\nhemorrhage.\\nAll countries should establish one or more referral hospital(s) \\nand develop expert teams that are familiar with this strategy, \\nthe technique, and indications to be able to offer DCR.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 41}), Document(page_content=\"\\u2003\\u2002\\u2003|\\u2003 45\\nESCOBAR Et Al.\\nhemorrhage and changing trends in modern obstetric perspective. \\nArch Gynecol Obstet . 2009;280:351–  355.\\n 10. Mukherjee S, Arulkumaran S. Post-  partum haemorrhage. Obstet \\nGynaecol Reprod Med . 2009;19:121–  126.\\n 11. Zhang Y, Yan J, Han Q, et al Emergency obstetric hysterectomy \\nfor life-  threatening postpartum hemorrhage: a 12-  year review. \\nMedicine . 2017;96:e8443.\\n 12. Escobar MF, García A, Fonseca J, Herrera E, Guerrero JE. Cirugía de \\ncontrol de daños: un concepto aplicable en ginecología y obstetri -\\ncia. Colombia Médica . 2005;36:110–  114.\\n 13. Goldberg SR, Anand RJ, Como JJ, et al Prophylactic antibiotic use \\nin penetrating abdominal trauma: an Eastern Association for the \\nSurgery of Trauma practice management guideline. J Trauma Acute \\nCare Surg . 2012;73(5 Suppl 4):S321–  S325.\\n 14. Godat L, Kobayashi L, Costantini T, Coimbra R. Abdominal damage \\ncontrol surgery and reconstruction: world society of emergency \\nsurgery position paper. World J Emerg Surg . 2013;8:53.\\n 15. Griggs C, Butler K. Damage control and the open abdomen: \\nchallenges for the nonsurgical intensivist. J Intensive Care Med . \\n2016;31:567–  576.\\n 16. Kirkpatrick AW, Roberts DJ, De Waele J, et al Intra-  abdominal hy -\\npertension and the abdominal compartment syndrome: updated \\nconsensus definitions and clinical practice guidelines from the \\nWorld Society of the Abdominal Compartment Syndrome. Intensive \\nCare Med . 2013;39:1190–  1206.\\n 17. Burlew CC. The open abdomen: practical implications for the prac -\\nticing surgeon. Am J Surg . 2012;204:826– 835.\\n11.2\\u2003 |\\u2003 Resuscitation\\nOnce the shock has occurred in PPH, it is estimated that the \\nmortality of patients will increase dramatically.1– 3 To mitigate \\nmetabolic complications, strategies such as hypotensive fluid re-\\nsuscitation and transfusion protocols have been studied for hemo -\\nstatic reanimation.\\nThere are two strategies for fluid resuscitation in patients with \\nhemorrhage: the aggressive approach and the hypotensive resusci -\\ntation approach. Aggressive resuscitation refers to the traditionally \\nused strategy in which the key principle is restoring the effective \\ncirculating blood volume, and rapid normalizing of blood pressure \\nwith administration of large amounts of crystalloids.2,4 Hypotensive \\nresuscitation, also called permissive hypotension, consists of restric -\\ntive crystalloid resuscitation during the early stages of a hemorrhagic \\nshock to maintain lower than normal systolic or mean blood pressure, \\nsustaining organ perfusion until control of the bleeding occurs.2,5\\nIn contrast, hemostatic reanimation is based on early and ag -\\ngressive blood product replacement, transfusing red blood cells \\n(PRBC), fresh frozen plasma (FFP), and platelets (PLT) in the same \\nproportion as found in circulating blood to correct coagulopathy.6– 8 \\nHypotensive resuscitation and hemostatic reanimation are the fun -\\ndamentals for DCR.9,10\\n11.2.1\\u2003 |\\u2003 Hypotensive resuscitation\\nThe concept of hypotensive resuscitation is because administering \\nsmall crystalloid volumes reduces the risk of dilutional coagulopathy and maintaining a lower blood pressure is less likely to disintegrate the \\npre- formed blood clots. Aggressive resuscitation may worsen coagu -\\nlopathy and hemorrhage by increasing intravascular hydrostatic pres -\\nsures, diluting coagulation factors, and inducing more hypothermia, \\nwhich results in deterioration of the triad of death.4,10,11 Furthermore, \\nan excessive rise in blood pressure could also result in higher red \\nblood cell loss leading to more hypoxia and acidosis in tissues.4,11\\n11.2.2\\u2003 |\\u2003 Intravenous fluids\\nAmong the initial strategies for reanimation, the administration of \\ncrystalloids in small boluses of 500 ml is recommended.10 Scientific \\nevidence recommends the use of balanced crystalloid solutions such \\nas Ringer's lactate owing to the risk of hyperchloremic acidosis and \\nthe worsening of kidney function with chlorine-  rich fluids (saline so-\\nlution).7 This is particularly important for LMICs, where saline-  based \\nsolutions are in abundance. After the administration of each bolus, \\nphysicians must assess the clinical status of patients, looking for an im -\\nprovement in signs and symptoms of shock resulting from blood loss.10\\n11.2.3\\u2003 |\\u2003 Targeted blood pressure\\nThe difference between aggressive and hypotensive resuscitation \\nlies within targeted blood pressure management.4 Mean arterial \\npressure (MAP) represents the perfusion of the majority of organs, \\ntherefore providing the target for clinicians to guide fluid adminis -\\ntration.11 Hemorrhagic shock animal models have demonstrated a \\npositive benefit in survival with MAP between 55–  60 mm Hg dur -\\ning active bleeding.10 The European guideline on management of \\nmajor bleeding and coagulopathy following trauma recommends \\npermissive hypotension with a systolic blood pressure target of 80– \\n90 mm Hg (MAP 50–  60 mm Hg) until major bleeding has been con -\\ntrolled (Recommendation Grade 1C).12\\n11.2.4\\u2003 |\\u2003 Aggressive approach and adverse outcomes\\nDuring hemorrhagic shock the endothelial glycocalyx becomes thin -\\nner and administration of large amounts of crystalloids exacerbates \\nthis state, leading to fluid extravasation that may cause cerebral, \\ncardiac, and pulmonary edema.7,10,11 Third spacing may also lead to \\ncardiac dysfunction, worsen hemodynamics, and decrease kidney \\nperfusion. Decreased kidney perfusion occurs because of an in -\\ncrease in intra-  abdominal pressure, which can additionally result in \\nabdominal compartment syndrome.7,11\\n11.2.5\\u2003 |\\u2003 Evidence\\nSeveral studies in trauma patients have demonstrated that hy -\\npotensive resuscitation is correlated with benefits to survival, \\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 42}), Document(page_content='46\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\nwith significantly lower PRBC and amounts of fluid required; in \\naddition, there is diminution in the occurrence of multiple organ \\ndysfunction and acute respiratory distress syndrome.2 Although \\nrecent evidence is mostly from trauma studies, a cohort study \\nof women with PPH showed that the group that received lower \\namounts of fluids had fewer signs of shock with less blood prod -\\nuct requirements.13 In addition, the study showed that increased \\nfluid administration leads to decreased concentrations of fibrin -\\nogen, hemoglobin, hematocrit, platelet count associated with \\nprolonged prothrombin time, and partial thromboplastin time.13 \\nThe study also demonstrated that administration of >4 L of flu -\\nids is associated with subsequent bleeding and adverse maternal \\noutcomes.14\\n11.2.6\\u2003 |\\u2003 Hemostatic resuscitation\\nResuscitation in hemorrhage was classically focused only on the \\nadministration of fluids and PRBC. The use of FFP, PLT, and cryo -\\nprecipitate was delayed until coagulopathy was demonstrated in \\nparaclinics.7 Hemostatic resuscitation limits the use of crystal -\\nloids and involves early administration of blood products (not only \\nPRBC), making massive transfusion protocols the cornerstone of \\nresuscitation.7,10\\n11.2.7\\u2003 |\\u2003 Transfusion ratios\\nIn hemostatic resuscitation, PRBC, FFP, and PLT are applied in a 1:1:1 \\nratio due to the resemblance with whole blood and because a “high \\nratio” is related to fewer complications and better patient survival \\noutcomes.6,7,10,15 If PRBC is not available, then whole blood can be \\nused instead in case of massive hemorrhage.\\nThe strongest evidence for massive transfusions comes from the \\nProspective, Observational, Multicenter, Major Trauma Transfusion \\n(PROMTT) and Pragmatic, Randomized, Optimal Platelet and Plasma \\nRatios (PROPPR) trials. The PROMTT study evidenced an improve -\\nment in mortality in the first 6 h for patients with high ratios of trans -\\nfusion ( <1:2 vs ≥1:1).16 Moreover, a secondary analysis from PROMTT \\nrevealed that early administration of plasma (first 3 h and within the \\nfirst 3–  6 transfused units) was related to a decrease in mortality at \\n24 h and 30 days.17 However, the PROPPR study demonstrated that \\npatients transfused with a 1:1:1 ratio achieved hemostasis and suf -\\nfered fewer deaths due to exsanguination at 24 h.18\\n11.2.8\\u2003 |\\u2003 Fibrinogen and cryoprecipitate\\nIn hemorrhages, fibrinogen is the first clotting factor to diminish its \\nconcentrations to critical levels, with values of < 200 mg/dl consid -\\nered an indication for component replacement.7,10 Achieving specific \\nfibrinogen levels is an important target during massive transfusion \\n(at least 150–  200 mg/dl in PPH).7Sources for fibrinogen replacement are FFP, cryoprecipitate, and \\nfibrinogen concentrates (which are not widely available). Because fi -\\nbrinogen concentration in FFP is variable and relatively low, and its \\nadministration may dilute the existent fibrinogen, most fibrinogen \\nreplacement is done with cryoprecipitate.12 A unit of cryoprecipitate \\ncontains 2 g fibrinogen for each 100 ml; thus, a unit of cryoprecipi -\\ntate will increase serum fibrinogen by 10 mg/dl.7 The usual dose of \\ncryoprecipitate is 10  units, which is estimated to raise serum fibrino-\\ngen by 100 mg/dl.7 Subsequent doses must be adjusted conforming \\nto serum fibrinogen levels.\\n11.2.9\\u2003 |\\u2003 Massive transfusion protocols\\nAs the underlying physiological imbalance and clinical course \\nin trauma seem similar to severe PPH, massive transfusion pro -\\ntocols with high ratios utilized for trauma may be useful for \\nPPH.19,20 Recommendations for ratios 1:1–  1:2 for transfusions \\nare different from previously proposed protocols with ratios of \\n6:4:1 or 4:4:1, as in the CMQCC Obstetric Hemorrhage Toolkit \\nand from other obstetrics societies.21 ACOG recommends admin -\\nistration of blood products in 1:1:1 ratio, mimicking whole blood \\nreplacement.22\\nMassive transfusion means requirements of ≥4 PRBC units \\n(some articles considered ≥10 PRBC within 24 h), replacement of \\ntotal blood volume within 24 h, or replacement of 50% of blood \\nvolume within 3 h.10 The protocol for massive transfusion is spe -\\ncific at each institution, but some schemes have been suggested \\nin the literature.\\nOnce the massive transfusion protocol has been activated, the \\nblood bank will send blood products in rounds to the operating or \\nlabor room. Each round has a specific number of PRBC, FFP, PLT, \\nand cryoprecipitate units according to the protocol established in \\nthe institution.\\nTypical rounds consist of 6 units PRBC, 6 units FFP, 6 units PLT or \\n1 platelet apheresis, and 10 units of cryoprecipitate (Table 10).7,23,24 \\nUnless inactivated, the blood bank will prepare and send the prod -\\nucts for rounds 2–  4 successively, and if the patient continues bleed -\\ning the protocol will start again from round 1.7\\nIt is very important to notify the blood bank as soon as the \\ntransfusion requirements decrease to stop the preparation of blood \\nproducts.7TABLE 10 \\u2003Massive transfusion protocol in obstetricsa\\nPRBCs FFP Platelets Cryoprecipitate\\nRound 1 6 U 6 U 6 U 10 U\\nRound 2 6 U 6 U 6 U 10 U\\nRound 3 Tranexamic acid 1 g intravenously over 10 min\\nRound 4 6 U 6 U 6 U\\naSource: Pacheco et al. [7].\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 43}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 47\\nESCOBAR Et Al.\\n11.2.10\\u2003 |\\u2003 Adverse outcomes\\nAlthough early transfusions are lifesaving and in theory help to \\nachieve hemostasis faster, thereby decreasing the number of \\nblood products administered, the application of multiple units \\nof blood products could be associated with a higher incidence of \\ntransfusion-  related complications. These complications include hy -\\nperkalemia, hypocalcemia, citrate toxicity, transfusion-  related im -\\nmunomodulation, transfusion-  related circulatory overload (TACO), \\ntransfusion-  related kidney injury, transfusion-  related acute lung \\ninjury (TRALI) (0.1 per 1000 units transfused), transfusion-  related \\nfebrile nonhemolytic reactions (0.8 per 1000 units transfused), and \\nacute hemolytic transfusion reaction (0.19 per 1000 units trans -\\nfused).22,24,25 Transfusion-  related infectious diseases are uncom -\\nmon (less than 1/100  000–  1 000  000).22,25\\nREFERENCES\\n 1. American College of Obstetricians and Gynecologists. ACOG \\nPractice Bulletin: Clinical Management Guidelines for Obstetrician-  \\nGynecologists Number 76, October 2006: postpartum hemor -\\nrhage. Obstet Gynecol . 2006;108:1039–  1047.\\n 2. Owattanapanich N, Chittawatanarat K, Benyakorn T, Sirikun J. \\nRisks and benefits of hypotensive resuscitation in patients with \\ntraumatic hemorrhagic shock: a meta-  analysis. Scand J Trauma \\nResusc Emerg Med . 2018;26:107.\\n 3. Cannon JW. Hemorrhagic shock. N Engl J Med . 2018;378:370–  379.\\n 4. Wang H, Chen MB, Zheng XW, Zheng QH. Effectiveness and safety \\nof hypotensive resuscitation in traumatic hemorrhagic shock: a pro -\\ntocol for meta-  analysis. Medicine . 2019;98:e18145.\\n 5. Carrick MM, Leonard J, Slone DS, Mains CW, Bar-  Or D. \\nHypotensive resuscitation among trauma patients. Biomed Res Int . \\n2016;2016:8901938.\\n 6. Johansson PI, Oliveri RS, Ostrowski SR. Hemostatic resuscita -\\ntion with plasma and platelets in trauma. J Emerg Trauma Shock . \\n2012;5:120–  125.\\n 7. Pacheco LD, Saade GR, Costantine MM, Clark SL, Hankins GD. An \\nupdate on the use of massive transfusion protocols in obstetrics. \\nAm J Obstet Gynecol . 2016;214:340–  344.\\n 8. Zwinkels RLJ, Endeman H, Hoeks SE, de Maat MPM, den \\nHartog D, Stolker RJ. The clinical effect of hemostatic resusci -\\ntation in traumatic hemorrhage; a before-  after study. J Crit Care . \\n2020;56:288–  293. 9. Spinella PC, Pidcoke HF, Strandenes G, et al. Whole blood for hemo -\\nstatic resuscitation of major bleeding. Transfusion . 2016;56(Suppl \\n2):S190–  202.\\n 10. Carvajal JA, Ramos I, Kusanovic JP, Escobar MF. Damage- \\ncontrol  resuscitation in obstetrics. J Matern Fetal Neonatal Med . \\n2022;35:785–  798.\\n 11. Bouglé A, Harrois A, Duranteau J. Resuscitative strategies in trau -\\nmatic hemorrhagic shock. Ann Intensive Care . 2013;3:1.\\n 12. Spahn DR, Bouillon B, Cerny V, et al. The European guideline on \\nmanagement of major bleeding and coagulopathy following trauma. \\nCrit Care . 2019;23:98.\\n 13. Gillissen A, van den Akker T, Caram-  Deelder C, et al. Association \\nbetween fluid management and dilutional coagulopathy in severe \\npostpartum haemorrhage: a nationwide retrospective cohort \\nstudy. BMC Pregnancy Childbirth . 2018;18:398.\\n 14. Henriquez DDCA, Bloemenkamp KWM, Loeff RM, et al. Fluid \\nresuscitation during persistent postpartum haemorrhage and ma -\\nternal outcome: a nationwide cohort study. Eur J Obstet Gynecol \\nReprod Biol . 2019;235:49–  56.\\n 15. Pham HP, Shaz BH. Update on massive transfusion. Br J Anaesth . \\n2013;111(Suppl 1):i71–  82.\\n 16. Holcomb JB, del Junco DJ, Fox EE, et al. The prospective, obser -\\nvational, multicenter, major trauma transfusion (PROMMTT) study: \\ncomparative effectiveness of a time-  varying treatment with com -\\npeting risks. JAMA Surg . 2013;148:127–  136.\\n 17. del Junco DJ, Holcomb JB, Fox EE, et al. Resuscitate early with \\nplasma and platelets or balance blood products gradually: findings \\nfrom the PROMMTT study. J Trauma Acute Care Surg . 2013;75(1 \\nSuppl 1):S24–  30.\\n 18. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, \\nplatelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortal -\\nity in patients with severe trauma: the PROPPR randomized clinical \\ntrial. JAMA . 2015;313:471–  482.\\n 19. Tanaka H, Matsunaga S, Yamashita T, et al. A systematic review of \\nmassive transfusion protocol in obstetrics. Taiwan J Obstet Gynecol . \\n2017;56:715–  718.\\n 20. Clark SL, Hankins GD. Preventing maternal death: 10 clinical dia -\\nmonds. Obstet Gynecol . 2012;119(2 Pt 1):360–  364.\\n 21. Bingham D, Melsop K, Main E. CMQCC Obstetric Hemorrhage \\nToolkit Hospital Level Implementation Guide. The California Maternal \\nQuality Care Collaborative (CMQCC) . Stanford University School of \\nMedicine; 2010.\\n 22. Committee on Practice Bulletins-  Obstetrics. Practice bulletin \\nno. 183: postpartum hemorrhage. Obstet Gynecol . 2017;130: \\ne168–  e186.\\n 23. Pacheco LD, Saade GR, Costantine MM, Clark SL, Hankins GD. The \\nrole of massive transfusion protocols in obstetrics. Am J Perinatol . \\n2013;30:1–  4.\\n 24. Kogutt BK, Vaught AJ. Postpartum hemorrhage: Blood prod -\\nuct management and massive transfusion. Semin Perinatol . \\n2019;43:44–  50.\\n 25. Vasudev R, Sawhney V, Dogra M, Raina TR. Transfusion-  related ad -\\nverse reactions: from institutional hemovigilance effort to National \\nHemovigilance program. Asian J Transfus Sci . 2016;10:31–  36.BOX 15\\u2003 FIGO recommends that all obstetricians are \\nfamiliar with resuscitative measures in the context of \\nPPH including massive transfusion protocols.  \\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 44}), Document(page_content=\"48\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\n12\\u2003 |\\u2003KEY STATEMENTS\\n 1. Care bundles have been associated with improved patient \\noutcomes when adherence is high. The goal of the PPH bun -\\ndle is to reduce the frequency of severe hemorrhage and \\nimprove maternal outcomes. There is still a need for good-  \\nquality research to determine whether the bundle approach \\nwill ultimately make a difference in saving women's lives from \\nPPH.\\n 2. In recent years, new scientific evidence and the availability of \\nnew technologies have driven important reflections about PPH. \\nTo guarantee quality of guidelines it is important to update the \\nevidence and base recommendations on the best quality stud -\\nies available. It is also essential to stimulate production of new \\nresearch on the key themes of PPH to reduce disparities among \\nguidelines. PPH guidelines have helped improve the care of \\nwomen around the world and their use should be stimulated in \\nall scenarios.\\n 3. The shock index indicator, defined as the ratio of heart rate to \\nsystolic blood pressure, is simple to use. It has better predictive \\nability than other vital signs because it detects acute changes \\nin the maternal cardiovascular system and appears as an early \\nmarker to predict adverse outcomes.\\n 4. Evidence continues to support oxytocin as the first-  line drug in \\nthe prevention of PPH in all births.\\n 5. Women with PPH should receive a fixed dose of 1 g tranexamic \\nacid in 10 ml (100 mg/ml) intravenously (1 ml/min) as soon as \\npossible after delivery and no more than 3 h after birth. A sec -\\nond dose of 1 g should be given intravenously if bleeding con -\\ntinues after 30 min or restarts within 24 h of the first dose. \\nTranexamic acid should be given in addition to usual treatments \\nfor the management of PPH including medical (uterotonics), \\nnonsurgical, and surgical interventions, regardless of the cause \\nof hemorrhage or the mode of delivery.\\n 6. The nonpneumatic antishock garment (NASG) is an effective \\nnonsurgical device that should be in every healthcare facility. \\nThe NASG, when used as a temporizing measure to recover \\nhemodynamic stability in the context of PPH, decreases mor -\\nbidity, mortality, and hypovolemic shock, and is of special impor -\\ntance in LMICs. While considerable research is still necessary to \\nimprove knowledge on implementation issues, professional as -\\nsociations and national and international guidelines should con -\\ntinue to encourage NASG use for refractory PPH management.\\n 7. Uterine balloon tamponade (UBT) is an effective nonsurgical \\ntechnique that when employed rapidly by a properly trained \\nperson with a proven device in the context of quality PPH care \\n(the PPH bundle) improves survival of women with refractory \\nPPH. National and international guidelines should include UBT \\nuse in the management of PPH.\\n 8. Interventional radiology may be indicated for the prevention \\nand treatment of PPH either before delivery, in cases of known \\nplacental abnormalities and implantation, or after delivery when \\nthe patient is hemorrhaging. Prophylactic catheterization of the uterine arteries, with embolization, can be considered an impor -\\ntant therapeutic strategy that is safe and effective for reducing \\nmaternal and fetal morbidity and mortality by controlling blood \\nloss.\\n 9. Regardless of the compression suture chosen, obstetricians \\nmust first quickly recognize the onset of PPH, safely admin -\\nister uterotonics, and place emergent compression sutures \\nif needed. In the immediate postoperative period, women \\nshould be monitored for complications such as hematometra, \\npyometra, and uterine synechiae. Most important is the ability \\nof the obstetrician to control bleeding using medical and sur -\\ngical interventions, stabilize the mother, and reduce maternal \\nmorbidity.\\n 10. PPH is a serious life-  threatening obstetric emergency and early \\nrecognition of this condition results in better outcomes. In cases \\nwhere medical treatment fails to control the bleeding, several \\nsurgical options exist. To date, no randomized controlled trials \\nhave assessed these techniques, nor compared the superiority \\nof one to another, and all the data are based on case reports and \\ncase series. Moreover, the use of these methods largely depends \\non the facilities provided in each institution and on the care pro -\\nviders’ skills and familiarity with the procedures. Hence, an ef -\\nfort should be exercised for better training of all care providers in \\nthese life-  saving techniques. Future fertility rate following these \\nprocedures remains underassessed due to the lack of long-  term \\nfollow-  up for these cases. In the future, more research should \\ntarget these surgical techniques to shy away from the more \\nmorbid procedures, thereby improving maternal and perinatal \\noutcomes.\\n 11. Damage control resuscitation (DCS) is a combination of resuscita -\\ntion and surgical interventions with the purpose of restoring he -\\nmostasis and normal physiology. These techniques have proven to \\nbe applicable in obstetrics, with satisfactory results controlling re-\\nfractory PPH and an overall decreased mortality of critically ill pa -\\ntients, especially in patients in whom conventional treatment can \\nbe linked to a high risk of failure. DCS is an available therapeutic \\napproach for the management of severe PPH, thus proper training \\nmust be widespread to implement this technique.\\n 12. Basic recommendations for resuscitation in PPH include admin -\\nistration of crystalloids in small boluses of 500 ml, checking clini -\\ncal signs and looking for its improvement, and use of balanced \\ncrystalloid solutions such as Ringer's lactate, which is preferred \\nover chlorine-  rich solutions. The target blood pressure in hypo-\\ntensive resuscitation is 80–  90 mm  Hg for systolic blood pressure \\nor 50–  60 mm Hg for mean blood pressure.\\n 13. In hemostatic reanimation, fewer crystalloids are administered \\nand, instead, transfusional replacement is started earlier with \\nhigh ratios of transfusion (1:1:1). During massive transfusions, \\nthe target for serum fibrinogen is 150–  200 mg/dl and the usual \\ndose of cryoprecipitate is 10 units; it is estimated that these will \\nraise the serum fibrinogen by 100 mg/dl. The protocol for mas -\\nsive transfusion is specific at each institution. Physicians should \\nbe familiar with their hospitals’ protocol and recommendations.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n\", metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 45}), Document(page_content='\\u2003\\u2002\\u2003|\\u2003 49\\nESCOBAR Et Al.\\n 14. Anyone who attends a birth can be taught simple home-  based life-  \\nsaving skills. The evidence-  based prevention and management of \\nPPH can be achieved with the use of relatively inexpensive drugs. \\nWomen should be monitored closely during the first hour after de -\\nlivery of the baby and placenta, and accurate blood loss measure -\\nment should be implemented. Barriers and gaps can be addressed \\nthrough providing an enabling environment through supportive policies, designing a formal plan for supplies, task shifting strategies, \\nand use of guidelines and protocols for successful implementation.\\n 15. Simulation training on how to manage PPH is encouraged, and \\neach hospital should have a protocol on the management of \\nPPH. OBGYN societies should lobby to have the essential medi -\\ncations that are needed to prevent and treat PPH readily avail -\\nable in all maternity centers.\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 46}), Document(page_content='50\\u2003|\\u2003\\u2003\\u2002\\nESCOBAR Et Al.\\n13\\u2003 |\\u2003IMPLEMENTATION OF THE FIGO \\nRECOMMENDATIONS BY HEALTH \\nSYSTEMS AND NATIONAL SOCIETIES FOR \\nTHE MANAGEMENT OF POSTPARTUM \\nHEMORRHAGE\\n1. FIGO must lobby and work with other international organi -\\nzations to reduce maternal mortality and morbidity due to \\nPPH.\\n2. FIGO recommends that all national societies work in collaboration \\nwith nurses and midwives to lobby with their respective regional \\nand national organizations to promote and implement these \\nrecommendations.\\n3. All OBGYN societies in conjunction with other healthcare socie -\\nties must endorse a strategy for effective prevention and treat -\\nment of PPH.\\n4. All national societies must lobby with their local national \\ngovernments to establish a PPH bundle approach and make \\nthe medical supplies and surgical equipment needed for the \\nmanagement of PPH readily available in all regions of their \\ncountries.5. All health systems are obligated to provide respectful care of the \\nwoman, the infant, and the associated family. Health systems \\nmust provide the appropriate and effective medications, water, \\noxygen, equipment, training, and transfer mechanisms to save the \\nlives of women and newborns.\\nMEMBERS OF THE FIGO SAFE \\nMOTHERHOOD AND NEWBORN HEALTH \\nCOMMITTEE, 2018–  2021\\nAnwar H. Nassar (Chair), Gerard H. Visser (Past Chair), Eytan \\nR. Barnea, Maria Fernanda Escobar, Yoon Ha Kim, Wanda Kay \\nNicholson, Rodolfo Pacagnella, Diana Ramasauskaite, Gerhard \\nTheron, Alison Wright.\\nHow to cite this article: Escobar MF, Nassar AH, Theron G, \\net al. FIGO recommendations on the management of \\npostpartum hemorrhage 2022. Int J Gynecol Obstet . \\n2022;157(Suppl. 1):3–  50. doi: 10.1002/ijgo.14116\\n 18793479, 2022, S1, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.14116 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\FIGO recommendations on the management of postpartum hemorrhage 2022.pdf', 'page': 47}), Document(page_content='Guía de \\nhemorragia posparto \\nCódigo Rojo', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 0}), Document(page_content='Guía de hemorragia posparto  \\nCódigo Rojo\\nGustavo Francisco Petro Urrego\\nAlcalde Mayor de Bogotá, D. C. \\nMauricio Alberto Bustamante García\\nSecretario Distrital de Salud\\nGiovanni Rubiano García\\nSubsecretario Distrital de Salud\\nElsa Graciela Martínez Echeverri\\nDirectora de Desarrollo de Servicios\\nConsuelo Peña Aponte\\nProfesional especializada, Área de Análisis y Políticas\\nTatiana Valentina Cabrera Sierra \\nProfesional especializada \\nGrupo Materno Perinatal\\nJorge Eduardo Caro Caro, Héctor Augusto \\nGonzález Galindo, Alvinzy II Velázquez Becerra, \\nReinaldo Niño Alba, Mauricio Jiménez Romero, \\nClaudia Marcela Villacis Becerra, Jesús Alberto Echevarría Baquero\\nOriana Obagi Orozco\\nJefe de la Oficina Asesora de Comunicaciones\\nGustavo Patiño Díaz\\nCorrector de estilo\\nJuan Carlos Vera Garzón\\nDiseño y diagramación\\nSecretaría Distrital de Salud\\n2014\\nPeriodo de investigación y desarrollo de la \\nGuía (2013)\\nGustavo Francisco Petro Urrego\\nAlcalde Mayor de Bogotá, D. C.\\nAldo Enrique Cadena Rojas\\nSecretario Distrital de Salud\\nGiovanni Rubiano García\\nSubsecretario Distrital de Salud\\nElsa Graciela Martínez Echeverry\\nDirectora de Desarrollo de Servicios \\nConsuelo Peña Aponte\\nProfesional especializada, Área de Análisis y Políticas\\nMartha Lucía Mora Moreno\\nProfesional especializada, Grupo Materno Perinatal', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 1}), Document(page_content='3\\nGuía de hemorragia posparto Código Rojo\\n1. Justificación y definición\\n1.1 Justificación\\nEs un hecho reconocido a nivel mundial que la oportunidad y la calidad de la atención \\nen el manejo de la hemorragia obstétrica son fundamentales para disminuir las com-\\nplicaciones y la mortalidad. Las principales razones para la alta mortalidad asociada \\na hemorragia son: la demora en el reconocimiento de la hipovolemia, falla en el reem-plazo adecuado del volumen y demora en la intervención quirúrgica (1).\\nLa mortalidad materna es de 400 por 100.000 nacidos vivos, lo que significa 529.000 \\nmuertes por año. De estas muertes, aproximadamente 150.000 son debidas a hemorra-gias obstétricas, la mayoría por hemorragia posparto (HPP), que en muchos países es la primera o segunda causa de mortalidad materna (1-3).\\nEn Bogotá, D. C., en 2012-2013 esta pérdida de sangre fue la primera causa de mortali-\\ndad materna: 12 casos (29%) en el 2012, 7 casos (29%) en el 2013 (2).\\nEl “código rojo” consiste en crear un esquema de trabajo organizado, de tal manera que \\ncuando se presente una hemorragia obstétrica le permita al equipo asistencial seguir los pasos indicados sin desviarse del objetivo, trabajar de manera ordenada y coordi-nada, y que pueda ser replicado en cada situación específica, logrando así disminuir la \\nmorbimortalidad generada por esta causa (nivel de evidencia 3, grado de recomendación \\nC) (1,4).\\n1.2 Niveles de evidencia y grados de recomendación \\n(clasificación de Oxford) (5)\\nNiveles de evidencia\\n1++Metaanálisis de alta calidad, revisiones sistemáticas de ensayos clínicos o ensayos clínicos de alta calidad con \\nmuy poco riesgo de sesgo.\\n1+Metaanálisis bien realizados, revisiones sistemáticas de ensayos clínicos o ensayos clínicos bien realizados con poco riesgo de sesgos.\\n1- Metaanálisis, revisiones sistemáticas de ensayos clínicos o ensayos clínicos con alto riesgo de sesgos.\\n2++Revisiones sistemáticas de alta calidad de estudios de cohortes o de casos y controles. Estudios de cohortes o de casos y controles con riesgo muy bajo de sesgo y con alta probabilidad de establecer una relación causal.\\n2+Estudios de cohortes o de casos y controles bien realizados con bajo riesgo de sesgo y con una moderada proba-bilidad de establecer una relación causal.\\n2-Estudios de cohortes o de casos y controles con alto riesgo de sesgo y riesgo significativo de que la relación no sea causal.\\n3 Estudios no analíticos, como informes de casos y series de casos.\\n4 Opinión de expertos.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 2}), Document(page_content='Guía de hemorragia posparto - Código Rojo4\\nGrados de recomendación\\nAPor lo menos un metaanálisis, revisión sistemática o ensayo clínico clasificado como 1++ y directamente aplicable a la \\npoblación diana de la guía; o un volumen de evidencia científica compuesto por estudios clasificados como 1+ y con gran consistencia entre ellos.\\nBUn volumen de evidencia científica compuesta por estudios clasificados como 2++, directamente aplicable a la pobla-ción diana de la guía y que demuestran gran consistencia entre ellos; o evidencia científica extrapolada desde estudios clasificados como 1++ o 1+.\\nCUn volumen de evidencia científica compuesta por estudios clasificados como 2+ directamente aplicables a la pobla-ción diana de la guía y que demuestran gran consistencia entre ellos; o evidencia científica extrapolada desde estudios clasificados como 2++.\\nDEvidencia científica de nivel 3 o 4; o evidencia científica extrapolada desde estudios clasificados como 2+. Los estudios clasificados como 1- y 2- no deben usarse en el proceso de elaboración de recomendaciones por su alto potencial de sesgo.\\n1.3 Definición de hemorragia posparto\\nSe considera hemorragia posparto si se presenta alguna de las siguientes situaciones:\\n\\ue0c1 Pérdida estimada de más de 500 cm3 de sangre en el posparto o más de 1.000 cm3 \\nposcesárea o menor con signos de choque (3,4).\\n\\ue0c1 Pérdida de todo el volumen sanguíneo en 24 horas.\\n\\ue0c1 Sangrado mayor a 150 cm3/min.\\n\\ue0c1 Pérdida del 50% del volumen en 20 minutos.\\n\\ue0c1 Descenso del hematocrito mayor o igual al 10%.\\n2. Objetivos y población objeto\\n2.1 Objetivo general\\nImplementar una guía que unifique el diagnóstico y manejo de la hemorragia posparto \\ny que contribuya a disminuir la mortalidad materna asociada a hemorragia.\\n2.2 Objetivos específicos\\n\\ue0c1 Protocolizar las mejores prácticas para el manejo de la hemorragia posparto.\\n\\ue0c1 Facilitar el reconocimiento de la paciente con hemorragia posparto e introducir el \\ndiagnóstico rutinario y objetivo del choque hipovolémico.\\n\\ue0c1 Disminuir la tasa de morbimortalidad materna y perinatal en los casos de hemorra-\\ngia durante la atención del parto.\\n\\ue0c1 Proporcionar las herramientas y sensibilizar a los profesionales de salud para que \\nlos tratamientos se realicen de la forma más oportuna y adecuada.\\n\\ue0c1 Establecer medidas universales para la prevención de la hemorragia posparto.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 3}), Document(page_content='Guía de hemorragia posparto - Código Rojo5\\n2.3 Población objeto\\nTodas las mujeres gestantes o en puerperio atendidas en Bogotá que presenten hemo -\\nrragia obstétrica.\\n3. Factores de riesgo, clasificación del choque \\nhipovolémico, etiología\\n3.1 Etiología y factores de riesgo\\nAproximadamente dos terceras partes (66%) de los casos de hemorragia posparto no \\ntienen un factor de riesgo conocido, por este motivo es indispensable aplicar las medi-\\ndas preventivas a toda la población obstétrica. Una adecuada atención prenatal puede \\nidentificar a aquellas pacientes que tienen uno o más factores de riesgo para presentar hemorragia posparto (tablas 1 y 2) (4).\\nTabla 1. Factores de riesgo para hemorragia posparto (4)\\nFactores de riesgo OR ajustado\\nPlacenta previa 13,1\\nAbrupcio  de placenta 12,6\\nCesárea de emergencia 3,6\\nEnfermedad de von Willebrand 3,3\\nCorioamnionitis 2,5\\nCesárea electiva 2,5\\nEmbarazo gemelar 2,3\\nPeso fetal >4.500 g 1,9\\nPolihidramnios 1,9\\nMultiparidad 1,9\\nSíndrome de HELLP 1,9\\nParto instrumentado, fórceps 1,9\\nInducción de trabajo de parto 1,6\\nObesidad 1,6\\nAntecedente de HPP 1,6\\nCesárea previa 1,5\\nTrabajo de parto prolongado 1,1\\nEdad >40 años 1,4', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 4}), Document(page_content='Guía de hemorragia posparto - Código Rojo6\\nIdentifique factores de riesgo para coagulopatía (historia clínica estructurada):\\n1. Sangrado genital abundante desde la menarquía.\\n2. Uno de los siguientes:\\n\\ue0c1 Hemorragia posparto\\n\\ue0c1 Sangrado relacionado con un procedimiento quirúrgico\\n\\ue0c1 Sangrado relacionado con un procedimiento dental\\n3. Dos o más de los siguientes síntomas:\\ue0c1 Equimosis una a dos veces al mes\\n\\ue0c1 Epistaxis una a dos veces al mes\\n\\ue0c1 Sangrado frecuente de encías\\n\\ue0c1 Antecedentes familiares de síntomas de sangrado\\nSe considera tamizaje positivo para trastorno de la hemostasia si cumple con uno o más de los ítems 1, 2, 3 de la historia clínica estructurada (nivel de evidencia 2, grado de recomendación B).\\nTabla 2. Principales causas de hemorragia posparto  \\nEtiología Causas Factores de riesgo\\nTono 70%\\nAtonía uterinaSobredistensión uteri-\\nna, parto prolongado/precipitadoGestación múltiple, polihidramnios, macrosomia, gran multípara, hidrocefalia severa\\nAgotamiento muscular \\nuterinoTrabajo de parto prolongado, corioamnionitis\\nTrauma 20% \\nLesiones canal del partoDesgarros del canal \\ndel partoParto intervenido, parto precipitado, episiotomía\\nRuptura uterina Parto intervenido, cirugía uterina previa, hiperdinamia\\nInversión uterina Acretismo, maniobra de Crede, excesiva tracción del cordón, gran multípara\\nTejido 9%\\nRetención de tejidosRetención de restos \\nplacentarios Acretismo, placenta previa, útero bicorne, leiomiomatosis, cirugía uterina previaAnormalidades de la placentación\\nTrombina 1% \\nAlteraciones de coagulaciónAdquiridasPreeclampsia, HELLP , embolia de líquido amniótico, sepsis, abrupcio  de placenta, \\nCID consumo, transfusiones masivas\\nCongénitas Enfermedad von Willebrand, hemofilia A\\nFuente: Fescina et al., (4).\\n3.2 Tipos de hemorragia posparto\\n\\ue0c1 Hemorragia temprana:  es la que se presenta durante las primeras 24 horas del \\nperiodo posparto, generalmente en las dos primeras horas, es la más frecuente y \\ngrave (4,6).\\n\\ue0c1 Hemorragia tardía:  ocurre entre las 24 horas y las 6 semanas del posparto, con \\nuna frecuencia entre el 5 y 10% de los partos (4,6).', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 5}), Document(page_content='Guía de hemorragia posparto - Código Rojo7\\n3.3 Diagnóstico y clasificación del choque hipovolémico\\nEl diagnóstico del choque es muy fácil en los casos extremos, pero puede ser difícil en \\nsus fases iniciales. Se calcula que la cantidad de sangre perdida puede ser subestimada \\nhasta en un 50%, por lo que se recomienda clasificar el choque de acuerdo con el peor \\nparámetro encontrado (no se recomienda hacerlo solo de acuerdo con la percepción subjetiva de la pérdida sanguínea) (nivel de evidencia 2, grado de recomendación B) (7).\\nLos signos, síntomas (sensorio, perfusión, pulso y presión arterial) y su relación con el \\ngrado de pérdida sanguínea y choque hipovolémico deben estar listados y expuestos (tabla de clasificación de choque y/o índice de choque) en el sitio de atención de par -\\ntos, cesárea y recuperación posparto, con el fin de orientar las estrategias de manejo \\n(tabla 3).\\nTabla 3. Estimación de las pérdidas de acuerdo con la evaluación del estado de \\nchoque  (7)\\nClasificación del choque hipovolémico\\nPérdida de volumen (%) \\ny ml para una mujer entre 50-70 kgSensorio Perfusión PulsoPresión arterial \\nsistólica (mm/hg)Grado del \\nchoque\\n10-15%500-1.000 mLNormal Normal 60-90 >90 Compensado\\n16-25%\\n1.000-1.500 mLNormal y/o \\nagitadaPalidez, frialdad 91-100 80-90 Leve\\n26-35%\\n1.500-2.000 mLAgitadaPalidez, frialdad \\nmás sudoración101-120 70-79 Moderado\\n>35%>2.000 mLLetárgica o \\ninconscientePalidez, frialdad \\nmás sudoración \\ny llenado capilar \\n>3 segundos>120 <70 Severo\\nFuente: Baskett (7).\\n4. Secuencia temporal del código rojo\\nPrincipios de manejo\\n\\ue0c1 Reposición adecuada de cristaloides de acuerdo con la clasificación del estadio \\nde choque (nivel de evidencia 1, grado de recomendación A).\\n\\ue0c1 Considerar coagulación intravascular diseminada por consumo después de una hora de choque.\\n\\ue0c1 Decisión oportuna del manejo quirúrgico (nivel de evidencia 2, grado de recomen-\\ndación B).', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 6}), Document(page_content='Guía de hemorragia posparto - Código Rojo8\\nSecuencia temporal \\n\\ue0c1 Minuto 0: activación\\n La institución debe tener un sistema de activación que permita al personal ente-\\nrarse inmediatamente de la emergencia.\\n Determinar sensorio, perfusión, pulso, presión arterial y oximetría.\\n\\ue0c1 Clasificar el choque\\n Cuando se activa un código rojo en baja complejidad se debe alertar al operador \\nde radio, enfermera jefe, primer y segundo médico, auxiliares de enfermería, labo-ratorio clínico.\\n Cuando se activa un código rojo en mediana y alta complejidad se debe alertar al ginecólogo, anestesiólogo, segundo médico, enfermera jefe, auxiliares de apoyo, laboratorio clínico, camillero, banco de sangre.\\n\\ue0c1 Minuto 1 a 20: reanimación\\n Oxígeno por cánula a 3 L/min (nivel de evidencia 2, grado de recomendación B). Canalizar 2 venas calibre grueso, catéter 14 o 16.\\n Tomar muestras (CH, hemoclasificación, TP , TPT, fibrinógeno).\\n Iniciar infusión de 500 mL de cristaloides calientes y continuar con bolos de 300 a 500 cm\\n3 de acuerdo con la respuesta hemodinámica.\\n Pasar sonda vesical a cistoflo para drenaje vesical y cuantificar diuresis.\\n Realizar masaje uterino bimanual (nivel de evidencia 2, grado de recomendación C).  \\nRevisión uterina bajo anestesia general: establezca diagnóstico etiológico (Nemo-tecnia 4 Ts).\\n Aplicar medicamentos de primera línea: oxitocina, misoprostol, metilergonovina \\n(8) (nivel de evidencia 2, grado de recomendación B).\\n− Oxitocina: a 40 U diluidas en 500 mL de cristaloides (para pasar en 4 horas a \\n125 mL/hora) (9) (nivel de evidencia 1).\\n− Metilergonovina amp. x 0,2 mg: 1 ampolla IM (10) (nivel de evidencia 1).\\n− Misoprostol tabletas x 200 mcg 5 tabletas intrarrectales (11,12).\\n Evite la hipotermia: utilice sábanas o mantas precalentadas y todos los cristaloi-\\ndes adminístrelos calientes  (nivel de evidencia 3, grado de recomendación D).\\nMedicamentos de primera línea\\nOxitocina 40 unidades intravenoso en 500 cm3 de Lactato Ringer. Pasar a 125 cm3 hora (160 mUI/min).\\nMisoprostol 1.000 mcg intrarrectal.\\nMetilergonovina 0,2 mg intramuscular.\\nEn los niveles de baja complejidad, todas las pacientes en quienes se activó un código \\nrojo deben ser trasladadas al nivel de mediana o alta complejidad más cercano de \\nforma inmediata posterior al manejo inicial.\\nEn choque severo o índice de choque mayor de 1 (Indicador: frecuencia cardiaca/sistó-\\nlica), inicie transfusión inmediata con las dos primeras unidades de sangre sin cruzar ', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 7}), Document(page_content='Guía de hemorragia posparto - Código Rojo9\\n–O negativo; si no está disponible, puede usar O positivo–, y solicite las unidades adi-\\ncionales cruzadas. Recuerde que si transfunde seis unidades o más de glóbulos rojos, \\ndebe conservar la relación 1:1:1, es decir, por cada unidad de glóbulos rojos una de \\nplasma y una de plaquetas (nivel de evidencia 2, grado de recomendación C).\\n\\ue0c1 20-60 minutos: estabilización\\n Conservar volumen circulante.\\n Atonía uterina: masaje uterino permanente (nivel de evidencia 2, grado de reco-\\nmendación C).\\n Usar oxitocina, misoprostol o metilergonovina con dosis adicionales de acuerdo \\ncon criterio clínico.\\n El ácido tranexámico se debe administrar en dosis de 1 g por vía IV cada 6 horas, \\nmínimo 4 dosis, en las siguientes situaciones:\\n− Hemorragia posparto secundaria a traumatismo del canal del parto.\\n− Sospecha de trastornos de la coagulación por historia clínica.\\n− Hemorragia posparto que no ceda al manejo médico después de la aplicación de las medidas iniciales (13) (niveles de evidencia 2 y 3, grado de recomendación C).\\n Iniciar inotrópicos y vasoactivos si persiste la hipotensión.\\nEscenario 1\\nSi la paciente continúa inestable hemodinámicamente: choque moderado, severo o \\ncon sangrado activo abundante, pasar a cirugía para histerectomía abdominal subto-\\ntal, total y empaquetamiento con tracción según criterio clínico ( figura 1) (nivel de evidencia 2, grado de recomendación C). En caso de sangrado en capa se recomienda \\ndesempaquetar al completar 12 a 24 horas posterior al procedimiento de acuerdo con \\nla evolución clínica. El procedimiento quirúrgico debe ser definido en conjunto con el segundo ginecólogo (14).\\nFigura 1. Empaquetamiento con tracción  \\nFuente: Modificada a partir de Hallak et al. (15).\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 8}), Document(page_content='Guía de hemorragia posparto - Código Rojo10\\nLos manejos quirúrgicos conservadores como sutura hemostática de B-Lynch, tapona-\\nmiento uterino, ligadura de arterias uterinas, ligadura de arterias hipogástricas no se \\nrecomiendan en pacientes con choque severo porque la evidencia es insuficiente (nivel \\nde evidencia 3, grado de recomendación D) (14).\\nEscenario 2\\nSi la paciente mejora con el manejo inicial —estabilidad hemodinámica y sangrado \\nescaso—:\\n\\ue0c1 Vigile el sangrado vaginal y el tono uterino cada 15 minutos, durante 4 horas.\\n\\ue0c1 Evalúe signos de perfusión (sensorio, llenado, oximetría, pulso y tensión arterial, cada 15 minutos).\\n\\ue0c1 Si fue una hemorragia por atonía, vigile el tono uterino cada 15 minutos.\\n\\ue0c1 Continúe los líquidos IV a razón de 200 mL/hora.\\n\\ue0c1 Continúe los uterotónicos por 24 horas; si fue una atonía: 10 unidades de oxito-cina en cada 500 cm\\n3 de L. Ringer.\\n\\ue0c1 Mantenga la oxigenación.\\n\\ue0c1 Defina la transfusión si es necesario (hemoglobina <7 g/dL, índice de choque mayor a 1 o según criterio clínico).  \\n\\ue0c1 Aplicación de antibiótico profiláctico de acuerdo con el protocolo institucional.\\n\\ue0c1 60 minutos y más: manejo avanzado\\n Pasado este tiempo se considera que la paciente cursa con coagulación intravascular  \\ndiseminada de consumo. Iniciar plasma fresco y plaquetas, relación glóbulos \\nrojos 1: plasma 1: plaquetas 1.\\n En caso de hemotransfusión masiva (mayor de 6 unidades de glóbulos rojos), ini-\\nciar plasma fresco y plaquetas, relación glóbulos rojos 1: plasma 1: plaquetas: 1.\\n Manejarla en unidad de cuidados intermedios y verificar si cumple criterios de ingreso a unidad de cuidados intensivos.\\n Conservar volumen circulatorio.\\n Valorar gasto urinario.\\nPrevención\\n1. Manejo activo tercer periodo.\\n\\ue0c1 Oxitocina 10 unidades diluidas endovenosas al salir hombro anterior para pasar \\nen 10 minutos. En caso de no contar con vena canalizada, aplicar 10 unidades de \\noxitocina intramuscular (nivel de evidencia 1, grado recomendación A) (2,16).\\n\\ue0c1 Pinzamiento del cordón según protocolos.\\n\\ue0c1 Tracción controlada del cordón (17).\\n\\ue0c1 Masaje uterino (17).\\n La carbetocina puede ser usada como medicamento alternativo a la oxitocina en pacientes con factores de riesgo para hemorragia posparto como embarazo geme-', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 9}), Document(page_content='Guía de hemorragia posparto - Código Rojo11\\nlar, sobredistensi ón uterina, miomatosis uterina, polihidramnios, corioamnionitis, \\nabrupcio de placenta, después del alumbramiento (2) (nivel de evidencia 2, grado \\nde recomendación C) .\\n2. Vigilancia inmediata en posparto: evolución médica durante las dos primeras horas \\nposparto o poscesárea para evaluar tono uterino, sangrado y otras complicaciones \\n(nivel de evidencia 3, grado de recomendación D).\\n5. Organización del equipo de trabajo\\nCon el fin de evitar el caos durante la asistencia a una situación crítica como es la hemo-\\nrragia obstétrica con choque hipovolémico, es necesario organizar el equipo humano \\ndisponible, asignándole funciones específicas, las cuales deben ser previamente cono-\\ncidas y estudiadas en los entrenamientos institucionales y pueden ser asimiladas con la ayuda de la lista de chequeo del código rojo. La organización del equipo mejora las condiciones de trabajo y facilita la realización de las funciones para la recuperación \\ny mantenimiento de la vida de la mujer en choque. Cada miembro participante en el \\ncódigo rojo debe cumplir sus funciones, con el fin de evitar la duplicación o la omisión de alguna de ellas. La activación del código la hace la primera persona que entra en contacto con la paciente que está sangrando.\\nFunciones de los participantes en el código rojo en niveles \\nde mediana y alta complejidad\\nMédico jefe\\nGinecólogo o médico que está atendiendo el parto o la cesárea.\\n\\ue0c1 Ubicación: lado derecho o frente al periné de la paciente.\\n\\ue0c1 Buscar la causa del choque.\\n\\ue0c1 Clasificar  el estado de choque.\\n\\ue0c1 Practicar revisión uterina y cervicovaginal.\\n\\ue0c1 Hacer masaje uterino bimanual.\\n\\ue0c1 Dar orden verbal de colocación de líquidos, hemoderivados y medicamentos \\nde segunda línea.\\n\\ue0c1 Revaluar estado de choque posreanimación inicial.\\n\\ue0c1 Realizar los procedimientos quirúrgicos.\\n\\ue0c1 Levantar el código rojo.\\n\\ue0c1 Informar a los familiares.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 10}), Document(page_content='Guía de hemorragia posparto - Código Rojo12\\nAnestesiólogo\\n\\ue0c1 Ubicación: cabecera de la paciente.\\n\\ue0c1 Aplicar anestesia general.\\nEnfermera jefe\\n\\ue0c1 Ubicación: lado izquierdo de la paciente.\\n\\ue0c1 Aplicar y registrar medicamentos de primera línea sin solicitar orden médica escrita \\no verbal.\\n\\ue0c1 Colocar sonda vesical a cistoflo.\\n\\ue0c1 Supervisar las funciones del personal auxiliar de enfermería.\\n\\ue0c1 Aplicar y registrar medicamentos de segunda línea de acuerdo con orden verbal \\ndel médico jefe.\\n\\ue0c1 Administrar hemoderivados\\nAuxiliar 1 de enfermería\\n\\ue0c1 Canalizar segunda vía de acceso venoso calibre 14 o 16.\\n\\ue0c1 Tomar muestras sanguíneas.\\n\\ue0c1 Pasar Lactato de Ringer 500 cm3 en bolo, caliente, y continuar infusión de acuerdo \\ncon la orden verbal del médico jefe.\\nAuxiliar 2 de enfermería\\n\\ue0c1 Diligenciar las órdenes de laboratorio.\\n\\ue0c1 Marcar los tubos de muestra y garantizar que lleguen al laboratorio.\\n\\ue0c1 Ordenar por escrito los hemoderivados de acuerdo con la indicación verbal del \\nginecólogo.\\n\\ue0c1 Anotar los eventos con registro de tiempo en el formato de activación de código rojo.\\nAuxiliar 3 de enfermería\\n\\ue0c1 Suministrar canasta de código rojo.\\n\\ue0c1 Llamar a laboratorio, camillero, anestesiólogo, segundo médico, enfermera jefe, \\ndemás personal necesario.\\n\\ue0c1 Calentar líquidos.\\n\\ue0c1 Recibir la sangre solicitada.\\n\\ue0c1 Suministrar los elementos adicionales necesarios.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 11}), Document(page_content='Guía de hemorragia posparto - Código Rojo13\\nCamillero\\n\\ue0c1 Suspender todas las actividades al llamado de código rojo.\\n\\ue0c1 Tener disponibilidad inmediata en la puerta de la sala de partos.\\n\\ue0c1 Llevar las muestras debidamente marcadas al laboratorio.\\n\\ue0c1 Esperar los hemoderivados y entregarlos en sala de partos.\\n\\ue0c1 Retirarse de partos solo cuando el médico jefe levante el código rojo.\\nLaboratorio clínico\\n\\ue0c1 Recibir y procesar las muestras debidamente marcadas.\\n\\ue0c1 Enviar a obstetricia hemoderivados solicitados.\\nSegundo médico\\n\\ue0c1 Ubicación: lado izquierdo de la paciente.\\n\\ue0c1 Hacer masaje uterino bimanual.\\n\\ue0c1 Apoyar la decisión de procedimientos quirúrgicos: histerectomía total  \\nvs. subtotal.\\nPaciente menor de edad hija de padres seguidores de la iglesia \\nTestigos de Jehová\\nManeje integralmente el código rojo sin considerar la determinación religiosa de los \\npadres o del menor: “predomina el cuidado de la salud sobre los condicionantes reli-\\ngiosos” (1).\\nEn caso de no contar con el personal suficiente mencionado anteriormente, se deberán \\najustar las funciones de acuerdo con la disponibilidad institucional.\\nPaciente que es atendida en un centro de baja complejidad\\nSi la paciente ingresa con hemorragia posparto a uno de los centros de atención médica inmediata (CAMI) o de baja complejidad de atención, se debe garantizar:\\nSecuencia temporal\\n\\ue0c1 Minuto 0: activación\\n− Determinar sensorio, perfusión y signos vitales completos.\\n− Alertar a laboratorio, radio, nivel de mediana o alta complejidad más cercano, \\nsegundo médico, enfermera jefe y auxiliares de apoyo.\\n− Iniciar calentamiento de líquidos.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 12}), Document(page_content='Guía de hemorragia posparto - Código Rojo14\\n\\ue0c1 Minuto 1 a 20: reanimación\\n− Oxígeno por cánula a 3 L/min.\\n− Canalizar 2 venas calibre grueso, catéter 14 o 16.\\n− Tomar muestras (CH, hemoclasificación, TP , TPT, fibrinógeno).\\n− 2.000 mL de Lactato Ringer en bolo caliente y continuar según orden médica.\\n− Clasificar el choque.\\n− Pasar sonda vesical a cistoflo.\\n− Hacer revisión uterina.\\n− Practicar masaje uterino bimanual.\\n− Aplicar medicamentos de primera línea: oxitocina, misoprostol, methilergo -\\nnovina.\\nMedicamentos de primera línea\\nOxitocina 40 unidades intravenoso en 500 cm3 de Lactato\\nRinger pasar a 125 cm3 hora (160 mUI/mL).\\nMisoprostol 1.000 mcg intrarrectal.\\nMetilergonovina 0,2 mg intramuscular.\\nTransporte inmediato al centro de atención de mediana o alta complejidad más cercano, \\nde preferencia en ambulancia medicalizada, con el equipo humano acompañante \\nentrenado en código rojo y que continúe durante el desplazamiento con la aplicación \\ndel código, con énfasis en el masaje uterino activo, las maniobras de reanimación, reemplazo de volumen y administración de medicamentos (goteo de oxitocina en caso de atonía) (nivel de evidencia 3), acompañamiento a la familia con explicación clara y \\nobjetiva que proceda de quien asume el proceso de coordinación del código rojo.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 13}), Document(page_content='Guía de hemorragia posparto - Código Rojo15\\nActivación\\nSangrado mayor de 1000 cm3\\nEvaluar: TA, FC, perfusión, sensorio Baja complejidadMediana o alta \\ncomplejidad\\nLlamar a: \\nPrimer y segundo ginecólogos, anestesió-\\nlogo, médico hospitalario, enfermera jefe, \\nauxiliares, camillero laboratorio.Llamar a primer y segundo mé-\\ndicos, enfermera jefe, auxiliares, \\ncamillero. Avisar al CRUE. \\nOxígeno por cánula a 3 l/min \\nCanalizar 2 venas calibre grueso, catéter 14 o 16. \\nTomar muestra: CH, hemoclasificación, TP , TPT, fibrinógeno. Bolo de 500 cm\\n3 de cristaloides calientes y continuar con bolos \\nde 300 a 500 cm3 de acuerdo con la respuesta hemodinámica. \\nClasificar el choque. Pasar sonda vesical a cistoflo. \\nRevisión uterina, masaje uterino bimanual. \\nOxitocina: 40 unidades en 500 cm\\n3 Ringer a 125 cm3/hora. \\nMisoprostol: 1.000 mcg, 5 tabletas intrarrectales Metilergonovina: 0,2 mg, 1 ampolla IM.\\nTransfundir \\nde acuerdo a \\norden verbal del \\nginecólogo jefeTraslado\\nInestabilidad \\nhemodinámica o \\nsangrado abundante\\nTraslado a Unidad de \\ncuidados Intermedios \\no Intensivos\\nVigile el sangrado vaginal cada 15 minutos por 4 hEvalúe sensorio, perfusión, pulso y TA cada 15 minutos \\nVigile la contracción uterina cada 15 minutos Continúe L. Ringer a 200 ml/hora, 10 unidades de \\noxitocina en cada 500 cm\\n3 de L. Ringer. \\nO2 por cánula a 2 l/min \\nDefina la transfusión si es necesarioFlujograma de manejo \\nEstabilidad hemodinámica y \\nsangrado escasoReclasificar choque y respuesta  \\na manejo inicial', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 14}), Document(page_content='Guía de hemorragia posparto - Código Rojo16\\nGUÍA DE CÓDIGO ROJO Página: 1 de 1\\nSEGUIMIENTO CÓDIGO ROJOVersión: 01\\nFecha: 2013-03-16\\nNOMBRES Y APELLIDOS: EDAD: HISTORIA CLÍNICA: EPS:\\nFECHA: HORA DE ACTIVACIÓN: HORA DE DESACTIVACIÓN:\\nMÉDICO(A) 1: MÉDICO(A) 2:\\nENFERMERO(A): ANESTESIÓLOGO(A):\\nASISTENTE 1: ASISTENTE 2: \\nASISTENTE 3: DIAGNÓSTICO:\\nFASE DEL CÓDIGOTIEMPO \\nCEROTIEMPO \\n1 - 20 MINUTOSTIEMPO \\n20 - 60 MINUTOSTIEMPO \\n> 60 MINUTOSTIEMPO \\n> 120 MINUTOS\\nHora de evaluación\\nSensorio\\nPerfusión (seg)\\nFrecuencia cardiacaTensión arterial sistólica\\nCLASIFICACIÓN DEL CHOQUE\\nChoque leve (16-25%)\\nChoque moderado \\n(26-35%)\\nChoque severo (> 35%)\\n-Índice de choque mayor a 1\\nDIURESIS1 HORA 2 HORAS 3 HORAS 4 HORAS\\nCRISTALOIDES\\nCuál y cantidad:OTROSCuál:\\nHEMODERIVADOS \\n(cantidad  y  hora de inicio)G. rojos (O-)\\nG. rojosPlasmaPlaquetas\\nCrios\\nPARACLÍNICOS  \\n(Marque con X)Hemoglobina Plaquetas TP TPT Fibrinógeno Otros\\nRESUL TADOS\\nOBSERVACIONES\\nNOMBRE Y FIRMA', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 15}), Document(page_content='Guía de hemorragia posparto - Código Rojo17\\nReferencias\\n1. Vélez-Álvarez B, Gómez Dávila J, Zuleta Tobón JJ. Código rojo: guía \\npara el manejo de la hemorragia obstétrica. Rev Colomb Obstet \\nGinecol. 2009;60:34-48.\\n2. Secretaría Distrital de Salud. Estadísticas salud pública Secretaría \\nDistrital e Salud. Base datos SIVIGILA- EEVV , 2011-2013. Bogotá: \\nSDS.\\n3. Queensland Clinical Guidelines. Primary postpartum haemorrhage. Maternity and neonatal [internet]. 2009 [citado: 2014, jun. 12]. Dis-\\nponible en www.health.qld.gov.au/qcg\\n4. Fescina R, Ortiz EI, Jarquin D. Guías para la atención de las princi-\\npales emergencias obstétricas. Centro Latinoamericano de Perina -\\ntología, Salud de la Mujer y Reproductiva CLAP/SMR. Organización \\nPanamericana de la Salud/Organización Mundial de la Salud OPS/\\nOMS. Ginebra: 2012.\\n5. Centre for Evidence-Based Medicine. Glossary [internet]. 2014 \\n[citado 2014, jun. 12]. Disponible en: http://www.cebm.net/glos-\\nsary/\\n6. World Health Organization (WHO). Managing postpartum haemo-\\nrrhage. Education material for teachers of midwifery. Midwifery edu-\\ncation modules, 2nd edition. Ginebra: WHO; 2008.\\n7. Baskett PJ. ABC of major trauma. Management of hypovolemic cho-\\nque. BMJ. 1990; 300:1453-7.\\n8. Alexander JTP , Sanghera J. Treatment for primary postpartum hae -\\nmorrhage. (Review). The Cochrane Library, 2008.\\n9. Cotter AM, Tolosa JE. Prophylactic oxytocin for the third stage of labour (Review). The Cochrane Library 2010, Issue 2.\\n10. Liabsuetrakul TCT, Peeyananjarassri K, Islam QM. Prophylactic use of ergot alkaloids in the third stage of labour (Review). The Cochrane \\nLibrary 2009, Issue 1.\\n11. Mousa HAAZ. Treatment for primary postpartum haemorrhage (Review). The Cochrane Library 2009.\\n12. American College of Obstetricians and Gynecologists. ACOG Practice \\nbulletin postpartum hemorrhage. Obstet Gynecol. 2006;108:1039-47.\\n13. Novikova NHG. Tranexamic acid for preventing postpartum haemo-rrhage (Review). The Cochrane Library 2010, Issue 7.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 16}), Document(page_content='18\\n14. Nan Schuurmans EA. Prevention and Management of Postpartum \\nHaemorrhage. J SOGC. 2000;88:42.\\n15. Hallak MDGI, Hurley TJ, et al. Transvaginal presure pack for life-threatening pelvic hemorrage secondary to placenta acreta. Obstet Gynecol. 1991;78:938-40.\\n16. Begley CMGG, Murphy DJ, Devane D, et al. Active versus expectant \\nmanagement for women in the third stage of labour (Review). The \\nCochrane Library 2010, Issue 7.\\n17. The International Confederation of Midwives (ICM), International Federation of Gynecology and Obstetrics (FIGO), Canadá. O&G. \\nManagement of the third stage of labour to prevenet postpartum \\nhemorrhage. JOGC, 2003.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guia Maternidad-Codigo Rojo colombia.pdf', 'page': 17}), Document(page_content='SOGC CLINICAL PRACTICE GUIDELINE\\nNo. 431, December 2022 (Replaces No. 235, October 2009 & No. 115, June 2002)\\nGuideline No. 431: Postpartum\\nHemorrhage and Hemorrhagic Shock\\n(En français : Directive clinique no 431 : Hémorragie post-partum et choc hémorragique)\\nThe English document is the original version. In the event of any discrepancy between the English and French content, the English version prevails.\\nThis clinical practice guideline was prepared by the authors and\\noverseen by the SOGC Clinical Practice Obstetrics committee. Itwas reviewed by the SOGC Obstetrical Content Review\\ncommittee and approved by the SOGC Guideline Management\\nand Oversight Committee and SOGC Board of Directors.This clinical practice guideline supersedes No. 235, published inOctober 2009 and No. 115, published in June 2002.\\nAuthors\\ndebbie Robinson, MD, Winnipeg, MB\\nMelanie Basso, RN, MSN, Vancouver, BC\\nCynthia Chan, MD, London, ON\\nKirsten Duckitt, MD, Campbell River, BCRyan Lett, MD, Regina, SKSOGC Clinical Practice eObstetrics Committee (2022):\\nDouglas Black (past-Chair), Mélina Castonguay, Cynthia Chan,Elissa Cohen (co-Chair), Christine Dallaire, Kirsten Duckitt,\\nSebastian Hobson (co-Chair), Isabelle Létourneau, Amy Metcalfe,\\nJ. Larry Reynolds, debbie Robinson, Marie-Ève Roy-Lacroix,Katherine Tyndall, Kathryn Versteeg\\nAcknowledgements: The authors would like to acknowledge\\nand thank special contributor Dr. Stephanie Cooper, MD, Calgary,AB, for her extensive contribution to the appended PPH\\nAppendices.\\nDisclosures: Statements were received from all authors.\\nDr. Ryan Lett has previously given lectures on intravenous ironand received an unrestricted educational honorarium from P ﬁzer;\\nhe also sits on the National Advisory Committee on Blood and\\nBlood Products as a representative for Saskatchewan. No other\\nrelationships or activities that could involve a con ﬂict of interest\\nwere declared.\\nAll authors have indicated that they meet the journal ’s\\nrequirements for authorship.\\nKeywords: postpartum hemorrhage; therapeutics; hemorrhagic\\nshock; obstetric delivery; preventive medicine\\nCorresponding author : debbie Robinson,\\ndebbie.robinson@umanitoba.caJ Obstet Gynaecol Can 2022;44(12):1293-1310\\nhttps://doi.org/10.1016/j.jogc.2022.10.002\\nª2022 The Society of Obstetricians and Gynaecologists of Canada/La\\nSociété des obstétriciens et gynécologues du Canada. Published by\\nElsevier Inc. All rights reserved.\\nThis document re ﬂects emerging clinical and scienti ﬁc advances as of the publication date and is subject to change. The information is not\\nmeant to dictate an exclusive course of treatment or procedure. Institutions are free to amend the recommendations. The SOGC suggests,\\nhowever, that they adequately document any such amendments.\\nInformed consent: Patients have the right and responsibility to make informed decisions about their care in partnership with their health care\\nprovider. In order to facilitate informed choice, patients should be provided with information and support that is evidence-based, culturallyappropriate, and personalized. The values, beliefs and individual needs of each patient in the context of their personal circumstances should beconsidered and the ﬁnal decision about care and treatment options chosen by the patient should be respected.\\nLanguage and inclusivity: The SOGC recognizes the importance to be fully inclusive and when context is appropriate, gender-neutral lan-\\nguage will be used. In other circumstances, we continue to use gendered language because of our mission to advance women ’s health. The\\nSOGC recognizes and respects the rights of all people for whom the information in this document may apply, including but not limited totransgender, non-binary, and intersex people. The SOGC encourages health care providers to engage in respectful conversation with their\\npatients about their gender identity and preferred gender pronouns and to apply these guidelines in a way that is sensitive to each person ’s\\nneeds.It is the Society of Obstetrician and Gynaecologists of Canada (SOGC) policy to review the content 5 years after publication, at which\\ntime the document may be revised to re ﬂect new evidence or the document may be archived\\nDECEMBER JOGC DÉCEMBRE 2022 l1293\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 0}), Document(page_content='RECOMMENDED CHANGES IN PRACTICE\\n1. Quantitative blood loss measurement should replace\\nestimated blood loss for all deliveries.\\n2. Maximum single dose oxytocin doses should be 3 IU IV rapid\\ninjection, or 10 IU intramuscular\\n3. In cases of severe obstetrical hemorrhage, the calculated\\nmaximum allowable blood loss and lab-based (or point-of-careebased) factor replacement should guide treatment\\nwhenever possible.\\n4. Misoprostol should only be used sublingually or orally for the\\nprevention and treatment of postpartum hemorrhage.\\nKEY MESSAGES\\n1. Reducing the risk of postpartum hemorrhage begins\\nantenatally and continued vigilance is needed throughout\\nlabour to recognize abnormal postpartum bleeding early.\\n2. Appropriate recognition and treatment of postpartum\\nhemorrhage can prevent serious morbidity while reducing\\ncosts to the health care system by minimizing costly\\ninterventions and length of hospital stays.\\n3. Simulation training followed by formal debrie ﬁng will improve\\noutcomes in the clinical setting.\\nABSTRACT\\nObjective: This guideline aims to provide evidence for prevention,\\nrecognition, and treatment of postpartum hemorrhage includingsevere hemorrhage leading to hemorrhagic shock.\\nTarget population: All pregnant patients.\\nBene ﬁts, harms, and costs: Appropriate recognition and treatment of\\npostpartum hemorrhage can prevent serious morbidity whilereducing costs to the health care system by minimizing more costlyinterventions and length of hospital stays.\\nEvidence: Medical literature, PubMed, ClinicalTrials.gov , the\\nCochrane Database, and grey literature were searched for articles,published between 2012 and 2021, on postpartum hemorrhage,uterotonics, obstetrical hemorrhage, and massive hemorrhage\\nprotocols.\\nValidation methods: The authors rated the quality of evidence and\\nstrength of recommendations using the Grading of\\nRecommendations Assessment, Development and Evaluation\\n(GRADE) approach. See online Appendix A (Tables A1 for\\ndeﬁnitions and A2for interpretations of strong and conditional\\n[weak] recommendations).\\nIntended Audience: All members of the health care team who care for\\nlabouring or postpartum women, including, but not restricted to,nurses, midwives, family physicians, obstetricians, andanesthesiologists.\\nRECOMMENDATIONS\\n1. An individualized risk assessment for postpartum hemorrhage\\nshould be documented in a checklist upon arrival to a labour unitand updated throughout labour and delivery ( strong, high ). The riskassessment should include a calculation of the maximum allow-\\nable blood loss ( good practice point ).\\n2. Both antenatal and postnatal anemia should be identi ﬁed and\\ntreated aggressively ( strong, high ).\\n3. Quantitative blood loss measurement should replace estimated\\nblood loss in all patients whenever possible ( strong, moderate ).\\n4. Staging and management of postpartum hemorrhage should be\\nbased on quantitative blood loss ( strong, high ).\\n5. Active management of the third stage of labour should be offered\\nto all women ( strong, high ).\\n6. Prophylactic intramuscular oxytocin can be used for patients at low\\nrisk for postpartum hemorrhage ( strong, high ).\\n7. For patients at high risk of postpartum hemorrhage, prophylactic\\nintravenous oxytocin should be used ( conditional, moderate ).\\n8. When given intravenously, oxytocin can be given either as a rapid\\ninfusion (max rate 1 IU/min) for 4 minutes, followed by 7.5 e15 IU/h\\nor as a 3 IU intravenous rapid injection ( strong, moderate )\\n9. If there is inadequate response to oxytocin within 4 minutes, a\\nsecond-line uterotonic should be administered ( strong, high ).\\n10. Carbetocin can be considered as a ﬁrst-line agent for postpartum\\nhemorrhage prophylaxis at cesarean delivery ( strong, moderate ).\\n11. Bimanual uterine compression and bladder emptying should be\\nperformed as ﬁrst-line measures while waiting for pharmacologic\\nagents to take effect ( good practice point ).\\n12. Misoprostol (sublingual/oral) is an effective adjunct to prophylactic\\nor therapeutic oxytocin in high-risk individuals ( strong, high )\\n13. Intramuscular ergotamine and intramuscular or intramyometrial\\ncarboprost, can both be used to treat active postpartum hemor-\\nrhage (\\nstrong, high ).\\n14. Rectal misoprostol is inferior to other routes (both in onset and in\\nbioavailability) and should not be used ( strong, moderate ).\\n15. Tranexamic acid can be used in all patients as an adjunct to ute-\\nrotonics in the setting of postpartum hemorrhage, and can be used\\nas a prophylactic agent in patients at high risk for postpartumhemorrhage ( strong, high ).\\n16. Uterine tamponade is an effective tool and should be considered\\nfor ongoing mild to moderate bleeding ( conditional, moderate ).\\n17. If the placenta has not been expelled spontaneously in the 30\\nminutes following delivery, measures should be taken to expeditedelivery of the placenta ( strong, high ).\\n18. When there is ongoing bleeding, examine the patient for the\\npresence of clots, retained placental tissue, or genital tract lacer-ations ( good practice point ).\\n19. In the case of uterine inversion, if immediate reversion is not\\npossible, transfer the patient to an operating room for uterinerelaxation and patient stabilization, as required ( good practice\\npoint )\\n20. If pharmacologic interventions have not controlled\\nbleeding, surgical intervention should be undertaken promptly(strong, high )\\n21. Compression sutures, ligation of uterine or internal iliac arteries,\\nand uterine artery embolization are all effective interventions that\\ncan be considered; however, hysterectomy should not be delayedin an unstable patient ( strong, high ).\\n22. Severe obstetrical hemorrhage should be managed by a multi-\\ndisciplinary team consisting of obstetrics, anaesthesia, nursing,and transfusion medicine ( strong, high ).\\n23. An obstetrical massive hemorrhage protocol, including de ﬁned\\nroles and responsibilities of each team member, should be used\\n(strong, moderate ).\\n24. Initial resuscitative and monitoring measures should include\\nintravenous access /C22, electrocardiography, oxygen saturation,\\nblood pressure, placement of an indwelling urethral catheter,\\neuthermia, and volume replacement with balanced crystalloid(good practice point ).\\n1294\\nlDECEMBER JOGC DÉCEMBRE 2022SOGC CLINICAL PRACTICE GUIDELINE\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 1}), Document(page_content='25. Four units red blood cells should be given prior to other blood\\nproducts in an actively bleeding patient who is approaching themaximum allowable blood loss, unless the patient has a coagu-\\nlation defect ( strong, moderate )\\n26. Fibrinogen levels should be measured in every moderate to severe\\ncase of postpartum hemorrhage, and if <2 g/L, should be replaced\\naccordingly ( strong, high ).27. A massive hemorrhage protocol with ratios of red blood cells\\nto fresh frozen plasma to platelets of 1:1:1: or 2:1:1 canbe used in the absence of timely lab results ( strong,\\nmoderate ).\\n28. Simulation training with all members of the multidisciplinary team\\nshould occur on a regular basis, ideally by a trained facilitator\\n(strong, high ).\\nDECEMBER JOGC DÉCEMBRE 2022\\nl1295PPH and Hemorrhagic Shock\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 2}), Document(page_content='INTRODUCTION\\nPostpartum hemorrhage (PPH) continues to be a sig-\\nniﬁcant contributor to maternal morbidity and mor-\\ntality, even in developed countries.1Between 2003 and 2010,\\nthe incidence of PPH in Canada was 5.6 per 100 deliveries.\\nInternational data from high resource countries suggest the\\nrate is closer to 10% when blood loss is actually measured,2\\nand this rate continues to rise, with uterine atony being the\\nprimary cause.3,4The traditional de ﬁnition of blood loss as\\n/C21500 mL with vaginal delivery or /C211000 mL with cesarean\\ndelivery (CD) is no longer suf ﬁcient, as visual estimates have\\nbeen found to be inaccurate, even for experienced pro-\\nviders.5,6In addition, many women of reproductive age\\nmaintain normal vital signs despite blood loss beyond these\\namounts. Since these factors can lead to delays in treatment\\ncausing adverse maternal outcomes,7,8accurate and cumu-\\nlative measurement of blood loss has emerged as the newstandard of care.\\n9\\nPrevention is key to reducing maternal morbidity from\\nPPH, as 60% of these patients have at least one identi ﬁable\\nantepartum or intrapartum risk factor.10Assessment for\\nthese risk factors, as well as early intervention, are integral\\nto mitigating potential adverse outcomes.\\nThis guideline provides a new approach to the early\\nidenti ﬁcation and management of PPH. Recommenda-\\ntions are based on emerging data that highlight the suc-cesses of obstetrical hemorrhage toolkits and care bundles\\nin reducing maternal morbidity and mortality.\\nThe California Maternal Quality Care Collaborative\\nimplemented a quality improvement initiative that led to a\\nreduction in PPH of 20.8%, compared with 1.2% in non-\\nparticipating hospitals.\\n11This guideline presents an\\nadapted model to prevent and manage PPH and com-\\nprises the following categories:\\n1. RISK ASSESSMENT\\n2. RISK REDUCTION\\n3. RECOGNIZE AND RE-EVALUATE\\n4. REACT5. RESUSCITATE\\n6. REVIEW\\nRISK ASSESSMENT\\nCauses and Risk Factors\\nThe four Ts (tone, tissue, trauma, thrombin) are well\\nknown. Evaluation of risk factors in each of these cate-\\ngories is important to determine a potential cause of PPH\\n(Table 1 ).Individualized risk should be documented in a\\nchecklist upon arrival to a labour unit and updated\\nthroughout labour and delivery (Appendix B ). Patients at\\nhigh risk for PPH deliver in a facility with easy access to amassive hemorrhage protocol (MHP) that takes into\\nconsideration local blood product supply, transport, and\\naccess to specialist advice.\\nAnemia\\nWomen with anemia (Hb <110 g/L) have less reserve to\\ncope with PPH. Anemia may also reduce oxygen deliveryto myometrial muscles resulting in uterine atony.\\n12In\\naddition, iron is a necessary cofactor for adenosine\\ntriphosphate (ATP) production in muscle cells, and iron\\ndeﬁciency itself may contribute to uterine atony.13\\nIron de ﬁciency anemia is a signi ﬁcant health problem for\\nwomen worldwide.14The prevalence of iron de ﬁciency\\nanemia in pregnancy is estimated at 41%, with higher rates\\nin low socioeconomic populations.14A study, conducted in\\nToronto, Canada, of pregnant women screened for iron\\ndeﬁciency anemia found that 91% of participants were iron\\ndeﬁcient (ferritin <50mg/L), with most having severe iron\\ndeﬁciency with a ferritin <20mg/L despite only 25% of\\nparticipants having a hemoglobin level <110 g/L.15These\\nﬁndings highlight the fact that by the time a low hemoglobin\\nis detected, the iron de ﬁciency is profound. Both hemo-\\nglobin and ferritin should be measured antenatally.\\nAnemia and iron de ﬁciency should be assessed and treated\\nat or before 28 weeks gestation. Ferrous salts, taken dailyor every other day, on an empty stomach is the ideal\\nmethod of iron supplementation.\\n16There is insuf ﬁcient\\nevidence to routinely co-administer ascorbic acid (vitamin\\nC).17Intravenous iron should be given if there is no\\nresponse (increase in Hb of 10 g/L) within 2 weeks.18\\nPostpartum anemia contributes to fatigue, postpartum\\ndepression, poor bonding, and poor lactation.19,20Oral\\niron supplementation should continue for at least 3\\nmonths postpartum and intravenous (IV) iron considered\\nwith hemoglobin <80 g/L, regardless of symptoms.16ABBREVIATIONS\\nCD cesarean delivery\\nMABL maximum allowable blood loss\\nMHP massive hemorrhage protocol\\nPPH postpartum hemorrhage\\nTXA tranexamic acid\\n1296 lDECEMBER JOGC DÉCEMBRE 2022SOGC CLINICAL PRACTICE GUIDELINE\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 3}), Document(page_content='RISK REDUCTION\\nThe California Collaborative found that underestimating\\nblood loss and relying on vital signs led to health care\\nproviders underestimating the severity of PPH and, more\\nimportantly, led to delays in treatment.11Denial is delay\\nshould be the new theme for PPH management strate-\\ngies.11The bene ﬁt of one or more PPH bundles (con-\\ntaining key medications, instruments, tamponade devices,sponges, sutures, etc.) can decrease the time to treatment\\nby having all potentially needed materials readily available.\\nAccurate Measurement of Blood Loss\\nSince visual estimates grossly underestimate the true volumeof blood loss, it is recommended that labour units begin to\\naccurately monitor and record ongoing bleeding .D r y\\nweights of sponges, towels, sheets, and other commonly\\nsoaked surfaces should be recorded on a standard form thatcan be accessed at any time to properly evaluate blood loss\\nin any patient. Measuring amniotic ﬂu i di nt h ed r a p e( c a l i -\\nbrated cones are available) and wiping the ﬂuid off the ﬂoor\\nbefore active bleeding begins will distinguish it from any\\npostpartum bleeding. Whenever possible, suction the am-\\nniotic ﬂuid at CD prior to delivering the infant and docu-\\nment its volume. Everything suctioned after this point\\nshould be considered blood loss. Sponges, towels, and\\ndrapes should be collected and weighed. A record of cu-\\nmulative blood loss for the ﬁrst 24 hours should be kept.\\nEstimated blood loss should be replaced by quantitative\\n(measured) blood loss ( Appendices C, D, E, F ).\\nClassi ﬁcation and Management Protocols for\\nStages of Postpartum Hemorrhage\\nA staging system based on quantitative blood loss,\\nregardless of vital signs, with detailed managementTable 1. Postpartum hemorrhage risk factors\\nEtiology Risk Factors\\nTone (uterine atony) Uterine overdistension /C15Polyhydramnios\\n/C15Multiple gestation\\n/C15Macrosomia\\nUterine exhaustion /C15Precipitous or prolonged labour\\n/C15Prolonged oxytocin use\\n/C15High parity\\n/C15General anaesthesia\\n/C15Anemia\\nInfection /C15Prolonged rupture of membranes\\n/C15Chorioamnionitis\\nDysfunctional uterine activity /C15Fibroids\\n/C15Placenta previa\\nTissue Retained products of conception Incomplete placental delivery (succenturiate lobe,\\nmorbidly adherent placenta)\\nTrauma Laceration of cervix, vagina, perineum /C15Precipitous or operative delivery\\n/C15Episiotomy extension\\n/C15Fetal malposition\\nExtension/lacerations at cesarean /C15Deep engagement\\n/C15Prolonged second stage\\n/C15Fetal malposition\\nUterine rupture Previous uterine surgery\\nUterine inversion /C15Nulliparity with fundal placenta\\n/C15Excessive cord traction\\nThrombin Pre-existing states /C15Hereditary coagulopathies (von Willebrand disease, hemophilia)\\n/C15Idiopathic thrombotic purpura\\nAcquired in pregnancy /C15Preeclampsia\\n/C15Disseminated intravascular coagulopathy\\n/C15Fetal demise\\n/C15Severe infection\\n/C15Abruption\\n/C15Amniotic ﬂuid embolism\\nIatrogenic /C15Therapeutic anticoagulation\\nDECEMBER JOGC DÉCEMBRE 2022 l1297PPH and Hemorrhagic Shock\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 4}), Document(page_content='protocols for each stage should be implemented.21(Clas-\\nsiﬁcation in Table 2 , for a more detailed table including\\nexpanded management protocols see Appendix G )\\nActive Management of the Third Stage of Labour\\nThe SOGC ﬁrst commented on the active management of\\nthe third stage of labour in 2000.22Three elements were\\noriginally included: a uterotonic after delivery of the\\nanterior shoulder, early cord clamping, and cord traction to\\ndeliver the placenta. Since that time, delayed cord clamping\\nhas become the standard of care as it improves neonatal\\noutcomes without increasing the incidence of PPH.23\\nFurthermore, in multiple trials and reviews, controlledcord traction has been shown to only decrease the lengthof the third stage by 4-6 minutes and blood loss by\\n<30 mL.\\n24e28Since there is limited evidence to suggest\\nthat expediting delivery of the placenta before 30 minutes\\nreduces the risk of PPH in an uncomplicated delivery,22\\nthe de ﬁnition of active management of the third stage of\\nlabour should be con ﬁned to the use of a uterotonic.\\nProviders choosing to employ controlled cord traction\\nshould only do so after signs of placental separation, and\\ntraction should be performed with uterine contraction as\\nthese measures reduce the risk of uterine inversion, cord\\navulsion, and partial detachment of the placenta.\\nAlthough prophylaxis with oxytocin for all patients has been\\ncommon practice, a 2019 Cochrane review found no clear\\nbeneﬁt to routine uterotonics in terms of PPH or hemo-\\nglobin in women at low risk of PPH, based on low quality\\nevidence.29They concluded that women at low risk for PPHshould be given the necessary information regarding the\\nbeneﬁts and risks of active management of the third stage of\\nlabour in order to make informed choices about their care.\\nSkin to skin contact may independently reduce the length of\\nthe third stage.30\\nOxytocin Free Interval Prior to Cesarean Delivery\\nThe longer oxytocin is used for the induction or\\naugmentation of labour, the less responsive the uterus\\nbecomes to it. Tran et al. showed a statistically signi ﬁcant\\nassociation between the length of the oxytocin free interval\\nprior to CD and the total estimated blood loss with the\\ngreatest bene ﬁt after 1 hour.31While the reduction in\\nblood loss in patients with a low BMI was not clinicallysigniﬁcant (7 mL/10-min recovery interval), the greatest\\nbeneﬁt was seen in women with a BMI >40 kg/m\\n2, where\\nblood loss was reduced by 45 mL per 10-minute recovery\\ninterval up to a maximum of 450 mL at 99 minutes. In\\nthese women, higher amounts and longer durations of\\noxytocin use were associated with an increased need for a\\nsecond-line uterotonic agent. When maternal and fetal\\nconditions are stable, providing an oxytocin wash-out in-\\nterval may be bene ﬁcial, particularly when the patient ’s\\nBMI is >40 kg/m2.\\nProphylactic Uterotonics ( Table 3 )\\nOxytocin\\nNumerous trials over more than 2 decades continue to\\nshow that oxytocin is the drug of choice for both the\\nprevention and treatment of PPH.32Compared with pla-\\ncebo, ergometrine, carboprost, or misoprostol, oxytocin isTable 2. Classi ﬁcation and management of PPH by stage\\nBlood loss, mL BP, mm HgaHR, bpmaSigns/symptoms Initial managementb\\nStage 0 /C15<500 vaginal\\n/C15<1000 CDNormal <100 Asymptomatic Active or physiologic management\\nof the third stage\\nStage 1 (mild) /C15500-1000 vaginal\\n/C151000 CDNormal <110 Often asymptomatic, or may\\nhave signs of severe PPHTherapeutic ﬁrst-line uterotonic\\nStage 2\\n(moderate)1000-1500 Postural\\nhypotension\\n(SBP 80-100)>110 May be asymptomatic, or\\nmay have signs of\\nsevere PPH/C15Second-line uterotonic\\n/C15Look for other causes\\nStage 3\\n(severe)>1500 SBP <80 >120 /C15Diaphoresis\\n/C15Delayed capillary re ﬁll time\\n/C15Tachypnea\\n/C15Pallor\\n/C15Oliguria/anuria\\n/C15Decreased level of\\nconsciousness\\n/C15Agitation\\n/C15Cool extremitiesFull resuscitation protocol\\naBP and HR may be variable.\\nbExpanded in Appendix G .\\nBP: blood pressure; CD: cesarean delivery; HR: heart rate; PPH: postpartum hemorrhage; SBP: systolic blood pressure.\\n1298 lDECEMBER JOGC DÉCEMBRE 2022SOGC CLINICAL PRACTICE GUIDELINE\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 5}), Document(page_content='either more effective, has fewer adverse effects, or\\nboth.33e35While the uterus is increasingly responsive to\\noxytocin as pregnancy progresses, there are fewer re-\\nceptors in the lower uterine segment than in the fundus,\\nand oxytocin has no direct effects on the cervix.36\\nOxytocin is most commonly given by IV or intramus-cular injection, though some research has been done on\\nthe inhaled and intramyometrial routes.\\n37,38For low-risk\\npatients, prophylaxis via any route is suf ﬁcient; for high-\\nrisk patients, the IV route is preferred.39\\nMuch research has been done on the effects of IV oxytocinat the time of CD. In an elective CD (no labour), as little as\\n1 IU of oxytocin can achieve uterine tonus. While similar\\nstudies have not been done in the context of a vaginal\\nbirth, it is reasonable to assume that the uterus will be at\\nleast as responsive after vaginal delivery than after an\\nintrapartum CD, where studies show an IV bolus of 3 IU\\nis sufﬁcient to cause maximal uterine tonus by 4 minutes.\\n40\\nInterestingly, a rapid IV infusion will provide the same\\nbeneﬁt at 4 minutes, when approximately 3 e4I Uo f\\noxytocin has entered the circulation.41,42\\nIn order to avoid overdosing oxytocin, the infusion should\\nbe put through a pump, hung as a separate mini-infusion\\nwith only 4 IU in 100 mL. At this point, an infusion of\\n7.5e15 IU/h is suf ﬁcient to maintain uterine tone; ahigher infusion rate or additional IV boluses will not\\nprovide any additional bene ﬁt. For high-risk patients, or\\nongoing bleeding, a second-line agent should be added.\\nOxytocin has known hemodynamic and cardiac side ef-\\nfects (mainly ST depression from vasoconstriction of\\ncoronary arteries) that are seldom recognized after vaginal\\nbirth, primarily because patients are not monitored to\\ndetect them and because the clinical signs are attributed to\\nother causes. Fortunately, these side effects are short lived;\\nhowever, they have contributed to maternal death indeveloped countries.\\n43,44When oxytocin is given quickly,\\nhypotension and ST changes begin to appear after as little\\nas 1 IU is administered but do not become noticeable until\\n3 IU is administered; these signs are signi ﬁcant at\\n/C215I U .40At 10 IU, 50% of women will experience ST\\ndepression, even non-pregnant, non-anesthetized control\\npatients.45These effects disappear when the 5 IU bolus\\nis given over 5 minutes. Rapid IV bolus should therefore\\nbe restricted to 3 IU or less, and an IV infusion is\\npreferred.\\nCarbetocin\\nCarbetocin is a synthetic, long-acting, heat stable, analogue\\nof oxytocin with equivalent af ﬁnity for the oxytocin re-\\nceptor. A single prophylactic 100 mg dose given IV over 30\\nseconds to 1 min provides similar or better clinical effectsTable 3. Prophylactic and ﬁrst-line therapeutic uterotonics\\nOxytocin (Syntocinon, Pitocin) Carbetocin (Duratocin)\\nUse Prophylaxis Prophylaxis AND ﬁrst-line therapeutic Prophylaxis\\nMechanism of action Uterotonic, direct stimulation of\\noxytocin receptorsaUterotonic, direct stimulation of\\noxytocin receptorsaStimulation of oxytocin\\nreceptors\\nDose and route /C153 IU IV rapid injection\\n/C1510 IU IM20e40 IU/L infusion erapid /C24þmin,\\nthen 7e15 IU/h once tone achieved/C15100mg slow IV injection\\n(/C2130 s)\\n/C15100mgI M\\nOnset of clinical action /C151e2 min (IV)\\n/C153e7 min (IM)4 min with rapid infusion /C151e2 min IV\\n/C153e4 min IM\\nHalf-life /C154e10 min (IV)\\n/C1515e30 min (IM)Ongoing 40 min\\nDuration of action /C1515e20 min (IV)\\n/C151e2 h (IM)Ongoing 1 h\\nAdverse effects /C15IV:\\no<1I Uenone\\no1e3I Ueminimal\\no>3I Uedose-related\\nincrease ST depression,\\nincrease in HR, drop in BP\\n/C15IM: minimal/C15Water retention\\n/C15Note: rate above 15 IU/h ineffective\\nafter 3 IU in circulation100mg dose side effects\\nequivalent to 5 IU slow\\nIV rapid injection oxytocin\\nNote: misoprostol and TXA may be given concurrently with these ﬁrst-line uterotonics for patients at high risk for PPH.\\naDecreased effect with prolonged use. Increased effect after oxytocin free interval.\\nDECEMBER JOGC DÉCEMBRE 2022 l1299PPH and Hemorrhagic Shock\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 6}), Document(page_content='and similar side effects as a 5 IU IV bolus of oxytocin\\ngiven at the same rate,46,47and some studies have shown\\nsmaller doses to be equally effective.48In addition, its long\\nhalf-life of 40 minutes reduces the need for additional\\nuterotonics when compared with oxytocin. The product\\nmonograph states that severe preeclampsia/eclampsia is a\\ncontraindication to its use; however, clinical trials in\\nwomen delivering vaginally or by cesarean found carbe-\\ntocin to be both safe and effective in this setting.49,50While\\ncarbetocin has not been studied as a therapeutic agent for\\nactive PPH, it should be considered a ﬁrst-line agent for\\nprophylaxis at CD. Emerging evidence suggests the use ofcarbetocin may also be considered as a ﬁrst-line prophy-\\nlactic uterotonic at vaginal delivery.\\n51\\nRECOGNIZE AND RE-EVALUATE\\nIt is crucial for care providers to rapidly recognize wheninitial measures have not adequately controlled bleeding.\\nFailure to discern both the extent and source of bleedingwill needlessly delay appropriate intervention. Recording\\nquantitative blood loss and vital signs for every post-\\npartum patient will help health care providers recognize\\nwhen blood loss has moved between stages and can\\nprompt intervention ( Appendix G )\\nRE-EVALUATE TONE\\nBimanual Uterine Compression and Bladder\\nEmptying\\nThe basic manoeuvre of manually compressing the uterus\\nsimultaneously through the abdomen and the vagina can\\nbe life-saving and should be actively used until the phar-\\nmacologic agents take effect, or surgical intervention is\\ninitiated. The lower uterine segment must be cleared ofclots to allow the uterus to contract. Catheterization\\nshould be an initial step in management of PPH as a full\\nbladder can impair the uterus ’ability to contract.Special Agents\\nMisoprostol\\nPG E1is available in 100 and 200 mg tablets and can be given\\nsublingually, orally, buccally, vaginally, and rectally. However,\\nan understanding of the pharmacokinetics of misoprostol,\\nborne out in clinical trials, will quickly eliminate most of\\nthese routes for treatment of PPH52(Table 4 ).\\nThe 2018 Cochrane review of all uterotonic agents found\\nmisoprostol alone was superior to placebo but inferior to\\noxytocin for preventing PPH; however, adding miso-\\nprostol to oxytocin prevented the need for additionaluterotonics.\\n47,53When used as an adjunctive treatment,\\nmisoprostol should be given sublingually as this route\\noffers the highest bioavailability with a rapid onset and a\\nmoderate duration of action. Doses above 400 mg are not\\nneeded, and, in fact, 200 mg may be suf ﬁcient.54Miso-\\nprostol should not be given rectally as this route offers the\\nlowest bioavailability and is associated with a maximum\\nserum concentration that may not reach clinically signi ﬁ-\\ncant levels.52,55While misoprostol is a valuable adjunct to\\nboth prophylactic and therapeutic uterotonics, the inject-\\nable agents (oxytocin, ergometrine, carboprost, and TXA)\\nhave a more rapid onset and may be more useful as an\\nindependent agent in active PPH. The main side effects of\\nmisoprostol, which are dose dependent, are shivering and\\nfever, nausea, vomiting, and diarrhea.\\nTranexamic Acid\\nTXA is an anti ﬁbrinolytic agent that inhibits the activation\\nof plasminogen to plasmin. Given intravenously, it has a\\nhalf-life of 2 hours.56Side effects include nausea, vomiting,\\ndiarrhea, seizures, deep vein thrombosis, and pulmonary\\nembolism, though seizures and thrombosis have not been\\ndemonstrated in clinical trials of PPH.57Two separate\\nrandomized trials showed prophylactic IV TXA (after cord\\nclamping in 1 trial, and preoperatively in the other)Table 4. Pharmacokinetics of misoprostol\\nAUC rankaOnset of action,bmin Tmax,cmin Cmax,dpg/mL (averaged) Duration of action,eh\\nSublingual 1 11 30 500 3\\nVaginal 2 20 75 300 4\\nOral 3 8 30 300 2\\nBuccal 4 20 75 200 4\\nRectal 5 100 75 100 4\\naAUC: area under the (concentration vs time) curve; re ﬂects bioavailability from highest (1) to lowest (5)\\nbHow rapidly clinical effect is seen.\\ncTmax: how rapidly the drug is completely absorbed.\\ndHow completely the drug is absorbed.\\neHow long clinical effect is seen.\\n1300 lDECEMBER JOGC DÉCEMBRE 2022SOGC CLINICAL PRACTICE GUIDELINE\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 7}), Document(page_content='reduced the blood loss at CD,58,59and 2 separate large\\nmeta-analyses, as well as one randomized controlled trial\\nshowed that 1g of IV TXA given in the setting of ongoing\\nPPH after vaginal delivery decreases blood loss, rate of\\nhysterectomy, and mortality.60e62In particular, when given\\nover 30e60 seconds, there was no difference in systolic or\\ndiastolic blood pressures compared with placebo.61TXA\\nshould be given whenever a second-line uterotonic is\\nadministered. Every 15-minute delay results in a 10%\\nreduction of TXA ef ﬁcacy and immediate treatment im-\\nproves survival by over 70% ( P<0.0001).63Prophylactic\\nuse (in addition to a prophylactic uterotonic agent) in in-dividuals at high risk of PPH (cesarean or vaginal delivery)\\nis a reasonable option. For a summary of special agents,\\nseeTable 5 .\\nUterotonics for Treatment of Postpartum\\nHemorrhage\\nAdditional agents should be used whenever the initial\\nagent has not produced suf ﬁcient uterine tone by 4 mi-\\nnutes, or concurrently with a prophylactic agent in patients\\nwith increased risk for PPH based on the ongoing\\nchecklist ( Table 6 ).\\nErgometrine\\nErgometrine, or ergonovine is an ergot alkaloid which directly\\nstimulates uterine and vascular smooth muscle to contract. It\\ncan be given intramuscularly or, in life-saving circumstances,as a slow IV injection.\\n64It is a potent uterotonic, but in the\\nsetting of anemia and hypovolemia, ergometrine can rarelyprecipitate coronary artery vasospasm and myocardial\\nischemia, even in patients without pre-existing cardiovascular\\nrisk factors.65Ergometrine should not be used in patients\\nwith essential or gestational hypertension,66or in patients on\\nHIV protease inhibitors.47,67,68Though undisputedly\\nextremely effective, potential adverse effects limit ergome-\\ntrine to a second-line agent.\\nCarboprost\\nCarboprost is a prostaglandin F 2athat causes contractions\\nin myometrial and intestinal smooth muscle cells.69It can\\nbe given by intramuscular or intramyometrial injection butcannot be given intravenously. Its ef ﬁcacy is equivalent to\\noxytocin after either cesarean or vaginal delivery but\\ncommon adverse effects, including nausea, vomiting,\\ndiarrhea, and fever limit its use to a second-line agent.\\n34,70\\nLoperamide should be given concurrently with carboprost\\nto counteract its diarrheal effects. As a member of the F\\nclass of prostaglandins, carboprost can cause broncho-\\nspasm and should not be used in patients with asthma.71\\nMechanical Options\\nTamponade\\nIntrauterine compression may control mild to moderate\\nblood loss. The Bakri balloon was designed for this pur-\\npose and its use prevents the need for further non-\\npharmacologic intervention in 75% e95% of cases.72,73It\\nshould be ﬁlled with 300 e500 mL of sterile solution, left\\nin situ for 8 e48 hours and then gradually de ﬂated. Anti-\\nbiotics should be considered if they have not already beenTable 5. Special agents\\nMisoprostol (Cytotec) Tranexamic acid (TXA)\\nIndication /C15Adjunct for prophylaxis with ﬁrst-line agents in\\nhigh-risk patients\\n/C15Adjunct for treatment with second-line uterotonics\\nin all patients with active PPH/C15Adjunct for prophylaxis with ﬁrst-line agents in very high-\\nrisk patients\\n/C15Adjunct for treatment with second-line uterotonics in\\nall patients with active PPH\\nMechanism of action Uterotonic; binds prostaglandin receptors Anti ﬁbrinolytic; inhibits activation of plasminogen to plasmin\\nDose/route/rate /C15200e400mg sublingual\\n/C15200e400mg oral1 g IV over 30 e60 s\\nOnset of action /C1511 min (sublingual)\\n/C158 min (oral)\\no both peak at 30 mind\\nHalf-life /C152 h (sublingual)\\n/C151.5 h (oral)2h\\nDuration of action /C153 h (sublingual)\\n/C152 h (oral)d\\nRepeat dosing d Every 30 min; max 2 doses\\nAdverse effects /C15Fever (especially with doses /C21600mg)\\n/C15Shivering, nausea/vomiting, diarrheaNausea/vomitingdiarrhea, Headache\\nCaution d VTE has not been seen in obstetrical clinical trials\\nIV: intravenous; PPH: postpartum hemorrhage; VTE: venous thromboembolism.\\nDECEMBER JOGC DÉCEMBRE 2022 l1301PPH and Hemorrhagic Shock\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 8}), Document(page_content='given, and a pack can be placed in the vagina if the balloon\\nis hourglassing through the cervix. If a Bakri balloon is not\\navailable, any balloon device can be used. Alternatively,\\nsystematically packing the uterus from cornua to cornua\\nwith laparotomy packs tied end to end may be considered;\\nhowever, this procedure requires more experience, more\\nanaesthesia, and a second procedure to remove. It may\\nalso mask blood loss and increase the risk of infection.\\nPacking should be used as a last resort until more de ﬁni-\\ntive treatment can be initiated. A running record of\\naccumulated quantitative blood loss and interventions\\nshould be easily accessible and visible to all members of\\nthe care team ( Appendix E, F, H, I ).\\nRE-EVALUATE SOURCE\\nRetained Placenta\\nRetained placenta occurs in 1% e3% of vaginal deliveries\\nand is the second leading cause of PPH.74Risk factors are\\nuterine atony, an adherent placenta, succenturiate lobe, and\\na trapped placenta behind a closed cervix. Internationally,\\nrecommendations for manual removal of the placenta varybetween 30 and 60 minutes, based on studies from the\\n1990s showing no increase in PPH until at least 30 minutes\\nhad passed.\\n74The majority of placentas (95%) will deliver\\nspontaneously by 18 minutes. A 2012 randomized\\ncontrolled trial con ﬁrmed a previous observational study\\nthat found patients who had manual removal of the\\nplacenta earlier than 30 minutes had less blood loss.75\\nSimilarly, a large retrospective study (n >28 000) showedwaiting more than 30 minutes for placental separation\\nincreased the risk of blood transfusion more than three-\\nfold.76More studies need to be done to be able to\\nrecommend the ideal time for manual removal of the\\nplacenta in a stable patient.\\nIntraumbilical oxytocin (20 IU in 30 mL saline), miso-\\nprostol (800 mg in 30 mL saline), or ergometrine (0.2 mg in\\n30 mL saline), as well as IV carbetocin (100 mg), or sub-\\nlingual misoprostol (400 mg) all have similar ef ﬁcacy for\\nexpelling the placenta within 30 minutes of administration\\n(62%e72%).77,78In the presence of heavy bleeding,\\ntransfer to an operating room for manual removal of the\\nplacenta should be expedited and curettage with a large\\ncurette may be needed. There is insuf ﬁcient evidence to\\nrecommend routine treatment with antibiotics.74\\nLacerations\\nLacerations of the vagina or cervix, or disruption of a\\nuterine scar should be ruled out by a formal examination\\nunder anaesthesia, and surgical repair of the injury should\\nbe completed. Vaginal packing may be required when\\ngeneralized bleeding from a deep venous plexus pre-\\ncludes proper repair. Re-opening the abdominal incision\\nafter CD to look for surgical bleeding should not be\\ndelayed.\\nUterine Inversion\\nThis rare but potentially life-threatening condition is\\nthought to be caused by excessive cord traction on aTable 6. Second-line uterotonics for treatment of postpartum hemorrhage\\nErgometrine/ergonovine Carboprost (Hemabate, PGF 2a)\\nMechanism of action Uterotonic; non-speci ﬁc activation of adrenergic and\\ndopaminergic receptors in uterine and vascular\\nsmooth muscleUterotonic; binds prostaglandin receptors\\nDose and route /C15250mg IM (preferred)\\n/C15250mg IV over 1 min (only in life-saving circumstances)250mg IM or IMM\\nOnset of action /C152e5 min (IM)\\n/C151e2 min (IV)5 min\\nHalf-life /C15T1/2a¼10 mina\\n/C15T1/2b¼2hb30 min\\nDuration of action 120 min 60 min\\nRepeat dosing Every 2 h, max 5 doses Every 15 min, max 5 doses\\nAdverse effects Nausea/vomiting, hypertension, vasoconstriction causing ST\\ndepression and chest painDiarrhea\\nCaution /C15Hypertension\\n/C15HIV medications (NNRTIs or protease inhibitors)\\n/C15Macrolide antibioticsCan cause bronchospasm in patients\\nwith asthma\\naT1/2a¼time for the drug to redistribute to other tissues;\\nbT1/2b¼time for the drug to re-enter and then be cleared from the circulation\\nIM: intramuscular; IMM: intramyometrial; IV: intravenous; NNRTI: non-nucleoside reverse transcriptase inhibitors; PGF 2a: prostaglandin F 2a.\\n1302 lDECEMBER JOGC DÉCEMBRE 2022SOGC CLINICAL PRACTICE GUIDELINE\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 9}), Document(page_content='fundal placenta or fundal pressure without a uterine\\ncontraction; however, there are no risk factors in most\\ncases.79Clinical diagnosis is based on the presence of brisk\\nvaginal bleeding, a mass in the vagina, and vasovagal\\nsyncope. If still attached, the placenta should not be\\nremoved prior to reversion. Prompt replacement may be\\nattempted; however, hypovolemic shock occurs rapidly,\\nand the patient should be urgently transferred to an\\noperating room if reversion cannot be accomplishedimmediately. Uterine relaxation with IV nitroglycerine in\\naddition to vasopressors may be required to revert the\\nuterus and reverse hemodynamic instability. If reversion is\\nunsuccessful, laparotomy may be required. Antibiotics and\\noxytocin should be given after reversion.\\nREACT\\nIf previous measures fail to control bleeding, urgent\\nabdominal surgical exploration is required. Bimanual\\ncompression should be continued while preparations in\\nthe operating room are being made and surgery is about to\\nbegin. Uterine compression sutures (B-Lynch, Cho),uterine artery ligation, internal iliac artery ligation, embo-\\nlization, and hysterectomy are possible interventions. This\\nguideline is not an instruction manual for those not skilled\\nat performing these procedures. Additional expertise\\nshould be sought urgently if the necessary procedure is\\nbeyond the skill set of the care provider.\\nCompression Sutures\\nThe B-Lynch technique uses an absorbable suture on a\\nlarge needle to create compression “suspenders, ”which\\nsuccessfully treat intractable uterine atony 75% of the\\ntime.\\n80Adding a second suture can further decrease the\\nneed for hysterectomy.81Cho square compression sutures,\\nincorporating both anterior and posterior walls of the\\nuterus, have similar ef ﬁcacy.82\\nUterine Artery Ligation\\nThe purpose of uterine artery ligation is not to obliterate\\nblood ﬂow to the uterus, but to temporarily slow it. Key\\naspects include bladder retraction (to prevent traction on\\nboth bladder and ureters caused by the suture) and use of\\nan absorbable suture on a large needle to secure the uterine\\nartery at the level of the isthmus (or 2 e3 cm below the\\nuterine incision at CD). Ensuring 2 cm of myometrium isincorporated into the suture will bundle the uterine artery\\nand vein and prevent complete occlusion of the uterine\\nartery. A second suture can be used superiorly to further\\ncompress ascending branches of the uterine artery. Alter-\\nnatively, if bleeding is predominantly coming from thelower uterine segment or cervical branches, a second stitch\\nplaced 3 cm inferior to the ﬁrst can be used to compress\\ndescending branches of the uterine artery. This location\\nincreases the risk of ureteric entrapment, and further\\nbladder dissection should be performed. Radiologic or\\ncystoscopic evaluation of ureteral patency is recommended.\\nBilateral Internal Iliac Artery Ligation\\nBilateral internal iliac artery ligation is extremely effective\\nat controlling obstetrical hemorrhage (including followinghysterectomy), with numerous case series reporting suc-\\ncess rates of 75% or higher.\\n83e85Unfortunately, bilateral\\ninternal iliac artery ligation requires more skill and expe-\\nrience. Retroperitoneal dissection to identify the bifurca-\\ntion of the common iliac artery is followed by ligation of\\nthe internal branch at least 2 cm distal to the bifurcation\\nwith an absorbable suture. Bilateral internal iliac artery\\nligation reduces pelvic blood ﬂow by 49% but immediate\\nincreased retrograde ﬂow in collateral vessels prevents\\npelvic ischemia. Resumption of menses and demonstration\\nofﬂow in distal uterine arteries in 90% of women within 6\\nmonths suggests that fertility is preserved.86\\nUterine or Internal Iliac Artery Embolization\\nEmbolization of either uterine or internal iliac arteries is\\nhighly effective and fertility sparing. When compared with\\nhysterectomy, blood loss and operative time are\\nsigniﬁcantly less.87,88The main drawbacks of embolization\\nare the availability of an interventional radiology\\ndepartment and a patient with a stable blood pressure. If\\nthese conditions are met and bleeding is ongoing, uterineartery embolization can be considered before proceeding\\nto hysterectomy. Uterine artery embolization can also be\\nconsidered post-hysterectomy for ongoing bleeding,\\nwhere a contributing vessel can be identi ﬁed. Uterine\\nartery embolization is particularly useful for cases\\nwhere bleeding is expected to be high and/or surgical\\ntreatment is expected to be dif ﬁcult (e.g., placenta previa,\\naccreta, severe obesity, or suspected intra-abdominal\\nadhesions). In these cases, an interventional radiology\\nconsult should be obtained pre-delivery and a plan\\nestablished, including the possibility of pre-deliveryplacement of arterial balloons.\\nHysterectomy\\nIn cases of massive obstetric hemorrhage, hysterectomy\\ncan be life-saving, and the biggest risk is waiting too long\\nto perform it. Successive clamping of pedicles without\\ntying them until the uterine arteries have been secured will\\nallow faster control of bleeding. Con ﬂicting opinions on\\nsubtotal versus total hysterectomy preclude a\\nDECEMBER JOGC DÉCEMBRE 2022 l1303PPH and Hemorrhagic Shock\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 10}), Document(page_content='recommendation, and clinical judgment on the source of\\nbleeding and type of hysterectomy is required.89\\nAbdominal Packing\\nWhen surgical hemostasis has been achieved, but ongoing\\nbleeding persists, disseminated intravascular coagulation,acidosis, and hypothermia are often contributing factors.\\nPacking the pelvis tightly with warm, moist packs and\\nleaving them in place for 24 e48 hours can provide the\\nnecessary time to reverse these factors.\\nRESUSCITATE\\nResuscitation requires ongoing communication andteamwork involving the obstetrical care provider and\\nanaesthesia and nursing teams. An algorithm, including\\nclinical signs and symptoms of PPH and hypovolemic\\nshock and their treatments, should clearly outline the re-\\nsponsibilities of various team members in order to opti-\\nmize maternal outcome\\n11(Appendix G ).\\nPPH is an active, ongoing process; lab results represent a\\npoint in time that has invariably passed. While formal lab\\ntests can help tailor therapy, waiting for results to initiate\\ntreatment can worsen patient outcomes.90Most parturi-\\nents are able to maintain hemodynamic stability despite\\nconsiderable blood loss. The recommended hemoglobin\\nlevel at which to transfuse has decreased over time. In\\n2003, the threshold was 80 g/L, and as of 2021 theconsensus is 70 g/L; however, with many patients able to\\ntolerate hemoglobin as low as 50 g/L, this threshold may\\nchange in the future. Patients with pre-existing anemia\\nmay tolerate lower hemoglobin levels better than those\\nwith acute anemia. Current recommendations suggest\\nthat vital sign changes and accurate measurements of\\nongoing blood loss should trigger resuscitation efforts.\\nEscalation of care (with or without transfusion) should\\noccur at blood loss intervals of 500, 1000, and 1500 mL\\n(mild/moderate/severe blood loss) so the team can\\nrespond appropriately if the patient is not tolerating theblood loss.\\nMaximum allowable blood loss (MABL)\\n91is an invaluable\\ntool to customize treatment of PPH and should be\\ncalculated for each individual patient and documented on\\nthe risk assessment form. This formula uses the patient ’s\\nmost recent hemoglobin level as the initial hemoglobin\\n(Hbi) and the hemoglobin at which transfusion may occur,\\nif clinically indicated, as the ﬁnal hemoglobin (Hb f); it in-\\ncorporates the patient ’s weight and total circulating blood\\nvolume and provides an individualized estimate of the\\npatient ’s tolerable blood loss before transfusion shouldoccur. The equation assumes that volume losses have been\\nreplaced with balanced crystalloid. In a healthy pregnancy,\\nthe total circulating blood volume is 100 mL/kg (range\\n90e200 mL/kg.) In obesity, or volume-contracted states\\nsuch as severe preeclampsia, total blood volume should be\\nestimated at 70 mL/kg.92\\nThe actual calculation is:\\nðHbi-HbfÞ/C2Pt’s Weight ðkgÞ/C2Total Blood Volume ðmL=kgÞ\\n½ðHbiþHbfÞ/C20:5/C138\\nThe following simpli ﬁed and more user-friendly version of\\nthis formula can be used to calculate MABL:\\nMABL ¼WtðkgÞ/C2100/C2½Hbi-70/C138\\nðHbiþ70Þ/C20:5\\nHypotension, tachycardia, oliguria, and altered mental\\nstatus indicate hypovolemic shock and should be treatedaggressively. The “lethal triad ”of coagulopathy, acidosis,\\nand hypothermia, which occurs in hemorrhagic shock,\\ncompounds the loss of volume and blood components.\\n8\\n(Appendix J )\\nInitial Steps\\nEstablish the following:\\n/C15Two large bore IV catheters\\n/C15Frequent BP monitoring (consider arterial line)\\n/C15Continuous EKG\\n/C15O2saturation monitor\\n/C15Temperature probe\\n/C15Foley catheter\\nOxygen, Temperature, Volume\\nOxygen supplementation of 8 e10 L/min will slow the\\nonset of tissue hypoxia. Hypothermia increases the risk of\\nmortality; keeping the patient dry, using warmed blankets\\nor forced air warmers, and warming all ﬂuids will help\\nmaintain euthermia.93Initial volume resuscitation should\\nuse Ringer ’s lactate in a ratio of 1 e2 mL per 1 mL blood\\nloss.94Higher volumes of crystalloid have been\\nassociated with poor maternal outcomes due to dilutional\\ncoagulopathy. At this time, there is no evidence to promote\\nthe use of colloids over crystalloids, as colloids are also\\nassociated with impaired coagulation. In the setting of\\nongoing massive hemorrhage, red blood cell (RBC)\\nadministration should occur before total blood loss equals\\nMABL.\\n1304 lDECEMBER JOGC DÉCEMBRE 2022SOGC CLINICAL PRACTICE GUIDELINE\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 11}), Document(page_content='Blood Products\\nRed Blood CellsRBCs are the ﬁrst step in the transfusion process, unless\\nthe patient has a known coagulation defect. Transfusing\\nRBCs is not without risk, and ongoing transfusion medi-\\ncine trials continue to demonstrate that the decision to\\ntransfuse must take into account the potential for harm.\\n92\\nPatients at high risk for PPH should have a blood type andscreening on admission to cross match blood, if needed. O\\nnegative, Kell negative emergency blood is the next best\\nalternative to cross-matched blood. There is no absolutehemoglobin level at which transfusion must occur, but\\nmaintaining a level between 70 and 90 g/L during active\\nhemorrhage is recommended.\\n95\\nTransfusion should occur when hemorrhage is unre-\\nsponsive to uterotonic measures and blood loss exceeds\\n150 mL/min ortotal loss is rapidly approaching the\\ncalculated MABL orwhen the patient develops symptoms\\nof inadequate perfusion, such as shortness of breath or\\ntachycardia unresponsive to ﬂuid in the presence of he-\\nmoglobin less than 90 g/L.\\nFatigue alone is not a symptom that warrants trans-\\nfusion.96Each unit of packed RBCs should increase the\\nhemoglobin by 10 g/L. If 4 units of RBCs have been\\ngiven, and blood loss is ongoing, activation of a MHP\\nshould be considered. Hemorrhage caused by uterine\\natony or birth-related trauma rarely requires additional\\ncoagulation factors or platelets, unless the volume of blood\\nloss is signi ﬁcantly greater than the MABL and/or dilu-\\ntional coagulopathy occurs. Hemorrhage due to placental\\nabruption, amniotic ﬂuid embolism, or disseminated\\nintravascular coagulation consumes platelets and factors\\nrapidly and replacement may be bene ﬁcial earlier in\\nresuscitation.97Cell salvage does not increase the risk of\\namniotic ﬂuid embolism and should be considered when\\nthe risk for severe PPH is high.19Intravenous iron is an\\nimportant adjuvant for a hemoglobin level <80 g/L once\\nbleeding has settled.16,98,99\\nPlatelets\\nPlatelet transfusion is necessary if blood loss is severe or if\\na consumptive coagulopathy develops. During active\\nhemorrhage, platelets should be transfused at a level\\nof 75 /C2109/L in order to maintain a level above\\n50/C2109/L.19There is no evidence to support a ﬁxed ratio\\nof platelets in obstetric hemorrhage; however, it is\\nacceptable to give 1 pooled dose of adult platelets\\n(4 U platelets, or 5 U in Québec) per 8 e10 U of RBCs,\\ntransfused in the absence of lab data and with ongoinghemorrhage.100Each dose should raise the platelet count\\nby 15e25/C2109/L.\\nFresh Frozen Plasma\\nThe goal of transfusion is to keep the INR <1.8. Donor\\nplasma has less ﬁbrinogen than the 5 g/L typically seen in\\nthe plasma of healthy parturients and is not the ﬁrst choice\\nfor its replacement.19Although plasma provides additional\\nclotting factors, most healthy women with moderate ob-stetric hemorrhage do not require these factors. However,\\nusing plasma in a ratio to RBCs of 1:2 or 1:1, as a global\\nreplacement, may improve outcomes in severe hemor-\\nrhage in trauma patients, particularly if timely lab values\\nare not available. Large volumes of plasma increase the\\nincidence of transfusion-related acute lung injury (TRALI)\\nand transfusion-associated cardiorespiratory overload\\n(TACO).\\n101\\nFibrinogen\\nFibrinogen levels <2 g/L are associated with poor out-\\ncomes and direct replacement below these levels is rec-\\nommended. Testing for ﬁbrinogen levels when blood loss\\nis<1500 mL is not predictive of severe PPH, and routine\\nadministration of ﬁbrinogen in the absence of hypo ﬁ-\\nbrinogenemia does not improve outcomes. Levels will\\ndrop more rapidly in the setting of abruption and amniotic\\nﬂuid embolism than in the setting of atony.94,96,97\\nEach unit of cryoprecipitate contains 150 e350 mg of\\nﬁbrinogen and a typical dose is 8 e10 U. Thawing is\\nrequired prior to use, and multiple donors are required for\\nsufﬁcient amounts, which increases the risk of transfusion\\nreactions.102,103\\nFibrinogen concentrates (RiaSTAP and FIBRYGA) do not\\nrequire thawing, provide accurate dosing, and decrease\\nboth the requirement for other blood products and the\\nincidence of circulatory overload.104Fibrinogen concen-\\ntrates also undergo viral inactivation and removal of an-\\ntigens and antibodies. Four grams of ﬁbrinogen\\nconcentrate is equivalent to 10 units of cryoprecipitate and\\ntypically raises plasma ﬁbrinogen levels by 1 g/L (60 mg/\\nkg dosing).102,103\\nMassive Hemorrhage Protocol\\nOriginally designed for trauma patients, MHP is now often\\nused in the setting of obstetrical hemorrhage. In the\\ntrauma literature, transfusing ﬁxed ratios of RBCs to fresh\\nfrozen plasma to platelets of either 1:1:1 or 2:1:1 after theﬁrst 4 units of packed RBCs has been shown to decrease\\nmortality.\\n94,96,97,105,106Therapy based on lab values\\nDECEMBER JOGC DÉCEMBRE 2022 l1305PPH and Hemorrhagic Shock\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 12}), Document(page_content='(including viscoelastography, where available [rotational\\nthromboelastometry, thromboelastography]) is superior to\\nratio-based approaches as it reduces the number of\\nproducts transfused, reduces transfusion overload and\\ntransfusion-related complications, and tailors therapy to\\nthe underlying coagulopathy.107,108\\nThe amount of blood loss that should trigger an MHP can\\nbe markedly different based on the patient ’s size, etiology\\nof hemorrhage, and underlying health issues (i.e., pre-\\neclampsia). Using a single blood loss volume to initiate an\\nMHP may result in some patients being transfused too\\nearly and others too late. Whenever the blood loss is\\napproaching the MABL and there is ongoing bleeding,\\nRBCs should be considered ﬁrst.94,96,97,105,106Canadian\\nstandard of care recommendations indicate that an MHP\\nshould be able to be mobilized and products delivered\\nwithin 10 minutes.109If local resources cannot reliably\\nmeet this timeline, consider initiating an MHP sooner.\\nIf the patient is stable and the bleeding is controlled after\\nthe initial 4 units of RBCs, the MHP products can be\\nreturned.\\nCoagulopathy does not occur in every PPH including\\nmassive PPH. When there is no coagulopathy, there is no\\nbeneﬁt to transfusion of coagulation products. The etiology\\nof the bleed matters, as atony and trauma are less likely to\\nrequire coagulation factor replacement than abruption,\\nabnormal placentation, or amniotic ﬂuid embolism. Testing\\nfor coagulopathy rarely demonstrates abnormalities when\\nthe blood loss is <1.5e2 L. When coagulopathy is present\\nin PPH, hypo ﬁbrinogenemia is the most common etiol-\\nogy,102,103and commonly coexists with hypocalcemia.\\nIonized calcium less than 1.16 mmol/L (rather than routine\\nor corrected calcium which may be normal) is the most\\naccurate way to measure calcium status in a hemorrhaging\\npatient and may be at least as important as ﬁbrinogen in\\nterms of risk reduction.110Calcium chloride is the agent of\\nchoice to replace calcium as it contains 3 times the\\nelemental calcium of calcium gluconate and does not\\nrequire liver metabolism. Fresh frozen plasma and platelets\\nare less commonly needed, but may be included in the\\nMHP , particularly after 4 to 8 units of RBCs, respectively.\\nFrequent monitoring of all these components (CBC, PTT,\\nINR, ﬁbrinogen, ionized calcium), as well as magnesium,\\nelectrolytes, hypothermia, and overall volume status are\\nnecessary components of any MHP . Tailoring therapy as\\nearly as feasible results in a patient-centred approach that isin keeping with the most up-to-date recommendations in\\ntransfusion medicine.Prothrombin Complex Concentrate\\nProthrombin complex concentrate contains vitamin\\nKedependent clotting factors and is indicated for reversal\\nof vitamin K antagonists (warfarin). Apart from patients\\nwith known factor II or X de ﬁciencies, in which case, a\\nhematologist should be consulted, there is currently no\\nrole for prothrombin complex concentrate in the treat-\\nment of PPH.\\n96,97,105\\nRecombinant Activated Factor VII\\nRecombinant activated factor VII (rFVIIa) provides a\\nthrombin burst and stabilizes clots, and should only be\\nadministered to patients with a ﬁbrinogen level >1g/L,\\nplatelets >20/C2109/L, and a near normal pH (7.4) and\\ntemperature (35.9/C14C). Given the absence of strong evi-\\ndence of bene ﬁt and the serious risk of thrombosis, rFVIIa\\nshould only be used in PPH as a last resort and in\\nconsultation with a transfusion medicine specialist or\\nhematologist.96,97,105\\nREVIEW\\nQuality care initiatives in many centres have clearly shown\\nthat strong teamwork and communication, along with\\nsimulation training and debrie ﬁng after any signi ﬁcant\\nPPH, improve outcomes. Key components of teamwork\\ninclude a process for standard and structured communi-\\ncation, effective use of clear language, psychological safetywhere team members are not fearful of speaking up,\\nsituational awareness, and effective leadership\\n111\\n(Appendix K ).\\nDebrie ﬁng after simulation led by a trained facilitator\\npromotes improved learning outcomes and enhances\\nfuture performance in the clinical setting.112Debrie ﬁng is\\nmore than feedback, it is “an interactive, bidirectional and\\nreﬂective conversation, ”113which will foster better\\ncommunication and teamwork in subsequent clinical sce-\\nnarios. As experiencing PPH can be traumatic, care pro-viders should have a conversation with the patient and\\ntheir family to explain the events and answer any questions\\nthey have. Debrie ﬁng after a signi ﬁcant PPH should occur\\nand should include all involved members of the health care\\nteam, as well as a separate discussion with the patient and\\nher family.\\nCONCLUSION\\nAlthough the acute treatment of PPH is key for any single\\npatient, the ongoing review practices is most important for\\n1306 lDECEMBER JOGC DÉCEMBRE 2022SOGC CLINICAL PRACTICE GUIDELINE\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 13}), Document(page_content='future patients. While standardized approaches for the\\nidenti ﬁcation and management of PPH may need to vary\\nbetween sites based on the availability of resources, best\\npractices include:\\n/C15a risk assessment for every patient, including calculation\\nof the MABL\\n/C15a standardized approach for collecting, weighing, and\\nreporting blood loss\\n/C15stage-based management strategies, including protocols\\nspeciﬁcally designed for massive blood loss\\n/C15‘hemorrhage carts ’for storing medications and supplies\\n/C15regular multidisciplinary staff training and simulation\\n/C15debrie ﬁng with formal review of adverse events.\\nTemplates for all these recommendations can be found in\\nthe supplementary toolkit.\\nSUPPLEMENTARY TOOLKIT\\nA supplementary toolkit related to this article can befound in the Online Appendix .\\nREFERENCES\\n1.Grobman WA, Bailit JL, Rice MM, et al. Frequency of and factors\\nassociated with severe maternal morbidity. Obstet Gynecol2014;123:804 e10.\\n2.Deneux-Tharaux C, Bonnet MP , Tort J. Épidémiologie de l ’hémorragie du\\npost-partum [Epidemiology of post-partum haemorrhage]. J GynecolObstet Biol Reprod (Paris) 2014;43:936 e50.\\n3.Mehrabadi A, Liu S, Bartholomew S, et al. Temporal trends in postpartum\\nhemorrhage and severe postpartum hemorrhage in Canada from 2003 to\\n2010. J Obstet Gynaecol Can 2014;36:21 e33.\\n4.Knight M, Callaghan WM, Berg C, et al. Trends in postpartum hemorrhage\\nin high resource countries: a review and recommendations from theInternational Postpartum Hemorrhage Collaborative Group. BMCPregnancy Childbirth 2009;9:55 .\\n5.Al Kadri HM, Al Anazi BK, Tamim HM. Visual estimation versus\\ngravimetric measurement of postpartum blood loss: a prospective cohortstudy. Arch Gynecol Obstet 2011;283:1207 e13.\\n6.Patel A, Goudar SS, Geller SE, et al. Drape estimation vs. visual\\nassessment for estimating postpartum hemorrhage [published erratumappears in Int J Gynaecol Obstet 2006;95:312]. Int J Gynaecol Obstet2006;93:220 e4.\\n7.Della Torre M, Kilpatrick SJ, Hibbard JU, et al. Assessing preventability for\\nobstetric hemorrhage. Am J Perinatol 2011;28:753 e60.\\n8.Seacrist MJ, VanOtterloo LR, Morton CH, et al. Quality improvement\\nopportunities identi ﬁed through case review of pregnancy-related deaths\\nfrom obstetric hemorrhage. J Obstet Gynecol Neonatal Nurs\\n2019;48:288 e99.\\n9.Rubenstein AF, Zamudio S, Al-Khan A, et al. Clinical experience with the\\nimplementation of accurate measurement of blood loss during cesareandelivery: in ﬂuences on hemorrhage recognition and allogeneic transfusion.\\nAm J Perinatol 2018;35:655 e9.10.Kramer MS, Berg C, Abenhaim H, et al. Incidence, risk factors and\\ntemporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol\\n2013;209:449.e1 e7.\\n11. California Maternal Quality Care Collaborative. Obstetric hemorrhage.\\nAvailable at: https://www.cmqcc.org/content/obstetric-hemorrhage-0 .\\nAccessed on June 1, 2021.\\n12.Kavle JA, Stoltzfus RJ, Witter F, et al. Association between anaemia during\\npregnancy and blood loss at and after delivery among women with vaginalbirths in Pemba Island, Zanzibar, Tanzania. J Health Popul Nutr\\n2008;26:232 e40.\\n13.Dziegala M, Josiak K, Kasztura M, et al. Iron de ﬁciency as energetic insult\\nto skeletal muscle in chronic diseases. J Cachexia Sarcopenia Muscle2018;9:802 e15.\\n14.Mawani M, Ali SA, Bano G, et al. Iron de ﬁciency anemia among women of\\nreproductive age, an important public health problem: situation analysis.Reprod Syst Sex Disord 2016;5:187 .\\n15.Tang G, Lausman A, Abdulrehman J, et al. Prevalence of iron de ﬁciency\\nand iron de ﬁ\\nciency anemia during pregnancy: a single centre Canadian\\nstudy. Blood 2019;134(Suppl 1):3389 .\\n16.Munoz M, Pena-Rosas J, Robinson S, et al. Patient blood management in\\nobstetrics: management of anaemia and hematinic de ﬁciencies in pregnancy\\nand in the post-partum period: NATA consensus statement. Transfus Med2018;28:22 e39.\\n17.Li N, Zhao G, Wu W , et al. The ef ﬁcacy and safety of vitamin c for\\niron supplementation in adult patients with irondeﬁciency anemia: a randomized clinical trial. JAMA Netw Open 2020;3:\\ne2023644 .\\n18.Pavord S, Daru J, Prasannan N, et al. UK guidelines on the management of\\niron de ﬁciency in pregnancy. Br J Haematol 2020;188:819 e30.\\n19.Munoz M, Stensballe J, Bucloy-Bouthors A-S, et al. Patient blood\\nmanagement in obstetrics: prevention and treatment of postpartumhaemorrhage. A NATA consensus statement. Blood Transfus2019;17:112 e36.\\n20.Khalafallah AA, Dennis AE, Ogden K, et al. Three-year follow-up of a\\nrandomised clinical trial of intravenous versus oral iron for anaemia inpregnancy. BMJ Open 2012;2:e000998 .\\n21. Cooper S. Alberta Health Services. PPH staging and management guidelines.\\nAvailable at: https://extranet.ahsnet.ca/teams/policydocuments/1/klink/et-\\nklink-ckv-post-partum-hemorrhage-adult-inpatient.pdf . Accessed on June 1,\\n2021.\\n22.Leduc D, Senikas V , Lalonde A. Active management of the third stage of\\nlabour: prevention and treatment of post partum hemorrhage. J ObstetGynaecol Can 2018;40:e841 e55.\\n23.Delayed Umbilical Cord Clamping After Birth: ACOG Committee\\nOpinion, Number 814. Obstet Gynecol 2020;136:e100 e6.\\n24.Hana ﬁS, El-Shehawy H, Meshmesh K. Impact of controlled cord traction\\nin the management of the third stage of labor on postpartum hemorrhage:\\na randomized controlled trial. EBWHJ 2014;4:78 e81.\\n25.Hofmeyr GJ, Mshweshwe NT, Gülmezoglu AM. Controlled cord traction\\nfor the third stage of labour. Cochrane Database Syst Rev2015;1:CD008020 .\\n26.Gülmezoglu AM, Lumbiganon P , Landoulsi S, et al. Active\\nmanagement of the third stage of labour with and without controlledcord traction: a randomised, controlled, non-inferiority trial. Lancet\\n2012;379:1721 e7.\\n27.Bartlett L, Cantor D, Lynam P , et al. Facility-based active management of\\nthe third stage of labour: assessment of quality in six countries in sub-Saharan Africa. Bull World Health Organ 2015;93:759 e67.\\n28.Althabe F, Alemán A, Tomasso G, et al. A pilot randomized controlled trial\\nof controlled cord traction to reduce postpartum blood loss. Int J GynaecolObstet 2009;107:4 e7.\\n29.Begley CM, Gyte GML, Devane D, et al. Active versus expectant\\nmanagement for women in the third stage of labour. Cochrane Database\\nSyst Rev 2019;(2):CD007412 .\\nDECEMBER JOGC DÉCEMBRE 2022\\nl1307PPH and Hemorrhagic Shock\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 14}), Document(page_content='30.Karimi FZ, Heidarian Miri H, Salehian M, et al. The effect of mother-infant\\nskin to skin contact after birth on third stage of labor: a systematic review\\nand meta-analysis. Iran J Public Health 2019;48:612 e20.\\n31.Tran G, Kanczuk M, Balki M. The association between the time from\\noxytocin cessation during labour to Cesarean delivery and postpartumblood loss: a retrospective cohort study. Can J Anesth 2017;64:820 e7.\\n32.Westhoff G, Cotter AM, Tolosa JE. Prophylactic oxytocin for the third\\nstage of labour to prevent postpartum haemorrhage. Cochrane DatabaseSyst Rev 2013;10:CD001808 .\\n33.Bilgin Z, Kömürcü N. Comparison of the effects and side effects of\\nmisoprostol and oxytocin in the postpartum period: a systematic review.\\nTaiwan J Obstet Gynecol 2019;58:748 e56.\\n34.Sunil Kumar KS, Shyam S, Batakurki P . Carboprost versus oxytocin for\\nactive management of third stage of labor: a prospective randomizedcontrol study. J Obstet Gynaecol India 2016;66(Suppl 1):229 e34.\\n35.McDonald S, Abbott JM, Higgins SP . Prophylactic ergometrine-oxytocin\\nversus oxytocin for the third stage of labour. Cochrane Database Syst Rev2004;1:CD000201 .\\n36. DrugBank Online. Oxytocin pharmacokinetics. Available at: https://go.\\ndrugbank.com/drugs/DB00107 . Accessed on June 1, 2021.\\n37.Mangla D, Goel JK, Goel R. Prophylactic intramyometrial oxytocin before\\nplacenta delivery during cesarean section prevents postpartum hemorrhage:a prospective randomized study of 150 women. J South Asian Feder ObstGynae 2012;4:93 e6.\\n38.Fernando D, Siederer S, Singh S, et al. Safety, tolerability and\\npharmacokinetics of single doses of oxytocin administered via an inhaledroute in healthy females: randomized, single blind, phase 1 study. Lancet2017;22:249 e55.\\n39.Oladapo OT, Okusanya BO, Abalos E, et al. Intravenous versus\\nintramuscular prophylactic oxytocin for the third stage of labour. CochraneDatabase Syst Rev 2020;(11):CD009332 .\\n40.Heesen M, Carvalho B, Carvalho JCA, et al. International consensus\\nstatement on the use of uterotonic agents during caesarean section.Anaesthesia 2019;74:1305 e19.\\n41.George RB, McKeen D, Chaplin AC, et al. Up-down determination of the\\nED(90) of oxytocin infusions for the prevention of postpartum uterineatony in parturients undergoing Cesarean delivery. Can J Anesth\\n2010;57:578 e82.\\n42.Lavoie A, McCarthy RJ, Wong CA. The ED90 of prophylactic oxytocin\\ninfusion after delivery of the placenta during Cesarean delivery in laboringcompared with nonlaboring women: an up-down sequential allocationdose-response study. Anesth Analg 2015;121:159 e64.\\n43.Lewis G, ed. Why mothers die 1997 e99. The con ﬁdential enquiry into\\nmaternal deaths in the United Kingdom. London (UK): RCOG Press; 2001 .\\n44.Farina Z, Fawcus S. Oxytocin eensuring appropriate use and balancing\\nefﬁcacy with safety. S Afr Med J 2015;105:271 e4.\\n45.Svanström MC, Biber B, Hanes M, et al. Signs of myocardial ischaemia\\nafter injection of oxytocin: a randomized double-blind comparison of\\noxytocin and methylergometrine during Caesarean section. Br J Anaesth2008;100:683 e9.\\n46.Mörtl MG, Friedrich S, Kraschl J, et al. Haemodynamic effects of\\ncarbetocin and oxytocin given as intravenous bolus on women undergoing\\ncaesarean delivery: a randomised trial. Int J Obstet Gynaecol2011;118:1349 e56.\\n47.Gallos ID, Papadopoulou A, Man R, et al. Uterotonic agents for preventing\\npostpartum haemorrhage: a network meta-analysis. Cochrane Database\\nSyst Rev 2018;12:CD011689 .\\n48.Khan M, Balki M, Ahmed I, et al. Carbetocin at elective Cesarean delivery:\\na sequential allocation trial to determine the minimum effective dose. Can JAnaesth 2014;61:242 e8.\\n49.Nucci B, Aya A, Aubry E, et al. Carbetocin for prevention of postcesarean\\nhemorrhage in women with severe preeclampsia: a before-after cohortcomparison with oxytocin. J Clin Anesth 2016;35:321 e5.50.Reyes OA, Gonzalez GM. Carbetocin versus oxytocin for prevention of\\npostpartum hemorrhage in patients with severe preeclampsia: a double-\\nblind randomized controlled trial. J Obstet Gynaecol Can2011;33:1099 e104.\\n51. Chao YS, McCormack S. Carbetocin for the prevention of post-partum\\nhemorrhage: a review of clinical effectiveness, cost-effectiveness, andguidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies inHealth. Available at: https://www.ncbi.nlm.nih.gov/books/NBK546425/ .\\nAccessed on July 29, 2019.\\n52.Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic\\nproﬁles, effects on the uterus and side effects. Int J Gynecol Obstet\\n2007:S160 e7.\\n53.Chaudhuri P, Majumdar A. Sublingual misoprostol as an adjunct to\\noxytocin during cesarean delivery in women at risk of postpartumhemorrhage. Int J Gynaecol Obstet 2015;128:48 e52.\\n54.Ugwu IA, Oluwasola TA, Enabor OO, et al. Randomized controlled\\ntrial comparing 200\\nmg and 400 mg sublingual misoprostol for prevention\\nof primary postpartum hemorrhage. Int J Gynaecol Obstet\\n2016;133:173 e7.\\n55.Barbieri R. Stop using rectal misoprostol for the treatment of\\npostpartum hemorrhage caused by uterine atony. OBG Manag 2016;28.8-10,12 .\\n56. Pharmacokinetics of tranexamic acid. Available at: https://go.drugbank.\\ncom/drugs/DB00302 . Accessed on June 1, 2021.\\n57. Chauncey J, Wieters J. Tranexamic acid - Stat Pearls. Available at: https://\\nwww.ncbi.nlm.nih.gov/books/NBK532909/ . Accessed on June 1, 2021.\\n58.Della Corte L, Saccone G, Locci M, et al. Tranexamic acid for treatment of\\nprimary postpartum hemorrhage after vaginal delivery: a systematic review\\nand meta-analysis of randomized controlled trials. J Matern Fetal Neonatal\\nMed 2020;33:869 e74.\\n59.Ray I, Bhattacharya R, Chakraborty S, et al. Role of intravenous tranexamic\\nacid on cesarean section blood loss: a prospective randomized study.J Obstet Gynaecol India 2016;66(Suppl 1):347 e52.\\n60.Xia Y , Grif ﬁths BB, Xue Q. Tranexamic acid for postpartum hemorrhage\\nprevention in vaginal delivery: a meta-analysis. Medicine (Baltimore)2020;99:e18792 .\\n61.Sentilhes L, Senat MV , Le Lous M, et al. Tranexamic acid for the\\nprevention of blood loss after cesarean delivery. N Engl J Med\\n2021;384:1623 e34.\\n62.Brenner A, Shakur-Still H, Chaudhri R, et al. The impact of early outcome\\nevents on the effect of tranexamic acid in post-partum haemorrhage: anexploratory subgroup analysis of the WOMAN trial. BMC PregnancyChildbirth 2018;18:215 .\\n63.Gayet-Ageron A, Prieto-Merino D, Ker K, et al. Effect of treatment delay\\non the effectiveness and safety of anti ﬁbrinolytics in acute severe\\nhaemorrhage: a meta-analysis of individual patient-level data from 40 138\\nbleeding patients. Lancet 2018;391:125 e32.\\n64. Pharmacokinetics of ergotamine. Available at: https://go.drugbank.com/\\ndrugs/DB01253 . Accessed on June 1, 2021.\\n65.Spencer SPE, Lowe SA. Ergometrine for postpartum hemorrhage and\\nassociated myocardial ischemia: two case reports and a review of theliterature. Clin Case Rep 2019;7:2433 e42.\\n66.Liabsuetrakul T, Choobun T, Peeyananjarassri K, et al. Prophylactic use of\\nergot alkaloids in the third stage of labour. Cochrane Database Syst Rev\\n2018;6:CD005456 .\\n67. Recommendations for the use of antiretroviral drugs during pregnancy and\\ninterventions to reduce perinatal HIV transmission in the United States.Available at: https://clinicalinfo.hiv.gov/en/guidelines/perinatal/\\nintrapartum-antiretroviral-therapyprophylaxis . Accessed on June 1, 2021.\\n68.Chelmow D. Postpartum haemorrhage: prevention. BMJ Clin Evid\\n2008;2008:1410 .\\n69.Bygdeman M. Pharmacokinetics of prostaglandins. Best Pract Res Clin\\nObstet Gynaecol 2003;17:707 e16.\\n1308\\nlDECEMBER JOGC DÉCEMBRE 2022SOGC CLINICAL PRACTICE GUIDELINE\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 15}), Document(page_content='70.Bai J, Sun Q, Zhai H. A comparison of oxytocin and carboprost\\ntromethamine in the prevention of postpartum hemorrhage in high-risk\\npatients undergoing cesarean delivery. Exp Ther Med 2014;7:46 e50.\\n71. Minigh J. Carboprost - an overview. The Comprehensive Pharmacology\\nReference; ScienceDirect Topics. Availableat: https://www.sciencedirect.com/\\ntopics/nursing-and-health-professions/carboprost . Accessed on June 1, 2022.\\n72.Likis FE, Sathe NA, Morgans AK, et al. Management of postpartum\\nhemorrhage. Comparative effectiveness review no. 151. AHRQpublication no. 15-EHC013-EF . Rockville (MD): Agency for Healthcare\\nResearch and Quality; 2015 .\\n73.Brown H, Okeyo S, Mabeya H, et al. The Bakri tamponade balloon as an\\nadjunct treatment for refractory postpartum hemorrhage. Int J GynaecolObstet 2016;135:276 e80.\\n74.Perlman NC, Carusi DA. Retained placenta after vaginal delivery:\\nrisk factors and management. Int J Womens Health 2019;11:527 e34.\\n75.Magann EF, Niederhauser A, Doherty DA, et al. Reducing hemodynamic\\ncompromise with placental removal at 10 versus 15 mins: a randomizedclinical trial. Am J Perinatol 2012;29:609 e14.\\n76.Shinar S, Schwartz A, Maslovitz S, et al. How long is safe? Setting the cutoff\\nfor uncomplicated third stage length: a retrospective case-control study.\\nBirth 2016;43:36 e41.\\n77.Maher MA, Sayyed TM, Elkhouly NI. Different routes and forms of\\nuterotonics for treatment of retained placenta: a randomized clinical trial.J Matern Fetal Neonatal Med 2017;30:2179 e84.\\n78.Harara R, Hanafy S, Zidan MS, et al. Intraumbilical injection of three\\ndifferent uterotonics in the management of retained placenta. J ObstetGynaecol Res 2011;37:1203 e7.\\n79. Thakur M, Thakur A. Uterine inversion. Treasure Island (FL): StatPearls\\nPublishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK525\\n971/ . Accessed on June 1, 2022.\\n80.Kaya B, Tuten A, Daglar K, et al. B-Lynch uterine compression sutures in\\nthe conservative surgical management of uterine atony. Arch GynecolObstet 2015;291:1005 e14.\\n81.S¸ahin H, Soylu Karap ınar O, S ¸ahin EA, et al. The effectiveness of\\nthe double B-lynch suture as a modi ﬁcation in the treatment\\nof intractable postpartum haemorrhage. J Obstet Gynaecol2018;38:796 e9.\\n82.Kwong LT, So PL, Wong SF. Uterine compression sutures with additional\\nhemostatic procedures for the management of postpartum hemorrhage.J Obstet Gynaecol Res 2020;46:2332 e9.\\n83.Joshi VM, Otiv SR, Majumder R, et al. Internal iliac artery ligation for\\narresting postpartum haemorrhage. BJOG 2007;114:356 e61.\\n84.Wang CY , Pan HH, Chang CC, et al. Outcomes of hypogastric\\nartery ligation and transcatheter uterine artery embolization inwomen with postpartum hemorrhage. Taiwan J Obstet Gynecol2019;58:72 e6.\\n85.\\nCamuzcuoglu H, Toy H, Vural M, et al. Internal iliac artery ligation for\\nsevere postpartum hemorrhage and severe hemorrhage after postpartum\\nhysterectomy. J Obstet Gynaecol Res 2010;36:538 e43.\\n86.Singh A, Kishore R, Saxena SS. Ligating internal iliac artery:\\nsuccess beyond hesitation. J Obstet Gynaecol India2016;66(Suppl 1):235 e41.\\n87.Liu Z, Wang Y, Yan J, et al. Uterine artery embolization versus\\nhysterectomy in the treatment of refractory postpartum hemorrhage: asystematic review and meta-analysis. J Matern Fetal Neonatal Med\\n2020;33:693 e705.\\n88.Kim TH, Lee HH, Kim JM, et al. Uterine artery embolization for primary\\npostpartum hemorrhage. Iran J Reprod Med 2013;11:511 e8.\\n89.Zhang Y, Yan J, Han Q, et al. Emergency obstetric hysterectomy for life-\\nthreatening postpartum hemorrhage: a 12-year review. Medicine(Baltimore) 2017;96:e8443 .90.Ballas J, Roberts S. Hypovolemic shock. In: Phelan JP , editor. Critical care\\nobstetrics .6\\nthed. Oxford (UK): John Wiley & Sons Ltd; 2019. p. 535 e45.\\n91.Gross J. Estimating allowable blood loss: corrected for dilution.\\nAnesthesiology 1983;58:277 e80.\\n92. Blood, still saving lives but .there are risks (video). Available at: https://\\nwww.blood.gov.au/health-professionals . Accessed on June 1, 2021.\\n93.Cohen WR. Obstetric hemorrhage and hypothermia: chilling facts. Open J\\nObstet Gynecol 2018;8:2160 e270.\\n94.Henriquez DDCA, Bloemenkamp KWM, Loeff RM, et al. Fluid\\nresuscitation during persistent postpartum haemorrhage and maternaloutcome: a nationwide cohort study. Eur J Obstetr Gynecol Reprod Biol\\n2019;235:49 e56.\\n95. Lotterman S, Sharma S. Blood transfusion. Treasure Island (FL): StatPearls\\nPublishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK4\\n99824/ . Accessed on June 1, 2021.\\n96.Prick BW , Jansen AJ, Steegers EA, et al. Transfusion policy after\\nsevere postpartum haemorrhage: a randomised non-inferiority trial. BJOG2014;121:1005 e14.\\n97.Collis R, Guasch E. Managing major obstetric haemorrhage:\\npharmacotherapy and transfusion. Best Pract Res Clin Anaesthesiol\\n2017;31:107 e24.\\n98.Chua S, Gupta S, Curnow J, et al. Intravenous iron vs blood for acute post-\\npartum anaemia (IIBAPPA): a prospective randomised trial. BMCPregnancy Childbirth 2017;17:424 .\\n99.Holm C, Thomsen LL, Norgaard A, et al. Single-dose intravenous iron\\ninfusion versus red blood cell transfusion for the treatment of severepostpartum anaemia: a randomized controlled pilot study. Vox Sang2017;112:122 e31.\\n100. Jones RM, de Lloyd L, Kealaher EJ, et al. Platelet count and transfusion\\nrequirements during moderate or severe postpartum haemorrhage.\\nAnaesthesia 2016;71:648 e56.\\n101. Ontario Regional Blood Coordinating Network (ORBCoN). Bloody easy 4:\\nblood transfusions, alternatives and transfusion reactions. A guide totransfusion medicine. 4\\nthed. ORBCON. Available at: ﬁle:///C:/Users/\\ncgreen/Downloads/EN_BE4-JULY11_FINAL.pdf . Accessed on June 1,\\n2021.\\n102. Lumbreras-Marquez MI, Villela-Franyutti D, Reale SC, et al. Coagulation\\nmanagement in obstetric anesthesia. Curr Anesthesiol Rep\\n2022;12:266 e76.\\n103. Ducloy-Bouthors AS, Mercier FJ, Grouin JM, et al. Early and systematic\\nadministration of ﬁbrinogen concentrate in postpartum haemorrhage\\nfollowing vaginal delivery: the FIDEL randomised controlled trial. BJOG2021;128:1814 e23.\\n104. Sahin AS, Ozkan S. Treatment of obstetric hemorrhage with ﬁbrinogen\\nconcentrate. Med Sci Monit 2019;25:1814 e21.\\n105. O’Brien KL, Shainker SA, Lockhart EL. Transfusion management of\\nobstetric hemorrhage. Transfus Med Rev 2018;32:249 e55.\\n106. Bell SF, Collis RE, Bailey C, et al. The incidence, aetiology, and coagulation\\nmanagement of massive postpartum haemorrhage: a two-year nationalprospective cohort study. Int J Obstet Anesth 2021;47:102983 .\\n107. Ramler PI, Gillissen A, Henriquez D, et al. Clinical value of early\\nviscoelastometric point-of-care testing during postpartum hemorrhagefor the prediction of severity of bleeding: a multicenter prospectivecohort study in the Netherlands. Acta Obstet Gynecol Scand2021;100:1656 e64.\\n108. McNamara H, Kenyon C, Smith R, et al. Four years ’experience of a\\nROTEM -guided algorithm for treatment of coagulopathy in obstetric\\nhaemorrhage. Anaesthesia 2019;74:984 e91.\\n109. Callum J, Yeh CH, Petrosoniak A, et al. A regional MHP\\ndeveloped through a modi ﬁed Delphi techni que. CMAJ Open\\n2019;7:E546 e61.\\nDECEMBER JOGC DÉCEMBRE 2022\\nl1309PPH and Hemorrhagic Shock\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 16}), Document(page_content='110. Epstein D, Solomon N, Korytny A, et al. Association between ionized\\ncalcium and severity of postpartum hemorrhage: a retrospective cohort\\nstudy. Brit J Anaesth 2021;126:1022 e8.\\n111. Leonard MW , Frankel AS. Role of effective teamwork and\\ncommunication in delivering safe, high-quality care. Mt Sinai J Med2011;78:820 e6.112. Cheng A, Eppich W , Kolbe M, et al. A conceptual framework for the\\ndevelopment of debrie ﬁng skills: a journey of discovery, growth and\\nmaturity. Simul Healthc 2020;15:55 e60.\\n113. Sawyer T, Eppich W , Brett-Fleegler M, et al. More than one way to debrief:\\na critical review of healthcare simulation debrie ﬁng methods. Simul Healthc\\n2016;11:209 e17.\\n1310\\nlDECEMBER JOGC DÉCEMBRE 2022SOGC CLINICAL PRACTICE GUIDELINE\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 17}), Document(page_content='APPENDIX A\\nTable 1. Key to Grading of Recommendations, Assessment, Development and Evaluation Quality of Evidence\\nGrade Deﬁnition\\nStrength of recommendation\\nStrong High level of con ﬁdence that the desirable effects outweigh the undesirable effects (strong recommendation\\nfor) or the undesirable effects outweigh the desirable effects (strong recommendation against)\\nConditionalaDesirable effects probably outweigh the undesirable effects (weak recommendation for) or the undesirable\\neffects probably outweigh the desirable effects (weak recommendation against)\\nQuality of evidence\\nHigh High level of con ﬁdence that the true effect lies close to that of the estimate of the effect\\nModerate Moderate con ﬁdence in the effect estimate:\\nThe true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantiallydifferent\\nLow Limited con ﬁdence in the effect estimate:\\nThe true effect may be substantially different from the estimate of the effect\\nVery low Very little con ﬁdence in the effect estimate:\\nThe true effect is likely to be substantially different from the estimate of effect\\naDo not interpret conditional recommendations to mean weak evidence or uncertainty of the recommendation.\\nAdapted from GRADE Handbook (2013), Table 5.1.\\nTable 2. Implications of Strong and Conditional recommendations, by guideline user\\nPerspective Strong Recommendation\\n/C15“We recommend that .”\\n/C15“We recommend to not .”Conditional (Weak) Recommendation\\n/C15“We suggest .”\\n/C15“We suggest to not .”\\nAuthors The net desirable effects of a course of action outweigh the\\neffects of the alternative course of action.It is less clear whether the net desirable consequences of\\na strategy outweigh the alternative strategy.\\nPatients Most individuals in the situation would want the\\nrecommended course of action, while only a small\\nproportion would not.The majority of individuals in the situation would want the\\nsuggested course of action, but many would not.\\nClinicians Most individuals should receive the course of action.\\nAdherence to this recommendation according to the\\nguideline could be used as a quality criterion orperformance indicator.Recognize that patient choices will vary by individual and\\nthat clinicians must help patients arrive at a care\\ndecision consistent with the patient ’s values and\\npreferences.\\nPolicymakers The recommendation can be adapted as policy in most\\nsettings.The recommendation can serve as a starting point for\\ndebate with the involvement of many stakeholders.\\nAdapted from GRADE Handbook (2013), Table 6.1.\\nDECEMBER JOGC DÉCEMBRE 2022 l1310.e1PPH and Hemorrhagic Shock\\nDownloaded for Anonymous User (n/a) at University of the Andes from ClinicalKey.com by Elsevier on August 19, \\n2023. For personal use only. No other uses without permission. Copyright ©2023. Elsevier Inc. All rights reserved.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guideline No. 431 Postpartum Hemorrhage and Hemorrhagic Shock.pdf', 'page': 18}), Document(page_content='Rev Colomb Obstet Ginecol 2013;64:425-452Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • Octubre-Diciembre 2013 • (425-452)\\nArtículo  de revisión\\nResumen\\nObjetivo:  formular recomendaciones basadas en \\nla mejor evidencia disponible que sirvan como guía \\npara los profesionales de salud en la prevención, \\ndetección y el manejo de la hemorragia posparto  \\ny de las complicaciones asociadas a la misma con \\nel fin de homogeneizar las conductas clínicas y \\ncontribuir a la reducción de la morbi-mortalidad materna.\\n1 Esta guía y sus secciones hacen parte de un grupo de 25 GAI basadas \\nen la evidencia que incorporan consideraciones económicas y de implementabilidad en el contexto del Sistema General de Seguridad Social en Salud colombiano, y que se desarrollaron por iniciativa del Ministerio de Salud y Protección Social y el Departamento de Ciencia, T ecnología e Innovación (Colciencias) en temas prioritarios y de alta prevalencia en el país mediante contrato otorgado a la Universidad Nacional de Colombia en el año 2010.Guía de práctica clínica para la prevención y el manejO de la hemOrra Gia pOspartO y cOmplicaciOnes \\ndel chOque hemOrráGicO\\n1\\nclinical practice guidelines for the prevention  \\nand management of post-partum bleeding and  \\nof hemorrhagic shock complications\\nRepresentantes del Grupo Desarrollador de la Guía - Universidad Nacional de  \\nColombia - Alianza Cinets*\\nRecibido: agosto 20/13 – Aceptado: noviembre 8/13\\nmateriales y métodos: el grupo desarrollador de \\nla Guía (GDG) elaboró esta GPC durante 2011-2012 \\nacorde con la Guía Metodológica para la elaboración \\nde Guías de Atención Integral en el Sistema General de Seguridad Social en Salud colombiano, basándo -\\nse en la evidencia científica disponible y sumando la participación activa de grupos de pacientes, socie -\\ndades científicas y grupos de interés. En particular, \\nla evidencia de esta Guía fue adaptada de las GPC \\ndel Royal College of Obstetricians and Gynaeco -\\nlogists (RCOG) “Prevention and management of \\npostpartum haemorrhage” (2009) y de la Organiza -\\nción Mundial de la Salud (OMS), “WHO guidelines \\nfor the management of postpartum haemorrhage \\nand retained placenta” (2009), y actualizada por \\nmedio de procedimientos sistemáticos, tanto para la búsqueda y la valoración de la evidencia, como \\npara la generación de recomendaciones. El nivel de ', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 0}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013426\\nevidencia y la fuerza de las recomendaciones fueron \\nexpresadas por medio del sistema del Scottish In -\\ntercollegiate Guidelines Network (SIGN).\\nresultados:  se presentan recomendaciones para la \\nprevención, detección y el tratamiento de la hemo -\\nrragia posparto a partir de 17 preguntas clínicas.conclusión:  se presenta una versión resumida de \\nlas recomendaciones y evidencia de esta Guía, que \\nse espera sea adoptada por los profesionales de la \\nsalud encargados de la atención del embarazo en el país para disminuir la morbilidad y mortalidad \\nasociada a la gestación.\\npalabras clave:  hemorragia posparto, choque he -\\nmorrágico, guías de práctica clínica, práctica clínica basada en la evidencia, Colombia.\\nAbstRAct\\nObjective:  To make recommendations based \\non the best available evidence designed to guide \\nhealthcare professionals in the prevention, detection \\nand management of post-partum bleeding and complications associated with it, in order to arrive \\nat uniform clinical practices and contribute to the \\nreduction of maternal morbidity and mortality. materials and methods: The Guideline \\nDeveloper Group (GDG) prepared this CPG during 2011-2012, in accordance with the Methodology Guideline for the development of Comprehensive \\nCare Guidelines of the Colombian General System \\nof Social Security, based on the available scientific evidence, and with the active participation of \\npatient groups, scientific societies and stakeholders. \\nIn particular, the evidence for these Guidelines was adapted from the CPG of the Royal College \\nof Obstetricians and Gynaecologists (RCOG) \\n“Prevention and management of postpartum haemorrhage” (2009) and of the World Health \\nOrganization (WHO), “WHO guidelines for the \\nmanagement of postpartum haemorrhage and \\nretained placenta” (2009) and updated through \\nsystematic procedures for the search and assessment of the evidence as well as for the generation of recommendations. The level of evidence and the power of the recommendations were expressed using the Scottish Intercollegiate Guidelines \\nNetwork (SIGN) system.\\nresults:  Recommendations are presented for the \\nprevention, detection and treatment of postpartum haemorrhage based on 17 clinical questions. \\nconclusion:  We present a summarized version of \\nthe recommendations and the evidence for these \\nguidelines, which are expected to be adopted by healthcare practitioners in charge of pregnancy \\ncare in Colombia, in order to reduce pregnancy-\\nassociated morbidity and mortality.\\nKey words: Postpartum haemorrhage, hemorragic \\nshock,  evidence-based clinical practice, Colombia.  \\nIntRoduccIón \\nLas complicaciones hemorrágicas asociadas el em -\\nbarazo continúan como una de las principales causas \\nde muerte materna en el mundo y en Colombia (1). \\nLa principal causa de hemorragia obstétrica es la hemorragia posparto. Según la Organización Mun -\\ndial de la Salud (OMS), la incidencia promedio de la hemorragia posparto en el mundo es de 6,09% (IC 95%: 6,06-6,11); esta cifra varía con la metodolo -\\ngía objetiva o subjetiva empleada para la medición del sangrado (10,55 y 7,23%, respectivamente). La hemorragia posparto masiva es un evento que se \\npresenta en 1,86% de los partos (IC 95%: 1,82-\\n1,9) y es la primera causa de muerte materna en el mundo. La incidencia en América Latina y el Caribe \\nse estima en 8,9% según una revisión sistemática \\nque evaluó este evento en diferentes regiones del \\nmundo (IC 95%: 8,03-9,86) (2). Estos mismos es -\\ntudios no confirmaron la influencia de los factores \\nde riesgo asociados tradicionalmente a la hemorra -\\ngia posparto como la multiparidad o el embarazo \\nmúltiple (3)\\n y, por el contrario, en dos tercios de \\nlas mujeres que la sufren no se logra identificar ', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 1}), Document(page_content='427\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\nningún factor de riesgo asociado (4). En los países \\nen vías de desarrollo el riesgo de morir a causa de \\nuna hemorragia posparto es de 1 por cada 1000 nacimientos en un periodo determinado, mientras \\nque en países desarrollados como el Reino Unido, \\nel riesgo es 100 veces menor. Cada año en el mundo aproximadamente 14 millones de mujeres sufren de hemorragia posparto y de ellas, 125.000 fallecen \\ndebido a la falta de reconocimiento de las causas y a \\ndeficiencias con el tratamiento oportuno y adecua -\\ndo (2). La hemorragia obstétrica no es solo la pri -\\nmera causa de muerte materna, sino que es también la primera causa de morbilidad obstétrica extrema \\n(5). Las principales complicaciones derivadas de la \\nhemorragia obstétrica incluyen el choque hipovo -\\nlémico, la coagulación intravascular diseminada, y \\nla disfunción o falla de órganos como el riñón, el \\nhígado y el pulmón. Las mujeres, además, se ven expuestas a los riesgos derivados de transfusiones masivas y a consecuencias como la realización de \\ncirugías radicales como la histerectomía. \\nLa disponibilidad de una Guía de Práctica Clínica \\n(GPC) para la prevención, detección temprana y \\ntratamiento de hemorragia posparto implica estan -\\ndarizar para Colombia el cuidado de la mujer gestan -\\nte, con énfasis en la necesidad de la prevención, la detección temprana y el tratamiento oportuno en todos los niveles de atención, a fin de reducir la \\nmorbimortalidad materna asociada y promover la \\noptimización de la salud materna y la calidad de  \\nla atención médica en todos los niveles de atención \\nobstétrica.\\nEn el presente artículo se presenta una versión \\nabreviada de la información contenida en la GPC de Embarazo y Parto referente a la sección de manejo \\nde las complicaciones hemorrágicas asociadas al em -\\nbarazo, en la que se muestra la evidencia relacionada \\npara cada tema y se presentan las recomendaciones \\nelaboradas por el GDG durante el proceso de de -\\nsarrollo de esta GPC. El grupo desarrollador de la \\nGuía (GDG) elaboró esta GPC durante 2011-2012 \\nacorde con la Guía Metodológica para la elabora -ción de Guías de Atención Integral en el Sistema \\nGeneral de Seguridad Social en Salud colombiano, \\nbasándose en la evidencia científica disponible y sumando la participación activa de grupos de pa -\\ncientes, sociedades científicas y grupos de interés. En particular, la evidencia de esta sección fue adap -\\ntada de las GPC del Royal College of Obstetricians and Gynaecologists (RCOG), “Prevention and \\nmanagement of postpartum haemorrhage” (2009) \\n(6) y de OMS, “WHO guidelines for the mana -\\ngement of postpartum haemorrhage and retained placenta” (2009) (7), y actualizada por medio de \\nprocedimientos sistemáticos, tanto para la búsqueda \\ny valoración de la evidencia como para la genera -\\nción de recomendaciones. El nivel de evidencia y la fuerza de las recomendaciones fueron expresadas por medio del sistema del Scottish Intercollegiate \\nGuidelines Network (SIGN). La versión completa \\nde esta GPC (incluida la búsqueda sistemática de información científica y la presentación detallada \\nde la evidencia científica), así como la versión para \\npacientes y sus anexos, están disponibles para la consulta de los interesados por diferentes medios \\n(físicos y electrónicos) (8, 9).\\n1. ¿cuáles son las intervenciones efectivas \\npara prevenir la hemorragia posparto al \\nfinalizar el segundo periodo del parto?\\nSe recomienda realizar manejo activo del \\nalumbramiento para disminuir la pérdida de sangre materna y reducir el riesgo de hemorragia posparto. \\nSe recomienda utilizar de forma rutinaria \\noxitócicos profilácticos en el manejo del \\nalumbramiento en todas las mujeres. \\nSe recomienda la administración de oxito -\\ncina 5 UI o 10 UI (según la presentación de \\noxitocina disponible) por vía intramuscular \\ncomo medicamento de elección para profi -\\nA\\nA\\nA', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 2}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013428\\nlaxis durante el alumbramiento en mujeres \\nque tengan parto por vía vaginal. \\nCuando exista un acceso venoso permea -\\nble, puede administrarse oxitocina 5 UI o \\n10 UI en infusión lenta diluida en 10 mL de cristaloides en un tiempo no inferior a 3 min. \\nSe recomienda el uso de 600 mcg de mi -\\nsoprostol por vía sublingual para profilaxis \\ndurante el alumbramiento cuando la oxito -\\ncina no esté disponible. No se recomienda la administración por vía intrarrectal. \\nNo se recomienda el uso de ácido tranexá -\\nmico para la prevención de la hemorragia \\nposparto.  \\nSe recomienda ligar y cortar el cordón um -\\nbilical entre el segundo y el tercer minuto después del nacimiento en todos los recién nacidos a término y pretérmino que nazcan vigorosos.  \\nUna revisión sistemática realizada en el año 2000 y \\nactualizada en el 2011, que incluyó siete ECC con 8.247 gestantes, encontró que el manejo activo del alumbramiento redujo el riesgo promedio de he -\\nmorragia primaria de 1.000 mL o más al momento del parto (RR = 0,34; IC 95%: 0,14-0,87) (10, 11). Los resultados también mostraron una reducción en la hemorragia de 500 mL o más en la necesidad \\nde transfusión y en el uso de uterotónicos terapéu -\\nticos. Asimismo, hubo un incremento en la presión \\narterial y el vómito después del manejo activo.Una revisión sistemática\\n que incluyó siete ECC \\ncon 5.800 pacientes comparó la profilaxis con \\noxitocina frente a no administrar uterotónicos. \\nLos autores encontraron que la oxitocina redujo el riesgo de hemorragia posparto alrededor del 60% y la necesidad de uterotónicos terapéuticos \\nalrededor del 50% (12).\\nUna revisión sistemática\\n que incluyó tres ECC \\ncon 1.671 pacientes evaluó el efecto de la admi -1++nistración de la oxitocina previa a la expulsión  \\nde la placenta comparado con la administración de \\noxitocina después de la expulsión de la placenta en \\nrelación con el manejo activo del alumbramiento \\npara prevenir la hemorragia posparto (13). No se encontraron diferencias significativas en la in -\\ncidencia de hemorragia posparto (RR = 0,81;  \\nIC 95%: 0,62-1,04), placenta retenida (RR = 1,54; \\nIC 95%: 0,76-3,11), duración del tercer periodo del \\nparto (DM = -0,30; IC 95%: -0,95 a 0,36), pér -\\ndida de sangre (DM = 22,32 mL; IC 95%: -58,21 \\na 102,68), necesidad de transfusión sanguínea \\n(RR = 0,79; IC 95%: 0,23-2,73), uso adicional de uterotónicos (RR = 1,10; IC 95%: 0,80-1,52) e incidencia de hemorragia posparto severa (RR = 0,98; IC 95%: 0,48-1,98). Una revisión sistemática que\\n incluyó seis ECC con \\n9.332 pacientes evaluó la efectividad de la profilaxis con ergometrina-oxitocina comparada con oxito -\\ncina en el tercer periodo del parto para prevención \\nde la hemorragia posparto (14). Se encontró que la \\ncombinación de ergometrina-oxitocina, oxitocina 5 UI y oxitocina 10 UI tiene eficacia similar en la prevención de la hemorragia posparto de más de \\n1.000 mL (combinación de ergometrina-oxitocina \\ncomparada con alguna dosis de oxitocina: OR = 0,78; IC 95%: 0,58-1,03; combinación de ergome -\\ntrina-oxitocina comparada con 5 UI de oxitocina: \\nOR = 0,14; IC 95%: 0,00-6,85; combinación \\nde ergometrina-oxitocina comparada con 10 UI  de oxitocina: OR = 0,78; IC 95%: 0,59-1,04). En la hemorragia posparto de mínimo 500 mL hubo una leve reducción en el riesgo con la combinación de ergometrina-oxitocina frente a otras dosis de \\noxitocina (OR = 0,82; IC 95%: 0,71-0,95; combi -\\nnación de ergometrina-oxitocina comparada con 5 \\nUI de oxitocina: OR = 0,43; IC 95%: 0,23-0,83; \\ncombinación de ergometrina-oxitocina compara -\\nda con 10 UI de oxitocina: OR = 0,85; IC 95%: 0,73-0,98).\\nUna revisión sistemática que incluyó 32 ECC con 42.621 pacientes evaluó el papel de las prostaglan -√\\nA\\nA\\nA\\n1++\\n1++1++\\n1++', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 3}), Document(page_content='429\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\ndinas en la prevención de la hemorragia posparto \\n(15). Se encontró que los uterotónicos inyectables convencionales fueron más efectivos que las pros -\\ntaglandinas para la profilaxis rutinaria y que la \\ninvestigación sobre prostaglandinas en el contexto \\nde la hemorragia obstétrica debe focalizarse en el tratamiento más que en la prevención (RR = 1,32; IC 95%: 1,16-1,51). Una revisión sistemática que incluyó 4 ECC evaluó \\nel efecto del misoprostol en la prevención de la \\nhemorragia posparto (16). El estudio concluyó que el misoprostol no es tan efectivo en la prevención \\nde la hemorragia posparto cuando se compara con \\nla oxitocina en dosis de 10 UI por vía intravenosa \\n(RR = 1,34; IC 95%: 1,16-1,55).\\nUna revisión sistemática de 6 ECC con 3.941 pacientes evaluó el efecto de los alcaloides del cornezuelo del centeno en la prevención de la hemorragia posparto (17). Se encontró que el uso \\nde estos agentes disminuyó la media de pérdida \\nde sangre (DM = -83,03 mL; IC 95%: -99,39 a 66,66), así como la hemorragia posparto menor o igual a 500 mL (RR = 0,38; IC 95%: 0,21-0,69) y \\nel uso de uterotónicos terapéuticos (RR = 0,25; IC \\n95%: 0,10-0,66). Los efectos adversos incluyeron elevación de la presión arterial y dolor después del parto que requirió analgesia.Una revisión sistemática enfocada en la efectivi -\\ndad del ácido tranexámico en la prevención de la hemorragia posparto incluyó dos ECC con 453 pacientes, y compara el uso de este agente (0,5 g y 1 g) con otros agentes o placebo en el tercer pe -\\nriodo del parto (18). La pérdida de sangre mayor a 400 mL fue menor en mujeres que recibieron ácido tranexámico por vía intravenosa después del parto vaginal o cesárea (RR = 0,51; IC 95%: \\n0,36-0,72). A pesar de los resultados, los autores \\nconcluyeron que se requieren más estudios para \\nconfirmar la eficacia y seguridad del ácido tra -\\nnexámico en el escenario de la prevención de la \\nhemorragia posparto.Una revisión sistemática que incluyó cinco ECC \\ncon 1.163 pacientes evaluó la carbetocina como \\nagente profiláctico para la prevención de la hemo -\\nrragia posparto (19). La carbetocina fue comparada \\ncon oxitocina o combinación de ergometrina-oxi -\\ntocina y placebo en mujeres con parto por vía va -\\nginal y por cesárea. Se encontró que la carbetocina \\nprobablemente es tan efectiva como la oxitocina en \\nla profilaxis del tercer periodo del parto, aunque \\nesta conclusión no está fundamentada en datos objetivos ya que la heterogeneidad de los ensayos \\nincluidos tanto en diseño como en desenlaces no \\npermitió la estimación combinada del efecto.Dos revisiones sistemáticas evaluaron el efecto del corte tardío del cordón umbilical como com -\\nponente del manejo activo del alumbramiento en relación con desenlaces maternos y neonatales.  \\nUna de ellas, que incluyó 29 ECC con 2.200 recién nacidos a término y pretérmino, comparó el corte del cordón umbilical dentro de los 30 segundos después del nacimiento, con el corte después de \\nlos primeros 30 segundos (20). Solo se encontraron \\ndiferencias en términos de la remoción manual de la placenta (RR = 0,45; IC 95%: 0,22-0,94). En -\\ntre los recién nacidos pretérmino se encontró un riesgo de hemorragia intraventricular menor que \\nen los recién nacidos a término (RR = 0,52; IC \\n95%: 0,28-0,98). La segunda revisión que incluyó 11 ECC con 2.989 recién nacidos comparó el corte tardío (definido como el corte después del primer minuto del parto) con el corte antes del primer minuto (21). No se encontraron diferencias en \\nrelación con la hemorragia posparto (RR = 1,22; \\nIC 95%: 0,96-1,55). Sin embargo, se encontró un incremento significativo en la necesidad de fotote -\\nrapia por ictericia en los recién nacidos con corte \\ntardío del cordón (RR = 0,59; IC 95%: 0,38-0,92). \\nDe igual forma, hubo un incremento en los niveles de hemoglobina de los recién nacidos con corte tardío del cordón (DM = 2,17g/dL; IC 95%: 0,28 a 4,06), aunque este efecto no persistió después de \\nseis meses de seguimiento.1++\\n1++1++1++\\n1++\\n1++', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 4}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013430\\nUna revisión sistemática evaluó el efecto del masaje \\nuterino en la prevención de la hemorragia posparto, identificando solo un ECC con 200 mujeres que comparó la realización del masaje uterino después \\ndel parto y antes de la expulsión de la placenta frente \\na no realizar ninguno de estos procedimientos (22). No se encontraron diferencias significativas en la pérdida de sangre de más de 500 mL (RR = 0,52; IC 95%: 0,16-1,67), ni en los casos de placenta re -\\ntenida. Se encontraron diferencias en la pérdida de sangre a los 30 min y 60 min en el grupo de masaje uterino (30 min: DM = -41,6 mL; IC 95%: -75,16 a \\n-8,04. 60 min: DM = -77,40 mL; IC 95%: -118,7a \\n-36,09). La necesidad de uterotónicos adicionales \\nse redujo en el grupo del masaje uterino (RR = \\n0,20; IC 95%: 0,08-0,50).  \\nLa evidencia indica que el manejo activo del \\nalumbramiento disminuye la pérdida de sangre \\nmaterna y reduce el riesgo de hemorragia pos -\\nparto de más de 1.000 mL. El agente de elección \\npara el manejo activo del alumbramiento debe ser  \\nla oxitocina en una dosis de 5 UI o 10 UI; aunque la vía de administración más frecuentemente usada es la intramuscular, el GDG consideró importante \\nsugerir la posibilidad de administrar la profilaxis \\ncon oxitocina por vía intravenosa cuando exista un acceso venoso permeable, dado que no hay evidencia \\nque favorezca la vía intramuscular (IM) sobre la \\nintravenosa (IV).\\nLa consideración del uso de otros agentes oxi -\\ntócicos diferentes a la oxitocina requiere de mayor evidencia que soporte su uso en la práctica diaria. Aunque el misoprostol no es tan efectivo como la \\noxitocina para la prevención de la hemorragia pos -\\nparto, puede ser usado cuando la oxitocina no esté \\ndisponible. El efecto específico del masaje uterino \\ncon uterotónicos o sin estos en la prevención de la \\nhemorragia posparto requiere más ensayos con ma -\\nyor número de participantes para evaluar su eficacia en estos casos. Por otra parte, retrasar el corte del cordón umbilical por al menos 2 o 3 min parece no incrementar el riesgo de hemorragia posparto.2. ¿cuál es la intervención más efectiva \\npara prevenir la hemorragia posparto en \\nuna paciente sometida a cesárea? \\nEn mujeres con parto por cesárea se reco -\\nmienda la administración de un bolo de 5 \\nUI de oxitocina diluidas en cristaloides por vía IV en un tiempo no inferior a 3 min, inmediatamente se extraiga el bebé. \\nEn mujeres con parto por cesárea se reco -\\nmienda adicionar una infusión de 30 UI de \\noxitocina en 500 mL de cristaloides para \\npasar en 4 horas, inmediatamente después de la administración del bolo inicial de 5 \\nUI de oxitocina. \\nCuatro ECC que incluyeron un total de 1.155 \\nmujeres evaluaron diferentes uterotónicos para la profilaxis en mujeres con parto por cesárea (23-26). Se encontró que la oxitocina 5 UI por vía \\nintravenosa lenta es la opción recomendada por su \\ndisminución de la pérdida sanguínea y la reducción de la necesidad de uterotónicos adicionales (RR = 2,1; IC 95%: 1,4-3,0). Así mismo se encontró que \\nuna dosis de carbetocina es al menos tan efectiva \\ncomo la oxitocina en infusión en la reducción de la pérdida de sangre (RR = 2,03; IC 95%: 1,1-2,08), pero su uso rutinario no se recomienda \\nactualmente por ser más costosa y por ser aún \\nescasa la información. Se concluyó que el uso de la carbetocina parece asociarse a una disminución en el uso de oxitócicos adicionales, pero no con la disminución de la incidencia de hemorragia pos -\\nparto (RR = 0,74; IC 95%: 0,57-0,95).\\nTres ECC que incluyeron 155 pacientes compara -\\nron los diferentes regímenes de dosificación de la \\noxitocina en la prevención de la hemorragia pos -\\nparto en mujeres sometidas a cesárea (27-29). Se \\nencontró que las dosis actuales (siendo estas 5 y \\n10 UI) pueden ser más altas que la dosis efectiva \\nnecesaria para prevenir la hemorragia (dosis efec -\\ntiva 90%, 0,29 UI por min (IC 95%: 0,15-0,43). De A\\nA\\n1++\\n1++1++', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 5}), Document(page_content='431\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\nigual forma, la evidencia demuestra que dosis altas \\nestán asociadas con alteraciones hemodinámicas en las gestantes (FC = +28 Lat frente a + 52 Lat; p < 0,001; PAM: -33 mm/Hg frente a -30 mm/\\nHg p < 0,001).\\nCuatro ECC que incluyeron 2.995 pacientes\\n evalua -\\nron los efectos de la infusión continua de oxitocina en un tiempo de cuatro horas después de una dosis inicial de 5 UI (30-33). Se encontró disminución \\nen el uso de uterotónicos adicionales (RR = 0,61 \\nIC 95%: 0,48-0,78), mejoría de la contracción uterina inicial (DP = 2,8 frente a 2,2 p < 0,01), y reducción de la pérdida de sangre (RR = 0,35; IC 95%: 0,20-0,63); no se encontró alteración de \\nlos parámetros hemodinámicos de las mujeres so -\\nmetidas a cesárea.\\nTres ECC que incluyeron 500 pacientes evaluaron la efectividad del misoprostol en diferentes dosis y por diferentes vías para la prevención de la hemo -\\nrragia poscesárea (34-36). Se encontró que en dosis de 200 mcg u 800 mcg por vía intrarrectal, intrauterina o sublingual, el misoprostol tiene una efectividad similar a la oxitocina en la disminución de la pérdida de sangre (608,91 mL frente a 673,9 \\nmL; p = 0,048) y en la disminución de uterotó -\\nnicos adicionales (34% frente a 14%; p = 0,032). \\nSin embargo, los autores subrayan que se requieren nuevos ensayos con poblaciones más grandes con el \\nfin de confirmar los hallazgos obtenidos.\\nUn ECC que incluyó 90 mujeres sometidas a ce -\\nsárea evaluó la efectividad del ácido tranexámico frente a placebo para la prevención de la hemorra -\\ngia posparto (37). En dosis de 1 g por vía intrave -\\nnosa se encontró una reducción de la pérdida de sangre (28,02 mL frente a 37,12 mL; p = 0,000).Un ECC que incluyó 377 mujeres evaluó la efectivi -\\ndad de la carbetocina como agente profiláctico para la prevención de la hemorragia poscesárea (38). Se \\nadministraron 100 mcg de carbetocina y se comparó \\ncon 5 UI de oxitocina por vía intravenosa. Los resul -\\ntados mostraron que un mayor número de mujeres requirieron oxitócicos adicionales en el grupo de oxitocina (RR = 0,74; IC 95%: 0,57-0,95).\\n1++Un ECC que incluyó 104 pacientes comparó una dosis de 100 mcg de carbetocina frente a 10 UI de oxitocina en infusión de dos horas en la prevención \\nde la hemorragia poscesárea (39). El promedio de \\nsangre perdida después de la administración de \\ncarbetocina fue 30 mL menos que después de la \\nadministración de oxitocina y el porcentaje de pa -\\ncientes con pérdida de sangre menor de 500 mL fue mayor en el grupo con carbetocina (81% frente a 55%; p = 0,05). \\n \\nLa evidencia indica que la oxitocina es el agente \\nde elección para la prevención de la hemorragia \\nposparto en mujeres sometidas a cesárea. Algunos estudios han subrayado que la dosis actualmente \\nutilizada puede ser más alta que la necesaria para \\nlograr el efecto deseado y, por tanto, estas dosis podrían producir cambios hemodinámicos im -\\nportantes en la mujer. De igual forma, la evidencia demuestra que la infusión de una dosis baja de oxitocina después de una dosis inicial reduce la \\nnecesidad de uterotónicos adicionales en cesárea, \\npero no afecta la ocurrencia general de hemorragia obstétrica mayor. Lo que es claro con la evidencia \\nactual es que la adición de una infusión de oxito -\\ncina en pacientes sometidas a cesárea electiva no \\nafecta los parámetros hemodinámicos maternos, ni \\ndurante, ni después de la cirugía.\\nAl parecer, la carbetocina puede ser tan efectiva \\ncomo la oxitocina en la reducción del sangrado después de parto por cesárea y en el uso de utero -\\ntónicos adicionales, no así para la hemorragia mayor \\nde 500 mL. La ventaja que ofrece la carbetocina \\nes la dosis única y no tener que utilizar infusiones \\nadicionales. Recientemente, la Comisión de Regu -\\nlación en Salud publicó un estudio de efectividad, seguridad y análisis económico de la carbetocina frente a la oxitocina en la prevención de la atonía uterina y hemorragia posparto de mujeres sometidas \\na cesárea.\\n La conclusión del análisis económico in -\\ndica que el uso de carbetocina resulta 70 veces más \\ncostoso en comparación con la oxitocina. Por tanto, no se puede emitir un concepto de favorabilidad o 1++\\n1++\\n1++1+', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 6}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013432\\nno favorabilidad para el uso de carbetocina en la \\nprevención de la hemorragia posparto en mujeres \\nsometidas a cesárea (40).\\n3. ¿cuáles son las intervenciones necesarias \\npara disminuir el riesgo de hemorragia grave y complicaciones en mujeres con diagnóstico antenatal de acretismo \\nplacentario? \\nEn pacientes con factores de riesgo para \\nacretismo placentario se recomienda realizar un ultrasonido con Doppler pla -\\ncen tario por personal calificado para \\nidentificar la localización y el grado de \\ninserción de la placenta. \\nSe recomienda que el ultrasonido con \\nDoppler se realice a una edad gestacional por encima del límite de viabilidad fetal.\\nSi se diagnostica acretismo placentario se \\nrecomienda planear la atención del parto \\npor un equipo multidisciplinario apropiado \\npara el manejo de la condición específica de \\nla paciente, en una institución que cuente \\ncon las ayudas diagnósticas pertinentes, \\ncon disponibilidad de glóbulos rojos, plas -\\nma, plaquetas y crioprecipitado, y el acceso a una unidad de cuidados intensivos. \\nNo existe evidencia suficiente para reco -\\nmendar o rechazar la oclusión profiláctica \\ncon balones de insuflación en las arterias hipogástricas en pacientes con acretismo placentario.  \\nOcho series de casos que incluyeron 36 mujeres \\nse enfocaron en las intervenciones con radiología profiláctica en forma de oclusión con balón o \\nembolización de arterias pélvicas en relación con \\ndesenlaces como pérdida de sangre, tiempo en unidad de cuidados intensivos, requerimientos de transfusión y necesidad de histerectomía (41-47). Tres de estas series sugieren que la intervención radiológica profiláctica es benéfica, mientras que \\nuna de ellas no encontró beneficios. \\nUna serie de casos de 11 pacientes a quienes se les practicó oclusión bilateral de la arteria iliaca in -\\nterna para el manejo de la placenta acreta reportó un 39,4% de disminución en la pérdida de sangre intraoperatoria y un 52,1% menos de sangre trans -\\nfundida en comparación con 14 mujeres a quienes \\nno se les realizó del procedimiento (48).\\nUna serie de casos con 167 mujeres mostró que dejar la placenta en su sitio, parcial o totalmente, \\nsin intento de removerla, se asoció con al menos \\nun beneficio en 131 mujeres (49). La resorción \\nespontánea de la placenta ocurrió en 87 casos con \\nun tiempo promedio desde el inicio del trabajo de parto de 13,5 semanas. \\nLa técnica del ultrasonido resulta importante \\npara realizar el diagnóstico antenatal de inserción \\nanormal de la placenta y la planeación de la atención \\ndel parto. El GDG consideró que el ultrasonido con Doppler debe ser realizado por personal calificado, \\nbuscando identificar al máximo la localización y el \\ngrado de inserción de la placenta. Así mismo, se consideró importante que estas ecografías se reali -\\ncen en una edad gestacional donde haya viabilidad fetal para mejorar los desenlaces maternos y fetales. \\nDejar la placenta acreta en su sitio  parece ser una \\nalternativa más segura que removerla. El tratamiento conservador para la placenta acreta puede ayudar a las mujeres a evitar una histerectomía y presenta bajas \\ntasas de morbilidad materna cuando se realiza en ins -\\ntituciones con los equipos y los recursos adecuados. \\n4. ¿cuál es la intervención más efectiva \\npara tratar la retención placentaria sin sangrado, después de manejo activo del \\nalumbramiento? \\nSi después de 30 min de haber realizado \\nel manejo activo del alumbramiento la placenta no se expulsa de forma espontá -D\\nD\\nD√\\n33\\n3\\nD', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 7}), Document(page_content='433\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\nnea, se recomienda administrar 10 UI de \\noxitocina intramuscular o intravenosa, en combinación con la tracción controlada del cordón umbilical. \\nSe recomienda una única tracción luego de \\nla administración de esta dosis de oxitocina.\\nSi la atención de la mujer se está realizando \\nen un primer nivel de atención y la placenta no se desprende con el manejo anterior, se recomienda iniciar la infusión de 20 UI de oxitocina en 500 mL de cristaloides a 60 mL/hora (40 miliunidades/min) y remitirla.  \\nSi la atención de la mujer se está realizan -\\ndo en instituciones de segundo y tercer nivel, y la placenta no se desprende en 30 min después de administrar la segunda dosis de oxitocina, se recomienda como \\nalternativa a métodos invasivos la inyec -\\nción en la vena umbilical con técnica aséptica de 800 mcg de misoprostol di -\\nsueltos en 30 cc de solución salina. \\nNo se recomienda la inyección de oxitocina \\no solución salina por vena umbilical para el manejo de la placenta retenida. \\nSi después de la realización de las manio -\\nbras antes descritas para el manejo de la \\nplacenta retenida sin sangrado, no hay respuesta, se recomienda hacer la extrac -\\nción manual teniendo presente el riesgo potencial de un acretismo. \\nUn ECC que incluyó 50 pacientes con placenta \\nretenida comparó el sulprostone frente a placebo \\npara evaluar la frecuencia de remoción manual de \\nla placenta (50). El ensayo fue suspendido antes \\nde alcanzar el tamaño de muestra propuesto y el \\nsulprostone fue dado al resto de las mujeres in -\\ncluidas. Con los datos preliminares se evidenció una reducción del riesgo de remoción manual de \\nla placenta (RR = 0,51; IC 95%: 0,34-0,86) y una \\ndisminución no estadísticamente significativa en el riesgo de la transfusión de sangre en el grupo de sulprostone. Una revisión sistemática que incluyó 15 ECC con 1.704 mujeres evaluó la inyección por vena um -\\nbilical de agentes para el manejo de la placenta \\nretenida, como solución salina sola, oxitocina más \\nsolución salina, oxitocina más solución salina más \\nexpansor de plasma y prostaglandina más solu -\\nción salina (51). La solución salina sola no mostró \\ndiferencias significativas en la remoción manual de la placenta (RR = 0,99; IC 95%: 0,84-1,16). La oxitocina más solución salina comparada con \\nmanejo expectante no mostró reducción en la \\nnecesidad de remover manualmente la placenta (RR = 0,87; IC 95%:0,74-1,03). La oxitocina más solución salina comparada con solución salina sola mostró una reducción en la remoción manual, re -\\nducción que no fue estadísticamente significativa (RR = 0,91; IC 95%: 0,82-1,00). La oxitocina más solución salina comparada con expansor de plasma no mostró diferencias significativas (RR = 1,34; IC 95%: 0,97-1,85). La prostaglandina más \\nsolución salina comparada con solución salina sola \\nfue asociada con una reducción significativa en la incidencia de remoción manual de la placenta (RR 0,42; IC95%: 0,22-0,82). La prostaglandina más solución salina comparada con oxitocina más so -\\nlución salina mostró una reducción significativa en la remoción manual de la placenta (RR = 0,43; IC 95%: 0,25-0,75). También se observó una reduc -\\nción del tiempo entre la inyección y la expulsión de \\nla placenta (DM = -6,00; IC 95%: -8,78 a -3,22).\\nUna revisión sistemática comparó el uso de toco -\\nlíticos solos o en combinación con uterotónicos, con no intervención o con otras intervenciones  \\nen el manejo de la placenta retenida en mujeres en \\nquienes había fallado el tratamiento con oxitocina. \\n(52). La revisión incluyó solo un ensayo clínico con \\n24 mujeres y los datos sugieren una reducción en \\nla necesidad de remoción manual de la placenta (RR = 0,04; IC 95%: 0,00-0,66), así como una \\nreducción de la pérdida de sangre durante el alum -\\nbramiento con el uso de nitroglicerina sublingual  \\n(Media = -262,5 mL; IC 95%: -364,95 a -160,05).\\n√√\\n√\\nB\\nA\\n1-1++\\n1++', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 8}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013434\\nLa inyección por la vena umbilical de prosta -\\nglandinas requiere de investigaciones adicionales, \\naunque los resultados de dos ensayos clínicos evi -\\ndencian un impacto en la disminución de remoción \\nmanual de la placenta.\\nEl consenso de expertos de la “Guía de práctica \\nclínica para el manejo de la hemorragia posparto \\ny placenta retenida” publicada por la OMS (7), no \\nhalló evidencia que soportara el uso de uterotó -\\nnicos para el manejo de la placenta retenida sin \\nsangrado. Sin embargo, este grupo recomendó la \\nadministración de una nueva dosis de oxitocina y \\nrealizar un nuevo intento de extracción por tracción \\ncontrolada. Ante esto el GDG junto, con el grupo de \\nexpertos consultados, consideró importante subra -\\nyar que no se debe mantener de forma persistente \\nla tracción controlada del cordón y que es suficiente \\nuna sola tracción para procurar la extracción de la placenta retenida como coadyuvante a la adminis -\\ntración de la oxitocina.\\nAsí mismo, dadas las condiciones geográficas \\ny la atención por niveles establecida en el sistema \\nde salud, es aconsejable diferenciar el manejo por \\nniveles de atención. Para el primer nivel resulta importante no intentar más de una sola tracción \\ny una dosis adicional de oxitocina. En su defecto, \\nes recomendable iniciar una infusión de oxitocina y remitir la paciente a un nivel superior, donde se \\npueda garantizar un manejo adecuado. El GDG \\ntambién consideró que la extracción manual debe realizarse en una institución que cuente con los \\nrecursos necesarios para atender cualquier compli -\\ncación derivada de un posible acretismo placentario.\\n5. ¿se recomienda el uso profiláctico de \\nantibióticos cuando se realiza revisión manual de la cavidad uterina?\\nSe recomienda administrar dosis única \\nparenteral de cefalosporina de primera ge -\\nneración inmediatamente antes de iniciar \\nla extracción manual de la placenta.En caso de alergia documentada a los be -\\ntalactámicos se recomienda administrar \\nclindamicina más gentamicina en dosis única.  \\nEn las instituciones que cuenten con per -\\nfil microbiológico se recomienda elegir el \\nantibiótico de acuerdo con dicho perfil. \\nUna revisión sistemática enfocada en estudios de \\nprofilaxis antibiótica después de extracción ma -\\nnual de la placenta no encontró ensayos clínicos \\ncentrados en este tema (53). No se encuentra evi -\\ndencia de alta calidad para el uso de antibióticos \\nprofilácticos.  \\nEl consenso de expertos de la guía de práctica \\nclínica para el manejo de la hemorragia posparto \\ny placenta retenida de la OMS (7) recomendó el \\nuso de cefalosporina de primera generación basa -\\ndos en evidencia indirecta de estudios realizados \\nen mujeres sometidas a cesárea y de muje  res con \\naborto. El GDG consideró la necesidad de incluir \\notra posibilidad antibiótica en los casos de alergia \\ndocumentada, así como la importancia de contar \\ncon un perfil microbiológico que apoye de forma más segura la elección del antibiótico que se va a \\nutilizar.\\n6. ¿cuáles son los criterios que determinan \\nel inicio del manejo del choque \\nhipovolémico?\\nPara la identificación del grado de choque \\nse recomienda la evaluación de los siguien -\\ntes parámetros clínicos: \\n•\\tSensorio\\t(estado\\tde\\tconciencia).\\n•\\tPerfusión\\t(color\\tde\\tla\\tpiel,\\ttemperatura\\t\\nde la piel y llenado capilar).\\n•\\tPulso.\\t\\n•\\tPresión\\tarterial.\\t\\t D√\\n√\\n1++\\nD', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 9}), Document(page_content='435\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\nSe recomienda clasificar el grado del cho -\\nque e iniciar el manejo con el peor pará -\\nmetro clínico encontrado. \\nUna revisión de tema acerca del manejo del choque \\nhipovolémico en pacientes con trauma indica que los principios del manejo y el tratamiento deben \\nser bien conocidos y entendidos. Esto incluye el \\nreconocimiento de signos de hipoperfusión a ór -\\nganos vitales como hipotensión, taquicardia, entre otros (54). \\nLa evidencia narrativa retoma los signos de cho -\\nque hipovolémico de la clasificación de Baskett (54), \\nenfatizando dos aspectos importantes: en primer lugar, debido al aumento del volumen plasmático que \\nocurre en la mujer durante el embarazo, cualquier \\nporcentaje de pérdida representa para la gestante un volumen mayor que en la mujer no embarazada. En \\nsegundo lugar, se debe tener en cuenta que las altera -\\nciones del pulso y la presión arterial son tardías en la \\nmujer embarazada, por tanto, el estado de conciencia \\ny la perfusión deben ser evaluados inicialmente. El \\nGDG consideró que el estado de choque lo establece el peor parámetro encontrado después de evaluar a \\nla mujer con hemorragia posparto.\\n7. ¿cuáles son las intervenciones más \\nefectivas para el manejo de la hemorragia \\nposparto con signos de choque?\\nSe recomienda que cuando se diagnosti -\\nque hemorragia posparto con cualquier \\ngrado de choque se active el protocolo de código rojo obstétrico que incluya simul -\\ntáneamente acciones en cuatro áreas de intervención: comunicación, resucitación, monitoreo e investigación de la causa y control del sangrado. \\nEn la hemorragia posparto con signos \\nde choque se recomiendan las siguientes \\nmedidas: •\\tAlertar\\tal\\tpersonal\\tde\\tsalud\\tentrenado\\t\\nen código rojo obstétrico.\\n•\\tAsignar\\ta\\tun\\tmiembro\\tdel\\tequipo\\tel\\tre-\\ngistro de los procedimientos realizados, \\nla administración de líquidos, medica -\\nmentos y signos vitales; idealmente en formato preestablecido.\\n•\\tGarantizar\\tla\\tdisponibilidad\\tde\\themode -\\nrivados, alertar al laboratorio y activar el sistema de referencia.\\n•\\tEvaluar\\tsistema\\trespiratorio.\\n•\\tAdministrar\\toxígeno\\tsuplementario\\tcon\\t\\nmáscara con bolsa, reservorio mínimo \\na 10 litros por minuto. En ausencia de máscara, suministrar oxígeno con cánu -\\nla nasal a 3 litros por minuto o sistema venturi 35-50%. \\n•\\tSe\\tdebe\\tmantener\\toximetría\\tde\\tpulso\\t\\npor encima del 95%. \\n•\\tGarantizar\\tal\\tmenos\\tdos\\taccesos\\tvenosos\\t\\npermeables de buen calibre. Se reco -\\nmienda al menos uno con catéter No. 14 o 16. \\n•\\tRealizar\\tla\\ttoma\\tde\\tmuestra\\tde\\tsangre\\t\\npara hemograma completo, pruebas cru -\\nzadas, pruebas de coagulación incluido fibrinógeno, pruebas de función renal, pruebas de función hepática y gases ar -\\nteriales.\\n•\\tIniciar\\ty\\tcontinuar\\tinfusión\\tde\\tcristaloi -\\ndes calentados a 39 °C, titulando cada \\n5 min la respuesta basada en los signos \\nde choque: sensorio conservado, pulso \\nradial presente, presión arterial sistólica mayor de 90 mm/Hg y llenado capilar \\n< 5 seg con bolos de 500 mL si alguno \\nde los parámetros se encuentra alterado.\\n•\\tInserción\\tde\\tsonda\\tFoley\\tpara\\tmonito -\\nrear volumen urinario.\\n•\\tMantener\\tcaliente\\ta\\tla\\tpaciente\\tcubrién -\\ndola con mantas y en posición supina. 4\\nC\\n√D', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 10}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013436\\n•\\tValoración\\ty\\tregistro\\tcada\\t15\\tmin\\tdel\\t\\npulso, presión arterial y frecuencia res -\\npiratorio una vez estabilizada la paciente.\\n•\\tUna\\tvez\\testabilizada\\tla\\tpaciente,\\tremitir\\t\\na un nivel de mayor complejidad que \\ngarantice la atención adecuada.\\n•\\tDocumentación\\t de\\tlos\\tprocedimientos,\\t\\nbalance de líquidos y hemoderivados transfundidos.  \\nUn estudio descriptivo con una población de 103 \\nparticipantes entre enfermeras, obstetras, anes -\\ntesiólogos y auxiliares de enfermería reconoce la estimación visual como un método para determi -\\nnar la pérdida de sangre y facilitar la resucitación temprana, minimizando el riesgo de coagulación intravascular diseminada y reduciendo la severidad \\ndel choque hemorrágico (55). \\nEn un estudio descriptivo con 62 pacientes se encontró que el promedio de pérdida de sangre estimada fue significativamente menor que la media de pérdida de sangre medida por algún \\nmétodo objetivo. Estos hallaz  gos mostraron que \\nla estimación visual de pérdida de sangre puede \\nresultar inadecuada (56).  \\nNo se encontró evidencia relacionada con la \\neficacia de las intervenciones o los procedimientos \\ncomplementarios necesarios para el manejo de la \\nhemorragia posparto. Para la atención se deben considerar al menos cuatro componentes: la co -\\nmunicación con todos los profesionales relevantes, la resucitación, el monitoreo e investigación de la causa del sangrado y las medidas para contrarrestar \\nel sangrado. Estos componentes deben ser iniciados \\nsimultáneamente para brindar un cuidado óptimo. \\nEs fundamental alertar tempranamente al grupo \\nde profesionales pertinente para el manejo de la hemorragia posparto. El GDG consideró importante definir una forma \\nestandarizada de activar el protocolo de atención y \\nadoptar el nombre de código rojo obstétrico para \\nnombrarlo. Así mismo, es importante reorganizar las acciones de intervención ante una mujer con hemorragia posparto, teniendo en cuenta las con -\\nsideraciones de la GPC del RCOG (6). Es indispen -\\nsable estructurar un enfoque de ABC que permita, además de la resucitación, la identificación de otros \\nproblemas. La urgencia y las medidas instauradas \\npara la resucitación y el control de la hemorragia necesitan estar en la medida del grado del choque. \\nDebe administrarse oxígeno en altas concentracio -\\nnes sin tener en cuenta la concentración del oxígeno materno. Usualmente, los niveles de conciencia y \\nel control de la oxigenación mejoran rápidamente una vez el volumen de circulación es restaurado.\\nEs indispensable establecer dos accesos veno -\\nsos de buen calibre y tomar muestras de sangre para optimizar el manejo y la necesidad de terapia transfusional. Los componentes principales de la \\nresucitación durante la hemorragia posparto son  \\nla restauración del volumen de sangre y la capacidad \\nde transportar oxígeno. El reemplazo de volumen \\ndebe ser llevado a cabo sobre la base de que la \\npérdida de sangre es, a menudo, subestimada (55, 56). El cuadro clínico debe ser el principal deter -\\nminante de la necesidad y urgencia de la transfusión de hemoderivados y no se debe perder el tiempo \\nesperando los resultados de laboratorio (57, 58). \\nUna vez que el sangrado está bajo control, se \\ndebe considerar transferir a la mujer a una unidad \\nde cuidados intensivos o a una unidad de cuidados \\nintermedios, dependiendo de la severidad del san -\\ngrado. Es necesario el monitoreo médico continuo y el registro de los parámetros en el tiempo sugerido \\nen formatos preestablecidos, los cuales darán a los profesionales que intervienen en el manejo de la \\nmujer señales visuales adecuadas sobre su evolución \\nclínica.3\\n3', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 11}), Document(page_content='437\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\n8. ¿cuáles son las medidas más efectivas \\npara la recuperación del volumen \\nsanguíneo en el manejo del choque hipovolémico por hemorragia obstétrica? \\nSe recomienda iniciar infusión de crista -\\nloides calentados a 39 °C, titulando cada \\n5 min la respuesta basada en los signos \\nde choque: sensorio conservado, llenado capilar < 5 seg, pulso radial presente y \\npresión arterial sistólica mayor de 90 mm/\\nHg con bolos de 500 mL si alguno de los \\nparámetros se encuentra alterado. \\nSe recomienda utilizar soporte vasopresor si  \\nla paciente continúa con inestabilidad \\nhemo  dinámica después de la reposi -\\nción de volumen y control del sitio de \\nsangrado. La selección del vasopre -\\nsor dependerá de los medicamentos  \\ny la vía de acceso disponibles. \\nUna revisión sistemática de 1988, actualizada en el \\n2011,  que incluyó 38 ECC con un total de 10.842 pacientes evaluó el uso de la albúmina en la recupe -\\nración del volumen de pacientes críticamente enfer -\\nmos (59, 60). La mortalidad se estimó en un 18%. El riesgo estimado de mortalidad con la administración de albúmina fue (RR = 1,05; IC 95%: 0,95-1,16).Una revisión sistemática de 65 ECC con 11.549 \\npacientes comparó la efectividad de los cristaloides \\ny los coloides en la resucitación y recuperación del volumen circulante en pacientes críticamente en -\\nfermos (61). El riesgo de muerte para las diferentes \\nintervenciones comparadas fue el siguiente: 23 en -\\nsayos compararon albúmina o fracción proteica en plasma (RR = 1,01; IC 95%: 0,92-1,10); 17 ensayos \\ncompararon hidroxietil almidón ( Hydroxyethyl starch ) \\n(RR = 1,18; IC 95%: 0,96-1,44); 11 ensayos com -\\npararon gelatina modificada (RR = 0,91; IC 95%: \\n0,49-1,72); nueve ensayos compararon dextrano \\n(RR = 1,24; IC 95%: 0,94-1,65), ocho ensayos \\ncompararon dextrano en cristaloides hipertónicos (RR = 0,88; IC 95%: 0,74-1,05). Una revisión sistemática que incluyó 23 ensayos \\nclínicos y 3.212 pacientes evaluó el uso de 11 \\ndiferentes vasopresores en el manejo del choque hipovolémico (62). No se encontraron diferencias en términos de la mortalidad (RR = 0,95; IC 95%: \\n0,87-1,03); sin embargo, fueron observadas más \\narritmias en los pacientes tratados con dopamina cuando se compararon con norepinefrina (RR = \\n0,43; IC 95%: 0,26-0,69). \\nEl uso de la albúmina y de coloides para el ma -\\nnejo de la hemorragia posparto no se recomienda \\nporque aunque no se encuentra evidencia directa en \\nla obstetricia, se considera que el manejo del choque \\nhipovolémico puede no diferir entre pacientes con \\ncondiciones específicas y variadas. Según esto, el riesgo de muerte de una mujer en el posparto con la administración de coloides puede ser similar al \\nreportado en otro tipo de pacientes.\\nAunque no existe evidencia de la cantidad de \\nvolumen por transfundir, la GPC del RCOG (6) propone un volumen total de 3,5 litros. El GDG \\ny el grupo de expertos consultados consideró que iniciar con volúmenes altos sin hacer una medición \\nfrecuente de los cambios en los parámetros clínicos \\npuede acarrear consecuencias en la recuperación de la mujer con choque hipovolémico; por este motivo, \\nse sugirió la evaluación cada 5 min de la respuesta \\na la infusión de cristaloides para determinar la continuidad en la infusión de los mismos.\\nProbablemente, la elección de un vasopresor en \\npacientes con choque no influye sobre el resultado más allá del efecto mismo del vasopresor. Ante esta \\nevidencia, el GDG consideró que se pueden utilizar \\nvasopresores una vez se halla verificado una adecua -\\nda reposición de volumen y un control adecuado del sitio del sangrado, pero sin que su uso retrase la implementación de otras medidas o una remisión a \\nun nivel de mayor complejidad. Seleccionar uno u \\notro vasopresor dependerá de la disponibilidad de los mismos, de la vía de acceso disponible para su administración y del entrenamiento del personal \\nque lo vaya a utilizar. √\\n√\\n1++\\n1++1++', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 12}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013438\\n9. ¿cuáles son las intervenciones más \\nefectivas para el control de la hemorragia \\npor atonía uterina? \\nPara el control de hemorragia por atonía \\nuterina se recomienda excluir otras causas de hemorragia posparto como retención de fragmentos de placenta o membranas, laceraciones o hematomas vaginales o cer -\\nvicales, ruptura uterina, hematomas de li -\\ngamentos, sangrado extragenital, inversión uterina o coagulopatía. \\nSe recomienda utilizar la nemotecnia de las \\n4 “T”: Tono, Trauma, Tejido y Trombina (coagulopatía). \\nSi la causa de la hemorragia es la atonía \\nuterina, se recomienda implementar las \\nsiguientes medidas hasta que cese el san -\\ngrado o se defina la necesidad de otra in -\\ntervención: \\n•\\tInserción\\tde\\tuna\\tsonda\\tFoley\\tpara\\teva-\\ncuar la vejiga.\\n•\\tCompresión\\tuterina\\tbimanual.\\n•\\tAdministrar\\t5\\tUI\\tde\\toxitocina\\tpor\\tvía\\tIV\\t\\nlenta, mientras se inicia una infusión de \\n30 UI de oxitocina diluida en 500 mL de cristaloides para pasar en 4 horas.\\n•\\tErgometrina\\t0,2\\tmg\\tpor\\tvía\\tIM.\\tRepetir\\t\\nuna sola dosis adicional después de 20 min. Puede continuarse 0,2 mg cada 4 a 6 horas, máximo 5 ampollas en 24 horas (contraindicada en mujeres con hipertensión).  \\nSe recomienda utilizar misoprostol 800 \\nmcg por vía sublingual solo si no se cuenta \\ncon oxitocina o maleato de metilergono -\\nvina para el manejo de la hemorragia pos -\\nparto.  \\nEl ácido tranexámico en dosis de 1 g por vía \\nIV se puede ofrecer como un tratamiento \\npara la hemorragia posparto si: la admi -nistración de la oxitocina seguida de las \\nopciones de tratamiento de segunda línea y el misoprostol no han logrado detener la hemorragia; o como complemento a la sutura de traumatismos del canal del par -\\nto identificados como causa del sangrado (desgarros del canal del parto).  \\nNo se recomienda el uso de carboprost para \\nel tratamiento de las mujeres con hemo -\\nrragia posparto.\\nUna revisión sistemática de 3 ECC con 462 pacien -\\ntes evaluó diferentes medidas para el tratamiento \\nde la hemorragia posparto con misoprostol (63). Dos ensayos compararon misoprostol 600 mcg y \\n1.000 mcg frente a placebo. El uso del misopros -\\ntol no se asoció con una reducción significativa \\nen la mortalidad materna (RR = 7,24; IC 95%: 0,38-138,6), la indicación de histerectomía (RR = 1,24; IC 95%: 0,04-40,78), el uso adicional de \\nuterotónicos (RR = 0,98; IC 95%: 0,78-1,24), la \\nnecesidad de transfusión de sangre (RR = 1,33; IC 95%: 0,81-2,18) y la evacuación de productos retenidos (RR = 5,17; IC 95%: 0,25-107). Un ensayo mostró mejor respuesta clínica al miso -\\nprostol rectal comparado con una combinación de syntometrina y oxitocina. No se encontraron ensayos con técnicas quirúrgicas, intervenciones radiológicas o drogas hemostáticas para manejo después de uterotónicos.\\nDos series de casos que incluyeron 263 pacientes \\nrelacionadas con la efectividad del carboprost fren -\\nte a otros agentes uterotónicos mostraron éxito en el control de la hemorragia posparto (64, 65).\\nUna revisión sistemática que incluyó 3 ECC con \\n122 pacientes evaluó el uso del misoprostol en el \\ntratamiento de la hemorragia posparto, así como su \\nvía y dosis óptima (66). Las vías de administración potenciales para el misoprostol incluyen la oral, la \\nsublingual, la rectal o una combinación de estas. \\nLa dosis por vía oral no puede exceder los 600 mcg por el riesgo de hiperpirexia. Un régimen de 200 √B\\nB\\nB\\nDD\\n1++\\n3\\n1+', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 13}), Document(page_content='439\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\nmcg oral más 200 a 400 mcg sublingual o rectal \\nparecieran ser buenas opciones. Para la pérdida de sangre de 500 mL o más, el riesgo relativo del misoprostol comparado con placebo fue 0,57 (IC \\n95%: 0,34-0,96).\\nUn ECC que incluyó 1.422 mujeres con parto por vía vaginal y diagnóstico de hemorragia posparto por atonía uterina evaluó la efectividad de 600 mcg de misoprostol en adición a la oxitocina compa -\\nrados con placebo (67). La proporción de mujeres con pérdidas de sangre superiores a los 500 mL o más en 60 min fue similar en ambos grupos (RR \\n= 1,02; IC 95%: 0,79-1,32). \\nDos ECC con 1.787 mujeres compararon el miso -\\nprostol en dosis de 800 mcg como medicamento de \\nprimera línea frente a la infusión de 40 UI de oxi -\\ntocina en el tratamiento de la hemorragia posparto (68, 69). En el primer estudio el sangrado fue con -\\ntrolado 20 min posterior al inicio del tratamiento \\nasignado en 363 mujeres del grupo de misoprostol \\ny 360 del grupo de oxitocina (RR = 0,99; IC 95%: 0,95-1,04). En el segundo ensayo se encontraron cifras de 440 mujeres del grupo de misoprostol y \\n468 mujeres del grupo de oxitocina para el mismo \\ndesenlace (RR = 0,94; IC 95%: 0,91-0,98).Un ECC que incluyó 144 mujeres en las que se administraron 4 g de ácido tranexámico en una hora y luego infusión de 1 g por hora por seis horas, \\ncomparado con placebo, evaluó este medicamento \\ncomo alternativa en el tratamiento de la hemorragia posparto (70). La pérdida de sangre fue menor en el grupo del ácido tranexámico (173 mL frente a \\n221 mL; p = 0,041).\\nUn ensayo clínico\\n en el que participaron 1.964 \\nmujeres con parto por vía vaginal evaluó el masaje uterino solo frente a la administración de 10 UI \\nde oxitocina por vía IM frente a la combinación de \\nambas intervenciones (71). La frecuencia de pér -\\ndida igual o superior a 300 mL de sangre fue mayor en el grupo de masaje solo frente a la combinación de masaje y oxitocina (RR = 1,88; IC 95%: 1,29-2,74) o con la oxitocina sola (RR = 1,71; IC 95%: \\n1,11-2,61).  El tratamiento debe estar acompañado por un \\nexamen clínico cuidadoso para comprobar que el \\nútero en efecto está atónico y que las otras fuentes \\nde sangrado, tales como traumas y laceraciones genitales o inversión uterina, han sido excluidas. \\nLa compresión uterina bimanual y el vaciamiento \\nde la vejiga para estimular la contracción uterina repre -\\nsentan la primera línea de manejo de la hemorragia posparto, así como la compresión de la aorta que, como \\nmedida temporal pero efectiva, permite lograr tiempo \\nen la resucitación con la reposición de volumen y en la elección del soporte quirúrgico apropiado. Aunque \\nno existen estudios publicados que provean evidencia \\npara estas intervenciones, el consenso de expertos de la guía del RCOG (6) y de la guía de la OMS (7), soportan la continuidad de su uso. \\nLa evidencia no muestra que la adición de \\nmisoprostol sea superior a la combinación de oxi -\\ntocina y ergometrina sola para el tratamiento de la hemorra  gia posparto primaria. La oxitocina es \\npreferida especialmente en mujeres con hiper -\\ntensión previa o preeclampsia. Los resultados de \\nensayos clínicos muestran que el uso de una dosis \\nde 800 mcg de misoprostol parece ser tan efectivo \\ncomo la oxitocina cuando se usa para detener el \\nsangrado posparto por sospecha de atonía uterina en mujeres que han recibido oxitocina profiláctica.\\nEl consenso de expertos de la guía del RCOG (6) \\nsugiere una dosis no mayor a 5 UI de oxitocina por vía intravenosa lenta, ya que tal recomendación está \\nen concordancia con las guías de otras organizacio -\\nnes. El GDG consideró importante adicionar una \\ninfusión de oxitocina que permita mejorar las con -\\ntracciones uterinas y así lograr disminuir la hemo -\\nrragia posparto. Por otra parte, no consideró útil la inclusión de una recomendación para apoyar el uso \\ndel carboprost como medicamento en el manejo de \\nla hemorragia posparto por atonía uterina debido a la ausencia de evidencia más consistente y de \\nmejor calidad, y por ser un medicamento que no \\nse consigue en el país.\\nEl GDG consideró importante incluir el ácido \\ntranexámico dentro de las recomendaciones, pero 1++\\n1++\\n1++\\n1++', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 14}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013440\\najustando la dosis y aclarando que solo se debe \\nusar cuando los demás agentes como la oxitocina, \\nla ergometrina y el misoprostol no hayan sido efectivos. Así mismo, por la ausencia de evidencia \\ndisponible, no se recomienda una segunda dosis de \\nácido tranexámico. Se requieren más estudios para aclarar la efectividad del masaje en el escenario de la hemorragia posparto.\\n10. ¿cuáles son las intervenciones más \\nefectivas para el control de la hemorragia \\nposparto por atonía uterina sin respuesta  \\nal manejo médico?\\nSe recomienda iniciar medidas de hemos -\\ntasia quirúrgica lo más pronto posible, si \\nel manejo inicial falla. Se recomienda que \\neste tiempo no supere nunca los 20 min.\\nSe recomienda el taponamiento uterino \\ncon balón hidrostático (incluye condón), como la primera opción quirúrgica para las mujeres con atonía uterina. \\nSe recomienda administrar dosis única \\nparenteral de cefalosporina de primera ge -\\nneración inmediatamente antes de insertar el balón. \\nEn caso de alergia documentada a los be -\\ntalactámicos, se recomienda administrar \\nclindamicina más gentamicina en dosis única.  \\nSe recomienda dejar una infusión de oxi -\\ntocina de 30 UI diluidas en 500 mL de cristaloides para pasar en 4 horas. \\nSe recomienda dejar el balón por un tiempo \\nmáximo de 24 horas y retirar en sitio donde se cuente con recurso humano calificado, hemoderivados y quirófano.  \\nNo se recomienda realizar taponamiento uterino con gasa. Se recomienda aplicar las siguientes me -\\ndidas quirúrgicas conservadoras depen -\\ndiendo de las circunstancias clínicas y la experticia de quien atiende a la mujer: \\n•\\tSuturas\\themostáticas\\tuterinas\\t(B-Lynch\\t\\no sutura compresiva modificada).\\n•\\tLigadura\\tbilateral\\tde\\tarterias\\tuterinas.\\n•\\tLigadura\\tbilateral\\tde\\tarterias\\tiliacas\\tin-\\nternas. \\n•\\tEmbolización\\tarterial\\tselectiva.\\t\\t\\nSe recomienda recurrir a la histerectomía \\nprontamente cuando las medidas anterio -\\nres fallen o las circunstancias clínicas lo indiquen desde el inicio (ejemplo: estallido uterino).\\nCinco series de casos que incluyen entre uno a 16 \\npacientes han reportado el uso de sonda Foley, el balón de Bakri, el catéter esofágico Sengstaken-Blakemore y el condón como taponamientos \\nefectivos en el manejo de la hemorragia posparto \\npor atonía uterina que no responde al tratamien -\\nto médico (72-76). En las cinco series de casos se reportaron como exitosos los taponamientos para \\nel control de la hemorragia posparto por atonía \\nuterina.Una serie de casos con cinco pacientes reportó éxito en el manejo de la hemorragia posparto con \\nsuturas compresivas a través de la técnica de B-\\nLynch (77).Una serie de casos que incluye tres pacientes re -\\nportó éxito en el manejo de hemorragia posparto con la técnica de B-Lynch (78).Tres series de casos que han incluido entre tres \\ny 14 mujeres con hemorragia posparto por ato -\\nnía uterina reportaron la efectividad en todos los \\ncasos manejados con diferentes tipos de suturas \\ncompresivas (79-81).\\nUna serie de casos describió 110 mujeres con he -\\nmorragia posparto de varias causas a quienes se les \\nrealizó ligadura de la arteria iliaca interna como √C\\n√\\n√C\\n√\\nCC\\nC\\n3\\n3\\n3\\n3\\n3', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 15}), Document(page_content='441\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\nprimera línea de intervención quirúrgica; 88 mu -\\njeres fueron sometidas a la ligadura de la arteria \\niliaca interna de forma terapéutica, el 39% de las cuales requirieron histerectomía (82).\\nUna serie de casos de 100 mujeres reportó un \\nporcentaje de éxito del 90% con la embolización arterial selectiva para la hemorragia obstétrica (83). Cuatro series de casos subsecuentes han reportado éxito en 1 de 1, 4 de 4,\\n 10 de 10 y 26 de 29 mujeres \\nque han sido sometidas a esta intervención (84-86).\\nUna revisión sistemática que incluyó 46 estudios \\nobservacionales o series de casos con 664 pacien -\\ntes evaluó los porcentajes de éxito de cada uno de los procedimientos quirúrgicos para el manejo \\nde la hemorragia posparto (87). Los resultados \\nacumulados no mostraron diferencias entre los porcentajes de la embolización arterial (90,7%), el taponamiento (84%), las suturas uterinas com -\\npresivas (91,7%) y la ligadura de arteria iliaca o \\ndesvascularización uterina (84,6%). \\nEl uso de agentes farmacológicos no debe \\nretrasar el recurso quirúrgico en los casos de he -\\nmorragia por atonía uterina. Una vez se toma la \\ndecisión, la elección del procedimiento depende \\nde la experiencia y la experticia del equipo de \\nprofesionales disponibles. Es importante tener en cuenta las aspiraciones reproductivas futuras de la mujer en la decisión de la secuencia apropiada de \\nintervenciones. Las técnicas quirúrgicas tales como \\nel taponamiento uterino y las suturas hemostáticas \\npueden detener el sangrado de forma inmediata \\ny facilitar una pronta decisión con respecto a la necesidad de la histerectomía. La técnica B-Lynch \\ncomo alternativa al manejo de la hemorragia pos -\\nparto es invaluable y puede proveer un primer paso \\nquirúrgico para detener la hemorragia cuando las \\nmedidas con oxitócicos han fallado.\\nEl GDG consideró importante incluir el ma -\\nnejo antibiótico cuando se utiliza el taponamiento \\nuterino con balón para el control de la hemorragia \\nposparto bajo los mismos preceptos formulados \\nen la revisión de la cavidad uterina y la extracción manual de la placenta. En relación con el tiempo durante el cual se debe dejar el balón, se consideró \\nque un máximo de 24 horas puede ser adecuado \\nen ausencia de evidencia clara sobre este tópico. La histerectomía no se debe retrasar hasta que la mujer esté in extremis o mientras se intentan pro -\\ncedimientos menos definitivos si el obstetra tiene menos experiencia en ellos.\\n11. ¿cuál es el mejor tipo de histerectomía \\nindicada para el manejo de la hemorragia posparto?\\nSe recomienda que el obstetra, de acuer -\\ndo con su experticia, la condición clínica \\nparticular de cada mujer y las condiciones técnicas del sitio operatorio, defina el tipo de histerectomía que va a realizar.\\nUna revisión sistemática de 24 series de casos, que \\nincluyó 981 mujeres en quienes se realizó histerec -\\ntomía posparto de emergencia, encontró que la his -\\nterectomía total fue más común en las mujeres que tenían adherencia anormal de la placenta (88). La morbilidad materna reportada en cuatro estudios no mostró diferencias significativas entre la histe -\\nrectomía subtotal (16 de 98) y total (15 de 49) (Z = 1,74; p = 0,08). El daño del tracto urinario fue la complicación más frecuente cuando se realizó histerectomía total comparada con subtotal, pero esta diferencia no fue estadísticamente significativa \\n(16 frente a 30%; p > 0,05).\\nLa técnica subtotal de histerectomía es la cirugía \\nde elección en muchos casos; hay menos trauma \\nen el cérvix y en el segmento inferior. Aunque no \\nse encuentra diferencia en la morbilidad materna entre la histerectomía total y subtotal, el daño del \\ntracto urinario fue la complicación reportada con \\nmás frecuencia cuando se realizó histerectomía total comparada con la subtotal. Se considera que \\nla experticia del clínico cobra relevancia en esta \\nintervención, ya que ante una hemorragia y un útero 3\\n2+\\nD\\n2+', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 16}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013442\\naumentado de tamaño, la probabilidad de que una \\nhisterectomía sea total o subtotal dependerá de \\notros factores adicionales.\\n12. ¿cuáles son las intervenciones más \\nefectivas para el control de la hemorragia posparto por acretismo placentario?\\nSi la placenta no se separa con las medi -\\ndas habituales, se recomienda no intentar \\nsepararla y remitir a una institución con \\ncapacidad resolutiva. El manejo médico o \\nla histerectomía con placenta in situ  están \\nasociados con menor pérdida sanguínea \\nque la separación.\\nSi la placenta se separa parcialmente se re -\\ncomienda que la porción desprendida sea \\nextraída, y la hemorragia que se presente sea manejada de acuerdo con las recomen -\\ndaciones planteadas. Las porciones que no se desprenden pueden ser dejadas en su lugar, pero la pérdida de sangre en tales circunstancias puede ser mayor y requiere el manejo de una hemorragia masiva de manera oportuna.\\nEn una serie de casos que incluyó 167 mujeres con \\nplacenta acreta en manejo expectante (definido como dejar la placenta parcial o totalmente en su sitio, sin intento de removerla a la fuerza) se reportó \\néxito en 131 mujeres referente a la prevención del \\nsangrado y a la realización de una histerectomía (49). A 18 mujeres se le realizó histerectomía y a otras 18 se les pudo retrasar este procedimiento \\npor unas horas. La resorción espontánea de la \\nplacenta ocurrió en 87 casos y el promedio de tiempo desde el parto hasta la resorción fue  \\nde 13,5 semanas.Dos series de casos que incluyeron 37 mujeres con \\nplacenta acreta que tuvieron cesárea reportan otros \\nprocedimientos como la ligadura, las suturas y la oclusión en el manejo de la hemorragia posparto por acretismo placentario (48, 89). Los resultados de estos procedimientos han sido positivos en la reducción de la pérdida de sangre (2.011 mL frente \\na 3.316 mL; p = 0,042) y en la media del volumen \\nde sangre transfundida (1.058 mL frente a 2.211 \\nmL; p = 0,005). \\nEl GDG consideró importante la opción de rea -\\nlizar ligadura bilateral de la arteria uterina, seguida \\nde una sutura de B-Lynch en mujeres con acretismo \\nplacentario que desean preservar su fertilidad. De igual forma, la opción de realizar oclusión perio -\\nperatoria de la arteria iliaca interna, si se cuenta con el recurso para realizarla, puede ser adecuada. Como punto importante, no se debe intentar tratar \\na estas pacientes en instituciones que no cuenten \\ncon recurso humano y tecnológico suficiente para manejar las complicaciones.\\nAsí mismo, se consideró como punto funda -\\nmental no intentar separar la placenta en lugares o instituciones donde no se cuente con personal y \\nequipos necesarios y suficientes para atender el caso. \\nPor tanto, una remisión oportuna a una institución de mayor complejidad donde se pueda realizar la \\nextracción de la placenta y al mismo tiempo el \\nmanejo de la hemorragia, es vital para disminuir los riesgos de morbilidad y mortalidad.\\n13. ¿cuál es la intervención más efectiva \\npara el manejo de la hemorragia obstétrica \\npor abrupcio de placenta?\\nSe recomienda que el manejo de la hemo -\\nrragia obstétrica por abrupcio de placenta \\nse realice en un nivel de alta complejidad, búsqueda y tratamiento activo de la coa -\\ngulopatía (considerar protocolo de trans -\\nfusión masiva) y soporte vital avanzado. \\nUna revisión sistemática de estudios de interven -\\nción no identificó ningún ECC para el manejo del \\nabrupcio de placenta (90).D\\nD\\n3\\n3√\\n1++', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 17}), Document(page_content='443\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\nUna serie de casos con 59 pacientes evalúo el \\nmanejo selectivo de las pacientes con abrupcio de placenta y determinó que la sobrevida neonatal se logra con una adecuada cesárea y con un peso fetal \\nmínimo de 1.500 g (91). \\nLa escasa evidencia actualizada y de calidad sobre \\nel manejo de la hemorragia por abrupcio de placenta \\nlleva a considerar intervenciones muy generales y \\nque indiscutiblemente van a estar supeditadas a la situación específica de cada mujer que presente \\nel evento. El GDG consideró que en mujeres con \\nabrupcio y feto muerto se debe evitar al máximo realizar una cesárea y se debe insistir en parto \\nvaginal, simultáneamente con el manejo integral \\nde la situación. \\n14. ¿cuáles son las recomendaciones \\ngenerales para el uso de hemoderivados en el tratamiento de la mujer con hemorragia \\nobstétrica?\\nSe recomienda realizar pruebas cruzadas \\nen hemorragia posparto.\\nEn los casos en que las pruebas cruzadas \\nno estén disponibles, se recomienda ini -\\nciar con sangre tipo O negativo o sangre específica sin pruebas cruzadas hasta que la sangre específica con pruebas cruzadas esté disponible.\\nSe recomienda, en caso de choque hemo -\\nrrágico grave, abrupcio de placenta con \\nfeto muerto o coagulopatía intravascular diseminada (CID) clínicamente evidente, aplicar un protocolo de transfusión masiva para servicios obstétricos.\\nEn aquellos sitios que tengan disponibili -\\ndad se recomienda reponer glóbulos rojos, \\nplasma fresco congelado y plaquetas en una \\nrelación 1:1:1.  \\nEn los sitios con limitación de recursos se \\npueden reponer glóbulos rojos y plasma \\nfresco congelado en una relación 1,5:1. Se recomienda administrar concentrado de \\nplaquetas si el conteo es menor de 50.000.\\nSe recomienda administrar crioprecipitado \\nsi el fibrinógeno es menor de 1 g/L. \\nNo se recomienda utilizar algún filtro \\nespecial de sangre porque disminuye la \\nvelocidad de infusión. \\nNo existe evidencia en hemorragia obsté -\\ntrica para recomendar o rechazar el uso de \\nfactor VII recombinante.\\nUna serie de casos que incluyó 27 pacientes some -\\ntidas a cesárea evaluó el efecto de la autotransfusión \\na través de un proceso denominado rescate celular intraoperatorio, mediante el cual la sangre perdida \\ndurante una cirugía es recolectada, filtrada y lim -\\npiada a fin de producir glóbulos rojos autólogos \\npara transfundir al paciente (92). En el proceso se retiraron de forma efectiva sustancias como alfaproteína y líquido amniótico de 23 pacientes. \\nEste procedimiento está siendo usado comúnmente \\nen cirugía cardiaca, ortopédica y vascular con  \\nuna reducción relativa de transfusión del 39% y una reducción del riesgo absoluto del 23%, sin aparente impacto adverso en desenlaces clínicos.\\nUna revisión sistemática que incluyó 45 estudios \\nobservacionales realizados en pacientes críticamen -\\nte enfermos evaluó la eficacia de la transfusión de glóbulos rojos para 272.596 pacientes (93). Los resultados de la revisión indican que la transfusión \\nde glóbulos rojos se asoció con mortalidad (OR = \\n1,7; IC 95%: 1,4-1,9). La infección nosocomial se asoció con la transfusión de glóbulos rojos en nueve estudios (OR = 1,8; IC 95%: 1,5-2,2).\\nUna revisión sistemática que incluyó 25 ensayos \\nclínicos con 3.503 pacientes sin hemofilia evaluó \\nla efectividad en el uso del factor VIIa para la pro -\\nfilaxis y el tratamiento de la hemorragia (94). No \\nse encontraron diferencias en términos de morta -\\nlidad con el uso profiláctico del factor VIIa (RR = 1,06; IC 95%: 0,5-2,24), pero hubo disminución en la pérdida promedio de sangre (DM = -243 mL; IC 95%: -399 a -146 mL). No hubo diferencias en 3\\nC\\nC\\n√\\n√\\n√C\\nC\\nC\\nB\\n3\\n2+\\n1++', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 18}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013444\\nel uso del factor VIIa en el número de pacientes \\ntransfundidos (RR = 0,91; IC 95%: 0,81-1,02), como tampoco en el número de eventos adversos tromboembólicos (RR = 1,32; IC 95%: 0,84-\\n2,06). Respecto al uso terapéutico del factor VIIa \\nno se encontraron diferencias para los desenlaces evaluados. No hubo diferencias en la reducción de la mortalidad (RR = 0,89; IC 95%: 0,77-1,03), ni en los eventos adversos tromboembólicos (RR = \\n1,21; IC 95%: 0,93-1,58). \\nOtra revisión sistemática de intervenciones no encon -\\ntró ensayos clínicos acerca del uso de intervenciones \\nhematológicas para tratar la coagulación intravascular \\ndiseminada en el embarazo y en el posparto como una \\nde las complicaciones más frecuentes en los eventos \\nde hemorragia obstétrica (95). \\nSi las pruebas cruzadas no están disponibles se \\ndebe brindar la mejor alternativa para restaurar la \\ncapacidad de transporte de oxígeno. La sangre tipo \\nO negativo puede ser el camino más seguro para evitar una incompatibilidad transfusional. Cuando \\nla pérdida de sangre alcance alrededor de los 4,5 \\nlitros y se hayan administrado grandes volúmenes de cristaloides, habrá defectos en los factores de coa -\\ngulación de la sangre y se tendrán que administrar algunos hemoderivados. \\nEl GDG consideró que la reposición de volumen \\ncon hemoderivados para mejorar la capacidad de transporte de oxígeno y corregir los problemas de coagulación debe hacerse en una relación 1:1:1. \\nEn instituciones donde la disponibilidad de he -\\nmoderivados no es muy amplia puede hacerse una \\nreposición en una relación de 1,5 a 1.\\n15. ¿cuál es la indicación más efectiva \\npara transfundir en ausencia de sangre O \\nnegativo? \\nEn ausencia de glóbulos rojos O negativo se \\nrecomienda iniciar con glóbulos rojos “O” positivo.  Una serie de casos que incluyó 4.241 pacientes \\nevaluó desenlaces como muerte y necesidad de transfusión masiva con la transfusión de glóbulos \\nrojos (96). Solo 1.236 pacientes los recibieron sin \\npruebas cruzadas. En este grupo de pacientes hubo un incremento en la mortalidad (OR = 2,15; IC \\n95%: 1,58-2,94) y en la necesidad de transfusión \\nmasiva (OR = 11,87; IC 95%: 8,43-16,7), pero los \\ngrupos de comparación diferían en sus condiciones \\nbasales, como edad y presencia de complicaciones.Una revisión de casos que incluyó 119 pacientes \\nevaluó los resultados de la transfusión de 568 \\nunidades de glóbulos rojos tipo “O” positivo sin pruebas cruzadas en la resucitación de pacientes con trauma (97). No se presentó ninguna reacción hemolítica aguda o sensibilización en mujeres jóve -\\nnes. Dentro de las 24 horas del ingreso fallecieron \\n38 pacientes, pero ninguna muerte fue atribuible a \\nreacción transfusional o incompatibilidad sanguí -\\nnea. Las complicaciones incluyeron arritmias (2 casos), SDRA (4 casos) y CID (7 casos). Ninguno \\nde los casos de CID se relacionó con incompati -\\nbilidad transfusional.\\nEn una serie de casos que incluyó 153 pacientes con trauma sometidos a transfusión de glóbulos rojos sin pruebas cruzadas (98), la tasa de mortalidad \\ngeneral fue de 45%, la cual se incrementó a 52 y \\n100% en pacientes que recibieron cuatro y cinco más unidades de glóbulos rojos, respectivamente. \\nAunque no todos los estudios relacionan las uni -\\ndades transfundidas con los desenlaces presentados, \\nparece claro que a pesar de brindar una seguridad \\nrelativa, la transfusión de glóbulos rojos sin pruebas cruzadas y de sangre tipo “O” positivo en ausencia \\nde sangre tipo “O” negativo se debe limitar y con -\\nsiderar en cada caso específico.1++\\nC3\\n3\\n3', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 19}), Document(page_content='445\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\n16. ¿cuáles son los aspectos logísticos para \\ntener en cuenta en el manejo del choque \\nhipovolémico por causa obstétrica? \\nSe recomienda que las instituciones de \\nsalud que atienden partos cuenten con un protocolo o guía para el manejo de la he -\\nmorragia posparto.\\nSe recomienda que las instituciones de sa -\\nlud de primer y segundo nivel que atienden \\npartos cuenten con un protocolo formal para la referencia de las mujeres a un nivel de mayor complejidad.\\nUn estudio antes y después acerca de la implemen -\\ntación de un sistema de auditoría en el manejo de \\nlas mujeres con hemorragia posparto encontró un aumento en la calidad de la adherencia a tres \\nestándares: tipificación y realización de pruebas \\ncruzadas, establecimiento de la hemoglobina y el hematocrito y el diligenciamiento del registro de ingesta y eliminación de líquidos (99). No hubo \\ncambios significativos en el seguimiento estrecho \\nde signos vitales, casos de mortalidad, acceso venoso, administración de fluidos y oxitócicos admi  nistrados.\\nEl consenso de expertos de la Guía para el \\nma nejo de la hemorragia posparto y la placenta \\nrete nida de la OMS (53) considera que la imple -\\nmentación de un protocolo formal es un proceso \\ncomplejo que requiere adaptaciones locales.\\n17. ¿cuál es la estrategia más efectiva \\npara mejorar las habilidades del personal \\nde salud en el manejo de la hemorragia \\nobstétrica?\\nSe recomienda entrenamiento en el ma -\\nnejo de la hemorragia posparto a todo el \\npersonal que atiende partos.Se recomienda que el entrenamiento para \\nel manejo de la hemorragia posparto se haga bajo la estrategia de simulación. A\\nUn ECC que incluyó 106 unidades de maternidad \\nen Francia evalúo la efectividad de una intervención combinada de educación, visitas periódicas, grupos \\nde discusión, recordatorios y revisiones con pares \\ncomparada con la difusión pasiva del protocolo de manejo en la incidencia de hemorragia pospar -\\nto (100). El porcentaje de hemorragia posparto fue 1,64% en las unidades intervenidas frente a 1,65% en las unidades de control, por lo que no se encontraron diferencias significativas. Algunos \\nelementos del manejo de la hemorragia posparto \\nfueron aplicados más frecuentemente en las uni -\\ndades con la intervención, como la ayuda de un grupo de expertos, o la tendencia a una segunda \\nlínea de tratamiento farmacológico y el análisis de \\nsangre a tiempo. Un ECC que incluyó 36 profesionales de la salud evaluó la enseñanza basada en lectura comparada con la enseñanza basada en simulación o la combi -\\nnación de ambas para el manejo de la hemorragia \\nposparto (101). Todos los equipos mejoraron en \\nsu desempeño y conocimiento. El equipo en el que se usó solo simulación fue el único grupo que demostró mejoramiento sostenido en el manejo clínico del caso, confidencia, habilidades de co -\\nmunicación y conocimiento. Este mismo grupo reportó habilidades transferibles y menos ansiedad en emergencias subsecuentes. Una revisión sistemática que incluyó 609 estudios \\ny 35.226 personas de diversas áreas de la salud \\ncomparó el entrenamiento basado en la simulación contra ninguna intervención. En comparación con la no intervención el entrenamiento por simulación se asoció con el conocimiento (RR = 1,20; IC 95%: \\n1,04-1,35), las habilidades de manejo del tiempo \\n(RR = 1,14; IC 95%: 1,03-1,25), las habilidades de proceso (RR = 1,09; IC 95%: 1,03-1,16), las habilidades del producto (RR = 1,18; IC 95%: D\\nD\\n3\\nAA\\n(á)\\n1+\\n1+\\n1++', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 20}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013446\\n0,98-1,37), los comportamientos del tiempo (RR \\n= 0,79; IC 95%: 0,47-1,10), otros comportamien -\\ntos (RR = 0,81; IC 95%: 0,66-0,96) y con efectos directos sobre los pacientes (RR = 0,50; IC 95%: \\n0,34-0,66) (102).  \\nAunque se requieren más estudios que permi -\\ntan mostrar cambios positivos en la incidencia de \\ncomplicaciones y de mortalidad a través del mejo -\\nramiento de habilidades técnicas, comunicacionales \\ny del conocimiento, es claro que el camino hacia \\neste propósito es el entrenamiento en escenarios de \\nsimulación y un acompañamiento continuo para el mantenimiento de las habilidades adquiridas.\\ndecLARAcIón de \\nconFLIctos de InteRÉs\\nEl trabajo científico de investigación, así como la \\nelaboración de las recomendaciones incluidas en el \\npresente documento, fueron realizados de manera \\nindependiente por el Grupo Desarrollador de Guías (GDG) de la Universidad Nacional de Colombia. \\nTodos los miembros del GDG, así como las perso -\\nnas que han participado tanto en la colaboración \\nexperta como en la revisión externa, realizaron \\ndeclaración de conflictos de interés previo a su \\nparticipación. Esta Guía se publica con el permisodel Ministerio de Salud y Protección Social y el \\nDepartamento de Ciencia, Tecnología e Innovación\\n(Colciencias). ISBN 978-958-57937-4-3.\\nActuALIZAcIón de LA GuÍA\\nLas recomendaciones de esta Guía deben actualizar -\\nse en los próximos tres años a partir de su expedi -\\nción, o previamente en caso de disponer de nuevas evidencias que modifiquen de manera significativa las recomendaciones aquí anotadas.\\nFuentes de FInAncIAcIón\\nMinisterio de Salud y Protección Social de Co -\\nlombia - Departamento de Ciencia, Tecnología e \\nInnovación (Colciencias).RepResent Antes deL  GRupo \\ndesARRoLLAdoR de LA  GuÍA  \\n- unIveRsIdAd nAcIonAL  de \\ncoLombIA  - ALIAnZA   \\ncInets  \\nJoaquín Guillermo Gómez Dávila MD, MSc. Médico cirujano. \\nEspecialista en Obstetricia y Ginecología. Magíster en Epide -\\nmiología. Director Centro NACER. Docente, Universidad de Antioquia.\\nJhon Henry Osorio Castaño, Enf. MSc. Coordinador Epidemio -\\nlogía Clínica de la subguía. Enfermero. Especialista en Gerencia \\nde IPS. Magíster en Epidemiología.Gladis Adriana Vélez Álvarez, MD, MSP. Médica cirujana. Especialista en Obstetricia y Ginecología. Magíster en Salud \\nPública. Coordinadora Área Salud Sexual y Reproductiva, \\nNACER-Universidad de Antioquia.John Jairo Zuleta Tobón MD, MSc. Médico cirujano. Especia -\\nlista en Obstetricia y Ginecología. Magíster en Epidemiología. Docente, Universidad de Antioquia, NACER.Juan Guillermo Londoño Cardona, MD. Médico cirujano. Es -\\npecialista en Obstetricia y Ginecología. Coordinador del Área \\nde Educación, NACER-Universidad de Antioquia. \\nJesús Arnulfo Velásquez Penagos, MD. Médico cirujano. Espe -\\ncialista en Obstetricia y Ginecología. Fellow en Cuidado Crítico Obstétrico. Coordinador de Mortalidad Materna-NACER. \\nDocente, Universidad de Antioquia\\nIngrid Arévalo-Rodríguez MSc, PhD (c). Epidemióloga clíni -\\nca, Universidad Nacional de Colombia. PhD (c) en Pediatría, \\nObstetricia y Ginecología, Medicina Preventiva y Salud Pública, Universidad Autónoma de Barcelona. Coordinadora General de Epidemiología Clínica de la Guía. Instructor asociado División \\nde Investigaciones, Fundación Universitaria de Ciencias de la \\nSalud, Hospital de San José-Hospital Infantil de San José.\\nPio Iván Gómez-Sánchez, MD, MSc, FACOG. Médico cirujano. \\nEspecialista en Obstetricia y Ginecología, y Epidemiología. Magíster en Salud Sexual y Reproductiva. Profesor Titular y Director del Grupo de Investigación en Salud Sexual y Repro -\\nductiva de la Facultad de Medicina, Universidad Nacional de \\nColombia. Líder general de la GPC.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 21}), Document(page_content='447\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\nReconocImIento \\nA InstItucIones pARtIcIp Antes \\nLas siguientes instituciones participaron en los consensos de \\nexpertos o reuniones de socialización de la GPC para la pre  ven-\\nción, detección temprana y tratamiento de las complica  ciones \\ndel embarazo, parto o puerperio:  Federación Colombiana  \\nde Obstetricia y Ginecología ( Fecolsog ), Sociedad Colombiana \\nde Anestesiología y Reanimación ( scare), Asociación Colombiana  \\nde Facultades de Medicina ( ascoFame), Asociación Colombiana \\nde Facultades de Enfermería ( acoFaen), Asociación Colombiana \\nde Empresas de Medicina Integral ( acemi), Academia Nacional \\nde Medicina, Colegio Médico Colombiano, Asociación Colom-\\nbiana de Hospitales y Clínicas, Instituto Nacional de Salud, Cafam IPS, Centro Médico Imbanaco, Clínica de Occidente, \\nClínica de la Mujer, Clínica del Norte, Clínica Materno Infan -\\ntil Farallones, Clínica el Rosario, Clínica El Prado, Fundación \\nCardioinfantil, Fundación Valle de Lili, Fundación Santafé de Bogotá, Hospital Militar, Hospital San José, Hospital Simón Bolívar, Fundación Universitaria de Ciencias de la Salud, Uni -\\nversidad de Antioquia, Universidad del Quindío, Universidad \\nLibre, Universidad Surcolombiana, Comfama, Metrosalud.\\nReFeRencIAs\\n1. WHO U, UNFPA, Bank. W . T rends in Maternal Mortality: \\n1990-2008: WHO Library Cataloguing-in-Publication \\nData; [2010 Jan 2012]. Disponible: http://whqlibdoc.\\nwho.int/publications/2010/9789241500265_eng.pdf.\\n2. Carroli G, Cuesta C, Abalos E, Gulmezoglu AM. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008;22:999-1012. Epub 2008/09/30.\\n3. Alcaldía de Medellín. Salud sexual y reproductiva, Universidad de Antioquia. Informe final de la vigilancia epidemiológica de la Morbilidad Obstétrica Severa en la ciudad de Medellín. Medellín: Secretaría de Salud, \\nDirección de Salud Pública. Nacer Salud sexual y \\nreproductiva, Universidad de Antioquia; 2008.\\n4. Lalonde A, Daviss BA, Acosta A, Herschderfer K. Postpartum hemorrhage today: ICM/FIGO initiative 2004-2006. Int J Gynaecol Obstet. 2006;94:243-53. Epub 2006/07/18.5. Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetric morbidity: case-control study. BMJ. 2001;322:1089-93. Epub 2001/05/05.\\n6. Royal College of Obstetricians and Gynaecologists. Prevention and Management of Postpartum Haemorrhage. London; 2009 [Visitado 2011 \\nJun 1]. Disponible en: http://www.rcog.org.uk/\\nwomens-health/clinical-guidance/prevention-and-\\nmanagement-postpartum-haemorrhage-green-\\ntop-52.\\n7. World Health Organization. WHO guidelines for the \\nmanagement of postpartum haemorrhage and retained \\nplacenta. Geneve: WHO Press; 2009 [Visitado 2011 Jun 1]. Disponible en: http://whqlibdoc.who.int/publications/2009/9789241598514_eng.pdf.\\n8. Ministerio de Salud y Protección Social, Colciencias. Guía de práctica clínica para la prevención, detección \\ntemprana y tratamiento de las complicaciones del \\nembarazo, parto o puerperio. Versión completa. Bogotá: Alianza CINETS; 2013. ISBN: 978-958-57937-4-3. Disponible en: http://www.guiascol \\ncienciasminproteccionsocialalianzacinets.org/index.\\nphp?option=com_wrapper&view=wrapper&Itemid=552.\\n9. Ministerio de Salud y Protección Social, Colciencias. Guía de práctica clínica para la prevención, detección \\ntemprana y tratamiento de las complicaciones \\ndel embarazo, parto o puerperio. Version para pacientes. Bogotá: Alianza Cinets; 2013. ISBN: 978-958-8838-07-6. Disponible en: h ttp://www.\\nguiascolcienciasminproteccionsocialalianzacinets.org/index.php?option=com_wrapper&view=wrapper&I\\ntemid=552 .\\n10. Prendiville WJ, Elbourne D, McDonald S. Active versus \\nexpectant management in the third stage of labour. Cochrane Database Syst Rev. 2000(3):CD000007. \\nEpub 2000/07/25.\\n11. Begley CM, Gyte GM, Devane D, McGuire W , Weeks \\nA. Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev. 2011(11):CD007412. Epub 2011/11/11.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 22}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013448\\n12. Elbourne DR, Prendiville WJ, Carroli G, Wood J, \\nMcDonald S. Prophylactic use of oxytocin in the third stage of labour. Cochrane Database Syst Rev. 2001(4):CD001808. Epub 2001/11/01.\\n13. Soltani H, Hutchon DR, Poulose TA. Timing of prophylactic uterotonics for the third stage of labour after vaginal birth. Cochrane Database Syst Rev. 2010(8):CD006173. Epub 2010/08/06.\\n14. McDonald S, Abbott JM, Higgins SP . Prophylactic \\nergometrine-oxytocin versus oxytocin for the \\nthird stage of labour. Cochrane Database Syst Rev. 2004(1):CD000201. Epub 2004/02/20.\\n15. Gulmezoglu AM, Forna F, Villar J, Hofmeyr \\nGJ. Prostaglandins for preventing postpartum \\nhaemorrhage. Cochrane Database Syst Rev. 2007(3): \\nCD000494. Epub 2007/07/20.\\n16. Alfirevic Z, Blum J, Walraven G, Weeks A, Winikoff B. Prevention of postpartum hemorrhage with \\nmisoprostol. Int J Gynaecol Obstet. 2007;99 Suppl \\n2:S198-201. Epub 2007/10/27.\\n17. Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam QM. Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database Syst Rev. \\n2007(2):CD005456. Epub 2007/04/20.\\n18. Novikova N, Hofmeyr GJ. T ranexamic acid for \\npreventing postpartum haemorrhage. Cochrane Database Syst Rev. 2010(7):CD007872. Epub \\n2010/07/09.\\n19. Peters NC, Duvekot JJ. Carbetocin for the prevention \\nof postpartum hemorrhage: a systematic review. Obstet Gynecol Surv. 2009;64:129-35. Epub 2009/01/23.\\n20. Mathew JL. Timing of umbilical cord clamping in \\nterm and preterm deliveries and infant and maternal \\noutcomes: a systematic review of randomized controlled trials. Indian Pediatr. 2011;48:123-9. Epub 2011/03/08.\\n21. McDonald SJ, Middleton P . Effect of timing of \\numbilical cord clamping of term infants on maternal \\nand neonatal outcomes. Cochrane Database Syst Rev. \\n2008(2):CD004074. Epub 2008/04/22.\\n22. Hofmeyr GJ, Abdel-Aleem H, Abdel-Aleem MA. Uterine massage for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2008(3): \\nCD006431. Epub 2008/07/23.\\n23. Dennehy KC, Rosaeg OP , Cicutti NJ, Krepski B, \\nSylvain JP . Oxytocin injection after caesarean delivery: \\nintravenous or intramyometrial? Can J Anaesth. \\n1998;45:635-9. Epub 1998/08/26.\\n24. Munn MB, Owen J, Vincent R, Wakefield M, Chestnut \\nDH, Hauth JC. Comparison of two oxytocin regimens \\nto prevent uterine atony at cesarean delivery: a \\nrandomized controlled trial. Obstet Gynecol. 2001;98:386-90. Epub 2001/09/01.\\n25. Lokugamage AU, Paine M, Bassaw-Balroop K, Sullivan KR, Refaey HE, Rodeck CH. Active management of the third stage at caesarean section: a randomised controlled trial of misoprostol versus syntocinon. Aust N Z J Obstet Gynaecol. 2001;41:411-4. Epub 2002/01/15.\\n26. Chou MM, MacKenzie IZ. A prospective, double-blind, randomized comparison of prophylactic intramyometrial 15-methyl prostaglandin F2 alpha, 125 micrograms, and intravenous oxytocin, 20 units, \\nfor the control of blood loss at elective cesarean \\nsection. Am J Obstet Gynecol. 1994;171:1356-60. Epub 1994/11/01.\\n27. George RB, McKeen D, Chaplin AC, McLeod L. Up-down determination of the ED(90) of oxytocin \\ninfusions for the prevention of postpartum uterine \\natony in parturients undergoing Cesarean delivery. Can J Anaesth. 2010;57:578-82. Epub 2010/03/20.\\n28. Svanstrom MC, Biber B, Hanes M, Johansson G, Naslund U, Balfors EM. Signs of myocardial ischaemia after injection of oxytocin: a randomized double-blind \\ncomparison of oxytocin and methylergometrine during \\nCaesarean section. Br J Anaesth. 2008;100:683-9. Epub 2008/04/04.\\n29. Butwick AJ, Coleman L, Cohen SE, Riley ET, \\nCarvalho B. Minimum effective bolus dose of oxytocin \\nduring elective Caesarean delivery. Br J Anaesth. 2010;104:338-43. Epub 2010/02/13.\\n30. Sheehan SR, Montgomery AA, Carey M, McAuliffe FM, Eogan M, Gleeson R, et al. Oxytocin bolus versus \\noxytocin bolus and infusion for control of blood loss ', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 23}), Document(page_content='449\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\nat elective caesarean section: double blind, placebo \\ncontrolled, randomised trial. BMJ. 2011;343:d4661. Epub 2011/08/03.\\n31. King KJ, Douglas MJ, Unger W , Wong A, King RA. \\nFive unit bolus oxytocin at cesarean delivery in \\nwomen at risk of atony: a randomized, double-blind, controlled trial. Anesth Analg. 2010;111:1460-6. Epub 2010/10/05.\\n32. Gungorduk K, Asicioglu O, Celikkol O, Olgac Y, Ark \\nC. Use of additional oxytocin to reduce blood loss at \\nelective caesarean section: A randomised control trial. Aust N Z J Obstet Gynaecol. 2010;50:36-9. Epub \\n2010/03/12.\\n33. McLeod G, Munishankar B, MacGregor H, Murphy DJ. Maternal haemodynamics at elective caesarean \\nsection: a randomised comparison of oxytocin 5-unit bolus and placebo infusion with oxytocin 5-unit bolus and 30-unit infusion. Int J Obstet Anesth. 2010;19:155-60. Epub 2010/03/03.\\n34. Quiroga R, Cantu R, T ello HE, Puente M, Montemayor R, Martinez A. [Intrauterine misoprostol for the prevention of bleeding cesarean]. Ginecol Obstet Mex. 2009;77:469-74. Epub 2009/11/12. \\n35. Chaudhuri P , Banerjee GB, Mandal A. Rectally administered misoprostol versus intravenous oxytocin infusion during cesarean delivery to reduce intraoperative and postoperative blood loss. Int J Gynaecol Obstet. 2010;109:25-9. Epub 2010/01/15.\\n36. Eftekhari N, Doroodian M, Lashkarizadeh R. The effect of sublingual misoprostol versus intravenous oxytocin in reducing bleeding after caesarean section. J Obstet Gynaecol. 2009;29:633-6. Epub 2009/09/17.\\n37. Sekhavat L, T abatabaii A, Dalili M, Farajkhoda T, T afti AD. Efficacy of tranexamic acid in reducing blood loss after cesarean section. J Matern Fetal Neonatal Med. 2009;22:72-5. Epub 2009/01/24.\\n38. Attilakos G, Psaroudakis D, Ash J, Buchanan R, Winter \\nC, Donald F, et al. Carbetocin versus oxytocin for the \\nprevention of postpartum haemorrhage following \\ncaesarean section: the results of a double-blind randomised trial. BJOG. 2010;117(8):929-36. Epub 2010/05/21.39. Borruto F, T reisser A, Comparetto C. Utilization of \\ncarbetocin for prevention of postpartum hemorrhage \\nafter cesarean section: a randomized clinical trial. Arch Gynecol Obstet. 2009;280:707-12. Epub \\n2009/02/21.\\n40. CRES. Informe Técnico 125: Efectividad, seguridad y análisis económico de la carbetocina versus la oxitocina \\npara la prevención de la atonía uterina y hemorragia \\nposparto; 2011.\\n41. Levine AB, Kuhlman K, Bonn J. Placenta accreta: \\ncomparison of cases managed with and without \\npelvic artery balloon catheters. J Matern Fetal Med. \\n1999;8:173-6. Epub 1999/07/16.\\n42. Alvarez M, Lockwood CJ, Ghidini A, Dottino P , Mitty HA, Berkowitz RL. Prophylactic and emergent arterial catheterization for selective embolization in obstetric hemorrhage. Am J Perinatol. 1992;9:441-4. Epub \\n1992/09/01.\\n43. Mitty HA, Sterling KM, Alvarez M, Gendler R. \\nObstetric hemorrhage: prophylactic and emergency arterial catheterization and embolotherapy. Radiology. \\n1993;188:183-7. Epub 1993/07/01.\\n44. Dubois J, Garel L, Grignon A, Lemay M, Leduc L. \\nPlacenta percreta: balloon occlusion and embolization of the internal iliac arteries to reduce intraoperative blood losses. Am J Obstet Gynecol. 1997;176:723-6. \\nEpub 1997/03/01.\\n45. Hansch E, Chitkara U, McAlpine J, El-Sayed Y, \\nDake MD, Razavi MK. Pelvic arterial embolization \\nfor control of obstetric hemorrhage: a five-year experience. Am J Obstet Gynecol. 1999;180(6 Pt 1):1454-60. Epub 1999/06/16.\\n46. Ojala K, Perala J, Kariniemi J, Ranta P , Raudaskoski T, T ekay A. Arterial embolization and prophylactic catheterization for the treatment for severe obstetric hemorrhage. Acta Obstet Gynecol Scand. \\n2005;84:1075-80. Epub 2005/10/20.\\n47. Bodner LJ, Nosher JL, Gribbin C, Siegel RL, Beale S, \\nScorza W . Balloon-assisted occlusion of the internal iliac arteries in patients with placenta accreta/percreta. Cardiovasc Intervent Radiol. 2006;29:354-61. Epub \\n2006/02/28.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 24}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013450\\n48. T an CH, T ay KH, Sheah K, Kwek K, Wong K, T an HK, \\net al. Perioperative endovascular internal iliac artery occlusion balloon placement in management of placenta accreta. AJR Am J Roentgenol. 2007;189:1158-63. \\nEpub 2007/10/24.\\n49. Sentilhes L, Ambroselli C, Kayem G, Provansal M, \\nFernandez H, Perrotin F, et al. Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol. 2010;115:526-34. Epub 2010/02/24.\\n50. van Beekhuizen HJ, de Groot AN, De Boo T, Burger D, Jansen N, Lotgering FK. Sulprostone reduces the need for the manual removal of the placenta in patients \\nwith retained placenta: a randomized controlled \\ntrial. Am J Obstet Gynecol. 2006;194:446-50. Epub \\n2006/02/07.\\n51. Nardin JM, Weeks A, Carroli G. Umbilical vein \\ninjection for management of retained placenta. Cochrane Database Syst Rev. 2011(5):CD001337. \\nEpub 2011/05/13.\\n52. Abdel-Aleem H, Abdel-Aleem MA, Shaaban OM. \\nT ocolysis for management of retained placenta. Cochrane Database Syst Rev. 2011(1):CD007708. Epub 2011/01/21.\\n53. Chongsomchai C, Lumbiganon P , Laopaiboon M. Prophylactic antibiotics for manual removal of retained placenta in vaginal birth. Cochrane Database Syst Rev. 2006(2):CD004904. Epub 2006/04/21.\\n54. Baskett PJ. ABC of major trauma. Management of hypovolaemic shock. BMJ. 1990;300:1453-7. Epub 1990/06/02.\\n55. Bose P , Regan F, Paterson-Brown S. Improving the accuracy of estimated blood loss at obstetric \\nhaemorrhage using clinical reconstructions. BJOG. \\n2006;113:919-24. Epub 2006/08/16.\\n56. Duthie SJ, Ven D, Yung GL, Guang DZ, Chan SY, Ma HK. Discrepancy between laboratory \\ndetermination and visual estimation of blood loss \\nduring normal delivery. Eur J Obstet Gynecol Reprod \\nBiol. 1991;38:119-24. Epub 1991/01/30.\\n57. Ho AM, Karmakar MK, Dion PW . Are we giving \\nenough coagulation factors during major trauma resuscitation? Am J Surg. 2005;190:479-84. Epub \\n2005/08/18.58. Hirshberg A, Dugas M, Banez EI, Scott BG, Wall MJ, Jr., Mattox KL. Minimizing dilutional coagulopathy in \\nexsanguinating hemorrhage: a computer simulation. J T rauma. 2003;54:454-63. Epub 2003/03/14.\\n59. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. \\nCochrane Injuries Group Albumin Reviewers. BMJ. \\n1998;317:235-40. Epub 1998/07/24.\\n60. Roberts I, Blackhall K, Alderson P , Bunn F, Schierhout G. \\nHuman albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database \\nSyst Rev. 2011(11):CD001208. Epub 2011/11/11.\\n61. Perel P , Roberts I. Colloids versus crystalloids for \\nfluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2011(3):CD000567. Epub 2011/03/18.\\n62. Havel C, Arrich J, Losert H, Gamper G, Mullner \\nM, Herkner H. Vasopressors for hypotensive shock. \\nCochrane Database Syst Rev. 2011(5):CD003709. Epub 2011/05/13.\\n63. Mousa HA, Alfirevic Z. T reatment for primary \\npostpartum haemorrhage. Cochrane Database Syst \\nRev. 2007(1):CD003249. Epub 2007/01/27.\\n64. Buttino L, Jr., Garite TJ. The use of 15 methyl F2 alpha prostaglandin (Prostin 15M) for the control of postpartum hemorrhage. Am J Perinatol. 1986;3:241-\\n3. Epub 1986/07/01.\\n65. Oleen MA, Mariano JP . Controlling refractory atonic \\npostpartum hemorrhage with Hemabate sterile solution. Am J Obstet Gynecol. 1990;162:205-8. Epub 1990/01/01.\\n66. Hofmeyr GJ, Walraven G, Gulmezoglu AM, \\nMaholwana B, Alfirevic Z, Villar J. Misoprostol to \\ntreat postpartum haemorrhage: a systematic review. BJOG. 2005;112:547-53. Epub 2005/04/22.\\n67. Widmer M, Blum J, Hofmeyr GJ, Carroli G, Abdel-\\nAleem H, Lumbiganon P , et al. Misoprostol as an \\nadjunct to standard uterotonics for treatment of post-partum haemorrhage: a multicentre, double-blind randomised trial. Lancet. 2010;375:1808-13. Epub 2010/05/25.\\n68. Blum J, Winikoff B, Raghavan S, Dabash R, Ramadan MC, Dilbaz B, et al. T reatment of post-partum ', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 25}), Document(page_content='451\\nGuía de práctica  clínica  para la prevención  y el manejo  de la hemorra Gia posparto  y complicaciones  del choque  hemorráGico\\nhaemorrhage with sublingual misoprostol versus \\noxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial. Lancet. 2010;375:217-23. Epub 2010/01/12.\\n69. Winikoff B, Dabash R, Durocher J, Darwish E, Nguyen TN, Leon W , et al. T reatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority \\ntrial. Lancet. 2010;375:210-6. Epub 2010/01/12.\\n70. Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin \\nF, Huissoud C, Keita-Meyer H, et al. High-dose \\ntranexamic acid reduces blood loss in postpartum \\nhaemorrhage. Crit Care. 2011;15:R117. Epub \\n2011/04/19.\\n71. Abdel-Aleem H, Singata M, Abdel-Aleem M, \\nMshweshwe N, Williams X, Hofmeyr GJ. Uterine massage to reduce postpartum hemorrhage after vaginal delivery. Int J Gynaecol Obstet. 2010;111:32-\\n6. Epub 2010/07/06.\\n72. Ikechebelu JI, Obi RA, Joe-Ikechebelu NN. The \\ncontrol of postpartum haemorrhage with intrauterine Foley catheter. J Obstet Gynaecol. 2005;25:70-2. \\nEpub 2005/09/09.\\n73. Bakri YN, Amri A, Abdul Jabbar F. T amponade-\\nballoon for obstetrical bleeding. Int J Gynaecol Obstet. 2001;74:139-42. Epub 2001/08/15.\\n74. Chan C, Razvi K, Tham KF, Arulkumaran S. The use of \\na Sengstaken-Blakemore tube to control post-partum \\nhemorrhage. Int J Gynaecol Obstet. 1997;58:251-2. Epub 1997/08/01.\\n75. Condous GS, Arulkumaran S, Symonds I, Chapman \\nR, Sinha A, Razvi K. The “tamponade test” in the \\nmanagement of massive postpartum hemorrhage. Obstet Gynecol. 2003;101:767-72. Epub 2003/04/12.\\n76. Akhter S, Begum MR, Kabir Z, Rashid M, Laila \\nTR, Zabeen F. Use of a condom to control massive \\npostpartum hemorrhage. Med Gen Med. 2003;5:38. \\nEpub 2003/11/06.\\n77. B-Lynch C, Coker A, Lawal AH, Abu J, Cowen MJ. \\nThe B-Lynch surgical technique for the control of massive postpartum haemorrhage: an alternative to hysterectomy? Five cases reported. Br J Obstet Gynaecol. 1997;104:372-5. Epub 1997/03/01.\\n78. Hayman RG, Arulkumaran S, Steer PJ. Uterine \\ncompression sutures: surgical management of \\npostpartum hemorrhage. Obstet Gynecol. 2002;99:502-6. Epub 2002/02/28.\\n79. Ghezzi F, Cromi A, Uccella S, Raio L, Bolis P , Surbek D. The Hayman technique: a simple method to treat \\npostpartum haemorrhage. BJOG. 2007;114:362-5. \\nEpub 2007/01/16.\\n80. Hwu YM, Chen CP , Chen HS, Su TH. Parallel vertical \\ncompression sutures: a technique to control bleeding \\nfrom placenta praevia or accreta during caesarean \\nsection. BJOG. 2005;112:1420-3. Epub 2005/09/20.\\n81. Kafali H, Demir N, Soylemez F, Yurtseven S. Hemostatic \\ncervical suturing technique for management of uncontrollable postpartum haemorrhage originating from the cervical canal. Eur J Obstet Gynecol Reprod \\nBiol. 2003;110:35-8. Epub 2003/08/23.\\n82. Joshi VM, Otiv SR, Majumder R, Nikam YA, \\nShrivastava M. Internal iliac artery ligation for arresting postpartum haemorrhage. BJOG. 2007;114:356-61. \\nEpub 2007/01/31.\\n83. Dildy GA, 3rd. Postpartum hemorrhage: new \\nmanagement options. Clin Obstet Gynecol. 2002;45:330-44. Epub 2002/06/06.\\n84. Hong TM, T seng HS, Lee RC, Wang JH, Chang CY. Uterine artery embolization: an effective treatment for intractable obstetric haemorrhage. Clin Radiol. 2004;59:96-101. Epub 2003/12/31.\\n85. Bloom AI, Verstandig A, Gielchinsky Y, Nadiari M, Elchalal U. Arterial embolisation for persistent \\nprimary postpartum haemorrhage: before or after \\nhysterectomy? BJOG. 2004;111:880-4. Epub 2004/07/24.\\n86. Yong SP , Cheung KB. Management of primary postpartum haemorrhage with arterial embolisation \\nin Hong Kong public hospitals. Hong Kong Med J. \\n2006;12:437-41. Epub 2006/12/07.\\n87. Doumouchtsis SK, Papageorghiou AT, Arulkumaran S. Systematic review of conservative management of postpartum hemorrhage: what to do when medical ', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 26}), Document(page_content='Revista Colombiana de Obstetricia y Ginecología Vol. 64 No. 4 • 2013452\\ntreatment fails. Obstet Gynecol Surv. 2007;62:540-7. \\nEpub 2007/07/20.\\n88. Rossi AC, Lee RH, Chmait RH. Emergency postpartum hysterectomy for uncontrolled postpartum bleeding: a \\nsystematic review. Obstet Gynecol. 2010;115:637-44. \\nEpub 2010/02/24.\\n89. Shahin AY, Farghaly TA, Mohamed SA, Shokry M, Abd-El-Aal DE, Youssef MA. Bilateral uterine artery ligation plus B-Lynch procedure for atonic postpartum \\nhemorrhage with placenta accreta. Int J Gynaecol \\nObstet. 2010;108:187-90. Epub 2009/12/01.\\n90. Neilson JP . Interventions for treating placental \\nabruption. Cochrane Database Syst Rev. 2003(1): \\nCD003247. Epub 2003/01/22.\\n91. Hurd WW , Miodovnik M, Hertzberg V , Lavin JP . \\nSelective management of abruptio placentae: a prospective study. Obstet Gynecol. 1983;61:467-73. Epub 1983/04/01.\\n92. Catling SJ, Williams S, Fielding AM. Cell salvage in obstetrics: an evaluation of the ability of cell salvage combined with leucocyte depletion filtration to remove amniotic fluid from operative blood loss at caesarean section. Int J Obstet Anesth. 1999;8:79-84. \\nEpub 2004/08/24.\\n93. Marik PE, Corwin HL. Efficacy of red blood cell \\ntransfusion in the critically ill: a systematic review of the literature. Crit Care Med. 2008;36:2667-74. Epub \\n2008/08/06.\\n94. Simpson E, Lin Y, Stanworth S, Birchall J, Doree \\nC, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. \\n2012;3:CD005011. Epub 2012/03/16.\\n95. Marti-Carvajal AJ, Comunian-Carrasco G, Pena-\\nMarti GE. Haematological interventions for treating disseminated intravascular coagulation during preg-\\nnancy and postpartum. Cochrane Database Syst Rev. \\n2011(3):CD008577. Epub 2011/03/18.\\n96. Inaba K, T eixeira PG, Shulman I, Nelson J, Lee J, \\nSalim A, et al. The impact of uncross-matched blood \\ntransfusion on the need for massive transfusion and \\nmortality: analysis of 5,166 uncross-matched units. \\nJ T rauma. 2008;65:1222-6. Epub 2008/12/17.\\n97. Cortés A, Bolaños F. Reanimación con glóbulos rojos \\nRh positivo y sin prueba cruzada en emergencias médicas. Colomb Med. 2004;35:185-90.\\n98. Ball CG, Salomone JP , Shaz B, Dente CJ, T allah C, Anderson K, et al. Uncrossmatched blood transfusions for trauma patients in the emergency department: incidence, outcomes and recommendations. Can J Surg. 2011;54:111-5. Epub 2011/01/22.\\n99. Kongnyuy EJ, Mlava G, van den Broek N. Using \\ncriteria-based audit to improve the management \\nof postpartum haemorrhage in resource limited countries: a case study of Malawi. Matern Child Health J. 2009;13:873-8. Epub 2008/09/10.\\n100. Deneux-Tharaux C, Dupont C, Colin C, Rabilloud M, T ouzet S, Lansac J, et al. Multifaceted intervention to decrease the rate of severe postpartum haemorrhage: the PITHAGORE6 cluster-randomised controlled trial. BJOG. 2010;117:1278-87. Epub 2010/06/25.\\n101. Birch L, Jones N, Doyle PM, Green P , McLaughlin A, Champney C, et al. Obstetric skills drills: evaluation of teaching methods. Nurse Educ T oday. 2007;27:915-22. Epub 2007/03/23.\\n102. Cook DA, Hatala R, Brydges R, Zendejas B, Szostek JH, Wang AT, et al. T echnology-enhanced simulation \\nfor health professions education: a systematic review \\nand meta-analysis. JAMA. 2011;306:978-88. Epub 2011/09/09.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Guía de hemorragia posparto Código Rojo FECOL.pdf', 'page': 27}), Document(page_content='Intravenous oxytocin dosing regimens for\\npostpartum hemorrhage prevention following cesarean\\ndelivery: a systematic review and meta-analysis\\nLaura C. Phung, MD; Elise K. Farrington, MD; Mairead Connolly, MD, MPH;\\nAlyce N. Wilson, MD, MPH; Brendan Carvalho, MBBCh, FRCA; Caroline S. E. Homer, PhD;\\nJoshua P. Vogel, PhD\\nIntroduction\\nPostpartum hemorrhage (PPH) is one of\\nthe leading causes of maternal mortality,accounting for nearly 20%1of the\\n295,000 maternal deaths that occurworldwide.\\n2The most common cause ofPPH is uterine atony,3hence increasing\\nthe use of uteronics for all women duringdelivery has been a key component of\\nFrom the Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, Australia (Drs Phung, Farrington, Connolly, Wilson, Homer, a nd\\nVogel); Faculty of Medicine, Dentistry and Health Sciences, Melbourne Medical School, The University of Melbourne, Melbourne, Australia (Drs Phun g,\\nFarrington, and Connolly); School of Population and Global Health, Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourn e,\\nMelbourne, Australia (Drs Wilson and Vogel); and Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Stanford, C A (Dr\\nCarvalho).\\nReceived Jan. 23, 2021; revised April 14, 2021; accepted April 30, 2021.\\nThe authors report no con ﬂict of interest.\\nThis study received no ﬁnancial support.\\nCorresponding author: Laura C. Phung, MD. lauracphung@gmail.com\\n0002-9378/$36.00 /C15ª2021 Elsevier Inc. All rights reserved. /C15https://doi.org/10.1016/j.ajog.2021.04.258OBJECTIVE: To compare the available evidence on intravenous oxytocin dosing regimens for the prevention of postpartum hemorrhage\\nfollowing cesarean delivery.\\nDATA SOURCES: We searched Ovid MEDLINE, Embase, Global Index Medicus, Cumulative Index of Nursing and Allied Health Literature,\\nCochrane Controlled Register of Trials, ClinicalTrials.gov , and the International Clinical Trials Registry Platform for eligible studies pub-\\nlished until February 2020.\\nSTUDY ELIGIBILITY CRITERIA: We included any randomized or nonrandomized study published in peer-reviewed journals that compared\\nat least 2 different dosing regimens of intravenous oxytocin for postpartum hemorrhage prevention in women undergoing cesarean\\ndelivery.\\nMETHODS: Two authors independently assessed the eligibility of studies, extracted the data, and assessed the risk of bias. The primary\\noutcome was incidence of postpartum hemorrhage /C211000 mL. Other review outcomes included use of additional uterotonics, blood loss,\\nand adverse maternal events. Data were analyzed according to the type of intravenous administration (bolus only, infusion only, or bolusplus infusion) and total oxytocin dose. A meta-analysis was performed on randomized trials and the results were reported as risk ratios ormean differences with 95% conﬁdence intervals. The Grading of Recommendations, Assessment, Development, and Evaluations scalewas used to rate the certainty of evidence. Findings from dose-ﬁnding trials and nonrandomized studies were reported narratively.\\nRESULTS: A total of 35 studies (7333 women) met our inclusion criteria and included 30 randomized trials and 5 nonrandomized studies.\\nThere were limited data available from the trials for most outcomes, and the results were not conclusive. Compared with bolus plus infusion\\nregimens, bolus only regimens probably result in slightly higher mean blood loss (mean difference, 52 mL; 95% conﬁdence interval, 0.4 e104\\nmL; moderate certainty). Among the bolus plus infusion regimens, initial bolus doses <5 IU may reduce nausea (risk ratio, 0.26; 95%\\nconﬁdence interval, 0.11 e0.63; low certainty) when compared with doses of 5 e9 IU. Total oxytocin doses of 5 e9 IU vs total doses of 10 e19\\nIU may increase the use of additional uterotonics (risk ratio, 13.00; 95% conﬁdence interval, 1.75 e96.37; low certainty). Effects on other\\noutcomes were generally inconclusive.\\nCONCLUSION: There are limited data available for comparisons of IV oxytocin regimens for postpartum hemorrhage prevention following\\ncesarean delivery. Bolus plus infusion regimens may lead to minor reductions in mean blood loss and initial bolus doses of <5 IU may\\nminimize nausea. Bolus only regimens of 10 IU vs bolus only regimens of 5 IU may decrease the need for additional uterotonics, however,\\nfurther comparative trials are required to understand the effects on other key outcomes, particularly hypotension.\\nKey words: abdominal delivery, birth, blood loss, dosing, drug administration, pregnancy, uterine atony, uterotonics\\n250 American Journal of Obstetrics &Gynecology SEPTEMBER 2021Systematic Reviews ajog.org', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 0}), Document(page_content='global efforts to reduce PPH-associated\\nmorbidity and mortality.4\\nIn 2018, the World Health Organiza-\\ntion (WHO) recommended that 10 in-ternational units (IU) of oxytocin shouldbe administered to all women duringdelivery, irrespective of the mode of de-livery (vaginal or cesarean delivery[CD]).\\n4This recommendation was\\ninformed by a Cochrane network meta-\\nanalysis of uterotonic agents for PPH\\nprevention by Gallos et al.5Based on\\nfurther evidence from observationalstudies suggesting dose-dependentadverse effects,\\n4the WHO recommen-\\ndations speci ﬁed that when used for PPH\\nprevention during CD, 10 IU oxytocinshould be administered as a divided dose\\nusing a smaller initial intravenous (IV)\\nbolus followed by infusion.\\n4However,\\nthe WHO Guideline DevelopmentGroup acknowledged that there wasinsufﬁcient evidence from randomized\\ncontrolled trials and speci ﬁed that\\nidentifying an optimal IV oxygocinregimen for PPH prophylaxis during CD\\nwas a high research priority.\\n4\\nPrevious reports have synthesized ev-\\nidence on oxytocin dosing regimens forPPH prevention during CD, however,none of these were systematic reviews orwere published nearly a decade ago.\\n6e8\\nAn up-to-date review and comparisonof studies are important to help guide\\nclinical practice and address the priority\\nidenti ﬁed by the WHO Guideline\\nDevelopment Group. The aim of thissystematic review was, therefore, toidentify and compare IVoxytocin dosingregimens during CD and determinewhether any regimens are superior.\\nMethods\\nWe conducted a systematic review inaccordance with the Preferred ReportingItems for Systematic Reviews and Meta-Analyses (PRISMA) guidance\\n9(Appendix\\nA). We followed a prespeci ﬁed protocol\\nregistered with the International Prospec-tive Register of Systematic Reviews(CRD42020175544),\\n10and outlined any\\ndeviations in Appendix B .E t h i c s\\napproval was not required because thiswas a systematic review of publiclyavailable data.\\nEligibility criteria\\nRandomized controlled trials (RCTs) andnonrandomized studies of interventions\\n(NRSIs) published in peer-reviewed\\njournals were eligible for inclusionwithout date restrictions. Conferenceabstracts were not included. We includedstudies written in English and thosewritten in other languages if we were ableto obtain adequate translations.Eligible studies were those that\\nincluded women who gave birth at anygestational age to a live or stillborn babyvia CD and included both planned andintrapartum CDs. Women were eligibleif they received IV oxytocin for PPHprevention either at or around the thirdstage of labor, recognizing that admin-\\nistration of oxytocin during the third\\nstage may not be possible or practicalduring a CD, particularly during anemergency CD.\\nStudies comparing at least 2 different\\nIV dosing regimens of oxytocin duringCD were eligible. Trials with coad-ministered interventions were eligible,\\nprovided that the use of cointerventions\\nwas identical in all trial arms.\\nOutcomes of interest\\nWe prespeci ﬁed 25 outcomes based on\\nthose used in the WHO recommenda-tions on uterotonics for PPH preven-tion,\\n4the PPH core outcome set,11and\\nthe 2019 Cochrane network meta-\\nanalysis on uterotonics for PPH pre-vention.\\n5The primary review outcome\\nwas incidence of PPH /C211000 mL, with\\nsecondary outcomes including PPH/C21500 mL, maternal death, severe\\nmaternal morbidity (intensive care unit[ICU] admissions), severe maternal\\nmorbidity (shock), use of additional\\nuterotonics, satisfactory uterine tone,use of surgical or invasive nonsurgicalinterventions, blood transfusion, meanvolumes of blood loss, change in he-moglobin measurements before vs afterbirth, any adverse maternal events(including nausea, vomiting, headache,\\nhypotension, chest pain, myocardial\\nischemia, cardiac arrythmia, dyspnea,bradycardia, tachycardia, or waterintoxication), breastfeeding at hospitaldischarge, maternal sense of well-being,and maternal satisfaction.\\nInformation sources, search strategy,\\nand study selection\\nA search strategy was developed inconsultation with an informationspecialist ( Supplemental Table 1 ). Be-\\ntween February 14, 2020, and February19, 2020, we searched the following 7electronic databases: Ovid MEDLINE,Embase, Global Index Medicus,AJOG at a Glance\\nWhy was this study conducted?\\nThe World Health Organization guidelines state that there is insuf ﬁcient evidence\\nto recommend a speci ﬁc oxytocin dosing regimen to prevent women from\\nexperiencing postpartum hemorrhage following a cesarean delivery. This sys-tematic review was conducted to identify and compare intravenous oxytocindosing regimens administered during cesarean deliveries and to determinewhether any regimens are superior.\\nKeyﬁndings\\nWe found limited and generally low-quality data for most outcomes and further\\nresearch is required. Bolus plus infusion regimens, with an initial bolus dose of<5 international units (IU), may have minor bene ﬁts. Bolus only regimens of 10\\nIU vs 5 IU may decrease the use of additional uterotonics, although the effects onadverse events (particularly hypotension) is unknown.\\nWhat does this add to what is known?\\nThis study compared data on all oxytocin regimens administered during cesareandelivery for postpartum hemorrhage prevention. It provides valuable informationfor clinical guidelines and future research.ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 251', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 1}), Document(page_content='Cumulative Index of Nursing and Allied\\nHealth Literature, Cochrane CentralRegister of Controlled Trials,ClinicalTrials.gov , and WHO Interna-\\ntional Clinical Trials Registry Platform.Recovered citations were de-duplicatedusing Endnote (Clarivate Analytics,Philadelphia, PA)\\n12and imported into\\nCovidence (Covidence, Melbourne,\\nAustralia)13for screening. Each unique\\ncitation was reviewed and independentlyassessed by 2 review authors (L.C.P.,E.K.F., and M.C.) for inclusion, initiallybased on titles and abstracts and then onthe full-text articles of potentially eligiblecitations. Disagreements were resolved\\nthrough discussion or consultation with\\nanother reviewer (J.P .V.). We alsoscreened the reference lists of allincluded studies, in addition to thereference list of the Gallos et al\\n5network\\nmeta-analysis for additional eligiblestudies.\\nData extraction and assessment of risk\\nof biasFor each study, 2 reviewers (L.C.P .,E.K.F., M.C.) double-extracted data us-ing a predesigned and pretested elec-tronic spreadsheet (Google Sheets). Dataabout the study design, year of publica-tion, period of recruitment, number of\\nparticipants, maternal age, gestational\\nage, primary and secondary review out-comes, and potential effect modi ﬁers\\n(type of CD, previous oxytocin admin-istration during childbirth, and previousrisk for PPH) were extracted. Disagree-ments between the reviewers at the titleand abstract, and full-text stages were\\n4% and 9%, respectively, and were\\nresolved through discussion or consul-tation with another reviewer (J.P.V.). Weattempted to contact the study authorsfor all studies for which further infor-mation was required.\\nEach included study was assessed for\\nrisk of bias by at least 2 review authors\\n(L.C.P ., E.K.F., M.C.). RCTs were assessed\\nusing the Cochrane Risk Of Bias 2.0(ROB 2.0, Cochrane, London, UnitedKingdom) tool,\\n14and NRSIs were\\nassessed using the Risk Of Bias In Non-randomized Studies of Interventions(ROBINS-I, Cochrane) tool.\\n15We made\\nan explicit judgment about the overallrisk of bias for each included study. In\\naddition, we assessed the risk of bias ofblood loss measurements using a similarapproach to Gallos et al\\n5(Supplemental\\nTable 2 ). Extracted data about the re-\\nview outcomes from RCTs were enteredinto the Review Manager 5 software(Cochrane)\\n16for the meta-analysis. Data\\nfrom NRSIs were reported narratively.\\nData synthesis\\nWe identi ﬁed the following 3 types of\\nstudies: comparative RCTs with /C212\\narms, dose- ﬁnding RCTs, and NRSIs.\\nComparative randomized controlled trials.\\nFor comparative RCTs, we ﬁrst assessed\\ntrial populations and methods usedbetween trials to judge whether theywere suf ﬁciently similar to warrant a\\nmeta-analysis. A random-effects modelwas used to assess all outcomes with >1\\ntrial. Results from dichotomous datawere presented as a summary risk ratio\\n(RR) with 95% con ﬁdence intervals (CI)\\nand as mean differences (MDs) forcontinuous data. For all meta-analyseswe used the Grading of Recommenda-tions Assessment, Development, andEvaluation (GRADE) approach\\n17to rate\\nthe certainty of evidence as very low, low,moderate, or high using GRADEpro\\nsoftware (Evidence Prime, Inc, Ontario,\\nCanada).\\n18We planned to assess publi-\\ncation bias using funnel plots if there were10 or more studies included in the meta-analysis, however, this was not donebecause of the limited number of studies.\\nWe conducted separate meta-analyses\\nfor (1) type of IV administration (bolus\\nonly, infusion only, or bolus plus infu-\\nsion) and (2) total oxytocin doseadministered. We calculated the totaloxytocin dose for each trial arm byadding all preplanned doses of oxytocindescribed in the study methods,including any doses used in a bolus,short infusion, and maintenance infu-\\nsion (studies were not included for\\nanalysis of total oxytocin dose if therewas insuf ﬁcient information to deter-\\nmine the total dose). Considering theavailable evidence (and to standardizethe analyses), trial arms were groupedinto 5 total oxytocin dose categories ( <5\\nIU, 5e9I U ,1 0 e19 IU, 20 e49 IU, and/C2150 IU) for comparison in pairwise\\nanalyses. In addition, among trials usingbolus plus infusion regimens, we iden-tiﬁed trials that studied the effects of\\nusing different initial bolus doses byvarying the initial bolus dose whilekeeping the infusion component iden-tical between trial arms. Hence, we also\\nanalyzed (3) the effects of different initial\\nbolus doses among trials using bolusplus infusion regimens. To accomplishthis, we grouped the initial bolus doses as<5 IU, 5 IU, or 10 IU for comparison in\\npairwise analyses.\\nIn line with the 2019 international\\nconsensus statement recommendation of\\na 2- to 4-hour maintenance infusion,\\n8we\\nperformed a subgroup analysis on studiesthat used a maintenance infusion be-tween 2 and 4 hours only. Owing tolimited available data, we were only ableto perform this for the analysis of initialbolus doses in a bolus plus infusionregimen.\\nWe planned to conduct subgroup\\nanalyses by type of CD (planned vsintrapartum), previous oxytocin admin-istration, and previous risk of PPH,however, these were not possible becauseof limited available data. We performedsensitivity analyses for risk of bias (onlyincluding studies with an overall low risk\\nof bias) and method of blood loss esti-\\nmation (only including studies that usedcalculated or volumetric assessment ofblood loss). When making statements onthe effects of an intervention, we adoptedstandardized language derived from San-tesso et al.\\n19\\nDose- ﬁnding trials and nonrandomized\\nstudies.The dose- ﬁnding RCTs used a 1-arm up-\\nand-down sequential allocation methodin which the oxytocin dose for the nextparticipant was adjusted according to theresponse of the preceding participant.\\n20\\nFor example, if the ﬁrst participant had\\na satisfactory response, the next partici-\\npant was allocated either an equal orlower dose using a biased-coin technique.Dose- ﬁnding trials did not make explicit,\\npairwise comparisons between dosingregimens, hence ﬁndings from these trials\\nwere reported narratively. Eligible NRSIswere also reported narratively.Systematic Reviews ajog.org\\n252 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 2}), Document(page_content='Results\\nStudy selection and characteristics\\nThe results of the search are summarizedin the PRISMA ﬂow diagram ( Figure 1 ).\\nWe identi ﬁed 9631 records of which\\n6626 records were excluded at the title\\nand abstract screening stage and 195 at\\nthe full-text review stage. The mostcommon reasons for exclusion wereduplicate study (n ¼72) and wrong\\narticle type (n ¼37). No further articles\\nwere identi ﬁed through screening of the\\nreference lists. In total, 35 studies of 7333women were included. We found 30\\nRCTs of which 26 were comparative\\nRCTs and 4 were dose- ﬁnding RCTs. We\\nfound 5 NRSIs of which 4 werecomparative and 1 was a dose- ﬁnding\\nstudy. A summary of the study charac-teristics and an overview of study com-parisons are provided in Tables 1 to 4\\nandSupplemental Table 3 . Among the 26\\ncomparative RCTs included, 9 were at an\\noverall high risk for bias and 15 were atlow risk for bias ( Supplemental Figures 1\\nand 2); the 4 dose- ﬁnding RCTs were\\nassessed to be at an overall high risk forbias. Of the 5 NRSIs, 2 were assessed tobe at an overall critical risk of bias andthe remaining 3 as at moderate risk\\n(Supplemental Figures 3 and4).\\nComparative randomized controlled\\ntrialsWe identi ﬁed 26 comparative RCTs (64\\ntrial arms) that included 5271 women.Of these, 19 RCTs were 2-arm trials, and7 RCTs were multi-arm trials (rangingfrom 3e6 arms). Sample sizes ranged\\nfrom 28 e2069 women, and 23 trials\\nincluded women undergoing planned\\nCD only. The types of IVadministrationsused were bolus only (14 arms), infusiononly (23 arms), and bolus plus infusion(27 arms). There were 26 different totaldoses of oxytocin used ranging from 1IUe260 IU. The most common total\\ndoses were 5 IU (11 arms) and 10 IU (8\\narms). We could not calculate the total\\ndose for 3 of the studies.\\n25,27,35Among\\nthose trial arms that used an infusioncomponent, the total infusion durationranged from 5 minutes to 24 hours, andthe rate of oxytocin administration var-ied from 0.7 IU per hour to 120 IU perhour. Among the 5 trials that compareddifferent initial bolus doses within a\\nbolus plus infusion regimen, the initial\\nbolus doses ranged from 0.5 e10 IU.\\nDose- ﬁnding trials and\\nnonrandomized studiesWe identi ﬁed 4 dose- ﬁnding RCTs (180\\nwomen). The sample sizes ranged from30e70 women. Two trials included\\nwomen undergoing planned CD only\\nand 1 trial included women undergoingintrapartum CD only. All studies usedeither an initial bolus or infusion fol-lowed by a maintenance infusion. Wefound 5 NRSIs that included 1840women with sample sizes ranging from41e1122 women. Of these, 4 werecomparative studies (3 2-arm studies, 1\\n3-arm study) and 1 was a dose- ﬁnding\\nstudy. The most common type of IVadministration was bolus only (4 arms).Doses ranged from 3 e80 IU with the\\nmost common dose being 5 IU (2 arms).\\nOutcomes\\nThe most commonly reported outcomes\\nwere the use of additional uterotonics\\n(28 studies) and mean blood loss (20studies). No data were available for 7outcomes (maternal deaths, ICU ad-missions, shock, water intoxication,breastfeeding after discharge, maternalsense of well-being, and maternal senseof satisfaction ( Supplemental Table 4 ).FIGURE 1\\nFlow diagram\\nPRISMA ﬂow diagram.\\nPRISMA , Preferred Reporting Items for Systematic Reviews and Meta-Analyses.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet\\nGynecol 2021.ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 253', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 3}), Document(page_content='TABLE 1\\nCharacteristics of included studies\\nFirst author,\\nyearStudy\\ndesign n Country CD type Oxytocin dosing regimens\\nComparative randomized controlled trials Arm 1 Arm 2 Arm 3 Arm 4 Arm 5 Arm 6 All arms\\nBhattacharya\\net al,2120132-arm RCT 80 India Planned Bolus\\n3I UInfusion\\n3I U— — — — Infusion (0.16 IU/\\nmin) after study\\nperiod\\nButwick\\net al,2220105-arm RCT 75 United States Planned No\\nbolusBolus\\n0.5 IUBolus\\n1I UBolus\\n3I UBolus\\n5I U— Infusion of 10 IU\\nover 2 h onceadequate UT plus\\ninfusion (0.16 IU/\\nmin) after studyperiod\\nCecilia et al,\\n23\\n20182-arm RCT 271 India Both Infusion\\n2.5 IU/h over\\n2e4hInfusion\\n10 IU/h over\\n8e12 h—————\\nDerbel et al,24\\n20162-arm RCT 87 Tunisia Planned Bolus\\n10 IUBolus\\n5I U— — — — Infusion of 25 IU\\nover 3 h\\nDufﬁeld\\net al,2520172-arm RCT 51 United States Planned Infusion of 10 IU\\nuntil dischargeInfusion of 60 IU\\nuntil discharge— — — — Bolus 1 IU\\nGhulmiyyah\\net al,2620173-arm RCT 189 Lebanon Planned 20 IU\\nover 30 min30 IU\\nover\\n30 min40 IU over 30\\nmin— — — Infusion of 30 IU\\nthen 20 IU then 10\\nIU for 24 h total\\nGolparvar\\net al,2720142-arm RCT 84 Iran Planned Infusion\\n15 IU/hInfusion\\n30 IU/h—————\\nGu¨ngo¨ rdu¨k\\net al,2820102-arm RCT 720 Turkey Planned Placebo infusion Infusion of 30 IU\\nover 4 h— — — — Bolus 5 IU\\nJonsson\\net al,2920102-arm RCT 103 Sweden Planned Bolus 5 IU Bolus 10 IU — — — — —\\nKajendran\\net al,3020172-arm RCT 92 Sri Lanka Planned Infusion of 20 IU\\nover 4 hPlacebo infusion — — — — Bolus 5 IU\\nKikutani\\net al,3120032-arm RCT 90 Japan Planned Bolus 10 IU over\\n30 sInfusion 10 IU\\nover 5 min—————\\nKim et al,32\\n20113-arm RCT 60 Korea Planned Infusion of 20 IU\\nover 40 minBolus 2 IU plus\\ninfusion of 10 IU\\nover 40 minBolus 5 IU plus\\ninfusion of 10\\nIU over 40 min————\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)Systematic Reviews ajog.org\\n254 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 4}), Document(page_content='TABLE 1\\nCharacteristics of included studies (continued)\\nFirst author,\\nyearStudy\\ndesign n Country CD type Oxytocin dosing regimens\\nComparative randomized controlled trials Arm 1 Arm 2 Arm 3 Arm 4 Arm 5 Arm 6 All arms\\nKing et al,33\\n20102-arm RCT 143 Canada Both Bolus 5 IU Placebo bolus ———— Infusion of 40 IU\\nover 30 min then\\ninfusion of 20 IUover 4 h\\nKiran et al,\\n34\\n20133-arm RCT 90 India Planned Bolus 0.5 IU Bolus 1 IU Bolus 2 IU — — — Infusion 20 IU\\nover 2 h\\nKovacheva\\net al,3520152-arm RCT 60 United States Planned Bolus 3 IU every 3\\nmin until\\nadequate UT ormaximum 3bolusesInfusion of 30 IU\\nuntil adequate UT———— Infusion of 30 IU\\nover 6 h\\nMunn et al,\\n36\\n20012-arm RCT 321 United States Intra Infusion of 10 IU\\nover 30 minInfusion of 80 IU\\nover 30 min———— Infusion of 20 IU\\nover 8 h\\nMurphy\\net al,3720092-arm RCT 115 Scotland Planned Placebo infusion Infusion of 30 IU\\nover 4 h———— Bolus 5 IU\\nPalacio et al,38\\n20112-arm RCT 104 Spain Planned Bolus 1 IU plus\\ninfusion of 2.5 IU/\\nh for 24 hInfusion of 20 IU\\nat 700 mIU/min\\nplus 10 IU/h for\\n24 h—————\\nPinder et al,39\\n20022-arm RCT 34 United\\nKingdomPlanned Bolus 5 IU Bolus 10 IU —————\\nQian et al,40\\n20196-arm RCT 145 China Planned No infusion Infusion of 1 IU/h\\nfor 1 hInfusion of 2\\nIU/h for 1 hInfusion of 3\\nIU/h for 1 hInfusion of 5\\nIU/h for 1 hInfusion of 8\\nIU/h for 1 hBolus 1 IU\\nSarna et al,41\\n19974-arm RCT 40 United States Planned Infusion of 5 IU\\nat 1 IU/minInfusion of 10 IU\\nat 1 IU/minInfusion of 15\\nIU at 1 IU/minInfusion of 20\\nIU at 1 IU/min———\\nSartain et al,42\\n20082-arm RCT 80 Australia Planned Bolus 2 IU Bolus 5 IU ———— Infusion of 40 IU\\nover 4 h\\nSheehan\\net al,4320112-arm RCT 2069 Ireland Planned Placebo infusion Infusion of 40 IU\\nover 4 h———— Bolus 5 IU\\nTaj and\\nOmmid,44\\n20142-arm RCT 50 India Planned Bolus 10 IU over\\n15 sInfusion of 10 IU\\nover 5 min—————\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 255', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 5}), Document(page_content='TABLE 1\\nCharacteristics of included studies (continued)\\nFirst author,\\nyearStudy\\ndesign n Country CD type Oxytocin dosing regimens\\nComparative randomized controlled trials Arm 1 Arm 2 Arm 3 Arm 4 Arm 5 Arm 6 All arms\\nTariq and\\nSyed,4520182-arm RCT 90 Pakistan Planned Bolus 5 IU over 10\\nsInfusion of 5 IU\\nover 5 min—————\\nThomas\\net al,4620072-arm RCT 28 United\\nKingdomPlanned Bolus 5 IU over 1 s Infusion of 5 IU\\nover 5 min—————\\nDose-ﬁnding randomized trials Initial dose Maintenance infusion to all patients\\nBalki et al,472006 1-arm\\nDF RCT30 Canada Intra Starting bolus 0.5 IU\\nSubsequently up or down by 0.5 IU (based on response\\nof preceding patient)Infusion of 40 mIU/min for up to 8 h\\nCarvalho et al,482004 1-arm\\nDF RCT40 USA Planned Starting bolus 0.5 IU\\nSubsequently up or down by 0.5 IU (based on responseof preceding patient)Infusion of 40 mIU/min until discharge\\nGeorge et al,\\n492010 1-arm\\nDF RCT40 Canada Planned Starting infusion at 0.4 IU/min\\nSubsequently up or down by 0.1 IU for 1 h (based on\\nresponse of preceding patient)Infusion of 30 IU until discharge\\nLavoie et al,502015 2-arm\\nDF RCT70 — Arm 1: intra;\\narm 2: plannedStarting infusion of 18 IU/h until end of CD\\nSubsequently up or down by 3 IU/h (based on responseof preceding patient)Infusion of 3.6 IU/h until discharge\\nNonrandomized studies of interventions Arm 1 Arm 2 Arm 3 All arms\\nAhmadi et al,\\n512018 2-arm NRSI 150 Iran — Infusion of 80 IU Infusion of 30 IU — —\\nHolleboom et al,522013 3-arm NRSI 1122 Netherlands Planned Bolus 5 IU Bolus 10 IU Bolus 5 IU plus\\ninfusion of 10 IU over2h—\\nPursche et al,\\n532012 2-arm NRSI 454 Germany Both Bolus 3 IU plus\\ninfusion at 100 mL/hInfusion with at least\\n120 mL/h——\\nTerblanche et al,542017 2-arm NRSI 73 Australia Planned Bolus 3 IU Bolus 5 IU — —\\nBeiranvand et al,552019 2-arm\\nDF NRSI41 Iran Arm 1: intra;\\narm 2: plannedBolus 1 IU bolus, plus\\n0.5 IU every min until\\nadequate UT— — Infusion 30 mU/min\\nCD, cesarean delivery; DF, dose-ﬁnding; GA, gestational age; intra, intrapartum; IU, international units; NRSI , nonrandomized studies of interventions; RCT, randomized controlled trial; UT, uterine tone.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.Systematic Reviews ajog.org\\n256 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 6}), Document(page_content='TABLE 2\\nOverview of study comparisons: type of intravenous administration\\nType of IV administration Bolus only Infusion Bolus plus infusion\\nBolus only No studies 5 RCTs (338 women,\\nall 2-arm trials)21,31,44e465 RCTs (3141 women)\\n/C15Four 2-arm trials28,30,37,43\\n/C15One 6-arm triala,40\\n1 NRSI (1122 women, 2-arm study)b,52\\nInfusion — No studies 5 RCTs (442 women)\\n/C15Three 2-arm trials32,35,38\\n/C15One 3-arm trialc,32\\n/C15One 4-arm triald,22\\n1 NRSI (454 women, 2-arm study)53\\nBolus plus infusion — — No studies\\nDose-ﬁnding studies (4 RCTs, 1 NRSI) are not included in this table.\\nIV, intravenous; NRSI , nonradomized studies of intervention; RCT, randomized controlled trial.\\naSix-arm study comparing bolus only with bolus plus infusion (B þI) vs BþIv sBþIv sBþIv sBþI;bThree-arm study comparing bolus only with bolus and B þI;cThree-arm study comparing infusion\\nwith BþI and B þI;d4-arm study comparing infusion with B þI and B þI and B þI.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.\\nTABLE 3\\nOverview of study comparisons: total oxytocin dose\\nDose <5I U 5 e9I U 1 0 e19 IU 20 e49 IU ‡50 IU\\n<5I U N o\\nstudies1 RCT (145 women)\\n/C151 IU vs 2 IU vs 3 IU\\nvs 4 IU vs 6 IU vs 9\\nIU40\\n1 NRSI (73 women)\\n/C153I Uv s5I U54No studies No studies No studies\\n5e9 IU — No studies 3 RCTs (177 women)\\n/C155I Uv s1 0I U29,39\\n/C155I Uv s1 0I Uv s\\n15 IU41\\n3 NRSI (1122 women)\\n/C155I Uv s1 0I Uv s\\n15 IU524 RCTs (2996 women)\\n/C155I Uv s3 5I U28,37\\n/C155I Uv s4 5I U43\\n/C155I Uv s2 5I U30No studies\\n10e19\\nIU— — No studies 2 RCTs (331 women)\\n/C1510 IU vs 30 IU23\\n/C1512 IU vs 15 IU vs\\n20 IU32No studies\\n20e49\\nIU— — — 3 RCTs (257 women)a\\n/C1542 IU vs 45 IU42\\n/C1530 IU vs 35 IU24\\n/C1520.5 IU vs 21 vs\\n22 IU341 RCT (321 women)\\n/C1530 IU vs 100 IU36\\n1 NRSI (150 women)\\n/C1530 IU vs 80 IU51\\n/C2150 IU — — — — 3 RCTs (436 women)a\\n/C1580 IU vs 90 IU\\nvs 100 IU26\\n/C1560 IU vs 65 IU33\\n/C1561 IU vs 260 IU38\\nFour dose-ﬁnding studies (4 RCTs, 1 NRSI) and 3 RCTs were not included because the total oxytocin dose could not be calculated.\\nIU, international unit; NRSI , nonrandomized studies of intervention; RCT, randomized controlled trial.\\naStudies compared outcomes within the same total oxytocin dose category and were not analyzed.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 257', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 7}), Document(page_content='Synthesis of results\\nMeta-analysis.\\nType of intravenous administration. A\\ntotal of 15 RCTs (3921 women)compared different types of IV admin-istration regimens ( Table 2 ,\\nSupplemental Table 5 ). The incidence of\\nPPH/C211000 mL was only reported for 1\\ncomparison (bolus only vs bolus plusinfusion).\\nBolus only vs infusion only. In 5 RCTs\\n(338 women), bolus only regimens werecompared with infusion only regimens.No study reported on the outcome ofincidence of PPH /C211000 mL. The effects\\nof either dosing regimen on the use ofadditional uterotonics, mean blood loss,or maternal adverse effects (nausea,\\nvomiting, chest pain, and myocardial\\nischemia) are inconclusive because thecertainty of evidence was very low. Noother outcomes were reported.\\nBolus only vs bolus plus infusion. In 5\\nRCTs (4580 women), bolus only regi-mens were compared with bolus plusinfusion regimens. The effect of either\\ndosing regimen on the outcome of\\nincidence of PPH /C211000 mL was\\ninconclusive because the certainty ofevidence was very low (4 trials of 2976women; RR, 1.44; 95% CI, 0.75 e2.76;\\nvery low certainty), although bolus onlyregimens slightly increased the meanblood loss (5 trials of 3068 women; MD,\\n52 mL; 95% CI, 0.4 e104 mL; moderate\\ncertainty) ( Figure 2 ) and decreased the\\nincidence of satisfactory uterine tone (1trial of 145 women; RR, 0.63; 95% CI,0.41e0.95; low certainty) ( Figure 3 ).\\nThere were no clear differences in themean change in hemoglobin (3 trials of\\n2260 women; MD, e0.05 g/dL; 95% CI,\\ne0.27 to 0.17 g/dL; high certainty) or\\nincidence of blood transfusion (3 trialsof 2870 women; RR, 1.55; 95% CI,0.47e5.13; low certainty). The effects of\\neither dosing regimen on the outcomesof incidence of PPH /C21500 mL, use of\\nadditional uterotonics, and maternaladverse effects (hypotension, nausea,\\nand chest pain) were inconclusive\\nbecause the certainty of evidence wasvery low. There were zero events re-ported for surgical or nonsurgical in-terventions, vomiting, bradycardia,tachycardia, and dyspnea. A sensitivityanalysis on risk of bias (including onlystudies at an overall low risk of bias)\\nsuggested no clear difference in mean\\nblood loss.\\nInfusion only vs bolus plus infusion. In\\n5 RCTs (442 women), infusion onlyregimens were compared with bolusplus infusion regimens. No study re-ported on the outcome of incidence ofPPH/C211000 mL. There were no clear\\ndifferences in the incidence of satisfac-\\nt o r yu t e r i n et o n e( 2t r i a l so f1 6 4women; RR, 0.98; 95% CI, 0.90 e1.06;\\nlow certainty), blood transfusion (1 trialof 145 women; RR, 0.35; 95% CI,0.04e3.26; low certainty), or maternal\\nadverse events (vomiting [1 trial of 60women; RR, 0.50; 95% CI, 0.06 e4.18;\\nlow certainty], headache [1 trial of 152\\nwomen; RR, 0.36; 95% CI, 0.01 e8.71;\\nlow certainty], hypotension [2 trials of263 women; RR, 0.60; 95% CI,0.34e1.05; moderate certainty], cardiac\\narrythmia [1 trial of 60 women; RR,1.50; 95% CI, 0.27 e8.34; low cer-\\ntainty], and tachycardia [1 trial of 143\\nwomen; RR, 0.96; 95% CI, 0.06 e15.04;\\nlow certainty]). The effects on use ofadditional uterotonics, mean bloodloss, and nausea were inconclusivebecause the certainty of evidence wasvery low. There were zero events re-ported for surgical interventions, chestpain, and dyspnea.\\nTotal oxytocin dose. A total of 17 RCTs\\n(4663 women) compared different totaloxytocin doses ( Table 3 ,Supplemental\\nTable 6 ). The outcome of the incidence\\nof PPH\\n/C211000 mL was reported for 2\\ncomparisons ( <5I Uv s5 e9 IU and 5 e9\\nIU vs 20 e49 IU).\\nTotal oxytocin dose of <5I Uv s5 e9\\nIU.One RCT40(145 women) compared\\na total oxytocin dose of <5 IU with 5 e9\\nIU. It reported zero incidences of PPH/C211000 mL with either dosing regimen.\\nThe effects on the use of additionaluterotonics, satisfactory uterine tone,mean blood loss, or maternal adverseevents (nausea, hypotension, chest pain)\\nwere inconclusive because the certainty\\nof evidence was very low. There werezero events reported for blood trans-fusions, vomiting, bradycardia, tachy-cardia, and dyspnea.\\nTotal oxytocin dose of 5 e9I Uv s1 0 e19\\nIU.Three RCTs (177 women) compared\\na total oxytocin dose of 5 e9 IU with\\n10e19 IU. No study reported on the\\nincidence of PPH /C211000 mL. The use of\\na total dose of 5 e9I Uv s1 0 e19 IU may\\nresult in a large increase in the use ofadditional uterotonics (2 trials of 137women; RR, 13.00; 95% CI, 1.75 e96.37;TABLE 4\\nOverview of study comparisons: initial bolus dose in a bolus plus infusion regimen\\nDose <5 IU 5 IU 10 IU\\n<5 IU 1 RCT (90 women)\\n/C150.5 IU vs 1 IU vs 2 IU343 RCTs (180 women)\\n/C150.5 IU vs 1 IU vs 3 IU vs 5 IU22\\n/C152I Uv s5I U32\\n/C152I Uv s5I U42No studies\\n5 IU — No studies 1 RCT (87 women)\\n/C155I Uv s1 0I U24\\n10 IU — — No studies\\nDose-ﬁnding studies (4 RCTs, 1 NRSI) are not included in this table.\\nIU, international unit; NRSI , nonrandomized studies of intervention; RCT, randomized controlled trial.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.Systematic Reviews ajog.org\\n258 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 8}), Document(page_content='low certainty) ( Figure 4 ). There was no\\nclear difference in myocardial ischemia(1 trial of 103 women; RR, 0.98; 95% CI,0.14e6.70; low certainty). The effect on\\nmean blood loss was inconclusive\\nbecause the certainty of evidence wasvery low. There were zero events re-ported for hypotension.\\nTotal oxytocin dose of 5 e9I Uv s2 0 e49\\nIU.Four RCTs (2996 women),\\ncompared a total oxytocin dose of5e9I Uw i t h2 0 e49 IU. The effects of\\neither dosing regimen on the out-\\ncomes of incidence of PPH /C211000\\nmL, PPH /C21500 mL, use of additional\\nuterotonics or blood transfusion, ormean blood loss were inconclusivebecause the certainty of evidence wasvery low. There was no clear differ-ence in the change in hemoglobin\\n(3 trials of 2260 women; MD, e0.05\\ng/dL; 95% CI, e0.27 to 0.17 g/dL; low\\ncertainty).\\nTotal oxytocin dose of 10 e19 IU vs\\n20e49 IU. Two RCTs (331 women)\\ncompared a total oxytocin dose of 10 e19\\nIU with 20 e49 IU. Neither\\nstudy reported on the incidence of PPH\\n/C211000 mL. The use of a total dose of\\n10e19 IU compared with of 20 e49 IUprobably reduces chest pain (1 trial of\\n271 women; RR, 0.05; 95% CI,0.00e0.81; moderate certainty)\\n(Supplemental Figure 5 ). There were no\\nclear differences in the incidence of\\nblood transfusion (1 trial of 271 women;RR, 0.86; 95% CI, 0.28 e2.62; low cer-\\ntainty), satisfactory uterine tone (1 trialof 271 women; RR, 1.05; 95% CI,1.00e1.09; moderate certainty), or\\ntachycardia (1 trial of 271 women; RR,0.84; 95% CI, 0.26 e2.69). The effects on\\nthe use of additional uterotonics, mean\\nblood loss, nausea, or vomiting wereinconclusive because the certainty ofevidence was very low.\\nTotal oxytocin dose of 20 e49 IU vs /C2150\\nIU.One RCT\\n36(321 women) compared\\na total oxytocin dose of 20 e49 IU with\\n/C2150 IU. It did not report on the inci-\\ndence of PPH /C211000 mL. The use of\\ndoses of 20 e49 IU compared with /C2150\\nIU may increase the use of additionaluterotonics (RR, 2.07; 95% CI,1.42e3.01; low certainty) ( Supplemental\\nFigure 6 ). There were no clear differ-\\nences in mean blood loss (MD, 20 mL;95% CI, e14 to 54 mL; low certainty) or\\nhypotension (RR, 1.05; 95% CI,\\n0.71e1.53; low certainty).Different bolus doses in bolus plus infusion\\nregimens. A total of 5 RCTs using\\noxytocin regimens of bolus plus infusion(357 women) compared different initial\\nbolus doses while keeping the infusion\\ncomponent identical for both trial arms(Table 4 ,Supplemental Table 7 ).\\nInitial bolus dose of <5 IU vs 5 IU in a\\nbolus plus infusion regimen. In 3 RCTs\\n(180 women) in which a bolus plusinfusion regimen was used, an initialbolus dose of <5 IU was compared with\\nthat of 5 IU. No study reported on the\\nincidence of PPH /C211000 mL. Data from\\nall 3 trials showed that initial bolus dosesof<5 IU may reduce nausea (RR, 0.29;\\n95% CI, 0.10 e0.81; low certainty)\\n(Supplemental Figure 7 ), but there were\\nno clear differences in the use of addi-tional uterotonics (RR, 1.08; 95% CI,\\n0.51e2.31; low certainty) or vomiting\\n(RR, 0.23; 95% CI, 0.05 e1.04; low cer-\\ntainty). The effect on mean blood losswas very uncertain owing to very lowcertainty about the evidence. There werezero events reported for surgical ornonsurgical interventions, blood trans-fusions, and maternal adverse events\\n(chest pain, cardiac arrythmia, dyspnea,\\nhypotension).FIGURE 2\\nBolus only vs bolus plus infusion: mean blood loss\\nCI, conﬁdence interval; IV, intravenous; SD, standard deviation.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.\\nFIGURE 3\\nBolus only vs bolus plus infusion: satisfactory uterine tone\\nCI, conﬁdence interval.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 259', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 9}), Document(page_content='Initial bolus dose of 5 IU vs 10 IU in a\\nbolus plus infusion regimen. One RCT24\\n(87 women) that employed a bolus plus\\ninfusion regimen compared an initialbolus dose of 5 IU with 10 IU. It did notreport on the incidence of PPH /C211000\\nmL and there were no clear differences in\\nmean blood loss (MD, 2 mL; 95% CI,\\ne135 to 138 mL; low certainty), cardiac\\narrythmia (RR, 0.34; 95% CI, 0.01 e8.14;\\nlow certainty), or chest pain (RR, 0.41;95% CI, 0.08 e2.00; low certainty). There\\nwere zero events reported for surgical ornonsurgical interventions and dyspnea.\\nWe were largely unable to perform\\nsensitivity and subgroup analyses owing\\nto limited available data. However, wheredata permitted these analyses, no sig-niﬁcant effects were found except where\\notherwise described.\\nNarrative synthesis.\\nWe reviewed dose- ﬁnding RCTs and\\nNRSIs separately. Findings from thesestudies are inconclusive, however, wereport the main ﬁndings below. The re-\\nsults were not reported as statistically\\nsigniﬁcant unless otherwise noted.\\nDose- ﬁnding studies. A total of 4 dose-\\nﬁnding RCTs (180 women) studied the\\ndifferent initial doses required to initiateuterine contraction when followed by amaintenance infusion. No study re-ported on the incidence of PPH /C211000\\nmL. The studies found that small doses\\n(0.3 IU as a bolus or 0.27 e0.29 IU/min\\nas a short infusion) may be adequate toprevent uterine atony during plannedCD\\n48e50and that higher doses of\\noxytocin may be required during intra-partum CD regardless of the type ofadministration.\\n47,50One dose- ﬁnding\\nNRSI55(83 women) reported that small\\ndoses (1 IU as a bolus) may be adequateto prevent uterine atony, with higher\\ndoses needed during intrapartum CD.\\nHypotension, secondary to oxytocinadministration, was noted in all studies,however, was not explored in relation tospeciﬁc doses or types of IV adminis-\\ntration regimens.Nonrandomized studies.Type of intravenous administration. One\\nstudy\\n52(1122 women, critical risk of bias)\\ncompared bolus only with bolus plusinfusion regimens. It suggested that morewomen who received bolus only regi-mens experienced PPH /C211000 mL than\\nwomen who received bolus plus infusionregimens, greater use of additional ute-rotonics, and increased incidence in\\nblood transfusions. There were no sig-\\nniﬁcant differences reported for any other\\noutcomes.\\n52Another study53(454\\nwomen, moderate risk of bias) comparedinfusion only with bolus plus infusionregimens. It did not report on the inci-dence of PPH /C211000 mL but suggested\\nthat women who received infusion only\\nregimens experienced a greater overall\\ndecrease in hemoglobin levels.\\nTotal oxytocin dose. One study\\n54(73\\nwomen, moderate risk of bias)compared a total oxytocin dose of 3 IUwith that of 5 IU. It did not report on theincidence of PPH /C211000 mL butsuggested more women who received 5\\nIU experienced vomiting whencompared with women who received 3IU. One study\\n52(1122 women, critical\\nrisk of bias) compared a total oxytocindose of 5 IU with that of 10 IU and 15 IU.It suggested that increased doses of\\noxytocin may result in less PPH /C211000\\nmL, the use of additional uterotonics andblood transfusions, and may lead tomore satisfactory uterine tone.\\n52One\\nstudy51(150 women, critical risk of bias)\\ncompared a total oxytocin dose of 30 IUwith that of 80 IU. It did not report onthe incidence of PPH /C211000 mL but\\nsuggested that 30 IU may lead to a sta-\\ntistically signi ﬁcant increase in the use of\\nadditional uterotonics and a decrease insatisfactory uterine tone. No signi ﬁcant\\ndifferences were reported for any otheroutcomes including hypotension.\\nComment\\nMain ﬁndings\\nWe identi ﬁed 35 studies of 7333 women\\ncomparing different IV oxytocin regi-mens for PPH prevention following CD.The evidence in general was limited anddata were lacking for most of the reviewoutcomes, with the data from 11 studiesat high or critical risk of bias. We did not\\nﬁnd any clear differences in the incidence\\nof PPH /C211000 mL, although data were\\nsparse for this outcome. Bolus plusinfusion regimens are possibly superiorto bolus only regimens in terms of asmall reduction in mean blood loss(around 52 mL) and increased uterineFIGURE 4\\nTotal oxytocin dose of 5 e9I Uv s1 0 e19 IU: use of additional uterotonics\\nCI, conﬁdence interval.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.Systematic Reviews ajog.org\\n260 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 10}), Document(page_content='tone, although these ﬁndings were based\\non a few trials. In general, we found noclear indication of a superior totaloxytocin dose (largely because of insuf-ﬁcient evidence). Although we found\\ndoses of 10 e19 IU is possibly better than\\ndoses of 5 e9 IU in terms of decreasing\\nthe use of additional uterotonics, there\\nwere limited data on adverse maternal\\nevents (particularly hypotension). Ofinterest, both studies used in the meta-analysis of this outcome exclusivelycompared 5 IU with 10 IU in a bolus onlyregimen.\\nOxytocin regimens were described\\nusing varying time intervals, which\\ncomplicated meaningful comparison.\\nHowever, available evidence suggeststhat when administering oxytocin in abolus plus infusion regimen, initial bolusdoses of <5 IU may lead to less nausea,\\nbut the effects of lower vs higher initialbolus doses on blood loss are not known.The infusion component of bolus plus\\ninfusion regimens most commonly\\ncontinued for 2 e4 hours.\\nFindings from nonrandomized\\nstudies, although not conclusive owingto a greater susceptibility to bias, werebroadly consistent with the ﬁndings of\\nmeta-analyses on RCTs. These generallyindicated that bolus plus infusion regi-\\nmens may be superior to bolus only\\nregimens and that higher oxytocin dosesmay be more effective but can increaseadverse maternal events. Among thebolus plus infusion regimens, 4 dose-ﬁnding RCTs reported that small initial\\ndoses (0.3 IU as a bolus or 0.27 e0.29 IU/\\nmin as a short infusion) may be adequate\\nto prevent uterine atony during planned\\nCD,\\n48e50with higher doses required at\\nintrapartum CD,47,50but the evidence\\nwas not conclusive and should be inter-preted with caution.\\nComparison with existing literature\\nOurﬁndings are broadly consistent with\\nprevious work on IV oxytocin dosing\\nregimens for PPH prevention followingat CD, including a 2012 systematic re-view\\n7of 7 RCTs (626 women) and a 2011\\nliterature review.6Both reviews recom-\\nmended the use of a small initial bolusdose (ranging between 0.3 and 3 IU)\\n6,7\\nwith 1 review further recommending abolus plus infusion regimen.7Both re-\\nviews further reported more adversehemodynamic events with higher dosesof oxytocin, which is consistent with ourﬁndings. Our ﬁndings are compatible\\nwith a 2019 international consensusstatement,\\n8which recommends using a 1\\nIU bolus followed by a 2.5 e7.5 IU/h\\ninfusion over 2 e4 hours and the WHO\\nrecommendation of 10 IU oxytocinadministered IVor intramuscular duringall births with doses divided into a smallinitial IV bolus with subsequent infusionduring CD.\\n4However, it is evident that\\ngood-quality trials comparing differentoxytocin dosing regimens are needed to\\nguide practice. It is noteworthy to\\nmention that national guidelines vary(Supplemental Table 8 ), probably\\nreﬂecting the lack of clear evidence to\\nguide practice. The 2017 AmericanCollege of Obstetricians and Gynecolo-gists guidelines recommend using adilute IV infusion (bolus dose of 10 IU)\\nfor PPH prevention without speci ﬁca-\\ntion for mode of delivery.\\n57Australian\\nguidelines only recommend prophylac-tic oxytocin for all births without speci-fying a dosing regimen.\\n61Carbetocin is\\nrecommended in Canada during plan-ned CD,\\n60and a bolus only oxytocin\\nregimen is recommended in the United\\nKingdom.58French guidelines recom-\\nmend a oxytocin bolus plus infusionregimen during CD, however, suggest aninitial bolus dose of 5 e10 IU.\\n59\\nStrengths and limitations\\nWe used a systematic and methodologi-cally robust approach to searching and\\nanalyzing literature without date or\\nlanguage restrictions. We included bothrandomized and nonrandomizedstudies, which allowed for a more thor-ough and nuanced investigation ofoxytocin dosing regimens. We also pre-speciﬁed outcomes that aligned with\\nWHO priority outcomes\\n4and the PPH\\ncore outcome set11and used the latest\\nand more sophisticated iterations of theCochrane risk of bias tools (ROB 2.0 andROBINS-I).\\n14,15\\nDespite this, evidence was generally\\nlimited for most outcomes. In a networkmeta-analysis by Gallos et al\\n5in which\\ndifferent uterotonic options werecompared, the authors similarly\\ndescribed inadequate reporting ofadverse events in trials of uterotonics forPPH prevention.\\n5The international\\nconsensus statement by Heesen et al8\\nalso called for further large studies onthis topic.\\n8Any such trials should be\\nsufﬁciently powered for important\\nhealth-related outcomes and should\\nclearly specify the dosing regimen. Spe-ciﬁcally, trials comparing different\\noxytocin doses of bolus plus infusionregimens should be conducted. Weconsider it particularly important thatfuture trials should report on theoutcome of PPH /C211000 mL, an impor-\\ntant outcome for clinical guideline de-\\ncision making.\\nWe also found hypotension to be a\\npoorly studied outcome, despite dose-dependent hypotension being welldescribed.\\n21,29,42,46,62Among RCTs, the\\neffects of different dosing regimens onhypotension were generally either\\ninconclusive or equivocal. No NRSI re-\\nported signi ﬁcant differences in the\\nincidence of hypotension. However, itwould not seem unreasonable to expectan increased incidence of hypotensionwith higher doses (particularly withbolus regimens), and it is likely that thecombination of a bolus plus infusion\\nregimen allows doses to exceed 5 IU\\nwhile avoiding signi ﬁcant hemodynamic\\ninstability. Indeed, we consider itparticularly important to prioritizeresearch in this area.\\nWe also did not ﬁnd any clear evidence\\nof diminishing returns from increasingdoses and/or longer time periods of\\ninfusion despite it also being well\\ndescribed.\\n22,26Again, this was largely\\nbecause of lack of good-quality data andis an area for which further research isrequired.\\nWe identi ﬁed a wide range of dosing\\nregimens that added to the complexity ofthis analysis and likely contributed to\\nhigh heterogeneity. Although we aimed\\nto standardize comparisons by usingtotal oxytocin dose, we were not able toaccount for other factors such as rate ofoxytocin administration or total infu-sion time. We acknowledge that our dosecategories are somewhat arbitrary,although necessary to standardize andajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 261', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 11}), Document(page_content='interpret comparisons. We also tried to\\nminimize the effect of subjective judg-ments on blood loss by including this inour risk of bias assessment and per-forming sensitivity analyses.\\nFinally, the majority of studies\\nincluded only women undergoing plan-ned CD with low risk of PPH. Hence,\\nthese ﬁndings may not be generalizable\\nto other, higher-risk groups of womenwho may require a different oxytocinregimen.\\nConclusions and implications\\nBased on current evidence, the mostappropriate oxytocin regimen may be\\nbolus plus infusion and an initial bolus\\nof<5 IU, although further trials are\\nneeded to con ﬁrm these conclusions.\\nBolus only regimens of 10 IU vs 5 IU maydecrease the use of additional utero-tonics, however, further research isrequired to understand the implicationson adverse events, particularly hypoten-\\nsion. In the absence of more robust evi-\\ndence, many current guidelines on PPHprevention following CD may warrantreconsideration. Further research isrequired, particularly in women at highrisk for PPH, for other important out-comes such as adverse maternal events,breastfeeding, and maternal well-being\\nand satisfaction.\\nFinal conclusion\\nThis systematic review and meta-\\nanalysis of IV oxytocin dosing regimensfor PPH prevention during CDs identi-ﬁed a lack of data for several important\\noutcomes. Future well-designed studiesare required to identify an optimaloxytocin dosing regimen for womenundergoing CD. Nevertheless, available\\ndata suggest that an IV bolus plus infu-\\nsion regimen, with an initial bolus doseof<5 IU, may be preferable. However,\\nthe degree of certainty for the evidencewas generally low, and further research isrequired to identify the optimal oxytocinregimen for PPH prevention duringCDs.\\n-\\nACKNOWLEDGMENTS\\nWe would like to acknowledge Patrick Condron\\n(The University of Melbourne, Melbourne,Australia) for his assistance with the search\\nstrategy; Dr Rangi de Silva, MBBS (Mercy Hos-\\npital for Women, Heidelberg, Australia) for herinsights on this topic; Dr Matthew Page, PhD(Monash University, Clayton, Australia) and Dr\\nTari Turner, PhD (Monash University) for their\\ninsights on data analysis; and Liz Comrie-Thomson (Burnet Institute, Melbourne,\\nAustralia) for her insights on the entire research\\nprocess. No acknowledged individual has anydisclosure pertaining to this review.\\nREFERENCES\\n1.Say L, Chou D, Gemmill A, et al. Global cau-\\nses of maternal death: a WHO systematic anal-ysis. Lancet Glob Health 2014;2:e323 –33.\\n2.World Health Organization. Trends in\\nmaternal mortality: 2000 to 2017: estimates by\\nWHO, UNICEF, UNFPA, World Bank Group andthe United Nations Population Division. Geneva:World Health Organization; 2019 .\\n3.Unterscheider J, Breathnach F, Geary M.\\nStandard medical therapy for postpartum hem-orrhage. In: Arulkumaran SS, Karoshi M,\\nKeith LG, Lalonde AB, B-Lynch C, eds.\\nA comprehensive textbook of postpartumhemorrhage. London, United Kingdom: SapiensPublishing; 2012. p. 355 –60.\\n4.World Health Organization. WHO recom-\\nmendations: uterotonics for the prevention ofpostpartum haemorrhage. 2018. Available at:https://apps.who.int/iris/bitstream/handle/\\n10665/277276/9789241550420-eng.pdf?ua ¼1\\n2018. Accessed Jan. 22, 2020.5.Gallos ID, Papadopoulou A, Man R, et al.\\nUterotonic agents for preventing postpartum\\nhaemorrhage: a network meta-analysis.Cochrane Database Syst Rev 2018;12:CD011689 .\\n6.Dyer RA, Butwick AJ, Carvalho B. Oxytocin\\nfor labour and caesarean delivery: implicationsfor the anaesthesiologist. Curr Opin Anaes-thesiol 2011;24:255 –61.\\n7.Stephens LC, Bruessel T. Systematic review\\nof oxytocin dosing at caesarean section.Anaesth Intensive Care 2012;40:247 –52.\\n8.Heesen M, Carvalho B, Carvalho JCA, et al.\\nInternational consensus statement on the use of\\nuterotonic agents during caesarean section.Anaesthesia 2019;74:1305 –19.\\n9.MIMS Australia. Oxytocin Apotex. 2018.\\nAvailable at: https://www-mimsonline-com-au.\\neu. Accessed April 4, 2020.\\n10.University of York Centre for Reviews and\\nDissemination. Prospero: international pro-\\nspective register of systematic reviews. Availableat: https://www.crd.york.ac.uk/prospero/ .\\nAccessed Feb. 12, 2020.\\n11.Meher S, Cuthbert A, Kirkham JJ, et al.\\nCore outcome sets for prevention and treat-ment of postpartum haemorrhage: an interna-\\ntional Delphi consensus study. BJOG\\n2019;126:83 –93.\\n12.EndNote . [computer program]. Philadel-\\nphia, PA: Clarivate Analytics; 2013 .13.Covidence systematic review software.\\nVeritas Health Innovation. Available at: www.\\ncovidence.org . Accessed Feb. 17, 2020.\\n14.Sterne JAC, Savovi /C19c J, Page MJ, et al. RoB\\n2: a revised tool for assessing risk of bias in\\nrandomised trials. BMJ 2019;366:l4898 .\\n15.Sterne JA, Hernán MA, Reeves BC, et al.\\nRobins-I: a tool for assessing risk of bias in non-\\nrandomised studies of interventions. BMJ\\n2016;355:i4919 .\\n16.Review manager (RevMan) [computer pro-\\ngram]. Version 5.3. Copenhagen: The Nordic\\nCochrane Centre, The Cochrane Collaboration;\\n2014 .\\n17.Schünemann H, Bro _zek J, Guyatt G,\\nOxman A. GRADE handbook for grading quality\\nof evidence and strength of recommendations.\\n2013. Available at: guidelinedevelopment.org/\\nhandbook 2013. Accessed Sep. 23, 2020.\\n18.Evidence Prime, Inc. GRADEpro GDT:\\nGRADEpro guideline development tool. 2020.Available at: gradepro.org 2020. Accessed Sep.\\n23, 2020.\\n19.Santesso N, Glenton C, Dahm P, et al.\\nGRADE guidelines 26: informative statements tocommunicate the ﬁndings of systematic reviews\\nof interventions. J Clin Epidemiol 2020;119:\\n126 –35.\\n20.Görges M, Zhou G, Brant R, Ansermino JM.\\nSequential allocation trial design in anesthesia: anintroduction to methods, modeling, and clinical\\napplications. Paediatr Anaesth 2017;27:240 –7.\\n21.Bhattacharya S, Ghosh S, Ray D, Mallik S,\\nLaha A. Oxytocin administration during cesar-\\nean delivery: randomized controlled trial to\\ncompare intravenous bolus with intravenousinfusion regimen. J Anaesthesiol Clin Pharmacol2013;29:32 –5.\\n22.Butwick AJ, Coleman L, Cohen SE,\\nRiley ET, Carvalho B. Minimum effective bolusdose of oxytocin during elective caesarean de-livery. Br J Anaesth 2010;104:338 –43.\\n23.Cecilia M, Vijayaselvi R, Bansal R, Lakshmi L,\\nJose R. Ten units intravenous oxytocin over 2-4 his as effective as 30 units over 8-12 h in preventing\\npostpartum hemorrhage after cesarean section:\\na randomized controlled trial. Indian J Pharmacol2018;50:279 –83.\\n24.Derbel M, Mekki D, Riahi A, Dimassi K,\\nMebazaa MS, Gara MF. Comparison of two\\noxytocin administration protocols in electivecesarean section: 5 iu versus 10 iu. Tunis Med2016;94:253 –8.\\n25.Dufﬁeld A, McKenzie C, Carvalho B, et al.\\nEffect of a high-rate versus a low-rate oxytocininfusion for maintaining uterine contractility dur-ing elective cesarean delivery: a prospective\\nrandomized clinical trial. Anesth Analg\\n2017;124:857 –62.\\n26.Ghulmiyyah LM, Usta IM, Ghazeeri G, et al.\\nIntravenous oxytocin use to decrease blood\\nloss during scheduled Cesarean delivery: a ran-domized double-blinded controlledtrial (OXYTRIAL). Am J Perinatol 2017;34:379 –87.\\n27.Golparvar M, Esterabi M, Talakoub R,\\nSaryazdi HH. Evaluation of in vivo effects ofoxytocin on coagulation of parturient duringSystematic Reviews ajog.org\\n262 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 12}), Document(page_content='cesarean delivery by thromboelastography.\\nJ Res Pharm Pract 2014;3:28 –33.\\n28.Güngördük K, Asicioglu O, Celikkol O,\\nOlgac Y, Ark C. Use of additional oxytocin toreduce blood loss at elective caesarean section:\\na randomised control trial. Aust N Z J Obstet\\nGynaecol 2010;50:36 –9.\\n29.Jonsson M, Hanson U, Lidell C, Nordén-\\nLindeberg S. ST depression at caesarean sec-\\ntion and the relation to oxytocin dose. A rando-mised controlled trial. BJOG 2010;117:76 –83.\\n30.Kajendran J, Silva GRC, Ranaraja SK.\\nEffects of 5 iu oxytocin bolus and 20 iu\\noxytocin infusion compared to 5 iu oxytocinbolus and normal saline infusion in the con-trol of blood loss during and after ante-\\npartum lower segment caesarean section: a\\nrandomized controlled trial. Ceylon Med J2017;62:121 –7.\\n31.Kikutani T, Oshima M, Sugimoto K,\\nShimada Y. Effects of intravenous infusion rate ofoxytocin on thoracic epidural pressure in partu-rients undregoing elective cesarean section.\\nJ Nippon Med Sch 2003;70:475 –9.\\n32.Kim TS, Bae JS, Park JM, Kang SK. He-\\nmodynamic effects of continuous intravenousinjection and bolus plus continuous intravenous\\ninjection of oxytocin in cesarean section. Korean\\nJ Anesthesiol 2011;61:482 –7.\\n33.King KJ, Douglas MJ, Unger W, Wong A,\\nKing RA. Five unit bolus oxytocin at cesarean\\ndelivery in women at risk of atony: a randomized,\\ndouble-blind, controlled trial. Anesth Analg2010;111:1460 –6.\\n34.Kiran S, Anand A, Singh T, Gupta N. To\\nestimate the minimum effective dose of oxytocinrequired to produce adequate uterine tone inwomen undergoing elective caesarean delivery.\\nEgypt J Anaesth 2013;29:161 –5.\\n35.Kovacheva VP, Soens MA, Tsen LC.\\nA randomized, Double-blinded Trial of a “Rule of\\nThrees ”algorithm versus continuous infusion of\\noxytocin during elective cesarean delivery.\\nAnesthesiology 2015;123:92 –100.\\n36.Munn MB, Owen J, Vincent R, Wake ﬁeld M,\\nChestnut DH, Hauth JC. Comparison of two\\noxytocin regimens to prevent uterine atony atcesarean delivery: a randomized controlled trial.Obstet Gynecol 2001;98:386 –90.\\n37.Murphy DJ, MacGregor H, Munishankar B,\\nMcLeod G. A randomised controlled trial ofoxytocin 5IU and placebo infusion versusoxytocin 5IU and 30IU infusion for the control of\\nblood loss at elective caesarean section –pilot\\nstudy. ISRCTN 40302163. Eur J Obstet Gyne-col Reprod Biol 2009;142:30 –3.\\n38.Palacio FJ, Morillas F, Ortiz-Gómez JR,\\nFornet I, Bermejo L, Cantalejo F. [Ef ﬁcacy of low-\\ndose oxytocin during elective cesarean section].Rev Esp Anestesiol Reanim 2011;58:6 –10.39.\\nPinder AJ, Dresner M, Calow C,\\nShorten GD, O ’Riordan J, Johnson R. Haemo-\\ndynamic changes caused by oxytocin duringcaesarean section under spinal anaesthesia. IntJ Obstet Anesth 2002;11:156 –9.\\n40.Qian XW, Drzymalski DM, Lv CC, Guo FH,\\nWang LY, Chen XZ. The ED50 and ED95 ofoxytocin infusion rate for maintaining uterine tone\\nduring elective caesarean delivery: a dose- ﬁnding\\nstudy. BMC Pregnancy Childbirth 2019;20:6 .\\n41.Sarna MC, Soni AK, Gomez M, Oriol NE.\\nIntravenous oxytocin in patients undergoing\\nelective cesarean section. Anesth Analg\\n1997;84:753 –6.\\n42.Sartain JB, Barry JJ, Howat PW,\\nMcCormack DI, Bryant M. Intravenous oxytocin\\nbolus of 2 units is superior to 5 units during elec-\\ntive caesarean section. Br J Anaesth 2008;101:822 –6.\\n43.Sheehan SR, Montgomery AA, Carey M,\\net al. Oxytocin bolus versus oxytocin bolus andinfusion for control of blood loss at electivecaesarean section: double blind, placebo\\ncontrolled, randomised trial. BMJ 2011;343:\\nd4661 .\\n44.Taj A, Ommid M. Haemodynamic effects of\\noxytocin as intravenous bolus or infusion on\\nwomen undergoing caesarean section. JK Sci\\n2014;16:52 –6.\\n45.Tariq M, Syed W. Comparison of haemo-\\ndynamic effect of equivalent dose of oxytocin\\ngiven as Bolus and in Fusion. Pak Armed Forces\\nMed J 2018;68:1517 –21.\\n46.Thomas JS, Koh SH, Cooper GM. Haemo-\\ndynamic effects of oxytocin given as i.v. bolus or\\ninfusion on women undergoing caesarean sec-tion. Br J Anaesth 2007;98:116 –9.\\n47.Balki M, Ronayne M, Davies S, et al. Mini-\\nmum oxytocin dose requirement after cesarean\\ndelivery for labor arrest. Obstet Gynecol2006;107:45 –50.\\n48.Carvalho JC, Balki M, Kingdom J,\\nWindrim R. Oxytocin requirements at elective\\ncesarean delivery: a dose- ﬁnding study. Obstet\\nGynecol 2004;104:1005 –10.\\n49.George RB, McKeen D, Chaplin AC,\\nMcLeod L. Up-down determination of theED(90) of oxytocin infusions for the prevention ofpostpartum uterine atony in parturients under-\\ngoing Cesarean delivery. Can J Anaesth\\n2010;57:578 –82.\\n50.Lavoie A, McCarthy RJ, Wong CA. The ED90\\nof prophylactic oxytocin infusion after delivery of\\nthe placenta during cesarean delivery in laboring\\ncompared with nonlaboring women: an up-downsequential allocation dose-response study.Anesth Analg 2015;121:159 –64.\\n51.Ahmadi F. A comparative study on infusion\\nof usual dose of oxytocin and 80 units dose ofoxytocin in the prevention of postpartumhemorrhage in cesarean section. J Adv Pharm\\nTechnol Res 2018;9:102 –6\\n.\\n52.Holleboom CAG, van Eyck J, Koenen SV,\\net al. Carbetocin in comparison with oxytocin inseveral dosing regimens for the prevention of\\nuterine atony after elective caesarean section in\\nthe Netherlands. Arch Gynecol Obstet2013;287:1111 –7.\\n53.Pursche T, Diedrich K, Banz-Jansen C.\\nBlood loss after caesarean section: dependingon the management of oxytocin application?Arch Gynecol Obstet 2012;286:633 –6.\\n54.Terblanche N, Otahal P, Messmer A, et al.\\nAn observational cohort study of 3 units versus 5units slow intravenous bolus oxytocin in womenundergoing elective caesarean delivery.\\nJ Physiol Pharmacol 2017;68:547 –53.\\n55.Beiranvand S, Karimi A, Vahabi S, Amin-\\nBidokhti A. Comparison of the mean minimum\\ndose of bolus oxytocin for proper uterine\\ncontraction during cesarean section. Curr ClinPharmacol 2019;14:208 –13.\\n56.McGuinness LA, Higgins JPT. Risk-of-\\nbias VISualization (robvis): an R package and\\nShiny web app for visualizing risk-of-biasassessments. Res Synth Methods 2021;12:55–61.\\n57.Committee on Practice Bulletins-Obstetrics.\\nPractice Bulletin No. 183: postpartum hemor-rhage. Obstet Gynecol 2017;130:e168 –86.\\n58.Prevention and management of postpartum\\nhaemorrhage: Green-top Guideline No. 52.\\nBJOG 2017;124:e106 –49.\\n59.Sentilhes L, Vayssière C, Deneux-\\nTharaux C, et al. Postpartum hemorrhage:\\nguidelines for clinical practice from the FrenchCollege of Gynaecologists and Obstetricians(CNGOF): in collaboration with the French So-\\nciety of Anesthesiology and Intensive Care\\n(SFAR). Eur J Obstet Gynecol Reprod Biol2016;198:12 –21.\\n60.Leduc D, Senikas V, Lalonde AB. No. 235-\\nactive management of the third stage of labour:\\nprevention and treatment of postpartum hem-orrhage. J Obstet Gynaecol Can 2018;40:\\ne841 –55.\\n61.Leung Y, Sgroi J, Vaughan J, et al. Man-\\nagement of postpartum haemorrhage (PPH).Royal Australian and New Zealand College of\\nObstetricians and Gynaecologists (RANZCOG).\\n2017. Available at: https://ranzcog.edu.au/\\nRANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%\\n20guidelines/Clinical-Obstetrics/Management-of-\\nPostpartum-Haemorrhage-(C-Obs-43)-Review-July-2017.pdf?ext ¼.pdf 2017. Accessed Oct.\\n29, 2020.\\n62.Langesceter E, Rosseland LA. Maternal\\nhemodynamics during cesarean delivery. ActaObstet Gynecol Scand 2006;85:126 .ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 13}), Document(page_content='APPENDIX A\\nPRISMA checklist\\nSection/topic R Checklist item Reported on page #\\nTITLE\\nTitle 1 Identify the report as a systematic review,\\nmeta-analysis, or both.1\\nABSTRACT\\nStructured summary 2 Provide a structured summary including, as applicable:\\nbackground; objectives; data sources; study eligibilitycriteria, participants, and interventions; study appraisal\\nand synthesis methods; results; limitations;\\nconclusions and implications of key ﬁndings;systematic review registration number.1\\nINTRODUCTION\\nRationale 3 Describe the rationale for the review in the context of\\nwhat is already known.2\\nObjectives 4 Provide an explicit statement of questions being\\naddressed with reference to participants,interventions, comparisons, outcomes, and studydesign (PICOS).2\\nMETHODS\\nProtocol and registration 5 Indicate if a review protocol exists, if and where it can\\nbe accessed (e.g., Web address), and, if available,\\nprovide registration information including registrationnumber.2\\nEligibility criteria 6 Specify study characteristics (e.g., PICOS, length of\\nfollow-up) and report characteristics (e.g., years\\nconsidered, language, publication status) used ascriteria for eligibility, giving rationale.2\\nInformation sources 7 Describe all information sources (e.g., databases with\\ndates of coverage, contact with study authors to\\nidentify additional studies) in the search and date last\\nsearched.2e3\\nSearch 8 Present full electronic search strategy for at least one\\ndatabase, including any limits used, such that it couldbe repeated.Supplemental\\nTable 1\\nStudy selection 9 State the process for selecting studies (i.e., screening,\\neligibility, included in systematic review, and, if\\napplicable, included in the meta-analysis).2e3\\nData collection process 10 Describe method of data extraction from reports (e.g.,\\npiloted forms, independently, in duplicate) and any\\nprocesses for obtaining and conﬁrming data from\\ninvestigators.3\\nData items 11 List and deﬁne all variables for which data were sought\\n(e.g., PICOS, funding sources) and any assumptionsand simpliﬁcations made.3\\nRisk of bias in individual studies 12 Describe methods used for assessing risk of bias of\\nindividual studies (including speciﬁcation of whether\\nthis was done at the study or outcome level), and howthis information is to be used in any data synthesis.3\\nSummary measures 13 State the principal summary measures (e.g., risk ratio,\\ndifference in means).3\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)Systematic Reviews ajog.org\\n263.e1 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 14}), Document(page_content='APPENDIX A\\nPRISMA checklist (continued)\\nSection/topic R Checklist item Reported on page #\\nSynthesis of results 14 Describe the methods of handling data and combining\\nresults of studies, if done, including measures ofconsistency (e.g., I2) for each meta-analysis.3\\nRisk of bias across studies 15 Specify any assessment of risk of bias that may affect\\nthe cumulative evidence (e.g., publication bias,\\nselective reporting within studies).3\\nAdditional analyses 16 Describe methods of additional analyses (e.g.,\\nsensitivity or subgroup analyses, meta-regression), ifdone, indicating which were pre-speciﬁed.3\\nRESULTS\\nStudy selection 17 Give numbers of studies screened, assessed for\\neligibility, and included in the review, with reasons for\\nexclusions at each stage, ideally with a ﬂow diagram.3e4&Figure 1\\nStudy characteristics 18 For each study, present characteristics for which data\\nwere extracted (e.g., study size, PICOS, follow-upperiod) and provide the citations.Table 1\\nRisk of bias within studies 19 Present data on risk of bias of each study and, if\\navailable, any outcome level assessment (see item 12).4,Supplemental\\nFigures 1 e4\\nResults of individual studies 20 For all outcomes considered (beneﬁts or harms),\\npresent, for each study: (a) simple summary data foreach intervention group (b) effect estimates andconﬁdence intervals, ideally with a forest plot.Supplemental\\nTables 5e7\\nSynthesis of results 21 Present results of each meta-analysis done, including\\nconﬁdence intervals and measures of consistency.4, 9e11,Supplemental\\nTables 5e7\\nRisk of bias across studies 22 Present results of any assessment of risk of bias across\\nstudies (see Item 15).Supplemental Figures 1 e4\\nAdditional analysis 23 Give results of additional analyses, if done (e.g.,\\nsensitivity or subgroup analyses, meta-regression [see\\nItem 16]).4, 9e11\\nDISCUSSION\\nSummary of evidence 24 Summarize the main ﬁndings including the strength of\\nevidence for each main outcome; consider theirrelevance to key groups (e.g., healthcare providers,users, and policy makers).11e13\\nLimitations 25 Discuss limitations at study and outcome level (e.g.,\\nrisk of bias), and at review-level (e.g., incomplete\\nretrieval of identiﬁed research, reporting bias).12e13\\nConclusions 26 Provide a general interpretation of the results in the\\ncontext of other evidence, and implications for future\\nresearch.13\\nFUNDING\\nFunding 27 Describe sources of funding for the systematic review\\nand other support (e.g., supply of data); role of fundersfor the systematic review.1\\nFor more information, visit: www.prisma-statement.org .\\nSupplemental Reference\\nMoher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263.e2', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 15}), Document(page_content='APPENDIX B\\nDeviations from protocol\\nProtocol Deviation Justiﬁcation\\nPrimary outcomes: PPH /C21500 mL and PPH /C211000 mL PPH /C21500 mL downgraded from primary outcome to\\nsecondary outcomeWe opted to downgrade PPH /C21500 mL from a primary\\nto a secondary outcome, considering that the deﬁnitionof PPH after CD is PPH /C211000 mL (as distinct from PPH\\nafter vaginal birth).\\nIncluded dyspnea and chest pain as additional\\nsecondary outcomesAdditional adverse events reported in some trials.\\nInclude only third stage administration of oxytocin Included administration of oxytocin at or around third\\nstagePracticality considerations means oxytocin not always\\nable to be delivered at third stage during CD.\\nRandom-effects model if I\\n2>30% Random-effects model for all analyses with >1 trial Given large heterogeneity of trials and as per Cochrane\\nhandbook, random-effects model provided a more\\nconservative estimate.\\nSpeciﬁc comparisons made between high dose vs low\\ndose bolus, and high dose vs low dose infusionWe further divided the comparison of studies into (1)\\ntype of IV administration and (2) total oxytocin doseusing the categories of <5 IU, 5e9 IU, 10e19 IU,\\n20e49 IU,/C2150 IU. Among studies comparing a bolus\\nplus infusion regimen, we further compared various\\ninitial bolus doses when followed by an infusion.The wide range of oxytocin regimens identiﬁed meant\\nthat our original approach of high and low dose was notpractical nor informative.\\nGRADE approach used to rate certainty of evidence. More accurately report study ﬁndings and draw\\nconclusions from the data.\\nSubgroup analysis for studies with maintenance\\ninfusions lasting 2 e4 h includedExplore hypothesis proposed by Heesen et al\\n8that\\nmaintenance infusion should be run for 2 e4h .\\nCD, cesarean delivery; GRADE , Grading of Recommendations, Assessment, Development, and Evaluations; PPH, postpartum hemorrhage.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.Systematic Reviews ajog.org\\n263.e3 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 16}), Document(page_content='SUPPLEMENTAL FIGURE 1\\nRandomized trials: risk of bias assessment by study\\nxx\\n++\\n++\\nxx\\n++\\n++\\n++\\nxx\\n−−\\n++\\n++\\n++\\n++\\n−−\\n−−\\n++\\n++\\n++\\nxx\\n++\\n++\\n++\\n−−\\n++\\n++\\n++\\n++\\n−−\\n++\\n−−xx\\n++\\n++\\nxx\\n++\\n++\\n++\\nxx\\n++\\nxx\\n++\\n++\\n++\\n++\\n−−\\n++\\n++\\n++\\nxx\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n−−\\n++\\n++xx\\nxx\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n−−\\n++\\n++\\n++\\n++\\n−−\\n++\\n++\\n++\\n++\\n−−\\n++\\n++\\n−−\\n−−\\nxx\\n++\\n++\\n++\\n++\\n++++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n−−\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n++\\n−−??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n??\\n++\\n??\\n??\\n????\\n++\\n++\\n??\\n++\\n??\\n++\\n++\\n++\\n++\\n??\\n++\\n++\\n??\\n??\\n++\\n??\\n++\\n++\\n++\\n++\\n++\\n??\\n++\\n??\\n??\\n++\\n??\\n++\\n??++\\n−−\\n++\\nxx\\n−−\\n−−\\n++\\n++\\nxx\\n++\\n++\\nxx\\n−−\\n−−\\n??\\n??\\n++\\nxx\\n++\\n−−\\nxx\\n++\\nxx\\nxxxx\\nxx\\n++\\nxx\\n++\\n++\\n++\\nxx\\n−−\\nxx\\n++\\n++\\n++\\n−−\\nxx\\n++\\n++\\n++\\nxx\\n−−\\n++\\n++\\n−−\\n−−\\nxx\\n++\\n++\\nxx\\n++\\n−−D1 D2 D3 D4 D5 D6 D7 Overall\\nBalki 2006\\nBhattacharya 2013\\nButwick 2010\\nCarvalho 2004\\nCecilia 2018\\nDerbel 2016\\nDuffield 2017\\nGeorge 2010\\nGhulmiyyah 2017\\nGolparvar 2014\\nGüngördük 2010\\nJonsson 2010\\nKajendran 2017\\nKikutani 2003\\nKim 2011\\nKing 2010\\nKiran 2013\\nKovacheva 2015\\nLavoie 2015\\nMunn 2001\\nMurphy 2009\\nPalacios 2011\\nPinder 2002\\nQian 2019\\nSarna 1997\\nSartain 2008\\nSheehan 2011\\nTaj 2014\\nTariq 2018\\nThomas 2007Risk of biasStudy\\nJudgement\\nx\\n−\\n+\\n?High\\nSome concerns\\nLow\\nNo information\\nNot applicable D1: DOMAIN 1: Randomisation\\n D2: DOMAIN 2: Deviations form the intended interventions\\n D3: DOMAIN 3: Missing outcome data\\n D4: DOMAIN 4: Measurement of the outcome\\n D5: DOMAIN 5: Selection of the reported result D6: DOMAIN 6 (OTHER): Conflicts of interest and funding source\\n D7: DOMAIN 7 (OTHER): Blood loss measurement\\nGenerated using robvis.56\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263.e4', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 17}), Document(page_content='SUPPLEMENTAL FIGURE 2\\nComparative randomized trials: risk of bias by domain\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet\\nGynecol 2021.\\nSUPPLEMENTAL FIGURE 3\\nNonrandomised studies of interventions: risk of bias by study\\nxx\\n++\\n−−\\n++\\n++!!\\n++\\n!!\\n++\\n++++\\n++\\n−−\\n++\\n−−??\\n++\\n??\\n−−\\n++++\\n−−\\n++\\n++\\n++−−\\n−−\\nxx\\n++\\n++++\\n++\\n++\\n++\\n++++\\n++\\n!!\\n++\\n++++\\n??\\nxx\\n++!!\\n−−\\n!!\\n−−\\n−−D1 D2 D3 D4 D5 D6 D7 D8 D9Overal l\\nAhmadi 2018\\nBeiranvand 2016\\nHolleboom 2013\\nPursche 2012\\nTerblanche 2017Risk of biasStudy\\nJudgement\\n!\\nx\\n−\\n+\\n?Critical\\nHigh\\nSome concerns\\nLow\\nNo informationNot applicable D1: Bias due to confounding\\n D2: Bias in selection of participants into the study\\n D3: Bias in classification of interventions\\n D4: Bias due to deviations from intended interventions\\n D5: Bias due to missing data\\n D6: Bias in measurement of outcomes D7: Bias in selection of the reported result\\n D8: Bias due to conflicts of interest and funding source\\n D9: Bias in the measurement of blood loss\\nGenerated using robvis.56\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet\\nGynecol 2021.Systematic Reviews ajog.org\\n263.e5 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 18}), Document(page_content='SUPPLEMENTAL FIGURE 4\\nNonrandomized studies of interventions: risk of bias by domain\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet\\nGynecol 2021.\\nSUPPLEMENTAL FIGURE 5\\nTotal oxytocin dose of 10 e19 IU vs 20 e49 IU: chest pain\\nCI, conﬁdence interval; IU, international unit.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263.e6', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 19}), Document(page_content='SUPPLEMENTAL FIGURE 6\\nTotal oxytocin dose of 20 e49 IU vs ‡50 IU: use of additional uterotonics\\nCI, conﬁdence interval; IU, international unit.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.\\nSUPPLEMENTAL FIGURE 7\\nInitial bolus dose of <5I Uv s5 e9 IU: nausea\\nCI, conﬁdence interval; IU, international unit.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.Systematic Reviews ajog.org\\n263.e7 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 20}), Document(page_content='SUPPLEMENTAL TABLE 1\\nSearch strategy\\nDatabase(s): Ovid MEDLINE(R) and Epub ahead of print, in-process, and other nonindexed citations and daily 1946 to February 14, 2020\\nNumber Searches Results\\n1 exp Oxytocin/ or (oxytocin or ocytocin or syntocinon or\\npitocin or oxytocic).mp. [mp ¼title, abstract, original\\ntitle, name of substance word, subject heading word,\\nﬂoating sub-heading word, keyword heading word,\\norganism supplementary concept word, protocolsupplementary concept word, rare disease\\nsupplementary concept word, unique identiﬁer,\\nsynonyms]28,066\\n2 exp Cesarean Section/ or (c?esarean or csection* or c\\nsection* or abdominal delivery or elective delivery orCS).mp.129,383\\n3 exp Postpartum Hemorrhage/ 6910\\n4 (h?em?or?hag* or pph or (blood adj2 loss) or bleed* or\\nuterine atony or atonic uterus).mp.538,153\\n5 3 or 4 538,153\\n6 exp drug administration routes/ 603,4117 ((oxytocin or oxytocic or syntocinon or pitocin or drug or\\ndrugs) adj5 (administ* or delivery or route or routes ordose or doses or dosing or dosage or dosages orintravenous or bolus or infusion or iv)).mp.876,861\\n8 6 or 7 1,338,847\\n9 1 and 2 and (5 or 8) 1565\\nDatabase(s): Embase Classic þEmbase 1947 to February 14, 2020\\n1 exp Oxytocin/ or (oxytocin or ocytocin or syntocinon or\\npitocin or oxytocic).mp. [mp ¼title, abstract, heading\\nword, drug trade name, original title, devicemanufacturer, drug manufacturer, device trade name,\\nkeyword, ﬂoating subheading word, candidate term\\nword]44,929\\n2 exp Cesarean Section/ or (c?esarean or csection* or c\\nsection* or abdominal delivery or elective delivery orCS).mp.204,077\\n3 exp Postpartum Hemorrhage/ 14,406\\n4 (h?em?or?hag* or pph or (blood adj2 loss) or bleed* or\\nuterine atony or atonic uterus).mp.968,513\\n5 3 or 4 968,513\\n6 exp drug administration routes/ 1,222,9627 ((oxytocin or oxytocic or syntocinon or pitocin or drug or\\ndrugs) adj5 (administ* or delivery or route or routes ordose or doses or dosing or dosage or dosages or\\nintravenous or bolus or infusion or iv)).mp.3,561,354\\n8 6 or 7 3,569,315\\n9 1 and 2 and (5 or 8) 4631\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263.e8', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 21}), Document(page_content='SUPPLEMENTAL TABLE 1\\nSearch strategy (continued)\\nDatabase(s): Ovid MEDLINE(R) and Epub ahead of print, in-process, and other nonindexed citations and daily 1946 to February 14, 2020\\nNumber Searches Results\\n1 exp Oxytocin/ or (oxytocin or ocytocin or syntocinon or\\npitocin or oxytocic).mp. [mp ¼title, abstract, heading\\nword, drug trade name, original title, device\\nmanufacturer, drug manufacturer, device trade name,\\nkeyword, ﬂoating subheading word, candidate termword]44,929\\n2 exp Cesarean Section/ or (c?esarean or csection* or c\\nsection* or abdominal delivery or elective delivery or\\nCS).mp.204,077\\n3 exp Postpartum Hemorrhage/ 14,406\\nDatabase: CINAHL CompleteInterface: EBSCOhost Research DatabasesSearch Screen: Advanced SearchDate: February 14, 2020(MM “Oxytocin”) or (oxytocin or ocytocin or syntocinon or pitocin or oxytocic) AND(MH “Cesarean Section þ”) or (c#esarean or csection* or c section* or abdominal delivery or elective delivery or CS) AND\\n((MH “Postpartum Hemorrhage”) or (h#em#or#hag* or pph or (blood N2 loss) or bleed* or uterine atony or atonic uterus)) or ((MH “Drug\\nAdministration þ”) or (oxytocin or oxytocic or syntocinon or pitocin or drug or drugs) N5 (administ* or delivery or route or routes or dose or doses or\\ndosing or dosage or dosages or intravenous or bolus or infusion or iv))\\n(797 results)Global Index Medicus, February 14, 2020tw:((tw:(oxytocin OR ocytocin OR syntocinon OR pitocin OR oxytocic)) AND (tw:(c?esarean OR csection* OR c section* OR abdominal delivery OR\\nelective delivery OR cs)) AND (tw:(h?em?or?hag* OR pph OR blood loss OR loss of blood OR bleed* OR uterine atony OR atonic uterus OR administ*\\nOR delivery OR route OR routes OR dose OR doses OR dosing OR dosage OR dosages OR intravenous OR bolus OR infusion OR iv)))\\n(686 results)CENTRALSearch Name: MDRP (19 Feb)Date Run: February 19, 2020, 02:16:59 PM\\nID Search Hits\\n#1 MeSH descriptor: [Oxytocin] explode all trees 1802\\n#2 ((oxytocin or ocytocin or syntocinon or pitocin or\\noxytocic)):ti,ab,kw4706\\n#3 MeSH descriptor: [Cesarean Section] explode all trees 2989\\n#4 ((c?esarean or csection* or “c section*” or “abdominal\\ndelivery” or “elective delivery” or CS)):ti,ab,kw18,468\\n#5 MeSH descriptor: [Postpartum Hemorrhage] explode\\nall trees621\\n#6 ((h*em*or*hag* or pph or “blood NEAR/2 loss” or\\nbleed* or “uterine atony” or “atonic uterus”)):ti,ab,kw63,385\\n#7 MeSH descriptor: [Administration, Intravenous]\\nexplode all trees18,229\\n#8 (((oxytocin or oxytocic or syntocinon or pitocin or drug\\nor drugs) NEXT/5 (administ* or delivery or route orroutes or dose or doses or dosing or dosage or dosages\\nor intravenous or bolus or infusion or iv))):ti,ab,kw149,407\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)Systematic Reviews ajog.org\\n263.e9 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 22}), Document(page_content='SUPPLEMENTAL TABLE 1\\nSearch strategy (continued)\\nID Search Hits\\n#9 #1 or #2 4706\\n#10 #3 or #4 18,468#11 #5 or #6 63,385#12 #7 or #8 162,486#13 #9 and #10 and (#11 or #12) 1048ICTRP, February 19, 2020Oxytocin AND hemorrhage (207)Oxytocin AND dose (163)Oxytocin AND bleed (191)ClinicalTrials.gov, February 19, 2020oxytocin (other terms) jPost Partum Hemorrhage (condition) (151)\\noxytocin (other terms) jBleed (condition) (178)\\noxytocin (other terms) jCaesarean (condition) jDose (intervention) (41)\\nICTRP , International Clinical Trials Registry Platform; MeSH , medical subject headings.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.\\nSUPPLEMENTAL TABLE 2\\nAssessment of risk of bias of methods of measuring blood loss\\nROB assessment\\n(RCTs)ROB assessment\\n(NRSIs) Description\\nLow Low Objective measurements such as calculated blood\\nloss, weighing sponges or volumetric assessment\\nHigh Critical Subjective measurement such as clinical or visual\\nestimates\\nMedium Moderate Mixture of objective and subjective measurementsUnclear Unclear Unspeciﬁed methods of measurement\\nNRSI , nonrandomized studies of intervention; RCT, randomized controlled trial.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263.e10', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 23}), Document(page_content='SUPPLEMENTAL TABLE 3\\nDosing regimens of all included studies\\nAuthor, year n Oxytocin dosing regimens\\nComparative RCTsArm 1 Arm 2 Arm 3 Arm 4 Arm 5 Arm 6\\nAll arms Study dose 30 minaStudy dose 30 minaStudy dose 30 minaStudy dose 30 minaStudy dose 30 minaStudy dose 30 mina\\nBhattacharya\\net al,21201380 Bolus 3 IU Infusion of 3 IU — — — — Infusion (0.16\\nIU/min) after\\nstudy period\\nButwick et al,22\\n201075 Bolus 0 IU Bolus 0.5 IU Bolus 1 IU Bolus 3 IU Bolus 5 IU — Infusion 10 IU\\nover 2 h onceadequate UT\\nplus infusion\\n(0.16 IU/min)after studyperiod\\nCecilia et al,\\n23\\n2018271 2.5 IU/h over\\n2e4h1.25 IU 10 IU/h over\\n8e12 h5I U — — — — —\\nDerbel et al,24\\n201687 10 IU 14 IU 5 IU 9 IU — — — — Infusion of 25\\nIU over 3 h\\nDufﬁeld et al,25\\n201751 Infusion 10\\nIU until d/cNEbInfusion of\\n60 IU until\\nd/cNEb— — — — Bolus 1 IU\\nGhulmiyyah\\net al,262017189 20 IU over 30 min 30 IU over 30 min 40 IU over 30 min — — — Infusion of 30\\nIU then 20 IUthen 10 IU for24 h total\\nGolparvar et al,\\n27\\n201484 15 IU/h 7.5 IU 30 IU/h 15 IU — — — — —\\nGu¨ngo¨ rdu¨k\\net al,282010720 Placebo\\ninfusion5 IU 30 IU over\\n4h12.5 IU — — — — Bolus 5 IU\\nJonsson et al,29\\n2010103 5 IU 10 IU — — — — —\\nKajendran et al,30\\n201792 20 IU over\\n4h10 IU Placebo\\ninfusion5 IU — — — — Bolus 5 IU\\nKikutani et al,31\\n200390 Bolus 10 IU Infusion 10 IU — — — — —\\nKim et al,322011 60 20 IU over\\n40 min15 IU Bolus 2 IU\\nplus infusionof 10 IU over\\n40 min9.5 IU Bolus 5 IU\\nplus infusionof 10 IU over\\n40 min12.5 IU — — — —\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)Systematic Reviews ajog.org\\n263.e11 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 24}), Document(page_content='SUPPLEMENTAL TABLE 3\\nDosing regimens of all included studies (continued)\\nAuthor, year n Oxytocin dosing regimens\\nComparative RCTsArm 1 Arm 2 Arm 3 Arm 4 Arm 5 Arm 6\\nAll arms Study dose 30 minaStudy dose 30 minaStudy dose 30 minaStudy dose 30 minaStudy dose 30 minaStudy dose 30 mina\\nKing et al,332010 143 Bolus\\n5I U45 IU Placebo\\nbolus40 IU — — — — Infusion of 40\\nIU over 30 min\\nthen infusionof 20 IU over 4h\\nKiran et al,\\n342013 90 Bolus 0.5 5.5 IU Bolus 1 IU 6 IU Bolus 2 IU 7 IU — — — Infusion of 20\\nIU over 2 h\\nKovacheva et al,35\\n201560 Bolus 3 IU\\nevery 3 minuntiladequate UT\\nor max of 3\\nbolusesNE\\nbInfusion of\\n30 IU untiladequate UTNE\\nb— — — — Infusion of 30\\nIU over 6 h\\nMunn et al,36\\n2001321 Infusion of 10 IU\\nover 30 minInfusion of 80 IU\\nover 30 min— — — — Infusion of 20\\nIU over 8 h\\nMurphy et al,37\\n2009115 Placebo\\ninfusion5 IU Infusion of\\n30 IU over\\n4h8.75 IU — — — — Bolus 5 IU\\nPalacio et al,38\\n2011104 Bolus 1 IU\\nplus infusionat 2.5 IU/h for\\n24 h2.125 IU Infusion of\\n20 IU at 700mIU/min plus\\n10 IU/h for\\n24 h21 IU — — — — —\\nPinder et al,\\n39\\n200234 Bolus 5 IU Bolus 10 IU — — — — —\\nQian et al,402019 145 No infusion 1 IU Infusion of 1\\nIU/h for 1 h1.5 IU Infusion of 2\\nIU/h for 1 h2 IU Infusion of 3\\nIU/h for 1 h2.5 IU Infusion of 5\\nIU/h for 1 h3.5 IU Infusion of 8\\nIU/h for 1 h5 IU Bolus 1 IU\\nSarna et al,41\\n199740 Infusion of 5 IU\\nat 1 IU/minInfusion of 10 IU\\nat 1 IU/minInfusion of 15 IU at 1 IU/\\nminInfusion of 20 IU at 1 IU/\\nmin—— —\\nSartain et al,42\\n200880 Bolus 2 IU 7 IU Bolus 5 IU 10 IU — — — — Infusion of 40\\nIU over 4 h\\nSheehan et al,43\\n20112069 Placebo\\ninfusion5 IU Infusion of\\n40 IU over 4\\nh10 IU — — — — Bolus 5 IU\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263.e12', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 25}), Document(page_content='SUPPLEMENTAL TABLE 3\\nDosing regimens of all included studies (continued)\\nAuthor, year n Oxytocin dosing regimens\\nComparative RCTsArm 1 Arm 2 Arm 3 Arm 4 Arm 5 Arm 6\\nAll arms Study dose 30 minaStudy dose 30 minaStudy dose 30 minaStudy dose 30 minaStudy dose 30 minaStudy dose 30 mina\\nTaj and Ommid,44\\n201450 Bolus 10 IU\\nover 15 sInfusion of 10 IU\\nover 5 min—— — — —\\nTariq and Syed,45\\n201890 Bolus 5 IU\\nover 10 sInfusion of 5 IU\\nover 5 min—— — — —\\nThomas et al,46\\n200728 Bolus 5 IU\\nover 1 sInfusion of 5 IU\\nover 5 min—— — — —\\nDose-ﬁnding randomized trialsInitial dose\\n(Dose in 30 min not estimable for all studies in this category) Maintenance infusion to all patients\\nBalki et al,472006 30 Starting bolus 0.5 IU\\nSubsequently up or down by 0.5 IU (based on response of preceding patient)Infusion 40 mU/min for up to 8 h\\nCarvalho et al,48\\n200440 Starting bolus 0.5 IU\\nSubsequently up or down by 0.5 IU (based on response of preceding patient)Infusion 40 mU/min until discharge\\nGeorge et al,49\\n201040 Starting infusion at 0.4 IU/min\\nSubsequently up or down by 0.1 IU for 1 h (based on response of preceding\\npatient)Infusion 30 IU until discharge\\nLavoie et al,50\\n201570 Starting infusion 18 IU/h until end CD\\nSubsequently up or down by 3 IU/h (based on response of preceding patient)Infusion 3.6 IU/h until discharge\\nNonrandomized studies of\\ninterventionsArm 1 Arm 2 Arm 3\\nAll arms Study dose 30 minaStudy dose 30 minaStudy dose 30 mina\\nAhmadi et al,51\\n2018150 Infusion 80 IU NEbInfusion 30 IU NEb——\\nHolleboom et al,52\\n20131122 Bolus 5 IU Bolus 10 IU Bolus 5 IU plus\\ninfusion of 10 IUover 2 h7.5 IU —\\nPursche et al,\\n53\\n2012454 Bolus 3 IU plus infusion of 3 IU in\\n500 mL at 100 mL/h3.3 IU Infusion with at least\\n120 mL/hNEb——\\nTerblanche\\net al,54201773 Bolus 3 IU Bolus 5 IU — —\\nBeiranvand\\net al,55201941 Bolus 1 IU bolus, plus 0.5 IU\\nevery min until adequate UTNEb— — Infusion at 30 mU/min\\nCD, cesarean delivery; d/c, discharge; IU, international unit; NE, not estimable; UT, uterine tone.\\naTotal oxytocin dose received by each arm within ﬁrst 30 minutes;bNot estimable because the study does provide enough information to reasonably estimate total dose received in 30 minutes.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.Systematic Reviews ajog.org\\n263.e13 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 26}), Document(page_content='SUPPLEMENTAL TABLE 4\\nAvailable data by outcome\\nOutcomeRCTs, number of\\ntrials (women)aNRSIs, number oftrials (women)aTotal, number oftrials (women)a\\nPPH/C211000 mL 8 (3324) 1 (1100) 9 (4424)\\nPPH/C21500 mL 1 (115) 1 (1100) 2 (1215)\\nAdditional uterotonics 25 (5053) 3 (1323) 28 (6376)Uterine tone 10 (1177) 3 (479) 13 (1656)Surgical or nonsurgical interventions 5 (385) 1 (1100) 6 (1485)Blood transfusion 12 (3994) 1 (1100) 13 (5094)Mean blood loss 18 (4329) 2 (1173) 20 (5502)Change in hemoglobin 4 (2400) 2 (1096) 6 (3496)Nausea 9 (727) 3 (162) 12 (889)Vomiting 10 (778) 2 (156) 12 (934)Headache 6 (477) 3 (162) 9 (639)Hypotension 10 (1048) 3 (162) 13 (1210)Chest pain 7 (687) 3 (1278) 10 (1965)Myocardial ischemia\\nb2 (173) 0 (0) 2 (173)\\nArrythmiac5 (416) 0 (0) 5 (416)\\nBradycardia 3 (236) 0 (0) 3 (236)Tachycardia 7 (794) 0 (0) 7 (794)Maternal deaths 0 (0) 0 (0) 0 (0)ICU admissions 0 (0) 0 (0) 0 (0)Shock 0 (0) 0 (0) 0 (0)Water intoxication 0 (0) 0 (0) 0 (0)Breastfeeding after discharge 0 (0) 0 (0) 0 (0)Maternal sense of well-being 0 (0) 0 (0) 0 (0)Maternal satisfaction 0 (0) 0 (0) 0 (0)\\nStudies were not included if there were zero events in both arms or if standard deviations were not provided with mean values.\\nICU, intensive care unit; NRSI , nonrandomized studies of intervention; PPH, postpartum hemorrhage; RCT, randomized controlled trial.\\naIncludes extra doses of oxytocin, prostaglandins (carboprost, misoprostol), and ergometrine;bIncludes troponin I rise and ST segment changes;cIncludes electrocardiogram changes.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263.e14', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 27}), Document(page_content='SUPPLEMENTAL TABLE 5\\nSummary of funding from randomized studies: type of IV administration\\nPatient or population: women undergoing cesarean delivery\\nOutcomes Anticipated absolute effects (95% CI)aRelative effect\\n(95% CI)Number of\\nwomen\\n(studies)Certainty of\\nevidence\\n(GRADE) CommentsSensitivity analyses\\n(risk of bias, methodof blood loss\\nmeasurement)Subgroup analyses\\n(maintenance\\ninfusion for 2 e4h )\\nType of IV administration: bolus only vs infusion only\\nRisk with infusion only Risk with bolus only\\nUse of additional\\nuterotonics359 per 1000 327 per 1000\\n(187e578)RR, 0.91\\n(0.52e1.61)78\\n(2 RCTs)4/C13/C13/C13\\nVery low\\nb,cEffect is inconclusive ROB: RR, 0.88\\n(0.44e1.75)Not estimablei\\nMean blood loss The mean blood loss was\\n600 mL in both armsMD, 0 mL ( e309 to 309) — 28\\n(1 RCT)4/C13/C13/C13\\nVery lowb,cEffect is inconclusive Not estimablejNot estimablei\\nNausea 80 per 1000 200 per 1000\\n(42e936)RR, 2.50\\n(0.53e11.70)50\\n(1 RCT)4/C13/C13/C13\\nVery lowb,cEffect is inconclusive Not estimablejNot estimablei\\nVomiting 40 per 1000 120 per 1000\\n(13e1000)RR, 3.00\\n(0.33e26.92)50\\n(1 RCT)4/C13/C13/C13\\nVery lowb,cEffect is inconclusive Not estimablejNot estimablei\\nChest pain Unable to calculate because there were zero events in\\ninfusion armRR, 7.00\\n(0.37e131.28)80\\n(1 RCT)4/C13/C13/C13\\nVery lowb,cEffect is inconclusive Not estimablejNot estimablei\\nMyocardial\\nischemiaUnable to calculate because there were zero events in\\ninfusion armRR, 11.00\\n(0.63e192.56)80\\n(1 RCT)4/C13/C13/C13\\nVery lowbedEffect is inconclusive Not estimablejNot estimablei\\nType of IV administration: bolus only vs bolus plus infusion only\\nRisk with bolus plus infusion Risk with bolus only\\nPPH/C211000 mL 119 per 1000 172 per 1000\\n(89e329)RR, 1.44\\n(0.75e2.76)2976\\n(4 RCTs)4/C13/C13/C13\\nVery lowe,fEffect is inconclusive Not requiredkNot estimablei\\nUse of additional\\nuterotonics120 per 1000 209 per 1000\\n(145e304)RR, 1.75\\n(1.21e2.54)3125\\n(5 RCTs)4/C13/C13/C13\\nVery lowe,fEffect is inconclusive ROB: RR, 1.60\\n(0.99e2.58)Not estimablei\\nPPH/C21500 mL 179 per 1000 259 per 1000\\n(127e532)RR, 1.45\\n(0.71e2.98)110 (1 RCT) 4/C13/C13/C13\\nVery lowc,gEffect is inconclusive Not estimablejNot estimablei\\nBlood transfusion 9 per 1000 14 per 1000\\n(4e46)RR, 1.55\\n(0.47e5.13)2870\\n(3 RCTs)44/C13/C13\\nLowf,hMay make no clear\\ndifferenceNot requiredkNot estimablei\\nBlood loss The mean blood loss ranged\\nfrom 569 e693 mLMD, 52 mL more\\n(0.4 more to 104 more)— 3068\\n(5 RCTs)444 /C13\\nModeratehBolus only regimensprobably slightlyincreases blood lossROB: MD, 53 mL\\n(e4 to 111 mL)Not estimable\\ni\\nBlood loss: not\\nrequiredj\\nChange inhemoglobinThe mean change in\\nhemoglobin ranged\\n0.88e11.9 g/dLMD, 0.05 g/dL less\\n(0.27 less to 0.17 more)— 2260\\n(3 RCTs)4444\\nHighMakes no clear\\ndifferenceNot required\\nkNot estimablei\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)Systematic Reviews ajog.org\\n263.e15 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 28}), Document(page_content='SUPPLEMENTAL TABLE 5\\nSummary of funding from randomized studies: type of IV administration (continued)\\nPatient or population: women undergoing cesarean delivery\\nOutcomes Anticipated absolute effects (95% CI)aRelative effect\\n(95% CI)Number of\\nwomen\\n(studies)Certainty of\\nevidence\\n(GRADE) CommentsSensitivity analyses\\n(risk of bias, methodof blood loss\\nmeasurement)Subgroup analyses\\n(maintenance\\ninfusion for 2 e4h )\\nNausea 92 per 1000 200 per 1000\\n(76e525)RR, 2.18\\n(0.83e5.73)145\\n(1 RCT)4/C13/C13/C13\\nVery low\\nc,gEffect is inconclusive Not estimablejNot estimablei\\nHypotension 142 per 1000 200 per 1000\\n(81e492)RR, 1.41\\n(0.57e3.47)145\\n(1 RCT)4/C13/C13/C13\\nVery lowc,gEffect is inconclusive Not estimablejNot estimablei\\nChest pain 50 per 1000 137 per 1000\\n(44e434)RR, 2.74\\n(0.87e8.67)145\\n(1 RCT)4/C13/C13/C13\\nVery lowc,gEffect is inconclusive Not estimablejNot estimablei\\nSatisfactory\\nuterine tone767 per 1000 483 per 1000\\n(314e728)RR, 0.63\\n(0.41e0.95)145\\n(1 RCT)44/C13/C13\\nLowf,gBolus only regimens\\nmay decreaseincidenceNot estimable\\njNot estimablei\\nSurgical or\\nnonsurgical\\ninterventionsUnable to calculate because zero events occurred in either arms 92\\n(1 RCT)—— — —\\nVomiting Unable to calculate because zero events occurred in either arms 145\\n(1 RCT)—— — —\\nBradycardia Unable to calculate because zero events occurred in either arms 145\\n(1 RCT)—— — —\\nTachycardia Unable to calculate because zero events occurred in either arms 145\\n(1 RCT)—— — —\\nDyspnea Unable to calculate because zero events occurred in either arms 145\\n(1 RCT)—— — —\\nType of IV administration: infusion only vs bolus plus infusion\\nRisk with bolus plus infusion Risk with infusion only\\nUse of additional\\nuterotonics143 per 1000 270 per 1000\\n(132e551)RR, 1.88\\n(0.92e3.84)441\\n(5 RCTs)4/C13/C13/C13\\nVery lowfehEffect is inconclusive ROB: RR, 1.59\\n(0.71e3.54)RR, 1.39\\n(0.87e2.22)\\nMean blood loss The mean blood loss ranged\\nbetween 455 e693 mLMD, 20 mL more\\n(13 less to 53 more)— 283\\n(3 RCTs)4/C13/C13/C13\\nVery lowb,fEffect is inconclusive ROB: MD, 43 mL\\n(e12 to 97 mL)MD, 90 mL\\n(e2 to 182 mL)\\nBlood loss: MD, 9 mL\\n(2e17 mL)\\nNausea 53 per 1000 49 per 1000\\n(17e145)RR, 1.05\\n(0.28e3.97)277\\n(3 RCTs)4/C13/C13/C13\\nVery lowb,cEffect is inconclusive ROB: RR, 3.45\\n(0.44e27.20)RR, 2.88\\n(0.12e69.49)\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263.e16', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 29}), Document(page_content='SUPPLEMENTAL TABLE 5\\nSummary of funding from randomized studies: type of IV administration (continued)\\nPatient or population: women undergoing cesarean delivery\\nOutcomes Anticipated absolute effects (95% CI)aRelative effect\\n(95% CI)Number of\\nwomen\\n(studies)Certainty of\\nevidence\\n(GRADE) CommentsSensitivity analyses\\n(risk of bias, methodof blood loss\\nmeasurement)Subgroup analyses\\n(maintenance\\ninfusion for 2 e4h )\\nHypotension 186 per 1000 111 per 1000\\n(63e195)RR, 0.60\\n(0.34e1.05)263\\n(2 RCTs)444 /C13\\nModerate\\nfProbably makes noclear differenceNot required\\nkNot estimablei\\nSatisfactory\\nuterine tone927 per 1000 918 per 1000\\n(834e1000)RR, 0.98\\n(0.90e1.06)164\\n(2 RCTs)44/C13/C13\\nLowd,fMay make no clear\\ndifferenceNot requiredkNot estimablei\\nBlood transfusion 41 per 1000 14 per 1000\\n(2e134)RR, 0.35\\n(0.04e3.26)143\\n(1 RCT)44/C13/C13\\nLowcMay make no cleardifferenceNot estimable\\njNot requiredl\\nVomiting 100 per 1000 50 per 1000\\n(6e418)RR, 0.50\\n(0.06e4.18)60\\n(1 RCT)44/C13/C13\\nLowcMay make no cleardifferenceNot estimable\\njNot estimablei\\nHeadache 13 per 1000 5 per 1000\\n(0e110)RR, 0.36\\n(0.01e8.71)152\\n(1 RCT)44/C13/C13\\nLowcMay make no cleardifferenceNot estimable\\njNot requiredl\\nCardiac arrythmia 67 per 1000 100 per 1000\\n(18e556)RR, 1.50\\n(0.27e8.34)60\\n(1 RCT)44/C13/C13\\nLowcMay make no cleardifferenceNot estimable\\njNot estimablei\\nTachycardia 14 per 1000 14 per 1000\\n(1e215)RR, 0.96\\n(0.06e15.04)143\\n(1 RCT)44/C13/C13\\nLowcMay make no cleardifferenceNot estimable\\njNot requiredl\\nSurgical\\ninterventionsUnable to calculate as zero events in both arms 75\\n(1 RCT)—— — —\\nChest pain Unable to calculate as zero events in both arms 75\\n(1 RCT)—— — —\\nDyspnea Unable to calculate as zero events in both arms 75\\n(1 RCT)—— — —\\nSensitivity analysis of risk of bias included studies only at overall low risk of bias.\\nSensitivity analysis of method of blood loss measurement included studies only at low risk of bias for that domain.Subgroup analysis included only studies using a bolus plus infusion regimen, for which the infusion duration ranged between 2 to 4 hours.GRADE working group grades of evidence were as follows:\\nHigh certainty: we are very conﬁdent that the true effect lies close to that of the estimate of the effect.\\nModerate certainty: we are moderately conﬁdent in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.\\nLow certainty: our conﬁdence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.Very low certainty: we have very little conﬁdence in the effect estimate; the true effect is likely to be substantially different from the estimate of e ffect.\\nCI, conﬁdence interval; IV, intravenous; MD, mean difference; PPH, postpartum hemorrhage; RCT, randomized controlled trial; ROB, risk of bias; RR, risk ratio.\\naThe risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and i ts 95% CI);bDowngraded for very serious risk of bias;cDowngraded for very serious imprecision;dDowngraded\\nfor serious indirectness;eDowngraded for very serious inconsistency;fDowngraded for serious imprecision;gDowngraded for serious risk of bias;hDowngraded for serious inconsistency;iNot estimable because no studies used maintenance infusion for 2 to 4\\nhours in both arms;jNot estimable because it was a single study;kNot required as all studies at low risk of bias;lNot required because all studies used maintenance infusion for 2 to 4 hours in both arms.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.Systematic Reviews ajog.org\\n263.e17 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 30}), Document(page_content='SUPPLEMENTAL TABLE 6\\nSummary of ﬁndings from randomized studies: total oxytocin dose\\nPatient or population: women undergoing cesarean delivery\\nOutcomes Anticipated absolute effectsa(95% CI)Relative effect\\n(95% CI)Number of\\nwomen\\n(studies)Certainty of\\nevidence\\n(GRADE) CommentsSensitivity analyses\\n(risk of bias, methodof blood loss\\nmeasurement)Subgroup analyses\\n(maintenance of\\ninfusion for 2 e4h )\\nTotal oxytocin dose: <5I Uv s5 e9I U\\nRisk with 5 e9 IU Risk with <5I U\\nPPH/C211000 Unable to calculate because zero events were recorded in either arm 145\\n(1 RCT)——— —\\nUse of additional\\nuterotonics120 per 1000 379 per 1000\\n(172e838)RR, 3.16\\n(1.43e6.98)145\\n(1 RCT)4/C13/C13/C13\\nVery low\\nbedEffect is\\ninconclusiveNot estimableiNot estimablej\\nMean blood loss The mean blood loss\\nranged from\\n642e661 mLMD, 20 mL more\\n(116 less to 156 more)— 145\\n(1 RCT)4/C13/C13/C13\\nVery lowbedEffect is\\ninconclusiveNot estimableiNot estimablej\\nNausea 100 per 1000 116 per 1000\\n(43e315)RR, 1.16\\n(0.43e3.15)145\\n(1 RCT)4/C13/C13/C13\\nVery lowb,c,eEffect is\\ninconclusiveNot estimableiNot estimablej\\nHypotension 100 per 1000 221 per 1000\\n(89e551)RR, 2.21\\n(0.89e5.51)145\\n(1 RCT)4/C13/C13/C13\\nVery lowb,c,eEffect is\\ninconclusiveNot estimableiNot estimablej\\nChest pain 60 per 1000 84 per 1000\\n(23e304)RR, 1.40\\n(0.39e5.06)145\\n(1 RCT)4/C13/C13/C13\\nVery lowb,c,eEffect is\\ninconclusiveNot estimableiNot estimablej\\nSatisfactory uterine tone 900 per 1000 621 per 1000\\n(522e747)RR, 0.69\\n(0.58e0.83)145\\n(1 RCT)4/C13/C13/C13\\nVery lowbedEffect is\\ninconclusiveNot estimableiNot estimablej\\nBlood transfusion Unable to calculate because zero events were recorded in either arm 145\\n(1 RCT)——— —\\nVomiting Unable to calculate because zero events were recorded in either arm 145\\n(1 RCT)——— —\\nBradycardia Unable to calculate because zero events were recorded in either arm 145\\n(1 RCT)——— —\\nTachycardia Unable to calculate because zero events were recorded in either arm 145\\n(1 RCT)——— —\\nDyspnea Unable to calculate because zero events were recorded in either arm 145\\n(1 RCT)——— —\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263.e18', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 31}), Document(page_content='SUPPLEMENTAL TABLE 6\\nSummary of ﬁndings from randomized studies: total oxytocin dose (continued)\\nPatient or population: women undergoing cesarean delivery\\nOutcomes Anticipated absolute effectsa(95% CI)Relative effect\\n(95% CI)Number of\\nwomen\\n(studies)Certainty of\\nevidence\\n(GRADE) CommentsSensitivity analyses\\n(risk of bias, methodof blood loss\\nmeasurement)Subgroup analyses\\n(maintenance of\\ninfusion for 2 e4h )\\nTotal oxytocin dose: 5 e9I Uv s1 0 e19 IU\\nRisk with\\n10e19 IURisk with\\n5e9I U\\nUse of additional\\nuterotonicsUnable to calculate because zero events were recorded\\nin the 10 e19 IU armRR, 13.00\\n(1.75e96.37)137\\n(2 RCTs)44/C13/C13\\nLow\\nb,d5e9 IU may\\nincrease\\nincidenceROB: RR, 18.64\\n(1.11e312.11)Not estimablej\\nMean blood loss The mean blood loss\\nranged 540 e578 mLMD, 58 mL more\\n(9 mL less to 124 mL more)— 133\\n(2 RCTs)4/C13/C13/C13\\nVery lowd,fEffect is\\ninconclusiveROB: MD, 45 mL\\n(e109 to 199 mL)Not estimablej\\nBlood loss: not\\nrequiredkNot estimablej\\nMyocardial ischemia 39 per 1000 38 per 1000\\n(5e263)RR 0.98\\n(0.14e6.70)103\\n(1 RCT)44/C13/C13\\nLOWeMay make nocleardifference.Not estimable\\niNot estimablej\\nHypotension Unable to calculate as zero events in both arms 60\\n(1 RCT)——— —\\nTotal oxytocin dose: 5 e9I Uv s2 0 e49 IU\\nRisk with\\n20e49 IURisk with\\n5e9I U\\nPPH/C211000 mL 129 per 1000 186 per 1000\\n(97e357)RR, 1.44\\n(0.75e2.76)2831\\n(4 RCTs)4/C13/C13/C13\\nVery lowc,d,gEffect is\\ninconclusiveNot estimableiNot estimablej\\nUse of additional\\nuterotonics110 per 1000 177 per 1000\\n(109e285)RR, 1.60\\n(0.99e2.58)2980\\n(4 RCTs)4/C13/C13/C13\\nVery lowc,d,hEffect is\\ninconclusiveNot estimableiNot estimablej\\nPPH/C21500 mL 179 per 1000 259 per 1000\\n(127e532)RR, 1.45\\n(0.71e2.98)110 (1 RCT) 4/C13/C13/C13\\nVery lowb,eEffect is\\ninconclusiveNot estimableiNot estimablej\\nBlood transfusion 9 per 1000 13 per 1000\\n(4e45)RR, 1.55\\n(0.47e5.13)2980\\n(4 RCTs)4/C13/C13/C13\\nVery lowc,d,hEffect is\\ninconclusiveNot estimableiNot estimablej\\nMean blood loss The mean blood loss\\nranged from 455 e610\\nmLMD, 53 mL more\\n(4 less to 111 more)— 2923\\n(4 RCTs)4/C13/C13/C13\\nVery lowc,gEffect is\\ninconclusiveNot estimableiNot estimablej\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)Systematic Reviews ajog.org\\n263.e19 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 32}), Document(page_content='SUPPLEMENTAL TABLE 6\\nSummary of ﬁndings from randomized studies: total oxytocin dose (continued)\\nPatient or population: women undergoing cesarean delivery\\nOutcomes Anticipated absolute effectsa(95% CI)Relative effect\\n(95% CI)Number of\\nwomen\\n(studies)Certainty of\\nevidence\\n(GRADE) CommentsSensitivity analyses\\n(risk of bias, methodof blood loss\\nmeasurement)Subgroup analyses\\n(maintenance of\\ninfusion for 2 e4h )\\nChange in hemoglobin The mean change in\\nhemoglobin ranged from0.88e12.1 g/dLMD, 0.05 g/dL less\\n(0.27 less to 0.17 more)— 2260\\n(3 RCTs)44/C13/C13\\nLow\\nc,dMakes no\\ncleardifferenceNot estimable\\niNot estimablej\\nTotal oxytocin dose: 10 e19 IU vs 20 e49 IU\\nRisk with\\n20e49 IURisk with\\n10e19 IU\\nUse of additional\\nuterotonics45 per 1000 15 per 1000\\n(5e46)RR, 0.32\\n(0.10e1.02)331\\n(2 RCTs)4/C13/C13/C13\\nVery lowc,d,fEffect is\\ninconclusiveRR, 1.01 (0.06\\ne15.94)Not estimablej\\nBlood transfusion 51 per 1000 44 per 1000\\n(14e135)RR, 0.86\\n(0.28e2.62)271\\n(1 RCT)44/C13/C13\\nLoweMay make nocleardifferenceNot estimable\\niNot estimablej\\nNausea 100 per 1000 200 per 1000\\n(47e856)RR, 2.00\\n(0.47e8.56)60\\n(1 RCT)4/C13/C13/C13\\nVery lowc,e,fEffect is\\ninconclusiveNot estimableiNot estimablej\\nVomiting 150 per 1000 50 per 1000\\n(9e276)RR, 0.33\\n(0.06e1.84)60\\n(1 RCT)4/C13/C13/C13\\nVery lowc,e,fEffect is\\ninconclusiveNot estimableiNot estimablej\\nChest pain 74 per 1000 4 per 1000\\n(0e60)RR, 0.05\\n(0.00e0.81)271\\n(1 RCT)444 /C13\\nModerated10e19 IU may\\nreduce\\nincidenceNot estimableiNot estimablej\\nTachycardia 44 per 1000 37 per 1000\\n(11e119)RR, 0.84\\n(0.26e2.69)271\\n(1 RCT)44/C13/C13\\nLoweMay make nocleardifferenceNot estimable\\niNot estimablej\\nMean blood loss The mean blood ranged\\nfrom 448 e457 mLMD, 9 mL less\\n(17 less to 0.7 less)—6 0\\n(1 RCT)4/C13/C13/C13\\nVery lowc,d,fEffect is\\ninconclusiveNot estimableiNot estimablej\\nSatisfactory uterine tone 949 per 1000 996 per 1000\\n(949e1000)RR, 1.05\\n(1.00e1.09)271\\n(1 RCT)444 /C13\\nModeratedProbablymakes no\\ncleardifferenceNot estimable\\niNot estimablej\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263.e20', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 33}), Document(page_content='SUPPLEMENTAL TABLE 6\\nSummary of ﬁndings from randomized studies: total oxytocin dose (continued)\\nPatient or population: women undergoing cesarean delivery\\nOutcomes Anticipated absolute effectsa(95% CI)Relative effect\\n(95% CI)Number of\\nwomen\\n(studies)Certainty of\\nevidence\\n(GRADE) CommentsSensitivity analyses\\n(risk of bias, methodof blood loss\\nmeasurement)Subgroup analyses\\n(maintenance of\\ninfusion for 2 e4h )\\nTotal oxytocin dose: 20 e49 IU vs /C2150 IU\\nRisk with\\n/C2150 IURisk with 20 e49 IU\\nUse of additional\\nuterotonics190 per 1000 393 per 1000\\n(270e572)RR, 2.07\\n(1.42e3.01)321\\n(1 RCT)44/C13/C13\\nLow\\nb,d20e49 IU may\\nincrease\\nincidenceNot estimableiNot estimablej\\nMean blood loss The mean blood ranged\\nfrom 937 e957 mLMD, 20 mL more\\n(14 less to 54 more)— 321\\n(1 RCT)44/C13/C13\\nLowfMay make nocleardifferenceNot estimable\\niNot estimablej\\nHypotension 241 per 1000 253 per 1000\\n(171e368)RR, 1.05\\n(0.71e1.53)321\\n(1 RCT)44/C13/C13\\nLowb,dMay make no\\nclear\\ndifferenceNot estimableiNot estimablej\\nSensitivity analysis of risk of bias included studies only at overall low risk of bias.\\nSensitivity analysis of method of blood loss measurement included studies only at low risk of bias for that domain.Subgroup analysis included only studies using a bolus plus infusion regimen for which the infusion duration ranged between 2 and 4 hours.GRADE Working Group grades of evidence:\\nHigh certainty: we are very conﬁdent that the true effect lies close to that of the estimate of the effect.\\nModerate certainty: we are moderately conﬁdent in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.\\nLow certainty: our conﬁdence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.Very low certainty: we have very little conﬁdence in the effect estimate; the true effect is likely to be substantially different from the estimate of e ffect.\\nCI, conﬁdence interval; MD, mean difference; PPH, postpartum hemorrhage; RCT, randomized controlled trial; ROB, risk of bias; RR, risk ratio.\\naThe risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and i ts 95% CI);bDowngraded for serious risk of bias;cDowngraded for serious indirectness;dDowngraded for\\nserious imprecision;eDowngraded for very serious imprecision;fDowngraded for very serious risk of bias;gDowngraded for very serious inconsistency;hDowngraded for serious inconsistency;iNot estimable because it was a single study;jNot estimable\\nbecause no studies used maintenance infusion for 2 to 4 hours in both arms\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.Systematic Reviews ajog.org\\n263.e21 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 34}), Document(page_content='SUPPLEMENTAL TABLE 7\\nSummary of ﬁndings from randomized studies: initial bolus dose in a bolus plus infusion regimen\\nPatient or population: women undergoing cesarean delivery\\nOutcomes Anticipated absolute effectsa(95% CI)Relative\\neffect\\n(95% CI)Number of\\nwomen\\n(studies)Certainty of\\nevidence\\n(GRADE) CommentsSensitivity analyses\\n(risk of bias, method\\nof blood loss\\nmeasurement)Subgroup\\nanalyses(maintenance\\ninfusion for\\n2e4h )\\nInitial bolus dose in a bolus plus infusion regimen: <5I Uv s5I U\\nRisk with <5 IU Risk with 5 IU\\nUse of additional\\nuterotonics133 per 1000 147 per 1000\\n(69e311)RR, 1.08\\n(0.51e2.31)179\\n(3 RCTs)44/C13/C13\\nLow\\nbMay make no cleardifferenceROB: RRe1.01\\n(0.45-2.24)RR, 1.01\\n(0.45e2.24)\\nNausea 253 per 1000 66 per 1000\\n(28e160)RR, 0.29\\n(0.10e0.81)179\\n(3 RCTs)44/C13/C13\\nLow\\nc,d<5 IU may reduce\\nincidenceROB: RR, 0.15\\n(0.04e0.54)RR, 0.15\\n(0.04e0.54)\\nVomiting 120 per 1000 26 per 1000\\n(6e119)RR, 0.23\\n(0.05e1.04)179\\n(3 RCTs)44/C13/C13\\nLowc,dMay make no clear\\ndifferenceROB: RR, 0.17\\n(0.02e1.32)RR, 0.17\\n(0.02e1.32)\\nMean blood loss The mean blood loss ranged\\nfrom446e451 mLMD, 4 mL more\\n(4 less to 13 more)—4 0\\n(1 RCT)4/C13/C13/C13\\nVery low\\nd,eEffect is inconclusive Not estimablefNot estimableg\\nSurgical or\\nnonsurgical\\ninterventionsUnable to calculate because zero events were recorded in either arm 59\\n(1 RCT)— ———\\nBlood transfusion Unable to calculate because zero events were recorded in either arm 59\\n(1 RCT)— ———\\nChest pain Unable to calculate because zero events were recorded in either arm 59\\n(1 RCT)— ———\\nCardiac arrythmia Unable to calculate because zero events were recorded in either arm 59\\n(1 RCT)— ———\\nDyspnea Unable to calculate because zero events were recorded in either arm 59\\n(1 RCT)— ———\\nHypotension Unable to calculate because zero events were recorded in either arm 40\\n(1 RCT)— ———\\nInitial bolus dose in a bolus plus infusion regimen: 5 IU vs 10 IU\\nRisk with 10 IU Risk with 5 IU\\nMean blood loss The mean blood loss ranged\\nfrom 875 e877 mLMD, 2 mL more\\n(135 less to 138 more)—8 7\\n(1 RCT)44/C13/C13\\nLowc,dMay make no clear\\ndifferenceNot estimablefNot requiredh\\nChest pain 114 per 1000 47 per 1000\\n(9e227)RR, 0.41\\n(0.08e2.00)87\\n(1 RCT)44/C13/C13\\nLowbEffect is inconclusive Not estimablefNot requiredh\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021. (continued)ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263.e22', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 35}), Document(page_content='SUPPLEMENTAL TABLE 7\\nSummary of ﬁndings from randomized studies: initial bolus dose in a bolus plus infusion regimen (continued)\\nPatient or population: women undergoing cesarean delivery\\nOutcomes Anticipated absolute effectsa(95% CI)Relative\\neffect\\n(95% CI)Number of\\nwomen\\n(studies)Certainty of\\nevidence\\n(GRADE) CommentsSensitivity analyses\\n(risk of bias, method\\nof blood loss\\nmeasurement)Subgroup\\nanalyses(maintenance\\ninfusion for\\n2e4h )\\nCardiac arrythmia 23 per 1000 8 per 1000\\n(0e185)RR, 0.34\\n(0.01e8.14)87\\n(1 RCT)44/C13/C13\\nLow\\nbMay make no cleardifferenceNot estimable\\nfNot requiredh\\nSurgical or nonsurgical\\ninterventionsUnable to calculate because zero events were recorded in either arm 87\\n(1 RCT)— ———\\nDyspnea Unable to calculate because zero events were recorded in either arm 87\\n(1 RCT)— ———\\nSensitivity analysis of risk of bias included studies only at an overall low risk of bias.\\nSensitivity analysis of method of blood loss measurement included studies only at low risk of bias for that domain.Subgroup analysis included only studies using a bolus plus infusion regimen, for which the infusion duration ranged between 2 e4 hours.\\nGRADE Working Group grades of evidence.\\nHigh certainty: we are very conﬁdent that the true effect lies close to that of the estimate of the effect.Moderate certainty: we are moderately conﬁdent in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.\\nLow certainty: our conﬁdence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.Very low certainty: we have very little conﬁdence in the effect estimate; the true effect is likely to be substantially different from the estimate of e ffect.\\nCI, conﬁdence interval; MD, mean difference; RCT, randomized controlled trial; ROB, risk of bias; RR, risk ratio.\\naThe risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and i ts 95% CI);bDowngraded for very serious imprecision;cDowngraded for serious risk of bias;dDowngraded for\\nserious imprecision;eDowngraded for very serious risk of bias;fNot estimable because it was a single study;gNot estimable because no studies used maintenance infusion for 2 to 4 hours in both arms;hNot required because all studies used maintenance infusion\\nfor 2 to 4 hours in both arms.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.Systematic Reviews ajog.org\\n263.e23 American Journal of Obstetrics &Gynecology SEPTEMBER 2021', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 36}), Document(page_content='SUPPLEMENTAL TABLE 8\\nGuidelines on oxytocin dosing recommendations with cesarean deliveries\\nCountry Governing body Recommendation\\nInternational WHO (2018) 10 IU IV or IM during all births, with doses to be divided\\nas a small IV bolus and an infusion at CD.4\\nInternational International consensus statement (2019) 1 IU bolus followed by 2.5 e7.5 IU/h infusion for around\\n2e4 h during planned CD.8\\nUnited States ACOG (2017) Dilute IV infusion (bolus dose of 10 IU).\\nNo speciﬁcation for CD.57\\nUnited Kingdom RCOG (2016) Oxytocin 5 IU IV by slow injection during CD.58\\nFrance CNGOF (2016) Oxytocin at 5 e10 IU IV by slow injection during CD plus\\nmaintenance infusion not exceeding 10 IU/h which canbe stopped after 2 h based on clinical judgment.\\n59\\nCanada SOCG (2018) Carbetocin 100 mg as IV bolus over 1 min during\\nelective CD.60\\nAustralia and New Zealand RANZCOG (2017) Prophylactic oxytocin recommended for all births. No\\nrecommendation on dose or dosing regimen provided.\\nNo speciﬁcation for CD.61\\nACOG , American College of Obstetricians and Gynecologists; CD, cesarean delivery; CNGOF , French National College of Obstetricians and Gynecologists; IV, intravenous; IM, intramuscular; IU, international units; RANZCOG , Royal Australian and New Zealand College\\nof Obstetricians and Gynaecologists; RCOG , Royal College of Obstetricians and Gynaecologists; SOGC , Society of Obstetricians and Gynaecologists of Canada; WHO , World Health Organization.\\nPhung. Oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery. Am J Obstet Gynecol 2021.ajog.org Systematic Reviews\\nSEPTEMBER 2021 American Journal of Obstetrics &Gynecology 263.e24', metadata={'source': '..\\\\public\\\\rawDataset\\\\Intravenous oxytocin dosing regimens.pdf', 'page': 37}), Document(page_content='Prevention and Management of Postpartum\\nHaemorrhage\\nGreen-top Guideline No. 52\\nDecember 2016\\nPlease cite this paper as: Mavrides E, Allard S, Chandraharan E, Collins P, Green L, Hunt BJ, Riris S, Thomson AJ on behalf\\nof the Royal College of Obstetricians and Gynaecologists. Prevention and management of postpartum haemorrhage.\\nBJOG 2016 ;124:e106 –e149.\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 0}), Document(page_content='DOI: 10.1111/1471-0528.14178\\nPrevention and Management of Postpartum Haemorrhage\\nThis is the second edition of this guideline, which was published in 2009 under the same title. The 2009 guideline\\nwas based on an earlier guideline on the management of postpartum haemorrhage (PPH) developed in 1998 underthe auspices of the Scottish Committee of the Royal College of Obstetricians and Gynaecologists (RCOG) andupdated in 2002.\\n1\\nExecutive summary of recommendations\\nPrediction and prevention of PPH\\nWhat are the risk factors for developing PPH and how can they be minimised?\\nRisk factors\\nRisk factors for PPH may present antenatally or intrapartum; care plans must be modi ﬁed as\\nand when risk factors arise. ✓\\nClinicians must be aware of risk factors for PPH and should take these into account whencounselling women about place of delivery.✓\\nWomen with known risk factors for PPH should only be delivered in a hospital with a bloodbank on site.D\\nMinimising risk –treating antenatal anaemia\\nAntenatal anaemia should be investigated and treated appropriately as this may reduce the\\nmorbidity associated with PPH. [ New 2016 ]D\\nMinimising risk –reducing blood loss at delivery\\nUterine massage is of no bene ﬁt in the prophylaxis of PPH. [ New 2016 ]A\\nProphylactic uterotonics should be routinely offered in the management of the third stage of\\nlabour in all women as they reduce the risk of PPH.A\\nRCOG Green-top Guideline No. 52 e107 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 1}), Document(page_content='For women without risk factors for PPH delivering vaginally, oxytocin (10 iu by intramuscular\\ninjection) is the agent of choice for prophylaxis in the third stage of labour. A higher dose ofoxytocin is unlikely to be bene ﬁcial.A\\nFor women delivering by caesarean section, oxytocin (5 iu by slow intravenous injection) should\\nbe used to encourage contraction of the uterus and to decrease blood loss.B\\nErgometrine –oxytocin may be used in the absence of hypertension in women at increased risk\\nof haemorrhage as it reduces the risk of minor PPH (500 –1000 ml).C\\nFor women at increased risk of haemorrhage, it is possible that a combination of preventative\\nmeasures might be superior to syntocinon alone to prevent PPH. [ New 2016 ] ✓\\nClinicians should consider the use of intravenous tranexamic acid (0.5 –1.0 g), in addition to oxytocin,\\nat caesarean section to reduce blood loss in women at increased risk of PPH. [ New 2016 ]A\\nHow should PPH be managed?\\nIdentiﬁcation of the severity of haemorrhage\\nClinicians should be aware that the visual estimation of peripartum blood loss is inaccurate and\\nthat clinical signs and symptoms should be included in the assessment of PPH. [ New 2016 ]C\\nCommunication and multidisciplinary care\\nCommunication with the woman\\nCommunication with the patient and her birthing partner is important, and clear information of\\nwhat is happening should be given from the outset. [ New 2016 ] ✓\\nWho should be informed when the woman presents with PPH?\\nRelevant staff with an appropriate level of expertise should be alerted of PPH. [ New 2016 ]✓\\nThe midwife in charge and the ﬁrst-line obstetric and anaesthetic staff should be alerted when\\nwomen present with minor PPH (blood loss 500 –1000 ml) without clinical shock. ✓\\nA multidisciplinary team involving senior members of staff should be summoned to attend to\\nwomen with major PPH (blood loss of more than 1000 ml) and ongoing bleeding or clinical shock. ✓\\nRCOG Green-top Guideline No. 52 e108 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 2}), Document(page_content='Resuscitation\\nMeasures for minor PPH\\nMeasures for minor PPH (blood loss 500 –1000 ml) without clinical shock:✓\\n/C15intravenous access (one 14-gauge cannula)\\n/C15urgent venepuncture (20 ml) for:\\n–group and screen\\n–full blood count\\n–coagulation screen, including ﬁbrinogen\\n/C15pulse, respiratory rate and blood pressure recording every 15 minutes\\n/C15commence warmed crystalloid infusion.\\nMeasures for major PPH\\nFull protocol for major PPH (blood loss greater than 1000 ml) and continuing to bleed or\\nclinical shock (see Appendix III):\\n/C15A and B –assess airway and breathing\\n/C15C–evaluate circulation\\n/C15position the patient ﬂat\\n/C15keep the woman warm using appropriate available measures\\n/C15transfuse blood as soon as possible, if clinically required\\n/C15until blood is available, infuse up to 3.5 l of warmed clear ﬂuids, initially 2 l of warmed\\nisotonic crystalloid. Further ﬂuid resuscitation can continue with additional isotonic\\ncrystalloid or colloid (succinylated gelatin). Hydroxyethyl starch should not be used.\\n/C15the best equipment available should be used to achieve rapid warmed infusion of ﬂuids\\n/C15special blood ﬁlters should not be used, as they slow infusions.\\nBlood transfusion\\nThere are no ﬁrm criteria for initiating red cell transfusion. The decision to provide blood\\ntransfusion should be based on both clinical and haematological assessment. [ New 2016 ] ✓\\nSelection of red cell units for transfusion\\nMajor obstetric haemorrhage protocols must include the provision of emergency blood with\\nimmediate issue of group O, rhesus D (RhD)-negative and K-negative units, with a switch to\\ngroup-speci ﬁc blood as soon as feasible. [ New 2016 ]D\\nIf clinically signi ﬁcant red cell antibodies are present, close liaison with the transfusion laboratory is\\nessential to avoid delay in transfusion in life-threatening haemorrhage. [ New 2016 ]D✓\\nRCOG Green-top Guideline No. 52 e109 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 3}), Document(page_content='All delivery units, especially small units without a blood bank on site, should maintain a supply\\nof group O, RhD-negative blood. [ New 2016 ] ✓\\nIntraoperative cell salvage should be considered for emergency use in PPH associated with\\ncaesarean section and with vaginal delivery. [ New 2016 ]D\\nBlood components\\nTransfusion of fresh frozen plasma (FFP)\\nIf no haemostatic results are available and bleeding is continuing, then, after 4 units of red\\nblood cells, FFP should be infused at a dose of 12 –15 ml/kg until haemostatic test results are\\nknown. [ New 2016 ]D\\nIf no haemostatic tests are available, early FFP should be considered for conditions with a\\nsuspected coagulopathy, such as placental abruption or amniotic ﬂuid embolism, or where\\ndetection of PPH has been delayed. [ New 2016 ]✓\\nIf prothrombin time/activated partial thromboplastin time is more than 1.5 times normal and\\nhaemorrhage is ongoing, volumes of FFP in excess of 15 ml/kg are likely to be needed tocorrect coagulopathy. [ New 2016 ]D\\nClinicians should be aware that these blood components must be ordered as soon as a need\\nfor them is anticipated, as there will always be a short delay in supply because of the need forthawing. [ New 2016 ]✓\\nFibrinogen\\nA plasma ﬁbrinogen level of greater than 2 g/l should be maintained during ongoing PPH.\\n[New 2016 ]C\\nCryoprecipitate should be used for ﬁbrinogen replacement. [ New 2016 ]D\\nTransfusion of platelets\\nDuring PPH, platelets should be transfused when the platelet count is less than 75 3109/l\\nbased on laboratory monitoring. [ New 2016 ]D\\nIs there a role for antiﬁbrinolytic drugs?\\nConsideration should be given to the use of tranexamic acid in the management of PPH.\\n[New 2016 ]B\\nRCOG Green-top Guideline No. 52 e110 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 4}), Document(page_content='Is there a role for recombinant factor VIIa (rFVIIa) therapy?\\nThe routine use of rFVIIa is not recommended in the management of major PPH unless as part\\nof a clinical trial. [ New 2016 ] ✓\\nMonitoring and investigation in major PPH: what investigations should be performed and how should women be\\nmonitored?\\nFull protocol for monitoring and investigation in major PPH (blood loss greater than 1000 ml)\\nand ongoing haemorrhage or clinical shock:\\n/C15immediate venepuncture (20 ml) for:\\n–cross-match (4 units minimum)\\n–full blood count\\n–coagulation screen, including ﬁbrinogen\\n–renal and liver function for baseline\\n/C15monitor temperature every 15 minutes\\n/C15continuous pulse, blood pressure recording and respiratory rate (using oximeter,\\nelectrocardiogram and automated blood pressure recording)\\n/C15Foley catheter to monitor urine output\\n/C15two peripheral cannulae, 14 gauge\\n/C15consider arterial line monitoring (once appropriately experienced staff available for insertion)\\n/C15consider transfer to intensive therapy unit once the bleeding is controlled or monitoring athigh dependency unit on delivery suite, if appropriate\\n/C15recording of parameters on a modi ﬁed early obstetric warning score (MEOWS) chart (see\\nAppendix IV)\\n/C15acting and escalating promptly when abnormal scores from a MEOWS chart are observed\\n/C15documentation of ﬂuid balance, blood, blood products and procedures.\\nWhat is the role of the anaesthetist in the management of PPH?\\nThe management of PPH requires a multidisciplinary approach: the anaesthetist plays a crucial\\nrole in maintaining haemodynamic stability and, if necessary, in determining and administeringthe most appropriate method of anaesthesia. [ New 2016 ]D\\nWhat methods should be employed to arrest the bleeding?\\nClinicians should be prepared to use a combination of pharmacological, mechanical and surgical\\nmethods to arrest PPH. These methods should be directed towards the causative factor. [ New 2016 ]D\\nWhat pharmacological and mechanical strategies can be used?\\nWhen uterine atony is perceived to be a cause of the bleeding, then a sequence of mechanical\\nand pharmacological measures should be instituted in turn until the bleeding stops. ✓D\\nRCOG Green-top Guideline No. 52 e111 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 5}), Document(page_content='What surgical treatments can be employed to arrest the bleeding?\\nIf pharmacological measures fail to control the haemorrhage, surgical interventions should be\\ninitiated sooner rather than later.D\\nIntrauterine balloon tamponade is an appropriate ﬁrst-line ‘surgical ’intervention for most\\nwomen where uterine atony is the only or main cause of haemorrhage.C\\nConservative surgical interventions may be attempted as second line, depending on clinicalcircumstances and available expertise.C\\nIt is recommended that a laminated diagram of the brace suture technique be kept in theatre.✓\\nResort to hysterectomy sooner rather than later (especially in cases of placenta accreta oruterine rupture) .C\\nIdeally and when feasible, a second experienced clinician should be involved in the decision for\\nhysterectomy. ✓\\nHow should secondary PPH be managed?\\nIn women presenting with secondary PPH, an assessment of vaginal microbiology should be\\nperformed (high vaginal and endocervical swabs) and appropriate use of antimicrobial therapyshould be initiated when endometritis is suspected. [ New 2016 ]D\\nA pelvic ultrasound may help to exclude the presence of retained products of conception,\\nalthough the diagnosis of retained products is unreliable. [ New 2016 ]C\\nSurgical evacuation of retained placental tissue should be undertaken or supervised by an\\nexperienced clinician.D\\nRisk management\\nTraining and preparation: what measures can be taken to ensure optimal management of PPH?\\nEvery maternity unit should have a multidisciplinary protocol for the management of PPH.[New 2016 ]✓\\nAll staff involved in maternity care should receive training in the management of obstetric\\nemergencies, including the management of PPH.B\\nTraining for PPH should be multiprofessional and include team rehearsals. [ New 2016 ]B\\nAll cases of PPH involving a blood loss of greater than 1500 ml should be the subject of a\\nformal clinical incident review.D\\nRCOG Green-top Guideline No. 52 e112 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 6}), Document(page_content='Documentation\\nAccurate documentation of a delivery with PPH is essential.✓\\nDebrieﬁng\\nAn opportunity to discuss the events surrounding the obstetric haemorrhage should be offered\\nto the woman (possibly with her birthing partner/s) at a mutually convenient time. ✓\\n1. Purpose and scope\\nPrimary postpartum haemorrhage (PPH) is the most common form of major obstetric haemorrhage. The traditional\\ndeﬁnition of primary PPH is the loss of 500 ml or more of blood from the genital tract within 24 hours of the birthof a baby.\\n2PPH can be minor (500 –1000 ml) or major (more than 1000 ml). Major can be further subdivided into\\nmoderate (1001 –2000 ml) and severe (more than 2000 ml). In women with lower body mass (e.g. less than 60 kg), a\\nlower level of blood loss may be clinically signiﬁcant.3The recommendations in this guideline apply to women\\nexperiencing a primary PPH of 500 ml or more.\\nSecondary PPH is deﬁned as abnormal or excessive bleeding from the birth canal between 24 hours and 12 weeks\\npostnatally.4This guideline also includes recommendations speciﬁc to the management of secondary PPH.\\nWomen with pre-existing bleeding disorders and women taking therapeutic anticoagulants are at increased risk of PPH;\\nthis guideline does not include speciﬁc recommendations for the management of such situations or for managinghaemorrhage in women who refuse blood transfusion. Guidance on these topics is available from other sources.\\n5–8\\nThis guideline has been developed primarily for clinicians working in consultant-led obstetric units in the UK;\\nrecommendations may be less appropriate for other settings where facilities, resources and routine practices differ.There is increasing emphasis on the availability of births at home or in midwife-led units.\\n9Obstetricians and\\nmidwives should develop guidelines for the management of obstetric emergencies that may occur in the community,including PPH. This is beyond the scope of this guideline.\\n10\\nThis guideline is restricted in scope to the management of PPH; the management of antepartum haemorrhage is thesubject of the RCOG Green-top Guideline No. 63.\\n11The prevention and management of PPH related to placenta\\npraevia and placenta praevia accreta is addressed in Green-top Guideline No. 27,12while Green-top Guideline No. 4713\\nprovides guidance on the appropriate use of blood and blood products in obstetric practice.\\n2. Introduction and background epidemiology\\nObstetric haemorrhage remains one of the major causes of maternal death in both developed and developingcountries. The 2011 –13 Conﬁdential Enquiries into Maternal Deaths and Morbidity report\\n3identiﬁed 13 direct deaths\\ndue to obstetric haemorrhage in the UK and Ireland; the report places obstetric haemorrhage as the second leadingcause of direct maternal deaths. The recommendations from the report focus on basic clinical skills, with promptrecognition of the severity of a haemorrhage and emphasise communication and teamwork in the management ofthese cases. A systematic review\\n14suggests that there may be regional variation in the prevalence of PPH.\\nStandardisation of the measurement of PPH is recommended so that data from different regions are comparable.15\\nRCOG Green-top Guideline No. 52 e113 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 7}), Document(page_content='3. Identi ﬁcation and assessment of evidence\\nThis guideline was developed in accordance with standard methodology for producing RCOG Green-top Guidelines.\\nThe Cochrane Library (including the Cochrane Database of Systematic Reviews and the Database of Abstracts of\\nReviews of Effects [DARE]), EMBASE, Trip, MEDLINE and PubMed (electronic databases) were searched for relevantrandomised controlled trials, systematic reviews and meta-analyses. The search was restricted to articles publishedbetween 2007 and September 2015. The databases were searched using the relevant Medical Subject Headings (MeSH)terms, including all subheadings, and this was combined with a keyword search. Search words included ‘postpartumh(a)emorrhage’, ‘factor VII’, ‘Syntocinon’, ‘carbetocin’, ‘carboprost’, ‘oxytocics’, ‘uterotonics’, ‘B-lynch suture’, ‘uterineartery embolism’, ‘bilateral internal iliac ligation’, ‘balloon, Rusch’, ‘Sengstaken catheters’, ‘thromboelastography’,‘thromboelastometry’, ‘ﬁbrinogen concentrate’, ‘point of care testing’ and the search limited to humans and the Englishlanguage. The National Library for Health and the National Guideline Clearinghouse were also searched for relevantguidelines and reviews. Guidelines and recommendations produced by organisations such as the British Committee forStandards in Haematology Transfusion Taskforce and national bodies were considered.\\nWhere possible, recommendations are based on available evidence and the areas where evidence is lacking are\\nannotated as ‘good practice points’. Further information about the assessment of evidence and the grading ofrecommendations may be found in Appendix I.\\n4. Prediction and prevention of PPH\\n4.1 What are the risk factors for developing PPH and how can they be minimised?\\n4.1.1 Risk factors\\nRisk factors for PPH may present antenatally or intrapartum; care plans must be modi ﬁed as\\nand when risk factors arise. ✓\\nClinicians must be aware of risk factors for PPH and should take these into account whencounselling women about place of delivery.✓\\nWomen with known risk factors for PPH should only be delivered in a hospital with a bloodbank on site.D\\nA number of case –control studies have identiﬁed antenatal and intrapartum risk factors for PPH (see\\nAppendix II),16–26although most cases of PPH have no identiﬁable risk factors.27These risk factors have\\nbeen summarised in a 2010 review.28Despite methodological limitations, these studies provide a guide to\\nlevels of risk, which can help clinicians in their discussions with women about setting for delivery (Table 1).The Conﬁdential Enquiry into Maternal and Child Health\\n29has recommended that women with known risk\\nfactors for PPH should not be delivered in a hospital without a blood bank on site.\\nThe Society of Obstetricians and Gynaecologists of Canada has published a guideline on the prevention\\nand management of PPH.30This summarises the causes of PPH as related to abnormalities of one or more\\nof four basic processes –‘the four Ts’: tone, trauma, tissue and thrombin. The most common cause of\\nPPH is uterine atony.27Evidence\\nlevel 4\\nRCOG Green-top Guideline No. 52 e114 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 8}), Document(page_content='4.1.2 Minimising risk –treating antenatal anaemia\\nAntenatal anaemia should be investigated and treated appropriately as this may reduce the\\nmorbidity associated with PPH.D\\nGuidelines from the National Institute for Health and Care Excellence (NICE)32recommend that pregnant\\nwomen should be offered screening for anaemia. The British Committee for Standards in Haematology33\\nhas produced guidelines on the investigation and management of anaemia in pregnancy. Haemoglobin (Hb)levels outside the normal UK range for pregnancy (110 g/l at ﬁrst contact and 105 g/l at 28 weeks) shouldbe investigated and iron supplementation considered if indicated. It is recommended that parenteral irontherapy should be considered antenatally for women with iron deﬁciency anaemia who do not respond tooral iron.\\n10Evidence\\nlevel 4\\nA population-based study34has indicated an association between antenatal anaemia (Hb less than 90 g/l)\\nand greater blood loss at delivery and postpartum.Evidence\\nlevel 3Table 1. Risk factors and the associated levels of risk for PPH\\nRisk factor The four Ts OR (95% CI)\\nMultiple pregnancy Tone 3.30 (1.00 –10.60)16\\n4.70 (2.40 –9.10)24\\nPrevious PPH Tone 3.60 (1.20 –10.20)16\\nPre-eclampsia Thrombin 5.00 (3.00 –8.50)16\\n2.20 (1.30 –3.70)31\\nFetal macrosomia Tone 2.11 (1.62 –2.76)20\\n2.40 (1.90 –2.90)24\\nFailure to progress in second stage Tone 3.40 (2.40 –4.70)23\\n1.90 (1.20 –2.90)31\\nProlonged third stage of labour Tone 7.60 (4.20 –13.50)16\\n2.61 (1.83 –3.72)20\\nRetained placenta Tissue 7.83 (3.78 –16.22)20\\n3.50 (2.10 –5.80)23\\n6.00 (3.50 –10.40)24\\nPlacenta accreta Tissue 3.30 (1.70 –6.40)23\\nEpisiotomy Trauma 4.70 (2.60 –8.40)16\\n2.18 (1.68 –2.76)20\\n1.70 (1.20 –2.50)24\\nPerineal laceration Trauma 1.40 (1.04 –1.87)20\\n2.40 (2.00 –2.80)23\\n1.70 (1.10 –2.50)24\\nGeneral anaesthesia Tone 2.90 (1.90 –4.50)31\\nRCOG Green-top Guideline No. 52 e115 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 9}), Document(page_content='4.1.3 Minimising risk –reducing blood loss at delivery\\nUterine massage is of no bene ﬁt in the prophylaxis of PPH.A\\nProphylactic uterotonics should be routinely offered in the management of the third stage of\\nlabour in all women as they reduce the risk of PPH.A\\nFor women without risk factors for PPH delivering vaginally, oxytocin (10 iu by intramuscularinjection) is the agent of choice for prophylaxis in the third stage of labour. A higher dose ofoxytocin is unlikely to be bene ﬁcial.A\\nFor women delivering by caesarean section, oxytocin (5 iu by slow intravenous injection) should\\nbe used to encourage contraction of the uterus and to decrease blood loss.B\\nErgometrine –oxytocin may be used in the absence of hypertension in women at increased risk\\nof haemorrhage as it reduces the risk of minor PPH (500 –1000 ml).C\\nFor women at increased risk of haemorrhage, it is possible that a combination of preventative\\nmeasures might be superior to syntocinon alone to prevent PPH. ✓\\nClinicians should consider the use of intravenous tranexamic acid (0.5 –1.0 g), in addition to\\noxytocin, at caesarean section to reduce blood loss in women at increased risk of PPH.A\\nUterine massage\\nA Cochrane review35analysed the effectiveness of uterine massage after birth, and before or after delivery\\nof the placenta, or both, to prevent PPH. Two randomised controlled trials (RCTs) were included and thereview found no signiﬁcant difference between groups.Evidence\\nlevel 1+\\nManagement of the third stage of labour\\nVarious Cochrane reviews have addressed prophylaxis in the third stage of labour for women deliveringvaginally.\\n35–38These have established that both active management and the use of prophylactic uterotonics\\nin the third stage of labour reduce the risk of PPH. Active management of the third stage of labourinvolves the use of interventions (including the use of uterotonics, early clamping of the umbilical cord andcontrolled cord traction) to expedite delivery of the placenta with the aim of reducing blood loss. Inexpectant management, signs of placental separation are awaited and the placenta is deliveredspontaneously. A Cochrane systematic review\\n39found that, for women at mixed levels of risk of bleeding,\\nactive management showed a reduction in the average risk of maternal primary haemorrhage at time ofbirth (more than 1000 ml; average risk ratio [RR] 0.34, 95% CI 0.14 –0.87) and maternal Hb less than 90 g/l\\nfollowing birth (average RR 0.50, 95% CI 0.30 –0.83).Evidence\\nlevel 1++\\nRCOG Green-top Guideline No. 52 e116 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 10}), Document(page_content='However, active management results in a lower birthweight, reﬂecting a lower blood volume from early\\ncord clamping.39A systematic review and meta-analysis of controlled trials40found that delaying clamping\\nfor at least 2 minutes is beneﬁcial to the newborn and that the beneﬁts extend into infancy. Therefore,active management of the third stage that includes routine early clamping of the umbilical cord can nolonger be recommended. A detailed consideration of the literature relating to the timing of cord clampingcan be found in RCOG Scientiﬁc Impact Paper No. 14.\\n41Guidance from NICE9recommends that the\\numbilical cord should not be clamped earlier than 1 minute from delivery of the baby if there are noconcerns over cord integrity or the baby’s wellbeing.Evidence\\nlevel 1+\\nOxytocin and ergometrine –oxytocin\\nMcDonald and colleagues’ meta-analysis36addressed prophylactic ergometrine –oxytocin versus oxytocin for the\\nthird stage of labour. This review indicated that ergometrine –oxytocin (Syntometrine/C226, Alliance, Chippenham,\\nWiltshire, UK), oxytocin 5 iu and oxytocin 10 iu have similar efﬁcacy in preventing PPH in excess of 1000 ml.Using the deﬁnition of PPH as blood loss of at least 500 ml, ergometrine –oxytocin was associated with a small\\nreduction in the risk of PPH (Syntometrine\\n/C226versus oxytocin any dose; OR 0.82, 95% CI 0.71 –0.95).\\nThere were major differences between ergometrine –oxytocin and oxytocin alone in the adverse effects of\\nnausea and vomiting, and elevation of blood pressure, with ergometrine –oxytocin carrying a ﬁve-fold increased\\nrisk (OR 4.92, 95% CI 4.03 –6.00). Thus, the advantage of a reduction in the risk of minor PPH needs to be\\nweighed against the adverse effects associated with the use of ergometrine –oxytocin.Evidence\\nlevel 1++\\nAn RCT,42using a primary outcome of any treatment of uterine atony or haemorrhage, assessed whether or\\nnot a higher dose of oxytocin after vaginal delivery was more effective than a low-dose regimen in preventingPPH after a vaginal delivery. Compared with 10 iu, administering 40 iu or 80 iu of prophylactic oxytocin didnot reduce overall PPH treatment when given in 500 ml over 1 hour for vaginal delivery. Evidence\\nlevel 1+\\nProstaglandins\\nThe use of prostaglandins for the prevention of PPH has been the subject of two Cochrane reviews.37,38\\nNeither intramuscular prostaglandins (such as carboprost, a 15-methyl prostaglandin F 2aanalogue) nor\\nmisoprostol (a prostaglandin E 1analogue given orally or sublingually) were preferable to conventional\\ninjectable uterotonics (oxytocin and/or ergometrine) for routine prophylaxis.37Furthermore, another\\nsystematic review43concluded that oxytocin is superior to misoprostol in the prevention of PPH.Evidence\\nlevel 1++\\nAppraisal of the evidence from both the Cochrane reviews, together with consideration of standard practice\\nin the UK, suggests that, for women delivering vaginally, oxytocin 10 iu by intramuscular injection is theregimen of choice for prophylaxis in the third stage of labour. Intramuscular oxytocin should be administeredwith the birth of the anterior shoulder, or immediately after the birth of the baby and before the cord isclamped and cut. This strategy has been endorsed in the NICE intrapartum care guideline.\\n9Evidence\\nlevel 1+\\nCarbetocin\\nA Cochrane review44has addressed the use of a longer-acting oxytocin derivative, carbetocin, in the\\nprevention of PPH. Carbetocin is licensed in the UK speciﬁcally for the indication of prevention of PPH inthe context of caesarean delivery. Use of carbetocin resulted in a statistically signiﬁcant reduction in theneed for further uterotonics compared with oxytocin for those undergoing a caesarean, but not for vaginaldelivery. However, there were no statistically signiﬁcant differences between carbetocin and oxytocin interms of risk of PPH.\\nEvidence\\nlevel 1++\\nRCOG Green-top Guideline No. 52 e117 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 11}), Document(page_content='Guidelines from the Society of Obstetricians and Gynaecologists of Canada30recommend that carbetocin\\n(100 micrograms given as an intravenous bolus over 1 minute) should be used for the prevention of PPH inelective caesarean deliveries. Randomised trials\\n45–50have compared different uterotonics (oxytocin,\\nergometrine –oxytocin, misoprostol, carbetocin and 15-methyl prostaglandin F 2a) for prophylaxis in women\\ndelivering by caesarean section. Appraisal of the evidence from these trials, together with consideration ofstandard practice in the UK, led the development group for the NICE caesarean section guideline\\n51to\\nrecommend oxytocin 5 iu by slow intravenous injection for prophylaxis in the context of caesarean delivery.Evidence\\nlevel 1+\\nTranexamic acid\\nThe use of tranexamic acid in the prevention of PPH in women considered to be at low risk of PPH wasaddressed in a Cochrane review.\\n52This found that blood loss greater than 400 or 500 ml was less\\ncommon in women who received tranexamic acid in addition to the usual uterotonic agent after vaginalbirth or caesarean section in a dosage of 1 or 0.5 g intravenously. Tranexamic acid was effective indecreasing the incidence of blood loss greater than 1000 ml in women who had undergone caesareansection (RR 0.43, 95% CI 0.23 –0.78; four studies; 1534 women), but not vaginal birth. Mean blood loss\\nuntil 2 hours postpartum was lower in the group of women who received intravenous tranexamic acidpostpartum (mean difference /C077.79 ml; 95% CI /C097.95 to /C057.64; ﬁve studies; 1186 women). The\\nauthors of the Cochrane review on the use of tranexamic acid in the prevention of PPH conclude thatfurther studies are required to investigate the risk of serious adverse effects, including thromboembolicevents, and the use of tranexamic acid in women considered to be at high risk of PPH (see section 5.3.6). Evidence\\nlevel 1++\\n5. How should PPH be managed?\\n5.1 Identiﬁcation of the severity of haemorrhage\\nClinicians should be aware that the visual estimation of peripartum blood loss is inaccurate and\\nthat clinical signs and symptoms should be included in the assessment of PPH.C\\nAs visual estimation often underestimates blood loss,53,54more accurate methods may be used, such as\\nblood collection drapes for vaginal deliveries55and the weighing of swabs.56However, a study57comparing\\nvisual estimation of blood loss with the use of a collector bag after vaginal delivery concluded that thelatter did not signiﬁcantly reduce the risk of severe PPH. Participating in clinical reconstructions mayencourage early diagnosis and prompt treatment of PPH.\\n58Written and pictorial guidelines may help staff\\nworking in labour wards to estimate blood loss.59Evidence\\nlevel 2+\\nClinical signs and symptoms of hypovolaemia should be included in the assessment of PPH. However,\\nclinicians should be aware that the physiological increase in circulating blood volume during pregnancymeans that the signs of hypovolaemic shock become less sensitive in pregnancy.\\n60In pregnancy, pulse and\\nblood pressure are usually maintained in the normal range until blood loss exceeds 1000 ml; tachycardia,tachypnoea and a slight recordable fall in systolic blood pressure occur with blood loss of 1000 –1500 ml.\\nA systolic blood pressure below 80 mmHg, associated with worsening tachycardia, tachypnoea and alteredmental state, usually indicates a PPH in excess of 1500 ml.\\n61Evidence\\nlevel 4\\nRCOG Green-top Guideline No. 52 e118 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 12}), Document(page_content='In nonpregnant patients, the shock index, calculated from the heart rate/systolic blood pressure, has been\\nemployed as an early marker of haemodynamic compromise.61A retrospective cohort study62concluded\\nthat the shock index identiﬁes women at risk of adverse outcomes secondary to PPH (e.g. admission to anintensive care unit) and compares favourably with conventional vital signs.Evidence\\nlevel 2 /C0\\nThe 2009 –12 Conﬁdential Enquiries into Maternal Deaths and Morbidity report3highlighted the importance\\nof correlating clinical signs and symptoms expected from different blood loss values to help target decisions\\non resuscitation, and also emphasised the importance of taking the woman’s weight into account. It is of note\\nthat the severity of haemorrhage was not recognised in 11 of the 17 (61%) women who died.Evidence\\nlevel 4\\n5.2 Communication and multidisciplinary care\\n5.2.1 Communication with the woman\\nCommunication with the patient and her birthing partner is important, and clear information of\\nwhat is happening should be given from the outset. ✓\\nPPH often occurs unexpectedly and can be very stressful for the woman and her partner or birth attendants; it is\\ncrucial that, where feasible, they are kept informed and reassured, if appropriate, of the clinical development andproposed management.\\n5.2.2 Who should be informed when the woman presents with PPH?\\nRelevant staff with an appropriate level of expertise should be alerted of PPH.✓\\nThe midwife in charge and the ﬁrst-line obstetric and anaesthetic staff should be alerted when\\nwomen present with minor PPH (blood loss 500 –1000 ml) without clinical shock. ✓\\nA multidisciplinary team involving senior members of staff should be summoned to attend to\\nwomen with major PPH (blood loss of more than 1000 ml) and ongoing bleeding or clinical shock. ✓\\nEarly involvement of appropriate senior staff (including the anaesthetic team and laboratory specialists) is fundamental\\nto the management of PPH. In minor PPH, the ﬁrst-line staff should be alerted and in major PPH, the followingmembers of staff should be called and summoned to attend:\\n/C15an experienced midwife (in addition to the midwife in charge)\\n/C15the obstetric middle grade\\n/C15the anaesthetic middle grade\\n/C15the on-call clinical haematologist with experience in major haemorrhage\\n/C15porters for delivery of specimens/blood.\\nFurthermore, the consultant obstetrician and consultant anaesthetist should be alerted, and the blood transfusion\\nlaboratory should be informed. One member of the team should be assigned the task of recording events, ﬂuids,drugs, blood and components transfused, and vital signs.\\nRCOG Green-top Guideline No. 52 e119 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 13}), Document(page_content='Clinicians and blood transfusion staff should liaise at a local level to agree:\\n/C15a standard form of words (such as ‘we need compatible blood now’ or ‘group-speciﬁc blood’) to be used in\\ncases of major obstetric haemorrhage\\n/C15a timescale in which to deliver various blood components.\\nThe use of the term ‘controlled major obstetric haemorrhage’ or ‘ongoing major obstetric haemorrhage’ may be\\nused to deﬁne the urgency to the team.\\nSenior obstetric staff must be receptive to concerns expressed by less experienced or junior medical\\npractitioners, and by midwives. The RCOG recommends that the consultant obstetrician should attend inperson when there is a PPH of more than 1500 ml where the haemorrhage is continuing.\\n63Evidence\\nlevel 4\\n5.3 Resuscitation\\n5.3.1 Measures for minor PPH\\nMeasures for minor PPH (blood loss 500 –1000 ml) without clinical shock:✓\\n/C15intravenous access (one 14-gauge cannula)\\n/C15urgent venepuncture (20 ml) for:\\n–group and screen\\n–full blood count\\n–coagulation screen, including ﬁbrinogen\\n/C15pulse, respiratory rate and blood pressure recording every 15 minutes\\n/C15commence warmed crystalloid infusion.\\n5.3.2 Measures for major PPH\\nFull protocol for major PPH (blood loss greater than 1000 ml) and continuing to bleed or\\nclinical shock (see Appendix III): ✓\\n/C15A and B –assess airway and breathing\\n/C15C–evaluate circulation\\n/C15position the patient ﬂat\\n/C15keep the woman warm using appropriate available measures\\n/C15transfuse blood as soon as possible, if clinically required\\n/C15until blood is available, infuse up to 3.5 l of warmed clear ﬂuids, initially 2 l of warmed isotonic\\ncrystalloid. Further ﬂuid resuscitation can continue with additional isotonic crystalloid or colloid\\n(succinylated gelatin). Hydroxyethyl starch should not be used.\\n/C15the best equipment available should be used to achieve rapid warmed infusion of ﬂuids\\n/C15special blood ﬁlters should not be used, as they slow infusions.\\nRCOG Green-top Guideline No. 52 e120 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 14}), Document(page_content='A high concentration of oxygen (10 –15 l/min) via a facemask should be administered, regardless of maternal oxygen\\nconcentration. If the airway is compromised owing to impaired conscious level, anaesthetic assistance should be\\nsought urgently. Usually, level of consciousness and airway control improve rapidly once the circulating volume isrestored.\\nEstablish two, 14-gauge intravenous lines; a 20 ml blood sample should be taken and sent for diagnostic tests,\\nincluding full blood count, coagulation screen, urea and electrolytes, and to cross-match packed red cells (4 units).The urgency and measures undertaken to resuscitate and arrest haemorrhage need to be tailored to the degree of\\nshock (Table 2).\\nThe cornerstones of resuscitation during PPH are restoration of both blood volume and oxygen-carrying\\ncapacity. Volume replacement must be undertaken on the basis that blood loss is oftenunderestimated.\\n59,64Compatible blood (supplied in the form of red cell concentrate) to replace red cell\\nloss should be transfused as soon as available, if necessary. The clinical picture should be the maindeterminant of the need for blood transfusion and time should not be unnecessarily spent awaitinglaboratory results.\\n65,66Obstetricians should draw on the expertise of their colleagues in anaesthesia,\\nhaematology and transfusion medicine in determining the most appropriate combination of intravenousclear ﬂuids, blood and blood products for continuing resuscitation. Guidance from the British Committeefor Standards in Haematology\\n67summarises the main therapeutic goals of the management of massive\\nblood loss as maintaining:Evidence\\nlevel 4\\n/C15Hb greater than 80 g/l\\n/C15platelet count greater than 50 9109/l\\n/C15prothrombin time (PT) less than 1.5 times normal\\n/C15activated partial thromboplastin time (APTT) less than 1.5 times normal\\n/C15ﬁbrinogen greater than 2 g/l.Table 2. Fluid therapy and blood product transfusion (see sections 5.3.3, 5.3.4 and 5.3.5)\\nCrystalloid Up to 2 l isotonic crystalloid.\\nColloid Up to 1.5 l colloid until blood arrives.Blood If immediate transfusion is indicated, give emergency group O, rhesus D\\n(RhD)-negative, K-negative red cell units. Switch to group-speci ﬁc\\nred cells as soon as feasible.\\nFresh frozen plasma (FFP) Administration of FFP should be guided by haemostatic testing and whether\\nhaemorrhage is continuing:\\n/C15If prothrombin time (PT) or activated partial thromboplastin time (APTT)\\nare prolonged and haemorrhage is ongoing, administer 12 –15 ml/kg of FFP.\\n/C15If haemorrhage continues after 4 units of red blood cells (RBCs) and\\nhaemostatic tests are unavailable, administer 4 units of FFP.\\nPlatelet concentrates Administer 1 pool of platelets if haemorrhage is ongoing and platelet count\\nless than 75 9109/l.\\nCryoprecipitate Administer 2 pools of cryoprecipitate if haemorrhage is ongoing and ﬁbrinogen\\nless than 2 g/l.\\nRCOG Green-top Guideline No. 52 e121 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 15}), Document(page_content='5.3.3 Fluid replacement\\nFluid replacement is a crucial component of PPH treatment, although a dilutional coagulopathy may occur\\nwhen large volumes of crystalloid, colloid or red cells are used with insufﬁcient transfusion of fresh frozenplasma (FFP) and platelets. Traditionally, a total volume of 3.5 l of clear ﬂuids (up to 2 l of warmed isotoniccrystalloid as rapidly as possible, followed by up to a further 1.5 l of warmed colloid if blood is still notavailable) comprises the maximum that should be infused while awaiting compatible packed red cells.\\n1While\\nthere is controversy as to the most appropriate ﬂuids for volume resuscitation,68–70the nature of ﬂuid\\ninfused is of less importance than rapid administration and warming of the infusion.71The woman needs to be\\nkept warm using appropriate measures to prevent hypothermia which in turn could exacerbate acidosis.72Evidence\\nlevel 4\\nThere have been no RCTs comparing the use of colloids with other replacement ﬂuids for the\\nresuscitation of women with PPH. Guidelines from the World Health Organization (WHO)73\\nrecommend that intravenous ﬂuid replacement for PPH should be with isotonic crystalloids inpreference to colloids. A Cochrane review\\n74compared colloids with crystalloids for ﬂuid resuscitation in\\ncritically ill, nonpregnant patients (patients with burns, trauma or following surgery). This reviewconcluded that resuscitation with colloids was not associated with an improvement in survival and thatthe use of one particular colloid, hydroxyethyl starch, might increase mortality.Evidence\\nlevel 1++\\n5.3.4 Blood transfusion\\nThere are no ﬁrm criteria for initiating red cell transfusion. The decision to provide blood\\ntransfusion should be based on both clinical and haematological assessment. ✓\\nThe use of blood and blood products in obstetric practice is addressed in the RCOG Green-top\\nGuideline No. 47.13There are no ﬁrm criteria for initiating red cell transfusion75,76and the decision to\\nprovide blood transfusion should be based on both clinical and haematological assessment. While bloodtransfusion is almost always required when the Hb is less than 60 g/l and rarely required when the Hbis more than 100 g/l, patients with acute haemorrhage can have normal Hb and clinical evaluation in thissituation is, therefore, extremely important. Between 2009 and 2012,\\n3there were at least three\\nmaternal deaths where an acute point of care Hb measurement result is thought to have falsely\\nreassured staff. Furthermore, the Serious Hazards of Transfusion reporting scheme has highlighted therisk of errors in using near patient testing of Hb measurements to guide transfusion.\\n77While single Hb/\\nhaematocrit estimations may be misleading and can lead to delays in initiating red cell transfusion, serialmeasurements may be helpful to monitor ongoing progress. Guidelines from the European Society ofAnaesthesiology\\n78recommend that repeated measurements of serum lactate and base deﬁcit, together with\\nhaematocrit/Hb, are made during haemorrhage and resuscitation to assess tissue perfusion and oxygenation;however, it has not yet been shown whether the outcome of severe bleeding can be improved if volumeresuscitation is guided by serum lactate concentration and base deﬁcit.Evidence\\nlevel 4\\nRCOG Green-top Guideline No. 52 e122 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 16}), Document(page_content='Selection of red cell units for transfusion.\\nMajor obstetric haemorrhage protocols must include the provision of emergency blood with\\nimmediate issue of group O, rhesus D (RhD)-negative and K-negative units, with a switch togroup-speci ﬁc blood as soon as feasible.D\\nIf clinically signi ﬁcant red cell antibodies are present, close liaison with the transfusion\\nlaboratory is essential to avoid delay in transfusion in life-threatening haemorrhage.D\\nAll delivery units, especially small units without a blood bank on site, should maintain a supplyof group O, RhD-negative blood.✓\\nIntraoperative cell salvage should be considered for emergency use in PPH associated withcaesarean section and with vaginal delivery.D\\nPregnant women (and women of childbearing age) who are RhD negative must only receive RhD-negative\\nblood to avoid the risk of D alloimmunisation.79Previous blood transfusion is an important cause of\\nalloimmunisation, with antibodies other than anti-D, in particular anti-K, causing severe haemolytic diseaseof the fetus and newborn .\\n80Accordingly, unless a woman is known to be K positive, only K-negative blood\\nshould be used for transfusion in women of childbearing age.79The aim of antibody screening is to\\ndetermine the presence of red cell antibodies of likely clinical signiﬁcance. In addition to the risk ofhaemolytic disease of the fetus and newborn,\\n80these red cell antibodies may have implications for the\\nselection of blood for transfusion in the mother owing to the risk of haemolytic transfusion reactions, andthe laboratory should select red cell units negative for the relevant antigen for cross-matching. Closeliaison with the transfusion laboratory is essential, with input if needed from the clinical haematology teamand specialist advice from the national blood service.Evidence\\nlevel 4\\nAll delivery units, especially small units without a blood bank on site, should maintain a supply of group O, RhD-\\nnegative blood, as this might offer the only means of restoring oxygen-carrying capacity within an acceptabletimescale. The minimum number of units of group O, RhD-negative, K-negative blood to be maintained on siteshould be agreed within local protocols and should reﬂect the likely period of delay in the arrival of further suppliesshould an emergency arise; small delivery units remote from the nearest blood bank will require a larger minimumsupply than those a short distance from a blood bank.\\nCross-matching versus electronic issue of blood\\nThe principles of blood grouping, antibody testing and selection of blood in pregnancy are addressed in the RCOGGreen-top Guideline No. 47.\\n13\\nThe majority of laboratories in the UK now use automated testing for blood grouping and antibody testingwith advanced information technology systems for documentation and reporting of results. The hospitaltransfusion laboratory can readily provide red cells that are ABO and RhD compatible using electronic issue\\nwith no cross-matching needed, provided that the patient does not have any antibodies and there are robust\\nautomated systems in place for antibody testing and identiﬁcation of the patient.\\n79In this setting, since blood\\ncan be readily issued, there is no need to reserve units for individual cases. Where electronic issue is notavailable, a locally agreed maximum surgical blood ordering schedule should be used to decide how many redcell units should be reserved and available for particular cases, based on the obstetric diagnosis. In unforeseenhaemorrhage, group O, RhD-negative and K-negative units must be immediately available for emergency use,with a switch to group-speciﬁc blood as soon as feasible.Evidence\\nlevel 4\\nRCOG Green-top Guideline No. 52 e123 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 17}), Document(page_content='Cytomegalovirus (CMV) status\\nIn elective transfusion in the antenatal period, CMV-seronegative products should be used to avoid\\ntransmission of CMV to the fetus, although, the UK policy of universal leucocyte depletion substantiallyreduces the risk of CMV transmission.\\n81,82In an emergency, such as PPH, standard leucocyte-depleted\\ncomponents should be given to avoid delay, and CMV-negative blood or platelets are not needed fortransfusion during delivery or in the postpartum period.\\n82Evidence\\nlevel 4\\nIntraoperative cell salvage\\nIntraoperative cell salvage (the process whereby blood shed during an operation is collected, ﬁlteredand washed to produce autologous red blood cells [RBCs] for transfusion to the patient) is commonlybeing used in cardiac, orthopaedic and vascular surgery with a relative reduction of blood transfusionof 38% and an absolute risk reduction of 21%. Cell salvage does not appear to impact adversely onclinical outcomes.\\n83,84Several bodies have endorsed cell salvage in obstetric practice, including NICE,85\\nthe Centre for Maternal and Child Enquiries (CMACE)10and the Association of Anaesthetists of Great\\nBritain and Ireland.86It has been proposed that cell salvage should be considered for emergency use\\nin PPH associated with both caesarean section and vaginal delivery.87Although large prospective trials\\nof cell salvage with autotransfusion in obstetrics are lacking to date, no single serious complicationleading to poor maternal outcome has been directly attributed to its use. A large RCT is currently inprogress comparing intraoperative cell salvage with donor blood transfusions (standard care) duringcaesarean section in women at risk of haemorrhage (SALVO study, UKCRN ID14032).\\n88Evidence\\nlevel 4\\n5.3.5 Blood components\\nThere are limited data to inform best clinical practice for the management of haemostatic impairment during PPH,\\nbut the principle of management is to prevent and treat haemostatic abnormalities during bleeding, but not tocorrect abnormalities in nonbleeding women. It is not known whether haemostasis should be corrected to normalityfor pregnant or nonpregnant women.\\nMethods to assess haemostatic impairment during PPH include clinical observation, laboratory-based tests\\n(PT, APTT, Clauss ﬁbrinogen and platelet count) and point of care testing.\\n89Studies in patients following\\nsurgery show that laboratory or point of care testing leads to appropriate use of blood components90and\\nboth may be used simultaneously. Coagulopathies may evolve rapidly and repeated testing (such as every30 minutes) during continued bleeding and observation of trends are more useful than single measurements.\\nEvidence\\nlevel 3Routine coagulation tests are widely available and have well-regulated quality control.89,91They include PT,\\nAPTT, Clauss ﬁbrinogen assay and platelet count. However, turnaround times are often too slow to beclinically useful in acute and rapidly evolving bleeds, and inevitably reﬂect the past haemostatic status of thewoman. Clauss ﬁbrinogen should always be measured as part of the routine coagulation screen because itfalls early and may be reduced to a clinically signiﬁcant level despite a normal PT/APTT.\\n89,91,92Platelet\\nnumber should be measured as part of the full blood count.\\nRCOG Green-top Guideline No. 52 e124 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 18}), Document(page_content='Point of care testing using viscoelastometry, such as thromboelastography (TEG/C226, Haemonetics, Braintree,\\nMassachusetts, USA) and rotational thromboelastometry (ROTEM/C226, Tem, Munich, Germany), combined\\nwith an agreed treatment algorithm, has been associated with decreased blood loss and blood product use,both outside and within the obstetric setting.\\n89,93,94The main advantage is that results are known sooner\\nthan for laboratory tests. Point of care testing using TEG/C226and ROTEM/C226has been recommended by the\\nObstetric Anaesthetists’ Association/Association of Anaesthetists of Great Britain and Ireland.95However,\\nNICE has concluded that there is insufﬁcient evidence to recommend the routine adoption ofviscoelastometric point of care testing in the management of PPH.\\n96If used, a quality control protocol\\nshould be agreed with the haematology laboratory.Evidence\\nlevel 4\\nTransfusion of FFP\\nIf no haemostatic results are available and bleeding is continuing, then, after 4 units of RBCs,\\nFFP should be infused at a dose of 12 –15 ml/kg until haemostatic test results are known.D\\nIf no haemostatic tests are available, early FFP should be considered for conditions with a\\nsuspected coagulopathy, such as placental abruption or amniotic ﬂuid embolism, or where\\ndetection of PPH has been delayed.✓\\nIf PT/APTT is more than 1.5 times normal and haemorrhage is ongoing, volumes of FFP inexcess of 15 ml/kg are likely to be needed to correct coagulopathy.D\\nClinicians should be aware that these blood components must be ordered as soon as a needfor them is anticipated, as there will always be a short delay in supply because of the need forthawing.✓\\nFormulaic protocols, such as 1:1 or 6:4 RBC:FFP, based on data derived from traumatic bleeding, have\\nbeen advocated for the management of major haemorrhage.69,71However, there is no evidence that this\\nimproves outcomes in PPH. The drawbacks of early FFP are that the majority of women with PPH willhave normal coagulation at the time of administration,\\n97–99and that it is associated with an increased risk\\nof transfusion-associated circulatory overload (TACO)100and transfusion-related acute lung injury.101FFP\\nresults in relatively small increments in ﬁbrinogen level, and to increase the level rapidly, cryoprecipitate orﬁbrinogen concentrate are required.\\n102\\nThere are limited data on the utility of laboratory and point of care coagulation tests to guide FFPreplacement during PPH. Abnormal PT/APTT suggests progression towards signiﬁcant haemostaticimpairment, while PT/APTT greater than 1.5 times normal demonstrate that severe and establishedhaemostatic impairment has occurred.\\n67,68,103\\nIf the PPH has stopped, no FFP is required. If haemorrhage is ongoing and the last PT/APTT results areavailable and are prolonged, 12 –15 ml/kg of FFP should be requested and infused with the aim of\\nmaintaining the PT/APTT at less than 1.5 times normal.\\n68If the PT/APTT is greater than 1.5 times normal,\\na larger volume of FFP is likely to be required to correct these parameters,104and this may be associated\\nwith an increased risk of TACO. If the PT/APTT are normal, then no FFP is required, although repeatedtesting should be performed if bleeding persists.Evidence\\nlevel 4\\nRCOG Green-top Guideline No. 52 e125 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 19}), Document(page_content='If the results of haemostatic tests are not available and haemorrhage is continuing then, after 4 units of\\nRBCs have been transfused, FFP should be infused at a dose of 12 –15 ml/kg and 6:4 RBC:FFP transfusion\\nmaintained until tests of haemostasis are available. Such empirical use of FFP is in line with publishedguidance.\\n67,68,71,105FFP transfusion earlier than this could be considered for placental abruption or\\namniotic ﬂuid embolism, because these situations are associated with early coagulopathy106,107or if\\ndiagnosis of PPH has been delayed.Evidence\\nlevel 4\\nIn rare cases of massive bleeding where women have been given 8 or more units of RBCs and they\\ncontinue to bleed, and still no coagulation results or platelet counts are available, then 2 pools ofcryoprecipitate and 1 pool of platelets should be infused.\\n108Evidence\\nlevel 3\\nFibrinogen\\nA plasma ﬁbrinogen level of greater than 2 g/l should be maintained during ongoing PPH.C\\nCryoprecipitate should be used for ﬁbrinogen replacement.D\\nObservational studies show that a ﬁbrinogen level of 1.0 –1.5 g/l is likely to be too low for adequate\\nhaemostasis during ongoing PPH.97,98,109 –111Fibrinogen below 3 g/l and especially below 2 g/l is associated\\nwith progression of bleeding, increased RBC and blood component requirements, and the need forinvasive procedures.\\n109Evidence\\nlevel 2+\\nA double-blind RCT112has shown that pre-emptive infusion of 2 g ﬁbrinogen concentrate in women with\\n500–1000 ml PPH has no beneﬁt; however, the ﬁbrinogen level at the time of randomisation was greater\\nthan 4 g/l in most women.Evidence\\nlevel 1\\nThe appropriate ﬁbrinogen intervention trigger or target level is unknown. A pragmatic view based on available\\nevidence is that, during continuing PPH, cryoprecipitate or ﬁbrinogen concentrate should be used to maintain aﬁbrinogen level of at least 2 g/l, even if PT/APTT are normal. Fibrinogen loss can be replaced by cryoprecipitateor ﬁbrinogen concentrate, although ﬁbrinogen concentrate is not licensed for acquired hypoﬁbrinogenaemia inthe UK. Similar clinical outcomes and increments in ﬁbrinogen have been reported for cryoprecipitate andﬁbrinogen concentrate, but these are based on limited data.\\n113It is expected that 2 pools of cryoprecipitate\\n(1 pool is taken from ﬁve donors) would increase the ﬁbrinogen level by about 1 g/l. Increasing the ﬁbrinogenlevel by 1 g/l requires about 60 mg/kg ﬁbrinogen concentrate.\\n114Observational studies report improved\\nclinical haemostasis and possible reduced use of FFP and post-transfusion-related events, such as TACO,94,115\\nassociated with infusion of ﬁbrinogen, but RCTs are required.93,113,114,116,117Evidence\\nlevel 3\\nTransfusion of platelets\\nDuring PPH, platelets should be transfused when the platelet count is less than 75 3109/l\\nbased on laboratory monitoring.D\\nThere is general consensus that platelets should be transfused at a trigger of 75 9109/l to maintain a level\\ngreater than 50 9109/l during ongoing PPH.68,71Evidence\\nlevel 4\\nRCOG Green-top Guideline No. 52 e126 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 20}), Document(page_content='5.3.6 Is there a role for antiﬁbrinolytic drugs?\\nConsideration should be given to the use of tranexamic acid in the management of PPH.B\\nA large RCT118found that early administration of tranexamic acid in the management of trauma in\\nnonpregnant patients resulted in a signiﬁcant reduction in death from haemorrhage. The dose employed inthis study was 1 g intravenously over 10 minutes followed by an infusion of 1 g over 8 hours. One RCT\\n119\\nassessed the role of high-dose tranexamic acid in PPH. Women with PPH greater than 800 ml followingvaginal delivery were randomly assigned to receive tranexamic acid (loading dose 4 g over 1 hour, theninfusion of 1 g/hour over 6 hours) or not; the study concluded that high-dose tranexamic acid can reduceblood loss, fall in Hb and the need for blood transfusion. The study was not powered to address safetyissues and speciﬁcally, the risk of the treatment causing deep vein thrombosis.\\nA Cochrane review\\n2on treatments for PPH found that trials testing the effectiveness of tranexamic acid\\nwere too small to draw meaningful conclusions. A large trial120is currently in progress aiming to\\ndetermine the effect of early administration of tranexamic acid on mortality, hysterectomy and other\\nmorbidities in women with PPH. The dose of tranexamic acid employed in this trial is 1 g by intravenousinjection; a second dose may be given after 30 minutes.Evidence\\nlevel 1+\\n5.3.7 Is there a role for recombinant factor VIIa (rFVIIa) therapy?\\nThe routine use of rFVIIa is not recommended in the management of major PPH unless as part\\nof a clinical trial. ✓\\nrFVIIa (NovoSeven/C226, Novo Nordisk, Bagsværd, Denmark) is an expensive product that is licensed in the\\nUK for the treatment of bleeding episodes in patients with speciﬁc inherited bleeding disorders. Outwithits licence, it has been used primarily in the management of uncontrolled haemorrhage in the traumasetting. It reduces blood loss through enhancement of tissue factor-dependent coagulation. Its effectivenessis markedly diminished by hypothermia, acidosis and low platelets, so effective resuscitation towardsnormal physiology is a prerequisite of its use.\\n121Evidence\\nlevel 3\\nThere are only poor quality data from anecdotal reports or patient registries to support its use.122\\nSystematic reviews of case series and observational studies have examined the use of rFVIIa in PPH.123,124\\nIn a review of the literature regarding the use of rFVIIa in the treatment of PPH, Ahonen122concluded that\\nrFVIIa should not be used to compensate for inadequate blood transfusion therapy; administration of bloodand blood products, as well as management of uterine atony, are essential in the treatment of PPH beforeconsidering administration of rFVIIa. A 2015 open-label RCT\\n125(n=84) found that administration of rFVIIa\\nlowered the risk of requiring second-line therapies by 44% (RR 0.56, 95% CI 0.42 –0.76) compared\\nwith controls (no rFVIIa) in women with PPH in whom uterotonics had failed to arrest the bleeding.All 84 women survived, but two women in the intervention group experienced a venousthromboembolism (2/42).\\nA study\\n126investigating the safety of rFVIIa when employed on an off-label basis to treat life-threatening\\nhaemorrhage found a signiﬁcant increase in the risk of arterial, but not venous, thromboembolic events whencompared with placebo (5.5% versus 3.2%).Evidence\\nlevel 1+\\nRCOG Green-top Guideline No. 52 e127 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 21}), Document(page_content='The use of rFVIIa may be considered as a treatment for life-threatening PPH, but should not delay or be considered\\na substitute for a life-saving procedure, such as embolisation or surgery, or transfer to a referral centre.\\n5.4 Monitoring and investigation in major PPH: what investigations should be performed and\\nhow should women be monitored?\\nFull protocol for monitoring and investigation in major PPH (blood loss greater than 1000 ml)\\nand ongoing haemorrhage or clinical shock:D\\n/C15immediate venepuncture (20 ml) for:\\n–cross-match (4 units minimum)\\n–full blood count\\n–coagulation screen, including ﬁbrinogen\\n–renal and liver function for baseline\\n/C15monitor temperature every 15 minutes\\n/C15continuous pulse, blood pressure recording and respiratory rate (using oximeter, electrocardiogram\\nand automated blood pressure recording)\\n/C15Foley catheter to monitor urine output\\n/C15two peripheral cannulae, 14 gauge\\n/C15consider arterial line monitoring (once appropriately experienced staff available for insertion)\\n/C15consider transfer to intensive therapy unit once the bleeding is controlled or monitoring at highdependency unit on delivery suite, if appropriate\\n/C15recording of parameters on a modi ﬁed early obstetric warning score (MEOWS) chart (see\\nAppendix IV)\\n/C15acting and escalating promptly when abnormal scores from a MEOWS chart are observed\\n/C15documentation of ﬂuid balance, blood, blood products and procedures.\\nContinuous physiological monitoring is necessary and the recording of parameters over time on a ﬂow chart that\\nwill give the reader good visual cues on the clinical progress of the patient (Appendix IV). The need to continuallyre-evaluate the woman’s physiological condition, even when bleeding appears to have stopped, is essential torecognise continuing bleeding.\\nThe presence of a central line not only provides a means of accurate central venous pressure monitoring,\\nbut also a route for rapid ﬂuid replacement. Nevertheless, the threshold for instituting invasive monitoringhas been controversial, with some authorities advising early recourse to central venous pressuremonitoring\\n127–129and others advocating caution.76,130The 2000 –02 report of the UK Conﬁdential\\nEnquiries into Maternal Deaths (CEMD)29included the recommendation: ‘Central venous and direct\\narterial pressure monitoring should be used when the cardiovascular system is compromised byhaemorrhage or disease’. Central venous pressure monitoring requires early involvement of a seniorskilled anaesthetist, who will usually take responsibility for this aspect of management. The use ofultrasound is more likely to make the procedure safer,\\n29as this procedure carries signiﬁcant morbidity and\\nmortality.131Once bleeding is under control, transfer to an intensive care or high dependency unit on\\ndelivery suite should be considered, depending on the severity of the blood loss (see section 5.6.3).Evidence\\nlevel 4\\nRCOG Green-top Guideline No. 52 e128 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 22}), Document(page_content='It is also important that once the bleeding is arrested and any coagulopathy is corrected, chemical\\nthromboprophylaxis is administered, as there is a high risk of thrombosis. Alternatively, anti-embolismstockings, foot impulse devices or intermittent pneumatic compression devices can be used if chemicalthromboprophylaxis is contraindicated, for example, in cases of thrombocytopenia.\\n132Evidence\\nlevel 4\\n5.5 What is the role of the anaesthetist in the management of PPH?\\nThe management of PPH requires a multidisciplinary approach: the anaesthetist plays a crucial\\nrole in maintaining haemodynamic stability and, if necessary, in determining and administeringthe most appropriate method of anaesthesia.D\\nAnaesthetists play an important role in the multidisciplinary team involved in the management of patients\\nwith PPH. A senior anaesthetist should be consulted early to help assess, initiate and continue promptresuscitation of these patients, using their expertise in ﬂuid and transfusion therapy as well as theirexperience in managing critically ill patients.\\n10\\nIf the patient needs to go to theatre for a surgical intervention, an experienced anaesthetist shouldpromptly assess the patient in order to decide on the most suitable mode of anaesthesia, depending onthe patient’s haemodynamic status. Central neuraxial anaesthesia has become the anaesthetic technique ofchoice in the obstetric population and this has resulted in a reduction in maternal mortality.\\n133\\nWhile general anaesthesia in obstetric patients is associated with increased morbidity and mortality whencompared with regional anaesthesia due to the physiological changes that occur in pregnancy,\\n9it may be\\npreferable in patients who are haemodynamically unstable or who have a coagulopathy.\\nThe patient may need high dependency or intensive care in the postoperative period. An obstetric early\\nwarning score system would help in the early identiﬁcation of continuous bleeding, especially in caseswhich are not apparent, as recommended by CMACE (see Appendix IV).\\n131Evidence\\nlevel 4\\n5.6 What methods should be employed to arrest the bleeding?\\nClinicians should be prepared to use a combination of pharmacological, mechanical and surgical\\nmethods to arrest PPH. These methods should be directed towards the causative factor.D\\nCareful clinical examination is required to determine the cause of PPH (see Table 1 and Appendix II for\\nthe risk factors and causes of PPH). A 2014 Cochrane review2addressing the treatment of primary PPH\\nfound no trials evaluating surgical techniques or radiological interventions for women with primary PPHthat were unresponsive to pharmacological methods. Thus, recommendations on treatment strategies arebased on observational data and consensus only.Evidence\\nlevel 4\\n5.6.1 What pharmacological and mechanical strategies can be used?\\nWhen uterine atony is perceived to be a cause of the bleeding, then a sequence of mechanical\\nand pharmacological measures should be instituted in turn until the bleeding stops. ✓\\nRCOG Green-top Guideline No. 52 e129 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 23}), Document(page_content='The most common cause of primary PPH is uterine atony.27The initial management of PPH should,\\ntherefore, involve measures to stimulate myometrial contractions. The following mechanical and\\npharmacological measures should be instituted/administered in turn:2\\n/C15palpate the uterine fundus and rub it to stimulate contractions (‘rubbing up the fundus’)\\n/C15ensure that the bladder is empty (Foley catheter, leave in place)\\n/C15oxytocin 5 iu by slow intravenous injection (may have repeat dose)\\n/C15ergometrine 0.5 mg by slow intravenous or intramuscular injection (contraindicated in\\nwomen with hypertension)\\n/C15oxytocin infusion (40 iu in 500 ml isotonic crystalloids at 125 ml/hour) unless ﬂuid restriction\\nis necessary\\n/C15carboprost 0.25 mg by intramuscular injection repeated at intervals of not less than 15 minutesto a maximum of eight doses (use with caution in women with asthma)\\n/C15misoprostol 800 micrograms sublingually.\\nThe simple mechanical and physiological measures of ‘rubbing up the fundus’ and emptying the bladder to\\nstimulate uterine contraction represent ﬁrst-line management of PPH. No published studies have beenidentiﬁed to provide an evidence base for these interventions; nevertheless, professional consensussupports their continued use.\\n134\\nDespite decades of empirical use in clinical practice, there are no trials comparing ergometrine withoxytocin as ﬁrst-line agents for the treatment of PPH. It seems appropriate to use both agents, althoughoxytocin is to be preferred initially, especially in women with hypertension or pre-eclampsia. Previousguidance\\n1advocated an initial dose of 10 iu oxytocin by slow intravenous injection for treatment (rather\\nthan prophylaxis) of PPH. The British National Formulary recommends a dose of 5 iu ‘by slowintravenous injection (dose may be repeated)’.\\n135The 1997 –99 report of the UK CEMD highlighted the\\nrisk of profound hypotension that may be associated with oxytocin injection.136This guideline has\\nadopted the CEMD recommendation that ‘When given as an intravenous bolus the drug should be givenslowly in a dose of not more than 5 iu’. This dosage is in line with guidance from other authorities.\\n30,135Evidence\\nlevel 4\\nThere are no trials comparing the prostaglandin carboprost (15-methyl prostaglandin F 2a) with other\\nuterotonic agents. Two case series from the USA,137,138comprising 26 and 237 cases, respectively, have\\nreported on the use of carboprost in the successful management of PPH, without resort to surgicalinterventions in 85% and 95% of cases. Two of the four failures in the smaller series were associated withplacenta accreta. If bleeding occurs at the time of caesarean section, intramyometrial injection ofcarboprost may be used (although not licensed). It is also possible to inject intramyometrial carboprostthrough the abdominal wall in the absence of laparotomy. The recommended dose is 250 microgramsintramuscularly. This may be repeated every 15 minutes to a total dose of 2 mg (eight doses). However, ifsigniﬁcant atonic haemorrhage continues after a third dose of carboprost, without signiﬁcant improvement(i.e. 30 minutes or more after the ﬁrst dose was given), the team should consider transfer to theoperating theatre for examination under anaesthesia, with an awareness of the impending need forlaparotomy and/or hysterectomy.\\nEvidence\\nlevel 3\\nRCOG Green-top Guideline No. 52 e130 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 24}), Document(page_content='Two systematic reviews,2,139which includes the 2014 Cochrane review, focused on misoprostol to treat\\nPPH and examined the optimal route and dosage, and its efﬁcacy. Compared with 40 iu oxytocin infusion,800 micrograms sublingual misoprostol was associated with a signiﬁcant increase in the number of womenwho had blood loss of at least 1000 ml (RR 2.65, 95% CI 1.04 –6.75) and who required blood transfusion\\n(RR 1.47, 95% CI 1.02 –2.14). The review authors concluded that oxytocin infusion should be\\nrecommended as ﬁrst-line treatment for primary PPH. When used following prophylactic uterotonics,misoprostol and oxytocin infusion work similarly.Evidence\\nlevel 1+\\nA study140of women in early pregnancy demonstrated that regardless of the route of administration\\n(vaginal, sublingual or rectal), misoprostol took 1.0 –2.5 hours to increase uterine tone. Clinicians should be\\naware of this delay in the clinical effect of misoprostol. Guidelines from WHO141and the International\\nFederation of Gynecology and Obstetrics142recommend that in the management of PPH, misoprostol is\\nadministered sublingually.Evidence\\nlevel 4\\n5.6.2 What surgical treatments can be employed to arrest the bleeding?\\nIf pharmacological measures fail to control the haemorrhage, surgical interventions should be\\ninitiated sooner rather than later.D\\nIntrauterine balloon tamponade is an appropriate ﬁrst-line ‘surgical ’intervention for most\\nwomen where uterine atony is the only or main cause of haemorrhage.C\\nConservative surgical interventions may be attempted as second line, depending on clinicalcircumstances and available expertise.C\\nIt is recommended that a laminated diagram of the brace suture technique be kept in theatre.✓\\nResort to hysterectomy sooner rather than later (especially in cases of placenta accreta oruterine rupture) .C\\nIdeally and when feasible, a second experienced clinician should be involved in the decision for\\nhysterectomy. ✓\\nThe use of pharmacological agents other than those detailed should not delay recourse to surgery. Once the\\ndecision is made to embark on surgical haemostasis, the most appropriate choice of procedure will depend, in part,on the experience and expertise of available staff.\\nCompression of the aorta may be a temporary but effective measure to allow time for resuscitation to catch up with\\nthe volume replacement and the appropriate surgical support to arrive. The judgement of senior clinicians, takinginto account the individual woman’s future reproductive aspirations, is required in deciding the appropriate sequenceof interventions.\\nThe management of placenta praevia accreta is associated with signiﬁcant morbidity and guidance is available in the\\nRCOG Green-top Guideline No. 27.\\n12\\nRCOG Green-top Guideline No. 52 e131 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 25}), Document(page_content='5.6.2.1 Uterine balloon tamponade\\nTamponade using various types of hydrostatic balloon catheter has superseded uterine packing for the\\ncontrol of atonic PPH.143Case series have used a Foley catheter,144Bakri balloon,145Sengstaken –\\nBlakemore oesophageal catheter146,147and a condom catheter.148The urological Rusch balloon has been\\ndescribed as preferable by virtue of larger capacity, ease of use and low cost.149A detailed protocol for\\nuterine tamponade using the Rusch balloon is available.149The 2014 Scottish Conﬁdential Audit of Severe\\nMaternal Morbidity report identiﬁed 339 women who had an estimated blood loss of 2500 ml or higher; in\\n82 cases, balloon tamponade was employed, successfully avoiding hysterectomy in 75 (91%) women.150\\nThis success rate is of the same order as that reported in other case series.Evidence\\nlevel 3\\nSome of the reports of balloon tamponade148,151describe the intervention as the ‘tamponade test’. A\\n‘positive test’ (control of PPH following inﬂation of the balloon) indicates that laparotomy is not required,whereas a ‘negative test’ (continued PPH following inﬂation of the balloon) is an indication to proceed tolaparotomy. The concept of balloon tamponade as a ‘test’ serves to afﬁrm its place as ﬁrst-line ‘surgical’\\nmanagement. There is no clear evidence on how long the balloon tamponade should be left in place. In\\nmost cases, 4 –6 hours of tamponade should be adequate to achieve haemostasis and ideally it should be\\nremoved during daytime hours, in the presence of appropriate senior staff, in case further intervention isnecessary.\\n146,147Evidence\\nlevel 4\\nA systematic review concluded that uterine balloon tamponade is an effective treatment for PPH in\\nresource-poor settings.152Evidence\\nlevel 2++\\n5.6.2.2 Haemostatic suturing\\nSeveral case series153have been published describing success with haemostatic brace sutures. The best\\nknown version, described by B-Lynch in 1997,154requires hysterotomy for its insertion and is particularly\\nsuitable when the uterus has already been opened for a caesarean section. A review published in 2005155\\nsummarised nine case series of B-Lynch suturing (a total of 32 cases), reporting success in all but one case.\\nIn 2002, Hayman et al.156described a modiﬁed compression suture which does not require hysterotomy,\\nand success in 10/11 women managed with this suture has been reported.157Other authors have\\ndescribed variants on these techniques.158,159Double vertical compression sutures have proved effective in\\ntreating PPH due to atony and placenta praevia. This may have a dual action of reducing uterine bloodﬂow and compressing the bleeding surface.\\n160\\nA prospective population-based study of 211 women treated with a uterine compression suture to controlPPH concluded that the overall failure rate of sutures leading to hysterectomy was 25%.\\n161There was no\\ndifference in failure rate among B-Lynch, modiﬁed B-Lynch and other suture techniques. Risk factors for ahysterectomy included increasing age and vaginal delivery. In addition, a prolonged delay of 2 –6 hours\\nbetween delivery and uterine compression suture was independently associated with a four-fold increasedrisk of hysterectomy. This emphasises the need for careful postpartum evaluation of blood loss to avoidprolonged delay in haemorrhage recognition.Evidence\\nlevel 3\\nRCOG Green-top Guideline No. 52 e132 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 26}), Document(page_content='The 2014 Scottish Conﬁdential Audit of Severe Maternal Morbidity report150identiﬁed 21 cases where\\nhaemostatic brace suturing was used for the management of PPH (greater than or equal to 2500 ml);hysterectomy was averted in 16 (76%) women. Again, this success rate is of the same order as thatreported in other case series. Evidence\\nlevel 3\\nThese observational data suggest that haemostatic suture techniques are effective in controlling severe PPH and in\\nreducing the need for hysterectomy. In the absence of comparative data to demonstrate that any one variant is\\nsuperior to another, obstetricians are encouraged to familiarise themselves with one technique under the\\nsupervision of an experienced colleague. It is recommended that a laminated diagram of the brace suture techniquebe kept in theatre.\\nA systematic review\\n162has concluded that compression sutures are associated with a low complication\\nrate. A higher risk of uterine ischaemia appeared to be caused when the procedure was combined withvessel ligation. No negative impact on fertility has been reported.\\nCase series have reported the combined use of haemostatic suturing and balloon tamponade in the\\nmanagement of PPH.\\n163–165Evidence\\nlevel 3\\n5.6.2.3 Stepwise uterine devascularisation and internal iliac artery ligation\\nStepwise uterine devascularisation describes the successive ligation of (i) one uterine artery, (ii) both\\nuterine arteries, (iii) low uterine arteries, (iv) one ovarian artery and (v) both ovarian arteries, in the\\nmanagement of PPH.166The original case series167of 103 patients with intractable PPH not responding to\\nmedical management was effective in all cases without the need for hysterectomy, leading some cliniciansto propose that stepwise uterine devascularisation should be the ﬁrst-line conservative surgical treatmentto control PPH.\\nWhen internal iliac artery ligation is being considered, a senior gynaecologist or vascular surgeon should be\\ninformed and involved since this technique requires a high degree of surgical skill and training, and may beassociated with ureteric injury. A case series described 84 women with PPH from various causes whounderwent internal iliac artery ligation as the ﬁrst-line surgical intervention. Hysterectomy wassubsequently required in 33 (39%) women.\\n168\\nA study of 45 women following internal iliac artery ligation suggests that subsequent fertility and pregnancyoutcomes are not impaired.\\n169Evidence\\nlevel 3\\nA systematic review170of fertility outcomes following the surgical management of PPH concluded that\\nuterine devascularisation techniques, including internal iliac artery ligation, did not adversely affect futurefertility, although, the number of studies and quality of evidence was limited.Evidence\\nlevel 2++\\nRCOG Green-top Guideline No. 52 e133 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 27}), Document(page_content='5.6.2.4 Selective arterial occlusion or embolisation by interventional radiology\\nA large retrospective study171has evaluated arterial embolisation in 251 patients after PPH. It was\\nsuccessful in arresting the bleeding in 86.5% (217/251). The analysis suggested that caesarean sectiondelivery, disseminated intravascular coagulation and transfusion of more than 10 units of packed red cellswere related to failed embolisation. Evidence\\nlevel 3\\nThe logistics of performing arterial occlusion or embolisation where the equipment or an interventional radiologist\\nmay not be available mean that uterine balloon tamponade is a more appropriate ﬁrst-line treatment.\\nFollow-up studies of 17172and 25173women who underwent arterial embolisation for treatment of PPH\\nsuggest that the intervention does not impair subsequent menstruation, fertility and obstetric outcomes.Selective arterial occlusion may also be effective after failed internal iliac artery ligation.\\n174Evidence\\nlevel 3\\n5.6.2.5 Hysterectomy\\nThe decision for hysterectomy should be made by an experienced consultant clinician and the decision\\npreferably discussed with a second experienced clinician when feasible.29Early recourse to hysterectomy is\\nrecommended, especially where bleeding is associated with placenta accreta or uterine rupture.12\\nHysterectomy should not be delayed until the woman is in extremis or while less deﬁnitive procedureswith which the surgeon has little experience are attempted. The procedure should be carried out by asurgeon who is experienced in carrying out hysterectomies. Subtotal hysterectomy is the operation ofchoice in many instances of PPH requiring hysterectomy, unless there is trauma to the cervix or amorbidly adherent placenta in the lower segment.Evidence\\nlevel 4\\nSequential reports of the Scottish Conﬁdential Audit of Severe Maternal Morbidity from 2003 until 2012,\\nsummarised in the ﬁnal 2014 publication,150have shown a statistically signiﬁcant fall in the proportion of\\nwomen with PPH (with blood loss greater than or equal to 2500 ml) requiring a hysterectomy to controlthe bleeding, and an increase in the use of conservative surgical techniques.Evidence\\nlevel 3\\n5.6.3 Intensive and high dependency units and post-PPH care\\nThe 2006 –08 CMACE report10identiﬁed that three deaths were due to la ck of optimal care following PPH, and in\\nparticular, a lack of routine observation in the postpartum period. Sequential reports10,131have recommended the\\nuse of MEOWS charts to alert caregivers to abn ormal trends in haemodynamic measurements.Evidence\\nlevel 4\\nA prospective audit175of the management of major PPH (deﬁned in the audit as blood loss of 2500 ml or\\nmore, transfused 5 or more units of packed red cells or received treatment for coagulopathy) found thatthe majority of women received high dependency care on the labour ward, while only 21% were admittedto intensive care. The authors concluded that care for these women may be better provided byobstetricians and anaesthetists on the labour ward, a view that others have shared.\\n176Evidence\\nlevel 3\\nRCOG Green-top Guideline No. 52 e134 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 28}), Document(page_content='6. How should secondary PPH be managed?\\nIn women presenting with secondary PPH, an assessment of vaginal microbiology should be\\nperformed (high vaginal and endocervical swabs) and appropriate use of antimicrobial therapy\\nshould be initiated when endometritis is suspected.D\\nA pelvic ultrasound may help to exclude the presence of retained products of conception(RPOC), although the diagnosis of retained products is unreliable.C\\nSurgical evacuation of retained placental tissue should be undertaken or supervised by anexperienced clinician.D\\nThe causes of secondary PPH are numerous and include endometritis, RPOC and subinvolution of the\\nplacental implantation site.177,178The management of women presenting with secondary PPH should\\ninclude an assessment of their haemodynamic status, an assessment of the blood loss and an evaluation ofthe woman’s concerns (for example, is her bleeding becoming inconvenient because it has persisted longerthan she had expected?).Evidence\\nlevel 4\\nInvestigations should include bacteriological testing for endometritis (high vaginal swab), although a low\\nyield of positive vaginal swab results has been reported in patients with secondary PPH.179In contrast,\\nPather et al.180found a high incidence of abnormal vaginal microbiology (52%) and endometritis in their\\ncase series, supporting the practice of routine assessment of vaginal microbiology and appropriate use ofantimicrobial therapy in women presenting with secondary PPH.Evidence\\nlevel 3\\nA Cochrane review investigated the effect of different antibiotic regimens for the treatment of postpartum\\nendometritis.181This review concluded that a combination of clindamycin and gentamicin is appropriate,\\nand that once uncomplicated endometritis has clinically improved with intravenous therapy, there is noadditional beneﬁt from further oral therapy. The management of women presenting with secondary PPHand sepsis is addressed in the RCOG Green-top Guideline No. 64b.\\n182Evidence\\nlevel 1 /C0\\nPelvic ultrasound scans are commonly performed on women presenting with secondary PPH to identify\\nany RPOC. Case series180,183 –186have reported a wide range of sensitivities and speciﬁcities of ultrasound\\nin the detection of RPOC (44 –94% and 16 –92%, respectively). These series suggest that the presence of\\nan echogenic mass and a thickened ‘endometrium’ is associated with RPOC. In a prospective observationalstudy\\n187of 79 women with secondary PPH, Mulic-Lutvica and Axelsson concluded that an echogenic mass\\nin the uterine cavity and an anteroposterior diameter of the cavity above the 90th centile (approximately25 mm on days 1 –7 postpartum) was associated with RPOC. Since the range of sensitivities and\\nspeciﬁcities of ultrasound in the detection of RPOC is so wide, the clinical ﬁndings, including the degree ofbleeding and whether the cervical os is open, should be taken into account before the decision toundertake surgery is made. It has been proposed that colour ﬂow Doppler imaging should be included inthe evaluation of the postpartum uterus, although, there is no strong evidence to support its use;\\n178its\\nuse may facilitate the diagnosis of pseudoaneurysms and arteriovenous malformations, which are rare butrecognised causes of secondary PPH.\\n188–190Evidence\\nlevel 3\\nRCOG Green-top Guideline No. 52 e135 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 29}), Document(page_content='Surgical evacuation of the uterus for RPOC is not without morbidity and can result in uterine\\nperforation (1.5%)180,191and Asherman’s syndrome.192It is, therefore, recommended that surgical\\nevacuation of retained placental tissue should be undertaken or supervised by an experienced clinician.An appropriately trained clinician may consider performing uterine evacuation under direct ultrasoundguidance.\\nA 2002 Cochrane review (assessed as up-to-date in January 2008) addressed treatments for secondary\\nPPH.\\n4No trials were identiﬁed which met the review group’s inclusion criteria and no recommendations\\nwere made regarding effective treatments. Uterotonics, such as misoprostol and ergometrine, have beenrecommended in the management of secondary PPH, although evidence to support their use islimited.\\n178Transcatheter arterial embolisation193and balloon tamponade194have been employed in cases\\nof secondary PPH with ongoing bleeding.Evidence\\nlevel 3\\n7. Risk management\\n7.1 Training and preparation: what measures can be taken to ensure optimal management of\\nPPH?\\nEvery maternity unit should have a multidisciplinary protocol for the management of PPH.✓\\nAll staff involved in maternity care should receive training in the management of obstetric\\nemergencies, including the management of PPH.B\\nTraining for PPH should be multiprofessional and include team rehearsals.B\\nAll cases of PPH involving a blood loss of greater than 1500 ml should be the subject of aformal clinical incident review.D\\nTo ensure optimal management of PPH, every unit should have a multidisciplinary protocol with\\nwhich staff should be familiar (see section 5). Updates on the management of obstetric emergencies(including the management of PPH) are a proactive approach to risk management. Skills drills shouldensure that all members of staff, including those working in the transfusion laboratory, are aware oftheir role in the management of PPH. A systematic review\\n195of the effectiveness of multidisciplinary\\nsimulation training in obstetric emergencies (including PPH) showed that teamwork training in asimulation setting resulted in improvement of knowledge, practical skills, communication and teamperformance. Training in a simulation centre did not further improve outcome compared with trainingat a local unit.Evidence\\nlevel 2++\\nThe RCOG recommends that all cases of PPH with an estimated blood loss of more than 1500 ml should\\nbe the subject of a formal clinical incident review.196Evidence\\nlevel 4\\nRCOG Green-top Guideline No. 52 e136 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 30}), Document(page_content='7.2 Documentation\\nAccurate documentation of a delivery with PPH is essential.✓\\nAccurate documentation is important for further clinical management, continuity of care and team work. In\\naddition, inadequate documentation can contribute to the likelihood of there being medicolegal\\nconsequences.197The team member recording events on the structured proforma, the scribe, is crucial in the\\nmanagement of PPH (see Appendix V); the proforma is effectively a checklist of available interventions, andteam leaders should communicate with the scribe during the PPH to ensure that no steps have been omitted.PPH should be notiﬁed through a clinical incident reporting or risk management system.Evidence\\nlevel 4\\nIt is important to record:\\n/C15the staff in attendance and the time they arrived\\n/C15the sequence of events\\n/C15the administration of different pharmacological agents, their timing and sequence\\n/C15the time of surgical intervention, where relevant\\n/C15the condition of the mother throughout the different steps\\n/C15the timing of the ﬂuid and blood products given.\\n7.3 Debrieﬁng\\nAn opportunity to discuss the events surrounding the obstetric haemorrhage should be offered\\nto the woman (possibly with her birthing partner/s) at a mutually convenient time. ✓\\nAfter obstetric emergencies, women can be psychologically affected by postnatal depression or fear of\\nfurther childbirth. Major PPH can be traumatic to women and their families and has been associated withthe subsequent development of post-traumatic stress disorder.\\n198Women who have experienced a major\\nPPH should be offered an opportunity to discuss the events surrounding their delivery. A discussion offuture pregnancy, including the likelihood of a repeat PPH and any fears regarding pregnancy andchildbirth that the woman may have should be addressed. This should include arrangements forappropriate investigations as necessary, such as testing for coagulopathies if there are other indicators andscreening for the rare complication of postpartum hypopituitarism (Sheehan syndrome) secondary tohypotension.\\n199Evidence\\nlevel 4\\n8. Recommendations for future research\\n/C15RCTs are required to identify the best drug combinations, route and dose of uterotonics for the treatment of\\nprimary PPH.\\n/C15The role of viscoelastometric point of care tests using TEG/C226and ROTEM/C226in the management of PPH\\nrequires evaluation.\\n/C15Studies are required to determine the optimal ratio of packed red cells to FFP in the management ofobstetric haemorrhage.\\nRCOG Green-top Guideline No. 52 e137 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 31}), Document(page_content='/C15Studies are required to determine the role of ﬁbrinogen concentrate in the management of PPH.\\n/C15The role of prothrombin complex concentrate in the management of PPH requires evaluation.\\n/C15RCTs are required to investigate the role of uterotonic agents (misoprostol and ergometrine) in the\\nmanagement of secondary PPH.\\n9. Auditable topics\\n/C15The proportion of women who are screened for antenatal anaemia (100%).\\n/C15The proportion of women who are offered uterotonics for the third stage of labour (100%).\\n/C15The proportion of women undergoing an assessment of risk factors for PPH when they present in labour (100%).\\n/C15Appropriate documentation of management, especially with the timing of events for women who have hadPPH (100%).\\n/C15Notiﬁcation to the risk management team of women with PPH involving a blood loss greater than1500 ml (100%).\\n/C15Proportion of the multidisciplinary team who have undergone skills drills training in PPH (100%).\\n10. Useful links and support groups\\n/C15Royal College of Obstetricians and Gynaecologists. Heavy bleeding after birth (postpartum haemorrhage).\\nInformation for you . London: RCOG; 2016 [https://www.rcog.org.uk/en/patients/patient-leaﬂets/heavy-bleeding-\\nafter-birth-postpartum-haemorrhage/].\\n/C15Royal College of Obstetricians and Gynaecologists. Blood transfusion, pregnancy and birth. Information for you .\\nLondon: RCOG; 2015 [https://www.rcog.org.uk/en/patients/patient-leaﬂets/blood-transfusion-pregnancy-and-birth/].\\n/C15Patient. Postpartum Haemorrhage [www.patient.co.uk/showdoc/40000261].\\n/C15Netdoctor.co.uk. I suffered with postpartum haemorrhage [www.netdoctor.co.uk/ate/womenshealth/207160.html].\\nReferences\\n1. Scottish Obstetric Guidelines and Audit Project. The Management\\nof Postpartum Haemorrhage: A Clinical Practice Guideline for\\nProfessionals involved in Maternity Care in Scotland . Pilot edition.\\nGlasgow: SOGAP, 1998. [http://healthcareimprovementscotland.org/his/idoc.ashx?docid=84ee51e6-d441-4dba-8ebf-4fa6a2857e0d&version=-1]. Accessed 2015 Jul 2.\\n2. Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alﬁrevic Z.\\nTreatment for primary postpartum haemorrhage. Cochrane\\nDatabase Syst Rev 2014;(2):CD003249.\\n3. Knight M, Tuffnell D, Kenyon S, Shakespeare J, Gray R,\\nKurinczuk JJ, editors, on behalf of MBRRACE-UK. Saving Lives,\\nImproving Mothers’ Care - Surveillance of maternal deaths in the UK2011-13 and lessons learned to inform maternity care from the UK\\nand Ireland Conﬁdential Enquiries into Maternal Deaths and\\nMorbidity 2009 –13. Oxford: National Perinatal Epidemiology\\nUnit, University of Oxford; 2015.\\n4. Alexander J, Thomas PW, Sanghera J. Treatments for secondary\\npostpartum haemorrhage. Cochrane Database Syst Rev 2002;(1):\\nCD002867.\\n5. Demers C, Derzko C, David M, Douglas J; Society of\\nObstetricians and Gynaecologists of Canada. Gynaecological andobstetric management of women with inherited bleeding\\ndisorders. SOGC Clinical Practice Guidelines No 163. J Obstet\\nGynaecol Can 2005;27:707 –18.\\n6. Baudo F, de Cataldo F; Italian Association of Haemophilia\\nCentres (AICE): Register of acquired factor VIII inhibitors (RIIA).Acquired factor VIII inhibitors in pregnancy: data from the\\nItalian Haemophilia Register relevant to clinical practice.\\nBJOG 2003;110:311 –4.\\n7. The Royal College of Surgeons of England. Code of Practice for the\\nSurgical Management of Jehovah’s Witnesses . London: The Royal\\nCollege of Surgeons of England; 2002.\\n8. The Association of Anaesthetists of Great Britain and Ireland.\\nManagement of Anaesthesia for Jehovah’s Witnesses , 2nd ed.\\nLondon: AAGBI; 2005.\\n9. National Institute for Health and Care Excellence. Intrapartum\\ncare: care of healthy women and their babies during childbirth . NICE\\nclinical guideline 190. Manchester: NICE; 2014.\\n10. Centre for Maternal and Child Enquiries (CMACE). Saving Mothers’\\nLives: reviewing maternal deaths to make motherhood safer: 2006 –08.\\nThe Eighth Report on Conﬁdential Enquiries into Maternal Deathsin the United Kingdom. BJOG 2011;118 Suppl 1:1 –203.\\nRCOG Green-top Guideline No. 52 e138 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 32}), Document(page_content='11. Royal College of Obstetricians and Gynaecologists. Antepartum\\nHaemorrhage . Green-top Guideline No. 63. London: RCOG; 2011.\\n12. Royal College of Obstetricians and Gynaecologists. Placenta\\nPraevia, Placenta Praevia Accreta and Vasa Praevia: Diagnosis andManagement . Green-top Guideline No. 27. London: RCOG; 2011.\\n13. Royal College of Obstetricians and Gynaecologists. Blood\\nTransfusion in Obstetrics . Green-top Guideline No. 47. London:\\nRCOG; 2015.\\n14. Calvert C, Thomas SL, Ronsmans C, Wagner KS, Adler AJ,\\nFilippi V. Identifying regional variation in the prevalence ofpostpartum haemorrhage: a systematic review and meta-analysis.PLoS ONE 2012;7:e41114.\\n15. Bryant A, Mhyre JM, Leffert LR, Hoban RA, Yakoob MY,\\nBateman BT. The association of maternal race and ethnicity and therisk of postpartum hemorrhage. Anesth Analg 2012;115:1127 –36.\\n16. Combs CA, Murphy EL, Laros RK Jr. Factors associated with\\npostpartum hemorrhage with vaginal birth. Obstet Gynecol\\n1991;77:69 –76.\\n17. Stones RW, Paterson CM, Saunders NJ. Risk factors for major\\nobstetric haemorrhage. Eur J Obstet Gynecol Reprod Biol\\n1993;48:15 –8.\\n18. Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B. Prevalence and risk\\nfactors of severe obstetric haemorrhage. BJOG 2008;115:1265 –72.\\n19. Tsu VD. Postpartum haemorrhage in Zimbabwe: a risk factor\\nanalysis. Br J Obstet Gynaecol 1993;100:327 –33.\\n20. Bais JM, Eskes M, Pel M, Bonsel GJ, Bleker OP. Postpartum\\nhaemorrhage in nulliparous women: incidence and risk factors in\\nlow and high risk women. A Dutch population-based cohort\\nstudy on standard ( ≥500 ml) and severe ( ≥1000 ml) postpartum\\nhaemorrhage. Eur J Obstet Gynecol Reprod Biol 2004;115:166 –72.\\n21. Magann EF, Evans S, Hutchinson M, Collins R, Howard BC,\\nMorrison JC. Postpartum hemorrhage after vaginal birth: ananalysis of risk factors. South Med J 2005;98:419 –22.\\n22. Magann EF, Evans S, Chauhan SP, Lanneau G, Fisk AD,\\nMorrison JC. The length of the third stage of labor and the risk\\nof postpartum hemorrhage. Obstet Gynecol 2005;105:290 –3.\\n23. Sheiner E, Sarid L, Levy A, Seidman DS, Hallak M. Obstetric risk\\nfactors and outcome of pregnancies complicated with early\\npostpartum hemorrhage: a population-based study. J Matern Fetal\\nNeonatal Med 2005;18:149 –54.\\n24. Sosa CG, Althabe F, Beliz /C19an JM, Buekens P. Risk factors for\\npostpartum hemorrhage in vaginal deliveries in a Latin-American\\npopulation. Obstet Gynecol 2009;113:1313 –9.\\n25. Brinsden PR, Clark AD. Postpartum haemorrhage after induced\\nand spontaneous labour. Br Med J 1978;ii:855 –6.\\n26. Selo-Ojeme DO, Okonofua FE. Risk factors for primary\\npostpartum haemorrhage. A case control study. Arch Gynecol\\nObstet 1997;259:179 –\\n87.\\n27. World Health Organization. WHO recommendations for the\\nprevention and treatment of postpartum haemorrhage . Geneva:\\nWHO; 2012.\\n28. Oyelese Y, Ananth CV. Postpartum hemorrhage: epidemiology,\\nrisk factors, and causes. Clin Obstet Gynecol 2010;53:147 –56.\\n29. Conﬁdential Enquiry into Maternal and Child Health. Why Mothers\\nDie 2000 –2002. The Sixth Report of the Conﬁdential Enquiries into\\nMaternal Deaths in the United Kingdom . London: RCOG Press; 2004.\\n30. Leduc D, Senikas V, Lalonde AB, Ballerman C, Biringer A,\\nDelaney M, et al.; Clinical Practice Obstetrics Committee;Society of Obstetricians and Gynaecologists of Canada. Activemanagement of the third stage of labour: prevention and\\ntreatment of postpartum hemorrhage. SOGC Clinical Practice\\nGuideline No. 235. J Obstet Gynaecol Can 2009;31:980 –93.31. Combs CA, Murphy EL, Laros RK Jr. Factors associated with\\nhemorrhage in cesarean deliveries. Obstet Gynecol 1991;77:\\n77–82.\\n32. National Institute for Health and Care Excellence. Antenatal Care .\\nNICE clinical guideline 62. Manchester: NICE; 2008.\\n33. Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C;\\nBritish Committee for Standards in Haematology. UK guidelineson the management of iron deﬁciency in pregnancy. Br J\\nHaematol 2012;156:588 –600.\\n34. Kavle JA, Stoltzfus RJ, Witter F, Tielsch JM, Khalfan SS,\\nCaulﬁeld LE. Association between anaemia during pregnancyand blood loss at and after delivery among women with vaginal\\nbirths in Pemba Island, Zanzibar, Tanzania. J Health Popul Nutr\\n2008;26:232 –40.\\n35. Hofmeyr GJ, Abdel-Aleem H, Abdel-Aleem MA. Uterine massage\\nfor preventing postpartum haemorrhage. Cochrane Database Syst\\nRev2013;(7):CD006431.\\n36. McDonald SJ, Abbott JM, Higgins SP. Prophylactic ergometrine-\\noxytocin versus oxytocin for the third stage of labour.\\nCochrane Database Syst Rev 2004;(1):CD000201.\\n37. Tunc /C223alp €O, Hofmeyr GJ, G €ulmezoglu AM. Prostaglandins for\\npreventing postpartum haemorrhage. Cochrane Database Syst Rev\\n2012;(8):CD000494.\\n38. Oladapo OT, Fawole B, Blum J, Abalos E. Advance misoprostol\\ndistribution for preventing and treating postpartum haemorrhage.Cochrane Database Syst Rev 2012;(2):CD009336.\\n39. Begley CM, Gyte GM, Devane D, McGuire W, Weeks A. Active\\nversus expectant management for women in the third stage of\\nlabour. Cochrane Database Syst Rev 2011;(11):CD007412.\\n40. Hutton EK, Hassan ES. Late vs early clamping of the umbilical\\ncord in full-term neonates: systematic review and meta-analysis\\nof controlled trials. JAMA 2007;297:1241 –52.\\n41. Royal College of Obstetricians and Gynaecologists. Clamping of\\nthe Umbilical Cord and Placental Transfusion . Scientiﬁc Impact Paper\\nNo. 14. London: RCOG; 2015.\\n42. Tita AT, Szychowski JM, Rouse DJ, Bean CM, Chapman V,\\nNothern A, et al. Higher-dose oxytocin and hemorrhage aftervaginal delivery: a randomized controlled trial. Obstet Gynecol\\n2012;119:293 –300.\\n43. Gizzo S, Patrelli TS, Di Gangi S, Carrozzini M, Saccardi C, Zambon A,\\net al. Which uterotonic is bette r to prevent the postpartum\\nhemorrhage? Latest news in terms of clinical efﬁcacy, side effects, and\\ncontraindications: a systematic review. Reprod Sci 2013;20:1011 –9.\\n44. Su LL, Chong YS, Samuel M. Carbetocin for preventing\\npostpartum haemorrhage. Cochrane Database Syst Rev 2012;(4):\\nCD005457.\\n45. Dennehy KC, Rosaeg OP, Cicutti NJ, Krepski B, Sylvain JP.\\nOxytocin injection after caesarean delivery: intravenous orintramyometrial? Can J Anaesth 1998;45:635 –9.\\n46. Munn MB, Owen J, Vincent R, Wakeﬁeld M, Chestnut DH,\\nHauth JC. Comparison of two oxytocin regimens to preventuterine atony at caesarean delivery: a randomized controlledtrial. Obstet Gynecol 2001;98:386 –90.\\n47. Lokugamage AU, Paine M, Bassaw-Balroop K, Sullivan KR,\\nEl Refaey H, Rodeck CH. Active management of the third stageat caesarean section: a randomised controlled trial of misoprostol\\nversus Syntocinon. Aust N Z J Obstet Gynaecol 2001;41:411 –4.\\n48. Chou MM, MacKenzie IZ. A prospective, double-blind,\\nrandomized comparison of prophylactic intramyometrial 15-methylprostaglandin F\\n2a, 125 micrograms, and intravenous oxytocin, 20\\nunits, for the control of blood loss at elective cesarean section.\\nAm J Obstet Gynecol 1994;171:1356 –60.\\nRCOG Green-top Guideline No. 52 e139 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 33}), Document(page_content='49. Boucher M, Horbay GL, Grifﬁn P, Deschamps Y, Desjardins C,\\nSchulz M, et al. Double-blind, randomized comparison of the\\neffect of carbetocin and oxytocin on intraoperative blood lossand uterine tone of patients undergoing cesarean section.J Perinatol 1998;18:202 –7.\\n50. Dansereau J, Joshi AK, Helewa ME, Doran TA, Lange IR, Luther ER,\\net al. Double-blind comparison of carbetocin versus oxytocin inprevention of uterine atony after cesarean section. Am J Obstet\\nGynecol 1999;180:670 –6.\\n51. National Collaborating Centre for Women’s and Children’s\\nHealth. Caesarean Section . London: RCOG; 2011.\\n52. Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for\\npreventing postpartum haemorrhage. Cochrane Database Syst Rev\\n2015;(6):CD007872.\\n53. Glover P. Blood loss at delivery: how accurate is your\\nestimation? Aust J Midwifery 2003;16:21 –4.\\n54. Toledo P, McCarthy RJ, Hewlett BJ, Fitzgerald PC, Wong CA.\\nThe accuracy of blood loss estimation after simulated vaginaldelivery. Anesth Analg 2007;105:1736 –40.\\n55. Patel A, Goudar SS, Geller SE, Kodkany BS, Edlavitch SA, Wagh K,\\net al. Drape estimation vs. visual assessment for estimatingpostpartum hemorrhage. Int J Gynaecol Obstet 2006;93:220 –4.\\n56. Schorn MN. Measurement of blood loss: review of the literature.\\nJ Midwifery Womens Health 2010;55:20 –7.\\n57. Zhang WH, Deneux-Tharaux C, Brocklehurst P, Juszczak E, Joslin M,\\nAlexander S; EUPHRATES Group. Effect of a collector bag formeasurement of postpartum blood loss after vaginal delivery: cluster\\nrandomised trial in 13 European countries. BMJ2010;340:c293.\\n58. Buckland SS, Homer CS. Estimating blood loss after birth: using\\nsimulated clinical examples. Women Birth 2007;20:85 –8.\\n59. Bose P, Regan F, Paterson-Brown S. Improving the accuracy of\\nestimated blood loss at obstetric haemorrhage using clinicalreconstructions. BJOG 2006;113:919 –24.\\n60. Rath WH. Postpartum hemorrhage –update on problems of\\ndeﬁnitions and diagnosis. Acta Obstet Gynecol Scand 2011;90:421 –8.\\n61. Allg €ower M, Burri C. [“Shock index”]. Dtsch Med Wochenschr\\n1967;92:1947 –50. German.\\n62. Nathan HL, El Ayadi A, Hezelgrave NL, Seed P, Butrick E, Miller S,\\net al. Shock index: an effective predictor of outcome in\\npostpartum haemorrhage? BJOG 2015;122:268 –75.\\n63. Royal College of Obstetricians and Gynaecologists. Responsibility of\\nConsultant On-Call . Good Practice No. 8. London: RCOG; 2009.\\n64. Duthie SJ, Ven D, Yung GL, Guang DZ, Chan SY, Ma HK.\\nDiscrepancy between laboratory determination and visualestimation of blood loss during normal delivery. Eur J Obstet\\nGynecol Reprod Biol 1991;38:119 –24.\\n65. Ho AM, Karmakar MK, Dion PW. Are we giving enough\\ncoagulation factors during major trauma resuscitation? Am J Surg\\n2005;190:479 –84.\\n66. Hirshberg A, Dugas M, Banez EI, Scott BG, Wall MJ Jr, Mattox KL.\\nMinimizing dilutional coagulopathy in exsanguinating hemorrhage:\\na computer simulation. J Trauma 2003;54:454 –63.\\n67. Hunt BJ, Allard S, Keeling D, Norfolk D, Stanworth SJ, Pendry K;\\nBritish Committee for Standards in Haematology. A practical\\nguideline for the haematological management of majorhaemorrhage. Br J Haematol 2015;170:788 –803.\\n68. British Committee for Standards in Haematology, Stainsby D,\\nMacLennan S, Thomas D, Isaac J, Hamilton PJ. Guidelines on themanagement of massive blood loss. Br J Haematol 2006;135:\\n634–41.\\n69. Cochrane Injuries Group Albumin Reviewers. Human albumin\\nadministration in critically ill patients: systematic review ofrandomised controlled trials. BMJ 1998;317:235 –40.70. Schierhout G, Roberts I. Fluid resuscitation with colloid or\\ncrystalloid solutions in critically ill patients: a systematic review\\nof randomised trials. BMJ 1998;316:961 –4.\\n71. Association of Anaesthetists of Great Britain and Ireland,\\nThomas D, Wee M, Clyburn P, Walker I, Brohi K, et al. Blood\\ntransfusion and the anaesthetist: management of massive\\nhaemorrhage. Anaesthesia 2010;65:1153 –61.\\n72. Luna GK, Maier RV, Pavlin EG, Anardi D, Copass MK,\\nOreskovich MR. Incidence and effect of hypothermia in seriously\\ninjured patients. J Trauma 1987;27:1014 –8.\\n73. World Health Organization. WHO guidelines for the management\\nof postpartum haemorrhage and retained placenta . Geneva: WHO;\\n2009. [http://apps.who.int/iris/bitstream/10665/44171/1/978924159-\\n8514_eng.pdf]. Accessed 2016 Feb 4.\\n74. Perel P, Roberts I, Ker K. Colloids versus crystalloids for ﬂuid\\nresuscitation in critically ill patients. Cochrane Database Syst Rev\\n2013;(2):CD000567.\\n75. Murphy MF, Wallington TB, Kelsey P, Boulton F, Bruce M, Cohen H,\\net al.; British Committee for Standards in Haematology, Blood\\nTransfusion Task Force. Guidelines for the clinical use of red cell\\ntransfusions. Br J Haematol 2001;113:24 –31.\\n76. United Kingdom Blood Services; Norfolk D, editor. Handbook of\\nTransfusion Medicine . 5th ed. Norwich: TSO; 2013.\\n77. Serious Hazards of Transfusion (SHOT). [www.shotuk.org/].\\nAccessed 2013 Aug 6.\\n78. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA,\\nDe Robertis E, Filipescu DC, et al. Management of severe\\nperioperative bleeding: guidelines from the European Society of\\nAnaesthesiology. Eur J Anaesthesiol 2013;30:270 –382.\\n79. British Committee for Standards in Haematology, Milkins C,\\nBerryman J, Cantwell C, Elliott C, Haggas R, et al. Guidelines for\\npre-transfusion compatibility procedures in blood transfusionlaboratories. Transfus Med 2013;23:3 –35.\\n80. Royal College of Obstetricians and Gynaecologists. The\\nManagement of Women with Red Cell Antibodies during Pregnancy .\\nGreen-top Guideline No. 65. London: RCOG; 2014.\\n81. Laupacis A, Brown J, Costello B, Delage G, Freedman J, Hume H,\\net al. Prevention of posttransfusion CMV in the era of universal\\nWBC reduction: a consensus statement. Transfusion 2001;41:\\n560–9.\\n82. Advisory Committee on the Safety of Blood, Tissues and Organs.\\nCytomegalovirus tested blood components - position statement .\\nLondon: Department of Health; 2012.\\n83. Carless PA, Henry DA, Moxey AJ, O’Connell D, Brown T,\\nFergusson DA. Cell salvage for minimising perioperative allogeneic\\nblood transfusion. Cochrane Database Syst Rev 2010;(4):CD001888.\\n84. Catling SJ, Williams S, Fielding AM. Cell salvage in obstetrics: an\\nevaluation of the ability of cell salvage combined with leucocytedepletion ﬁltration to remove amniotic ﬂuid from operative\\nblood loss at caesarean section. Int J Obstet Anesth 1999;8:79 –84.\\n85. National Institute for Health and Clinical Excellence.\\nIntraoperative blood cell salvage in obstetrics . NICE interventional\\nprocedure guidance 144. Manchester: NICE; 2005.\\n86. Wee MY, Thomas D, Verma R, Jones J, Catling S, Isaac J, et al.;\\nThe Association of Anaesthetists of Great Britain and Ireland.Blood Transfusion and the Anaesthetist: Intra-operative Cell Salvage .\\nAAGBI Safety Guideline. London: AAGBI; 2009.\\n87. Liumbruno GM, Liumbruno C, Rafanelli D. Intraoperative cell\\nsalvage in obstetrics: is it a real therapeutic option? Transfusion\\n2011;51:2244 –56.\\n88. Geoghegan J, Middleton L, Moore P, Subseson G, Khan K,\\nDaniels J. Routine cell salvage during elective caesarean section: apilot randomised trial. Int J Obstet Anesth 2015;24:86 –7.\\nRCOG Green-top Guideline No. 52 e140 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 34}), Document(page_content='89. Solomon C, Collis RE, Collins PW. Haemostatic monitoring\\nduring postpartum haemorrhage and implications for\\nmanagement. Br J Anaesth 2012;109:851 –63.\\n90. Avidan MS, Alcock EL, Da Fonseca J, Ponte J, Desai JB,\\nDespotis GJ, et al. Comparison of structured use of routine\\nlaboratory tests or near-patient assessment with clinical judgement\\nin the management of bleeding after cardiac surgery. Br J Anaesth\\n2004;92:178 –86.\\n91. Allard S, Green L, Hunt BJ. How we manage the haematological\\naspects of major obstetric haemorrhage. Br J Haematol 2014;\\n164:177 –88.\\n92. Bell SF, Rayment R, Collins PW, Collis RE. The use of ﬁbrinogen\\nconcentrate to correct hypoﬁbrinogenaemia rapidly during\\nobstetric haemorrhage. Int J Obstet Anesth 2010;19:218 –23.\\n93. Collis RE, Collins PW. Haemostatic management of obstetric\\nhaemorrhage. Anaesthesia 2015;70 Suppl 1:78 –86, e27 –8.\\n94. Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A.\\nIntroduction of an algorithm for ROTEM-guided ﬁbrinogenconcentrate administration in major obstetric haemorrhage.\\nAnaesthesia 2015;70:166 –75.\\n95. Plaat F, Bogod D, Bythell V, Mushambi M, Clyburn P, Lucas N, et al.;\\nAssociation of Anaesthetists of Great Britain & Ireland; ObstetricAnaesthetists’ Association. OAA / AAGBI Guidelines for Obstetric\\nAnaesthetic Services 2013 . London: AAGBI; 2013.\\n96. National Institute for Health and Care Excellence. Detecting,\\nmanaging and monitoring haemostasis: viscoelastometric point of caretesting (ROTEM, TEG and Sonoclot systems) . NICE diagnostics\\nguidance 13. Manchester: NICE; 2014.\\n97. Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B,\\nKeita H, et al.; PPH Study Group. The decrease of ﬁbrinogen is\\nan early predictor of the severity of postpartum hemorrhage.\\nJ Thromb Haemost 2007;5:266 –73.\\n98. Collins PW, Lilley G, Bruynseels D, Laurent DB, Cannings-John R,\\nPrecious E, et al. Fibrin-based clot formation as an early and rapid\\nbiomarker for progression of postpartum hemorrhage: a\\nprospective study. Blood 2014;124:1727 –36.\\n99. de Lloyd L, Bovington R, Kaye A, Collis RE, Rayment R, Sanders J,\\net al. Standard haemostatic tests following major obstetric\\nhaemorrhage. Int J Obstet Anesth 2011;20:135 –41.\\n100. Li G, Rachmale S, Kojicic M, Shahjehan K, Malinchoc M, Kor DJ, et al.\\nIncidence and transfusion risk factors for transfusion-associatedcirculatory overload among medical intensive care unit patients.\\nTransfusion 2011;51:338 –43.\\n101. Teoﬁli L, Bianchi M, Za nﬁni BA, Catarci S, Sicuranza R, Spartano S,\\net al. Acute lung injury complicating blood transfusion in\\npost-partum hemorrhage: incidence and risk factors. Mediterr\\nJ Hematol Infect Dis 2014;6:e2014.069.\\n102. Collins PW, Solomon C, Sutor K, Crispin D, Hochleitner G,\\nRizoli S, et al. Theoretical modelling of ﬁbrinogen\\nsupplementation with therapeutic plasma, cryoprecipitate, or\\nﬁbrinogen concentrate. Br J Anaesth 2014;113:585 –95.\\n103. Hiippala ST, Myllyl €a GJ, Vahtera EM. Hemostatic factors and\\nreplacement of major blood loss with plasma-poor red cell\\nconcentrates.\\nAnesth Analg 1995;81:360 –5.\\n104. Chowdary P, Saayman AG, Paulus U, Findlay GP, Collins PW.\\nEfﬁcacy of standard dose and 30 ml/kg fresh frozen plasma in\\ncorrecting laboratory parameters of haemostasis in critically ill\\npatients. Br J Haematol 2004;125:69 –73.\\n105. Duguid J, O’Shaughnessy DF, Atterbury C, Bolton Maggs P,\\nMurphy M, Thomas D, et al.; British Committee for Standards in\\nHaematology, Blood Transfusion Task Force. Guidelines for the\\nuse of fresh-frozen plasma, cryoprecipitate and cryosupernatant.Br J Haematol 2004;126:11 –28.106. Tikkanen M. Placental abruption: epidemiology, risk factors and\\nconsequences. Acta Obstet Gynecol Scand 2011;90:140 –9.\\n107. Levi M. Pathogenesis and management of peripartum coagulopathic\\ncalamities (disseminated intravascular coagulation and amnioticﬂuid embolism). Thromb Res 2013;131 Suppl 1:S32 –4.\\n108. Green L, Knight M, Seeney F, Hopkinson C, Collins PW,\\nCollis RE, et al. The haematological features and transfusionmanagement of women who required massive transfusion for\\nmajor obstetric haemorrhage in the UK: a population based\\nstudy. Br J Haematol 2016;172:616 –24.\\n109. Cortet M, Deneux-Tharaux C, Dupont C, Colin C, Rudigoz RC,\\nBouvier-Colle MH, et al. Association between ﬁbrinogen level\\nand severity of postpartum haemorrhage: secondary analysis of a\\nprospective trial. Br J Anaesth 2012;108:984 –9.\\n110. De Lloyd L, Collins PW, Kaye A, Collis RE. Early ﬁbrinogen as a\\npredictor of red cell requirements during postpartum\\nhaemorrhage. Int J Obstet Anesth 2012;21 Suppl 1:S13.\\n111. Gayat E, Resche-Rigon M, Morel O, Rossignol M, Mantz J,\\nNicolas-Robin A, et al. Predictive factors of advanced\\ninterventional procedures in a multicentre severe postpartum\\nhaemorrhage study. Intensive Care Med 2011;37:1816 –25.\\n112. Wikkelsø AJ, Edwards HM, Afshari A, Stensballe J, Langhoff-Roos J,\\nAlbrechtsen C, et al.; FIB-PPH trial group. Pre-emptive treatment\\nwith ﬁbrinogen concentrate for postpartum haemorrhage:\\nrandomized controlled trial. Br J Anaesth 2015;114: 623 –33.\\n113. Ahmed S, Harrity C, Johnson S, Varadkar S, McMorrow S,\\nFanning R, et al. The efﬁcacy of ﬁbrinogen concentrate\\ncompared with cryoprecipitate in major obstetric haemorrhage –\\nan observational study. Transfus Med 2012;22:344 –9.\\n114. Gollop ND, Chilcott J, Benton A, Rayment R, Jones J, Collins PW.\\nNational audit of the use of ﬁbrinogen concentrate to correct\\nhypoﬁbrinogenaemia. Transfus Med 2012;22:350 –5.\\n115. Mallaiah S, Chevannes C, McNamara H, Barclay P. A reply.\\nAnaesthesia 2015;70:760 –1.\\n116. Glover NJ, Collis RE, Collins P. Fibrinogen concentrate use\\nduring major obstetric haemorrhage. Anaesthesia 2010;65:\\n1229 –30.\\n117. Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired\\nhypoﬁbrinogenaemic states. Transfus Med 2008;18:151 –\\n7.\\n118. CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K,\\nCoats T, et al. The importance of early treatment with tranexamicacid in bleeding trauma patients: an exploratory analysis of the\\nCRASH-2 randomised controlled trial. Lancet 2011;377:1096 –101,\\n1101.e1 –2.\\n119. Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin F, Huissoud C,\\nKeita-Meyer H, et al.; The EXADELI Study Group. High-dose\\ntranexamic acid reduces blood loss in postpartum haemorrhage.Crit Care 2011;15:R117.\\n120. Shakur H, Elbourne D, G €ulmezoglu M, Alﬁrevic Z, Ronsmans C,\\nAllen E, et al. The WOMAN Trial (World Maternal\\nAntiﬁbrinolytic Trial): tranexamic acid for the treatment ofpostpartum haemorrhage: an international randomised, doubleblind placebo controlled trial. Trials 2010;11:40.\\n121. Ahonen J. The role of recombinant activated factor VII in\\nobstetric hemorrhage. Curr Opin Anaesthesiol 2012;25:309 –14.\\n122. Alﬁrevic Z, Elbourne D, Pavord S, Bolte A, Van Geijn H,\\nMercier F, et al. Use of recombinant activated factor VII in\\nprimary postpartum hemorrhage: the Northern EuropeanRegistry 2000 –2004. Obstet Gynecol 2007;110:1270 –8.\\n123. Franchini M, Franchi M, Bergamini V, Salvagno GL, Montagnana M,\\nLippi G. A critical review on the use of recombinant factor VIIa in\\nlife-threatening obstetric postpartum hemorrhage. Semin Thromb\\nHemost 2008;34:104 –12.\\nRCOG Green-top Guideline No. 52 e141 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 35}), Document(page_content='124. Franchini M, Franchi M, Bergamini V, Montagnana M, Salvagno GL,\\nTargher G, et al. The use of recombinant activated FVII in\\npostpartum hemorrhage. Clin Obstet Gynecol 2010;53: 219 –27.\\n125. Lavigne-Lissalde G, Aya AG, Mercier FJ, Roger-Christoph S,\\nChauleur C, Morau E, et al. Recombinant human FVIIa for\\nreducing the need for invasive second-line therapies in severe\\nrefractory postpartum hemorrhage: a multicenter, randomized,open controlled trial. J Thromb Haemost 2015;13:520 –9.\\n126. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant\\nactivated factor VII in randomized clinical trials. N Engl J Med\\n2010;363:1791 –800.\\n127. de Groot AN. Prevention of postpartum haemorrhage. Baillieres\\nClin Obstet Gynaecol 1995;9:619 –31.\\n128. Walker ID, Walker JJ, Colvin BT, Letsky EA, Rivers R, Stevens R;\\nHaemostasis and Thrombosis Task Force. Investigation andmanagement of haemorrhagic disorders in pregnancy. J Clin Pathol\\n1994;47:100 –8.\\n129. Patel N, editor. Maternal Mortality –the Way Forward. Some\\nImplications of the Report on Conﬁdential Enquiries into Maternal\\nDeaths in the United Kingdom 1985 -87. London: RCOG; 1992.\\n130. Franchini M, Lippi G, Franchi M. The use of recombinant\\nactivated factor VII in obstetric and gynaecological haemorrhage.BJOG 2007;114:8 –15.\\n131. Conﬁdential Enquiry into Maternal and Child Health. Saving\\nMothers’ Lives: Reviewing maternal deaths to make motherhood safer -\\n2003 -2005. The Seventh Report of the Conﬁdential Enquiries into\\nMaternal Deaths in the United Kingdom . London: CEMACH; 2007.\\n132. Royal College of Obstetricians and Gynaecologists. Reducing the\\nRisk of Venous Thromboembolism during Pregnancy and thePuerperium . Green-top Guideline No. 37a. London: RCOG; 2015.\\n133. Palmer SK. Anaesthesia care for obstetric patients in the United\\nStates. In: Reynolds F, editor. Regional Analgesia in Obstetrics:\\nA Millennium Update . London: Springer-Verlag London; 2000.\\npp. 3 –10.\\n134. Rajan PV, Wing DA. Postpartum hemorrhage: evidence-based\\nmedical interventions for prevention and treatment. Clin Obstet\\nGynecol 2010;53:165 –81.\\n135. Joint Formulary Committee. British National Formulary , 69th ed.\\nLondon: BMJ Group and Pharmaceutical Press; 2015.\\n136. Lewis G, editor. The National Institute for Clinical Excellence;\\nThe Scottish Executive Health Department; The Department ofHealth, Social Services and Public Safety: Northern Ireland. Why\\nMothers Die 1997 –1999. The ﬁfth report of the Conﬁdential\\nEnquiries into Maternal Deaths in the United Kingdom . London:\\nRCOG Press; 2001.\\n137. Buttino L Jr, Garite TJ. The use of 15 methyl F\\n2alpha\\nprostaglandin (Prostin 15M) for the control of postpartumhemorrhage. Am J Perinatol 1986;3:241 –3.\\n138. Oleen MA, Mariano JP. Controlling refractory atonic postpartum\\nhemorrhage with Hemabate sterile solution. Am J Obstet Gynecol\\n1990;162:205 –8.\\n139. Hofmeyr GJ, Walraven G, G €ulmezoglu AM, Maholwana B,\\nAlﬁrevic Z, Villar J. Misoprostol to treat postpartum\\nhaemorrhage: a systematic review. BJOG 2005;112:547 –53.\\n140. Meckstroth KR, Whitaker AK, Bertisch S, Goldberg AB, Darney PD.\\nMisoprostol administered by epithelial routes. Drug absorption and\\nuterine response. Obstet Gynecol 2006;108:582 –90.\\n141. Tang J, Kapp N, Dragoman M, de Souza JP. WHO\\nrecommendations for misoprostol use for obstetric andgynecologic indications. Int J Gynaecol Obstet 2013;121:186 –9.\\n142. International Federation of Gynecology and Obstetrics.\\nTreatment of Post-Partum Haemorrhage with Misoprostol . FIGO\\nGuideline Annotated Version. London: FIGO; 2012.[www.k4health.org/toolkits/post partumhemorrhage/treatment-\\npost-partum-haemorrhage-misoprostol-ﬁgo-guideline-annotated].\\nAccessed 2016 Feb 4.\\n143. Georgiou C. Balloon tamponade in the management of\\npostpartum haemorrhage: a review. BJOG 2009;116:748 –57.\\n144. Ikechebelu JI, Obi RA, Joe-Ikechebelu NN. The control of\\npostpartum haemorrhage with intrauterine Foley catheter.J Obstet Gynaecol 2005;25:70 –2.\\n145. Bakri YN, Amri A, Abdul Jabbar F. Tamponade-balloon for\\nobstetrical bleeding. Int J Gynaecol Obstet 2001;74:139 –42.\\n146. Chan C, Razvi K, Tham KF, Arulkumaran S. The use of a\\nSengstaken-Blakemore tube to control post-partum hemorrhage.\\nInt J Gynaecol Obstet 1997;58:251 –2.\\n147. Condous GS, Arulkumaran S, Symonds I, Chapman R, Sinha A,\\nRazvi K. The “tamponade test” in the management ofmassive postpartum hemorrhage. Obstet Gynecol 2003;101:\\n767–72.\\n148. Akhter S, Begum MR, Kabir Z, Rashid M, Laila TR, Zabeen F.\\nUse of a condom to control massive postpartum hemorrhage.\\nMedGenMed 2003;5:38.\\n149. Keriakos R, Mukhopadhyay A. The use of the Rusch balloon for\\nmanagement of severe postpartum haemorrhage. J Obstet\\nGynaecol 2006;26:335 –8.\\n150. Lennox C, Marr L; Reproductive Health Programme, Healthcare\\nImprovement Scotland. Scottish Conﬁdential Audit of Severe\\nMaternal Morbidity: reducing avoidable harm. 10th Annual Report .\\nEdinburgh: Healthcare Improvement Scotland; 2014.\\n151. Frenzel D, Condous GS, Papageorghiou AT, McWhinney NA.\\nThe use of the ‘tamponade test’ to stop massive obstetrichaemorrhage in placenta accreta. BJOG 2005;112:676 –7.\\n152. Tindell K, Garﬁnkel R, Abu-Haydar E, Ahn R, Burke TF,\\nConn K, et al. Uterine balloon tamponade for the treatment ofpostpartum haemorrhage in resource-poor settings: a systematicreview. BJOG 2013;120:5 –14.\\n153. Matsubara S, Yano H, Ohkuchi A, Kuwata T, Usui R, Suzuki M.\\nUterine compression sutures for postpartum hemorrhage: anoverview. Acta Obstet Gynecol Scand 2013;92:378 –85.\\n154. B-Lynch C, Coker A, Lawal AH, Abu J, Cowen MJ. The B-Lynch\\nsurgical technique for the control of massive postpartum\\nhaemorrhage: an alternative to hysterectomy? Five casesreported. Br J Obstet Gynaecol 1997;104:372 –5.\\n155. Harma M, Gungen N, Ozturk A. B-Lynch uterine compression\\nsuture for postpartum haemorrhage due to placenta praevia\\naccreta. Aust N Z J Obstet Gynaecol 2005;45:93 –5.\\n156. Hayman RG, Arulkumaran S, Steer PJ. Uterine compression\\nsutures: surgical management of postpartum hemorrhage.\\nObstet Gynecol 2002;99:502 –6.\\n157. Ghezzi F, Cromi A, Uccella S, Raio L, Bolis P, Surbek D.\\nThe Hayman technique: a simple method to treat postpartum\\nhaemorrhage. BJOG 2007;114:362 –5.\\n158. Hwu YM, Chen CP, Chen HS, Su TH. Parallel vertical\\ncompression sutures: a technique to control bleeding fromplacenta praevia or accreta during caesarean section. BJOG\\n2005;112:1420 –3.\\n159. Kafali H, Demir N, Soylemez F, Yurtseven S. Hemostatic cervical\\nsuturing technique for management of uncontrollable postpartum\\nhaemorrhage originating from the cervical canal. Eur J Obstet\\nGynecol Reprod Biol 2003;110:35 –8.\\n160. Makino S, Tanaka T, Yorifuji T, Koshiishi T, Sugimura M, Takeda S.\\nDouble vertical compression sutures: A novel conservativeapproach to managing post-partum haemorrhage due to placentapraevia and atonic bleeding. Aust N Z J Obstet Gynaecol\\n2012;52:290 –2.\\nRCOG Green-top Guideline No. 52 e142 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 36}), Document(page_content='161. Kayem G, Kurinczuk JJ, Alﬁrevic Z, Spark P, Brocklehurst P,\\nKnight M; U.K. Obstetric Surveillance System (UKOSS). Uterine\\ncompression sutures for the management of severe postpartumhemorrhage. Obstet Gynecol 2011;117:14 –20.\\n162. Fotopoulou C, Dudenhausen JW. Uterine compression sutures\\nfor preserving fertility in severe postpartum haemorrhage: an\\noverview 13 years after the ﬁrst description. J Obstet Gynaecol\\n2010;30:339 –49.\\n163. Diemert A, Ortmeyer G, Hollwitz B, Lotz M, Somville T,\\nGlosemeyer P, et al. The combination of intrauterine balloontamponade and the B-Lynch procedure for the treatment of severepostpartum hemorrhage. Am J Obstet Gynecol 2012;206:65.e1 –4.\\n164. Yoong W, Ridout A, Memtsa M, Stavroulis A, Aref-Adib M,\\nRamsay-Marcelle Z, et al. Application of uterine compressionsuture in association with intrauterine balloon tamponade(‘uterine sandwich’) for postpartum hemorrhage. Acta Obstet\\nGynecol Scand 2012;91:147 –51.\\n165. Nelson WL, O’Brien JM. The uterine sandwich for persistent\\nuterine atony: combining the B-Lynch compression suture and an\\nintrauterine Bakri balloon. Am J Obstet Gynecol 2007;196:e9 –10.\\n166. AbdRabbo SA. Stepwise uterine devascularization: a novel\\ntechnique for management of uncontrolled postpartum hemorrhagewith preservation of the uterus. Am J Obstet Gynecol 1994;171:\\n694–700.\\n167. Sentilhes L, Gromez A, Descamps P, Marpeau L. Why stepwise\\nuterine devascularization should be ﬁrst-line conservativesurgical treatment to control severe postpartum hemorrhage?\\nActa Obstet Gynecol Scand 2009;88:490 –2.\\n168. Joshi VM, Otiv SR, Majumder R, Nikam YA, Shrivastava M.\\nInternal iliac artery ligation for arresting postpartum\\nhaemorrhage. BJOG 2007;114:356 –61.\\n169. Nizard J, Barrinque L, Frydman R, Fernandez H. Fertility and\\npregnancy outcomes following hypogastric artery ligationfor severe post-partum haemorrhage. Hum Reprod 2003;18:844 –8.\\n170. Doumouchtsis SK, Nikolopoulos K, Talaulikar VS, Krishna A,\\nArulkumaran S. Menstrual and fertility outcomes following thesurgical management of postpartum haemorrhage: a systematicreview. BJOG 2014;121:382 –8.\\n171. Lee HY, Shin JH, Kim J, Yoon HK, Ko GY, Won HS, et al. Primary\\npostpartum hemorrhage: outcome of pelvic arterial embolizationin 251 patients at a single institution. Radiology 2012;264:903 –9.\\n172. Salomon LJ, de Tayrac R, Castaigne-Meary V, Audibert F, Musset D,\\nCiorascu R, et al. Fertility and pregnancy outcome following\\npelvic arterial embolization for severe post-partum haemorrhage.A cohort study. Hum Reprod 2003;18:849 –52.\\n173. Descargues G, Mauger Tinlot F, Douvrin F, Clavier E, Lemoine\\nJP, Marpeau L. Menses, fertility and pregnancy after arterialembolization for the control of postpartum haemorrhage.Hum Reprod 2004;19:339 –43.\\n174. Fargeaudou Y, Morel O, Soyer P, Gayat E, Sirol M, Boudiaf M,\\net al. Persistent postpartum haemorrhage after failed arterialligation: value of pelvic embolisation. Eur Radiol 2010;20:1777 –85.\\n175. Brace V, Kernaghan D, Penney G. Learning from adverse clinical\\noutcomes: major obstetric haemorrhage in Scotland, 2003 –05.\\nBJOG 2007;114:1388 –96.\\n176. Duffy S, Gaffney G. Maternal admissions to ICU –time to re-\\nevaluate. Ir Med J 2001;94:248 –9.\\n177. Neill A, Thornton S. Secondary postpartum haemorrhage.\\nJ Obstet Gynaecol 2002;22:119 –22.\\n178. Babarinsa IA, Hayman RG, Draycott TJ. Secondary post-partum\\nhaemorrhage: challenges in evidence-based causes and\\nmanagement. Eur J Obstet Gynecol Reprod Biol 2011;159:255 –60.179. Rome RM. Secondary postpartum haemorrhage. Br J Obstet\\nGynaecol 1975;82:289 –92.\\n180. Pather S, Ford M, Reid R, Sykes P. Postpartum curettage: an\\naudit of 200 cases. Aust N Z J Obstet Gynaecol 2005;45:368 –71.\\n181. French L, Smaill FM. Antibiotic regimens for endometritis after\\ndelivery. Cochrane Database Syst Rev 2004;(4):CD001067.\\n182. Royal College of Obstetricians and Gynaecologists. Bacterial\\nSepsis following Pregnancy . Green-top Guideline No. 64b. London:\\nRCOG; 2012.\\n183. Carlan SJ, Scott WT, Pollack R, Harris K. Appearance of the\\nuterus by ultrasound immediately after placental delivery withpathologic correlation. J Clin Ultrasound 1997;25:301 –8.\\n184. de Vries JI, van der Linden RM, van der Linden HC. Predictive\\nvalue of sonographic examination to visualize retained placentadirectly after birth at 16 to 28 weeks. J Ultrasound Med 2000;\\n19:7–12.\\n185. Edwards A, Ellwood DA. Ultrasonographic evaluation of the\\npostpartum uterus. Ultrasound Obstet Gynecol 2000;16:640 –3.\\n186. Sadan O, Golan A, Girtler O, Lurie S, Debby A, Sagiv R, et al.\\nRole of sonography in the diagnosis of retained products of\\nconception. J Ultrasound Med 2004;23:371 –4.\\n187. Mulic-Lutvica A, Axelsson O. Ultrasound ﬁnding of an echogenic\\nmass in women with secondary postpartum hemorrhage is\\nassociated with retained placental tissue. Ultrasound Obstet\\nGynecol 2006;28:312 –9.\\n188. Yi SW, Ahn JH. Secondary postpartum hemorrhage due to a\\npseudoaneurysm rupture at the fundal area of the uterus: a case\\ntreated with selective uterine arterial embolization. Fertil Steril\\n2010;93:2048 –9.\\n189. Arab TS, Dy J. Pseudoaneurysm of the vaginal artery as a\\ncause of postpartum haemorrhage. J Obstet Gynaecol 2011;31:\\n185–6.\\n190. Chitra TV, Panicker S. Pseudoaneurysm of uterine artery: a rare\\ncause of secondary postpartum hemorrhage. J Obstet Gynaecol\\nIndia 2011;61:641 –4.\\n191. King PA, Duthie SJ, Dong ZG, Ma HK. Secondary postpartum\\nhaemorrhage. Aust N Z J Obstet Gynaecol 1989;29:394 –8.\\n192. Jensen PA, Stromme WB. Amenorrhea secondary to puerperal\\ncurettage (Asherman’s syndrome).\\nAm J Obstet Gynecol\\n1972;113:150 –7.\\n193. Sharma AM, Burbridge BE. Uterine artery pseudoaneurysm in\\nthe setting of delayed postpartum hemorrhage: successful\\ntreatment with emergency arterial embolization. Case Rep Radiol\\n2011;2011:373482.\\n194. Agrawal R, Legge F, Pollard K, Al-Inizi S. Massive secondary\\npostpartum haemorrhage managed with insertion of a Bakri\\nballoon catheter after surgical evacuation of the uterus. S Afr J\\nObstet Gynaecol 2011;17:36 –7.\\n195. Meri /C19en AE, van de Ven J, Mol BW, Houterman S, Oei SG.\\nMultidisciplinary team training in a simulation setting for acute\\nobstetric emergencies: a systematic review. Obstet Gynecol\\n2010;115:1021 –31.\\n196. Royal College of Obstetricians and Gynaecologists. Improving\\nPatient Safety: Risk Management for Maternity and Gynaecology .\\nClinical Governance Advice No. 2. London: RCOG; 2009.\\n197. Penney G, Brace V. Near miss audit in obstetrics. Curr Opin\\nObstet Gynecol 2007;19:145 –50.\\n198. Beck CT. Post-traumatic stress disorder due to childbirth: the\\naftermath. Nurs Res 2004;53:216 –24.\\n199. D €okmetas /C223HS, Kilicli F, Korkmaz S, Yonem O. Characteristic\\nfeatures of 20 patients with Sheehan’s syndrome. Gynecol Endocrinol\\n2006;22:279 –83.\\nRCOG Green-top Guideline No. 52 e143 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 37}), Document(page_content='Appendix I: Explanation of guidelines and evidence levels\\nClinical guidelines are: ‘systematically developed statements which assist clinicians and patients in making decisions\\nabout appropriate treatment for speciﬁc conditions’. Each guideline is systematically developed using a standardised\\nmethodology. Exact details of this process can be found in Clinical Governance Advice No. 1 Development of RCOG\\nGreen-top Guidelines (available on the RCOG website at www.rcog.org.uk/green-top-development ). These\\nrecommendations are not intended to dictate an exclusive course of management or treatment. They must beevaluated with reference to individual patient needs, resources and limitations unique to the institution and variationsin local populations. It is hoped that this process of local ownership will help to incorporate these guidelines intoroutine practice. Attention is drawn to areas of clinical uncertainty where further research may be indicated.\\nThe evidence used in this guideline was graded using the scheme below and the recommendations formulated in a\\nsimilar fashion with a standardised grading scheme.\\nClassi ﬁcation of evidence levels Grades of recommendations\\n1++ High-quality meta-analyses, systematic reviews\\nof randomised controlled trials or randomisedcontrolled trials with a very low risk of biasAAt least one meta-analysis, systematic reviews orRCT rated as 1 ++, and directly applicable to the\\ntarget population; orA systematic review of RCTs or a body ofevidence consisting principally of studies rated as1+, directly applicable to the target population and\\ndemonstrating overall consistency of results1+ Well-conducted meta-analyses, systematic\\nreviews of randomised controlled trials or\\nrandomised controlled trials with a low riskof bias\\n1– Meta-analyses, systematic reviews of\\nrandomised controlled trials or randomisedcontrolled trials with a high risk of bias\\nBA body of evidence including studies rated as 2 ++\\ndirectly applicable to the target population, anddemonstrating overall consistency of results; orExtrapolated evidence from studies rated as 1 ++\\nor 1+2++ High-quality systematic reviews of\\ncase–control or cohort studies or high-quality\\ncase–control or cohort studies with a very\\nlow risk of confounding, bias or chance and ahigh probability that the relationship is causal\\n2+ Well-conducted case –control or cohort\\nstudies with a low risk of confounding, bias orchance and a moderate probability that therelationship is causalCA body of evidence including studiesrated as 2 +directly applicable to the target\\npopulation, and demonstrating overallconsistency of results; orExtrapolated evidence from studies ratedas 2++\\n2– Case –control or cohort studies with a high risk\\nof confounding, bias or chance and a signiﬁcant\\nrisk that the relationship is not causal\\n3 Non-analytical studies, e.g. case reports, case\\nseriesDEvidence level 3 or 4; orExtrapolated evidence from studies rated as 2 +\\n4 Expert opinionGood practice point\\n✓Recommended best practice based on the\\nclinical experience of the guideline developmentgroup\\nRCOG Green-top Guideline No. 52 e144 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 38}), Document(page_content='Appendix II: The causes of PPH30\\nThe four Ts Risk factors/notes\\nTone: abnormalities of uterine contraction\\nOverdistension of uterus Polyhydramnios, multiple gestation, macrosomia\\nIntra-amniotic infection Fever, prolonged rupture of membranes\\nFunctional/anatomic distortion of uterus Rapid labour, prolonged labour, ﬁbroids, placenta\\npraevia, uterine anomalies\\nUterine relaxants, e.g. magnesium and nifedipine Terbutaline, halogenated anaesthetics, glyceryl trinitrate\\nBladder distension May prevent uterine contraction\\nTissue: retained products of conception\\nRetained cotyledon or succenturiate lobe\\nRetained blood clots\\nTrauma: genital tract injury\\nLacerations of the cervix, vagina or perineum Precipitous delivery, operative delivery\\nExtensions, lacerations at caesarean section Malposition, deep engagementUterine rupture Previous uterine surgery\\nUterine inversion High parity with excessive cord traction\\nThrombin: abnormalities of coagulation\\nPre-existing states\\nHaemophilia A History of hereditary coagulopathies or liver disease\\nIdiopathic thrombocytopenic purpura Bruisingvon Willebrand ’s disease\\nHistory of previous PPH\\nAcquired in pregnancy\\nGestational thrombocytopenic Bruising\\nPre-eclampsia with thrombocytopenia e.g. HELLP Elevated blood pressure\\nDisseminated intravascular coagulation\\na) Gestational hypertensive disorder of\\npregnancy with adverse conditionsCoagulopathy\\nb) in utero fetal demise Fetal demise\\nc) severe infection Fever, neutrophilia/neutropeniad) abruption Antepartum haemorrhagee) amniotic ﬂuid embolus Sudden collapse\\nTherapeutic anticoagulation History of thromboembolic disease\\nAbbreviations: HELLP haemolysis, elevated liver enzymes and low platelet count; PPH postpartum haemorrhage.\\nRCOG Green-top Guideline No. 52 e145 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 39}), Document(page_content='Appendix III: Aﬂow chart of the different steps for the management of major PPH\\nResuscitation, monitoring, investigation and treatment should occur simultaneously\\nMajor obstetric haemorrhage\\nBlood loss greater than 1000 ml\\nContinuing major obstetric haemorrhage or clinical shock\\nCall for help\\nSenior midwife/obstetrician and anaesthetist\\nAlert haematologist\\nAlert blood transfusion laboratory\\nAlert consultant obstetrician on call\\nResuscitation\\nAirway\\nBreathing\\nCirculation\\nOxygen mask (15 l)\\nFluid balance (e.g. 2 l isotonic crystalloid, 1.5 l colloid)\\nBlood transfusion (O RhD-negative or group-specific blood)\\nBlood products (FFP, PLT, c ryoprecipitate, factor VIIa)\\nKeep patient warm\\nTheatre\\nIs the uterus contracted?\\nExamination under anaesthesia\\nHas any clotting abnormality been corrected?\\nIntrauterine balloon tamponade\\nBrace suture\\nConsider interventional radiologyMonitoring and investigations\\n14-gauge cannula x 2\\nFBC, coagulation, U&Es, LFTs\\nCross-match (4 units, FFP, PLT, \\ncryoprecipitate)\\nECG, oximeter\\nFoley catheter\\nHb bedside testing\\nBlood productsConsider central and arterial lines\\nCommence record chart\\nWeigh all swabs and estimate blood lossMedical treatment\\nRub up the uterine fundus\\nEmpty bladder\\nOxytocin 5 iu, slow IV (repeat if necessary)\\nErgometrine 0.5 mg, slow IV or IM\\nOxytocin infusion (40 iu in 500 ml)\\nCarboprost 0.25 mg IM every 15 minutes up \\nto 8 times\\nCarboprost (intramyometrial) 0.5 mg\\nMisoprostol 800 micrograms sublingually\\nConsider tranexamic acid 1 g IV\\nSurgery\\nStepwise uterine devascularisation\\nBilateral internal iliac ligation\\nHysterectomy (second experienced clinician)\\nUterine artery embolisation\\nHigh-dependency unit\\nor intensive care unit\\nAbbreviations: ECG electrocardiogram; FBC full blood count; FFP f r e s hf r o z e np l a s m a ; Hbhaemoglobin; IVintravenous; IM\\nintramuscular; LFTs liver function tests; PLT platelets; PPH postpartum haemorrhage; RhD rhesus D; U&Es urea and\\nelectrolytes.\\nRCOG Green-top Guideline No. 52 e146 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 40}), Document(page_content='Appendix IV: Obstetric early warning chart\\nOBSTETRIC EARLY WARNING CHART.\\nNAME: DOB:FOR MATERNITY USE ONLY\\nWARD: CHI:\\nDate :\\nTime :\\nRESP (write\\n     rate in    corresp.\\n       box)\\n    >30\\n21-30\\n11-20\\n0-10\\n90-100%\\nSaturations\\nO2 Conc.Temp HEART RATE Systolic blood pressure Diastolic blood pressure<90%\\n%>30\\n21-30\\n11-20\\n0-10\\n90-100%\\n<90%\\n%\\n39\\n38\\n37\\n36\\n3539\\n38\\n37\\n36\\n35\\n170\\n160\\n150\\n140\\n130\\n120\\n110\\n100\\n90\\n80\\n70\\n60\\n50\\n40\\n170180190200\\n160\\n150\\n140130\\n120\\n110\\n100\\n90\\n80\\n70\\n60\\n50\\n130\\n120\\n110\\n100\\n90\\n80\\n70\\n60\\n50\\n40\\nPassed Urine\\nLochiaY or N\\nNormal\\nHeavy / Foul\\n2+\\n> 2+\\nClear / Pink\\nAlert\\nVoice\\nPain /\\nUnresponsive\\n2-3\\n0-1\\nYES ( /checkbld)\\nYES ( /checkbld)NO (/checkbld)\\nNO (/checkbld)GreenY or N\\nNormal\\nHeavy / Foul\\n2+\\n> 2+\\nClear / Pink\\nAlert\\nVoice\\nPain /\\nUnresponsive\\n2-3\\n0-1\\nYES ( /checkbld)\\nYES ( /checkbld)NO (/checkbld)\\nNO (/checkbld)GreenProteinuria\\nLiquor\\nNEURO\\nRESPONSE\\n(/checkbld)\\n   \\nPain Score     (no.) \\nNausea\\n    (\\n/checkbld) \\nLooks unwell\\nLooks unwell\\nTotal Yellow Scores\\nTotal Red Scores170\\n160\\n150140\\n130\\n120\\n110\\n100\\n90\\n80\\n70\\n60\\n50\\n40\\n170180190200\\n160\\n150\\n140\\n130\\n120\\n110\\n100\\n90\\n80\\n70\\n60\\n50\\n130\\n120\\n110\\n100\\n90\\n80\\n70\\n60\\n50\\n40CONTACT DOCTOR FOR EARLY INTERVENTION IF PATIENT TRIGGERS ONE RED OR TWO YELLOW SCORES AT ANY ONE TIME\\nRCOG Green-top Guideline No. 52 e147 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 41}), Document(page_content='Time of call-out: ……………………………………………………… Call-out by: ………………………………………………. Date: ………………………………………\\nTeam member Name Time arrived Drug Dose Time\\nOn-call obstetric consultant Oxytocin 5 iu slow IV\\nOn-call obstetric registrar Ergometrine 500 micrograms/1 ampule (if normal BP) IM \\nIV\\nOn-call obstetric ST1-2/GPVTS/FY Oxytocin infusion 40 iu in 500 ml physiological saline IV via \\ninfusion pump at 125 ml/hour\\nOn-call anaesthetic consultant Carboprost 0.25 mg IM (dose 1)\\nOn-call anaesthetic registrar Carboprost 0.25 mg IM (dose 2)\\nOn-call operating department practitioner Carboprost 0.25 mg IM (dose 3)\\nAlert blood transfusion laboratory Carboprost 0.25 mg IM (dose 4)\\nOn-call gynaecology ST1-2/GPVTS/FY Carboprost 0.25 mg IM (dose 5)\\nSenior midwife Carboprost 0.25 mg IM (dose 6)\\nMidwife Carboprost 0.25 mg IM (dose 7)\\nPorter Carboprost 0.25 mg IM (dose 8)\\nCell saver technician Misoprostol 800 micrograms SL or 1000 micrograms PR\\nTranexamic acid 1 g IV\\nBlood sent Time Observations Initial management Time\\nTime Pulse BP Oxygen given\\nFBC Bed head down\\nCross-match units IV cannula no. 1\\nCoagulation screen IV cannula no. 2\\nPlacenta delivered   Yes No \\nUrinary catheter with urometer Further interventions Time\\nFluids Transfer to theatre\\nType Volume Time Intrauterine balloon tamponade\\nBrace suture\\nInterventional radiology called\\nStepwise uterine devascularisation\\nBilateral internal artery ligation\\nHysterectomy\\nAbbreviations: BP blood pressure; FBC full blood count; FYFoundation Year doctor; GPVTS trainee in general practice; IMintramuscular; IVintravenous;\\nPRper rectum; SLsublingual; STspecialty trainee.\\nAdapted from the Chelsea and Westminster Hospital Haemorrhage pro forma.Appendix V: Example obstetric haemorrhage chart\\nRCOG Green-top Guideline No. 52 e148 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 42}), Document(page_content='This guideline was produced on behalf of the Royal College of Obstetricians and Gynaecologists by:\\nMs E Mavrides MRCOG, London; Dr S Allard, NHS Blood and Transplant and Barts Health NHS Trust,\\nLondon; Dr E Chandraharan FRCOG, London; Professor P Collins, Cardiff University; Dr L Green,Consultant Haematologist, NHS Blood and Transplant and Barts Health NHS Trust, London;\\nProfessor BJ Hunt, King’s College London; Mr S Riris MRCOG, London; and Dr AJ Thomson MRCOG,\\nPaisley, Scotland\\nand peer reviewed by:\\nAdvisory Committee on the Safety of Blood, Tissues and Organs, London; Dr J Ahonen, Helsinki University Hospital,Helsinki, Finland; Dr TSA Arab, Jeddah University, Jeddah, Kingdom of Saudi Arabia; Sir S Arulkumaran FRCOG, London;\\nDr P Barclay, Liverpool Women’s Hospital; British Maternal and Fetal Medicine Society, London; Dr M Boucher, Centre\\nd’Obst /C19etrique-Gyn /C19ecologie, Montreal, Canada; Bradford Hospitals NHS Foundation Trust; Dr TV Chitra, PSG Institute of\\nMedical Sciences & Research, Coimbatore, India; Dr P Dixit FRCOG, Patna, India; Dr AHD Diyaf MRCOG, Barnstaple;Dr AS Ducloy-Bouthors, Pole d’Anesth /C19esie-R /C19eanimation, Lille, France; Mr DI Fraser FRCOG, Norwich; Dr S Gazzo,\\nUniversity of Padova, Padua, Italy; Mr M Grifﬁths FRCOG, Luton; Mr HKS Hinshaw FRCOG, Sunderland; Professor C Homer,\\nUniversity of Technology Sydney, Australia; Dr RG Hughes FRCOG, Edinburgh; Dr AJJ Kirkpatrick FRCOG, Frimley;Professor S Kozek-Langenecker, Evangelisches Krankenhaus Vienna, Austria; Dr EF Magann, University of Arkansas for the\\nMedical Sciences, Little Rock, Arkansas, USA; Dr S Makino, Juntendo University School of Medicine, Tokyo, Japan;\\nDr WL Martin FRCOG, Birmingham; Dr A Mulic-Lutvica, Uppsala University Hospital, Sweden; Dr OT Oladapo, OlabisiOnabanjo University, Sagamu, Nigeria; PSG Institute of Medical Sciences & Research, Coimbatore, India; Dr S Pavord,\\nLeicester Royal Inﬁrmary; Dr PV Rajan, Northwestern University, Chicago, Illinois, USA; Dr W Rath, University Hospital\\nRWTH Aachen, Germany; Dr K Razvi FRCOG, Westcliff-on-Sea; Miss J Rogers, Princess Anne Hospital, Southampton; RoyalCollege of Anaesthetists; Royal College of Midwives; Dr MN Schorn, Vanderbilt University, Nashville, Tennessee, USA;\\nMr DO Selo-Ojeme FRCOG, Enﬁeld; Ms H Shakur, London School of Hygiene and Tropical Medicine; Dr T Sibanda MRCOG,\\nWellington, New Zealand; Dr CG Sosa, University of Uruguay, Montevideo, Uruguay; Professor PJ Steer FRCOG, London;Dr L Teoﬁli, Universit /C18a Cattolica del Sacro Cuore, Rome, Italy; Dr M Tikkanen, University Central Hospital, Helsinki, Finland;\\nMr DJ Tuffnell FRCOG, Bradford; Dr A Wikkelsø, Herlev Hospital, Herlev Ringvej, Denmark; Dr SW Yi, University of Ulsan,\\nGangneung, South Korea.\\nThe committee lead reviewer was: Dr PS Arunakumari FRCOG, Basildon.\\nThe chairs of the Guidelines Committee were: Dr M Gupta\\n1MRCOG, London; Dr P Owen2FRCOG, Glasgow, Scotland;\\nand Dr AJ Thomson1MRCOG, Paisley, Scotland.\\n1co-chairs from June 20142until May 2014.\\nAll RCOG guidance developers are asked to declare any conﬂicts of interest. A statement summarising any conﬂicts\\nof interest for this guideline is available from: www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg52/ .\\nThe ﬁnal version is the responsibility of the Guidelines Committee of the RCOG.\\nThe review process will commence in 2019, unless otherwise indicated.\\nDISCLAIMER\\nThe Royal College of Obstetricians and Gynaecologists produces guidelines as an educational aid to good clinical practice.\\nThey present recognised methods and techniques of clinical practice, based on published evidence, for consideration byobstetricians and gynaecologists and other relevant health professionals. The ultimate judgement regarding a particular\\nclinical procedure or treatment plan must be made by the doctor or other attendant in the light of clinical data presented\\nby the patient and the diagnostic and treatment options available.\\nThis means that RCOG Guidelines are unlike protocols or guidelines issued by employers, as they are not intended to be\\nprescriptive directions deﬁning a single course of management. Departure from the local prescriptive protocols orguidelines should be fully documented in the patient’s case notes at the time the relevant decision is taken.\\nRCOG Green-top Guideline No. 52 e149 of e149 ª2016 Royal College of Obstetricians and Gynaecologists\\n 14710528, 2017, 5, Downloaded from https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14178 by Cochrane Colombia, Wiley Online Library on [19/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prevention and Management of Postpartum Haemorrhage.pdf', 'page': 43}), Document(page_content='International  Journal  of \\nEnvironmental Research\\nand Public Health\\nSystematic Review\\nProphylactic Dose of Oxytocin for Uterine Atony during\\nCaesarean Delivery: A Systematic Review\\nVilda Baliuliene1,*, Migle Vitartaite2and Kestutis Rimaitis1\\n/gid00030/gid00035/gid00032/gid00030/gid00038/gid00001/gid00033/gid00042/gid00045 /gid00001\\n/gid00048/gid00043/gid00031/gid00028/gid00047/gid00032/gid00046\\nCitation: Baliuliene, V .; Vitartaite, M.;\\nRimaitis, K. Prophylactic Dose of\\nOxytocin for Uterine Atony during\\nCaesarean Delivery: A Systematic\\nReview. Int. J. Environ. Res. Public\\nHealth 2021 ,18, 5029. https://\\ndoi.org/10.3390/ijerph18095029\\nAcademic Editor: Andrea Tinelli\\nReceived: 8 April 2021\\nAccepted: 6 May 2021\\nPublished: 10 May 2021\\nPublisher’s Note: MDPI stays neutral\\nwith regard to jurisdictional claims in\\npublished maps and institutional afﬁl-\\niations.\\nCopyright: © 2021 by the authors.\\nLicensee MDPI, Basel, Switzerland.\\nThis article is an open access article\\ndistributed under the terms and\\nconditions of the Creative Commons\\nAttribution (CC BY) license (https://\\ncreativecommons.org/licenses/by/\\n4.0/).1Department of Anaesthesiology, Lithuanian University of Health Sciences, Eiveniu str. 2,\\nLT-50009 Kaunas, Lithuania; kestutis.rimaitis@lsmuni.lt\\n2Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, A. Mickeviciaus str. 9,\\nLT-44307 Kaunas, Lithuania; migle.vitartaite@stud.lsmu.lt\\n*Correspondence: vilda.baliuliene@lsmuni.lt; Tel.: +370-67-267569\\nAbstract: Objective—to overview, compare and generalize results of randomized clinical trials an-\\nalyzing different oxytocin doses to prevent postpartum hemorrhage, initiate and maintain uterine\\ncontraction after Caesarean delivery. Methods—‘PubMed’, ‘EMBASE’, ‘CENTRAL’, and ‘CINAHL’\\nelectronic databases were searched for clinical trials analyzing the effectiveness of different dose\\nof oxytocin given intravenously during surgery for uterine contraction and to reduce postpartum\\nhemorrhage. A systematic review of relevant literature sources was performed. Results—our\\nsearch revealed 813 literature sources. A total of 15 randomized clinical trials, comparing different\\ndoses of oxytocin bolus and infusion used after caesarean delivery have met the selection criteria.\\nConclusion—oxytocin bolus 0.5–3 UI is considered an effective prophylactic dose. Recommended\\neffective prophylactic oxytocin infusion dose is 7.72 IU/h, but it is unanswered whether we really\\nneed a prophylactic infusion of oxytocin if we choose effective bolus dose size and rate. Adverse\\nhemodynamic effects were observed when a 5 UI oxytocin bolus was used. However, topics such\\nas bolus dose size, infusion dose size and requirement as well as bolus injection rate, still remain\\nunanswered. The doses that are recommended in the guidelines of peripartum hemorrhage prophy-\\nlaxis are not conﬁrmed by randomized controlled double-blind trials and more research should cover\\nthis topic.\\nKeywords: oxytocin; uterine contraction; caesarean delivery; hemorrhage\\n1. Introduction\\nEarly postpartum hemorrhage can occur if oxytocin is not used or if the dose of its\\nbolus or infusion is too small. The American College of Obstetricians and Gynecologist\\ndeﬁnes early (primary) postpartum hemorrhage as at 1000 mL or more of total blood\\nloss or loss of blood accompanied by signs and symptoms of hypovolemia within 24 h\\nfollowing the delivery, including intrapartum loss [ 1]. The Royal College of Obstetricians\\nand Gynecologists divides it into minor (500–1000 mL) and major (1000 mL and more)\\ncategories. They also deﬁne late (secondary) postpartum hemorrhage as abnormal or\\nexcessive bleeding later than 24 h post-birth but no later than 12 weeks [ 2]. Parturient\\nhemorrhage has been the main cause of maternal morbidity and mortality for many years\\nall over the world. Postpartum hemorrhage is one of the most common complications\\nafter caesarean delivery, which is an important surgical intervention performed in obstetric\\npractice. This has to be considered because caesarean delivery rates in the developing\\nworld countries keep getting higher [ 3,4]. Minimizing the amount of blood lost during\\ncaesarean delivery has a great beneﬁt to decrease postoperative morbidity and to decrease\\nthe risks associated with blood transfusions. The routine use of oxytocin correlates with a\\nsigniﬁcant reduction in the occurrence of postpartum hemorrhage (PPH) [5–7].\\nFinding an optimal dose of oxytocin in patients undergoing caesarean delivery is a\\nproblem of great importance because it is mandatory to achieve an adequate balance be-\\nInt. J. Environ. Res. Public Health 2021 ,18, 5029. https://doi.org/10.3390/ijerph18095029 https://www.mdpi.com/journal/ijerph', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 0}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 2 of 14\\ntween effective uterine contraction to limit postpartum hemorrhage and oxytocin-induced\\nadverse events.\\nThe aim of this review was to analyze the randomized controlled trials and to ﬁnd the\\nbest and lowest possible prophylactic dose of oxytocin during caesarean delivery (CD).\\n2. Methods\\nThe design of this systematic review of the literature is followed by the Preferred Re-\\nporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines.\\nData were identiﬁed from searches of MEDLINE (PubMed), Excerpta Medica Database\\n(EMBASE), Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index\\nto Nursing and Allied Health Literature (CINAHL) databases and conducted up to the\\n15 November 2020. The combination of keywords included terms ‘oxytocin’ and ‘caesarean’\\nand ‘dose’ or ‘hemorrhage’ in PubMed Advanced Search Builder in all ﬁelds accordance\\nwith the PICO criteria: ‘participants’ were limited to pregnant women, ‘interventions’ covered\\nwere randomized controlled clinical trials on caesarean delivery , ‘comparator’— comparing\\noxytocin with placebo or a different dose of oxytocin, ‘outcomes’ discovered after a thor-\\nough analysis of researches and classiﬁed into categories according to the trial type and\\nmost common ﬁndings. Records were screened by the title, abstract and full text by two\\nindependent investigators (V .B. and M.V .). Any disagreements were resolved through\\nevaluation and discussion or by consulting a third independent investigator who made\\nthe ﬁnal decision. Inclusion criteria were: (1) full text articles published in English; (2) not\\nolder than 2004; (3) single, double or triple-blinded randomized trials of different oxytocin\\nintravenous dosage and/or placebo; (4) caesarean delivery; (5) aged over 18. However,\\nwe review or meta-analyze systematic review articles, commentaries, abstract-only publi-\\ncations, guidelines, case reports, trials with oxytocin and carbetocin, other than oxytocin\\nuterotonic agent, but not randomized trials, and dose-ranging trials were excluded.\\nThe detailed search ﬂowchart is presented in Figure 1.\\nInt. J. Environ. Res. Public Health 2021 , 18, x 2 of 13 \\n \\n Finding an optimal dose of oxytocin in patients undergoing caesarean delivery is a \\nproblem of great importance because it is mandatory to achieve an adequate balance be-\\ntween effective uterine contraction to limit postpartum hemorrhage  and oxytocin -induced \\nadverse events.  \\nThe aim of this review was to analyze  the ra ndomized controlled trials and to find \\nthe best and lowest possible prophylactic dose of oxytocin during caesarean delivery \\n(CD).  \\n2. Methods  \\nThe design of this systematic review of the literature is followed by the Preferred \\nReporting Items for Systematic Reviews and Meta -Analyses (PRISMA) statement guide-\\nlines. Data were identified from searches of MEDLINE (PubMed),  Excerpta Medica Data-\\nbase (EMBASE), Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative \\nIndex to Nursing and Allied Health Lite rature (CINAHL) databases and conducted up to \\nthe 15  November 2020. The combination of keywords included terms ‘oxytocin’ and ‘cae-\\nsarean’ and ‘dose’ or ‘ hemorrhage ’ in PubMed Advanced Search Builder in all fields ac-\\ncordance with the PICO criteria: ‘partici pants’ were limited to pregnant women, ‘inter-\\nventions’ covered were randomized controlled clinical trials on caesarean delivery, ‘com-\\nparator’—comparing oxytocin with placebo or a different dose of oxytocin, ‘outcomes’ \\ndiscovered after a thorough analysis o f researches and classified into categories according \\nto the trial type and most common findings. Records were screened by the title, abstract \\nand full text by two independent investigators (V .B. and M .V.). Any disagreements were \\nresolved through evaluatio n and discussion or by consulting a third independent investi-\\ngator who made the final decision. Inclusion criteria were: (1) full text articles published \\nin English; (2) not older than 2004; (3) single, double or triple -blinded randomized trials \\nof differe nt oxytocin intravenous dosage and/or placebo; (4) caesarean delivery; (5) age d \\nover 18. However, we review or meta -analy ze systematic review articles, commentaries, \\nabstract -only publications, guidelines, case reports, trials with oxytocin and carbetocin , \\nother than oxytocin uterotonic agent, but not randomized trials, and dose -ranging trials \\nwere excluded.  \\nThe detailed search flowchart is presented in Figure  1. \\n \\nFigure 1 . Flow chart  \\nFigure 1. Flow chart', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 1}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 3 of 14\\n3. Results\\n3.1. Study Selection Process\\nThe research yielded 813 results, extracted from one database. All duplicates were\\nremoved, 526 articles were checked manually for relevance by screening their titles and\\nabstracts. A total 120 results met the inclusion criteria, but only 15 were included after a\\nfull-text review. Only full-text articles were selected because the information given in the\\nabstract was not sufﬁcient for the thorough analysis. The randomized trials, conducted\\nin 2008–2020, which compared different doses of oxytocin or oxytocin and placebo given\\nfor patients during CD, in order to investigate the effect of the drug on PPH and uterine\\ncontraction, were analyzed. A total of 105 publications were excluded for reasons explained\\nin Picture 1.\\n3.2. Characteristics of Included Studies\\nThose 15 selected trials could be divided into several groups: those that investigate\\ndifferent bolus dose (5 trials), those that investigate different infusion dose (9 trials), and\\nthose that investigate both (1 trial). A summary of the results of 15 analyzed studies is\\nprovided in Table 1.\\n3.3. Synthesis of Results\\nAll 15 trials (bolus/infusion/both) included in this systematic review were investi-\\ngated and compared in 4 categories: PPH and blood loss, uterine contraction, and hemody-\\nnamics. The summarized results can be seen in Table 2.\\nButwick and colleagues compared 75 women divided into 5 groups to receive 0, 0.5,\\n1, 3, or 5 IU oxytocin bolus intravenously, diluted with 5 mL of 0.9% normal saline and\\nadministered over the time period of 15 s. Adequate uterine tonus was measured at 2,\\n3, 6, and 9 min. There were no signiﬁcant differences of adequate uterine tonus at 2 min\\nbetween the groups. Sixty-six per cent of participants in the placebo group had adequate\\nuterine tonus at 3 min and 100% of the parturient receiving 3 IU of oxytocin ( p= 0.04). This\\nstudy results indicated that adequate uterine tonus for patients during caesarean delivery\\ncan be achieved using a small, 0.5–3 IU bolus of oxytocin plus continuous infusion of\\n250 mL normal saline with 10 IU of oxytocin [8].\\nSartain with co-authors studied data of 80 women, who were given 2 IU or 5 IU\\noxytocin bolus over 5–10 s and oxytocin infusion of at rate 10 IU/h for 4 h (40 IU totally)\\nafter delivery. No difference was found in blood loss, uterine tone, or need for additional\\nuterotonic drugs. Nonetheless, heart rate was found higher, mean arterial pressure was\\nfound smaller, and frequency of nausea and antiemetic drugs were bigger in the 5 IU\\noxytocin bolus group [9].\\nSomjit and co-authors compared 5 IU and 10 IU oxytocin bolus infused over 15 s and\\nfollowed by the infusion with 20 IU of oxytocin (2.5 IU/h) impact on uterine contraction.\\nFewer patients, who received 10 IU oxytocin bolus needed additional uterotonic agents.\\nBlood loss and the uterine tone did not differ signiﬁcantly. They concluded that 5 IU was\\nnon-inferior to 10 IU oxytocin [10].\\nKing with co-authors investigated the impact of 5 IU oxytocin bolus injected over\\n30 s on women who have at least one risk factor for uterine atony. One hundred and\\nforty-three participants were divided into 2 groups: one group received 5 IU oxytocin bolus\\nfollowed by 40 IU in 500 mL and 20 IU in 1 L saline oxytocin infusions and the second were\\ngiven placebo bolus. The number of women requiring an additional dose of uterotonic\\nagents was similar in both groups. They found a signiﬁcant difference in uterine tone\\nafter delivery, which was bigger in the group who received 5 IU oxytocin bolus ( p< 0.001).\\nHowever, this result was transient and disappeared after 5 min. Therefore, this study\\nrevealed that there is no difference in PPH between women who receive oxytocin bolus\\nand those who do not [11].', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 2}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 4 of 14\\nTable 1. Descriptive characteristics of the different trials which researched oxytocin’s bolus, infusion or both.\\nPrimary AuthorCountry, Year\\nof PublishingTrial Type No. of Patients Type of Anaesthesia Inclusion Criteria Exclusion Criteria Elective CD\\nButwick [8] USA, 2010 Double-blind, randomized 75 Spinal anesthesiaASA I or II, age between 18 and 40 yr,\\nsingleton pregnancies, and elective CD\\nwith a pfannensteil incision,\\nspinal anesthesiaActive labor, ruptured membranes, known drug\\nallergy to oxytocin, multiple gestation, signiﬁcant\\nobstetric disease, known risk factors for postpartum\\nhemorrhage, inherited or acquired coagulation\\ndisorder and thrombocytopeniaYes\\nSartain [9] Australia, 2008 Double-blind, randomized 80 CSEElective caesarean section under\\nregional anesthesiaPatients at increased risk of uterine\\natony or excessive\\nbleeding (more than two previous Caesarean\\nsections, a history of previous post-partum\\nhemorrhage, known placenta praevia or accreta,\\ntwin pregnancy, and polyhydramnios) or\\ncardiovascular instability (pre-eclampsia\\nor essential hypertension)Yes\\nSomjit [10] Thailand, 2020 Double-blind, randomized 155 Spinal anesthesiaSingleton pregnancy, age 18–40 years,\\n37–41 completed weeks of gestational\\nage, ASA class II and scheduled\\ncaesarean delivery under spinal\\nanesthesiaSpinal anesthesia had failed or was inadequate,\\nprevious uterine surgery other than caesarean\\nsection, high risk of uterine atony (macrosomia,\\nchorioamnionitis, polyhydramnion„ uterine mass) or\\npostpartum hemorrhage (placenta praevia or other\\nplacenta disorders, history of postpartum\\nhemorrhage, coagulopathy, thrombocytopenia, or\\npre-eclampsia), or known allergies to oxytocinYes\\nKing [11] Canada, 2010 Double-blind, randomized 143Epidural/spinal/CSE/\\nGA/neuraxial + GAPatients scheduled for elective and or\\nemergency caesarean delivery at a\\ntime when an investigator was\\navailable were approachedCardiac disease, hemodynamic instability before\\ncommencement of surgery, bleeding disorders, or\\nyounger than 19 years, or could not understand or\\nread EnglishYes/No\\nJonsson [12] Sweden, 2009 Double-blind, randomized 103 Spinal anesthesiaElective caesarean section under spinal\\nanesthesia, ≥18 years oldMultiple pregnancy, obesity (body mass index > 35),\\ncomplications to the pregnancy or nonproﬁciency in\\nthe Swedish languageYes\\nKovacheva [13] USA, 2015 Double-blind, randomized 60 Spinal anesthesiaASA I or II, between 18 and 40 yrs of\\nage, with singleton pregnancies, and\\nundergoing an elective caesarean\\ndelivery with a pfannenstiel incision\\nand a spinal anesthesia.Presence of labor, ruptured membranes, maternal or\\nfetal risk factors for uterine atony, previous uterine\\nsurgery (except for one previous caesarean delivery\\nwith a low-transverse uterine incision), maternal\\nrisks for hemorrhage, contraindications to spinal\\nanesthesia or any of the uterotonic agents, and\\nmaternal or obstetrician refusal.Yes\\nCecilia [14] India, 2018 Double-blind, randomized 271 Not knownAll the women who underwent\\nelective and emergency CD during the\\nstudy period were included in the\\nstudy if they gave informed consent.Anaemia, placenta previa, abruptio placentae,\\nhaemolysis, elevated liver enzymes, and low platelet\\nsyndrome, presence of bleeding disorders,\\nintraoperative atony of uterus requiring additional\\nuterotonics or severe intraoperative blood loss\\nrequiring blood transfusion, severe fetal distress,\\nprevious PPHYes', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 3}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 5 of 14\\nTable 1. Cont.\\nPrimary AuthorCountry, Year\\nof PublishingTrial Type No. of Patients Type of Anaesthesia Inclusion Criteria Exclusion Criteria Elective CD\\nGhulmiyyah [15] Lebanon, 2016 Double-blind, randomized 189 Not knownSingleton gestation, elective CD at\\nterm with no obstetric or\\nmedical complicationMultifetal gestation, hypertensive disorders,\\nchorioamnionitis, suspected macrosomia,\\npolyhydramnios, history of PPH, clotting disorders,\\nantecedent intake of magnesium sulphate, history of\\nuterine ﬁbroids, placenta previa/abruption/accrete\\nor those who were in laborYes\\nDufﬁeld [16] USA, 2017 Double-blind, randomized 51Intrathecal anesthesia\\nusing a spinal or combined\\nspinal-epidural techniqueASA physical class 2, singleton\\npregnancies, ≥37 weeks’ gestational\\nage, elective CD with a pfannansteil\\nincision, and aged between\\n18 and 40 yrs.Patients with signiﬁcant medical or obstetric disease,\\nactive labor or ruptured membranes, placenta previa\\nor other placental disorders, multiple gestation,\\nknown uterine abnormalities, and\\nallergies to oxytocin.Yes\\nGungorduk [17] Turkey, 2010 Double-blind, randomized 720 General anesthesiaEstimated gestational age over\\n38 weeks and required elective\\ncaesarean sectionAny risk factor for postpartum hemorrhage, anemia,\\nmultiple gestation, antepartum hemorrhage, uterine\\nﬁbroids, polyhydramnion, emergency CD, a history\\nof uterine atony and postpartum bleeding, current or\\nprevious history of signiﬁcant disease including\\nheart disease, liver, renal disorders or\\nknown coagulopathyYes\\nKajendran [18] Sri Lanka, 2017 Double-blind, randomized 92 Spinal anesthesiaPregnant women, who were at term,\\nwith singleton pregnancies and had a\\nplanned elective caesarean sectionWomen who were in established labor, had multiple\\npregnancies, established or suspected cases of\\nchorioamnionitis, both minor and major degree\\nplacenta praevia and established or suspected cases\\nof placental abruption, previous history of\\npostpartum hemorrhage and coagulation disorders,\\nand women with a history of or had ultrasonically\\nproven ﬁbroids.Yes\\nMcLeods [19] UK, 2010 Double-blind, randomized 74 Spinal anesthesia Elective caesarean sectionPlacenta praevia, multiple pregnancy, known\\nbleeding disorder or use of anticoagulant therapy, a\\nhistory of major obstetric hemorrhage or if the\\nsurgeon felt that participation was not appropriate,\\ntechnical problems in the time leading up to\\nadministration of oxytocin.Yes\\nMurphy [20] UK, 2009 Double-blind, randomized 110 Regional anesthesiaElective lower segment\\ncaesarean sectionPlacenta praevia, multiple pregnancy, known\\nbleeding disorder or use of anti-coagulant therapy, a\\npast history of a major obstetric hemorrhage or if the\\nsurgeon felt that participation was not appropriate\\nfor any reason.Yes', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 4}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 6 of 14\\nTable 1. Cont.\\nPrimary AuthorCountry, Year\\nof PublishingTrial Type No. of Patients Type of Anaesthesia Inclusion Criteria Exclusion Criteria Elective CD\\nSheehan [21] Ireland, 2011 Double-blind, randomized 2058 Spinal anesthesiaHealthy women at term (>36 weeks)\\nwith singleton pregnancy booked for\\nelective CDPlacenta praevia, thrombocytopenia, coagulopathies,\\nprevious major obstetric hemorrhage (>1000 mL),\\nknown ﬁbroids, or women who received\\nanticoagulant treatment, did not understand English,\\nyounger than 18 years.Yes\\nQian [22] China, 2020 Triple-blind, randomized 150 Epidural anesthesiaASA II, aged 18–40 years old, body\\nmass index < 40 kg/m2, singleton\\npregnancy, ≥37 weeks’ gestation age,\\nelective CDplanned with a pannenstiel\\nincision, and planning\\nepidural anesthesia.Maternal refusal, emergency CD, active labor,\\nruptured membranes, pregnancy-induced\\nhypertension, placental abnormalities, multiple\\ngestation, uterine ﬁbroids, history of prior\\nperipartum hemorrhage, coagulation disorders,\\noxytocin allergy, contraindication to epidural\\nanesthesia, and the need for\\npharmacological anxiolysisYes\\nUSA—United States of America, ASA—American Society of Anesthesiologists, CD—caesarean delivery, CSE—combined spinal-epidural, GA—general anesthesia, UK—United Kingdom.\\nTable 2. Results of studies included in systematic review.\\nInvestigation\\nObjectPrimary Author Placebo or Other Group Treatment Investigative Group TreatmentResults\\nUterine Tone Blood Loss PPH Incidence ECG And Hemodynamics\\nBolus dose Butwick [8]Normal saline bolus IV over 15 s\\nand 10 IU oxytocin in 250 mL 0.9%\\nnormal saline over 2 h0.5/1/3/5 IU IV oxytocin bolus over\\n15 s and 10 IU oxytocin in 250 mL\\n0.9% normal saline over 2 hNo difference observed\\nat 2 min between\\nall groups.No difference observed No dataHypotension occurred more often\\nin 5 IU group vs. 0 at 1 min.\\nBolus dose Somjit [10]5 IU IV oxytocin bolus over 15 s\\nfollowed by 20 IU oxytocin in 1 L of\\nRinger’s lactate at over 8 h10 IU IV oxytocin bolus over 15 s\\nfollowed by 20 IU oxytocin in 1 L of\\nRinger’s lactate at over 8 hNo difference observed No difference observed 0 No difference observed\\nBolus dose King [11]3 mL normal saline IV over 30 s\\nfollowed by 40 IU oxytocin in\\n500 mL of normal saline over 30 min\\nvia infusion pump, then a second\\ninfusion of 20 IU oxytocin in 1 L\\nnormal saline over 8 h5 IU IV oxytocin bolus over 30 s\\nfollowed by 40 IU oxytocin in\\n500 mL of normal saline over 30 min\\nvia infusion pump, then a second\\ninfusion of 20 IU oxytocin in 1 L\\nnormal saline over 8 hUterine tone score was\\nbigger in investigative\\ngroup, but disappeared\\nafter 5 minNo difference observed No data No difference observed\\nBolus dose Sartain [9]2 IU IV oxytocin bolus over 5–10 s\\nand 40 IU oxytocin in 1 L of\\nHartmann’s solution over 4 h5 IU IV oxytocin bolus over 5–10 s\\nand 40 IU oxytocin in 1 L of\\nHartmann’s solution over 4 hNo difference observed No difference observed No dataAfter oxytocin bolus increased HR\\nwas observed <1 min, at 1 min\\nMAP decreased and was greater\\nin the 5 IU, not 2 IU group.\\n57.5 per cent of 5 IU group HR\\nincrease over 30 beats/min 15 per\\ncent in the same group\\nexperienced MAP decrease more\\nthan 30 mm Hg', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 5}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 7 of 14\\nTable 2. Cont.\\nInvestigation\\nObjectPrimary Author Placebo or Other Group Treatment Investigative Group TreatmentResults\\nUterine Tone Blood Loss PPH Incidence ECG And Hemodynamics\\nBolus dose Jonsson [12]5 IU IV oxytocin bolus over 1 min\\nfollowed by 30 IU oxytocin in\\n500 mL 0.9% saline at a rate\\nsufﬁcient to control uterine atony10 IU IV oxytocin bolus over 1 min\\nfollowed by 30 IU oxytocin in\\n500 mL 0.9% saline at a rate\\nsufﬁcient to control uterine atony9 women in 5 IU group\\nneeded additional\\nuterotonic agentNo difference observed6 (4 in 5 IU and 2 in\\n10 IU groups)Less frequently ST depression and\\ndecrease in MAP at 2 min was\\nobserved in 5 IU oxytocin group\\nInfusion dose Cecilia [14]30 IU oxytocin IV in 1500 mL IV\\nﬂuids over 8–12 h10 IU oxytocin IV in 500 mL of IV\\nﬂuids over 2–4 hAtonic uterus in\\n7 women (2.5 per cent)\\nin 30 IU groupNo difference observed 2 (1 in each group) No difference observed\\nInfusion dose Ghulmiyyah [15]20/30/40 IU IV oxytocin in 500 mL of lactated Ringer solution over 30 min\\nfollowed by consecutively 30 IU then 20 IU then 10 IU of oxytocin in each\\n1000 mL of lactated Ringer solution (a total of 3 L) for 24 h postpartum.No difference observed No difference observed 0 No difference observed\\nInfusion dose Dufﬁeld [16]1 IU IV oxytocin bolus and 10 IU\\noxytocin in 1000 mL lactated\\nRinger’s solution for 4 h.1 IU IV oxytocin bolus and 60 IU\\noxytocin in 1000 mL lactated\\nRinger’s solution for 4 h.No difference observed No difference observed 8 (4 in each group) No difference observed\\nInfusion dose Gungorduk [17]5 IU IV oxytocin bolus over 5–10 s\\nand a 500 mL of lactated Ringer’s\\nsolution for 4 h.5 IU IV oxytocin bolus over 5–10 s\\nand a 30 IU oxytocin infusion in\\n500 mL of lactated Ringer’s solution\\nfor 4 hPlacebo group required\\nmore frequent additional\\nuterotonic agentThe amount of lost\\nblood smaller in the\\ninvestigative group.\\nPlacebo group required\\nmore frequent blood\\ntransfusion46 in placebo group and\\n18 in oxytocin group\\n(12.8 and 5 per cent\\nrespectively)No difference observed\\nInfusion dose Kajendran [18]5 IU IV oxytocin bolus over 5–10 s\\nand 500 mL of 0.9% normal saline\\nfor 4 h5 IU IV oxytocin bolus over 5–10 s\\nand 20 IU oxytocin in 500 mL 0.9%\\nnormal saline solution for 4 hNo need for additional\\nuterotonic agent in\\nboth groupsInvestigative group\\namount of blood loss\\nwas smallerNo data No data\\nInfusion dose Murphy [20]5 IU IV oxytocin bolus and 500 mL\\nof Hartmann’s solution for 4 h5 IU IV oxytocin bolus and 30 IU\\noxytocin in 500 mL of Hartmann’s\\nsolution for 4 hInvestigative\\ngroup—almost none\\nneeded additional\\nuterotonic agentInvestigative group\\namount of lost blood\\nwas lower3 (2 in placebo and 1 in\\noxytocin group)No data\\nInfusion dose McLeods [19]5 IU IV oxytocin bolus over 3 min\\nand a placebo infusion of\\nHartmann’s solution 500 mL\\nover 4 h.5 IU IV oxytocin bolus over 3 min\\nand a 30 IU oxytocin infusion\\nin 500 mLNo data No data No data No difference observed\\nInfusion dose Sheehan [21]5 IU oxytocin IV bolus over 1 min\\nand 500 mL of 0.9% saline IV over 4\\nh5 IU oxytocin IV bolus over 1 min\\nand 40 IU oxytocin in 500 mL 0.9%\\nsaline solution IV over 4 hPlacebo group—\\nmore frequently\\nneeded additional\\nuterotonic agentNo difference observed317 (159 in bolus group\\nand 158 in bolus and\\ninfusion group)No data\\nInfusion dose Qian [22]1 IU IV oxytocin bolus over 15 s and\\n50 mL normal saline over 1 h1 IU IV oxytocin bolus over 15 s and\\n1/2/3/5/8 IU oxytocin in 50 mL\\nnormal saline over 1 h3,5,8 IU oxytocin groups\\nrequired rescue oxytocin\\nbolus or uterotonic agentNo difference observed 0 No difference observed\\nBolus dose,\\ninfusion doseKovacheva [13]3 mL of 0.9% saline bolus over 15 s\\nand 30 IU oxytocin in 500 mL 0.9%\\nsaline, wide-open infusion ﬂow rate3 IU in 3 mL IV oxytocin bolus over\\n15 s and 500 mL 0.9% saline,\\nwide-open infusion ﬂow rateInvestigative group\\nrequired less additional\\noxytocinNo difference observed No data No difference observed\\nIU—international unit, IV—intravenous, HR—heart rate, MAP—mean arterial pressure.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 6}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 8 of 14\\nJonsson with colleagues investigated 5 and 10 IU of oxytocin IV bolus, injected over\\n1 min, impact on electrocardiography. Further doses of uterotonic drugs were available\\nupon request. They found a signiﬁcant difference in the occurrence of ST depressions\\nassociated with oxytocin administration. The conclusion was that 5 IU has less effect on\\nchanges in ECG [12].\\nKovacheva and colleagues from Boston conducted a study where one group of\\n30 women received 3 IU oxytocin bolus (over 15 s) and 500 mL saline infusion and the\\nother group of the same size were given placebo bolus and 30 IU oxytocin in 500 mL\\ninfusion. Both groups received additional oxytocin according to uterine tone, assessed\\nbetween 3 min and 12 min, if necessary. Women who received oxytocin bolus also received\\nless oxytocin overall to achieve adequate uterine tone. No differences in hemodynamic or\\nblood loss occurred [13].\\nCecilia and colleagues conducted a trial of 271 women randomized into 2 groups: the\\nﬁrst group received 10 IU of oxytocin in 500 mL of ﬂuids over 2–4 h, while the second\\ngroup was given 30 IU of oxytocin in 1500 mL of ﬂuids over 8–12 h. The atonic uterus\\nwas seen in 1 patient from the ﬁrst group and 7 women from the second group ( p= 0.03).\\nPostoperative fall in blood pressure, tachycardia, and amount of blood loss during the\\noperation and postoperative period and blood transfusions were similar between groups.\\nThe conclusion was that a low-dose oxytocin regimen is as effective as a high-dose oxytocin\\nregimen in the prevention of PPH in the postoperative period after caesarean delivery [ 14].\\nGhulmiyyah and colleagues randomly assigned 189 patients into 3 groups where\\nwomen received 20, 30, or 40 IU of oxytocin in 500 mL solution over 30 min. No signiﬁcant\\ndifference in the change of hemoglobin concentration was observed. This implies that 20 IU\\noxytocin diluted in 500 mL solution is an appropriate dose for the prevention of PPH [ 15].\\nDufﬁeld with colleagues included 51 women: 24 patients received 10 IU of oxytocin\\nin 1 L solution and 27 received 60 IU of oxytocin in 1 L solution. Additional bolus doses of\\n1 IU oxytocin were given after evaluating uterine contraction between 2 min and 20 min at\\n2 min intervals if requested. They did not observe any statistically signiﬁcant difference\\nin excessive blood loss between groups, concluding that both low and high infusion of\\noxytocin works in the same preventive regime [16].\\nGungorduk and co-authors investigated 360 women who were given 5 IU of oxytocin\\nbolus (over 5–10 s) and consecutive infusion with placebo and other 360 participants re-\\nceived 5 IU of oxytocin bolus and consecutive infusion of 30 IU of oxytocin. Mean estimated\\nblood loss ( p< 0.001) greater than 1000 mL were signiﬁcantly less in the group of patients\\nwho were given 30 IU oxytocin infusion. More women in the placebo group required an\\nadditional uterotonic agent ( p< 0.001) and blood transfusion ( p= 0.03). This study revealed\\nthat 30 IU oxytocin infusion given after bolus lowers the blood loss after CD [17].\\nKajendran with other researchers aimed to ﬁnd out the difference in blood loss between\\ntwo groups of patients, who were given 5 IU oxytocin bolus over 5–10 and 46 were given\\n20 IU oxytocin in 500 mL saline, and the other half were given just 500 mL saline later. The\\nblood loss in the group of 20 IU oxytocin infusion was signiﬁcantly less ( p= 0.046). Visual\\nestimation of blood loss made by the surgeon ( p= 0.01) and anesthetist ( p= 0.03) was also\\nsigniﬁcantly higher in the placebo group [18].\\nMcLeod studied hemodynamic differences between 2 groups of women: both groups\\nwere given 5 UI oxytocin bolus over 3 min and 39 patients received 30 UI oxytocin infusion\\nor 35 women were given placebo infusion. There were no signiﬁcant differences between\\ngroups during the 4-h study period. An additional oxytocin infusion after the bolus does\\nnot have a signiﬁcant impact on patient hemodynamic [19].\\nMurphy with other scientists compared the blood loss of 110 women divided in\\nthe same 2 groups as McLeod did. They favored the group with oxytocin infusion be-\\ncause the blood loss was lower, PPH occurred rarely and almost none needed additional\\nuterotonic agent [20].\\nSheehan with co-authors conducted a study of 2058 women, who received 5 IU\\nbolus over 1 min, but half of them were given 40 IU oxytocin infusion ant others were', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 7}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 9 of 14\\ngiven a placebo infusion. No difference was found in PPH between groups ( p= 0.86).\\nThere was a signiﬁcant difference in uterotonic agent need, it was higher in the placebo\\ngroup ( p< 0.001) [21].\\nQian and others conducted a trial in 2018 to ﬁnd out the rate of oxytocin infusion.\\nAll 150 women received 1 IU bolus of oxytocin followed by an oxytocin infusion at\\n0, 1, 3, 5, 8 IU/h. They found a 95% effective dose to be 7.72 IU/h and that the total\\noxytocin dose administered after delivery could be decreased if an infusion of oxytocin\\nis given [22].\\n4. Discussion\\nProphylactic uterotonic agents can prevent PPH and are routinely recommended.\\nA systematic Cochrane review on uterotonic agents, which included 196 clinical trials\\n(135,559 women), and was published in 2018, concluded that oxytocin is effective for\\npreventing peripartum hemorrhage when compared with placebo or no treatment. Er-\\ngometrine plus oxytocin combination, misoprostol plus oxytocin combination and car-\\nbetocin may have some additional desirable effects compared with oxytocin, but the\\ncombination of two drugs is associated with more frequent side effects [23].\\nThe main concern related to this topic is that there is not one opinion on what dosage of\\nthe uterotonic drug should be administered to prevent uterine atony and PPH. Despite the\\nfact that oxytocin is used in everyday obstetric practice, it seems that it is used empirically.\\nThe guidelines present a wide variety of oxytocin bolus doses and different infusion dose\\nand rate and are based on expert opinion mostly, that means that recommendations are\\nnot strong.\\nThe current WHO recommendation, published in 2018, for preventing PPH is 10 IU of\\nintramuscular or intravenous oxytocin for the prevention of PPH for all births. That dose is\\nnot related to a high rate of side effects and it also can be divided into a smaller intravenous\\nbolus and an infusion. A rapid intravenous bolus injection must be avoided. One of the\\nimportant research priorities indicated by WHO is the identiﬁcation of the optimal regimen\\nof intravenous oxytocin at caesarean section [24].\\nA study conducted in Canada in 2016–2017 showed that for both high- and low-\\nrisk CD participants doctors use 5 IU IV oxytocin bolus, although the range differs from\\n3 to 10 IU. In addition to bolus, they also use an infusion: 20 IU (range 20–40)/L for low-risk\\nCD and 40 IU (range 20–60)/L for high-risk CD [ 25]. This study inspired the release of a\\nnewly updated guideline in Canada. However, the same recommendation concerning CD\\nremained as in the 2009 version, stating that 100 µg of carbetocin should be given as an IV\\nbolus over 1 min instead of continuous oxytocin infusion [ 26] The. American College of\\nObstetricians and Gynecologists also released updated recommendations for postpartum\\nhemorrhage in 2017. But prevention of uterine atony was not discussed separately; the\\nclosest recommendation was 10 IU of oxytocin bolus IV [ 27]. NATA consensus statements\\non prevention and treatment of postpartum hemorrhage were issued in 2019. They rec-\\nommended administering an adjusted 5–10 IU intravenous oxytocin dose as the preferred\\npreventive treatment [ 28]. The Royal College of Obstetricians and Gynecologists in the\\nUnited Kingdom released updated recommendations for the prevention and management\\nof postpartum hemorrhage in 2016. They recommend the same 5 IU oxytocin dose by\\nslow IV injection [ 5]. Guidelines released in France in 2015 stated that for prevention of\\npostpartum hemorrhage after CD should be used 5–10 IU of oxytocin dose, injected slowly\\n(at least one-minute) IV [29].\\nIt is very important to remember the fact that oxytocin is used for uterine atony\\nprophylactics for most obstetric patients as supplementation of endogenous oxytocin.\\nCarvalho dose-ﬁnding study results revealed that bolus should be only 0.35 IU, but it\\nshould be followed by oxytocin infusion [30].\\nBalki and co-authors compared 30 women who were given 0.5 IU/mL IV oxytocin\\nafter the delivery. If the patient did not respond adequately to the initial bolus of oxytocin,\\nthe initial dose for the next patient was increased by 0.5 IU. All patients received 20 IU', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 8}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 10 of 14\\noxytocin in 1 L saline. All patients who received 3.5 IU initial oxytocin dose showed\\nadequate uterine response within 1–2 min. An important fact is that all parturients were\\ngiven oxytocin before CD for a minimum of 2 h, so the sensitivity of oxytocin receptors\\ncould be reduced. This study indicated that women undergoing CD for labor arrest require\\napproximately 3 IU of oxytocin as a bolus to achieve adequate uterine contraction and\\ncontinuous oxytocin infusion of 20 IU in 1 L saline after that [31].\\nThese two studies revealed that an adequate dosage of oxytocin bolus can be as small\\nas 3 IU or even less and an additional continuous infusion of oxytocin is needed. The\\nprevious oxytocin administration has no inﬂuence on the dose.\\nA cross-sectional study carried out by Beiranvand et al. concluded that the minimum\\neffective dose is 1 IU, and in those in labor progress 1–1.5 IU, both followed by 20 IU\\noxytocin in 1000 mL infusion [ 32]. The previously mentioned up-down sequential method\\nstudy of Carvalho also resulted in a small minimum effective dose.\\nWe analyzed 5 studies investigating superior bolus dose. The four trials comparing\\nconstant continuous infusion of oxytocin and different bolus doses [ 10–13], two of them\\nhad the placebo group [ 10,13] found that smaller bolus dose or even no bolus dose has\\nthe same effect as the bigger one. Sartain concluded that 2 IU is superior to 5 IU espe-\\ncially if hemodynamics was analyzed [ 11]. In the study of Butwick, more than a half of\\npatients in the placebo group didn’t require a bolus dose [ 10], which is also conﬁrmed by\\nKing, his study revealed that there is no difference in PPH between women who receive\\noxytocin bolus and those who do not [ 13]. Jonsson conducted a trial without continuous\\ninfusion and also concluded that a smaller dose has lower incidence of cardiovascular side\\neffects [ 14]. The cardiovascular effect of oxytocin is very important. It is detected that 10 IU\\noxytocin bolus may cause temporary hypotension and tachycardia as well as myocardial\\nischemia [ 33]. Therefore, when comparing the cardiovascular system response to oxytocin\\ndosage, a lower strategic tactic should be approached.\\nBoth Cecilia, Ghulmiyyah, and partly King, investigated the effect of oxytocin infusion\\nwithout bolus dose. All of them found that the bolus of oxytocin is not necessary to achieve\\nadequate and wanted uterine contraction and prevent PPH and the smaller dose of oxytocin\\n(10–20) given as continuous infusion has the same effect as the bigger one [ 13,16,17].\\nThis should also be taken into the consideration, as previously discussed, cardiovascular\\nchanges are observed almost in every patient given at least 5 IU bolus of oxytocin, so the\\nstrategy of using only the infusion of oxytocin could be further researched or bolus dose\\nshould be as small as possible.\\nThe inclusion criteria met only one study investigating different bolus doses and\\ncontinuous infusion of oxytocin. Kovacheva found out that the clinical effect is similar,\\nbut additional doses of oxytocin and side effects are lower in the bolus group. The results\\nsuggest that prophylactic bolus dose is sufﬁcient [ 15]. The possibility to avoid the infusion\\ndose helps to reduce the total dose of oxytocin.\\nDufﬁeld compared low and high doses of oxytocin given as a continuous infusion.\\nThat study conﬁrmed the previously mentioned result that both low (10 IU) and high\\n(60 IU) infusion of oxytocin works in the same preventive regime [18].\\nAlthough Dufﬁeld says that both high and low-dose infusions work in the same\\nway, receptor overstimulation should be taken into the consideration. It is known that\\nclinical use of high-dose of oxytocin infusion longer than 3 to 4 h may diminish the\\nresponse of uterus tonus to oxytocin [ 34]. Robinson and colleagues in their study about\\noxytocin-induced desensitization of the oxytocin receptor concluded that oxytocin-induced\\ndesensitization of myocytes to oxytocin stimulation occurred over a clinically relevant\\ntime frame (4.2 h). Continued responsiveness of the cells to prostaglandin stimulation\\nafter 6 h of oxytocin pre-treatment indicated that post-receptor signaling pathways were\\nmaintained, which indicates that the oxytocin receptor is likely involved in the mechanism\\nof myocyte desensitization to oxytocin stimulation [ 34]. Especially if as high as 60 IU doses\\nof oxytocin were used to prevent PPH. High doses work in the same way as low ones do', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 9}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 11 of 14\\nbecause receptors cannot bind more hormone molecules to themselves, meaning that there\\nis no actual effect on uterine contraction after infusing oxytocin for too long and too much.\\nWe included ﬁve studies that had a very similar design. The bolus dose of oxytocin\\n5 IU was given and it was followed by infusion with placebo or oxytocin. Oxytocin dose\\nranged between studies from 20 to 40 IU. The conclusion is that additional oxytocin infusion\\nlowers the risk of PPH, reduces the need for additional uterotonic agents, and does not\\nhave a signiﬁcant impact on patients’ hemodynamic [ 19–23]. The discussion remains if and\\nwhen the oxytocin, given as an infusion, is for prophylactic or for treatment of uterine atony\\nbecause the infused oxytocin dose in mentioned studies is more appropriate for uterine\\natony treatment. The trials investigating the oxytocin effect on uterine tonus during CD,\\nhave superiority over studies conducted in natural delivery because there is a possibility to\\nevaluate real uterine tonus visually and by palpation and to ﬁnd out the smallest effective\\ndose of the hormone.\\nOne more point for discussion is the duration of oxytocin infusion. It is different\\nand ranges from one hour till 24 h between studies. We should take into account that\\na long-lasting infusion could reduce the sensitivity of oxytocin receptors as mentioned\\nbefore and oxytocin could lose its power in the case of real uterine atony. Further, one more\\nunanswered question is what duration of continuous infusion should be considered as\\nprophylactic. It is known that clinical use of high-dose of oxytocin infusion longer than\\n3 to 4 h may diminish the response of uterus tonus to oxytocin [34].\\nThe only study of Qian discusses prophylactic oxytocin infusion dose. They found\\na 95% effective dose to be 7.72 IU/h and that the total oxytocin dose administered after\\ndelivery can be decreased if the infusion of oxytocin is given [24].\\nThe international consensus statement on the use of uterotonic agents during caesarean\\nsection was published in 2019. Researchers from 8 different countries reached an agreement\\nthat oxytocin is the ﬁrst-line drug in both elective and intrapartum CD. For the ﬁrst one\\nbolus of 1 IU oxytocin and infusion starting at 2.5–7.5 IU/h is recommended. For the latter,\\n3 IU oxytocin bolus over ≥30 s and infusion starting at 7.5–15 IU/h was decided [35].\\nOxytocin given in very high doses, change the mean level of arterial blood pressure\\nin an opposing manner, however, under basal physiological conditions, oxytocin does\\nnot contribute to blood pressure maintenance [ 36]. The hypotensive action of oxytocin,\\ndemonstrated in animal models, is believed to be mediated by the direct effect on oxytocin\\nreceptors in the heart and the indirect effect of the release of atrial natriuretic peptide, brain\\nnatriuretic peptide, and nitric oxide in the cardiovascular tissues [ 30]. This hormone has\\nwidely known cardiovascular side-effects, mostly in decreasing blood pressure by causing\\nperipheral vasodilation, increasing the HR, cases of myocardial ischemia, and arrhythmias.\\nThomas with his colleagues examined the effect of 5 IU bolus and 5 IU oxytocin infusion\\nover 5 min. Both heart rate and blood pressure were lower in the bolus group, meaning\\nthat bolus should be injected slower than it is widely used [37].\\nLangesaeter et al. with invasive monitoring (LiDCOPlus®monitor) in healthy preg-\\nnant women, observed an increase in cardiac index, decreased systemic vascular resistance,\\nand systolic blood pressure (range of 36–62 mmHg) 45 s after oxytocin injection [ 38].\\nThis same group of authors studied 18 patients with preeclampsia who underwent ce-\\nsarean section. With the same monitoring as the previous study (LiDCOPlus®) connected\\nto the radial artery of patients, the authors found an increased heart rate and decreased\\nsystemic vascular resistance and blood pressure in all patients receiving oxytocin (5 IU)\\nafter delivery [ 39]. The hemodynamic instability that can occur during postpartum hemor-\\nrhage may not be solely due to hypovolemia, but the association of both hypovolemia and\\nuse of oxytocin bolus [40].\\nThis review has several limitations. We could apply more strict inclusion criteria and\\ninclude only randomized double-blind placebo controlled trials. The meta-analysis would\\nprovide more reliable results and conclusions; it’s an option for future work.\\nMost studies mentioned the rate of bolus injection and it ranges from 5 s till 3 min [ 10–\\n15,19–21,23,24]. Further research investigating prophylactic bolus dose infusion rate is', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 10}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 12 of 14\\nnecessary. It is possible that the slower bolus infusion rate could reduce the frequency of\\nside effects, or the request of additional doses of uterotonic drugs, or even the necessity of\\noxytocin prophylactic infusion.\\n5. Conclusions\\nOxytocin is the routinely used and effective uterotonic drug, but the unanswered\\ntopic still remains the bolus dose size, infusion dose size and requirement and bolus\\ninjection rate. The doses that are recommended in the guidelines of peripartum hemorrhage\\nprophylaxis are not conﬁrmed by randomized controlled double-blind trials and are only\\nsupported by expert opinion and studies with low evidence rates. Oxytocin bolus 0.5–3 UI\\nis considered an effective prophylactic dose. The effective prophylactic oxytocin infusion\\ndose is 7.72 I U/h. However, it is unanswered whether this prophylactic infusion dose of\\noxytocin is required if an effective bolus dose, size and rate are chosen. In the cases we use\\nan oxytocin infusion we should separate if it is the prophylactic infusion or the treatment\\nof atony. Adverse hemodynamic effects were observed when a 5 UI oxytocin bolus was\\nused. This must be taken into consideration, especially among female patients with any\\npre-existing heart conditions. One of the important research priorities is the identiﬁcation\\nof the optimal regiment of intravenous oxytocin at caesarean section.\\nAuthor Contributions: Conceptualization, methodology, V .B. and K.R.; formal analysis, V .B., M.V .,\\nK.R.; investigation, V .B. and M.V .; data curation, V .B., M.V ., K.R.; writing—original draft preparation,\\nV .B., M.V ., K.R.; writing—review and editing, V .B., M.V ., K.R.; visualization, M.V .; supervision, K.R.\\nand V .B.; project administration, V .B. and M.V . All authors have read and agreed to the published\\nversion of the manuscript.\\nFunding: This research received no external funding.\\nInstitutional Review Board Statement: Not applicable.\\nInformed Consent Statement: Not applicable.\\nData Availability Statement: No additional data available.\\nConﬂicts of Interest: The authors declare no conﬂict of interest.\\nReferences\\n1. American College of Obstetricians and Gynecologists. Obstetric Data Deﬁnitions (Version 1.0). Revitalize 2014 . Available\\nonline: https://www.acog.org/-/media/project/acog/acogorg/ﬁles/pdfs/publications/revitalize-ob.pdf?la=en&hash=D9\\nECE1577C2A0B535F42C1B8DC492070 (accessed on 30 March 2021).\\n2. Prevention and Management of Postpartum Haemorrhage: Green-Top Guideline No. 52. Bjog Int. J. Obstet. Gynaecol. 2017 ,\\n124, e106–e149. [CrossRef]\\n3. Niino, Y. The Increasing Cesarean Rate Globally and What We Can Do about It. Biosci. Trends 2011 ,5, 139–150. [CrossRef]\\n4. Kambo, I.; Bedi, N.; Dhillon, B.S.; Saxena, N.C. A Critical Appraisal of Cesarean Section Rates at Teaching Hospitals in India.\\nInt. J. Gynecol. Obstet. 2002 ,79, 151–158. [CrossRef]\\n5. Othman, E.R.; Fayez, M.F.; el Aal, D.E.M.A.; El-Dine Mohamed, H.S.; Abbas, A.M.; Ali, M.K. Sublingual Misoprostol versus\\nIntravenous Oxytocin in Reducing Bleeding during and after Cesarean Delivery: A Randomized Clinical Trial. Taiwan J.\\nObstet. Gynecol. 2016 ,55, 791–795. [CrossRef]\\n6. Evensen, A.; Anderson, J.M. Postpartum Hemorrhage: Prevention and Treatment. Am. Fam. Physician 2017 ,95, 442–449.\\n7. Feduniw, S.; Warzecha, D.; Szymusik, I.; Wielgos, M. Epidemiology, Prevention and Management of Early Postpartum\\nHemorrhage—A Systematic Review. Ginekol. Pol. 2020 ,91, 38–44. [CrossRef] [PubMed]\\n8. Butwick, A.J.; Coleman, L.; Cohen, S.E.; Riley, E.T.; Carvalho, B. Minimum Effective Bolus Dose of Oxytocin during Elective\\nCaesarean Delivery. Br. J. Anaesth. 2010 ,104, 338–343. [CrossRef]\\n9. Sartain, J.B.; Barry, J.J.; Howat, P .W.; McCormack, D.I.; Bryant, M. Intravenous Oxytocin Bolus of 2 Units Is Superior to 5 Units\\nduring Elective Caesarean Section. Br. J. Anaesth. 2008 ,101, 822–826. [CrossRef] [PubMed]\\n10. Somjit, M.; Surojananon, J.; Kongwattanakul, K.; Kasemsiri, C.; Sirisom, M.; Prawannoa, K.; Thepsuthammarat, K.; Komwilaisak,\\nR. Comparison of Low Dose versus High Dose of Oxytocin for Initiating Uterine Contraction during Cesarean Delivery:\\nA Randomized, Controlled, Non-Inferiority Trial. Int. J. Women’s Health 2020 ,12, 667–673. [CrossRef] [PubMed]\\n11. King, K.J.; Douglas, M.J.; Unger, W.; Wong, A.; King, R.A.R. Five Unit Bolus Oxytocin at Cesarean Delivery in Women at Risk of\\nAtony: A Randomized, Double-Blind, Controlled Trial. Anesth. Analg. 2010 ,111, 1460–1466. [CrossRef]', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 11}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 13 of 14\\n12. Jonsson, M.; Hanson, U.; Lidell, C.; Nord én-Lindeberg, S. ST Depression at Caesarean Section and the Relation to Oxytocin Dose.\\nA Randomised Controlled Trial. Bjog Int. J. Obstet. Gynaecol. 2010 ,117, 76–83. [CrossRef]\\n13. Kovacheva, V .P .; Soens, M.A.; Tsen, L.C. A Randomized, Double-Blinded Trial of a “Rule of Threes” Algorithm versus Continuous\\nInfusion of Oxytocin during Elective Cesarean Delivery. Anesthesiology 2015 ,123, 92–100. [CrossRef]\\n14. Cecilia, M.; Vijayaselvi, R.; Bansal, R.; Lakshmi, L.; Jose, R. Ten Units Intravenous Oxytocin over 2–4 h Is as Effective as 30 Units\\nover 8–12 h in Preventing Postpartum Hemorrhage after Cesarean Section: A Randomized Controlled Trial. Indian J. Pharm. 2018 ,\\n50, 279–283.\\n15. Ghulmiyyah, L.M.; Usta, I.M.; Ghazeeri, G.; Taher, N.; Abu-Ghannam, G.; Tamim, H.; Nassar, A.H. Intravenous Oxytocin Use\\nto Decrease Blood Loss during Scheduled Cesarean Delivery: A Randomized Double-Blinded Controlled Trial (OXYTRIAL).\\nAm. J. Perinatol. 2017 ,34, 379–387. [CrossRef]\\n16. Dufﬁeld, A.; McKenzie, C.; Carvalho, B.; Ramachandran, B.; Yin, V .; El-Sayed, Y.Y.; Riley, E.T.; Butwick, A.J. Effect of a High-Rate\\nVersus a Low-Rate Oxytocin Infusion for Maintaining Uterine Contractility during Elective Cesarean Delivery: A Prospective\\nRandomized Clinical Trial. Anesth. Analg. 2017 ,124, 857–862. [CrossRef]\\n17. GÜngÖrdÜk, K.; Asicioglu, O.; Celikkol, O.; Olgac, Y.; Ark, C. Use of Additional Oxytocin to Reduce Blood Loss at Elective\\nCaesarean Section A Randomised Control Trial. Aust. N. Zealand J. Obstet. Gynaecol. 2010 ,50, 36–39. [CrossRef] [PubMed]\\n18. Kajendran, J.; Silva, G.R.C.; Ranaraja, S.K. Effects of 5 IU Oxytocin Bolus and 20 IU Oxytocin Infusion Compared to 5 IU Oxytocin\\nBolus and Normal Saline Infusion in the Control of Blood Loss during and after Ante-Partum Lower Segment Caesarean Section:\\nA Randomized Controlled Trial. Ceylon Med. J. 2017 ,62, 121. [CrossRef]\\n19. McLeod, G.; Munishankar, B.; MacGregor, H.; Murphy, D.J. Maternal Haemodynamics at Elective Caesarean Section: A Ran-\\ndomised Comparison of Oxytocin 5-Unit Bolus and Placebo Infusion with Oxytocin 5-Unit Bolus and 30-Unit Infusion. Int. J.\\nObstet. Anesth. 2010 ,19, 155–160. [CrossRef] [PubMed]\\n20. Murphy, D.J.; MacGregor, H.; Munishankar, B.; McLeod, G. A Randomised Controlled Trial of Oxytocin 5IU and Placebo Infusion\\nversus Oxytocin 5IU and 30IU Infusion for the Control of Blood Loss at Elective Caesarean Section-Pilot Study. ISRCTN 40302163.\\nEur. J. Obstet. Gynecol. Reprod. Biol. 2009 ,142, 30–33. [CrossRef]\\n21. Sheehan, S.R.; Montgomery, A.A.; Carey, M.; McAuliffe, F.M.; Gleeson, R.; Geary, M.; Murphy, D.J. Oxytocin Bolus versus Oxytocin\\nBolus and Infusion for Control of Blood Loss at Elective Caesarean Section: Double Blind, Placebo Controlled, Randomised Trial.\\nBMJ 2011 ,343, 46–61. [CrossRef] [PubMed]\\n22. Qian, X.W.; Drzymalski, D.M.; Lv, C.C.; Guo, F.H.; Wang, L.Y.; Chen, X.Z. The ED50 and ED95 of Oxytocin Infusion Rate for\\nMaintaining Uterine Tone during Elective Caesarean Delivery: A Dose-Finding Study. BMC Pregnancy Childbirth 2020 ,20, 6.\\n[CrossRef] [PubMed]\\n23. Gallos, I.D.; Williams, H.M.; Price, M.J.; Merriel, A.; Gee, H.; Lissauer, D.; Moorthy, V .; Tobias, A.; Deeks, J.J.; Widmer, M.; et al.\\nUterotonic agents for preventing postpartum haemorrhage: A network meta-analysis. Cochrane Database Syst. Rev. 2018 ,\\n12. [CrossRef]\\n24. World Health Organization. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. In WHO\\nRecommendations: Uterotonics for the Prevention of Postpartum Haemorrhage ; World Health Organization: Geneva, Switzerland,\\n2018; pp. 1–53.\\n25. Thorneloe, B.; Carvalho, J.C.A.; Downey, K.; Balki, M. Uterotonic Drug Usage in Canada: A Snapshot of the Practice in Obstetric\\nUnits of University-Afﬁliated Hospitals. Int. J. Obstet. Anesth. 2019 ,37, 45–51. [CrossRef]\\n26. Leduc, D.; Senikas, V .; Lalonde, A.B.; Ballerman, C.; Biringer, A.; Delaney, M.; Duperron, L.; Girard, I.; Jones, D.; Lee, L.S.Y.; et al.\\nActive Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage. J. Obstet. Gynaecol. Can.\\n2009 ,31, 980–993. [CrossRef]\\n27. American College of Obstetricians and Gynecologists. Postpartum Hemorrhage. Obs. Gynecol. 2017 ,130, e168–e186.\\n[CrossRef] [PubMed]\\n28. Muñoz, M.; Stensballe, J.; Ducloy-Bouthors, A.S.; Bonnet, M.P .; de Robertis, E.; Fornet, I.; Gofﬁnet, F.; Hofer, S.; Holzgreve, W.;\\nManrique, S.; et al. Patient Blood Management in Obstetrics: Prevention and Treatment of Postpartum Haemorrhage. A NATA\\nConsensus Statement: A Multidisciplinary Consensus Statement. Blood Transfus. 2019 ,17, 112–136. [CrossRef]\\n29. Sentilhes, L.; Vayssi ère, C.; Deneux-Tharaux, C.; Aya, A.G.; Bayoumeu, F.; Bonnet, M.P .; Djoudi, R.; Dolley, P .; Dreyfus, M.;\\nDucroux-Schouwey, C.; et al. Postpartum Hemorrhage: Guidelines for Clinical Practice from the French College of Gynaecologists\\nand Obstetricians (CNGOF): In Collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). Eur. J. Obstet.\\nGynecol. Reprod. Biol. 2016 ,198, 12–21. [CrossRef]\\n30. Carvalho, J.C.A.; Balki, M.; Kingdom, J.; Windrim, R. Oxytocin Requirements at Elective Cesarean Delivery: A Dose-Finding\\nStudy. Am. Coll. Obstet. Gynecol. 2004 ,104, 1005–1010. [CrossRef]\\n31. Balki, M.; Ronayne, M.; Davies, S.; Fallah, S.; Kingdom, J.; Windrim, R.; Carvalho, J. Minimum Oxytocin Dose Requirement after\\nCesarean Delivery for Labor Arrest. Obstet. Gynecol. 2006 ,107, 45–50. [CrossRef]\\n32. Beiranvand, S.; Karimi, A.; Vahabi, S.; Amin-Bidokhti, A. Comparison of the Mean Minimum Dose of Bolus Oxytocin for Proper\\nUterine Contraction during Cesarean Section. Curr. Clin. Pharmacol. 2019 ,14, 208–213. [CrossRef] [PubMed]\\n33. Svanström, M.C.; Biber, B.; Hanes, M.; Johansson, G.; Näslund, U.; Bålfors, E.M. Signs of Myocardial Ischaemia after Injection of\\nOxytocin: A Randomized Double-Blind Comparison of Oxytocin and Methylergometrine during Caesarean Section. Br. J. Anaesth.\\n2008 ,100, 683–689. [CrossRef]', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 12}), Document(page_content='Int. J. Environ. Res. Public Health 2021 ,18, 5029 14 of 14\\n34. Robinson, C.; Schumann, R.; Zhang, P .; Young, R.C. Oxytocin-Induced Desensitization of the Oxytocin Receptor. Am. J.\\nObstet. Gynecol. 2003 ,188, 497–502. [CrossRef] [PubMed]\\n35. Heesen, M.; Carvalho, B.; Carvalho, J.C.A.; Duvekot, J.J.; Dyer, R.A.; Lucas, D.N.; McDonnell, N.; Orbach-Zinger, S.; Kinsella, S.M.\\nInternational Consensus Statement on the Use of Uterotonic Agents during Caesarean Section. Anaesthesia 2019 ,74, 1305–1319.\\n[CrossRef] [PubMed]\\n36. Japundži´ c-Žigon, N.; Lozi´ c, M.; Šarenac, O.; Murphy, D. Vasopressin & Oxytocin in Control of the Cardiovascular System:\\nAn Updated Review. Curr. Neuropharmacol. 2019 ,18, 14–33. [CrossRef]\\n37. Thomas, J.S.; Koh, S.H.; Cooper, G.M. Haemodynamic Effects of Oxytocin given as i.v. Bolus or Infusion on Women Undergoing\\nCaesarean Section. Br. J. Anaesth. 2007 ,98, 116–119. [CrossRef]\\n38. Langesæter, E.; Rosseland, L.A.; Stubhaug, A. Hemodynamic Effects of Oxytocin during Cesarean Delivery. Int. J. Gynecol. Obstet.\\n2006 ,95, 46–47. [CrossRef]\\n39. Langesæter, E.; Rosseland, L.A.; Stubhaug, A. Haemodynamic Effects of Oxytocin in Women with Severe Preeclampsia. Int. J.\\nObstet. Anesth. 2011 ,20, 26–29. [CrossRef]\\n40. Archer, T.L.; Knape, K.; Liles, D.; Wheeler, A.S.; Carter, B. The Hemodynamics of Oxytocin and Other Vasoactive Agents during\\nNeuraxial Anesthesia for Cesarean Delivery: Findings in Six Cases. Int. J. Obstet. Anesth. 2008 ,17. [CrossRef]', metadata={'source': '..\\\\public\\\\rawDataset\\\\Prophylactic Dose of Oxytocin.pdf', 'page': 13}), Document(page_content='Risk Factors for Atonic Postpartum Hemorrhage:\\nA Systematic Review and Meta-analysis\\nHolly B. Ende, MD , M. James Lozada, DO , David H. Chestnut, MD , Sarah S. Osmundson, \\nMD, MS, Rachel L. Walden, MLIS , Matthew S. Shotwell, PhD , Jeanette R. Bauchat, MD, MS\\nDepartments of Anesthesiology, Obstetrics and Gynecology, and Biostatistics, Vanderbilt \\nUniversity Medical Center, and the Annette and Irwin Eskind Family Biomedical Library, Vanderbilt \\nUniversity, Nashville, Tennessee.\\nAbstract\\nOBJECTIVE: To identify and quantify risk factors for atonic postpartum hemorrhage.\\nDATA SOURCES: PubMed, CINAHL, EMBASE, Web of Science, and and ClinicalTrials.gov \\ndatabases were searched for English language studies with no restrictions on date or location. \\nStudies included randomized trials, prospective or retrospective cohort studies, and case–control \\nstudies of pregnant patients who developed atonic postpartum hemorrhage and reported at least \\none risk factor.\\nMETHODS OF STUDY SELECTION: Title, abstract, and full-text screening were performed \\nusing the Raayan web application. Of 1,239 records screened, 27 studies were included in this \\nreview. Adjusted or unadjusted odds ratios (ORs), relative risks, or rate ratios were recorded or \\ncalculated. For each risk factor, a qualitative synthesis of low and moderate risk of bias studies \\nclassifies the risk factor as definite, likely, unclear, or not a risk factor. For risk factors with \\nsufficiently homogeneous definitions and reference ranges, a quantitative meta-analysis of low and \\nmoderate risk of bias studies was implemented to estimate a combined OR.\\nTABULATION, INTEGRATION, AND RESULTS: Forty-seven potential risk factors for atonic \\npostpartum hemorrhage were identified in this review, of which 15 were judged definite or likely \\nrisk factors. The remaining 32 assessed risk factors showed no association with atonic postpartum \\nhemorrhage or had conflicting or unclear evidence.\\nCONCLUSION: A substantial proportion of postpartum hemorrhage occurs in the absence of \\nrecognized risk factors. Many risk factors for atonic hemorrhage included in current risk-\\nassessment tools were confirmed, with the greatest risk conferred by prior postpartum hemorrhage \\nof any etiology, placenta previa, placental abruption, uterine rupture, and multiple gestation. Novel \\nrisk factors not currently included in risk-assessment tools included hypertension, diabetes, and \\nethnicity. Obesity and magnesium were not associated with atonic postpartum hemorrhage in this \\nreview.\\nCorresponding author: Holly B. Ende, Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN; \\nholly.ende@vumc.org. \\nEach author has confirmed compliance with the journal’s requirements for authorship.\\nFinancial Disclosure\\nThe authors did not report any potential conflicts of interest.\\nHHS Public Access\\nAuthor manuscript\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nPublished in final edited form as:\\nObstet Gynecol . 2021 February 01; 137(2): 305–323. doi:10.1097/AOG.0000000000004228.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 0}), Document(page_content='SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42020157521.\\nPostpartum hemorrhage affects 3–10% of deliveries and accounts for nearly 20% of \\nmaternal deaths worldwide.1,2 Although there are many etiologies, uterine atony is the most \\ncommon and accounts for nearly 70% of cases.3 Patients who experience postpartum \\nhemorrhage can have increased morbidity and mortality, which can be attenuated by \\nidentifying patients at risk, early preparation, and increased vigilance.1,4 Risk stratification \\nfor postpartum hemorrhage is commonly performed using an assessment tool from one of \\nseveral organizations, such as the California Maternal Quality Care Collaborative, \\nAssociation of Women’s Health, Obstetric and Neonatal Nurses, or the American College of \\nObstetricians and Gynecologists.5–7 Although these risk-assessment tools have the support \\nof major medical societies, recent evidence suggests that the tools have only moderate \\npredictive value for severe hemorrhage in the highest risk groups and that a significant \\nportion of hemorrhages (up to 43%) occur in those deemed low risk.8,9 This limitation may \\nbe partly due to the tools’ development via expert consensus opinion and a lack of \\nsystematically reviewed evidence to support or refute the included risk factors. A recently \\npublished meta-analysis that evaluated the association between maternal demographics and \\ncomorbidities, and postpartum hemorrhage evaluated only four potential risk factors and \\nfound body mass index, nulliparity, and hypertensive disorders to confer risk of postpartum \\nhemorrhage.11 Additionally, existing tools assess the risk of all postpartum hemorrhage \\netiologies simultaneously, which may confound attempts at risk prediction because each \\netiology of postpartum hemorrhage is likely associated with different risk factors. \\nFurthermore, current tools fail to account for the relative contribution of each risk factor or \\nto provide mechanisms to quantify risk for a given patient when more than one risk factor is \\npresent. Because each etiology of postpartum hemorrhage likely has a unique set of risk \\nfactors, evaluating each etiology separately may improve the ability to delineate individual \\npatient risk. The systematic identification and quantification of risk factors for atonic \\npostpartum hemorrhage may allow the development of more reliable, weighted risk-\\nstratification tools. Thus, this systematic review aimed to identify risk factors that increase \\nthe odds of a patient developing postpartum hemorrhage due only to uterine atony after \\nvaginal or cesarean delivery.\\nSOURCES\\nThis review follows the PRISMA (Preferred Reporting Items for Systematic Reviews and \\nMeta-analyses) statement11 and was registered with the PROSPERO International \\nProspective Register for Systematic Reviews (registration number CRD42020157521).\\nThe PubMed (National Library of Medicine), CI-NAHL (EBSCO), EMBASE (Ovid), Web \\nof Science (Clarivate), and ClinicalTrials.gov  (National Institutes of Health) databases were \\nsearched in November 2018 for English language studies with no restrictions on date or \\ngeographic location. PubMed MeSH headings included, but were not limited to, postpartum \\nhemorrhage; uterine hemorrhage; uterine inertia; causality; epidemiology; incidence; \\nmethylergonovine; misoprostol; oxytocin; prevalence; probability; risk assessment; risk \\nfactors; and risk, in addition to corresponding keywords (full search strategies are shown in Ende et al. Page 2\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 1}), Document(page_content='Appendix 1, available online at http://links.lww.com/AOG/C163 ). The PubMed search was \\ntranslated for CINAHL, EMBASE, Web of Science, and clinicaltrials.gov .\\nSTUDY SELECTION\\nEligibility for inclusion was limited to randomized clinical trials, prospective or \\nretrospective cohort studies, and case–control studies written in the English language with \\npregnant patients who developed postpartum uterine atony or atonic postpartum hemorrhage. \\nDefinitions of atonic postpartum hemorrhage varied by study and included some \\ncombination of clinical diagnoses, second-line uterotonic administration, estimated blood \\nloss, need for transfusion, or International Classification of Diseases codes (Table 1). Studies \\nwere excluded if they reported postpartum hemorrhage data without specifying etiology or if \\nthey did not report the incidence of at least one risk factor for postpartum hemorrhage in a \\nuterine atony subgroup. Case reports, case series, and unpublished meeting abstracts were \\nexcluded. Two blinded authors screened abstracts, and a third blinded author resolved \\nconflicts. Full-text articles were obtained for all included abstracts. Full-text article review \\nwas conducted by the same two blinded authors, with conflicts resolved in the same manner. \\nTitle, abstract, and full-text screening were performed using the Raayan web application.12\\nThe risk of bias for each included study was assessed using the Risk of Bias Assessment \\nTool for Nonrandomized Studies.13 This tool was chosen because of the nonrandomized \\nnature of all included studies as well as its scope in assessing multiple sources of bias, \\nincluding those related to selection, performance, detection, attrition, and reporting. Six \\ndomains of risk of bias were assessed, including: 1) selection of participants, 2) confounding \\nvariables, 3) measurement of exposure, 4) blinding of outcome assessments, 5) incomplete \\noutcome data, and 6) selective outcome reporting. Bias scoring proceeded after training each \\nscorer on the assessment tool to ensure good inter-rater reliability correlation. Two authors \\n(D.H.C., H.B.E.) independently assessed the risk of bias for each study, with disagreements \\nresolved by a third blinded author (J.R.B.). Studies were found to have a low risk of bias if \\nthey attained a low-risk classification in all six evaluated domains. Studies were considered a \\nmoderate risk of bias if at least one domain was rated unclear risk (but no domains were \\nrated high risk). Finally, studies were found to have a high risk of bias if at least one domain \\nwas rated high risk.\\nAll data were collected independently by co-investigators into a study spreadsheet and \\nverified by a separate author. In addition to baseline study characteristics including country \\nof origin, study design, the number of patients, and inclusion and exclusion criteria, data \\nwere collected on all risk factors for atonic postpartum hemorrhage reported in the study. \\nFor each risk factor, adjusted or unadjusted odds ratios (aOR, uOR), relative risks (aRR, \\nuRR), or rate ratios (arr, urr) were recorded when available. If not explicitly reported, uOR \\nand 95% CI were calculated with a 2×2 table using the number of patients with and without \\na given risk factor who developed atonic postpartum hemorrhage.14 The primary outcome \\nassessed in all studies was the OR, RR, or rr of risk factors associated with atonic \\npostpartum hemorrhage. For each identified risk factor, low and moderate risk of bias studies \\nwere synthesized qualitatively to label each risk factor as definite, likely, unclear, or not a \\nrisk factor based on the number of total studies evaluating the factor and percentage of Ende et al. Page 3\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 2}), Document(page_content='studies showing a positive association (Box 1). For risk factors with sufficiently \\nhomogeneous definitions and reference ranges, a quantitative meta-analysis of low and \\nmoderate risk of bias studies was implemented to estimate a combined OR. The inverse \\nvariance random effects method was used for meta-analysis.15 This method requires only \\neffect estimates (ie, OR or risk ratios) and their SEs. The SEs were estimated by \\nbacktransforming the 95% confidence limits using the standard normal distribution. The \\nDerSimonian-Laird estimator was used to estimate the between-study variance in effects.16 \\nOwing to the rarity of uterine atony (and, thus, the near-equivalence of the OR and RR), \\nstudies that reported a risk ratio were included. Adjusted and unadjusted risk ratios and ORs \\nwere included. The I2 statistic and a P-value against the null hypothesis (ie, I250) are \\nreported for each subgroup. The I2 statistic represents the percentage of variability in the \\neffect estimates that is attributable to study heterogeneity (compared with sampling \\nheterogeneity). Meta-analysis was implemented in R 3.6.3 (https://www.r-pro ject.org) , using \\nthe “metafor” 2.4 add-on package.\\nRESULTS\\nThe database search revealed 1,977 total records, and 1,239 records were screened after \\nremoving duplicates. After excluding 871 records based on title and abstract review, 368 \\nfull-text articles were assessed for eligibility (Fig. 1). Twenty-seven studies reported data for \\nat least one risk factor for atonic postpartum hemorrhage and were included in the narrative \\nsummary. Of those, 19 studies contributed data to the qualitative synthesis and 13 to the \\nmeta-analysis. Table 1 summarizes the study design, patient population, study definitions of \\npostpartum hemorrhage and uterine atony, and the risk factors assessed in the included \\nstudies. The scoring for risk of bias for each study is reported in Figure 2.\\nA total of 47 unique risk factors were identified in the search: 15 relating to maternal history \\nor demographics, 11 to maternal comorbidities, six pregnancy-related factors, eight labor-\\nrelated factors, and seven delivery-related factors. For qualitative comparison, the authors \\ncharacterized each risk factor as definite, likely, unclear, or not a risk factor based on the \\nnumber of low and moderate risk of bias studies that showed statistically significant \\nevidence that the risk factor was associated with atony (Box 1).\\nSix variables were found to be definite risk factors for atonic postpartum hemorrhage, based \\non either all low and moderate risk of bias studies showing a positive association (if at least \\nthree studies) or the majority of low and moderate risk of bias studies showing a positive \\nassociation (if at least five studies). Definite risk factors included being of Asian race, a \\nhistory of prior postpartum hemorrhage of any etiology in a previous pregnancy, preexisting \\nor gestational diabetes mellitus, placental disorders (including retained placenta, placenta \\nprevia, vasa previa, and placental abruption, but excluding abnormal placentation), \\nprolonged labor (as defined in each study and presented in Appendix 2, available online at \\nhttp://links.lww.com/AOG/C163 ), and genital tract trauma sustained during delivery. An \\nadditional nine variables were deemed likely associated with atonic postpartum hemorrhage, \\nand these included being of Hispanic ethnicity, nulliparity, hypertensive diseases of \\npregnancy, multiple gestation, chorioamnionitis, uterine rupture, predelivery oxytocin \\nexposure, induction of labor, and instrumented vaginal delivery. Some variables that are Ende et al. Page 4\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 3}), Document(page_content='traditionally considered risk factors for postpartum hemorrhage were not found to be \\nassociated specifically with atonic postpartum hemorrhage in this review but may confer risk \\nfor hemorrhage due to other etiologies. These included maternal obesity, leiomyomas, \\npolyhydramnios, prolonged second stage of labor, magnesium exposure, and cesarean \\ndelivery. Meta-analysis was implemented for 24 risk factors with at least two low or \\nmoderate risk of bias studies demonstrating homogeneous risk factor definitions and \\nreference ranges (Figs. 3–7). Table 2 displays a summary of qualitative and quantitative \\n(where applicable) results for each risk factor. Appendix 2 (http://links.lww.com/AOG/\\nC163 ), includes a complete list of articles that report on each risk factor and the statistical \\nassociations reported, therein. A narrative summary of all risk factors, with the explanations \\nof qualitative and quantitative synthesis results for each factor can be found in Appendix 3, \\navailable online at http://links.lww.com/AOG/C163 . Further details on studies reporting on \\nrace or ethnicity as risk factors for atonic postpartum hemorrhage, including who classified \\neach patient’s race, classifications used, and data on missing data and “other” classifications, \\ncan be found in Appendix 4, available online at http://links.lww.com/AOG/C163 .\\nDISCUSSION\\nThis systematic review highlights several previously unrecognized risk factors for atonic \\npostpartum hemorrhage that are not included in current risk-assessment tools, and it \\nquestions whether other risk factors used in current tools are, in fact, supported by published \\nevidence. This review also provides further evidence supporting the validity of many risk \\nfactors already included in risk-stratification tools and provides quantitative estimates of \\ntheir contribution to atonic postpartum hemorrhage risk. Although some risk factors \\npresented may cause postpartum hemorrhage independently, for example genital tract \\ntrauma or abnormal placentation, these factors also appear to contribute to uterine atony, \\nand, thus, are captured in this review.\\nPerhaps most importantly, current risk-assessment tools fail to include some definite or \\nlikely risk factors that appear to be well-established in the literature. Hispanic ethnicity (OR \\n1.23, 95% CI 1.20–1.25) and Asian race (OR 1.39, 95% 1.33–1.46) were associated with \\natonic postpartum hemorrhage in this review and are missing from current risk-assessment \\ntools. The ORs for ethnicity and race are comparable with those for commonly cited risk \\nfactors, including induction of labor (OR 1.23, 95% 1.10–1.39) and macrosomia (OR 1.46, \\n95% 1.35–1.57). Given the mounting evidence of disparities in the care of minority women, \\nwe may be failing to anticipate the increased risk of postpartum hemorrhage in these \\npopulations.17 These associations do not imply causation, and it is unclear whether the \\nunderlying mechanism of these relationships are biological, social, or a byproduct of \\ndisparities or systematic racism.18 Specific attention must be paid when including race or \\nethnicity in risk-prediction systems, because recent evidence suggests that these algorithms \\nmay perpetuate health care disparities.19,20\\nHypertensive disease (OR 1.84, 95% 1.45–2.33) and diabetes mellitus (OR 1.22, 95% 1.08–\\n1.39), both of which are known to be associated with vascular and perfusion abnormalities, \\nalso emerged as previously underappreciated risk factors for atonic postpartum hemorrhage.\\n21–23 We hypothesize that the vascular pathophysiology of these diseases may contribute Ende et al. Page 5\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 4}), Document(page_content='directly to the development of atony and hemorrhage; however, genetic susceptibility to both \\natony and hypertension or diabetes in specific patient populations may also explain this \\nassociation and certainly warrants further investigation.24,25 Interestingly, high vaginal \\nlacerations and cervical trauma are not included in current risk-assessment tools. However, \\nhigh vaginal and cervical lacerations demonstrated higher OR than either instrumented \\ndelivery or perineal trauma, both of which are included in the Association of Women’s \\nHealth, Obstetric and Neonatal Nurses’ risk-stratification tool.6 Although nulliparity and \\nprolonged first stage of labor were found to be associated with atonic postpartum \\nhemorrhage and are not included in the current risk-assessment tools, they may be associated \\nwith other risk factors that are included, such as induction of labor, oxytocin use, and \\nchorioamnionitis. Of these factors, chorioamnionitis demonstrated the highest OR of 1.93 \\n(95% CI 1.56–2.39) and may contribute significantly to an increased risk associated with \\nnulliparity or prolonged first stage of labor. Finally, uterine rupture was found to be \\nassociated with atonic postpartum hemorrhage. Although not specifically described in the \\nstudies that reported this association, hemorrhage attributable to uterine atony presumably \\noccurred after repair of the uterine defect.\\nAdditionally, some risk factors currently included in risk-assessment tools are not supported \\nby this literature review of atonic postpartum hemorrhage, although an association with \\nother etiologies of postpartum hemorrhage would not be captured by this study. Prolonged \\nsecond stage of labor (which is included in nearly all risk-assessment tools) did not emerge \\nas a definite risk factor for atonic postpartum hemorrhage in our systematic review and \\nmeta-analysis, with combined OR 1.10 (95% CI 0.82–1.48). Polyhydramnios did not emerge \\nas a risk factor for atonic postpartum hemorrhage in quantitative analysis, with combined \\nOR 1.29 (95% CI 0.94–1.76), despite the historical identification of polyhydramnios as a \\ncause of atonic postpartum hemorrhage due to uterine overdistention. Macrosomia and \\nmultiple gestation, which are implicated by a similar mechanism, did demonstrate increased \\nrisk with combined OR of 1.46 (95% CI 1.35–1.57) and 2.16 (95% CI 1.53–3.06), \\nrespectively. Uterine overdistention alone, however, may not fully explain the variability in \\nthe risk of atony that is observed between these three conditions. For example, multiple \\ngestation pregnancies are frequently due to in vitro fertilization, which has been associated \\nwith increased risk of postpartum hemorrhage possibly due to abnormalities of placental \\nimplantation and endometrial function.26 Additionally, there may be some underlying \\nimmunologic, vascular, or genetic pathophysiology that overlaps with infertility and atonic \\npostpartum hemorrhage.27–30\\nObesity and magnesium exposure are additional factors included in most risk-assessment \\ntools; however, neither showed associations with atonic postpartum hemorrhage in this \\nreview. It is possible that the underlying conditions (ie, diabetes mellitus, hypertension) are \\nthe real risk factors, as discussed above, leaving the clinical impression that obesity and \\nmagnesium increase postpartum hemorrhage risk and leading some studies to find a positive \\neffect. Given the retrospective nature of most included studies, however, magnesium \\nexposure and dosing may have been inadequately captured, hindering the ability to \\ndemonstrate an association with atonic postpartum hemorrhage.Ende et al. Page 6\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 5}), Document(page_content='Cesarean delivery and uterine leiomyomas are included in the risk-assessment tools but were \\nnot found to be associated with atonic postpartum hemorrhage by either qualitative or \\nquantitative analysis. Because intrapartum cesarean delivery is associated with factors (eg, \\nprolonged labor and oxytocin exposure) shown to increase the risk of atonic postpartum \\nhemorrhage, this may contribute to a positive association in studies or a clinical impression \\nthat cesarean delivery is significantly associated with atonic postpartum hemorrhage. The \\noccurrence of leiomyomas varies significantly in size, location, vascularity, and previous \\nsurgical interventions, which may influence the ability to determine the significance of \\nleiomyomas as a risk factor in published studies.\\nFinally, many risk factors already included in widely adopted risk-assessment tools are \\nfurther confirmed in this systematic review as associated with atonic postpartum hemorrhage\\n—prior postpartum hemorrhage, multiple gestation, placental disorders (previa or \\nabruption), chorioamnionitis, predelivery oxytocin exposure, induction of labor, prolonged \\nlabor, perineal trauma, and instrumented vaginal delivery. Although some of these factors \\n(eg, abnormal placentation, birth canal trauma) are etiologies for postpartum hemorrhage \\nthemselves, the evidence presented here suggests that they are additionally associated with \\nthe development of uterine atony. This evidence further supports the inclusion of these \\nfactors when stratifying risk, and our data may help health care professionals improve tools \\nby assigning a quantitative weight to risk factors with a stronger association with atonic \\npostpartum hemorrhage. Additionally, current tools likely can be further improved by more \\nnuanced definitions of some factors shown to have a robust association with atonic \\npostpartum hemorrhage. For example, further delineation of genital tract trauma may be \\nwarranted; although episiotomy or perineal tear (OR 1.67, 95% 1.28–2.18) is included in \\nsome current risk-assessment tools, high vaginal laceration and cervical laceration are not \\n(OR 2.19, 95% 1.13–4.24, and 5.70, 95% 2.56–12.67, respectively).\\nThe data for oxytocin exposure, which also are already included in current risk-assessment \\ntools, presented the most significant challenge in the interpretation of results for this \\nsystematic review. Although qualitative synthesis suggested an association between \\npredelivery oxytocin exposure and atonic postpartum hemorrhage, the meta-analysis failed \\nto confirm the association (combined OR 1.15, 95% 0.95–1.40). Importantly, two low risk of \\nbias studies were not included in the meta-analysis because of heterogeneity in defining the \\nexposure and reference ranges (eg, evaluating oxytocin per unit dose). With conflicting \\nresults, it is essential also to consider the mechanism by which oxytocin likely contributes to \\natonic postpartum hemorrhage, namely that tachyphylaxis to oxytocin occurs during labor, \\nthereby decreasing efficacy of the primary drug used for the active management the third \\nstage of labor.31–33 Further investigation is needed to determine the cut-offs for the amount \\nor duration of oxytocin that leads to an increased risk of atony.\\nAlthough the risk-assessment tools may be refined by adding, keeping or removing risk \\nfactors, the individual weights and whether each individually or in combination defines an \\nindividual patient’s postpartum hemorrhage risk as moderate or high remains undetermined. \\nWhen preparing and allocating resources for potential postpartum hemorrhage, the use of \\nrisk scores that weigh the variable contribution of risk factors may be preferable to the use of \\ntools that merely collate a list of diagnoses with many associated or overlapping risk factors. Ende et al. Page 7\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 6}), Document(page_content='To this end, recent headway has been made in using statistical modeling and machine \\nlearning to predict postpartum hemorrhage.34 Notably, however, a substantial proportion of \\npostpartum hemorrhage occurs in the absence of recognized risk factors.\\nThe strengths of this systematic review include the systematic approach to identifying all \\npublications that included risk factors for atonic postpartum hemorrhage and the division of \\nrisk factors into maternal, pregnancy-related, labor-related, and delivery-related conditions \\nto provide a logical progression of possible etiologies of atonic postpartum hemorrhage. \\nFinally, we evaluated each variable, both qualitatively and quantitatively, to summarize a \\nlarge number of studies in a comprehensive review. The results of this systematic review and \\nmeta-analysis, however, must be considered in the context of several limitations. First, we \\nhad to accept the authors’ definitions of atonic postpartum hemorrhage, which varied from \\nstudy to study. The most common definitions in large database studies were rather \\nconsistent, using International Classification of Diseases codes for postpartum hemorrhage \\ndue to atony. The variability occurred primarily in the smaller studies, which used \\ndefinitions of postpartum hemorrhage that included estimated blood loss, postpartum \\nhemoglobin or hematocrit drop, and clinical diagnosis, with additional definitions for the \\ndiagnosis of atony including uterotonic administration, medical team diagnosis, or other \\nsurgical interventions. These definitions represent a spectrum of pathology, and each study’s \\ndefinition may have affected the magnitude of associations of any given risk factor. Second, \\nbecause all authors were fluent only in English, we restricted our search to English-language \\nstudies, which contributed to publication bias. Third, for thoroughness we did include in the \\nnarrative summary studies with a high risk of bias; however, we included only studies with a \\nlow or moderate risk of bias when evaluating each risk factor, both qualitatively and \\nquantitatively. Fourth, the types of effect estimates reported and the factors used to adjust for \\npotential confounding were heterogeneous across studies. Additionally, nearly all reported \\nORs and RRs reflect weak associations (range 1–2), which are likely below the \\ndiscriminatory ability of the included cohort and case–control studies. These observations \\nmay result from unmeasured bias or confounding.35 Lastly, to summarize risk factors \\nqualitatively, we had to provide a unique definition to categorize a risk factor as definite, \\nlikely, or unclear. Although these definitions were created de novo for this review, a post hoc \\nevaluation revealed that for those variables designated definite risk factors, all (six of six) \\nshowed statistically significant combined OR. Of the variables designated likely, eight of \\nnine were amenable to meta-analysis, and seven showed statistically significant increased \\nodds of atonic postpartum hemorrhage. Finally, 15 variables were classified as unclear risk \\nfactors, with only six of those demonstrating data homogeneous enough for meta-analysis, \\nand of those, only one (macrosomia) demonstrated a statistically significant OR.\\nIn summary, this systematic review and meta-analysis of risk factors for postpartum \\nhemorrhage due to uterine atony provides critical insights to help guide future obstetric care. \\nBy more narrowly defining our focus to only atonic postpartum hemorrhage, we aimed to \\nprovide more definitive evidence supporting or refuting presumed risk factors, given that \\neach etiology of postpartum hemorrhage likely has a unique set of contributing factors. \\nThese findings should lead researchers and clinicians to refine current risk-assessment tools \\nfurther. Future tools should include weighted values for risk factors or modeling risk levels Ende et al. Page 8\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 7}), Document(page_content='by the etiology of postpartum hemorrhage. Finally, the genetic basis for postpartum \\nhemorrhage warrants further investigation and eventual inclusion into risk-assessment tools.\\nSupplementary Material\\nRefer to Web version on PubMed Central for supplementary material.\\nAcknowledgments\\nSarah S. Osmundson is supported by grant number K23DA047476 from the National Institute of Drug Abuse.\\nREFERENCES\\n1. Bateman BT, Berman MF, Riley LE, Leffert LR. The epidemiology of postpartum hemorrhage in a \\nlarge, nationwide sample of deliveries. Anesth Analg 2010;110:1368–73. doi: 10.1213/\\nANE.0b013e3181d74898 [PubMed: 20237047] \\n2. Sosa CG, Althabe F, Belizán JM, Buekens P. Risk factors for postpartum hemorrhage in vaginal \\ndeliveries in a LatinAmerican population. Obstet Gynecol 2009;113:1313–9. doi: 10.1097/\\nAOG.0b013e3181a66b05 [PubMed: 19461428] \\n3. Oyelese Y , Scorza WE, Mastrolia R, Smulian JC. Postpartum hemorrhage. Obstet Gynecol Clin \\nNorth Am 2007;34:421–41, x. doi: 10.1016/j.ogc.2007.06.007 [PubMed: 17921008] \\n4. Girard T, Mörtl M, Schlembach D. New approaches to obstetric hemorrhage: the postpartum \\nhemorrhage consensus algorithm. Curr Opin Anaesthesiol 2014;27:267–74. doi: 10.1097/\\nACO.0000000000000081 [PubMed: 24739248] \\n5. Bingham D, Melsop K, Main E. CMQCC Obstetric hemorrhage hospital level implementation \\nguide. Stanford University; 2010\\n6. The AWHONN Postpartum Hemorrhage Project. Postpartum hemorrhage (PPH) risk assessment \\ntable 1.0. Accessed June 8, 2020. https://mygnosis.com/Content/Chunks/3504/assets/pdfs/\\nPPH_Risk_Assessment_Table-7-17-15.pdf\\n7. American College of Obstetricians and Gynecologists. Maternal safety bundle for obstetric \\nhemorrhage. Accessed May 26, 2020. https://www.acog.org/community/districts-and-sections/\\ndistrict-ii/programs-and-resources/safe-motherhood-initiative/obstetric-hemorrhage\\n8. Kawakita T, Mokhtari N, Huang JC, Landy HJ. Evaluation of risk-assessment tools for severe \\npostpartum hemorrhage in women undergoing cesarean delivery. Obstet Gynecol 2019; 134:1308–\\n16. doi: 10.1097/AOG.0000000000003574 [PubMed: 31764744] \\n9. Dilla AJ, Waters JH, Yazer MH. Clinical validation of risk stratification criteria for peripartum \\nhemorrhage. Obstet Gynecol 2013;122:120–6. doi: 10.1097/AOG.0b013e3182941c78 [PubMed: \\n23743452] \\n10. Durmaz A, Komurcu N. Relationship between maternal characteristics and postpartum \\nhemorrhage: a meta-analysis study. J Nurs Res 2018;26:362–72. doi: 10.1097/\\njnr.0000000000000245 [PubMed: 29219937] \\n11. Moher D, Liberati A, Tetzlaff J, Altman DG Preferred reporting items for systematic reviews and \\nmeta-analyses: the PRISMA statement. Int J Surg 2010;8:336–41. doi: 10.1016/j.ijsu.2010.02.007 \\n[PubMed: 20171303] \\n12. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for \\nsystematic reviews. Syst Rev 2016;5:210. doi: 10.1186/s13643-016-0384-4 [PubMed: 27919275] \\n13. Kim SY , Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of \\nbias for nonrandomized studies showed moderate reliability and promising validity. J Clin \\nEpidemiol 2013;66:408–14. doi: 10.1016/j.jclinepi.2012.09.016 [PubMed: 23337781] \\n14. Morris JA, Gardner MJ. Calculating confidence intervals for relative risks (odds ratios) and \\nstandardised ratios and rates. Br Med J (Clin Res Ed) 1988;296:1313–6. doi: 10.1136/\\nbmj.296.6632.1313Ende et al. Page 9\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 8}), Document(page_content='15. Borenstein M, Hedges LV , Higgins JP, Rothstein HR. A basic introduction to fixed-effect and \\nrandom-effects models for meta-analysis. Res Synth Methods 2010;1:97–111. doi: 10.1002/\\njrsm.12 [PubMed: 26061376] \\n16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88. doi: \\n10.1016/0197-2456(86)90046-2 [PubMed: 3802833] \\n17. Leonard SA, Main EK, Scott KA, Profit J, Carmichael SL Racial and ethnic disparities in severe \\nmaternal morbidity prevalence and trends. Ann Epidemiol 2019;33:30–6. doi: 10.1016/\\nj.annepidem.2019.02.007 [PubMed: 30928320] \\n18. Kaplan JB, Bennett T. Use of race and ethnicity in biomedical publication. JAMA 2003;289:2709–\\n16. doi: 10.1001/jama.289.20.2709 [PubMed: 12771118] \\n19. Obermeyer Z, Powers B, V ogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to \\nmanage the health of populations. Science 2019;366:447–53. doi: 10.1126/science.aax2342 \\n[PubMed: 31649194] \\n20. Vyas DA, Eisenstein LG, Jones DS. Hidden in plain sight - reconsidering the use of race correction \\nin clinical algorithms. N Engl J Med 2020;383:874–82. doi: 10.1056/NEJMms2004740 [PubMed: \\n32853499] \\n21. Turbeville HR, Sasser JM. Preeclampsia beyond pregnancy: long-term consequences for mother \\nand child. Am J Physiol Ren Physiol 2020;318:F1315–26. doi: 10.1152/ajprenal.00071.2020\\n22. Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and \\nvascular dysfunction in hypertension. Biomed Res Int 2014;2014:406960. doi: \\n10.1155/2014/406960\\n23. Huang D, Refaat M, Mohammedi K, Jayyousi A, Al Suwaidi J, Abi Khalil C Macrovascular \\ncomplications in patients with diabetes and Prediabetes. Biomed Res Int 2017;2017:7839101. doi: \\n10.1155/2017/7839101\\n24. Luft FC. Molecular genetics of human hypertension. Curr Opin Cardiol 2020;35:249–57. doi: \\n10.1097/HCO.0000000000000722 [PubMed: 32068615] \\n25. Gaulton KJ. Mechanisms of type 2 diabetes risk loci. Curr Diab Rep 2017;17:72. doi: 10.1007/\\ns11892-017-0908-x [PubMed: 28741265] \\n26. Nyfløt LT, Sandven I, Stray-Pedersen B, Pettersen S, Al-Zirqi I, Rosenberg M, et al. Risk factors \\nfor severe postpartum hemorrhage: a case-control study. BMC Pregnancy Childbirth 2017; 17:17. \\ndoi: 10.1186/s12884-016-1217-0 [PubMed: 28068990] \\n27. Escobar MF, Hincapie MA, Barona JS. Immunological role of the maternal uterine microbiota in \\npostpartum hemorrhage. Front Immunol 2020;11:504. doi: 10.3389/fimmu.2020.00504 [PubMed: \\n32296425] \\n28. Ehsani M, Mohammadnia-Afrouzi M, Mirzakhani M. Female unexplained infertility: a disease \\nwith imbalanced adaptive immunity. J Hum Reprod Sci 2019;12:274–82. doi: 10.4103/\\njhrs.JHRS_30_19 [PubMed: 32038075] \\n29. Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of \\nendometriosis-associated infertility. Obstet Gynecol Clin North Am 2012;39:535–49. doi: \\n10.1016/j.ogc.2012.10.002 [PubMed: 23182559] \\n30. Tanbo T, Fedorcsak P. Endometriosis-associated infertility: aspects of pathophysiological \\nmechanisms and treatment options. Acta Obstet Gynecol Scand 2017;96:659–67. doi: 10.1111/\\naogs.13082 [PubMed: 27998009] \\n31. Dyer RA, Butwick AJ, Carvalho B. Oxytocin for labour and caesarean delivery: implications for \\nthe anaesthesiologist. Curr Opin Anaesthesiol 2011;24:255–61. doi: 10.1097/\\nACO.0b013e328345331c [PubMed: 21415725] \\n32. World Health Organization. WHO recommendations for the prevention and treatment of \\npostpartum haemorrhage. World Health Organization; 2012.\\n33. Gülmezoglu AM, Lumbiganon P, Landoulsi S, Widmer M, Abdel-Aleem H, Festin M, et al. Active \\nmanagement of the third stage of labour with and without controlled cord traction: a randomised, \\ncontrolled, non-inferiority trial. Lancet 2012; 379:1721–7. doi: 10.1016/S0140-6736(12)60206-2 \\n[PubMed: 22398174] Ende et al. Page 10\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 9}), Document(page_content='34. Venkatesh KK, Strauss RA, Grotegut CA, Heine RP, Chescheir NC, Stringer JSA, et al. Machine \\nlearning and statistical models to predict postpartum hemorrhage. Obstet Gynecol 2020;135: 935–\\n44. doi: 10.1097/AOG.0000000000003759 [PubMed: 32168227] \\n35. Grimes DA, Schulz KF. False alarms and pseudo-epidemics: the limitations of observational \\nepidemiology. Obstet Gynecol 2012;120:920–7. doi: 10.1097/AOG.0b013e31826af61a [PubMed: \\n22996110] \\n36. Bateman BT, Hernandez-Diaz S, Huybrechts KF, Palmsten K, Mogun H, Ecker JL, et al. \\nOutpatient calcium-channel blockers and the risk of postpartum haemorrhage: a cohort study. \\nBJOG 2013;120:1668–7. doi: 10.1111/1471-0528.12428 [PubMed: 24020971] \\n37. Bekabil TT, Tsaedu FA, Debelew GT. Maternal complications of twin deliveries in Jimma \\nUniversity Specialized Hospital, Southwest Ethiopia: a facility-based cohort study. Gaziantep Med \\nJ 2015;21:84–9.\\n38. Bryant A, Mhyre JM, Leffert LR. The association of maternal race and ethnicity and the risk of \\npostpartum hemorrhage. Anesth Analg 2012;115:1127–36. doi: 10.1213/ANE.0b013e3182691e62 \\n[PubMed: 22886840] \\n39. Callaghan WM, Kuklina EV , Berg CJ. Trends in postpartum hemorrhage: United States, 1994–\\n2006. Am J Obstet Gynecol 2010;202:353–6. doi: 10.1016/j.ajog.2010.01.011 [PubMed: \\n20350642] \\n40. Chalouhi SE, Tarutis J, Barros G. Risk of postpartum hemorrhage among Native American women. \\nInt J Gynaecol Obstet 2015;131:269–72. doi: 10.1016/j.ijgo.2015.05.037 [PubMed: 26534873] \\n41. Driessen M, Bouvier-Colle MH, Dupont C, Khoshnood B, Rudigoz RC, Deneux-Tharaux C \\nPostpartum hemorrhage resulting from uterine atony after vaginal delivery: factors associated with \\nseverity. Obstet Gynecol 2011;117:21–31. doi: 10.1097/AOG.0b013e318202c845 [PubMed: \\n21173641] \\n42. Feerasta SH, Motiei A, Motiwala S, Zuberi NF. Uterine atony at a tertiary care hospital in Pakistan: \\na risk factor analysis. JPMA J Pakistan Med Assoc 2000;50:132–6.\\n43. Foley A, Gunter A, Nunes KJ, Shahul S, Scavone BM Patients undergoing cesarean delivery after \\nexposure to oxytocin during labor require higher postpartum oxytocin doses. Anesth Analg \\n2018;126:920–4. doi: 10.1213/ANE.0000000000002401 [PubMed: 28858899] \\n44. Grotegut CA, Paglia MJ, Johnson LN. Oxytocin exposure during labor among women with \\npostpartum hemorrhage secondary to uterine atony. Am J Obstet Gynecol 2011;204:56.e1–6. doi: \\n10.1016/j.ajog.2010.08.023 [PubMed: 21047614] \\n45. Guillaume A, Sananès N, Poirier V , Gaudineau A, Fritz G, Boudier E, et al. Benefits of cord blood \\ncollection in the prevention of post-partum hemorrhage: a cohort study. J Matern Fetal Neonatal \\nMed 2015;28:2111–4. doi: 10.3109/14767058.2014.979401 [PubMed: 25341670] \\n46. Harvey SA, Lim E, Gandhi KR. Racial-ethnic disparities in postpartum hemorrhage in Native \\nHawaiians, Pacific Islanders, and Asians. J Asia Pac Med Public Health 2017;76:128–32.\\n47. Joseph KS, Sheehy O, Mehrabadi A. Can drug effects explain the recent temporal increase in \\natonic postpartum haemorrhage? Paediatric perinatal Epidemiol 2015;29:220–31. doi: 10.1111/\\nppe.12190\\n48. Kahr MK, Franke D, Brun R. Blood group O: a novel risk factor for increased postpartum blood \\nloss? Haemophilia 2018;24:e207–12. doi: 10.1111/hae.13537 [PubMed: 29877601] \\n49. Kovacheva VP, Soens MA, Tsen LC. Serum uric acid as a novel marker for uterine atony and post-\\nspinal vasopressor use during cesarean delivery. Int J Obstet Anesth 2013;22: 200–8. doi: 10.1016/\\nj.ijoa.2013.04.005 [PubMed: 23702182] \\n50. Lao TT, Sahota DS, Cheng YK. Advanced maternal age and postpartum hemorrhage - risk factor \\nor red herring?. J Matern Fetal Neonatal Med 2014;27:243–6. doi: \\n10.3109/14767058.2013.807240 [PubMed: 23713943] \\n51. Looft E, Simic M, Ahlberg M, Snowden JM, Cheng YW, Stephansson O Duration of second stage \\nof labour at term and Pushing time: risk factors for postpartum haemorrhage. Paediatr Perinat \\nEpidemiol 2017;31:126–33. doi: 10.1111/ppe.12344 [PubMed: 28195653] \\n52. Lutomski JE, Byrne BM, Devane D, Greene RA. Increasing trends in atonic postpartum \\nhaemorrhage in Ireland: an 11-year population-based cohort study. BJOG 2012;119:306–14. doi: \\n10.1111/j.1471-0528.2011.03198.x [PubMed: 22168794] Ende et al. Page 11\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 10}), Document(page_content='53. Marshall AL, Durani U, Bartley A, Hagen CE, Ashrani A, Rose C, et al. The impact of postpartum \\nhemorrhage on hospital length of stay and inpatient mortality: a National Inpatient Sample-based \\nanalysis. Am J Obstet Gynecol 2017;217:344. e1–6. doi: 10.1016/j.ajog.2017.05.004 [PubMed: \\n28502758] \\n54. Mehrabadi A, Hutcheon JA, Lee L, Kramer MS, Liston RM, Joseph KS Epidemiological \\ninvestigation of a temporal increase in atonic postpartum haemorrhage: a population-based \\nretrospective cohort study. BJOG 2013;120:853–62. doi: 10.1111/1471-0528.12149 [PubMed: \\n23464351] \\n55. Oberg AS, Hernandez-Diaz S, Palmsten K, Almqvist C, Bateman BT Patterns of recurrence of \\npostpartum hemorrhage in a large population-based cohort. Am J Obstet Gynecol 2014;210: 229–\\n8. doi: 10.1016/j.ajog.2013.10.872 [PubMed: 24351791] \\n56. Regalia AL, Acmet E, Limonta Ghezzi GV . Logistic regression analysis highlighted previous \\natony, pre-eclampsia, oxytocin induction and augmentation of labour, macrosomia, slow labour, \\nKristeller manoevres to be risk factors for uterine atony. Ital J Gynaecol Obstet 2001;3:120–23.\\n57. Siddiqui M, Minhaj M, Mueller A, Tung A, Scavone B, Rana S, et al. Increased Perinatal \\nmorbidity and mortality among Asian American and Pacific Islander women in the United States. \\nAnesth Analg 2017;124:879–86. doi: 10.1213/ANE.0000000000001778 [PubMed: 28099290] \\n58. Tran G, Kanczuk M, Balki M. The association between the time from oxytocin cessation during \\nlabour to cesarean delivery and postpartum blood loss: a retrospective cohort study. Can J Anaesth \\n2017;64:820–7. doi: 10.1007/s12630-017-0874-4 [PubMed: 28421545] \\n59. Vendittelli F, Barasinski C, Pereira B, Lémery D. Incidence of immediate postpartum hemorrhages \\nin French maternity units: a prospective observational study (HERA study). BMC Pregnancy \\nChildbirth 2016;16:242. doi: 10.1186/s12884-016-1008-7 [PubMed: 27552986] \\n60. Waheed G, Toheed R, Mansha M, Bin Ayub T. Comparison of causes of postpartum haemorrhage \\nfollowing vaginal deliveries and caesarean sections in a tertiary care hospital of Pakistan. Pakistan \\nJ Med Health Sci 2013;7:5885–9.\\n61. Wetta LA, Szychowski JM, Seals S, Mancuso MS, Biggio JR, Tita AT Risk factors for uterine \\natony/postpartum hemorrhage requiring treatment after vaginal delivery. Am J Obstet Gynecol \\n2013;209:51–6. doi: 10.1016/j.ajog.2013.03.011 [PubMed: 23507549] Ende et al. Page 12\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 11}), Document(page_content='Box 1.\\nDefining the Strength of a Risk Factor\\nDefinite\\nAll low and moderate risk of bias studies positive (at least three studies)\\nMajority (more than 50%) low and moderate risk of bias studies positive (at least five \\nstudies)\\nLikely\\nAll low and moderate risk of bias studies positive (two studies)\\nMajority (more than 50%) low and moderate risk of bias studies positive (2–4 studies)\\nUnclear\\nAll low and moderate risk of bias studies positive (one study)\\nLow and moderate risk of bias studies show mixed or conflicting results\\nA majority (more than 50%) of studies negative but at least one low or moderate risk of \\nbias study positive\\nNot a risk factor\\nNo low or moderate risk of bias studies positiveEnde et al. Page 13\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 12}), Document(page_content='Fig. 1. \\nFlow diagram of studies identified for systematic review.\\nEnde. Atonic Hemorrhage Risk Systematic Review. Obstet Gynecol 2021.Ende et al. Page 14\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 13}), Document(page_content='Fig. 2. \\nRisk of bias assessment. Risk of bias assessments were performed using the Risk of Bias \\nAssessment Tool for Nonrandomized Studies.13 Green (+)  indicates low risk of bias, blue (?) \\nindicates unclear risk of bias, and red (X)  indicates high risk of bias. For the summary of \\nrisk of bias, studies were considered overall low risk of bias ( green + ) if they were classified \\nas low risk in all six domains. Studies were considered a moderate risk of bias ( yellow  —) if \\nat least one domain was rated unclear risk (but no domains were rated high risk) and high \\nrisk ( red X ) if at least one domain was rated high risk.Ende et al. Page 15\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 14}), Document(page_content='Ende. Atonic Hemorrhage Risk Systematic Review. Obstet Gynecol 2021.Ende et al. Page 16\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 15}), Document(page_content='Fig. 3. \\nMeta-analysis of history and demographic risk factors. Forest plots of odds ratios (ORs) that \\nwere included in the quantitative meta-analysis and the associated overall ORs. For each \\nOR, the size of the gray square region  is proportional to the corresponding study weight. \\nDiamond-shaped intervals  represent the overall ORs. I2 represents the fraction of variability \\namong the individual ORs that cannot be explained by sampling variability. aOR, adjusted \\nodds ratio; uOR, unadjusted odds ratio; aRR, adjusted relative risk; PPH, postpartum \\nhemorrhage; CD, cesarean delivery.\\nEnde. Atonic Hemorrhage Risk Systematic Review. Obstet Gynecol 2021.Ende et al. Page 17\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 16}), Document(page_content='Fig. 4. \\nMeta-analysis of maternal comorbidity risk factors. Forest plots of odds ratios (ORs) that \\nwere included in the quantitative meta-analysis and the associated overall ORs. For each \\nOR, the size of the gray square region  is proportional to the corresponding study weight. \\nDiamond-shaped intervals  represent the overall ORs. I2 represents the fraction of variability \\namong the individual ORs that cannot be explained by sampling variability. aOR, adjusted \\nodds ratio; uOR, unadjusted odds ratio; aRR, adjusted relative risk; uRR, unadjusted relative \\nrisk.\\nEnde. Atonic Hemorrhage Risk Systematic Review. Obstet Gynecol 2021.Ende et al. Page 18\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 17}), Document(page_content='Fig. 5. \\nMeta-analysis of pregnancy-related risk factors. Forest plots of odds ratios (ORs) that were \\nincluded in the quantitative meta-analysis and the associated overall ORs. For each OR, the \\nsize of the gray square region  is proportional to the corresponding study weight. Diamond-\\nshaped intervals  represent the overall ORs. I2 represents the fraction of variability among the \\nindividual ORs that cannot be explained by sampling variability. aOR, adjusted odds ratio; \\naRR, adjusted relative risk; uRR, unadjusted relative risk.\\nEnde. Atonic Hemorrhage Risk Systematic Review. Obstet Gynecol 2021.Ende et al. Page 19\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 18}), Document(page_content='Fig. 6. \\nMeta-analysis of labor-related risk factors. Forest plots of odds ratios (ORs) that were \\nincluded in the quantitative meta-analysis and the associated overall ORs. For each OR, the \\nsize of the gray square region  is proportional to the corresponding study weight. Diamond-\\nshaped intervals  represent the overall ORs. I2 represents the fraction of variability among the \\nindividual ORs that cannot be explained by sampling variability. aOR, adjusted odds ratio; \\nuOR, unadjusted odds ratio; aRR, adjusted relative risk; uRR, unadjusted relative risk.\\nEnde. Atonic Hemorrhage Risk Systematic Review. Obstet Gynecol 2021.Ende et al. Page 20\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 19}), Document(page_content='Fig. 7. \\nMeta-analysis of delivery-related risk factors. Forest plots of odds ratios (ORs) that were \\nincluded in the quantitative meta-analysis and the associated overall ORs. For each OR, the \\nsize of the gray square region  is proportional to the corresponding study weight. Diamond-\\nshaped intervals  represent the overall ORs. I2 represents the fraction of variability among the \\nindividual ORs that cannot be explained by sampling variability. aOR, adjusted odds ratio; \\naRR, adjusted relative risk; uRR, unadjusted relative risk.\\nEnde. Atonic Hemorrhage Risk Systematic Review. Obstet Gynecol 2021.Ende et al. Page 21\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.\\nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 20}), Document(page_content='Author Manuscript Author Manuscript Author Manuscript Author ManuscriptEnde et al. Page 22Table 1.\\nSummary of Article Characteristics\\nAuthor and Year Study Country Study Design Study Years No. of Patients Rate of Atonic PPH n (%) Mode of Delivery\\nBateman et al, 20101 United States Retrospective cohort 1995–2004 (2004 data for risk \\nfactor analysis)876,641 Atonic PPH: 20,353 (2.3) VD CD\\nBateman et al, 201336 United States Retrospective cohort 2000–2007 9,750 Calcium channel blocker: \\n1,226Atonic PPH: 201 (2.1) VD CD\\nBekabil et al, 201537 Ethiopia Prospective cohort 2012–2013 432 Twin: 144 Atony: 16 (3.7) VD CD\\nBryant* et al, 201238 United States Retrospective cohort 2005–2008 2,488,974 Atonic PPH: 53,266 (2.1) VD CD\\nCallaghan et al, 201039 United States Retrospective cohort 1994–2006 10,481,197 Atonic PPH: 212, 00 (2) VD CD\\nChalouhi* etal, 201540 United States Retrospective cohort 2009–2012 1,062 Atony: 87 (8.2) VD\\nDriessen et al, 201141 France Prospective cohort 2004–2006 146,876 Atonic PPH: 4,550 (3.1) VD\\nFeerasta et al, 200042 Pakistan Retrospective case- control 1987–1997 332 Case: 112, Control: 220 NA (case-control) VD\\nFoley et al, 201843 United States Retrospective cohort 2015 402 Atony: 195 (48.5) CD\\nDefinition of Atonic PPH Risk Factors Assessed Covariates Adjusted For Exclusion Criteria\\nICD code Age, mode of delivery, HDP, diabetes, uterine leiomyoma, prior \\nCD, polyhydramnios, chorioamnionitis, precipitous delivery, long \\nlabor, medical induction of labor, multiple gestation, stillbirth, \\nantepartum hemorrhage, retained placentaLogistic regression included all risk factors \\nassessedMissing data on maternal age\\nICD code Calcium channel blocker administration Age, race, ethnicity, HDP, diabetes, obesity, renal \\ndisease, leiomyomas, prior CD, placenta previa, \\nmultiple gestation, mode of delivery, induction of \\nlaborPreterm labor or preterm delivery, \\nmigraine, arrhythmia, angina, Raynaud, \\nexposure to multiple antihypertensives, \\nout of hospital delivery, no diagnosis of \\npre-existing or gestational hypertension\\nPPH: undefined Atony: \\nundefinedMultiple gestation None None\\nICD code Race and ethnicity (African American, Hispanic, Asian or Pacific \\nIslander)Induction of labor, multiple gestation, \\npolyhydramnios, diabetes, chorioamnionitis, \\nstillbirth, grand multiparity, preeclampsia, \\nobesity, leiomyomas, placental abruption, \\nplacenta previa, previous CD, chronic anemia, \\nretained placenta, prolonged laborRace or ethnicity data missing or coded as \\na category not included in the study\\nICD code Mode of delivery Age None\\nPPH: EBL Atony: uterotonic† Ethnicity (Native American) None Multiple gestation, preterm delivery, \\ncoagulopathy\\nPPH: EBL or Hgb drop of more \\nthan 2 g per dLMaternal age, BMI, prior PPH, fibroma, hydramnios, parity, \\nmultiple gestation, type of onset of labor, epidural analgesia, \\nprolonged labor, oxytocin during labor, prolonged expulsive Logistic regression included all risk factors \\nassessedIncomplete data, CD, PPH of etiology \\nother than atony\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 21}), Document(page_content='Author Manuscript Author Manuscript Author Manuscript Author ManuscriptEnde et al. Page 23Definition of Atonic PPH Risk Factors Assessed Covariates Adjusted For Exclusion Criteria\\nAtony: uterotonic† or other \\nintervention,‡ case report form \\nto elucidate etiologyefforts, gestational age, instrumented VD, prophylactic uterotonics, \\nbirth weight\\nPPH: undefined Atony: \\nundefined†Parity, stillbirth or neonatal death, prior PPH, prior CD, HDP, \\nantenatal anemia, multiple gestation, history of preterm labor, use \\nof tocolytics, diabetes, polyhydramnios, amnionitis, uterine \\nleiomyomas, induced labor, augmented labor, prolonged labor, \\nmode of delivery, precipitous delivery, epidural, macrosomiaLogistic regression included all risk factors \\nassessedNone\\nPPH: EBL, Hgb drop, \\ntransfusion Atony: uterotonicPredelivery oxytocin exposure Nulliparity, hypertension, diabetes, multiple \\ngestation, polyhydramnios, premature rupture of \\nmembranes, preterm rupture of membranes, \\nprolonged rupture of membranes, placenta previa, \\nplacental abruption, chorioamnionitis, \\nmacrosomiaGeneral anesthesia, postpartum oxytocin \\ndose not charted\\nAuthor and Year Study Country Study Design Study Years No. of Patients Rate of Atonic PPH n (%) Mode of Delivery\\nGrotegut* et al, 201144 United States Retrospective case- control 2000–2004 108 Case: 54, control: 54 NA (case-control) VD CD\\nGuillaume et al, 201545 France Retrospective cohort 2011–2013 7,810 Atonic PPH: 202 (2.6) VD\\nHarvey* et al, 201746 United States Retrospective cohort 1995–2013 243,693 Atonic PPH: 8,962 (3.7) VD CD\\nJoseph et al, 201547 Canada Retrospective case- control 1998–2009 138,704 Case: 6,378, control: 31,795 NA (case-control) VD CD\\nKahr et al, 201848 Switzerland Prospective cohort 2015–2016 1,487 Atony: 71 (4.8) VD CD\\nKovacheva et al, 201349 United States Retrospective cohort 2009 345 Atony: 35 (10) CD\\nLao et al, 201450 Hong Kong Retrospective cohort 1998–2008 64,886 Atonic PPH: 1,194 (1.8) VD CD\\nLooft et al, 201751 Sweden Retrospective cohort 2008–2014 57,267 Atonic PPH: 2,659 (4.6) VD\\nDefinition of Atonic PPH Risk Factors Assessed Covariates Adjusted For Exclusion Criteria\\nPPH: ICD+chart review for \\ntransfusionPredelivery oxytocin exposure, race, BMI, \\nadmission hematocrit, induction status, \\npreeclampsia, magnesium therapy, \\nchorioamnionitisRace, BMI, admission hematocrit, induction status, magnesium \\ntreatment, chorioamnionitisNone\\nAtony: uterotonic† or other \\nintervention‡\\nPPH: EBL Cord blood collection Age, grand multiparity, diabetes, induction of labor, long labor, \\noxytocin augmentation, prophylactic postpartum oxytocin, \\ninstrumented delivery, birth weight, vaginal tearing, placental \\nretentionMultiple gestation, gestational age less than 37 \\nwkAtony: medical team \\ndiagnosis\\nICD code Ethnicity (Native Hawaiians and Other Pacific \\nIslanders, Asian, White)Age, delivery type, prior CD, smoking, obesity, substance abuse, \\nmultiple gestation, multiparity, HDP, diabetes, labor induction, \\npolyhydramnios, chorioamnionitis, placental abruption, placenta \\nprevia, prolonged laborNon-Hawaii residents, records lacking race-\\nethnicity data, race-ethnicity other than Native \\nHawaiians and Other Pacific Islanders, Asian, \\nor White\\nICD code Maternal medication use (antidepressants, \\naspirin, nonsteroidal antiinflammatory drugs, Age, welfare status, rural vs urban residence, prior CD, alcoholism, \\nliver disease, thrombocytopenia, multiple gestation, preeclampsia, None\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 22}), Document(page_content='Author Manuscript Author Manuscript Author Manuscript Author ManuscriptEnde et al. Page 24Definition of Atonic PPH Risk Factors Assessed Covariates Adjusted For Exclusion Criteria\\nbeta-agonists, and antihistamines), multiple \\npregnancies, placenta previa or abruption, \\npolyhydramnios, prolonged labor, preeclampsia \\nor eclampsia, epidural, labor induction, perineal \\ntrauma, uterine rupture, mode of delivery, \\nchorioamnionitis, alcohol use disorder, liver \\ndisease, thrombocytopenia, asthmapolyhydramnios, placenta previa, placental abruption, epidural \\nanalgesia, labor induction, prolonged first stage, prolonged second \\nstage, mode of delivery, uterine rupture, cervical laceration, severe \\nperineal tear, chorioamnionitis\\nPPH: EBL or Hgb drop \\nAtony: undefinedBlood group O None Gestational age less than 22 wk, primary \\ncoagulopathy or blood-clotting disorder, no \\ninformed consent, maternal age younger than \\n18 y\\nPPH: Difference between \\npreoperative and \\npostoperative hematocrit \\nAtony: uterotonic†Serum uric acid level Uric acid level, use of magnesium, duration of oxytocin, \\npolyhydramnios, oligohydramnios, chorioamnionitis, abnormal \\nplacentation, gestational age, birth weightMultiple gestation, no serum uric acid \\nmeasured within 24 hours of CD, incomplete \\nmedical records, general anesthesia, pre-\\nexisting coagulation abnormalities, \\nhyperuricemia before pregnancy\\nPPH: EBL Atony: \\nundefinedMaternal age None Maternal age younger than 20 y, gestational \\nage less than 24 wk, multiple gestation, \\nspontaneous miscarriage, therapeutic abortion, \\nincomplete data\\nICD code Length of the second stage Length of pushing Age, height, BMI, smoking, induction of labor, oxytocin use during \\nfirst stage of labor, gestational age, birth weightNoncephalic presentation, CD, missing data\\nAuthor and Year Study Country Study Design Study Years No. of Patients Rate of Atonic PPH n (%) Mode of Delivery\\nLutomski et al, 201252 Ireland Retrospective cohort 1999–2009 649,019 Atonic PPH: 12,800 (2.0) VD CD\\nMarshall* et al, 201753 United States Retrospective cohort 2012–2013 1,352,691 Atonic PPH: 31,549 (2.3) VD CD\\nMehrabadi et al, 201354 Canada Retrospective cohort 2001–2010 371,193 Atonic PPH: Total number not reported VD CD\\nOberg et al, 201455 Sweden Retrospective cohort 1997–2009 538,332 women, 914,939 \\npregnanciesAtonic PPH: 17,818 (1.9) VD (atonic PPH data analyzed VD \\nonly)\\nRegalia et al, 200156 Italy Retrospective cohort 1995–1999 10,756 Atony: 427 (4.0) VD\\nSiddiqui* et al, 201757 United States Retrospective cohort 2002–2013 21,898,501 Atonic PPH: 499,189 (2.3) VD CD\\nTran et al, 201758 Canada Retrospective cohort 2013–2015 490 Atonic PPH: 80 (16) CD\\nVendittelli et al, 201659 France Prospective cohort 2011 129,110 Atonic PPH: 2,490 (1.9) VD CD\\nWaheed et al, 201360 Pakistan Retrospective cohort 2006–2009 8,713 Atonic PPH: 93 (1.1) VD CD\\nDefinition of Atonic PPH Risk Factors Assessed Covariates Adjusted For Exclusion Criteria\\nICD code Maternal age, hypertension, diabetes, mode of delivery, multiple \\ngestation, large fetus, episiotomy, genital tract trauma, prolonged \\nfirst stage, prolonged second stage, placental disorders, amniotic \\ncavity infection, polyhydramniosAge, marital status, socioeconomic status, \\nhypertension, diabetes, mode of delivery, \\ninduction of labor, multiple gestation, \\nmacrosomia, episiotomy, genital tract trauma, \\nprolonged labor, placenta previa, vasa previa, None\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 23}), Document(page_content='Author Manuscript Author Manuscript Author Manuscript Author ManuscriptEnde et al. Page 25Definition of Atonic PPH Risk Factors Assessed Covariates Adjusted For Exclusion Criteria\\nplacental abruption, chorioamnionitis, \\npolyhydramnios\\nICD code Race, parity None Incomplete data\\nICD code Maternal age, parity, birthweight, BMI, gestational age, smoking \\nstatus, multiple gestation, mode of delivery, prior CD, epidural \\nanalgesia, induction, oxytocin augmentation, uterine rupture, third or \\nfourth degree perineal tear, high vaginal laceration, cervical \\nlaceration, placenta previa, placental abruption, breech, transverse \\nlie, polyhydramnios, prolonged first stage, prolonged second stage, \\npreeclampsia, chorioamnionitis, forceps, vacuum, forceps and \\nvacuumLogistic regression included all risk factors \\nassessedIncomplete data\\nICD code History of PPH according to type Year of birth, age, civil status, country of \\norigin, chronic hypertension, diabetes, \\ncoagulopathy, leiomyomasMultiple gestation\\nPPH: undefined Maternal age, BMI, gestational age, parity, fetal weight, prior atony, \\nprior CD or uterine scar, uterine leiomyomas, preeclampsia, fever in \\nlabor, hydramnios, labor induction, labor velocity of progress, use of \\nKristeller maneuvers, nonvertex cephalic presentationLogistic regression included all risk factors \\nassessedMultiple gestation, placental risk factors for PPH, \\ngestational age less than 35 wk, CD, incomplete \\ndata Atony: undefined\\nICD code Ethnicity None Ethnicity other than Caucasian or Asian American \\nand Pacific Islander\\nPPH: EBL and drop in hct Length of the oxytocin recovery period, BMI Preeclampsia, chorioamnionitis, morbid \\nobesity, macrosomia, multiple gestation, \\npolyhydramnios, oxytocin induction, dose \\nand duration of oxytocin augmentationAny mode of delivery other than intrapartum CD \\nfor labor arrest, women not receiving 2h or more \\nof oxytocin augmentation during labor, gestational \\nage less than 37 or more than 41 wk, PPH cause \\nother than atony, incomplete data, general \\nanesthesiaAtony: uterotonic† or \\nother intervention‡\\nPPH: EBL Mode of delivery None None\\nAtony: undefined\\nPPH: EBL or change in \\nvital signsMode of delivery None None\\nAtony: medical team \\ndiagnosis, uterine \\nmassage, uterotonic†\\nAuthor and Year Study Country Study Design Study Years No. of Patients Rate of Atonic PPH n (%) Mode of Delivery\\nWetta* et al, 201361 United States Secondary analysis of randomized controlled trial 2008–2010 1,798 Atony: 118 (6.6) VD\\nDefinition of Atonic PPH Risk Factors Assessed Covariates Adjusted For Exclusion Criteria\\nPPH: EBL Atony: medical team \\ndiagnosisAge, oxytocin dose, BMI, ethnicity, race, augmentation, induction, \\nbirthweight, parity, preeclampsia, magnesium use, twin gestation, \\nchorioamnionitis, hydramnios, amnioinfusion, epidural anesthesia, \\nbreastfeeding, artificial rupture of membranesLogistic regression included all \\nrisk factors assessedGestational age less than 24 wk, CD, fetal \\ndemise, pulmonary edema, coagulopathy, \\ncardiomyopathy\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 24}), Document(page_content='Author Manuscript Author Manuscript Author Manuscript Author ManuscriptEnde et al. Page 26PPH, postpartum hemorrhage; VD, vaginal delivery; CD, cesarean delivery; ICD, International Classification of Diseases; HDP, hypertensive disorders of pregnancy; EBL, estimated blood loss; Hgb, \\nhemoglobin; BMI, body mass index; hct, hematocrit; NA, not applicable.*Article evaluates race or ethnicity as risk factor for atonic postpartum hemorrhage. Additional information regarding classifications of race or ethnicity used, who classified patients, whether options were \\ndefined by participants or investigators, reasons race or ethnicity were assessed, missing data, and “other” categories is presented in Appendix 4, http://links.lww.com/AOG/C163 .\\n†Uterotonic administration was in addition to standard oxytocin therapy.‡“Other interventions” included the use of a Bakri balloon, uterine massage, uterine artery embolization, or surgical interventions.\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 25}), Document(page_content='Author Manuscript Author Manuscript Author Manuscript Author ManuscriptEnde et al. Page 27Table 2.\\nSummary of Qualitative and Quantitative Results for Assessed Risk Factors\\nRisk Factors Qualitative Synthesis Result Meta-Analysis Result [OR (95% CI)]\\nHistory and demographic\\n Young age Unclear Not applicable\\n Old age Unclear Not applicable\\n Hispanic Likely 1.23 (1.20–1.25)\\n Asian Definite 1.39 (1.33–1.46)\\n Native American Not Not applicable\\n Black or African American Unclear 1.00 (0.78–1.29)\\n Nulliparity Likely Not applicable\\n Prior postpartum hemorrhage Definite 2.25 (1.02–4.96)\\n Prior cesarean delivery Unclear 1.12 (0.96–1.32)\\n Blood group O Not Not applicable\\n Calcium channel blocker exposure Not Not applicable\\n Antidepressant exposure Unclear Not applicable\\n Aspirin exposure Not Not applicable\\n Nonsteroidal antiinflammatory drug exposure Not Not applicable\\n Doxylamine exposure Not Not applicable\\nMaternal comorbidity\\n Hypertension Likely 1.84 (1.45–2.33)\\n Diabetes Definite 1.22 (1.08–1.39)\\n Anemia Unclear Not applicable\\n Obesity Not Not applicable\\n Leiomyomas Unclear 1.31 (0.55–3.10)\\n Liver disease Not Not applicable\\n Thrombocytopenia Not Not applicable\\n Asthma Not Not applicable\\n Elevated uric acid Unclear Not applicable\\n Alcohol use disorder Not Not applicable\\n Smoking Not Not applicable\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 26}), Document(page_content='Author Manuscript Author Manuscript Author Manuscript Author ManuscriptEnde et al. Page 28Risk Factors Qualitative Synthesis Result Meta-Analysis Result [OR (95% CI)]\\nPregnancy-related\\n Polyhydramnios Unclear 1.29 (0.94–1.76)\\n Multiple gestation Likely 2.16 (1.53–3.06)\\n Malpresentation Unclear Not applicable\\n Macrosomia Unclear 1.46 (1.35–1.57) (more than 4,000 g)\\n Placental disorders (previa or abruption) Definite 2.74 (1.57–4.79)\\n Antepartum hemorrhage Unclear Not applicable\\n Stillbirth Unclear Not applicable\\nLabor-related\\n Chorioamnionitis Likely 1.93 (1.56–2.39)\\n Uterine rupture Likely 2.35 (1.65–3.35)\\n Predelivery oxytocin exposure Likely 1.15 (0.95–1.40)\\n Induction of labor Likely 1.23 (1.10–1.39)\\n Prolonged labor Definite 1.76 (1.53–2.03) (all labor)\\n1.31 (1.24–1.38) (1st stage)\\n1.10 (0.82–1.48) (2nd stage)\\n Epidural Unclear 0.94 (0.72–1.23)\\n Magnesium exposure Not Not applicable\\n Tocolytic exposure Not Not applicable\\nDelivery-related\\n Gestational age Not Not applicable\\n Genital tract trauma Definite 1.67 (1.28–2.18) (perineal laceration)\\n2.19 (1.13–4.24) (high vaginal laceration)\\n5.70 (2.56–12.67) (cervical laceration)\\n Instrumented vaginal delivery Likely 1.67 (1.40–2.00)\\n Cesarean delivery Unclear Not applicable\\n Cord blood collection Not Not applicable\\n Breastfeeding Not Not applicable\\nOR, odds ratio.\\nObstet Gynecol . Author manuscript; available in PMC 2021 August 04.', metadata={'source': '..\\\\public\\\\rawDataset\\\\Risk Factors for Atonic Postpartum Hemorrhage.pdf', 'page': 27}), Document(page_content='  \\nWHO recommendations \\nfor the prevention  \\nand treatment of  \\npostpartum haemorrhage\\nFor more information, please contact:\\nDepartment of Reproductive Health and Research  \\nWorld Health Organization  \\nAvenue Appia 20, CH-1211 Geneva 27  \\nSwitzerland  \\nFax: +41 22 791 4171  \\nE-mail: reproductivehealth@who.int  \\nwww.who.int/reproductivehealth\\nMaternal, Newborn, Child and Adolescent Health\\nE-mail: mncah@who.intwww.who.int/maternal_child_adolescent\\n', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 0}), Document(page_content=' ', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 1}), Document(page_content='WHO recommendations for the  \\nprevention and treatment of  \\npostpartum haemorrhage', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 2}), Document(page_content='WHO Library Cataloguing-in-Publication Data\\n WHO recommendations for the prevention and treatment of postpartum haemorrhage.\\n 1.Postpartum hemorrhage – prevention and control. 2.Postpartum hemorrhage – therapy.  \\n 3.Obstetric labor complications. 4.Guideline.  I.World Health Organization.\\n\\t ISBN\\t978\\t92\\t4\\t154850\\t2\\t \\t \\t (NLM\\tclassification:\\t\\tWQ\\t330)\\n© World Health Organization 2012\\nAll rights reserved. Publications of the World Health Organization are available on the WHO web site \\n(www.who.int)\\tor\\tcan\\tbe\\tpurchased\\tfrom\\tWHO\\tPress,\\tWorld\\tHealth\\tOrganization,\\t20\\t Avenue\\tAppia,\\t1211\\t\\nGeneva\\t27,\\tSwitzerland\\t(tel.:\\t+41\\t22\\t791\\t3264;\\tfax:\\t+41\\t22\\t791\\t4857;\\te-mail:\\tbookorders@who.int).\\t  \\nRequests for permission to reproduce or translate WHO publications – whether for sale or for noncom -\\nmercial\\tdistribution\\t–\\tshould\\tbe\\taddressed\\tto\\tWHO\\tPress\\tthrough\\tthe\\tWHO\\tweb\\tsite\\t(http://www.who.int/\\nabout/licensing/copyright_form/en/index.html).\\nThe designations employed and the presentation of the material in this publication do not imply the \\nexpression\\tof\\tany\\topinion\\twhatsoever\\ton\\tthe\\tpart\\tof\\tthe\\tWorld\\tHealth\\tOrganization\\tconcerning\\tthe\\tlegal\\t\\nstatus\\tof\\tany\\tcountry,\\tterritory,\\tcity\\tor\\tarea\\tor\\tof\\tits\\tauthorities,\\tor\\tconcerning\\tthe\\tdelimitation\\tof\\tits\\t\\nfrontiers\\tor\\tboundaries.\\tDotted\\tlines\\ton\\tmaps\\trepresent\\tapproximate\\tborder\\tlines\\tfor\\twhich\\tthere\\tmay\\tnot\\t\\nyet be full agreement.\\nThe\\tmention\\tof\\tspecific\\tcompanies\\tor\\tof\\tcertain\\tmanufacturers’ \\tproducts\\tdoes\\tnot\\timply\\tthat\\tthey\\tare\\ten -\\ndorsed or recommended by the World Health Organization in preference to others of a similar nature that \\nare\\tnot\\tmentioned.\\tErrors\\tand\\tomissions\\texcepted,\\tthe\\tnames\\tof\\tproprietary\\tproducts\\tare\\tdistinguished\\t\\nby initial capital letters.\\nAll\\treasonable\\tprecautions\\thave\\tbeen\\ttaken\\tby\\tthe\\tWorld\\tHealth\\tOrganization\\tto\\tverify\\tthe\\tinformation\\t\\ncontained\\tin\\tthis\\tpublication.\\t\\tHowever,\\tthe\\tpublished\\tmaterial\\tis\\tbeing\\tdistributed\\twithout\\twarranty\\tof\\t\\nany\\tkind,\\teither\\texpressed\\tor\\timplied.\\t\\t The\\tresponsibility\\tfor\\tthe\\tinterpretation\\tand\\tuse\\tof\\tthe\\tmaterial\\t\\nlies with the reader.  In no event shall the World Health Organization be liable for damages arising from \\nits use.  \\nPrinted in Italy', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 3}), Document(page_content='Contents\\nAcknowledgements\\t 1\\nAbbreviations 2\\nExecutive summary 3\\nBox\\tA:\\t\\t Recommendations\\tfor\\tthe\\tprevention\\tof\\tPPH\\t 5\\nBox\\tB:\\t\\t Recommendations\\tfor\\tthe\\ttreatment\\tof\\tPPH\\t 6\\nBox\\tC:\\t\\t Recommendations\\ton\\torganization\\tof\\tcare\\t 7\\n1. Background 8\\n2. Methods 9\\n3. Results 12\\nBox\\t1:\\t\\t Recommendations\\tfor\\tthe\\tprevention\\tof\\tPPH\\t–\\tuterotonics\\t 15\\nBox\\t2:\\t\\t Recommendations\\tfor\\tthe\\tprevention\\tof\\tPPH\\t–\\tcord\\tmanagement\\t  \\nand\\tuterine\\tmassage\\t 16\\nTable\\t1:\\tRecommendation\\tstatus\\tof\\tthe\\tindividual\\tcomponents\\tof\\t  \\nthe\\tactive\\tmanagement\\tof\\tthe\\tthird\\tstage\\tof\\tlabour,\\tbased\\ton\\twho\\t  \\ndelivers the intervention 18\\nBox\\t3:\\t\\t Recommendations\\tfor\\tthe\\tprevention\\tof\\tPPH\\tin\\tcaesarean\\tsections\\t 18\\nBox\\t4:\\t\\t Recommendations\\tfor\\tthe\\ttreatment\\tof\\tPPH\\t–\\tuterotonics\\t 19\\nBox\\t5:\\t\\t Recommendations\\tfor\\tthe\\ttreatment\\tof\\tPPH\\t–\\tfluid\\tresuscitation\\t  \\nand\\ttranexamic\\tacid\\t 19\\nBox\\t6:\\t\\t Recommendations\\tfor\\tthe\\ttreatment\\tof\\tPPH\\t–\\tmanoeuvres\\tand\\t  \\nother procedures 20\\nBox\\t7:\\t\\t Recommendations\\tfor\\tthe\\ttreatment\\tof\\tretained \\tplacenta\\t 21\\nBox\\t8:\\t\\t Health \\tSystems\\tand\\t Organization\\tof\\tCare\\trecommendations\\t\\t 22\\nBox\\t9:\\t\\t Statements\\trelated\\t to\\ttopics\\tfor\\twhich\\tthere\\tis\\tinsufficient\\t  \\nevidence to issue a recommendation 23\\n4. Research implications 24\\n5. Dissemination and implementation of the guideline 25\\n6. Applicability issues 26\\n7. Updating the guideline 27\\nReferences 27\\nAnnex 1.  External experts, WHO staff involved in the preparation of  \\nthe guideline, and summary of declarations of interest 29\\nAnnex 2.  Critical outcomes for decision making 33\\nAnnex 3:  Summary of the considerations related to the strength of the recom -\\nmendations (Balance Worksheets) 34\\nBox\\t1.\\t\\t Summary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\t  \\nthe\\trecommendations\\t(Recommendations\\t1–5)\\t\\t 34', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 4}), Document(page_content='The\\tstandardized\\tcriteria\\tused\\tin\\tgrading\\tthe\\tevidence,\\tthe\\tnarrative\\tsummaries\\tof\\t\\nevidence and GRADE tables are not included in this document . This material has \\nbeen published in a separate document entitled “WHO recommendations for post \\xad\\npartum haemorrhage: evidence base ”\\tand\\tcan\\tbe\\taccessed\\tonline\\tat:\\twww.who.int/\\nreproductivehealth/publications/maternal_perinatal_health/9789241548502/en/Box\\t2.\\t\\t Summary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\t  \\nthe\\trecommendations\\t(Recommendations\\t6–10)\\t\\t 35\\nBox\\t3.\\t\\t Summary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\t  \\nthe\\trecommendations\\t(Recommendations\\t11–15)\\t\\t 36\\nBox\\t4.\\t\\t Summary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\t  \\nthe\\trecommendations\\t(Recommendations\\t16–20)\\t\\t 37\\nBox\\t5.\\t\\t Summary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\t  \\nthe\\trecommendations\\t(Recommendations\\t21–25)\\t\\t 38\\nBox\\t6.\\t\\t Summary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\t  \\nthe\\trecommendations\\t(Recommendations\\t26–30)\\t\\t 39\\nBox\\t7.\\t\\t Summary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\t  \\nthe\\trecommendations\\t(Recommendations\\t31–32)\\t\\t 40\\nBox\\t8.\\t\\t Template\\tfor\\tthe\\tsummary\\tof\\tconsiderations\\trelated\\tto\\t  \\nthe\\tstrength\\tof\\tthe\\trecommendations\\twith\\texplanations\\tfor\\t  \\ncompleting the template  41', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 5}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n1\\nAcknowledgements\\nWork\\ton\\tthis\\tguideline\\twas\\tinitiated\\tby\\t A.\\tMetin\\tGülmezoglu\\tand\\tJoão\\tPaulo\\tSouza,\\t\\nof\\tthe\\tWHO\\tDepartment\\tof\\tReproductive\\tHealth\\tand\\tResearch,\\tand\\tby\\tMatthews\\t\\nMathai,\\tof\\tthe\\tWHO\\tDepartment\\tof\\tMaternal,\\tNewborn,\\tChild\\tand\\t Adolescent\\tHealth.\\t\\nJoão\\tPaulo\\tSouza\\tcoordinated\\tthe\\tdevelopment\\tof\\tthe\\tpresent\\tguideline\\tand\\tdrafted\\t\\nthis\\tdocument.\\tEdgardo\\t Abalos\\tand\\tVirginia\\tDiaz,\\tof\\tthe\\tCentro\\tRosarino\\tde\\tEstudios\\t\\nPerinatales\\t(CREP),\\tRosario,\\t Argentina,\\treviewed\\tthe\\tscientific\\tevidence\\trelated\\tto\\t\\nthe\\tprevention\\tand\\ttreatment\\tof\\tPostpartum\\tHaemorrhage\\t(PPH)\\tand\\tproduced\\tthe\\t\\nGRADE\\ttables\\tused\\tin\\tthis\\tguideline.\\tNatasha\\tHezelgrave,\\tof\\tthe\\t Academic\\tWomen’s\\t\\nHealth\\tCentre,\\tKing’s\\tCollege\\tLondon\\t(KCL),\\tUnited\\tKingdom\\t(UK),\\tdrafted\\tthe\\tnar -\\nrative\\tsummaries\\tof\\tevidence.\\t The\\tGRADE\\ttables\\twere\\tdouble-checked\\tby\\tKanokwa -\\nroon\\tWatananirun\\t(Fon)\\tof\\tthe\\tUniversity\\tof\\tBangkok,\\t Thailand.\\t A.\\tMetin\\tGülmezo -\\nglu,\\tMatthews\\tMathai\\tand\\tEdgardo\\t Abalos\\tcommented\\ton\\tthe\\tdraft\\tdocument\\tbefore\\t\\nit was reviewed by Natasha Hezelgrave and participants at the WHO Technical \\nConsultation\\ton\\tthe\\tPrevention\\tand\\t Treatment\\tof\\tPPH\\t(see\\t Annex\\t1).\\t\\nThanks\\tto\\tZahida\\tQureshi,\\tof\\tthe\\tUniversity\\tof\\tNairobi,\\tKenya,\\tfor\\tserving\\tas\\tthe\\t\\nChairperson\\tof\\tthe\\t Technical\\tConsultation.\\tWe\\tacknowledge\\tgratefully\\tthe\\tvaluable\\t\\nfeedback\\tgiven\\tby\\ta\\tlarge\\tnumber\\tof\\tinternational\\tstakeholders\\tduring\\tthe\\tonline\\t\\nconsultation\\twhich\\ttook\\tplace\\tas\\tpart\\tof\\tthis\\tprocess.\\nWHO\\tis\\tgrateful\\tfor\\tthe\\tcontinued\\tsupport\\tof\\tthe\\tUnited\\tStates\\t Agency\\tfor\\tInter -\\nnational\\tDevelopment\\t(USAID)\\tin\\tthis\\tarea\\tof\\twork.\\tSpecial\\tthanks\\tare\\talso\\tdue\\tto\\t\\nGynuity\\tHealth\\tProjects\\tfor\\tproviding\\tadditional\\tfinancial\\tsupport\\tfor\\tthis\\tguideline\\t\\nwork.\\tWHO\\talso\\twishes\\tto\\tthank\\tthe\\tauthors\\tof\\tthe\\tsystematic\\treviews\\tused\\tin\\tthis\\t\\nguideline for their assistance and collaboration in updating them. WHO is also grate -\\nful\\tto\\tthe\\tCochrane\\tPregnancy\\tand\\tChildbirth\\tGroup,\\tespecially\\tthe\\tstaff\\tat\\ttheir\\t\\nLiverpool\\toffice\\tin\\tthe\\tUnited\\tKingdom,\\tfor\\ttheir\\tsupport\\tin\\tupdating\\tthe\\tCochrane\\t\\nreviews.', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 6}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n2\\nAbbreviations\\nAGREE Appraisal of Guidelines Research and Evaluation\\nAMTSL  Active Management of the Third Stage of Labour\\nCCT Controlled Cord Traction \\nCI\\t Confidence\\tInterval\\nGREAT\\t Guideline\\tdevelopment,\\tResearch\\tpriorities,\\tEvidence\\tsynthesis,\\t  \\n\\t\\t \\t Applicability\\tof\\tevidence,\\t Transfer\\tof\\tknowledge\\t(a\\tWHO\\tproject)\\nGDG Guideline Development Group\\nGRADE\\t Grading\\tof\\tRecommendations\\t Assessment,\\tDevelopment\\tand\\tEvaluation\\nHIV\\t Human\\timmunodeficiency\\tvirus\\nIM Intramuscular\\nIU\\t International\\tUnit\\nIV Intravenous\\nMCA\\t Maternal,\\tChild\\tand\\t Adolescent\\tDepartment\\nµg Microgram \\nMMR Maternal Mortality Ratio\\nPICO\\t Population,\\tInterventions,\\tComparisons,\\tand\\tOutcomes\\nPO\\t Per\\tOs\\t(orally)\\nPPH Postpartum Haemorrhage\\nRCT Randomized Controlled Trial\\nRevMan\\t Review\\tManager\\t(software)\\nRR\\t Relative\\tRisk\\nOR Odds Ratio\\nUSAID\\t United\\tStates\\t Agency\\tfor\\tInternational\\tDevelopment', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 7}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n3\\nExecutive summary\\nIntroduction\\nPostpartum\\tHaemorrhage\\t(PPH)\\tis\\tcommonly\\tdefined\\tas\\ta\\tblood\\tloss\\tof\\t500\\tml\\tor\\t\\nmore within 24 hours after birth. PPH is the leading cause of maternal mortality in \\nlow-income countries and the primary cause of nearly one quarter of all maternal \\ndeaths\\tglobally.\\tMost\\tdeaths\\tresulting\\tfrom\\tPPH\\toccur\\tduring\\tthe\\tfirst\\t24\\thours\\tafter\\t\\nbirth:\\tthe\\tmajority\\tof\\tthese\\tcould\\tbe\\tavoided\\tthrough\\tthe\\tuse\\tof\\tprophylactic\\tutero -\\ntonics during the third stage of labour and by timely and appropriate management. \\nImproving health care for women during childbirth in order to prevent and treat PPH \\nis an essential step towards the achievement of the Millennium Development Goals. \\nThe primary objective of this guideline therefore is to provide a foundation for the \\nstrategic policy and programme development needed to ensure the sustainable \\nimplementation of effective interventions for reducing the global burden of PPH. \\nGuideline development methods\\nThe procedures used in the development of this guideline are outlined in the “ WHO \\nhandbook for guideline development ”1.\\tBriefly,\\tthese\\tprocedures\\tare:\\t(i)\\tthe\\tidenti -\\nfication\\tof\\tquestions\\trelated\\tto\\tclinical\\tpractice\\tand\\thealth\\tpolicy\\tfor\\twhich\\tanswers\\t\\nare\\tneeded,\\t(ii)\\tthe\\tretrieval\\tof\\tup-to-date\\tresearch-based\\tevidence,\\t(iii)\\tthe\\tas -\\nsessment\\tand\\tsynthesis\\tof\\tevidence,\\t(iv)\\tthe\\tformulation\\tof\\trecommendations\\tusing\\t\\ninput\\tfrom\\ta\\twide\\trange\\tof\\tstakeholders,\\tand\\t(v)\\tthe\\tformulation\\tof\\tplans\\tfor\\tthe\\t\\ndissemination,\\timplementation,\\timpact\\tevaluation\\tand\\tupdating\\tof\\tthe\\tguideline.\\t\\nThe\\tscientific\\tevidence\\tfor\\tthe\\trecommendations\\twas\\tsynthesized\\tusing\\tthe\\tGrading\\t\\nof\\tRecommendations\\t Assessment,\\tDevelopment\\tand\\tEvaluation\\t(GRADE)\\tmethodol -\\nogy.\\tFor\\teach\\tof\\tthe\\tprevious\\tWHO\\trecommendations\\ton\\tPPH\\t(2007\\tand\\t2009)\\tand\\t\\nfor\\tall\\tthe\\tnewly-added\\tquestions,\\tevidence\\tprofiles\\twere\\tprepared\\tbased\\ton\\t22\\t\\nup-to-date systematic reviews. The revised and new recommendations were devel -\\noped\\tand\\tadopted\\tby\\tan\\tinternational\\tgroup\\tof\\texperts\\twho\\tparticipated\\tin\\tthe\\tWHO\\t\\nTechnical\\tConsultation\\ton\\tthe\\tPrevention\\tand\\t Treatment\\tof\\tPPH,\\theld\\tin\\tMontreux,\\t\\nSwitzerland,\\t6–8\\tMarch\\t2012.\\t\\nThe WHO Technical Consultation adopted 32 recommendations and these are shown \\nin\\tBoxes\\t A,\\tB\\tand\\tC.\\tFor\\teach\\trecommendation,\\tthe\\tquality\\tof\\tthe\\tsupporting\\tevi -\\ndence\\tis\\tgraded\\tas\\t‘very\\tlow’,\\t‘low’,\\t‘moderate’ \\tor\\t‘high’.\\t The\\tcontributing\\tstake -\\nholders\\tqualified\\tthe\\tstrength\\tof\\tthese\\trecommendations\\tby\\ttaking\\tthe\\tquality\\tof\\tthe\\t\\nevidence and other factors into account (including the values and preferences of \\nstakeholders,\\tthe\\tmagnitude\\tof\\teffect,\\tthe\\tbalance\\tof\\tbenefits\\tversus\\tdisadvantages,\\t\\nresource\\tusage,\\tand\\tthe\\tfeasibility\\tof\\teach\\trecommendation).\\t To\\tensure\\tthat\\teach\\t\\nrecommendation\\tis\\tcorrectly\\tunderstood\\tand\\tused\\tin\\tpractice,\\tadditional\\tremarks\\t\\nhave\\talso\\tbeen\\tincluded,\\tand\\tthese\\tare\\tnoted\\tin\\tthe\\tfull\\tdocument\\tbelow\\tthe\\trecom -\\nmendations.\\tReaders\\tshould\\trefer\\tto\\tthese\\tremarks\\tin\\tthe\\tfull\\tversion\\tof\\tthe\\tguide -\\nline if they are in any doubt about the meaning of each recommendation.\\n1 WHO handbook for guideline development .\\tGeneva,\\tWorld\\tHealth\\tOrganization,\\t2012.', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 8}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n4\\nRecommendations for PPH prevention\\nThe intrinsic contribution of each component of the ‘active management of the \\nthird\\tstage\\tof\\tlabour’ \\twas\\texamined\\tin\\tlight\\tof\\tnew\\tavailable\\tevidence,\\tand\\trelevant\\t\\nrecommendations were made. All women giving birth should be offered uterotonics \\nduring\\tthe\\tthird\\tstage\\tof\\tlabour\\tfor\\tthe\\tprevention\\tof\\tPPH;\\toxytocin\\t(IM/IV,\\t10\\tIU)\\t\\nis recommended as the uterotonic drug of choice. Other injectable uterotonics and \\nmisoprostol are recommended as alternatives for the prevention of PPH in settings \\nwhere\\toxytocin\\tis\\tunavailable.\\t The\\timportance\\tof\\tcontrolled\\tcord\\ttraction\\t(CCT)\\twas\\t\\nrevisited because of new evidence. This intervention is now regarded as optional \\nin\\tsettings\\twhere\\tskilled\\tbirth\\tattendants\\tare\\tavailable,\\tand\\tis\\tcontraindicated\\tin\\t\\nsettings\\twhere\\tskilled\\tattendants\\tdo\\tnot\\tassist\\twith\\tbirths.\\tEarly\\tcord\\tclamping\\tis\\t\\ngenerally contraindicated. Continuous uterine massage is not recommended as an \\nintervention\\tto\\tprevent\\tPPH\\tin\\twomen\\twho\\thave\\treceived\\tprophylactic\\toxytocin,\\t\\nas\\tit\\tmay\\tcause\\tmaternal\\tdiscomfort,\\trequire\\ta\\tdedicated\\thealth\\tprofessional,\\tand\\t\\nmay\\tnot\\tlead\\tto\\ta\\treduction\\tof\\tblood\\tloss.\\tHowever,\\tsurveillance\\tof\\tuterine\\ttonus\\t\\nthrough\\tabdominal\\tpalpation\\tis\\trecommended\\tin\\tall\\twomen\\tfor\\tearly\\tidentification\\t\\nof\\tpostpartum\\tuterine\\tatony.\\tIn\\tsummary,\\tthe\\tGuideline\\tDevelopment\\tGroup\\t(GDG)\\t\\nconsidered the use of uterotonics as the main intervention within the active man -\\nagement\\tof\\tthird\\tstage\\tof\\tlabour\\tpackage.\\tIn\\tthis\\tcontext,\\tthe\\tuse\\tof\\tmisoprostol\\tfor\\t\\nthe\\tprevention\\tof\\tPPH\\tby\\tcommunity\\thealth\\tcare\\tworkers\\tand\\tlay\\thealth\\tworkers\\tis\\t\\nsupported\\tin\\tsettings\\twhere\\tskilled\\tbirth\\tattendants\\tare\\tnot\\tpresent.\\nThe GDG also issued recommendations for reducing blood loss during the third stage \\nof\\tlabour\\tin\\tcaesarean\\tsections.\\tOxytocin\\tis\\tthe\\trecommended\\tuterotonic\\tdrug\\tfor\\t\\nthe prevention of PPH in caesarean sections. Cord traction is recommended in pref -\\nerence to manual removal when assisting placental delivery in caesarean sections.\\nRecommendations for PPH treatment\\nThe\\tuse\\tof\\tuterotonics\\t(oxytocin\\talone\\tas\\tthe\\tfirst\\tchoice)\\tplays\\ta\\tcentral\\trole\\tin\\t\\nthe\\ttreatment\\tof\\tPPH.\\tUterine\\tmassage\\tis\\trecommended\\tfor\\tthe\\ttreatment\\tof\\tPPH\\t\\nas\\tsoon\\tas\\tit\\tis\\tdiagnosed,\\tand\\tinitial\\tfluid\\tresuscitation\\twith\\tisotonic\\tcrystalloids\\tis\\t\\nrecommended.\\t The\\tuse\\tof\\ttranexamic\\tacid\\tis\\tadvised\\tin\\tcases\\tof\\trefractory\\tatonic\\t\\nbleeding or persistent trauma-related bleeding. The use of intrauterine balloon \\ntamponade is recommended for refractory bleeding or if uterotonics are unavail -\\nable.\\tBimanual\\tuterine\\tcompression,\\texternal\\taortic\\tcompression,\\tand\\tthe\\tuse\\tof\\t\\nnon-pneumatic\\tanti-shock\\tgarments\\tare\\trecommended\\tas\\ttemporizing\\tmeasures\\tuntil\\t\\nsubstantive care is available. If there is persistent bleeding and the relevant re -\\nsources\\tare\\tavailable,\\tuterine\\tartery\\tembolization\\tshould\\tbe\\tconsidered.\\tIf\\tbleeding\\t\\npersists,\\tdespite\\ttreatment\\twith\\tuterotonic\\tdrugs\\tand\\tother\\tconservative\\tinterven -\\ntions,\\tsurgical\\tintervention\\tshould\\tbe\\tused\\twithout\\tfurther\\tdelay.\\nIf\\tthe\\tthird\\tstage\\tof\\tlabour\\tlasts\\tmore\\tthan\\t30\\tminutes,\\tCCT \\tand\\tIV/IM\\toxytocin\\t\\n(10\\tIU)\\tshould\\tbe\\tused\\tto\\tmanage\\tthe\\tretained\\tplacenta.\\tIf\\tthe\\tplacenta\\tis\\tretained\\t\\nand\\tbleeding\\toccurs,\\tthe\\tmanual\\tremoval\\tof\\tthe\\tplacenta\\tshould\\tbe\\texpedited.\\t\\nWhenever\\tthe\\tmanual\\tremoval\\tof\\tthe\\tplacenta\\tis\\tundertaken,\\ta\\tsingle\\tdose\\tof\\tpro -\\nphylactic antibiotics is recommended.\\nThe GDG also issued recommendations related to the organization of PPH care. \\nHealth facilities delivering maternity services should adopt formal protocols for the \\nprevention and treatment of PPH and for patient referral. The use of PPH treatment ', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 9}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n5\\nsimulations for pre-service and in-service training programmes was recommended. \\nFinally,\\tthe\\tGDG\\trecommended\\tthat\\tthe\\tuse\\tof\\tuterotonics\\tfor\\tthe\\tprevention\\tof\\tPPH\\t\\nshould\\tbe\\tmonitored\\tand\\ta\\tspecific\\tindicator\\twas\\tsuggested.\\nBox A: Recommendations for the prevention of PPH\\n1. The use of uterotonics for the prevention of PPH during the third stage of labour is recom -\\nmended\\tfor\\tall\\tbirths.\\t(Strong\\trecommendation,\\tmoderate-quality\\tevidence)\\n2. Oxytocin\\t(10\\tIU,\\tIV/IM)\\tis\\tthe\\trecommended\\tuterotonic\\tdrug\\tfor\\tthe\\tprevention\\tof\\tPPH.\\t\\n(Strong\\trecommendation,\\tmoderate-quality\\tevidence)\\n3. In\\tsettings\\twhere\\toxytocin\\tis\\tunavailable,\\tthe\\tuse\\tof\\tother\\tinjectable\\tuterotonics\\t(if\\tappro -\\npriate\\tergometrine/methylergometrine\\tor\\tthe\\tfixed\\tdrug\\tcombination\\tof\\toxytocin\\tand\\tergo -\\nmetrine)\\tor\\toral\\tmisoprostol\\t(600  µg)\\tis\\trecommended.\\t(Strong\\trecommendation,\\tmoderate-\\nquality\\tevidence)\\n4. In\\tsettings\\twhere\\tskilled\\tbirth\\tattendants\\tare\\tnot\\tpresent\\tand\\toxytocin\\tis\\tunavailable,\\tthe\\t\\nadministration\\tof\\tmisoprostol\\t(600  µg\\tPO)\\tby\\tcommunity\\thealth\\tcare\\tworkers\\tand\\tlay\\thealth\\t\\nworkers\\tis\\trecommended\\tfor\\tthe\\tprevention\\tof\\tPPH.\\t(Strong\\trecommendation,\\tmoderate-\\nquality\\tevidence)\\n5. In\\tsettings\\twhere\\tskilled\\tbirth\\tattendants\\tare\\tavailable,\\tCCT \\tis\\trecommended\\tfor\\tvaginal\\t\\nbirths if the care provider and the parturient woman regard a small reduction in blood loss \\nand\\ta\\tsmall\\treduction\\tin\\tthe\\tduration\\tof\\tthe\\tthird\\tstage\\tof\\tlabour\\tas\\timportant\\t(Weak\\trecom -\\nmendation,\\thigh-quality\\tevidence)\\t\\n6.\\tIn\\tsettings\\twhere\\tskilled\\tbirth\\tattendants\\tare\\tunavailable,\\tCCT \\tis\\tnot\\trecommended.\\t(Strong\\t\\nrecommendation,\\tmoderate-quality\\tevidence)\\n7. Late\\tcord\\tclamping\\t(performed\\tafter\\t1\\tto\\t3\\tminutes\\tafter\\tbirth)\\tis\\trecommended\\tfor\\tall\\tbirths\\t\\nwhile\\tinitiating\\tsimultaneous\\tessential\\tnewborn\\tcare.\\t(Strong\\trecommendation,\\tmoderate-\\nquality\\tevidence)\\n8. Early\\tcord\\tclamping\\t(<1\\tminute\\tafter\\tbirth)\\tis\\tnot\\trecommended\\tunless\\tthe\\tneonate\\tis\\tas -\\nphyxiated\\tand\\tneeds\\tto\\tbe\\tmoved\\timmediately\\tfor\\tresuscitation.\\t(Strong\\trecommendation,\\t\\nmoderate-quality\\tevidence)\\n9. Sustained uterine massage is not recommended as an intervention to prevent PPH in women \\nwho\\thave\\treceived\\tprophylactic\\toxytocin.\\t(Weak\\trecommendation,\\tlow-quality\\tevidence)\\n10. Postpartum\\tabdominal\\tuterine\\ttonus\\tassessment\\tfor\\tearly\\tidentification\\tof\\tuterine\\tatony\\tis\\t\\nrecommended\\tfor\\tall\\twomen.\\t(Strong\\trecommendation,\\tvery-low-quality\\tevidence)\\n11. Oxytocin\\t(IV\\tor\\tIM)\\tis\\tthe\\trecommended\\tuterotonic\\tdrug\\tfor\\tthe\\tprevention\\tof\\tPPH\\tin\\tcaesar -\\nean\\tsection.\\t(Strong\\trecommendation,\\tmoderate-quality\\tevidence)\\n12. Controlled cord traction is the recommended method for removal of the placenta in caesar -\\nean\\tsection.\\t(Strong\\trecommendation,\\tmoderate-quality\\tevidence)', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 10}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n6\\nBox B: Recommendations for the treatment of PPH\\n13. Intravenous\\toxytocin\\talone\\tis\\tthe\\trecommended\\tuterotonic\\tdrug\\tfor\\tthe\\ttreatment\\tof\\tPPH.\\t\\n(Strong\\trecommendation,\\tmoderate-quality\\tevidence)\\n14. If\\tintravenous\\toxytocin\\tis\\tunavailable,\\tor\\tif\\tthe\\tbleeding\\tdoes\\tnot\\trespond\\tto\\toxytocin,\\tthe\\tuse\\t\\nof\\tintravenous\\tergometrine,\\toxytocin-ergometrine\\tfixed\\tdose,\\tor\\ta\\tprostaglandin\\tdrug\\t(includ -\\ning\\tsublingual\\tmisoprostol,\\t800\\t µg)\\tis\\trecommended.\\t(Strong\\trecommendation,\\tlow-quality\\t\\nevidence)\\n15. The use of isotonic crystalloids is recommended in preference to the use of colloids for the \\ninitial\\tintravenous\\tfluid\\tresuscitation\\tof\\twomen\\twith\\tPPH.\\t(Strong\\trecommendation,\\tlow-qual -\\nity\\tevidence)\\n16.\\tThe\\tuse\\tof\\ttranexamic\\tacid\\tis\\trecommended\\tfor\\tthe\\ttreatment\\tof\\tPPH\\tif\\toxytocin\\tand\\tother\\t\\nuterotonics fail to stop bleeding or if it is thought that the bleeding may be partly due to \\ntrauma.\\t(Weak\\trecommendation,\\tmoderate-quality\\tevidence)\\n17. Uterine\\tmassage\\tis\\trecommended\\tfor\\tthe\\ttreatment\\tof\\tPPH.\\t(Strong\\trecommendation,\\tvery-\\nlow-quality\\tevidence)\\n18. If\\twomen\\tdo\\tnot\\trespond\\tto\\ttreatment\\tusing\\tuterotonics,\\tor\\tif\\tuterotonics\\tare\\tunavailable,\\t\\nthe use of intrauterine balloon tamponade is recommended for the treatment of PPH due to \\nuterine\\tatony.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n19. If\\tother\\tmeasures\\thave\\tfailed\\tand\\tif\\tthe\\tnecessary\\tresources\\tare\\tavailable,\\tthe\\tuse\\tof\\tuter -\\nine\\tartery\\tembolization\\tis\\trecommended\\tas\\ta\\ttreatment\\tfor\\tPPH\\tdue\\tto\\tuterine\\tatony.\\t(Weak\\t\\nrecommendation,\\tvery-low-quality\\tevidence)\\n20. If bleeding does not stop in spite of treatment using uterotonics and other available conserva -\\ntive\\tinterventions\\t(e.g.\\tuterine\\tmassage,\\tballoon\\ttamponade),\\tthe\\tuse\\tof\\tsurgical\\tinterven -\\ntions\\tis\\trecommended.\\t(Strong\\trecommendation,\\tvery-low-quality\\tevidence)\\n21. The use of bimanual uterine compression is recommended as a temporizing measure until ap -\\npropriate care is available for the treatment of PPH due to uterine atony after vaginal deliv -\\nery.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n22. The\\tuse\\tof\\texternal\\taortic\\tcompression\\tfor\\tthe\\ttreatment\\tof\\tPPH\\tdue\\tto\\tuterine\\tatony\\tafter\\t\\nvaginal birth is recommended as a temporizing measure until appropriate care is available. \\n(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n23. The\\tuse\\tof\\tnon-pneumatic\\tanti-shock\\tgarments\\tis\\trecommended\\tas\\ta\\ttemporizing\\tmeasure\\t\\nuntil\\tappropriate\\tcare\\tis\\tavailable.\\t(Weak\\trecommendation,\\tlow-quality\\tevidence)\\n24. The\\tuse\\tof\\t uterine\\tpacking\\tis\\tnot\\trecommended\\t for\\tthe\\ttreatment\\t of\\tPPH\\tdue\\tto\\tuterine\\t atony\\t\\nafter\\tvaginal\\tbirth.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n25. If\\tthe\\tplacenta\\tis\\tnot\\texpelled\\tspontaneously,\\tthe\\tuse\\tof\\tIV/IM\\toxytocin\\t(10\\tIU)\\tin\\tcombina -\\ntion\\twith\\tcontrolled\\tcord\\ttraction\\tis\\trecommended.\\t(Weak\\trecommendation,\\tvery-low-quality\\t\\nevidence)\\n26.\\tThe use of ergometrine for the management of retained placenta is not recommended as this \\nmay\\tcause\\ttetanic\\tuterine\\tcontractions\\twhich\\tmay\\tdelay\\tthe\\texpulsion\\tof\\tthe\\tplacenta.\\t(Weak\\t\\nrecommendation,\\tvery-low-quality\\tevidence)\\n27. The\\tuse\\tof\\tprostaglandin\\tE2\\talpha\\t(dinoprostone\\tor\\tsulprostone)\\tfor\\tthe\\tmanagement\\tof\\tre -\\ntained\\tplacenta\\tis\\tnot\\trecommended.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n28. A\\tsingle\\tdose\\tof\\tantibiotics\\t(ampicillin\\tor\\tfirst-generation\\tcephalosporin)\\tis\\trecommended\\tif\\t\\nmanual\\tremoval\\tof\\tthe\\tplacenta\\tis\\tpractised.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevi -\\ndence)', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 11}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n7\\nBox C: Organization of care\\n29. The use of formal protocols by health facilities for the prevention and treatment of PPH is \\nrecommended.\\t(Weak\\trecommendation,\\tmoderate-quality\\tevidence)\\n30. The use of formal protocols for referral of women to a higher level of care is recommended \\nfor\\thealth\\tfacilities.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n31. The use of simulations of PPH treatment is recommended for pre-service and in-service train -\\ning\\tprogrammes.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n32. Monitoring the use of uterotonics after birth for the prevention of PPH is recommended as \\na\\tprocess\\tindicator\\tfor\\tprogrammatic\\tevaluation.\\t(Weak\\trecommendation,\\tvery-low-quality\\t\\nevidence)', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 12}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n8\\n1. Background\\nPostpartum\\tHaemorrhage\\t(PPH)\\tis\\tcommonly\\tdefined\\tas\\ta\\tblood\\tloss\\tof\\t500\\tml\\tor\\t\\nmore\\twithin\\t24\\thours\\tafter\\tbirth,\\twhile\\tsevere\\tPPH\\tis\\tdefined\\tas\\ta\\tblood\\tloss\\tof\\t\\n1000\\tml\\tor\\tmore\\twithin\\tthe\\tsame\\ttimeframe.\\tPPH\\taffects\\tapproximately\\t2%\\tof\\tall\\t\\nwomen\\twho\\tgive\\tbirth:\\tit\\tis\\tassociated\\tnot\\tonly\\twith\\tnearly\\tone\\tquarter\\tof\\tall\\tma -\\nternal deaths globally but is also the leading cause of maternal mortality in most \\nlow-income\\tcountries.\\tPPH\\tis\\ta\\tsignificant\\tcontributor\\tto\\tsevere\\tmaternal\\tmorbidity\\t\\nand long-term disability as well as to a number of other severe maternal conditions \\ngenerally\\t associated\\t with\\tmore\\tsubstantial\\t blood\\tloss,\\tincluding\\t shock\\tand\\t organ\\tdys -\\nfunction.\\t(1–3)\\nUterine\\tatony\\tis\\tthe\\tmost\\tcommon\\tcause\\tof\\tPPH,\\tbut\\tgenital\\ttract\\ttrauma\\t(i.e.\\tvagi -\\nnal\\tor\\tcervical\\tlacerations),\\tuterine\\trupture,\\tretained\\tplacental\\ttissue,\\tor\\tmaternal\\t\\ncoagulation disorders may also result in PPH. Although the majority of women who \\nexperience\\tPPH\\tcomplications\\thave\\tno\\tidentifiable\\tclinical\\tor\\thistorical\\trisk\\tfactors,\\t\\ngrand\\tmultiparity\\tand\\tmultiple\\tgestation\\tare\\tassociated\\twith\\tan\\tincreased\\trisk\\tof\\t\\nbleeding\\tafter\\tbirth.\\tPPH\\tmay\\tbe\\taggravated\\tby\\tpre-existing\\tanaemia\\tand,\\tin\\tsuch\\t\\ninstances,\\tthe\\tloss\\tof\\ta\\tsmaller\\tvolume\\tof\\tblood\\tmay\\tstill\\tresult\\tin\\tadverse\\tclinical\\t\\nsequelae.\\t(4)\\nDuring\\tthe\\tsecond\\thalf\\tof\\tthe\\t20th\\tcentury,\\ta\\tpackage\\tof\\tinterventions\\tperformed\\t\\nduring the third stage of labour became the cornerstone for the prevention of \\nPPH.\\tThis\\tapproach\\tbecame\\tknown\\tas\\tthe\\t“active\\tmanagement\\tof\\tthe\\tthird\\tstage\\t\\nof\\tlabour”\\tand\\tconsisted\\tinitially\\tof\\tthe\\tfollowing\\tcomponents:\\tthe\\tadministration\\t\\nof\\ta\\tprophylactic\\tuterotonic\\tafter\\tthe\\tdelivery\\tof\\ta\\tbaby,\\tearly\\tcord\\tclamping\\tand\\t\\ncutting,\\tand\\tthe\\tcontrolled\\ttraction\\tof\\tthe\\tumbilical\\tcord.\\tUterine\\tmassage\\tis\\talso\\t\\nfrequently included as part of the active management of the third stage of labour. \\nIn contrast to active\\tmanagement,\\t expectant  management involves instead waiting \\nfor signs of placenta separation and allows for the placenta to be delivered sponta -\\nneously,\\tor\\taided\\tby\\tnipple\\tstimulation\\tor\\tgravity.\\tCompared\\twith\\texpectant\\tman -\\nagement,\\tthe\\tactive\\tmanagement\\tof\\tthe\\tthird\\tstage\\tof\\tlabour\\tis\\tassociated\\twith\\ta\\t\\nsubstantial\\treduction\\tin\\tthe\\toccurrence\\tof\\tPPH.\\t(5)\\nIt\\tis\\tgenerally\\tassumed\\tthat\\tby\\tpreventing\\tand\\ttreating\\tPPH,\\tmost\\tPPH-associated\\t\\ndeaths could be avoided. The prevention and treatment of PPH are therefore \\nvital steps towards improving the health care of women during childbirth and the \\nachievement\\tof\\tthe\\tMillennium\\tDevelopment\\tGoals.\\t To\\treach\\tthese\\tobjectives,\\t\\nhealth\\tworkers\\tin\\tdeveloping\\tcountries\\tshould\\tbe\\tgiven\\taccess\\tto\\tappropriate\\tmedi -\\ncations and be trained in procedures relevant to the management of PPH. Countries \\nalso need evidence-based guidance to inform their health policies and improve their \\nhealth outcomes. \\nGiven\\tthe\\tavailability\\tof\\tnew\\tscientific\\tevidence\\trelated\\tto\\tthe\\tprevention\\tand\\ttreat -\\nment\\tof\\tPPH,\\tthe\\taim\\tof\\tthis\\tdocument\\tis\\tto\\trevise\\tprevious\\tWHO\\trecommendations\\t\\nfor the prevention and treatment of PPH and to add new recommendations. The \\nprimary goal of this guideline is to provide a foundation for the implementation of \\nstrategic policy and programme developments for interventions shown to have been \\neffective in reducing the burden of PPH. Health professionals responsible for de -\\nveloping national and local protocols and health policies constitute the main target \\naudience\\tof\\tthis\\tdocument.\\tObstetricians,\\tmidwives,\\tgeneral\\tmedical\\tpractitioners,\\t\\nhealth\\tcare\\tmanagers\\tand\\tpublic\\thealth\\tpolicy-makers,\\tparticularly\\tin\\tunder-re -', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 13}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n9\\nsourced settings are also targeted. The guidance provided is evidence-informed and \\ncovers topics related to the management of PPH that were selected and prioritized \\nby\\tan\\tinternational,\\tmultidisciplinary\\tgroup\\tof\\thealth\\tcare\\tworkers,\\tconsumers\\tand\\t\\nother\\tstakeholders.\\t This\\tdocument\\testablishes\\tgeneral\\tprinciples\\tof\\tPPH\\tcare\\tand\\tit\\t\\nis intended to inform the development of protocols and health policies related to \\nPPH. This document is not intended to provide a comprehensive practical guide for \\nthe prevention and treatment of PPH.\\n2. Methods\\nThis guideline is an update of the “ WHO recommendations for the prevention of \\nPPH” published in 2007 and the “ WHO guidelines for the management of PPH and \\nretained placenta ”\\tpublished\\tin\\t2009\\t(6,7).\\t This\\tdocument\\trepresents\\tWHO’s\\tnor -\\nmative support for using evidence-informed policies and practices in all countries. \\nThe\\tguideline\\tforms\\tpart\\tof\\ta\\tWHO\\tknowledge-to-action\\tproject\\tentitled\\tGREAT \\t\\n(Guideline\\tdevelopment,\\tResearch\\tpriorities,\\tEvidence\\tsynthesis,\\t Applicability\\tof\\t\\nevidence,\\t Transfer\\tof\\tknowledge)\\t(8)\\tand\\twas\\tdeveloped\\tusing\\tstandardized\\toperat -\\ning procedures in accordance with the process described in the “WHO handbook for \\nguideline development ” (9).\\tIn\\tsummary,\\tthe\\tprocess\\tincluded:\\t(i)  the\\tidentification\\t\\nof\\tcritical\\tquestions\\tand\\tcritical\\toutcomes,\\t(ii)  the\\tretrieval\\tof\\tthe\\tevidence,\\t(iii)\\tthe\\t\\nassessment\\tand\\tsynthesis\\tof\\tevidence,\\t(iv)  the\\tformulation\\tof\\trecommendations,\\tand\\t\\n(v) planning\\tfor\\tthe\\tdissemination,\\timplementation,\\timpact\\tevaluation\\tand\\tupdating\\t\\nof the guideline.\\nTwo\\ttechnical\\tgroups\\thave\\tworked\\tin\\tthe\\tdevelopment\\tof\\tthis\\tguideline.\\t A\\tsmall\\t\\noperative\\tgroup\\tcomposed\\tof\\tstaff\\tfrom\\tthe\\tWHO’s\\tDepartment\\tof\\tReproductive\\t\\nHealth\\tand\\tResearch,\\tand\\tDepartment\\tof\\tMaternal,\\tNewborn,\\tChild\\tand\\t Adolescent\\t\\nHealth\\t(MCA),\\tas\\twell\\tas\\ttwo\\texternal\\texperts\\t(see\\t Annex\\t1\\t–\\t The\\tguideline\\tsteer -\\ning\\tgroup)\\tand\\ta\\tlarger\\tgroup\\twith\\tinternational\\tstakeholders\\tincluding\\tmidwives,\\t\\nobstetricians,\\tneonatologists,\\tresearchers,\\texperts\\tin\\tresearch\\tsynthesis,\\texperts\\tin\\t\\nhealth\\tcare\\tprogrammes,\\tand\\tconsumer\\trepresentatives\\t(the\\tGuideline\\tDevelopment\\t\\nGroup\\t–\\tGDG).\\t The\\tguideline\\tsteering\\tgroup\\twas\\tformed\\tin\\tthe\\tvery\\tbeginning\\tof\\tthe\\t\\nproject and reviewed the previous WHO guidelines on prevention and treatment of \\nPPH\\t(6,7).\\t This\\tgroup\\tprepared\\ta\\tlist\\tof\\tpotential\\tadditional\\tquestions\\trelated\\tto\\tthe\\t\\nprevention\\tand\\ttreatment\\tof\\tPPH.\\tNext,\\tthe\\tGDG\\treviewed\\tand\\tprioritized\\tthe\\tdraft\\t\\nquestions. The guideline steering group then produced a list of all the questions to \\nbe addressed. This included both questions from the earlier versions of the guideline \\nas well as new ones. The guideline steering group also adopted the outcomes used \\nin\\tthe\\t2007\\tand\\t2009\\tguideline\\tdocuments.\\t These\\toutcomes,\\tas\\tbefore,\\twere\\trated\\t\\non\\ta\\tscale\\tfrom\\t1\\tto\\t9.\\t A\\tquestion\\tor\\toutcome\\twas\\tdefined\\tas\\t‘critical’ \\tif\\tit\\twas\\tgiven\\t\\nan\\taverage\\tscore\\tof\\t7\\tor\\tmore.\\tQuestions\\tand\\toutcomes\\twith\\ta\\tscore\\tof\\tbetween\\t\\n4\\tand\\t6\\twere\\tconsidered\\t‘important\\tbut\\tnot\\tcritical’,\\twhile\\tthose\\twith\\ta\\tscore\\tlower\\t\\nthan 4 were not considered to be important for the purposes of the guideline  \\n(Annex\\t2).', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 14}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n10\\nCochrane\\tsystematic\\treviews\\tof\\trandomized\\tcontrolled\\ttrials\\t(RCTs)\\twere\\tthe\\tpri -\\nmary source of evidence for the recommendations2.\\tUsing\\tthe\\tassembled\\tlist\\tof\\t\\nquestions\\tand\\toutcomes,\\tthe\\tguideline\\tsteering\\tgroup\\tidentified\\tCochrane\\tsystematic\\t\\nreviews that were either relevant or potentially relevant and then evaluated wheth -\\ner\\tany\\tneeded\\tupdating.\\t A\\treview\\twas\\tconsidered\\tto\\tbe\\toutdated\\tif\\tthe\\tlast\\tspecified\\t\\ndate\\tfor\\tnew\\ttrial\\tsearches\\twas\\ttwo\\tyears\\tago\\tor\\tmore,\\tor\\tif\\tthere\\twere\\trelevant\\t\\nstudies\\tstill\\tawaiting\\tassessment,\\tas\\tidentified\\tby\\tthe\\tstandard\\tsearch\\tprocedures\\tof\\t\\nthe\\tCochrane\\tPregnancy\\tand\\tChildbirth\\tGroup.\\tUpdates\\twere\\tperformed\\tusing\\tspe -\\ncific\\tstandard\\tsearch\\tstrategies.\\t The\\tcorresponding\\tauthors\\tof\\tthe\\toutdated\\treviews\\t\\nwere\\tinvited\\tto\\tupdate\\tthem\\twithin\\ta\\tspecified\\ttime\\tperiod.\\tIn\\tinstances\\tin\\twhich\\t\\nthe\\tcorresponding\\tauthors\\twere\\tunable\\tto\\tdo\\tso,\\tthe\\tupdates\\twere\\tundertaken\\tby\\t\\nmembers of the guideline steering group. The search strategies employed to identify \\nthe\\ttrials\\tand\\tthe\\tspecific\\tcriteria\\tfor\\ttrial\\tinclusion\\tand\\texclusion\\tare\\tdescribed\\tin\\t\\nthe individual systematic reviews. A systematic review of literature that included \\nnon-randomized trials was carried out by the guideline steering group members \\nwhen\\trandomized-trial\\tdata\\trelated\\tto\\tspecific\\tquestions\\twere\\tscarce.\\nThe\\tfollowing\\tprocedures\\twere\\tused\\tto\\textract\\tthe\\tevidence\\tfor\\tthis\\tguideline\\tfrom\\t\\neach\\tof\\tthese\\tsystematic\\treviews:\\tfirst,\\tthe\\tmost\\trecent\\tversion\\tof\\tthe\\tReview\\t\\nManager\\t(RevMan)\\tfile\\twas\\tretrieved\\tfrom\\tthe\\tCochrane\\tPregnancy\\tand\\tChildbirth\\t\\nCochrane\\tGroup\\tand\\tcustomized\\tto\\treflect\\tthe\\tkey\\tcomparisons\\tand\\toutcomes\\t(those\\t\\nthat\\twere\\tnot\\trelevant\\tto\\tthe\\tguideline\\twere\\texcluded).\\t Then\\tthe\\tRevMan\\tfile\\twas\\t\\nexported\\tto\\tthe\\tGRADE\\tprofiler\\tsoftware\\t(Grading\\tof\\tRecommendations\\t Assessment,\\t\\nDevelopment\\t and\\tEvaluation)\\t and\\tGRADE\\tcriteria\\t were\\tused\\tto\\tcritically\\t appraise\\t the\\t\\nretrieved\\tscientific\\tevidence.\\tFinally,\\tevidence\\tprofiles\\t(in\\tthe\\tform\\tof\\tGRADE\\ttables)\\t\\nwere prepared for each comparison. An online content management system devel -\\noped\\tfor\\tthe\\tGREAT \\tproject,\\tnamely\\tthe\\t Guideline Production System,  was used to \\nhandle\\tand\\tshare\\telectronic\\tfiles.\\nThe evidence presented in the GRADE tables was derived from a larger body of data \\nextracted\\tprimarily\\tfrom\\tCochrane\\treviews\\twhich,\\tin\\tmany\\tcases,\\tcontained\\tmultiple\\t\\ncomparisons\\t(Evidence\\tBase\\t(EB)\\t Tables\\t1\\tto\\t70).\\tEach\\tGRADE\\ttable\\trelates\\tto\\tone\\t\\nspecific\\tquestion\\tor\\tcomparison,\\tbut\\tsome\\tGRADE\\ttables\\tdo\\tnot\\tcontain\\tdata\\tfor\\tall\\t\\ncritical outcomes. This is because data for those outcomes were not available in the \\nCochrane reviews. The raw data which constitute the basis of the GRADE tables are \\nnot\\tincluded\\tin\\tthis\\tdocument,\\tbut\\treaders\\tinterested\\tin\\thow\\tthese\\tGRADE\\ttables\\t\\nwere constructed may request access to this information. The guideline steering \\ngroup\\tused\\tthe\\tinformation\\tpresented\\tin\\tthe\\tGRADE\\ttables\\tto\\tcheck\\tif\\tany\\texisting\\t\\nrecommendations\\t(included\\tin\\tthe\\t2007\\tor\\t2009\\tdocuments)\\tneeded\\tto\\tbe\\trevised,\\t\\nand to draft recommendations that related to the new questions. Each recom -\\nmendation was allocated to a thematic module which included the narrative sum -\\nmaries of evidence and the relevant GRADE tables. The standardized criteria used \\nin\\tgrading\\tthe\\tevidence\\tand\\tthe\\tthematic\\tmodules\\t(including\\tthe\\tGRADE\\ttables)\\t\\nare not included in this document . They have been published separately online \\nin a document entitled “ WHO recommendations for preventing and treating PPH: \\nevidence base ”\\t(www.who.int/reproductivehealth/publications/maternal_perina -\\ntal_health/9789241548502/en).\\n2\\tAs\\tpart\\tof\\tthe\\tCochrane\\tpre-publication\\teditorial\\tprocess,\\treviews\\tare\\tcommented\\ton\\tby\\tthree\\tpeers\\t\\n(one\\teditor\\tand\\ttwo\\treferees\\texternal\\tto\\tthe\\teditorial\\tteam)\\tand\\tthe\\tGroup’s\\tStatistical\\t Adviser\\t(see\\t\\nhttp://www.cochrane.org/cochrane-reviews ).\\t“The Cochrane Handbook for Systematic Reviews of Inter \\xad\\nventions ” describes in detail the process of preparing and maintaining Cochrane systematic reviews on \\nthe effects of health care interventions.', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 15}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n11\\nA preliminary online consultation was held to review the draft recommendations. \\nThe draft recommendations and supporting evidence were made available to a large \\nnumber\\tof\\tinternational\\tstakeholders\\twho\\twere\\tthen\\tasked\\tto\\trespond\\tto\\tan\\tonline\\t\\nsurvey.\\tIn\\taddition,\\tthe\\tpreliminary\\tonline\\tconsultation\\tidentified\\tother\\tprevious\\t\\nrecommendations that needed to be discussed at the WHO Technical Consultation \\non\\tthe\\tPrevention\\tand\\t Treatment\\tof\\tPPH\\theld\\tin\\tMontreux,\\tSwitzerland,\\t6–8\\tMarch\\t\\n2012.\\tA\\tsubset\\tof\\tthe\\tinternational\\tgroup\\tof\\texperts\\t(who\\thad\\tparticipated\\tin\\tthe\\t\\nonline\\tconsultations)\\tand\\tother\\tadditional\\texperts\\twere\\tinvited\\tto\\tattend\\tthe\\t Techni -\\ncal\\tConsultation\\t(see\\t Annex\\t1\\tfor\\ta\\tfull\\tlist\\tof\\tparticipants).\\t The\\tdraft\\trecommen -\\ndations,\\tthe\\tnarrative\\tsummaries\\tof\\tevidence,\\tthe\\tGRADE\\ttables\\tfor\\tthe\\tnew\\tand\\t\\nprevious\\trecommendations,\\tand\\tother\\trelated\\tdocuments\\twere\\tprovided\\tin\\tadvance\\t\\nto\\tparticipants.\\tBalance\\tworksheets\\twere\\tused\\tduring\\tthe\\t Technical\\tConsultation\\tto\\t\\nsummarize\\tthe\\tvalues,\\tpreferences\\tand\\tjudgements\\tmade\\tabout\\tthe\\tstrength\\tof\\tthe\\t\\nnew and revised recommendations.\\nDeclaration of interest by participants in the WHO Technical Con -\\nsultation\\nAccording\\tto\\tWHO\\tregulations,\\tall\\texperts\\tmust\\tdeclare\\ttheir\\trelevant\\tinterests\\tprior\\t\\nto participation in WHO meetings. All GDG members and participants were therefore \\nrequired to complete a Declaration of Interest Form before the meeting. These were \\nreviewed by the guideline steering group before the group composition and invita -\\ntions\\twere\\tfinalized.\\t The\\texternal\\tadvisers\\talso\\tverbally\\tdeclared\\tpotential\\tconflicts\\t\\nof interest at the beginning of the meeting. The procedures for the management \\nof\\tconflicts\\tof\\tinterests\\twere\\tundertaken\\tin\\taccordance\\twith\\tthe\\t“ WHO guidelines \\nfor declaration of interests (WHO experts) ”.\\tIn\\tsummary,\\tall\\tmembers\\tof\\tthe\\tGDG\\t\\ndeclared\\tthat\\tthey\\thad\\tno\\tcommercial\\tor\\tfinancial\\tinterests\\tthat\\twere\\tdirectly\\tor\\t\\nindirectly\\trelated\\tto\\tthe\\ttopic\\tof\\tthe\\tmeeting/guideline.\\tSeven\\tmembers\\tof\\tthe\\t\\nGDG\\twere\\tinvolved\\tin\\tacademic\\twork\\trelated\\tto\\tthe\\ttopic\\tof\\tthe\\tguideline,\\tbut\\tthis\\t\\ninvolvement\\twas\\tnot\\tconsidered\\tto\\tbe\\ta\\tconflict\\tof\\tinterest\\tand\\tthe\\tfull\\tparticipation\\t\\nof\\tall\\tthe\\tselected\\texperts\\twas\\tdeemed\\tappropriate.\\t A\\ttable\\tsummarizing\\tthe\\tdecla -\\nrations\\tof\\tinterest\\tmade\\tby\\tmembers\\tof\\tthe\\tGDG\\tis\\tincluded\\tin\\t Annex\\t1.\\t\\nDecision-making during the Technical Consultation\\nAt\\tthe\\tbeginning\\tof\\tthe\\t Technical\\tConsultation,\\tthe\\tparticipants\\tdiscussed\\tand\\tad -\\nopted a list of recommendations which needed to be addressed during the meeting. \\nThis included the new recommendations as well as previous recommendations that \\nneeded to be reviewed and possibly revised.\\nThe\\tfollowing\\tprotocol\\twas\\tused\\tfor\\tthe\\t Technical\\tConsultation:\\tthe\\tmeeting\\twas\\t\\nstructured to allow participants to discuss the proposed list of recommendations and \\nthese\\trecommendations\\twere\\trevised,\\tas\\tneeded,\\tthrough\\tgroup\\tdiscussion.\\t The\\tfinal\\t\\nadoption\\tof\\teach\\trecommendation\\twas\\tmade\\tby\\tconsensus\\t–\\tdefined\\tas\\tthe\\tagree -\\nment by three quarters or more of the participants – provided that those who dis -\\nagreed did not feel strongly about their position. Strong disagreements were record -\\ned\\tas\\tsuch\\tin\\tthe\\tguideline.\\tIf\\tthe\\tparticipants\\twere\\tunable\\tto\\treach\\ta\\tconsensus,\\t\\nthe\\tdisputed\\trecommendation,\\tor\\tany\\tother\\tdecision,\\twas\\tput\\tto\\ta\\tvote.\\t A\\trecom -\\nmendation\\tor\\tdecision\\tstood\\tif\\ta\\tsimple\\tmajority\\t(more\\tthan\\thalf\\tof\\tthe\\tparticipants)\\t\\nvoted\\tin\\tsupport\\tof\\tit,\\tunless\\tthe\\tdisagreement\\trelated\\tto\\ta\\tsafety\\tconcern,\\tin\\twhich\\t\\ncase the WHO Secretariat would choose not to issue a recommendation at all. WHO \\nstaff\\tattending\\tthe\\tmeeting,\\texternal\\ttechnical\\texperts\\tinvolved\\tin\\tthe\\tcollection\\t', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 16}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n12\\nand\\tgrading\\tof\\tthe\\tevidence,\\tand\\tobservers\\twere\\tnot\\teligible\\tto\\tvote.\\tIn\\taddition\\tto\\t\\ndiscussing\\tthe\\tscientific\\tevidence\\tand\\tits\\tquality,\\trelevant\\tapplicability\\tissues,\\tcosts\\t\\nand\\tother\\tjudgements\\twere\\talso\\ttaken\\tinto\\tconsideration\\twhen\\tformulating\\tthe\\tfinal\\t\\nrecommendations.\\nThe strength of each recommendation was determined during the Technical Con -\\nsultation.\\tBy\\tdefault,\\tthe\\tstrength\\tof\\tthe\\trecommendations\\tdiscussed\\twas\\taligned\\t\\ninitially with the quality of the evidence (i.e.  at\\tthe\\tstart\\tof\\tthe\\tdiscussion,\\tstrong\\t\\nrecommendations\\twere\\tbased\\ton\\tevidence\\tof\\t‘moderate’ \\tand\\t‘high’ \\tquality,\\twhile\\t\\nweak\\trecommendations\\twere\\tbased\\ton\\tevidence\\tof\\t‘low’ \\tand\\t‘very\\tlow’ \\tquality).\\t  \\nIn\\taddition\\tto\\tthe\\tquality\\tof\\tthe\\tevidence,\\tthe\\tfollowing\\tfactors\\twere\\tconsidered\\t\\nwhen\\tdetermining\\tthe\\tfinal\\trecommendation\\tand\\tits\\tstrength:\\tvalues\\tand\\tpreferenc -\\nes,\\tthe\\tmagnitude\\tof\\teffect,\\tthe\\tbalance\\tof\\tbenefits\\tversus\\tdisadvantages,\\tresource\\t\\nusage,\\tand\\tfeasibility.\\tValues\\tand\\tpreferences,\\tresource\\tusage,\\tand\\tthe\\tfeasibility\\tof\\t\\neach\\trecommendation\\twere\\tbased\\ton\\tthe\\texperience\\tand\\topinion\\tof\\tthe\\tGDG\\tmem -\\nbers.\\tBalance\\tworksheets\\twere\\tused\\tto\\tnote\\tand\\tsynthesize\\tthese\\tconsiderations\\t\\n(Annex\\t3,\\tBoxes\\t1\\tto\\t8)\\tand\\trecord\\tthe\\treasons\\tfor\\tchanges\\tmade\\tto\\tthe\\tdefault\\t\\nstrength of the recommendations.\\nDocument preparation and peer review\\nPrior\\tto\\tthe\\t Technical\\tConsultation,\\tthe\\tguideline\\tsteering\\tgroup\\tprepared\\ta\\tprelimi -\\nnary version of this document using a guideline reporting template which had been \\ndeveloped\\tas\\tpart\\tof\\tthe\\tWHO’s\\tGREAT \\tproject.\\t The\\tdraft\\tguideline\\twas\\treviewed\\tby\\t\\nTechnical\\tConsultation\\tparticipants\\tat\\tthe\\tmeeting\\tin\\tMontreux.\\tDuring\\tthe\\tmeeting,\\t\\nthe\\tdraft\\tguideline\\twas\\tmodified\\tin\\tline\\twith\\tparticipant\\tdeliberation\\tand\\tcomments.\\t\\nFeedback\\treceived\\tduring\\tthe\\tpreliminary\\tonline\\tconsultation\\twas\\talso\\tdiscussed\\tand\\t\\nincorporated\\tinto\\tthe\\tdocument\\twhere\\tappropriate.\\t After\\tthe\\tmeeting,\\tmembers\\tof\\t\\nthe\\tguideline\\tsteering\\tgroup\\tworked\\tto\\tensure\\tthat\\ta\\trevised\\tversion\\tof\\tthe\\tdocu -\\nment\\taccurately\\treflected\\tthe\\tdeliberations\\tand\\tdecisions\\tof\\tthe\\tparticipants.\\t The\\t\\nrevised\\tdraft\\tguideline\\tdocument\\twas\\tsent\\tto\\ttwo\\texternal\\tpeer\\treviewers\\tand\\ttheir\\t\\ninputs were carefully evaluated by the guideline steering group and document revi -\\nsions\\tmade\\taccordingly.\\t The\\tguideline\\tsteering\\tgroup\\trefrained\\tfrom\\tmaking\\tsubstan -\\ntive\\tchanges\\tafter\\tthe\\tmeeting\\tin\\tMontreux\\tto\\tthe\\tguideline\\tscoping\\t(such\\tas\\tthe\\t\\nfurther\\texpansion\\tof\\tthe\\tguideline\\tscoping)\\tor\\tto\\tthe\\trecommendations.\\t The\\trevised\\t\\nversion was returned electronically to those who had attended the Technical Consul -\\ntation for their approval.\\n3. Results\\nThis guideline includes 32 recommendations for the prevention and treatment of \\nPPH.\\tSeven\\tof\\tthese\\trecommendations\\tare\\tnew,\\twhile\\tthe\\tothers\\thave\\tbeen\\trevised\\t\\nin light of new evidence. Most of the previous 2007 and 2009 recommendations \\nremain\\tunchanged\\tin\\tessence,\\tdespite\\tupdates\\tto\\tthe\\tevidence\\tbase.\\t The\\twording\\t\\nof the previous recommendations has been revised to enhance the clarity of the \\nguidance provided. The recommendations included in this guideline are based on \\na\\ttotal\\tof\\t22\\tCochrane\\tsystematic\\treviews\\tsummarized\\tin\\t70\\tGRADE\\ttables.\\tBoxes\\t\\n1 to 8 present the most up-to-date WHO recommendations for the prevention and \\ntreatment\\tof\\tPPH.\\tWhere\\tapplicable,\\tremarks\\trelated\\tto\\tspecific\\trecommendations\\t\\nare\\talso\\tshown\\tin\\tthese\\tboxes\\tand\\tnew\\trecommendations\\tare\\tmarked\\twith\\tasterisks.\\t\\nNarrative summaries of evidence supporting the recommendations are presented ', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 17}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n13\\nin\\tthe\\telectronic\\tappendix\\ttogether\\twith\\tthe\\tcorresponding\\tGRADE\\ttables\\t(see\\tthe\\t\\n“WHO recommendations for preventing and treating PPH: evidence base ” at  \\nwww.who.int/reproductivehealth/publications/maternal_perinatal_health/  \\n9789241548502/en).\\tBox\\t9\\tpresents\\tstatements\\trelated\\tto\\ttopics\\tfor\\twhich,\\taccord -\\ning\\tto\\tthe\\tassessments\\tof\\tthe\\tGDG,\\tthere\\twas\\tinsufficient\\tevidence\\tto\\tissue\\ta\\trecom -\\nmendation.\\tBalance\\tworksheets\\tsummarizing\\tthe\\tvalues,\\tpreferences\\tand\\tjudge -\\nments\\tmade\\tabout\\tthe\\tstrength\\tof\\tthe\\trecommendations\\tare\\tpresented\\tin\\t Annex\\t3,\\t\\nBoxes\\t1\\tto\\t8.\\nThe\\tdevelopment\\tof\\tthese\\trecommendations\\tinvolved\\t130\\tstakeholders\\twho\\tpar -\\nticipated\\tin\\tthe\\tonline\\tpreliminary\\tsurvey\\t(representing\\tall\\tWHO\\tregions),\\tand\\t25\\t\\nexperts\\twho\\tparticipated\\tin\\tthe\\tWHO\\t Technical\\tConsultation.\\nRecommendations for PPH prevention\\nThe contribution of each component of the ‘active management of the third stage of \\nlabour’\\twas\\texamined\\tin\\tlight\\tof\\tnew\\tavailable\\tevidence,\\tand\\trelevant\\trecommenda -\\ntions\\twere\\tmade.\\tBox\\t1\\tpresents\\trecommendations\\tconcerning\\tthe\\tuse\\tof\\tuteroton -\\nics for the prevention of PPH. All women giving birth should be offered uteroton -\\nics\\tduring\\tthe\\tthird\\tstage\\tof\\tlabour\\tto\\tprevent\\tPPH\\tand\\tIM/IV\\toxytocin\\t(10\\tIU)\\tis\\t\\nrecommended as the uterotonic drug of choice. Other injectable uterotonics (i.e. \\nergometrine/methylergometrine,\\tor\\tthe\\tfixed\\tdrug\\tcombination\\tof\\toxytocin\\tand\\t\\nergometrine)\\tand\\tmisoprostol\\tare\\trecommended\\tas\\talternatives\\tfor\\tthe\\tprevention\\t\\nof\\tPPH\\tin\\tsettings\\twhere\\toxytocin\\tis\\tunavailable.\\tBox\\t2\\tcontains\\trecommendations\\t\\nrelated to cord management and uterine massage. The importance of controlled \\ncord\\ttraction\\t(CCT)\\twas\\trevisited\\tbecause\\tof\\tnew\\tevidence.\\t This\\tintervention\\tis\\tnow\\t\\nregarded\\tas\\toptional\\tin\\tsettings\\twhere\\tskilled\\tbirth\\tattendants\\tare\\tavailable,\\tand\\t\\nis\\tcontraindicated\\tin\\tsettings\\twhere\\tskilled\\tattendants\\tdo\\tnot\\tassist\\twith\\tbirths.\\t\\nEarly cord clamping is generally contraindicated. Continuous uterine massage is \\nnot recommended as an intervention to prevent PPH for women who have received \\nprophylactic\\toxytocin,\\tbecause\\tthe\\tmassage\\tmay\\tcause\\tmaternal\\tdiscomfort,\\tre -\\nquire\\ta\\tdedicated\\thealth\\tprofessional,\\tand\\tmay\\tnot\\tlead\\tto\\ta\\treduction\\tof\\tblood\\tloss.\\t\\nHowever,\\tsurveillance\\tof\\tthe\\tuterine\\ttonus\\tthrough\\tabdominal\\tpalpation\\tis\\trecom -\\nmended\\tfor\\tall\\twomen\\tfor\\tthe\\tearly\\tidentification\\tof\\tpostpartum\\tuterine\\tatony.\\t Table\\t\\n1 summarizes the recommendation status of the individual components of the active \\nmanagement\\tof\\tthe\\tthird\\tstage\\tof\\tlabour.\\tIn\\tsummary,\\tthe\\tGDG\\tconsidered\\tthe\\tuse\\t\\nof uterotonics as the main intervention within the active management of third stage \\nof\\tlabour\\tpackage.\\tIn\\tthis\\tcontext,\\tthe\\tuse\\tof\\tmisoprostol\\tfor\\tthe\\tprevention\\tof\\tPPH\\t\\nby\\tcommunity\\thealth\\tcare\\tworkers\\tand\\tlay\\thealth\\tworkers\\tis\\tsupported\\tin\\tsettings\\t\\nwhere\\tskilled\\tbirth\\tattendants\\tare\\tnot\\tpresent.\\nRecommendations for reducing blood loss during the third stage of labour in caesar -\\nean\\tsections\\tare\\tpresented\\tin\\tBox\\t3.\\tOxytocin\\tis\\tthe\\trecommended\\tuterotonic\\tdrug\\t\\nfor the prevention of PPH in caesarean sections. Cord traction is recommended in \\npreference to manual removal when assisting placental delivery in caesarean sec -\\ntions.\\nRecommendations for PPH treatment\\nThe\\tuse\\tof\\tuterotonics\\t(oxytocin\\talone\\tas\\tthe\\tfirst\\tchoice)\\tplays\\ta\\tcentral\\trole\\tin\\t\\nthe\\ttreatment\\tof\\tPPH\\t(see\\tBoxes\\t4\\tand\\t5).\\tUterine\\tmassage\\tis\\trecommended\\tfor\\tthe\\t\\ntreatment\\tof\\tPPH\\tas\\tsoon\\tas\\tit\\tis\\tdiagnosed\\t(see\\tBox\\t6)\\tand\\tthe\\tinitial\\tfluid\\tresus -', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 18}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n14\\ncitation\\twith\\tisotonic\\tcrystalloids\\tis\\trecommended.\\t The\\tuse\\tof\\ttranexamic\\tacid\\tis\\t\\nadvised in cases of refractory atonic bleeding or persistent trauma-related bleed -\\ning\\t(see\\tBox\\t5).\\t The\\tuse\\tof\\tintrauterine\\tballoon\\ttamponade\\tis\\trecommended\\tfor\\t\\nrefractory\\tbleeding\\tor\\tif\\tuterotonics\\tare\\tunavailable.\\tBimanual\\tuterine\\tcompression,\\t\\nexternal\\taortic\\tcompression,\\tand\\tthe\\tuse\\tof\\tnon-pneumatic\\tanti-shock\\tgarments\\tare\\t\\nrecommended as temporizing measures until substantive care is available. If there is \\npersistent\\tbleeding\\tand\\tthe\\trelevant\\tresources\\tare\\tavailable,\\tuterine\\tartery\\temboli -\\nzation should be considered. If bleeding persists despite treatment with uterotonic \\ndrugs\\tand\\tother\\tconservative\\tinterventions,\\tsurgical\\tintervention\\tshould\\tbe\\tused\\t\\nwithout further delay.\\nIf\\tthe\\tthird\\tstage\\tof\\tlabour\\tlasts\\tmore\\tthan\\t30\\tminutes,\\tCCT \\tand\\tIV/IM\\toxytocin\\t  \\n(10\\tIU)\\tshould\\tbe\\tused\\tto\\tmanage\\tthe\\tretained\\tplacenta.\\tIf\\tthe\\tplacenta\\tis\\tretained\\t\\nand\\tbleeding\\toccurs,\\tthe\\tmanual\\tremoval\\tof\\tthe\\tplacenta\\tshould\\tbe\\texpedited.\\t\\nWhenever\\tthe\\tmanual\\tremoval\\tof\\tthe\\tplacenta\\tis\\tundertaken,\\ta\\tsingle\\tdose\\tof\\tpro -\\nphylactic\\tantibiotics\\tis\\trecommended\\t(see\\tBox\\t7).\\nThe GDG also issued recommendations related to the organization of PPH care (see \\nBox\\t8).\\tHealth\\tfacilities\\tdelivering\\tmaternity\\tservices\\tshould\\tadopt\\tformal\\tproto -\\ncols for the prevention and treatment of PPH and for patient referral. The use of \\nPPH treatment simulations for pre-service and in-service training programmes was \\nrecommended.\\tFinally,\\tthe\\tGDG\\trecommended\\tthat\\tthe\\tuse\\tof\\tuterotonics\\tfor\\tthe\\t\\nprevention\\tof\\tPPH\\tshould\\tbe\\tmonitored\\tand\\ta\\tspecific\\tindicator\\twas\\tsuggested.\\nThe\\tGDG\\tfound\\tinsufficient\\tevidence\\tto\\trecommend\\tone\\troute\\tover\\tanother\\tfor\\tthe\\t\\nprevention\\tof\\tPPH\\twith\\toxytocin,\\tthe\\tuse\\tof\\trecombinant\\tfactor\\tVIIa\\tfor\\tthe\\ttreat -\\nment\\tof\\tPPH,\\tintraumbilical\\tvein\\tinjection\\tof\\toxytocin\\tfor\\ttreatment\\tof\\tretained\\t\\nplacenta,\\tand\\tthe\\tantenatal\\tdistribution\\tof\\tmisoprostol.\\t The\\tGDG\\talso\\tfound\\tinsuffi -\\ncient evidence to recommend self-administration for the prevention of PPH and the \\nmeasurement\\tof\\tblood\\tloss\\tover\\tclinical\\testimation\\t(see\\tBox\\t9).', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 19}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n15\\nBox 1: Recommendations for the prevention of PPH – uterotonics\\n1. The use of uterotonics for the prevention of PPH during the third stage of labour is recom -\\nmended\\tfor\\tall\\tbirths.\\t(Strong\\trecommendation,\\tmoderate-quality\\tevidence)\\n2. Oxytocin\\t(10\\tIU,\\tIV/IM)\\tis\\tthe\\trecommended\\tuterotonic\\tdrug\\tfor\\tthe\\tprevention\\tof\\tPPH.\\t\\n(Strong\\trecommendation,\\tmoderate-quality\\tevidence)\\n3. In\\tsettings\\twhere\\toxytocin\\tis\\tunavailable,\\tthe\\tuse\\tof\\tother\\tinjectable\\tuterotonics\\t(e.g.\\ter -\\ngometrine/methylergometrine\\tor\\tthe\\tfixed\\tdrug\\tcombination\\tof\\toxytocin\\tand\\tergometrine)\\t\\nor\\toral\\tmisoprostol\\t(600  µg)\\tis\\trecommended.\\t(Strong\\trecommendation,\\tmoderate-quality\\t\\nevidence)\\n4. In\\tsettings\\twhere\\tskilled\\tbirth\\tattendants\\tare\\tnot\\tpresent\\tand\\toxytocin\\tis\\tunavailable,\\tthe\\t\\nadministration\\tof\\tmisoprostol\\t(600  µg\\tPO)\\tby\\tcommunity\\thealth\\tcare\\tworkers\\tand\\tlay\\thealth\\t\\nworkers\\tis\\trecommended\\tfor\\tthe\\tprevention\\tof\\tPPH.\\t(Strong\\trecommendation,\\tmoderate-\\nquality\\tevidence)\\nRemarks\\n•\\tAvailable\\tcomparisons\\tare\\tlimited,\\tbut\\ta\\tsignificant\\tdifference\\tbetween\\tthe\\tbenefits\\tof\\toxytocin\\tand\\t\\nergometrine\\tis\\tunlikely.\\t These\\trecommendations\\tplace\\ta\\thigh\\tvalue\\ton\\tavoiding\\tthe\\tadverse\\teffects\\tof\\t\\nergometrine\\tand\\tassume\\ta\\tsimilar\\tbenefit\\tfrom\\tusing\\toxytocin\\tand\\tergometrine\\tfor\\tthe\\tprevention\\tof\\t\\nPPH. \\n•\\tCaution\\tshould\\tbe\\texercised\\twhen\\topting\\tfor\\tergot\\tderivatives\\tfor\\tthe\\tprevention\\tof\\tPPH\\tas\\tthese\\tdrugs\\t\\nhave\\tclear\\tcontraindications\\tin\\twomen\\twith\\thypertensive\\tdisorders.\\t Thus,\\tit\\tis\\tprobably\\tsafer\\tto\\tavoid\\t\\nthe use of ergot derivatives in unscreened populations.\\n•\\tMisoprostol\\t(600\\t�g\\tPO)\\twas\\tregarded\\tby\\tthe\\tGDG\\tas\\tan\\teffective\\tdrug\\tfor\\tthe\\tprevention\\tof\\tPPH.\\tHow- \\t�g\\tPO)\\twas\\tregarded\\tby\\tthe\\tGDG\\tas\\tan\\teffective\\tdrug\\tfor\\tthe\\tprevention\\tof\\tPPH.\\tHow-\\tPO)\\twas\\tregarded\\tby\\tthe\\tGDG\\tas\\tan\\teffective\\tdrug\\tfor\\tthe\\tprevention\\tof\\tPPH.\\tHow -\\never,\\tthe\\tGDG\\tconsidered\\tthe\\trelative\\tbenefits\\tof\\toxytocin\\tcompared\\tto\\tmisoprostol\\tin\\tpreventing\\tblood\\t\\nloss,\\tas\\twell\\tas\\tthe\\tincreased\\tadverse\\teffects\\tof\\tmisoprostol\\tcompared\\tto\\toxytocin.\\t The\\tGDG\\tacknowl -\\nedged\\tthat\\tthere\\tis\\tno\\tevidence\\tto\\tshow\\tthat\\ta\\t600  µg\\tdose\\tof\\tmisoprostol\\tprovides\\tgreater\\tefficacy\\tover\\t\\na\\t400�g\\t�g\\tdose.\\tLower\\tdoses\\thave\\ta\\tlower\\tside-effect\\tprofi \\tle\\tbut\\tthe\\teffi \\tcacy\\tof\\tlower\\tdoses\\tof\\tmiso-�g\\t�g\\tdose.\\tLower\\tdoses\\thave\\ta\\tlower\\tside-effect\\tprofi \\tle\\tbut\\tthe\\teffi \\tcacy\\tof\\tlower\\tdoses\\tof\\tmiso-\\tdose.\\tLower\\tdoses\\thave\\ta\\tlower\\tside-effect\\tprofile\\tbut\\tthe\\tefficacy\\tof\\tlower\\tdoses\\tof\\tmiso -\\nprostol\\thas\\tnot\\tbeen\\tevaluated\\tsufficiently.\\n•\\tThe\\trecommendations\\tconcerning\\talternative\\tuterotonics\\tshould\\tnot\\tdetract\\tfrom\\tthe\\tobjective\\tof\\tmak -\\ning\\toxytocin\\tas\\twidely\\taccessible\\tas\\tpossible.\\n•\\tIn view of past concerns regarding the community-level distribution of misoprostol and the potential \\nfor\\tserious\\tconsequences\\tof\\tadministration\\tbefore\\tbirth,\\tthe\\tGDG\\tplaces\\temphasis\\ton\\ttraining\\tpersons\\t\\nadministering\\tmisoprostol\\tand\\tmonitoring\\tcommunity\\tdistribution\\tinterventions\\twith\\tscientifically\\tsound\\t\\nmethods and appropriate indicators.', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 20}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n16\\nBox 2: Recommendations for the prevention of PPH – cord management and uterine massage\\n5. In\\tsettings\\twhere\\tskilled\\tbirth\\tattendants\\tare\\tavailable,\\tCCT \\tis\\trecommended\\tfor\\tvaginal\\t\\nbirths if the care provider and the parturient woman regard a small reduction in blood loss \\nand\\ta\\tsmall\\treduction\\tin\\tthe\\tduration\\tof\\tthe\\tthird\\tstage\\tof\\tlabour\\tas\\timportant.\\t(Weak\\trecom -\\nmendation,\\thigh-quality\\tevidence)\\t\\n6.\\tIn\\tsettings\\twhere\\tskilled\\tbirth\\tattendants\\tare\\tunavailable,\\tCCT \\tis\\tnot\\trecommended.\\t(Strong\\t\\nrecommendation,\\tmoderate-quality\\tevidence)\\n7. Late\\tcord\\tclamping\\t(performed\\tapproximately\\t1\\tto\\t3\\tminutes\\tafter\\tbirth)\\tis\\trecommended\\t\\nfor\\tall\\tbirths\\twhile\\tinitiating\\tsimultaneous\\tessential\\tnewborn\\tcare.\\t(Strong\\trecommendation,\\t\\nmoderate-quality\\tevidence)\\n8. Early\\tcord\\tclamping\\t(<1\\tminute\\tafter\\tbirth)\\tis\\tnot\\trecommended\\tunless\\tthe\\tneonate\\tis\\tas -\\nphyxiated\\tand\\tneeds\\tto\\tbe\\tmoved\\timmediately\\tfor\\tresuscitation.\\t(Strong\\trecommendation,\\t\\nmoderate-quality\\tevidence)\\n9. Sustained uterine massage is not recommended as an intervention to prevent PPH in women \\nwho\\thave\\treceived\\tprophylactic\\toxytocin.\\t(Weak\\trecommendation,\\tlow-quality\\tevidence)\\n10. Postpartum\\tabdominal\\tuterine\\ttonus\\tassessment\\tfor\\tearly\\tidentification\\tof\\tuterine\\tatony\\tis\\t\\nrecommended\\tfor\\tall\\twomen.\\t(Strong\\trecommendation,\\tvery-low-quality\\tevidence)\\nRemarks\\n•\\tRecommendations\\t5\\tand\\t6\\tare\\tbased\\ton\\ta\\tlarge\\tRCT \\tin\\twhich\\toxytocin\\t10\\tIU\\twas\\tused\\tfor\\tthe\\tprevention\\t\\nof\\tPPH\\tin\\tall\\tparticipants.\\tBased\\ton\\tthis\\tevidence,\\tCCT \\twas\\tregarded\\tas\\tsafe\\twhen\\tapplied\\tby\\tskilled\\t\\nbirth\\tattendants\\tas\\tit\\tprovides\\tsmall\\tbeneficial\\teffects\\ton\\tblood\\tloss\\t(average\\treduction\\tof\\t11\\tml\\ton\\t\\nblood\\tloss)\\tand\\ton\\tthe\\tduration\\tof\\tthe\\tthird\\tstage\\tof\\tlabour\\t(average\\treduction\\tof\\t6\\tminutes).\\t The\\tdeci -\\nsion\\tto\\timplement\\tCCT \\tin\\tthe\\tcontext\\tof\\ta\\tprophylactic\\tuterotonic\\tdrug\\tshould\\tbe\\tdiscussed\\tby\\tthe\\tcare\\t\\nprovider and the woman herself. \\n•\\tIf\\tergot\\talkaloids\\tare\\tused\\tfor\\tthe\\tprevention\\tof\\tPPH,\\tthen\\tCCT \\tto\\tminimize\\tplacenta\\tretention\\tis\\tre -\\ngarded as essential.\\n•\\tThere\\tis\\tinsufficient\\tevidence\\tto\\tdetermine\\tthe\\tbenefit\\tor\\trisk\\tof\\tCCT \\twhen\\tused\\tin\\tconjunction\\twith\\t\\nmisoprostol. \\n•\\tCCT\\tis\\tthe\\tfirst\\tintervention\\tto\\ttreat\\tretained\\tplacenta,\\ttherefore\\tthe\\tteaching\\tof\\tCCT \\tin\\tmedical\\tand\\t\\nmidwifery curricula is essential.\\n•\\tThe evidence base for recommendations for the timing of cord clamping includes both vaginal and cae -\\nsarean births. The GDG considers this recommendation to be equally important for caesarean sections.\\n•\\tDelayed clamping should be performed during the provision of essential newborn care. For essential \\nnewborn\\tcare\\tand\\tresuscitation,\\tplease\\trefer\\tto\\tthe\\tWHO\\tguidelines\\ton\\tneonatal\\tresuscitation.\\t(10)\\t\\n•\\tThe recommendations for the timing of cord clamping apply equally to preterm and term births. The \\nGDG\\tconsiders\\tthe\\tbenefits\\tof\\tdelayed\\tclamping\\tfor\\tpreterm\\tinfants\\tto\\tbe\\tparticularly\\timportant.\\n(Continued on next page)', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 21}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n17\\nBox 2: Recommendations for the prevention of PPH – cord management and uterine massage\\n5. In\\tsettings\\twhere\\tskilled\\tbirth\\tattendants\\tare\\tavailable,\\tCCT \\tis\\trecommended\\tfor\\tvaginal\\t\\nbirths if the care provider and the parturient woman regard a small reduction in blood loss \\nand\\ta\\tsmall\\treduction\\tin\\tthe\\tduration\\tof\\tthe\\tthird\\tstage\\tof\\tlabour\\tas\\timportant.\\t(Weak\\trecom -\\nmendation,\\thigh-quality\\tevidence)\\t\\n6.\\tIn\\tsettings\\twhere\\tskilled\\tbirth\\tattendants\\tare\\tunavailable,\\tCCT \\tis\\tnot\\trecommended.\\t(Strong\\t\\nrecommendation,\\tmoderate-quality\\tevidence)\\n7. Late\\tcord\\tclamping\\t(performed\\tapproximately\\t1\\tto\\t3\\tminutes\\tafter\\tbirth)\\tis\\trecommended\\t\\nfor\\tall\\tbirths\\twhile\\tinitiating\\tsimultaneous\\tessential\\tnewborn\\tcare.\\t(Strong\\trecommendation,\\t\\nmoderate-quality\\tevidence)\\n8. Early\\tcord\\tclamping\\t(<1\\tminute\\tafter\\tbirth)\\tis\\tnot\\trecommended\\tunless\\tthe\\tneonate\\tis\\tas -\\nphyxiated\\tand\\tneeds\\tto\\tbe\\tmoved\\timmediately\\tfor\\tresuscitation.\\t(Strong\\trecommendation,\\t\\nmoderate-quality\\tevidence)\\n9. Sustained uterine massage is not recommended as an intervention to prevent PPH in women \\nwho\\thave\\treceived\\tprophylactic\\toxytocin.\\t(Weak\\trecommendation,\\tlow-quality\\tevidence)\\n10. Postpartum\\tabdominal\\tuterine\\ttonus\\tassessment\\tfor\\tearly\\tidentification\\tof\\tuterine\\tatony\\tis\\t\\nrecommended\\tfor\\tall\\twomen.\\t(Strong\\trecommendation,\\tvery-low-quality\\tevidence)\\nRemarks\\n•\\tRecommendations\\t5\\tand\\t6\\tare\\tbased\\ton\\ta\\tlarge\\tRCT \\tin\\twhich\\toxytocin\\t10\\tIU\\twas\\tused\\tfor\\tthe\\tprevention\\t\\nof\\tPPH\\tin\\tall\\tparticipants.\\tBased\\ton\\tthis\\tevidence,\\tCCT \\twas\\tregarded\\tas\\tsafe\\twhen\\tapplied\\tby\\tskilled\\t\\nbirth\\tattendants\\tas\\tit\\tprovides\\tsmall\\tbeneficial\\teffects\\ton\\tblood\\tloss\\t(average\\treduction\\tof\\t11\\tml\\ton\\t\\nblood\\tloss)\\tand\\ton\\tthe\\tduration\\tof\\tthe\\tthird\\tstage\\tof\\tlabour\\t(average\\treduction\\tof\\t6\\tminutes).\\t The\\tdeci -\\nsion\\tto\\timplement\\tCCT \\tin\\tthe\\tcontext\\tof\\ta\\tprophylactic\\tuterotonic\\tdrug\\tshould\\tbe\\tdiscussed\\tby\\tthe\\tcare\\t\\nprovider and the woman herself. \\n•\\tIf\\tergot\\talkaloids\\tare\\tused\\tfor\\tthe\\tprevention\\tof\\tPPH,\\tthen\\tCCT \\tto\\tminimize\\tplacenta\\tretention\\tis\\tre -\\ngarded as essential.\\n•\\tThere\\tis\\tinsufficient\\tevidence\\tto\\tdetermine\\tthe\\tbenefit\\tor\\trisk\\tof\\tCCT \\twhen\\tused\\tin\\tconjunction\\twith\\t\\nmisoprostol. \\n•\\tCCT\\tis\\tthe\\tfirst\\tintervention\\tto\\ttreat\\tretained\\tplacenta,\\ttherefore\\tthe\\tteaching\\tof\\tCCT \\tin\\tmedical\\tand\\t\\nmidwifery curricula is essential.\\n•\\tThe evidence base for recommendations for the timing of cord clamping includes both vaginal and cae -\\nsarean births. The GDG considers this recommendation to be equally important for caesarean sections.\\n•\\tDelayed clamping should be performed during the provision of essential newborn care. For essential \\nnewborn\\tcare\\tand\\tresuscitation,\\tplease\\trefer\\tto\\tthe\\tWHO\\tguidelines\\ton\\tneonatal\\tresuscitation.\\t(10)\\t\\n•\\tThe recommendations for the timing of cord clamping apply equally to preterm and term births. The \\nGDG\\tconsiders\\tthe\\tbenefits\\tof\\tdelayed\\tclamping\\tfor\\tpreterm\\tinfants\\tto\\tbe\\tparticularly\\timportant.•\\tSome\\thealth\\tprofessionals\\tworking\\tin\\tareas\\tof\\thigh\\tHIV\\tprevalence\\thave\\texpressed\\tconcern\\tregard -\\ning delayed cord clamping as part of management of the third stage of labour. These professionals are \\nconcerned\\tthat\\tduring\\tplacental\\tseparation,\\ta\\tpartially\\tdetached\\tplacenta\\tcould\\tbe\\texposed\\tto\\tmaternal\\t\\nblood and this could lead to a micro-transfusion of maternal blood to the baby. It has been demonstrat -\\ned\\tthat\\tthe\\tpotential\\tfor\\tmaternal-to-child\\ttransmission\\tof\\tHIV\\tcan\\ttake\\tplace\\tat\\tthree\\tdifferent\\tpoints\\t\\nin\\ttime:\\tmicro-transfusions\\tof\\tmaternal\\tblood\\tto\\tthe\\tfetus\\tduring\\tpregnancy\\t(intra-uterine\\tHIV\\ttransmis -\\nsion),\\texposure\\tto\\tmaternal\\tblood\\tand\\tvaginal\\tsecretions\\twhen\\tthe\\tfetus\\tpasses\\tthrough\\tthe\\tbirth\\tcanal\\t\\nin\\tvaginal\\tdeliveries\\t(intra-partum\\ttransmission),\\tand\\tduring\\tbreastfeeding\\t(postnatal\\tinfection).\\tFor\\tthis\\t\\nreason,\\tthe\\tmain\\tintervention\\tto\\treduce\\tthe\\tmaternal-to-child\\ttransmission\\tis\\tthe\\treduction\\tof\\tmater -\\nnal\\tviral\\tload\\tthrough\\tthe\\tuse\\tof\\tantiretroviral\\tdrugs\\tduring\\tpregnancy,\\tchildbirth\\tand\\tpostnatal\\tperiod.\\t\\nThere is no evidence that delaying the cord clamping increases the possibility of HIV transmission from \\nthe mother to the newborn. Maternal blood percolates through the placental intervillous space through -\\nout\\tpregnancy\\twith\\ta\\trelatively\\tlow\\trisk\\tof\\tmaternal\\tfetal\\ttransmission\\tbefore\\tdelivery.\\tIt\\tis\\thighly\\tun -\\nlikely\\tthat\\tseparation\\tof\\tthe\\tplacenta\\tincreases\\texposure\\tto\\tmaternal\\tblood,\\tand\\tis\\thighly\\tunlikely\\tthat\\t\\nit\\tdisrupts\\tthe\\tfetal\\tplacental\\tcirculation\\t(i.e.\\tit\\tis\\tunlikely\\tthat\\tduring\\tplacenta\\tseparation\\tthe\\tnewborn\\t\\ncirculation\\tis\\texposed\\tto\\tmaternal\\tblood).\\t Thus,\\tthe\\tproven\\tbenefits\\tof\\ta\\t1\\t–\\t3\\tminute\\tdelay\\tat\\tleast\\tin\\t\\nclamping\\tthe\\tcord\\toutweigh\\tthe\\ttheoretical,\\tand\\tunproven,\\tharms.\\tLate\\tcord\\tclamping\\tis\\trecommended\\t\\neven\\tamong\\twomen\\tliving\\twith\\tHIV\\tor\\twomen\\twith\\tunknown\\tHIV\\tstatus.\\n•\\tThere\\tis\\ta\\tlack\\tof\\tevidence\\tregarding\\tthe\\trole\\tof\\tuterine\\tmassage\\tfor\\tPPH\\tprevention\\twhen\\tno\\tuterotonic\\t\\ndrugs\\tare\\tused,\\tor\\tif\\ta\\tuterotonic\\tdrug\\tother\\tthan\\toxytocin\\tis\\tused.\\t\\n•\\tAlthough\\tthe\\tGDG\\tacknowledged\\tthat\\tone\\tsmall\\tstudy\\treported\\tthat\\tsustained\\tuterine\\tmassage\\tand\\tclot\\t\\nexpulsion\\twere\\tassociated\\twith\\ta\\treduction\\tin\\tthe\\tuse\\tof\\tadditional\\tuterotonics,\\tthere\\tis\\tlack\\tof\\trobust\\t\\nevidence\\tsupporting\\tother\\tbenefits.\\tHowever,\\tthe\\tGDG\\tconsidered\\tthat\\troutine\\tand\\tfrequent\\tuterine\\t\\ntone\\tassessment\\tremains\\ta\\tcrucial\\tpart\\tof\\timmediate\\tpostpartum\\tcare,\\tparticularly\\tfor\\tthe\\toptimization\\t\\nof early PPH diagnosis.\\n•\\tBased\\ton\\tthe\\tmost\\trecent\\tevidence,\\tunderstanding\\tof\\tthe\\tcontribution\\tof\\teach\\tcomponent\\tof\\tthe\\tactive\\t\\nmanagement\\tof\\tthe\\tthird\\tstage\\tof\\tlabour\\tpackage\\thas\\tevolved.\\t The\\tGDG\\tconsidered\\tthat\\tthis\\tpackage\\t\\nhas\\ta\\tprimary\\tintervention:\\t\\tthe\\tuse\\tof\\tan\\tuterotonic.\\tIn\\tthe\\tcontext\\tof\\toxytocin\\tuse,\\tCCT \\tmay\\tadd\\ta\\t\\nsmall\\tbenefit,\\twhile\\tuterine\\tmassage\\tmay\\tadd\\tno\\tbenefit\\tfor\\tthe\\tprevention\\tof\\tPPH.\\tEarly\\tcord\\tclamping\\t\\nis generally contraindicated.(Continued from previous page)', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 22}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n18\\nBox 3: Recommendations for the prevention of PPH in caesarean sections\\n11. Oxytocin\\t(IV\\tor\\tIM)\\tis\\tthe\\trecommended\\tuterotonic\\tdrug\\tfor\\tthe\\tprevention\\tof\\tPPH\\tin\\tcaesar -\\nean\\tsection.\\t(Strong\\trecommendation,\\tmoderate-quality\\tevidence)\\n12. Cord traction is the recommended method for the removal of the placenta in caesarean sec -\\ntion.\\t(Strong\\trecommendation,\\tmoderate-quality\\tevidence)\\nRemarks\\n•\\tThe\\tGDG\\tnoted\\tthat,\\tin\\tterms\\tof\\tblood\\tloss,\\tthere\\twas\\tnot\\tenough\\tevidence\\tto\\trecommend\\toxytocin\\t\\ninfusion\\tover\\tIV\\tbolus\\tinjection.\\tHowever,\\tdue\\tto\\tconcerns\\tregarding\\tadverse\\thaemodynamic\\teffects,\\t  \\nthe\\tGDG\\tconsidered\\tthat\\tif\\tan\\tIV\\tbolus\\tinjection\\tis\\tused,\\ta\\tslow\\tinjection\\trate\\tis\\tpreferred\\tand\\ta\\trapid\\t\\ninjection rate should be avoided. \\n•\\tThe\\tGDG\\tnoted\\tthat\\tthe\\tcombination\\tof\\tan\\toxytocin\\tinfusion\\tafter\\tan\\tinitial\\tIV\\tbolus\\tof\\toxytocin\\tafter\\t\\ncaesarean delivery reduces the need for additional uterotonic agents but does not affect the overall  \\noccurrence of major obstetric haemorrhage. \\n•\\tThe GDG noted that carbetocin is associated with a reduction in the use of additional uterotonic agents \\nbut\\twith\\tno\\tdifference\\tin\\tthe\\toccurrence\\tof\\tmajor\\tobstetric\\thaemorrhage.\\tIn\\taddition,\\tthe\\tGDG\\tnoted\\t\\nthat\\tthe\\tuse\\tof\\tcarbetocin\\tis\\tconsiderably\\tmore\\texpensive\\tthan\\toxytocin.\\t This\\tremark\\tis\\tequally\\tappli -\\ncable to vaginal deliveries.Table\\t1:\\tRecommendation\\tstatus\\tof\\tthe\\tindividual\\tcomponents\\tof\\tthe\\tactive\\tmanagement\\t  \\nof\\tthe\\tthird\\tstage\\tof\\tlabour,\\tbased\\ton\\twho\\tdelivers\\tthe\\tintervention\\nSkilled  \\nbirth attendantNon-skilled  \\nbirth attendantSelf-administered\\nUterotonics In favour In favour Research*\\nEarly cord clamping Against Against Against\\nControlled cord traction Conditional** Against Against\\nContinuous uterine massage Against*** Against Research****\\n* Distribution of misoprostol during the antenatal period for self-administration during the third stage of labour\\n**\\tSmall\\treduction\\tin\\tblood\\tloss\\tand\\tin\\tthe\\tlength\\tof\\tthe\\tthird\\tstage;\\tadoption\\tbased\\ton\\tthe\\tvalues\\tand\\tpreferences\\tof\\tthe\\t\\nwoman and the health care provider\\n***\\tRoutine\\tuterine\\ttone\\tassessment\\tremains\\ta\\tvital\\tpart\\tof\\tclinical\\tdecision\\tmaking\\tand\\tshould\\tbe\\tpractised\\tduring\\tthe\\tthird\\t\\nstage of labour\\n**** Self-administered uterine massage in the absence of uterotonics', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 23}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n19\\nBox 4: Recommendations for the treatment of PPH – uterotonics\\n13. Intravenous\\toxytocin\\tis\\tthe\\trecommended\\tuterotonic\\tdrug\\tfor\\tthe\\ttreatment\\tof\\tPPH.\\t(Strong\\t\\nrecommendation,\\tmoderate\\tquality\\tevidence)\\n14. If\\tintravenous\\toxytocin\\tis\\tunavailable,\\tor\\tif\\tthe\\tbleeding\\tdoes\\tnot\\trespond\\tto\\toxytocin,\\tthe\\tuse\\t\\nof\\tintravenous\\tergometrine,\\toxytocin-ergometrine\\tfixed\\tdose,\\tor\\ta\\tprostaglandin\\tdrug\\t(includ -\\ning\\tsublingual\\tmisoprostol,\\t800\\t µg)\\tis\\trecommended.\\t(Strong\\trecommendation,\\tlow-quality\\t\\nevidence)\\nRemarks\\n•\\tThe\\tGDG\\trecommended\\tIV\\toxytocin\\tas\\tthe\\tfirst\\tline\\tuterotonic\\tdrug\\tfor\\tthe\\ttreatment\\tof\\tPPH,\\tincluding\\t\\nwhen\\twomen\\thave\\talready\\treceived\\tthis\\tdrug\\tfor\\tthe\\tprophylaxis\\tof\\tPPH.\\n•\\tThe\\tGDG\\trecognized\\tthat\\tIV\\toxytocin\\tmay\\tnot\\tbe\\tavailable\\tin\\tall\\tsettings.\\tIt\\tencourages\\thealth\\tcare\\t\\ndecision-makers\\tin\\tthese\\tsettings\\tto\\tstrive\\tto\\tmake\\toxytocin\\tavailable.\\n•\\tIn\\tsettings\\twhere\\tIV\\toxytocin\\tis\\tunavailable\\tto\\twomen\\twho\\thave\\treceived\\tprophylactic\\tIM\\toxytocin\\tduring\\t\\nthe\\tthird\\tstage\\tof\\tlabour,\\tthe\\tGDG\\tconsidered\\tmisoprostol\\tto\\tbe\\ta\\tvalid\\talternative.\\n•\\tIf\\tPPH\\tprophylaxis\\twith\\tmisoprostol\\thas\\tbeen\\tadministered\\tand\\tif\\tinjectable\\tuterotonics\\tare\\tunavailable,\\t\\nthere\\tis\\tinsufficient\\tevidence\\tto\\tguide\\tfurther\\tmisoprostol\\tdosing\\tand\\tconsideration\\tmust\\tbe\\tgiven\\tto\\tthe\\t\\nrisk\\tof\\tpotential\\ttoxicity.\\n•\\tThere\\tis\\tno\\tadded\\tbenefit\\tto\\toffering\\tmisoprostol\\tsimultaneously\\tto\\twomen\\treceiving\\toxytocin\\tfor\\tthe\\t\\ntreatment\\tof\\tPPH\\t(i.e.\\tadjunct\\tmisoprostol).\\n•\\tThe\\tGDG\\tnoted\\tthat\\tthe\\ttwo\\tlargest\\ttrials\\tof\\tmisoprostol\\tfor\\tthe\\ttreatment\\tof\\tPPH\\t(Winikoff\\t2010,\\tBlum\\t\\n2010)\\treported\\tthe\\tuse\\tof\\ta\\t800 \\tμg\\tdose administered sublingually. The majority of the GDG members \\nagreed that 800 \\tμg\\tis\\tan\\tacceptable\\tsublingual\\tmisoprostol\\t dose\\tfor\\tthe\\ttreatment\\tof\\tPPH,\\tthough\\tsome\\t\\nmembers\\tof\\tthe\\tGDG\\texpressed\\tconcern\\trelated\\tto\\tthe\\trisk\\tof\\thyperpyrexia\\tassociated\\twith\\tthis\\tdosage.\\n•\\tIf\\tIV\\toxytocin\\thas\\tbeen\\tused\\tfor\\tthe\\ttreatment\\tof\\tPPH\\tand\\tthe\\tbleeding\\tdoes\\tnot\\tstop,\\tthere\\tis\\ta\\tpaucity\\t\\nof data to recommend preferences for second line uterotonic drug treatment. Decisions in such situ -\\nations\\tmust\\tbe\\tguided\\tby\\tthe\\texperience\\tof\\tthe\\tprovider,\\tthe\\tavailability\\tof\\tthe\\tdrugs,\\tand\\tby\\tknown\\t\\ncontraindications.\\n•\\tIn\\tsituations\\tin\\twhich\\tIM\\toxytocin\\tcan\\tbe\\tadministered\\tand\\tthere\\tis\\tno\\tpossibility\\tof\\tIV\\ttreatment\\twith\\t\\nergot\\talkaloids/injectable\\tprostaglandins,\\tthere\\tis\\ta\\tpaucity\\tof\\tdata\\tto\\trecommend\\ta\\tpreference\\tof\\tIM\\t\\noxytocin\\tover\\tmisoprostol\\tor\\tother\\tuterotonics.\\tDecisions\\tin\\tsuch\\tsituations\\tmust\\tbe\\tguided\\tby\\tthe\\texpe -\\nrience\\tof\\tthe\\tprovider,\\tthe\\tavailability\\tof\\tthe\\tdrugs,\\tand\\tby\\tknown\\tcontraindications.\\nBox 5: Recommendations for the treatment of PPH – fluid resuscitation and tr anexamic acid\\n15. The use of isotonic crystalloids is recommended in preference to the use of colloids for the \\nintravenous\\tfluid\\tresuscitation\\tof\\twomen\\twith\\tPPH.\\t(Strong\\trecommendation,\\tlow-quality\\t\\nevidence)\\n16.\\tThe\\tuse\\tof\\ttranexamic\\tacid\\tis\\trecommended\\tfor\\tthe\\ttreatment\\tof\\tPPH\\tif\\toxytocin\\tand\\tother\\t\\nuterotonics fail to stop the bleeding or if it is thought that the bleeding may be partly due to \\ntrauma.\\t(Weak\\trecommendation,\\tmoderate-quality\\tevidence)\\nRemarks\\n•\\tEvidence\\tfor\\tthe\\trecommendation\\tof\\ttranexamic\\tacid\\twas\\textrapolated\\tfrom\\tthe\\tliterature\\ton\\tsurgery\\t\\nand\\ttrauma,\\twhich\\tshows\\ttranexamic\\tacid\\tto\\tbe\\ta\\tsafe\\toption\\tfor\\tthe\\ttreatment\\tof\\ttrauma-related\\t\\nbleeding. ', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 24}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n20\\nBox 6: Recommendations for the treatment of PPH – manoeuvres and other procedures\\n17. Uterine\\tmassage\\tis\\trecommended\\tfor\\tthe\\ttreatment\\tof\\tPPH.\\t(Strong\\trecommendation,\\tvery-\\nlow-quality\\tevidence)\\n18. If\\twomen\\tdo\\tnot\\trespond\\tto\\ttreatment\\tusing\\tuterotonics,\\tor\\tif\\tuterotonics\\tare\\tunavailable,\\t\\nthe use of intrauterine balloon tamponade is recommended for the treatment of PPH due to \\nuterine\\tatony.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n19. If\\tother\\tmeasures\\thave\\tfailed\\tand\\tif\\tthe\\tnecessary\\tresources\\tare\\tavailable,\\tthe\\tuse\\tof\\tuter -\\nine\\tartery\\tembolization\\tis\\trecommended\\tas\\ta\\ttreatment\\tfor\\tPPH\\tdue\\tto\\tuterine\\tatony.\\t(Weak\\t\\nrecommendation,\\tvery-low-quality\\tevidence)\\n20. If bleeding does not stop in spite of treatment using uterotonics and other available conserva -\\ntive\\tinterventions\\t(e.g.\\tuterine\\tmassage,\\tballoon\\ttamponade),\\tthe\\tuse\\tof\\tsurgical\\tinterven -\\ntions\\tis\\trecommended.\\t(Strong\\trecommendation,\\tvery-low-quality\\tevidence)\\n21. The use of bimanual uterine compression is recommended as a temporizing measure until \\nappropriate care is available for the treatment of PPH due to uterine atony after vaginal \\ndelivery.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n22. The\\tuse\\tof\\texternal\\taortic\\tcompression\\tfor\\tthe\\ttreatment\\tof\\tPPH\\tdue\\tto\\tuterine\\tatony\\tafter\\t\\nvaginal birth is recommended as a temporizing measure until appropriate care is available. \\n(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n23. The\\tuse\\tof\\tnon-pneumatic\\tanti-shock\\tgarments\\tis\\trecommended\\tas\\ta\\ttemporizing\\tmeasure\\t\\nuntil\\tappropriate\\tcare\\tis\\tavailable.\\t(Weak\\trecommendation,\\tlow-quality\\tevidence)\\n24. The\\tuse\\tof\\tuterine\\tpacking\\tis\\tnot\\trecommended\\tfor\\tthe\\ttreatment\\tof\\tPPH\\tdue\\tto\\tuterine\\t\\natony\\tafter\\tvaginal\\tbirth.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\nRemarks\\n•\\tThe GDG noted that the application of these interventions requires training and that maternal discom -\\nfort and complications associated with these procedures have been reported.\\n•\\tUterine\\tmassage\\tas\\ta\\ttherapeutic\\tmeasure\\tis\\tdefined\\tas\\tthe\\trubbing\\tof\\tthe\\tuterus\\tachieved\\tthrough\\tthe\\t\\nmanual massaging of the abdomen. This is typically sustained until the bleeding stops or the uterus con -\\ntracts. The GDP considered that uterine massage should be started once PPH has been diagnosed.\\n•\\tThe\\tinitial\\trubbing\\tof\\tthe\\tuterus\\tand\\texpression\\tof\\tblood\\tclots\\tare\\tnot\\tregarded\\tas\\ttherapeutic\\tuterine\\t\\nmassage.\\n•\\tWhen\\trating\\tthe\\trecommendation\\t#17\\tas\\t‘strong’,\\tthe\\tlow\\tcost\\tand\\tsafety\\tof\\tuterine\\tmassage\\twere\\t\\ntaken\\tinto\\taccount.\\n•\\tThe use of balloon tamponade was considered by the GDG to be a measure that can potentially avoid \\nsurgery\\tor\\tas\\ta\\ttemporizing\\tmeasure\\twhile\\tawaiting\\ttransfer\\tto\\ta\\thigher\\tlevel\\tfacility.\\t The\\tGDG\\tacknowl -\\nedges\\tthat\\tballoon\\ttamponade\\tcan\\tbe\\tobtained\\twith\\tspecific\\tdevices\\tas\\twell\\tas\\twith\\tlower\\tcost\\tadapta -\\ntions,\\tincluding\\tthose\\tbased\\ton\\tthe\\tuse\\tof\\tcondoms\\tand\\tsurgical\\tgloves.\\n•\\tThe\\tGDG\\tnoted\\tthat\\tuterine\\tartery\\tembolization\\trequires\\tsignificant\\tresources,\\tin\\tterms\\tof\\tthe\\tcost\\tof\\t\\nthe\\ttreatment,\\tthe\\tfacilities,\\tand\\tthe\\ttraining\\tof\\thealth\\tcare\\tworkers.\\n•\\tThe\\tGDG\\tnoted\\tthat\\tconservative\\tsurgical\\tapproaches\\tshould\\tbe\\ttried\\tfirst.\\tIf\\tthese\\tdo\\tnot\\twork,\\tthey\\t\\nshould\\tbe\\tfollowed\\tby\\tmore\\tinvasive\\tprocedures.\\tCompression\\tsutures,\\tfor\\texample,\\tmay\\tbe\\tattempted\\t\\nas\\ta\\tfirst\\tintervention,\\tand\\tif\\tthese\\tfail,\\tthen\\tuterine,\\tutero-ovarian\\tand\\thypogastric\\tvessel\\tligation\\tmay\\t\\nbe\\ttried.\\tIf\\tlife-threatening\\tbleeding\\tcontinues\\teven\\tafter\\tligation,\\tthen\\ta\\tsubtotal\\t(otherwise\\tknown\\tas\\t\\nsupracervical)\\tor\\ttotal\\thysterectomy\\tshould\\tbe\\tperformed.\\n•\\tThe\\tGDG\\tacknowledged\\tthat\\tthe\\tlevel\\tof\\thealth\\tcare\\tprovider\\tskills\\twill\\tplay\\ta\\trole\\tin\\tthe\\tselection\\tand\\t\\nsequence of the surgical interventions.\\n(Continued on next page)', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 25}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n21\\n•\\tExternal\\taortic\\tcompression\\thas\\tlong\\tbeen\\trecommended\\tas\\ta\\tpotential\\tlife-saving\\ttechnique,\\tand\\tme -\\nchanical\\tcompression\\tof\\tthe\\taorta,\\tif\\tsuccessful,\\tslows\\tblood\\tloss.\\t The\\tGDG\\tplaced\\ta\\thigh\\tvalue\\ton\\tthis\\t\\nprocedure as a temporizing measure in the treatment of PPH.\\n•\\tThe\\tGDG\\tnoted\\tthat\\tresearch\\tevaluating\\tthe\\tpotential\\tbenefits\\tand\\tharms\\tof\\tnon-pneumatic\\tanti-shock\\t\\ngarments\\tis\\tongoing.\\tBased\\ton\\tthe\\tevidence\\tavailable,\\tthe\\tGDG\\tregarded\\tnon-pneumatic\\tanti-shock\\tgar -\\nments as a temporizing measure while transfer is awaited.\\n•\\tThe\\tGDG\\tnoted\\tthat\\tthere\\twas\\tno\\tevidence\\tof\\tbenefit\\tof\\tuterine\\tpacking\\tand\\tplaced\\ta\\thigh\\tvalue\\ton\\t\\nconcerns regarding its potential harm.\\nBox 7: Recommendations for the treatment of retained placenta\\n25. If\\tthe\\tplacenta\\tis\\tnot\\texpelled\\tspontaneously,\\tthe\\tuse\\tof\\tadditional\\toxytocin\\t(10  IU,\\tIV/IM)\\tin\\t\\ncombination\\twith\\tcontrolled\\tcord\\ttraction\\tis\\trecommended.\\t(Weak\\trecommendation,\\tvery-\\nlow-quality\\tevidence)\\n26.\\tThe use of ergometrine for the management of a retained placenta is not recommended as \\nthis\\tmay\\tcause\\ttetanic\\tuterine\\tcontractions\\twhich\\tmay\\tdelay\\tthe\\texpulsion\\tof\\tthe\\tplacenta.\\t\\n(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n27. The\\tuse\\tof\\tprostaglandin\\tE2\\talpha\\t(dinoprostone\\tor\\tsulprostone)\\tin\\tthe\\tmanagement\\tof\\tre -\\ntained\\tplacenta\\tis\\tnot\\trecommended.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n28. A\\tsingle\\tdose\\tof\\tantibiotics\\t(ampicillin\\tor\\tfirst-generation\\tcephalosporin)\\tis\\trecommended\\tif\\t\\nmanual\\tremoval\\tof\\tthe\\tplacenta\\tis\\tpractised.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevi -\\ndence)\\nRemarks\\n•\\tThe GDG found no empirical evidence to support recommending the use of uterotonics for the manage -\\nment of a retained placenta in the absence of haemorrhage. The above recommendation was reached \\nby consensus.\\n•\\tThe\\tWHO\\tguide,\\t“ Managing complications in pregnancy and childbirth ”\\t(WHO,\\t2007),\\tstates\\tthat\\tif\\ta\\t\\nplacenta\\tis\\tnot\\texpelled\\twithin\\t30\\tminutes\\tafter\\tthe\\tdelivery\\tof\\ta\\tbaby,\\tthe\\twoman\\tshould\\tbe\\tdiagnosed\\t\\nas\\thaving\\ta\\tretained\\tplacenta.\\tSince\\tthere\\tis\\tno\\tevidence\\tfor\\tor\\tagainst\\tthis\\tdefinition,\\tthe\\tdelay\\tused\\t\\nbefore this condition is diagnosed is left to the judgement of the clinician.\\n•\\tThe\\tsame\\tWHO\\tguide\\talso\\tsuggests\\tthat\\tin\\tthe\\tabsence\\tof\\thaemorrhage,\\tthe\\twoman\\tshould\\tbe\\tobserved\\t\\nfor\\ta\\tfurther\\t30\\tminutes\\tafter\\tthe\\tinitial\\t30\\tminutes,\\tbefore\\tthe\\tmanual\\tremoval\\tof\\tthe\\tplacenta\\tis\\tat -\\ntempted.\\t The\\tGDG\\tnoted\\tthat\\tspontaneous\\texpulsion\\tof\\tthe\\tplacenta\\tcan\\tstill\\toccur,\\teven\\tin\\tthe\\tabsence\\t\\nof bleeding. A conservative approach is therefore advised and the timing of the manual removal of the \\nplacenta\\tas\\ta\\tdefinitive\\ttreatment\\tis\\tleft\\tto\\tthe\\tjudgement\\tof\\tthe\\tclinician.\\n•\\tThe\\trecommendation\\tregarding\\tthe\\tuse\\tof\\tprostaglandin\\tE2\\tis\\tinformed\\tby\\ta\\tlack\\tof\\tevidence\\ton\\tthis\\t\\nquestion\\tand\\talso\\tby\\tconcerns\\trelated\\tto\\tadverse\\tevents,\\tparticularly\\tcardiac\\tevents.\\n•\\tDirect\\tevidence\\tof\\tthe\\tvalue\\tof\\tantibiotic\\tprophylaxis\\tafter\\tthe\\tmanual\\tremoval\\tof\\tthe\\tplacenta\\twas\\tnot\\t\\navailable.\\t The\\tGDG\\tconsidered\\tindirect\\tevidence\\tof\\tthe\\tbenefit\\tof\\tprophylactic\\tantibiotics\\tfrom\\tstudies\\t\\nof\\tcaesarean\\tsection\\tand\\tabortion,\\tas\\twell\\tas\\tobservational\\tstudies\\tof\\tother\\tintrauterine\\tmanipulations.\\n•\\tCurrent\\tpractice\\tsuggests\\tthat\\tampicillin\\tor\\tfirst-generation\\tcephalosporins\\tmay\\tbe\\tadministered\\twhen\\t\\nthe manual removal of the placenta is performed.\\n•\\tThis\\tquestion\\twas\\tidentified\\tas\\ta\\tresearch\\tpriority\\tfor\\tsettings\\tin\\twhich\\tprophylactic\\tantibiotics\\tare\\tnot\\t\\nroutinely administered and those with low infectious morbidity. (Continued from previous page)', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 26}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n22\\nBox 8: Health Systems and Organization of Care recommendations for the prevention and \\ntreatment of PPH\\n29. The use of formal protocols by health facilities for the prevention and treatment of PPH is \\nrecommended.\\t(Weak\\trecommendation,\\tmoderate-quality\\tevidence)\\n30. The use of formal protocols for referral of women to a higher level of care is recommended \\nfor\\thealth\\tfacilities.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n31. The use of simulations of PPH treatment is recommended for pre-service and in-service train -\\ning\\tprogrammes.\\t(Weak\\trecommendation,\\tvery-low-quality\\tevidence)\\n32. Monitoring the use of uterotonics after birth for the prevention of PPH is recommended as \\na\\tprocess\\tindicator\\tfor\\tprogrammatic\\tevaluation.\\t(Weak\\trecommendation,\\tvery-low-quality\\t\\nevidence)\\nRemarks\\n•\\tRoutine\\tand\\tfrequent\\tuterine\\ttone\\tassessment\\tremains\\ta\\tcrucial\\tpart\\tof\\timmediate\\tpostpartum\\tcare,\\t\\nparticularly for optimizing the early diagnosis of PPH.\\n•\\tThe\\tGDG\\tacknowledged\\tthat\\tthe\\timplementation\\tof\\tformal\\tprotocols\\tis\\ta\\tcomplex\\tprocess\\twhich\\twill\\t\\nrequire the local adaptation of general guidelines.\\n•\\tThe\\tGDG\\tplaced\\ta\\thigh\\tvalue\\ton\\tthe\\tcosts\\tof\\tsimulation\\tprogrammes\\tand\\tacknowledged\\tthat\\tthere\\tare\\t\\ndifferent\\ttypes\\tof\\tsimulation\\tprogrammes.\\tSome\\tprogrammes\\tare\\thi-tech,\\tcomputerized\\tand\\tcostly\\twhile\\t\\nothers\\tare\\tless\\texpensive\\tand\\tmore\\tlikely\\tto\\tbe\\taffordable\\tin\\tlow-\\tand\\tmiddle-income\\tcountries.\\t The\\t\\nGDG\\tidentified\\timprovement\\tin\\tcommunication\\tbetween\\thealth\\tcare\\tproviders\\tand\\tpatients\\tand\\ttheir\\t\\nfamily members as an important priority in the training of health care providers in PPH management.\\n•\\tThe GDG recommended monitoring the use of prophylactic uterotonics. This recommendation is based \\non\\texperience\\tfrom\\tother\\tareas\\tof\\thealth\\tcare,\\tparticularly\\tchild\\thealth,\\twhere\\tcontent-based\\thealth\\t\\nindicators are common and regarded as useful for programmatic purposes. The suggested indicator is \\ncalculated as the number of women receiving prophylactic uterotonic drugs after birth divided by all \\nwomen giving birth.', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 27}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n23\\nBox 9: Statements related to topics for which there is insufficient ev idence to issue a recom -\\nmendation\\nA.\\t There\\tis\\tinsufficient\\tevidence\\tto\\trecommend\\tone\\toxytocin\\troute\\tover\\tanother\\tfor\\tthe\\tprevention\\tof\\tPPH.\\nB.\\t There\\tis\\tinsufficient\\tevidence\\tto\\trecommend\\tthe\\tuse\\tof\\trecombinant\\tfactor\\tVIIa\\tfor\\tthe\\ttreatment\\tof\\t\\nPPH.\\nC.\\t There\\tis\\tinsufficient\\tevidence\\tto\\trecommend\\tthe\\tuse\\tof\\tintraumbilical\\tvein\\tinjection\\tof\\toxytocin\\tas\\ta\\t\\ntreatment for retained placenta.\\nD.\\t There\\tis\\tinsufficient\\tevidence\\tto\\trecommend\\tthe\\tantenatal\\tdistribution\\tof\\tmisoprostol\\tto\\tpregnant\\t\\nwomen for self-administration for the prevention of PPH. \\nE.\\t There\\tis\\tinsufficient\\tevidence\\tto\\trecommend\\tthe\\tmeasurement\\tof\\tblood\\tloss\\tover\\tclinical\\testimation\\tof\\t\\nblood loss.\\nRemarks\\n•\\tThe\\tGDG\\tnoted\\tthat\\tthere\\tare\\tthree\\tongoing\\ttrials\\tin\\twhich\\tthe\\tIV\\tand\\tIM\\troutes\\tfor\\toxytocin\\tadministra -\\ntion are being compared for the prevention of PPH.\\n•\\tThe\\tGDG\\tconsidered\\tthere\\tto\\tbe\\tinsufficient\\tevidence\\tto\\trecommend\\tthe\\tuse\\tof\\toxytocin\\tinfusion\\tover\\t\\nIV\\tbolus\\tinjection\\twith\\tregard\\tto\\tblood\\tloss.\\tHowever,\\tin\\tlight\\tof\\tconcerns\\tabout\\tthe\\tpotential\\tadverse\\t\\nhaemodynamic\\teffects,\\tthe\\tGDG\\tconsidered\\tthat\\tif\\tIV\\tbolus\\tinjection\\ttreatment\\tis\\tto\\tbe\\tused\\tthen\\ta\\t\\nslow injection rate is preferred and a rapid injection rate should be avoided.\\n•\\tIn\\tthe\\tcontext\\tof\\tPPH,\\tthe\\tGDP \\tconsidered\\tthat\\tthe\\tuse\\tof\\trecombinant\\tfactor\\tVIIa\\tshould\\tbe\\tlimited\\tto\\t\\nwomen\\twith\\tspecific\\thaematological\\tindications.\\t The\\tgroup\\tregarded\\tthe\\trecombinant\\tfactor\\tVIIa\\tas\\ta\\t\\npotentially\\tlife-saving\\tdrug,\\tbut\\tnoted\\tthat\\tit\\tis\\talso\\tassociated\\twith\\tlife-threatening\\tside-effects.\\tMore -\\nover,\\trecombinant\\tfactor\\tVIIa\\tis\\texpensive\\tand\\tmay\\tbe\\tdifficult\\tto\\tadminister.\\n•\\tThe\\tGDG\\tacknowledged\\tthat\\twhile\\tthere\\tis\\ta\\tpaucity\\tof\\tdata\\tto\\trecommend\\tintraumbilical\\tvein\\tinjec -\\ntion\\tof\\toxytocin\\tas\\ta\\ttreatment\\tfor\\tretained\\tplacenta,\\tthe\\tprocedure\\titself\\thas\\tnot\\tbeen\\tshown\\tto\\tcause\\t\\nharm\\tand\\tdemonstrates\\ta\\tnon-significant\\ttrend\\ttowards\\ta\\tlower\\trisk\\tof\\trequiring\\tthe\\tmanual\\tremoval\\tof\\t\\nthe placenta.\\n•\\tThe\\tGDG\\tacknowledged\\tthat\\ta\\tnumber\\tof\\tcountries\\thave\\tembarked\\ton\\tcommunity-level\\tprogrammes\\tof\\t\\nmisoprostol\\tdistribution\\tand\\tconsidered\\tthat\\tthis\\tshould\\tbe\\tdone\\tin\\tthe\\tcontext\\tof\\tresearch\\t(where\\treli -\\nable\\tdata\\ton\\tcoverage,\\tsafety\\tand\\thealth\\toutcomes\\tcan\\tbe\\tcollected).\\n•\\tThe GDG noted that all trials included in the systematic review on the measurement of blood loss were \\nconducted in developed countries and views the applicability of this evidence to low- and middle-\\nincome countries as very uncertain.', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 28}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n24\\n4. Research implications\\nThe\\tGDG\\tidentified\\timportant\\tknowledge\\tgaps\\tthat\\tneed\\tto\\tbe\\taddressed\\tthrough\\t\\nprimary\\tresearch.\\tIn\\tthis\\tguideline,\\trecommendations\\tbased\\ton\\tevidence\\tquality\\tthat\\t\\nwas\\trated\\tas\\t‘very\\tlow’ \\tor\\t‘low’ \\trequire\\tfurther\\tresearch.\\tConversely,\\tfurther\\tre -\\nsearch\\tis\\tnot\\ta\\tpriority\\tfor\\tthose\\trecommendations\\tbased\\ton\\tevidence\\tof\\t‘moderate’ \\t\\nor\\t‘high’ \\tquality.\\tKnowledge\\tgaps\\tidentified\\tin\\tthe\\t2007\\tand\\t2009\\tWHO\\tdocuments\\t\\nwere\\talso\\treviewed.\\t The\\tidentified\\tknowledge\\tgaps\\twere\\tprioritized\\tby\\tconsidering\\t\\nwhether\\tsuch\\tresearch\\twould\\tbe\\tfeasible,\\tinnovative,\\toriginal,\\tlikely\\tto\\tpromote\\t\\nequity,\\tand\\tcontribute\\tto\\tthe\\treduction\\tof\\tthe\\tburden\\tof\\tPPH.\\t The\\tmain\\tbarriers\\tto\\t\\nscaling\\tup\\tthe\\tintervention\\twere\\talso\\tconsidered\\tin\\tthis\\tprioritization\\texercise.\\nThe GDG noted that research is either planned or ongoing for some of the research \\npriorities\\tidentified.\\tHowever,\\tthere\\tis\\tno\\tcertainty\\tthat\\tthese\\tinvestigations\\twill\\t\\nprovide\\tconclusive\\tresults,\\tand\\tthe\\ttopics\\thave\\ttherefore\\tremained\\tlisted\\tas\\tre -\\nsearch priorities in this document.\\nKey research priority\\nIn\\tsettings\\twhere\\tthe\\tuse\\tof\\tinjectable\\tuterotonics\\tis\\tnot\\tfeasible,\\twhat\\tare\\tthe\\tef -\\nfects of antenatal distribution of misoprostol to pregnant women for self-administra -\\ntion during the third stage of labour?\\nOther research questions \\n•\\tWhat\\tis\\tthe\\tminimum\\teffective\\tdose\\tof\\toxytocin\\tfor\\tthe\\tprevention\\tof\\tPPH?\\t\\n•\\tWhat\\tare\\tthe\\teffects\\tof\\tIM\\toxytocin\\t(versus\\tIV\\toxytocin)\\tfor\\tthe\\tprevention\\tof\\t\\nPPH?\\n•\\tCan\\toxytocin\\tbe\\tadministered\\tsafely\\tby\\tunskilled\\tattendants?\\n•\\tWhat\\tare\\tthe\\teffects\\tof\\tbuccal\\tand\\tsublingual\\tuse\\tof\\toxytocin\\tfor\\tthe\\tprevention\\t\\nof PPH?\\n•\\tWhat is the minimum effective dose of misoprostol for the prevention of PPH?\\n•\\tWhat is the minimum effective dose of misoprostol for the treatment of PPH?\\n•\\tWhat\\tare\\teffects\\tand\\tsafety\\tof\\tmisoprostol\\tas\\ttreatment\\tfor\\tPPH,\\tin\\twomen\\twho\\t\\nreceived\\tmisoprostol\\tas\\tPPH\\tprophylaxis?\\t\\n•\\tShould\\tmisoprostol\\tbe\\tused\\tin\\taddition\\tto\\toxytocin\\tfor\\tPPH\\tprevention?\\n•\\tWhat\\tare\\tthe\\teffects\\tof\\ttranexamic\\tacid\\tin\\tPPH\\ttreatment?\\n•\\tWhat are the effects of uterine massage for the prevention of PPH?\\n•\\tWhat\\tare\\tthe\\teffects\\tof\\tuterine\\tmassage\\tto\\tprevent\\tPPH,\\twhere\\toxytocin\\tis\\tnot\\t\\navailable? \\n•\\tWhat are the effects of uterine balloon or tamponade in the treatment of PPH?\\n•\\tWhat\\tare\\tthe\\teffects\\tof\\tuterine\\tmassage\\tto\\tprevent\\tPPH,\\twhere\\tonly\\tmisoprostol\\t\\nis available? ', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 29}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n25\\n•\\tWhat\\tare\\tthe\\teffects\\tof\\tprophylactic\\tantibiotics\\tafter\\tmanual\\textraction\\tof\\tthe\\t\\nplacenta as part of the treatment of retained placenta?\\n•\\tWhat are the effects of the use of misoprostol for the treatment of retained \\nplacenta?\\n•\\tWhat\\tare\\teffects\\tof\\tergometrine\\t(in\\tcombination\\tor\\tnot\\twith\\toxytocin)\\tafter\\t\\ncaesarean section for the prevention of PPH?\\n•\\tWhat\\tis\\tthe\\toptimal\\ttime\\tfor\\tcord\\tclamping\\tin\\tthe\\tcontext\\tof\\tphysiologic\\tand\\tac -\\ntive management of third stage of labour?\\n•\\tWhat\\tis\\tthe\\tappropriate\\ttime\\tto\\tadminister\\toxytocin\\tfor\\tPPH\\tprevention,\\trela -\\ntive\\tto\\tcord\\tclamping\\tand\\tplacental\\tdelivery?\\t(i.e.\\tbefore/after\\tcord\\tclamping,\\t\\nbefore/after\\tplacenta\\tdelivery)\\n•\\tWhich clinical consequences of blood loss are of greatest value for the diagnosis \\nand treatment of PPH?\\n•\\tWhat\\tis\\tthe\\trole\\tof\\tlay\\thealth\\tworkers\\tin\\tmanagement\\tof\\tPPH?\\n5. Dissemination and implementation of \\nthe guideline\\nThe ultimate goal of this guideline is to improve the quality of care and health \\noutcomes related to PPH. Therefore the dissemination and implementation of this \\nguideline\\tare\\tcrucial\\tsteps\\tthat\\tshould\\tbe\\tundertaken\\tby\\tthe\\tinternational\\tcommu -\\nnity and local health care services. The WHO Department of Reproductive Health \\nand\\tResearch\\thas\\tadopted\\ta\\tformal\\tknowledge-to-action\\tframework\\tfor\\tthe\\tdissemi -\\nnation,\\tadaptation\\tand\\timplementation\\tof\\tguidelines\\t(8).\\tIn\\taddition\\tto\\tthis\\tframe -\\nwork,\\ta\\tlist\\tof\\tpriority\\tactions\\twas\\testablished\\tduring\\tthe\\tWHO\\t Technical\\tConsulta -\\ntion which will be used by the WHO and other partners to foster the dissemination \\nand\\timplementation\\tof\\tthis\\tguideline\\t(EB\\tBox\\t2).\\nGuideline dissemination and evaluation\\nThe recommendations in this guideline will be disseminated through a broad net -\\nwork\\tof\\tinternational\\tpartners,\\tincluding\\tWHO\\tcountry\\tand\\tregional\\toffices,\\tmin -\\nistries\\tof\\thealth,\\tWHO\\tcollaborating\\tcentres,\\tother\\tUnited\\tNations\\tagencies,\\tand\\t\\nnon-governmental organizations. They will also be published on the WHO website \\nand\\tin\\tThe\\tWHO\\tReproductive\\tHealth\\tLibrary\\t(11),\\twhere\\tthey\\twill\\tbe\\taccompanied\\t\\nby an independent critical appraisal based on the AGREE instrument (Appraisal of \\nGuidelines\\tResearch\\tand\\tEvaluation)\\twhich\\tcan\\tbe\\tfound\\tat\\thttp://www.agreecol -\\nlaboration.org/instrument.\\t A\\tpolicy\\tbrief\\twill\\talso\\tbe\\tdeveloped\\tfor\\ta\\twide\\trange\\tof\\t\\npolicy-makers,\\tprogramme\\tmanagers\\tand\\tclinicians,\\tand\\tthen\\tdisseminated\\tthrough\\t\\nWHO\\tcountry\\toffices.\\nGuideline implementation\\nThe successful introduction of evidence-based policies related to the prevention and \\nmanagement of PPH into national programmes and health care services depends on \\nwell-planned and participatory consensus-driven processes of adaptation and imple -', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 30}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n26\\nmentation.\\t These\\tprocesses\\tmay\\tinclude\\tthe\\tdevelopment\\tor\\trevision\\tof\\texisting\\t\\nnational guidelines or protocols based on this document.\\nThe recommendations contained in the present guideline should be adapted into \\nlocally-appropriate\\tdocuments\\tthat\\tare\\table\\tto\\tmeet\\tthe\\tspecific\\tneeds\\tof\\teach\\t\\ncountry\\tand\\thealth\\tservice.\\tModifications\\tto\\tthe\\trecommendations,\\twhere\\tnecessary,\\t\\nshould\\tbe\\tlimited\\tto\\tweak\\trecommendations\\tand\\tjustifications\\tfor\\tany\\tchanges\\tmade\\t\\nin\\tan\\texplicit\\tand\\ttransparent\\tmanner.\\t\\nAn enabling environment should be created for the use of these recommendations \\n(for\\texample,\\tby\\twidening\\tthe\\tavailability\\tof\\tuterotonics),\\tincluding\\tchanges\\tin\\tthe\\t\\nbehaviour of health care practitioners to enable the use of evidence-based practic -\\nes. Local professional societies may play important roles in this process and an all-\\ninclusive\\tand\\tparticipatory\\tprocess\\tshould\\tbe\\tencouraged.\\t The\\tWHO’s\\tDepartment\\tof\\t\\nReproductive\\tHealth\\tand\\tResearch\\thas\\tpublished\\tspecific\\tguidance\\ton\\tthe\\tintroduc -\\ntion\\tof\\tthe\\tWHO’s\\treproductive\\thealth\\tguidelines\\tand\\ttools\\tin\\tnational\\tprogrammes.\\n6. Applicability issues\\nAnticipated impact on the organization of care and  \\nresources\\nThe evidence-based prevention and management of PPH can be achieved with the \\nuse\\tof\\trelatively\\tinexpensive\\tdrugs.\\tHowever,\\tthe\\tGDG\\tnoted\\tthat\\tthe\\tfollowing\\tis -\\nsues should be considered before the recommendations made in this current guide -\\nline\\tare\\tapplied:\\n•\\tWomen\\tshould\\tnot\\tbe\\tleft\\talone\\tduring\\tthe\\tfirst\\thours\\tafter\\tdelivery\\tof\\tthe\\tbaby\\t\\nand the placenta\\n•\\tIn\\tsettings\\twhere\\toxytocin\\tis\\tused,\\tattention\\tshould\\tbe\\tpaid\\tto\\tthe\\toxytocin\\tcold\\t\\nchain\\t(i.e.\\tthe\\trequirements\\tof\\ta\\ttemperature-controlled\\tsupply\\tchain)\\n•\\tHealth services adopting late cord clamping should also adopt strategies to iden -\\ntify\\t(and\\tif\\tnecessary\\tto\\ttreat)\\tneonatal\\tjaundice\\nMonitoring and evaluating the guideline implementation\\nThe implementation of the recommendations in this guideline should be monitored \\nat\\tthe\\thealth-service\\tlevel.\\tInterrupted\\ttime\\tseries,\\tclinical\\taudits\\tor\\tcriterion-based\\t\\nclinical audits could be used to obtain relevant data related to the management of \\nPPH.\\tClearly-defined\\treview\\tcriteria\\tand\\tindicators\\tare\\tneeded\\tand\\tthese\\tcould\\tbe\\t\\nassociated with locally-agreed targets. The GDG strongly recommends that the cov -\\nerage of prophylactic uterotonics be used as a process indicator for the monitoring \\nand prevention of PPH.\\n•\\tProphylactic\\tUterotonic\\tCoverage\\tIndicator:\\t The\\tsuggested\\tindicator\\tis\\tcalculat -\\ned as the number of women receiving prophylactic uterotonics during the third \\nstage of labour divided by all women giving birth\\nThis\\tindicator\\tprovides\\tan\\toverall\\tassessment\\tof\\tadherence\\tto\\ta\\tkey\\trecommendation\\t\\nincluded\\tin\\tthis\\tguideline.\\t The\\tuse\\tof\\tother\\tlocally-agreed\\tand\\tmore\\tspecific\\tindica -', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 31}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n27\\ntors\\t(e.g.\\tthe\\tassessment\\tof\\tthe\\tuse\\tof\\tspecific\\tuterotonics)\\tmay\\tbe\\tnecessary\\tto\\t\\nobtain a more complete assessment of the quality of care related to the prevention \\nand\\ttreatment\\tof\\tPPH.\\tWHO\\thas\\tdeveloped\\tspecific\\tguidance\\tfor\\tevaluating\\tthe\\tqual -\\nity\\tof\\tcare\\tfor\\tsevere\\tmaternal\\tcomplications\\t(including\\tPPH)\\tbased\\ton\\tthe\\tnear-miss\\t\\nand\\tcriterion-based\\tclinical\\taudit\\tconcepts\\t(13).\\n7. Updating the guideline\\nThis\\tguideline\\twill\\tbe\\tupdated\\tin\\t2017\\tor\\tfollowing\\tthe\\tidentification\\tof\\tnew\\tevi -\\ndence that indicates a need to revise these recommendations. WHO welcomes sug -\\ngestions regarding additional questions for inclusion in the updated guideline. Please \\ne-mail\\tyour\\tsuggestions\\tto:\\treproductivehealth@who.int.\\nReferences\\n1. Khan\\tKS,\\tWojdyla\\tD,\\tSay\\tL,\\tGülmezoglu\\t AM,\\tVan\\tLook\\tPF.\\tWHO\\tanalysis\\tof\\tcauses\\t\\nof\\tmaternal\\tdeath:\\t A\\tsystematic\\treview.\\t Lancet.\\t2006;367\\t(9516):\\t1066–74.\\t\\n2. Campbell\\tOM,\\tGraham\\tWJ.\\tLancet\\tMaternal\\tSurvival\\tSeries\\tSteering\\tGroup.\\t\\nStrategies\\tfor\\treducing\\tmaternal\\tmortality:\\tgetting\\ton\\twith\\twhat\\tworks.\\t Lancet . \\n2006;368\\t(9543):\\t1284–99.\\t\\n3. World Health Organization. World Health Organization multicountry survey on \\nmaternal and newborn health .\\tGeneva:\\tWHO;\\t2012\\t\\n4. World Health Organization. Managing complication in pregnancy and child\\xad\\nbirth: a guide for midwives and doctors .\\tGeneva:\\tWHO;\\t2000.\\t Available\\tfrom:\\t\\nhttp://www.who.int/reproductivehealth/publications/maternal_perinatal_\\t\\nhealth/9241545879/en/index.html\\t\\n5. Begley\\tCM,\\tGyte\\tGM,\\tDevane\\tD,\\tMcGuire\\tW,\\tWeeks\\t A.\\tActive\\tversus\\texpect -\\nant management for women in the third stage of labour. Cochrane Data \\xad\\nbase Syst Rev. \\t2011(11).\\t Available\\tfrom:\\thttp://onlinelibrary.wiley.com/\\ndoi/10.1002/14651858.CD007412.pub3/abstract\\n6.\\tWorld Health Organization. WHO recommendations for the prevention of post \\xad\\npartum haemorrhage .\\tGeneva:\\tWHO;\\t2007.\\t Available\\tfrom:\\thttp://whqlibdoc.\\nwho.int/hq/2007/WHO_MPS_07.06_eng.pdf\\t\\n7. World Health Organization. WHO guidelines for the management of postpar \\xad\\ntum haemorrhage and retained placenta .\\tGeneva:\\tWHO;\\t2009.\\t Available\\tfrom:\\t\\nhttp://whqlibdoc.who.int/publications/2009/9789241598514_eng.pdf\\t\\n8. World Health Organization. Knowledge to action framework and the G.R.E.A.T \\nproject.\\tGeneva:\\tWHO;\\t2010.\\t Available\\tfrom:\\thttp://www.who.int/reproduc-\\ntivehealth/topics/best_practices/greatproject_KTAframework/en/index.html\\t\\n9. World Health Organization. WHO Handbook for guideline development.  \\nGeneva:\\tWHO;\\t2012.\\t Available\\tfrom:\\thttp://apps.who.int/iris/bitstre\\nam/10665/75146/1/9789241548441_eng.pdf', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 32}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n28\\n10. World Health Organization. Guidelines on basic newborn resuscitation.  \\nGeneva:\\tWHO;\\t2012.\\t Available\\tfrom:\\thttp://apps.who.int/iris/bitstre\\nam/10665/75157/1/9789241503693_eng.pdf\\n11. World Health Organization. The WHO Reproductive Health Library. \\tGeneva:\\tWHO.\\t\\nAvailable\\tfrom:\\twww.who.int/rhl\\n12. World Health Organization.  Introducing WHO’s sexual and reproductive health \\nguidelines and tools into national programmes: principles and process of adap\\xad\\ntation and implementation. \\tGeneva:\\tWHO;\\t2007.\\t Available\\tfrom:\\thttp://www.\\t\\nwho.int/reproductivehealth/publications/general/RHR_07_09/en/index.html\\t\\n13. World Health Organization. Evaluating the quality of care for severe preg \\xad\\nnancy complications: the WHO near \\xadmiss approach for maternal health. \\nGeneva:\\tWHO;\\t2011.\\t Available\\tfrom:\\thttp://whqlibdoc.who.int/publica -\\ntions/2011/9789241502221_eng.pdf\\t\\nThe full list of references that support the recommendations is included in the docu -\\nment entitled “WHO recommendations for post partum haemorrhage: evidence base” \\nand\\tcan\\tbe\\taccessed\\tonline\\tat:\\twww.who.int/reproductivehealth/publications/mater -\\nnal_perinatal_health/9789241548502/en/', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 33}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n29\\nAnnex 1. External experts, WHO staff involved in the \\npreparation of the guideline, and summary of decla -\\nrations of interest\\nA. Guideline Development Group (participants in the WHO Technical Consultation)\\nMembers (WHO External Advisers) \\nProfessor Hany Abdel-Aleem\\nProfessor of Obstetrics and Gynecology\\nWomen’s\\tHealth\\tCenter\\nAssiut\\tUniversity\\tHospital\\nAssiut\\nEgypt\\nDr Catherine Deneux-Tharaux\\nMedical Epidemiologist and Researcher\\nInserm\\tU953\\nRecherche épidémiologique en santé périnatale et \\nsanté des femmes et des enfants\\nHôpital Tenon\\nParis\\nFrance\\nDr Bukola Fawole\\nSenior Lecturer\\nDepartment of Obstetrics and Gynaecology\\nCollege of Medicine\\nUniversity\\tof\\tIbadan\\nIbadan\\nNigeria\\nDr Atf Ghérissi\\nMaître\\tAssistante\\tUniversitaire\\ten\\tSciences\\tde\\t\\nl’Education\\tappliquées\\tà\\tla\\tSanté\\nEcole Supérieure des Sciences et Techniques de la \\nSanté\\tUniversité\\t\\nTunis-El Manar\\nTunisia\\nMs Gill Gyte\\nResearch Associate  \\nCochrane Pregnancy and Childbirth Group  \\nUniversity\\tof\\tLiverpool  \\nLiverpool\\tWomen’s\\tHospital\\tNHS\\t Trust \\nCrown Street  \\nUnited\\tKingdomDr Justus Hofmeyr\\nDirector\\nEffective\\tCare\\tResearch\\tUnit\\t\\nUniversity\\tof\\tthe\\tWitwatersrand/\\t  \\nUniversity\\tof\\tFort\\tHare/\\t  \\nEastern Cape Department of Health\\nAmalinda Drive\\nPrivate Bag X9047\\nEast London \\nEastern Cape 5201\\nSouth Africa\\nDr Simon Lewin\\nSenior Researcher\\nGlobal\\tHealth\\tUnit\\nNorwegian\\tKnowledge\\tCentre\\tfor\\tthe\\tHealth\\t\\nServices\\t&\\tMedical\\tResearch\\tCouncil,\\tSouth\\t Africa\\nOslo\\nNorway\\nProfessor Syeda Batool Mazhar\\nProfessor of Obstetrics and Gynaecology\\nMother\\tand\\tChild\\tHealth\\tCentre\\t(MCH)\\tPakistan\\t\\nInstitute of Medical Sciences\\nIslamabad\\nPakistan\\nProfessor Suneeta Mittal\\nProfessor of Obstetrics and Gynecology \\nOfficer-in-Charge\\tof\\tthe\\tWHO\\tCollaborating\\t\\nCentre for Research on Human Reproduction\\nAll India Institute of Medical Sciences\\nNew Delhi\\nIndia\\nDr Enrique Oyarzun\\nChairman \\nDepartment Obstetrics and Gynaecology\\nFacultad de Medicina\\nPontificia\\tUniversidad\\tCatólica\\tde\\tChile\\nSantiago\\nChile', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 34}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n30\\nDr Zahida Qureshi\\nSenior Lecturer\\nDepartment of Obstetrics and Gynaecology\\nUniversity\\tof\\tNairobi\\nNairobi\\nKenya\\nProfessor Hamid Rushwan\\nChief\\tExecutive  \\nInternational Federation of Gynecology and Obstetrics\\nFIGO\\tHouse,\\tSuite\\t3\\nWaterloo\\tCourt,\\t10\\t Theed\\tStreet\\nLondon \\nSE1 8ST\\nUnited\\tKingdom\\nDr Jeffrey Michael Smith\\nDirector,\\tMaternal\\tHealth,\\tMCHIP\\nWashington\\nUSA\\nDr Tran Son Thach\\nPerinatal Epidemiologist\\nAustralian Research Centre for Health of Women and \\nBabies\\nDiscipline of Obstetrics and Gynaecology\\nThe\\tUniversity\\tof\\t Adelaide\\nWomen’s\\tand\\tChildren’s\\tHospital\\nKing\\tWilliam\\tRoad\\nAustralia\\nDr Dilys Walker\\nAssociate Professor\\nDepartment of Global Health and Obstetrics & \\nGynecology\\nUniversity\\tof\\tWashington\\nNinth\\t&\\tJefferson\\tBuilding,\\tHarborview\\tMedical\\tCenter  \\nSeattle,\\tWA\\nUSAObservers\\nMs Deborah Armbruster\\nSenior Maternal and Newborn Health Advisor\\nCenter\\tfor\\tPopulation,\\tHealth\\tand\\tNutrition\\nUnited\\tStates\\t Agency\\tfor\\tInternational\\tDevelopment\\nWashington D.C.\\nUSA\\nMs Jennifer Blum\\nGynuity Health Projects\\nNew\\tYork\\t\\nUSA\\nMs Claire Glenton\\nSenior Researcher\\nNordic\\tCochrane\\tCentre,\\tNorwegian\\tBranch/\\t  \\nGlobal\\tHealth\\tUnit\\t\\nNorwegian\\tKnowledge\\tCentre\\tfor\\tthe\\tHealth\\tServices\\nOslo\\nNorway\\nDr Sarah Rosenbaum \\nNorwegian\\tKnowledge\\tCentre\\tfor\\tthe\\t Health Services\\nOslo\\nNorway\\nMs Mary Ellen Stanton\\nSenior Reproductive Health Advisor\\nCenter\\tfor\\tPopulation,\\tHealth\\tand\\tNutrition\\nUnited\\tStates\\t Agency\\tfor\\tInternational\\tDevelopment\\nWashington D.C.\\nUSA\\nMs Clare Waite\\nProject Manager\\nMisoprostol for Post-Partum Haemorrhage in Low \\nResource Settings\\nInternational Federation of Gynecology and \\nObstetrics\\nFIGO House\\nLondon \\nUnited\\tKingdom\\nDr Beverly Winikoff\\nGynuity Health Projects\\nNew\\tYork\\nUSA\\t', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 35}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n31\\nWHO Regional and Country Offices\\nAFRO\\nDr Alicia Carbonell\\nNational\\tProfessional\\tOfficer\\nMaking\\tPregnancy\\tSafer\\tand\\tReproductive\\tHealth\\nBureau\\tde\\tpays\\tde\\tl’OMS\\t  \\nPO\\tBox\\tCP \\t377\\t \\nMaputo \\nMozambique\\nSEARO\\nDr Narimah Awin\\nMedical\\tOfficer\\nMaking\\tPregnancy\\tSafer\\tand\\tReproductive\\tHealth\\nDepartment of Family and Research\\nWorld Health Organization  \\nRegional\\tOffice\\tfor\\tSouth-East\\t Asia \\nWorld\\tHealth\\tHouse,\\tIndraprastha\\tEstate  \\nMahatma Gandhi Marg  \\nNew Delhi 110 002\\nIndia\\nWPRO\\nDr Hiromi Obara\\nMedical\\tOfficer\\nMaternal and Child Health and Nutrition\\nBuilding Healthy Communities and Populations\\nWorld Health Organization \\nRegional\\tOffice\\tfor\\tthe\\tWestern\\tPacific\\nP.O.\\tBox\\t2932  \\n1000 Manila  \\nPhilippines \\nExternal Secretariat\\nDr Edgardo Abalos\\nCentro Rosarino de Estudios Perinatales\\t(CREP)\\nRosario \\nArgentina\\nDr Virginia Diaz\\nCentro\\tRosarino\\tde\\tEstudios\\tPerinatales\\t(CREP)\\nRosario \\nArgentina\\nDr Natasha Hezelgrave\\nAcademic\\tClinical\\tFellow,\\tObstetrics\\tand\\tGynaecology\\nKings\\tCollege\\tLondon\\nGuy’s\\t&\\tSt\\t Thomas’ \\tNHS\\tFoundation\\t Trust\\nLondon\\nUnited\\tKingdomWHO Secretariat\\nDr Michael Mbizvo\\nDirector \\nDepartment of Reproductive Health and Research\\nDr Ana Pilar Betran\\nMedical\\tOfficer\\nImproving Maternal and Perinatal Health\\nResearch,\\tEvidence\\tand\\tNorms\\nDepartment of Reproductive Health and Research\\nDr Metin Gülmezoglu\\nLead Specialist\\nImproving Maternal and Perinatal Health\\nResearch,\\tEvidence\\tand\\tNorms\\nDepartment of Reproductive Health and Research\\nDr Matthews Mathai\\nCoordinator\\nEpidemiology,\\tMonitoring\\tand\\tEvaluation\\nDepartment of \\nMaternal,\\tNewborn,\\tChild\\tand\\t Adolescent\\t\\nHealth\\t(MCA)\\nDr João Paulo Souza\\nMedical\\tOfficer\\nImproving\\tMaternal\\tand\\tPerinatal\\tHealth\\tResearch,\\t\\nEvidence and Norms\\nDepartment of Reproductive Health and Research\\nDr Joshua Vogel\\nImproving\\tMaternal\\tand\\tPerinatal\\tHealth\\tResearch,\\t\\nEvidence and Norms\\nDepartment of Reproductive Health and Research\\nDr Mariana Widmer\\nTechnical\\tofficer\\nImproving\\tMaternal\\tand\\tPerinatal\\tHealth\\tResearch,\\t\\nEvidence and Norms\\nDepartment of Reproductive Health and Research\\nB. Guideline Steering Group\\nDr A. Metin Gülmezoglu (WHO)\\nDr Matthews Mathai (WHO)\\nDr João Paulo Souza (WHO)\\nDr Edgardo Abalos (CREP)\\nDr Virginia Diaz (CREP)\\nDr Natasha Hezelgrave (KCL)', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 36}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n32\\nC. Summary of the declarations of interest: Members of the GDG\\nName Region Country Declaration of Conflict \\nof interest  \\n(please indicate ‘yes’ or \\n‘no’ for each section)Advice from  \\nLegal Department \\n(please indicate \\n‘yes’ or ‘no’)Meeting \\nrestriction: \\nPlease indicate \\nsee below for \\nexplanation)\\nA B C D\\nProfessor Hany \\nAbdel-AleemEMRO Egypt Y N         N N N N\\nDr Catherine \\nDeneux-TharauxEURO France Y N N N N N\\nDr\\tBukola\\tFawole AFRO Nigeria N N N N N N\\nDr Atf Ghérissi EMRO Tunisia N N N N N N\\nMs Gill Gyte EURO UK Y N N N N N\\nDr\\tJustus\\tHofmeyr AFRO South \\nAfricaY N N N N N\\nDr Simon Lewin EURO Norway/\\nSouth \\nAfricaN N N N N N\\nProfessor Syeda \\nBatool MazharEMRO Pakistan N N N N N N\\nDr Enrique \\nOyarzunAMRO Chile N N N N N N\\nDr\\tZahida\\tQureshi AFRO Kenya Y N N N N N\\nProfessor \\nHamid Rushwan EURO Sudan/UK N N N N N N\\nDr\\tJeffrey\\tMichael\\t\\nSmithAMRO USA N N N N N N\\nDr Tran Son Thach WPRO Vietnam\\t/\\nAustraliaY N N N N N\\nDr\\tDilys\\tWalker AMRO USA Y N N N N N\\nA:\\tInvolved\\tin\\tacademic\\twork\\trelated\\tto\\tthe\\ttopic\\tof\\tthe\\tmeeting/guideline\\nB:\\tDeclared\\tany\\tcommercial\\tfinancial\\tinterest,\\trelated\\tto\\tthe\\ttopic\\tof\\tthe\\tmeeting/guideline\\nC:\\tDeclared\\tany\\tcommercial\\tfinancial\\tinterest,\\t not directly \\trelated\\tto\\tthe\\ttopic\\tof\\tthe\\tmeeting/guideline\\nD:\\tDeclared\\tnon-commercial\\tinterest\\tor\\tgrants\\trelated\\tto\\tthe\\ttopic\\tof\\tthe\\tmeeting/guideline', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 37}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n33\\nAnnex 2. Critical outcomes for decision making\\nPPH prevention\\nCritical outcomes\\nFewer maternal deaths\\nFewer\\tevents\\tof\\tsevere\\tPPH\\t(blood\\tloss\\t>1000\\tml)\\nLess use of blood transfusion\\nImportant outcomes\\nFewer admissions to intensive care unit\\nBlood\\tloss\\t≥500\\tml\\nAdditional uterotonics\\nMean blood loss\\nPostpartum anaemia\\nBreastfeeding\\nLess anaemia in infancy\\nAny side effect of intervention\\nAny side effect requiring treatment\\nNausea\\nVomiting\\nDiarrhoea\\nHeadache\\nAbdominal pain\\nHigh blood pressure\\nShivering\\nMaternal\\ttemperature\\t≥38\\t °C\\nMaternal\\ttemperature\\t≥40\\t °CPPH treatment\\nCritical outcomes\\nAdditional\\tblood\\tloss\\t≥500\\tml\\nAdditional\\tblood\\tloss\\t≥1000\\tml\\nBlood transfusion\\nAdditional uterotonics\\nInvasive non-surgical interventions\\nSurgical\\tinterventions\\t(including\\thysterectomy)\\nMaternal\\ttemperature\\t≥40\\t °C\\nProcedure-related complications\\nInfections\\nSevere morbidity\\nMaternal transfer\\nReduction\\tof\\ttime\\tfrom\\tdecision-making\\tto\\timplemen -\\ntation\\nAvailability of drugs and treatment\\nImportant outcomes\\nAccuracy in blood loss assessment\\nMean blood loss\\nPostpartum anaemia\\nAdditional\\tnon-surgical\\tinterventions\\t(e.g.\\texternal\\t\\naortic\\tcompression\\tand\\tcompression\\tgarments)\\nArtery embolization\\nNausea,\\tvomiting\\tor\\tshivering\\nMaternal\\ttemperature\\t≥38\\t °C\\nDelayed initiation of breastfeeding\\nProlonged hospitalization', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 38}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n34\\nAnnex 3: Summary of the considerations related to the strength of the recommen -\\ndations (Balance Worksheets)\\nBox\\t1.\\tSummary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\tthe\\trecommendations\\t(Recommendations\\t1–5)\\t\\nRecommendation 1 2 3 4 5\\nIntervention Uterotonics for PPH \\npreventionOxytocin for PPH prevention Other uterotonics for PPH \\npreventionMisoprostol by community \\nhealth workers for PPH \\npreventionCCT by skilled birth \\nattendants for PPH \\nprevention\\nQuality\\tof\\tthe\\t\\nevidence\\uf0a8High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0fd High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\nValues and \\npreferences\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\nAbsolute \\nmagnitude of \\neffect\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\nBalance of \\nbenefits\\tversus\\t\\ndisadvantages\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0a8\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0fd\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0a8\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0fd\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\nResource use \\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\nFeasibility \\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\nRecommendation \\ndirection\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\nOverall\\tranking \\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 39}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n35\\nAnnex 3: Summary of the considerations related to the strength of the recommen -\\ndations (Balance Worksheets)\\nBox\\t1.\\tSummary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\tthe\\trecommendations\\t(Recommendations\\t1–5)\\t\\nRecommendation 1 2 3 4 5\\nIntervention Uterotonics for PPH \\npreventionOxytocin for PPH prevention Other uterotonics for PPH \\npreventionMisoprostol by community \\nhealth workers for PPH \\npreventionCCT by skilled birth \\nattendants for PPH \\nprevention\\nQuality\\tof\\tthe\\t\\nevidence\\uf0a8High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0fd High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\nValues and \\npreferences\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\nAbsolute \\nmagnitude of \\neffect\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\nBalance of \\nbenefits\\tversus\\t\\ndisadvantages\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0a8\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0fd\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0a8\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0fd\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\nResource use \\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\nFeasibility \\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\nRecommendation \\ndirection\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\nOverall\\tranking \\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\nBox\\t2.\\tSummary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\tthe\\trecommendations\\t(Recommendations\\t6–10)\\t\\nRecommendation 6 7 8 9 10\\nIntervention CCT by unskilled birth \\nattendants for PPH \\npreventionLate cord clamping for PPH \\npreventionEarly cord clamping for PPH \\npreventionSustained uterine massage \\nfor PPH preventionPostpartum abdominal \\nassessment of uterine tonus\\nQuality\\tof\\tthe\\nevidence\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0fd Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\nValues and \\npreferences\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\nAbsolute \\nmagnitude of \\neffect\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\nBalance of \\nbenefits\\tversus\\t\\ndisadvantages\\uf0a8\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0fd\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0a8\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0fd Disadvantages outweigh \\nbenefits\\uf0a8\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0fd\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\nResource use \\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\nFeasibility \\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0fd\\tYes,\\tglobally\\n\\uf0a8\\tYes,\\tconditionally\\uf0fd\\tYes,\\tglobally\\n\\uf0a8\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0fd\\tYes,\\tglobally\\n\\uf0a8\\tYes,\\tconditionally\\nRecommendation \\ndirection\\uf0a8 In favour of the \\nintervention\\n\\uf0fd Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0a8 In favour of the \\nintervention\\n\\uf0fd Against the intervention\\uf0a8 In favour of the \\nintervention\\n\\uf0fd Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\nOverall\\tranking \\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 40}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n36\\nBox\\t3.\\tSummary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\tthe\\trecommendations\\t(Recommendations\\t11–15)\\t\\nRecommendation 11 12 13 14 15\\nIntervention Oxytocin for PPH prevention \\nin CSCCT for PPH prevention in \\nCSOxytocin for PPH treatment Other uterotonic drugs for \\nPPH treatmentIsotonic crystalloids for PPH \\ntreatment\\nQuality\\tof\\tthe\\t\\nevidence\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0fd Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0fd Low\\n\\uf0a8 Very low\\nValues and \\npreferences\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\nAbsolute \\nmagnitude of \\neffect\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\nBalance of \\nbenefits\\tversus\\t\\ndisadvantages\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\nResource use \\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\nFeasibility \\uf0fd\\tYes,\\tglobally\\n\\uf0a8\\tYes,\\tconditionally\\uf0fd\\tYes,\\tglobally\\n\\uf0a8\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\nRecommendation \\ndirection\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\nOverall\\tranking \\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 41}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n37\\nBox\\t3.\\tSummary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\tthe\\trecommendations\\t(Recommendations\\t11–15)\\t\\nRecommendation 11 12 13 14 15\\nIntervention Oxytocin for PPH prevention \\nin CSCCT for PPH prevention in \\nCSOxytocin for PPH treatment Other uterotonic drugs for \\nPPH treatmentIsotonic crystalloids for PPH \\ntreatment\\nQuality\\tof\\tthe\\t\\nevidence\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0fd Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0fd Low\\n\\uf0a8 Very low\\nValues and \\npreferences\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\nAbsolute \\nmagnitude of \\neffect\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\nBalance of \\nbenefits\\tversus\\t\\ndisadvantages\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\nResource use \\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\nFeasibility \\uf0fd\\tYes,\\tglobally\\n\\uf0a8\\tYes,\\tconditionally\\uf0fd\\tYes,\\tglobally\\n\\uf0a8\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\nRecommendation \\ndirection\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\nOverall\\tranking \\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\nBox\\t4.\\tSummary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\tthe\\trecommendations\\t(Recommendations\\t16–20)\\t\\nRecommendation 16 17 18 19 20\\nIntervention Tranexamic acid for PPH \\ntreatmentUterine massage for PPH \\ntreatmentIntrauterine balloon \\ntamponade for PPH \\ntreatmentUterine artery embolization \\nfor PPH treatmentSurgical interventions for \\nPPH treatment\\nQuality\\tof\\tthe\\t\\nevidence\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\nValues and \\npreferences\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\nAbsolute \\nmagnitude of \\neffect\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\nBalance of \\nbenefits\\tversus\\t\\ndisadvantages\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\nResource use \\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\nFeasibility \\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0fd\\tYes,\\tglobally\\n\\uf0a8\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\nRecommendation \\ndirection\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\nOverall\\tranking \\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0fd Strong recommendation\\n\\uf0a8\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0fd Strong recommendation*\\n\\uf0a8\\tWeak\\trecommendation', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 42}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n38\\nBox\\t5.\\tSummary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\tthe\\trecommendations\\t(Recommendations\\t21–25)\\t\\nRecommendation 21 22 23 24 25\\nIntervention Bimanual uterine \\ncompression for PPH \\ntreatmentExternal aortic compression \\nfor PPH treatmentNon-pneumatic anti-shock \\ngarment for PPH treatmentUterine packing for PPH \\ntreatmentUterotonics and CCT for \\nretained placenta\\nQuality\\tof\\tthe\\t\\nevidence\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0fd Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\nValues and \\npreferences\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\nAbsolute \\nmagnitude of \\neffect\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\nBalance of \\nbenefits\\tversus\\t\\ndisadvantages\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\nResource use \\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\nFeasibility \\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\nRecommendation \\ndirection\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\nOverall\\tranking \\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 43}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n39\\nBox\\t5.\\tSummary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\tthe\\trecommendations\\t(Recommendations\\t21–25)\\t\\nRecommendation 21 22 23 24 25\\nIntervention Bimanual uterine \\ncompression for PPH \\ntreatmentExternal aortic compression \\nfor PPH treatmentNon-pneumatic anti-shock \\ngarment for PPH treatmentUterine packing for PPH \\ntreatmentUterotonics and CCT for \\nretained placenta\\nQuality\\tof\\tthe\\t\\nevidence\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0fd Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\nValues and \\npreferences\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\nAbsolute \\nmagnitude of \\neffect\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0fd Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\nBalance of \\nbenefits\\tversus\\t\\ndisadvantages\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\nResource use \\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0fd Less resource intensive\\n\\uf0a8 More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\nFeasibility \\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\nRecommendation \\ndirection\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\nOverall\\tranking \\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\nBox\\t6.\\tSummary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\tthe\\trecommendations\\t(Recommendations\\t26–30)\\t\\nRecommendation 26 27 28 29 30\\nIntervention Ergometrine for retained \\nplacentaProstaglandin E2 alpha for \\nretained placentaAntibiotics with manual \\nremoval for retained \\nplacentaFormal protocols for PPH \\ntreatmentFormal protocols for patient \\nreferral\\nQuality\\tof\\tthe\\t\\nevidence\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0fd Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\nValues and \\npreferences\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\nAbsolute \\nmagnitude of \\neffect\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\nBalance of \\nbenefits\\tversus\\t\\ndisadvantages\\uf0a8\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0fd Disadvantages outweigh \\nbenefits\\uf0a8\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0fd Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\nResource use \\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\nFeasibility \\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\nRecommendation \\ndirection\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0a8 In favour of the \\nintervention\\n\\uf0fd Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\nOverall\\tranking \\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 44}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n40\\nBox\\t7.\\tSummary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\tthe\\trecommendations\\t  \\n(Recommendations\\t31–32)\\t\\nRecommendation 31 32\\nIntervention Simulations of PPH \\ntreatmentMonitoring the use of \\nuterotonics\\nQuality\\tof\\tthe\\t\\nevidence\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\nValues and \\npreferences\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\nAbsolute magnitude \\nof effect\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\nBalance of \\nbenefits\\tversus\\t\\ndisadvantages\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\nResource use \\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\nFeasibility \\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\nRecommendation \\ndirection\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\nOverall\\tranking \\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 45}), Document(page_content='WHO recommendations for the prevention and treatment of postpartum haemorrhage\\n41\\nBox\\t7.\\tSummary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\tthe\\trecommendations\\t  \\n(Recommendations\\t31–32)\\t\\nRecommendation 31 32\\nIntervention Simulations of PPH \\ntreatmentMonitoring the use of \\nuterotonics\\nQuality\\tof\\tthe\\t\\nevidence\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0fd Very low\\nValues and \\npreferences\\uf0fd\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariability\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0fd\\tSignificant\\tvariability\\nAbsolute magnitude \\nof effect\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0fd\\tSmall\\teffect\\t(0.5<RR<2)\\nBalance of \\nbenefits\\tversus\\t\\ndisadvantages\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\uf0fd\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\tdisadvantages\\t\\nare balanced\\n\\uf0a8 Disadvantages outweigh \\nbenefits\\nResource use \\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\uf0a8 Less resource intensive\\n\\uf0fd More resource intensive\\nFeasibility \\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\uf0a8\\tYes,\\tglobally\\n\\uf0fd\\tYes,\\tconditionally\\nRecommendation \\ndirection\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\uf0fd In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\nOverall\\tranking \\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\uf0a8 Strong recommendation\\n\\uf0fd\\tWeak\\trecommendation\\nBox\\t8.\\tTemplate\\tfor\\tthe\\tsummary\\tof\\tconsiderations\\trelated\\tto\\tthe\\tstrength\\tof\\tthe\\trecommendations\\twith\\texplanations\\tfor\\tcompleting\\tthe\\ttemplate\\t\\nRecommendation Which recommendation?\\nIntervention What is the intervention?\\nQuality\\tof\\tthe\\t\\nevidence\\uf0a8 High\\n\\uf0a8 Moderate\\n\\uf0a8 Low\\n\\uf0a8 Very lowThe\\thigher\\tthe\\tquality\\tof\\tthe\\tevidence,\\tthe\\tstronger\\tthe\\trecommendation.\\nIf\\tthe\\tevidence\\tquality\\tis\\t‘low’ \\tor\\t‘very\\tlow’,\\tconsider\\tmore\\tcarefully\\tthe\\tother\\tcriteria\\tbelow\\tin\\tdeciding\\tthe\\tstrength\\tof\\tthe\\t\\nrecommendation.\\nValues and \\npreferences\\uf0a8\\tNo\\tsignificant\\tvariability\\n\\uf0a8\\tSignificant\\tvariabilityThis\\trefers\\tto\\tvalues\\tplaced\\tby\\thealth\\tworkers,\\tpolicy-makers,\\tpatients\\tand\\tother\\tstakeholders\\ton\\tthe\\tintended\\toutcomes\\tof\\t\\nthe interventions.\\nIf\\tthere\\tis\\twide\\tvariability\\tbetween\\tthe\\tvalues\\tand\\tpreferences\\tof\\tvarious\\tstakeholders,\\tthe\\tintervention\\tis\\tless\\tlikely\\tto\\thave\\ta\\t\\nstrong recommendation.\\nMagnitude of \\neffect in critical \\noutcomes\\uf0a8 Large effect (RR>2 or \\nRR<0.5)\\n\\uf0a8\\tSmall\\teffect\\t(0.5<RR<2)This refers to the potential of the intervention to have large effects. The effects can be enhanced by being combined with \\nother\\tinterventions.\\tConsider\\twhich\\tpotential\\tassociations\\t(or\\t‘bundles’)\\tcan\\tenhance\\teffects.\\nThe\\tlarger\\tthe\\tpotential\\teffects\\tand\\tthe\\tlonger\\tthe\\ttime\\tperiod\\tof\\tthe\\tpotential\\teffects,\\tthe\\tmore\\tlikely\\tthe\\tintervention\\tis\\tto\\t\\nhave a strong recommendation.\\nBalance of \\nbenefits\\tversus\\t\\ndisadvantages\\uf0a8\\tBenefits\\toutweigh\\t\\ndisadvantages\\n\\uf0a8\\tBenefits\\tand\\t\\ndisadvantages are \\nbalanced\\n\\uf0a8 Disadvantages outweigh \\nbenefitsBenefits\\trefer\\tto\\tthe\\tintended\\tpositive\\teffects\\tof\\tan\\tintervention\\t.\\nDisadvantages refer to the potentially negative effects of an intervention as well as its unintended effects.\\nThe\\tfewer\\tthe\\tpotentially\\tnegative\\teffects\\tthere\\tare,\\tthe\\tmore\\tlikely\\tthe\\tintervention\\tis\\tto\\treceive\\ta\\tstrong\\trecommendation.\\nResource use \\uf0a8 Less resource intensive\\n\\uf0a8 More resource intensiveThe\\tresources\\tneeded\\tfor\\tthe\\timplementation\\tof\\ta\\trecommendation\\tmay\\tinclude\\tfinancial\\tresources,\\thuman\\tresources,\\t\\nand\\tinfrastructure\\tor\\tequipment.\\tIdeally,\\tthe\\tcost\\tof\\tthe\\tbenefits\\tof\\tan\\tintervention\\tshould\\tbe\\treasonable,\\taffordable\\tand\\t\\nsustainable.\\tIt\\tshould\\tbe\\tremembered\\tthat\\tcapital\\tcosts,\\tsuch\\tas\\tthose\\trequired\\tfor\\tinfrastructural\\tdevelopment,\\tmay\\tbe\\t\\ninitially\\thigh\\tbut\\tmay\\talso\\tyield\\tlong-term\\tbenefits.\\t\\nGenerally,\\tinterventions\\tthat\\tincur\\thigher\\tincremental\\tor\\trecurrent\\tcosts\\tare\\tless\\tlikely\\tto\\tbe\\tstrongly\\trecommended.\\nFeasibility \\uf0a8\\tYes,\\tglobally\\n\\uf0a8\\tYes,\\tconditionallyPolitical\\tcommitment\\tand\\twide\\tstakeholder\\tengagement\\tare\\tprerequisites\\tfor\\tinterventions.\\t The\\t‘technical’ \\tfeasibility\\tof\\t\\ninterventions\\talso\\tdepends\\ton\\tsufficiently\\tfunctional\\torganizational\\tand\\tinstitutional\\tstructures\\tto\\tmanage,\\tfollow\\tthrough,\\t\\nand monitor the implementation of the recommendation. The elements of technical feasibility vary considerably by country \\nand\\tby\\tcontext;\\twhere\\tthese\\telements\\tare\\tlikely\\tto\\tbe\\tfunctional\\tacross\\ta\\twide\\tvariety\\tof\\tsettings\\tit\\tis\\tmore\\tlikely\\tthat\\t\\ninterventions will receive strong recommendations.\\nRecommendation \\ndirection\\uf0a8 In favour of the \\nintervention\\n\\uf0a8 Against the intervention\\nOverall\\tranking \\uf0a8 Strong recommendation\\n\\uf0a8\\tWeak\\trecommendationStrength of the recommendation.', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 46}), Document(page_content='  \\nWHO recommendations \\nfor the prevention  \\nand treatment of  \\npostpartum haemorrhage\\nFor more information, please contact:\\nDepartment of Reproductive Health and Research  \\nE-mail: reproductivehealth@who.int  \\nwww.who.int/reproductivehealth\\nMaternal, Newborn, Child and Adolescent Health\\nE-mail: mncah@who.int\\nwww.who.int/maternal_child_adolescent\\nWorld Health Organization  \\nAvenue Appia 20, CH-1211 Geneva 27  \\nSwitzerland', metadata={'source': '..\\\\public\\\\rawDataset\\\\WHO recommendations for the prevention and treatment of postpartum haemorrhage.pdf', 'page': 47})]\n"
     ]
    }
   ],
   "source": [
    "print(docs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "8 |   \n",
      "ESCOBAR Et Al.\n",
      "2 | FIGO RECOMMENDATIONS FOR \n",
      "THE PREVENTION AND TREATMENT OF \n",
      "POSTPARTUM HEMORRHAGE\n",
      "Health workers at all levels of care (particularly in LMICs) need \n",
      "to have access to appropriate medications1 and training in PPH \n",
      "prevention and management procedures. All attempts should be \n",
      "made to reduce PPH using cost-  effective, resource-  appropriate \n",
      "interventions. At first, all should be done to avoid PPH and re -\n",
      "duce the need for expensive, lifesaving surgical interventions. The \n",
      "routine use of active management of the third stage of labor by \n",
      "all attendants, regardless of where they practice, should be rec -\n",
      "ommended.2 All birth attendants must know how to provide safe \n",
      "care (physiologic management) to prevent PPH in the absence of \n",
      "uterotonic drugs.3\n",
      "2.1  |  FIGO recommendations for prevention of \n",
      "postpartum hemorrhage\n",
      "1. The use of uterotonics for prevention of PPH during the third \n",
      "stage of labor is recommended for all births.4,5 Oxytocin (10 IU \n",
      "intravenously/intramuscularly [IV/IM]) is recommended for the \n",
      "prevention of PPH for vaginal delivery and cesarean section.4,5 \n",
      "In settings where oxytocin is used, attention should be paid \n",
      "to the oxytocin cold chain.6\n",
      "2. In settings where oxytocin is unavailable or its quality can-\n",
      "not be guaranteed, the use of other injectable uterotonics (if \n",
      "appropriate ergometrine/methylergometrine 200 μg IM/IV;  \n",
      "hypertensive disorders can be safely excluded prior to its use) \n",
      "or oral misoprostol (400–600 µg orally) or carbetocin 100 µg \n",
      "IM/IV is recommended for the prevention of PPH.4,5\n",
      "3. The combinations of ergometrine plus oxytocin or misoprostol plus \n",
      "oxytocin may be more effective uterotonic drug strategies for the \n",
      "prevention of PPH ≥500 ml compared with the current standard, \n",
      "oxytocin. This comes at the expense of a higher risk of adverse ef -\n",
      "fects (vomiting and hypertension with ergometrine and fever with \n",
      "misoprostol).7\n",
      "4. In settings where skilled birth attendants are not present to ad -\n",
      "minister injectable uterotonics and oxytocin is unavailable, the \n",
      "administration of misoprostol (400–  600 μ g orally) by community \n",
      "healthcare workers and lay health workers is recommended for \n",
      "the prevention of PPH.4,5\n",
      "5. In settings where skilled birth attendants are unavailable, con -\n",
      "trolled cord traction (CCT) is not recommended.4\n",
      "6. Sustained uterine massage is not recommended as an interven -\n",
      "tion to prevent PPH in women who have received prophylactic \n",
      "oxytocin.8\n",
      "7. Postpartum abdominal uterine tonus assessment for early identi -\n",
      "fication of uterine atony is recommended for all women.4\n",
      "8. Oxytocin (IV or IM) and CCT is the recommended method for removal \n",
      "of the placenta for the prevention of PPH in cesarean delivery.42.2  |  FIGO recommendations for treatment of \n",
      "postpartum hemorrhage\n",
      " 1. Intravenous oxytocin alone is the recommended first-  line \n",
      "uterotonic drug for the treatment of PPH.3,4\n",
      " 2. If intravenous oxytocin is unavailable, or if the bleeding \n",
      "does not respond to oxytocin, the use of intramuscular er -\n",
      "gometrine, oxytocin–  ergometrine fixed dose, or a prosta -\n",
      "glandin drug (including sublingual misoprostol, 800  μg) is \n",
      "recommended.3,4,9,10\n",
      " 3. There is no evidence about the safety and efficacy of an additional \n",
      "800- μg dose of misoprostol for treatment of PPH when given to \n",
      "women who have already received 600 μg of prophylactic misopros -\n",
      "tol orally.\n",
      " 4. The use of isotonic crystalloids is recommended in preference to \n",
      "the use of colloids for the initial intravenous fluid resuscitation \n",
      "of women with PPH.4,11\n",
      " 5. Early use of intravenous tranexamic acid as soon as PPH is diag -\n",
      "nosed but within 3 h of birth in addition to standard care is rec -\n",
      "ommended for women with clinically diagnosed PPH following \n",
      "vaginal birth or cesarean delivery.12– 14\n",
      " 6. Administration of 1 g (100 mg/ml) tranexamic acid intravenously at \n",
      "1 ml/min (i.e. administered over 10 min), with a second dose of 1 g in -\n",
      "travenously if bleeding continues after 30 min, or if bleeding restarts\n"
     ]
    }
   ],
   "source": [
    "print(pages[5].page_content)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
